Doxorubicin (Synonyms: Hydroxydaunorubicin)

Cat. No.: HY-15142A: FAQs
Data Sheet Handling Instructions

Molarity Calculator

Doxorubicin (Hydroxydaunorubicin), a broad-spectrum anthracycline antibiotic with cytotoxic properties, is an anti-cancer chemotherapy agent. Doxorubicin has fluorescence properties. Doxorubicin inhibits topoisomerase II with an IC₅₀ of 2.67 μM, thus stopping DNA replication. Doxorubicin reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin induces apoptosis and autophagy. Doxorubicin inhibits human DNA topoisomerase I with an IC₅₀ of 0.8 μM.

For research use only. We do not sell to patients.

Doxorubicin Chemical Structure

CAS No. : 23214-92-8

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Doxorubicin:

Doxorubicin hydrochloride

Other Forms of Doxorubicin:

Doxorubicin hydrochloride In-stock
Doxorubicin-¹³C,d₃ TFA Get quote

430 Publications Citing Use of MCE Doxorubicin

IHC

: Doxorubicin purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2019 Nov 25;10(12):887. [Abstract]; Doxorubicin or CPT-11 significantly promoted KRT8 expression in chordoma cells in vitro. Western blotting analysis and quantification of KRT8 protein expression (normalized to GAPDH expression).

: Doxorubicin purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2019 Nov 25;10(12):887. [Abstract]; Doxorubicin or CPT-11 significantly promoted KRT8 expression in chordoma cells in vitro. Representative images of immunofluorescence staining of KRT8 of CM318 and UCH1 cell line.

: Doxorubicin purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2019 Jan;130:557-567. [Abstract]; Representative pictures of Live/Dead staining of effects of 7,8-DHF on high dose of Dox-induced cell death and MMP reduction of H9c2 cells.

: Doxorubicin purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2019 Sep;23(9):6034-6047. [Abstract]; Effects of YWPC (50 mg/L for 24 h) on DOX (5 μM for 24 h)-induces dissipation of mitochondrial membrane potential measured in H9C2 cells loaded with JC-1 using fluorescence microscopy.

: Doxorubicin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2018 Oct 8;9(1):4139. [Abstract]; One hour after treated with UV or 2 h after treated with MMS, Camptothecin (CPT) (10 μM), or Doxorubicin (DOX; 0.5 μM), HEK293T cells expressing HA-SUMO2 and His-RhoB are subjected to sumoylation assay to detect the SUMO2 conjugation of RhoB.

: Doxorubicin purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2018 Jan 2;128(1):483-499. [Abstract]; Immunoblotting for EZH2 in lysates of immortalized mouse podocytes after treatment with Adriamycin (300 ng/mL) for 48 hours (n=6).

: Doxorubicin purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2018 Sep 19;37(1):232. [Abstract]; Immunoblotting shows that both P-gp protein expression is significantly decreased in 24 h after US exposure in MCF-7/ADR and HEPG2/ADM cells.

: Doxorubicin purchased from MedChemExpress. Usage Cited in: Nanoscale Res Lett. 2018 Nov 3;13(1):350. [Abstract]; HY-15142

: Doxorubicin purchased from MedChemExpress. Usage Cited in: Cell Signal. 2017 May 1;36:108-116. [Abstract]; PAQR3 affects DNA damage repair. AGS cells are treated with different doses of VP-16 (for 24 h), CDDP (for 24 h) and Doxorubicin (for 10 h) as indicated, followed by immunoblotting with the antibodies.

: Doxorubicin purchased from MedChemExpress. Usage Cited in: Cell Physiol Biochem. 2017;42(3):965-973. [Abstract]; U937 cells are treated with Thapsigargin (TG, 1 μM), NSC 125973 (PTX, 5nM) as well as Doxorubincin (DOX, 1 μM) for 12 hours and the indicated proteins are detected by Western blot.

: Doxorubicin purchased from MedChemExpress. Usage Cited in: Nat Med. 2016 May;22(5):547-56. [Abstract]; Immunofluorescent staining for α-actinin (ACTN2) and cardiac troponin T (TNNT2) to demonstrate sarcomeric organization in hiPSC–CMs derived from patients who do not experience Doxorubicin–induced cardiotoxicity (DOX) versus those who do experience Doxorubicin-induced cardiotoxicity (DOXTOX) after 24 h treatment with Doxorubicin. Scale bar, 20 µm.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All ADC Cytotoxin Isoform Specific Products:

View All Isoforms

Auristatin Calicheamicins Camptothecins Daunorubicins/Doxorubicins Duocarmycins Maytansinoids Pyrrolobenzodiazepines Traditional Cytotoxic Agents

View All Antibiotic Isoform Specific Products:

View All Isoforms

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

View All Topoisomerase Isoform Specific Products:

View All Isoforms

Topoisomerase Topo I Topo II

View All AMPK Isoform Specific Products:

View All Isoforms

NUAK1 NUAK2 AMPK AMPK α1β1γ1 AMPK α2β1γ1 AMPK α1β2γ1 AMPK α2β2γ1

View All HIV Isoform Specific Products:

View All Isoforms

HIV HIV-1 HIV-2

Biological Activity
Purity & Documentation
References
Customer Review

Description

Doxorubicin (Hydroxydaunorubicin), a broad-spectrum anthracycline antibiotic with cytotoxic properties, is an anti-cancer chemotherapy agent. Doxorubicin has fluorescence properties. Doxorubicin inhibits topoisomerase II with an IC₅₀ of 2.67 μM, thus stopping DNA replication. Doxorubicin reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin induces apoptosis and autophagy^[1]^[2]. Doxorubicin inhibits human DNA topoisomerase I with an IC₅₀ of 0.8 μM^[3].

IC₅₀ & Target^[1]^[2]^[3]^[7]

Topoisomerase I

0.8 μM (IC₅₀)

Topoisomerase II

2.67 μM (IC₅₀)

Daunorubicins/Doxorubicins

HIV-1

Cellular Effect

Cell Line	Type	Value	Description	References
143B	IC₅₀	0.1 μM Compound: DOX	Cytotoxicity against human 143B cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human 143B cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
16HBE14o-	GI₅₀	0.18 μM Compound: Adriamycin	Growth inhibition of human 16HBE cells by sulforhodamine B assay Growth inhibition of human 16HBE cells by sulforhodamine B assay	[PMID: 24650643]
184B5	GI₅₀	1.15 μM Compound: Doxorubicin	Cytotoxicity against human 184B5 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human 184B5 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29670691]
184B5	GI₅₀	1.2 μM Compound: Doxorubicin	Antiproliferative activity against human 184B5 cells after 72 hrs by MTT assay Antiproliferative activity against human 184B5 cells after 72 hrs by MTT assay	[PMID: 30071406]
1A9	EC₅₀	0.1 μM Compound: doxorubicin	Cytotoxicity against human 1A9 cells after 72 hrs Cytotoxicity against human 1A9 cells after 72 hrs	[PMID: 17378530]
3Y1 cell line	GI₅₀	3.8 nM Compound: adriamycin	Cytotoxicity against rat 3Y1 cells after 72 hrs by MTT assay Cytotoxicity against rat 3Y1 cells after 72 hrs by MTT assay	[PMID: 10691710]
4T1	IC₅₀	0.481 μM Compound: Doxorubicin	Cytotoxicity activity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
4T1	IC₅₀	0.99 μM Compound: Doxorubicin	Cytotoxicity against mouse 4T1 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against mouse 4T1 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 27496212]
4T1	IC₅₀	90 nM Compound: Doxorubicin	Cytotoxicity against mouse 4T1 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay Cytotoxicity against mouse 4T1 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay	[PMID: 35213166]
5637	IC₅₀	0.02 μM Compound: doxo	Antiproliferative activity against human 5637 cell line by MTT assay Antiproliferative activity against human 5637 cell line by MTT assay	[PMID: 16913700]
5-8F	IC₅₀	0.34 μM Compound: DOX	Antiproliferative activity against human 5-8F cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human 5-8F cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36709571]
769-P	IC₅₀	0.45 μM Compound: Doxorubicin	Anticancer activity against human 769-P cells by MTT assay Anticancer activity against human 769-P cells by MTT assay	[PMID: 31404864]
786-0	GI₅₀	< 0.046 μM Compound: Dox	Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26454648]
786-0	GI₅₀	0.02 μg/mL Compound: Doxorubicin	Cytotoxicity against human 786-0 cells by sulforhodamine B assay Cytotoxicity against human 786-0 cells by sulforhodamine B assay	[PMID: 26913941]
786-0	GI₅₀	0.025 μg/mL Compound: DOX; Doxo	Antiproliferative activity against human 786-0 cells after 48 hrs by SRB assay Antiproliferative activity against human 786-0 cells after 48 hrs by SRB assay	[PMID: 26859070]
786-0	GI₅₀	0.04 μg/mL Compound: DOX	Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay	[PMID: 21041092]
786-0	GI₅₀	0.11 μM Compound: Dox	Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay	[PMID: 28505535]
786-0	IC₅₀	0.13 μM Compound: Doxorubicin	Cytotoxicity against human 786-O cells assessed as growth inhibition by MTS assay Cytotoxicity against human 786-O cells assessed as growth inhibition by MTS assay	[PMID: 24824796]
786-0	GI₅₀	0.13 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human 786-0 cells after 48 hrs by SRB assay Cytotoxicity against human 786-0 cells after 48 hrs by SRB assay	[PMID: 23871905]
786-0	GI₅₀	0.13 μM Compound: Doxorubicin	Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
786-0	GI₅₀	0.13 μM Compound: Doxorubicin	Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
786-0	GI₅₀	0.15 μg/mL Compound: Doxorubicin	Cytotoxicity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Cytotoxicity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 26561866]
786-0	GI₅₀	0.15 μg/mL Compound: DOX	Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 25062010]
786-0	GI₅₀	0.15 μM Compound: DOXO	Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human 786-0 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 31247374]
786-0	GI₅₀	0.16 μM Compound: Doxorubicin	Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human 786-0 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 33477019]
786-0	GI₅₀	0.18 μg/mL Compound: Doxorubicin	Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay	[PMID: 22410248]
A 172	IC₅₀	0.13 μM Compound: DOX	Antiproliferative activity against human A-172 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Antiproliferative activity against human A-172 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 34968902]
A 172	IC₅₀	0.2 μM Compound: Dox	Cytotoxicity against human A172 cells after 72 hrs by MTT assay Cytotoxicity against human A172 cells after 72 hrs by MTT assay	[PMID: 30659997]
A204	IC₅₀	0.006482 μM Compound: Doxorubicin	Antiproliferative activity against human A204 cells assessed as inhibition of cell growth incubated for 7 days by CellTiterGlo assay Antiproliferative activity against human A204 cells assessed as inhibition of cell growth incubated for 7 days by CellTiterGlo assay	[PMID: 30540463]
A2058	CC₅₀	1.79 μM Compound: Doxorubicin	Cytotoxicity against human A2058 cells after 72 hrs by MTT assay Cytotoxicity against human A2058 cells after 72 hrs by MTT assay	[PMID: 29792325]
A2058	EC₅₀	6.5 μM Compound: 12	Dark toxicity in human A2058 cells assessed as decrease in cell viability after 24 hrs by MTT assay Dark toxicity in human A2058 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 29172528]
A2780	GI₅₀	< 0.1 μM Compound: ADR	Cytotoxicity against human A2780 cells after 48 hrs by SRB assay Cytotoxicity against human A2780 cells after 48 hrs by SRB assay	[PMID: 20673627]
A2780	GI₅₀	< 0.1 μM Compound: ADR	Anticancer activity against human A2780 cells by SRB method Anticancer activity against human A2780 cells by SRB method	[PMID: 22104151]
A2780	GI₅₀	< 0.1 μM Compound: ADR	Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B assay	[PMID: 21737288]
A2780	IC₅₀	0.0096 μM Compound: Doxirubicin	Concentration required to inhibit A2780-cell growth by 50% Concentration required to inhibit A2780-cell growth by 50%	[PMID: 9703471]
A2780	EC₅₀	0.01 μM Compound: Doxorubicin	Cytotoxicity against human A2780 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 33049606]
A2780	EC₅₀	0.01 μM Compound: DR	Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32956968]
A2780	IC₅₀	0.01 μM Compound: DX	Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32422522]
A2780	IC₅₀	0.02 μM Compound: doxorubicin	Antiproliferative activity against human A2780 cells after 3 days by MTT assay Antiproliferative activity against human A2780 cells after 3 days by MTT assay	[PMID: 19093883]
A2780	IC₅₀	0.044 μM Compound: Doxorubicin	Cytotoxicity against human A2780 cells assessed as intracellular ATP level after 72 hrs by luminometry Cytotoxicity against human A2780 cells assessed as intracellular ATP level after 72 hrs by luminometry	[PMID: 21354800]
A2780	IC₅₀	0.05 μM Compound: Doxorubicin	Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33823396]
A2780	IC₅₀	0.1 μM Compound: adriamycin	Cytotoxicity against human A2780 cells by MTT assay Cytotoxicity against human A2780 cells by MTT assay	[PMID: 17190442]
A2780	IC₅₀	0.123 μM Compound: Dox	Cytotoxicity against human A2780 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human A2780 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 30599418]
A2780	GI₅₀	0.16 μM Compound: ADR	Growth inhibition of human A2780 cells after 48 hrs by SRB assay Growth inhibition of human A2780 cells after 48 hrs by SRB assay	[PMID: 20031423]
A2780	GI₅₀	0.16 μM Compound: ADR	Growth inhibition of human A2780 cells by SRB assay Growth inhibition of human A2780 cells by SRB assay	[PMID: 22361684]
A2780	GI₅₀	0.16 μM Compound: ADR	Anticancer activity against human A2780 cells by SRB method Anticancer activity against human A2780 cells by SRB method	[PMID: 21676506]
A2780	GI₅₀	0.16 μM Compound: ADR	Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay	[PMID: 23849207]
A2780	GI₅₀	0.16 μM Compound: ADR	Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay	[PMID: 22364746]
A2780	GI₅₀	0.16 μM Compound: ADR	Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B assay	[PMID: 18657979]
A2780	GI₅₀	0.16 μM Compound: ADR	Cytotoxicity against human A2780 cells after 24 hrs by WST-1 assay Cytotoxicity against human A2780 cells after 24 hrs by WST-1 assay	[PMID: 20732817]
A2780	GI₅₀	0.17 μM Compound: adriamycin	Cytotoxicity against human A2780 cells after 24 hrs by SRB method Cytotoxicity against human A2780 cells after 24 hrs by SRB method	[PMID: 18262426]
A2780	GI₅₀	0.17 μM Compound: ADR, Adriamycin	Growth inhibition of human A2780 cells by SRB method Growth inhibition of human A2780 cells by SRB method	[PMID: 18207392]
A2780	IC₅₀	0.18 μM Compound: ADM; DOX	Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31491611]
A2780	IC₅₀	0.27 μM Compound: DOX	Cytotoxicity against human A2780 cells after 48 hrs by MTT assay Cytotoxicity against human A2780 cells after 48 hrs by MTT assay	[PMID: 26386603]
A2780	IC₅₀	0.33 μM Compound: Adriamycin	Cytotoxicity against human A2780 cells by MTT assay Cytotoxicity against human A2780 cells by MTT assay	[PMID: 22070654]
A2780	IC₅₀	0.5 μM Compound: ADR	Cytotoxicity against human A2780 cells by SRB assay Cytotoxicity against human A2780 cells by SRB assay	[PMID: 18656370]
A2780	IC₅₀	0.5 μM Compound: ADR	Cytotoxicity against human A2780 cells by sulforhodamine B assay Cytotoxicity against human A2780 cells by sulforhodamine B assay	[PMID: 17822905]
A2780	IC₅₀	0.6 μM Compound: Doxorubicin	Antiproliferative activity against human A2780 cells assessed as cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human A2780 cells assessed as cell viability incubated for 48 hrs by MTS assay	[PMID: 33348171]
A2780	IC₅₀	0.6 μM Compound: Adriamycin	Cytotoxicity against human A2780 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A2780 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26356746]
A2780	IC₅₀	0.71 μM Compound: DOX	Antiproliferative activity against human A2780 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human A2780 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32996316]
A2780	IC₅₀	0.98 μM Compound: DOX	Cytotoxicity against human A2780 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human A2780 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 27149641]
A2780	IC₅₀	1.3 μM Compound: Doxorubicin	Cytotoxicity against human A2780 cells after 24 hrs by MTT assay Cytotoxicity against human A2780 cells after 24 hrs by MTT assay	[PMID: 26252628]
A2780	IC₅₀	1.9 μM Compound: DOX	Antiproliferative activity against taxol-resistant human A2780 cells after 48 hrs by SRB method Antiproliferative activity against taxol-resistant human A2780 cells after 48 hrs by SRB method	[PMID: 25061803]
A2780	IC₅₀	23 nM Compound: doxorubicin	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay Cytotoxicity against human A2780 cells after 72 hrs by MTT assay	[PMID: 23886686]
A-375	EC₅₀	0.009 μM Compound: Doxorubicin	Induction of senescence in human A-375 cells treated for 3 days by Hoechst staining based imaging analysis Induction of senescence in human A-375 cells treated for 3 days by Hoechst staining based imaging analysis	[PMID: 33859796]
A-375	EC₅₀	0.009 μM Compound: Dox	Induction of senescence-like phenotype in human A-375 cells assessed as increase in morphological changes after 72 hrs by staining based imaging assay Induction of senescence-like phenotype in human A-375 cells assessed as increase in morphological changes after 72 hrs by staining based imaging assay	[PMID: 33268144]
A-375	IC₅₀	0.01 μM Compound: doxorubicin	Cytotoxicity against human A375 cells after 24 hrs by MTT assay Cytotoxicity against human A375 cells after 24 hrs by MTT assay	[PMID: 18281125]
A-375	IC₅₀	0.01 μM Compound: doxorubicin	Cytotoxicity against human A375 cells after 24 hrs by MTT assay Cytotoxicity against human A375 cells after 24 hrs by MTT assay	[PMID: 17400463]
A-375	IC₅₀	0.01 μM Compound: Doxorubicin	Antiproliferative activity against human A375 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method Antiproliferative activity against human A375 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	[PMID: 25937235]
A-375	IC₅₀	0.024 μM Compound: Doxorubicin	Cytotoxicity activity against human A375 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against human A375 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
A-375	IC₅₀	0.13 μM Compound: DOX	Antiproliferative activity against human A375 cells after 72 hrs by MTT assay Antiproliferative activity against human A375 cells after 72 hrs by MTT assay	[PMID: 21496972]
A-375	IC₅₀	0.19 μM Compound: ADM; DOX	Antiproliferative activity against human A375 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human A375 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31491611]
A-375	IC₅₀	0.26 μM Compound: DOX	Cytotoxicity against human A-375 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay Cytotoxicity against human A-375 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay	[PMID: 35612499]
A-375	IC₅₀	0.33 μM Compound: DOX	Antiproliferative activity against human A-375 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human A-375 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 35818137]
A-375	IC₅₀	0.37 μM Compound: DOX	Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay	[PMID: 29597166]
A-375	IC₅₀	0.4 μM Compound: Doxorubicin	Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A375 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29789258]
A-375	IC₅₀	0.4 μM Compound: Doxorubicin	Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay	[PMID: 35271771]
A-375	IC₅₀	0.75 μM Compound: ADM	Cytotoxicity against human A375 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human A375 cells after 72 hrs by sulforhodamine B assay	[PMID: 23639650]
A-375	IC₅₀	1 μM Compound: ADM	Cytotoxicity against human A375 cells after 72 hrs by MTT assay Cytotoxicity against human A375 cells after 72 hrs by MTT assay	[PMID: 26280921]
A-375	IC₅₀	1 μM Compound: ADM	Cytotoxicity against human A375 cells after 72 hrs by MTT assay Cytotoxicity against human A375 cells after 72 hrs by MTT assay	[PMID: 25874331]
A-375	IC₅₀	1.2 μM Compound: Doxorubicin	Anticancer activity against human A375 cells by MTT assay Anticancer activity against human A375 cells by MTT assay	10.1039/C4MD00219A
A-375	IC₅₀	1.8 μg/mL Compound: doxorubicin	Cytotoxicity against human A375 cells after 24 hrs by MTT assay Cytotoxicity against human A375 cells after 24 hrs by MTT assay	[PMID: 12608856]
A-375	IC₅₀	2.1 μM Compound: Doxorubicin	Cytotoxicity against human A-375 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A-375 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32975117]
A-375	IC₅₀	5.51 μM Compound: Doxorubicin	Anticancer activity against human A375 cells after 48 hrs by MTT assay Anticancer activity against human A375 cells after 48 hrs by MTT assay	[PMID: 22136907]
A-375	IC₅₀	6.35 μM Compound: Dox	Antiproliferative activity against human A375 cells for 24 hrs by MTT assay Antiproliferative activity against human A375 cells for 24 hrs by MTT assay	[PMID: 24929289]
A-375	IC₅₀	7.01 μM Compound: Doxorubicin	Cytotoxicity against human A375 spheroid cells assessed as reduction in spheroid cell viability after 48 hrs by MTT assay Cytotoxicity against human A375 spheroid cells assessed as reduction in spheroid cell viability after 48 hrs by MTT assay	[PMID: 30433783]
A-375	IC₅₀	7.2 μM Compound: Doxo	Cytotoxicity against human A375 cells after 48 hrs by MTT assay Cytotoxicity against human A375 cells after 48 hrs by MTT assay	[PMID: 25563891]
A-431	GI₅₀	0.0012 μM Compound: Doxorubicin	Antiproliferative activity against human A431 cells by SRB assay Antiproliferative activity against human A431 cells by SRB assay	[PMID: 19394218]
A-431	IC₅₀	0.03 μM Compound: Dox	Anticancer activity against human A431 cells after 48 hrs by MTT assay Anticancer activity against human A431 cells after 48 hrs by MTT assay	[PMID: 22209733]
A-431	IC₅₀	0.05 μM Compound: adriamycin	Growth inhibition of human A431 cells by MTT assay Growth inhibition of human A431 cells by MTT assay	[PMID: 17049252]
A-431	IC₅₀	0.16 μM Compound: DOX	Cytotoxicity against human A431 cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human A431 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
A-431	GI₅₀	0.18 μM Compound: Doxorubicin	Growth inhibition of human A431 cells after 2 days by SRB assay Growth inhibition of human A431 cells after 2 days by SRB assay	[PMID: 22000924]
A-431	GI₅₀	0.18 μM Compound: Doxorubicine	Growth inhibition of human A431 cells after 2 days by sulforhodamine B assay Growth inhibition of human A431 cells after 2 days by sulforhodamine B assay	[PMID: 20045222]
A-431	IC₅₀	0.19 μM Compound: Doxorubicin	Cytotoxicity against human A431 cells after 72 hrs by MTT assay Cytotoxicity against human A431 cells after 72 hrs by MTT assay	[PMID: 18692939]
A-431	IC₅₀	0.37 μM Compound: Doxorubicin	Cytotoxicity against human A431 cells after 48 hrs by MTT assay Cytotoxicity against human A431 cells after 48 hrs by MTT assay	[PMID: 20846862]
A-431	EC₅₀	0.7 μM Compound: Doxorubicin	Antiproliferative activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35567964]
A-431	ED₅₀	1.2 x 10^-2 μg/mL Compound: Adriamycin	Cytotoxicity against human A431 cells by MTT assay Cytotoxicity against human A431 cells by MTT assay	[PMID: 7714533]
A-431	IC₅₀	1.35 nM Compound: DOX	Cytotoxicity against human A431 cells by SRB assay Cytotoxicity against human A431 cells by SRB assay	[PMID: 24890652]
A-431	IC₅₀	1.43 μM Compound: Doxorubicin	Antiproliferative activity against human A431 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human A431 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31546197]
A498	ED₅₀	0.00286 μg/mL Compound: adriamycin	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 11087592]
A498	ED₅₀	0.0156 μg/mL Compound: adriamycin	Cytotoxicity against human A-498 cells after 7 days by MTT assay Cytotoxicity against human A-498 cells after 7 days by MTT assay	[PMID: 10514307]
A498	IC₅₀	0.035 μM Compound: adriamycin	Antitumor activity against human A498 cells by methylene blue staining method Antitumor activity against human A498 cells by methylene blue staining method	[PMID: 17656091]
A498	GI₅₀	0.1 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human A498 cells after 48 hrs by SRB assay Cytotoxicity against human A498 cells after 48 hrs by SRB assay	[PMID: 23871905]
A498	GI₅₀	0.1 μM Compound: Doxorubicin	Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
A498	GI₅₀	0.1 μM Compound: Doxorubicin	Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
A498	ED₅₀	1 x 10^-2 μg/mL Compound: Adriamycin	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 9214729]
A498	ED₅₀	1 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 8882434]
A498	ED₅₀	1.1 ng/mL Compound: adriamycin	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	10.1021/np970510f
A498	IC₅₀	1.1 μM Compound: Doxorubicin	Antiproliferative activity against human A498 cells after 48 hrs by SRB assay Antiproliferative activity against human A498 cells after 48 hrs by SRB assay	[PMID: 30503942]
A498	ED₅₀	1.13 x 10^-1 μg/mL Compound: Adriamycin	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 9322367]
A498	ED₅₀	1.22 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 9134750]
A498	ED₅₀	1.58 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 9584396]
A498	ED₅₀	1.78 ng/mL Compound: Adriamycin	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 8946743]
A498	ED₅₀	1.9 ng/mL Compound: adriamycin	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 10395501]
A498	ED₅₀	1.9 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human A-498 cells by MTT assay Cytotoxicity against human A-498 cells by MTT assay	[PMID: 9917277]
A498	ED₅₀	1.97 ng/mL Compound: Adriamycin	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 7494147]
A498	ED₅₀	1.98 ng/mL Compound: adriamycin	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 9599253]
A498	ED₅₀	2.26 ng/mL Compound: adriamycin	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 11325235]
A498	ED₅₀	2.86 ng/mL Compound: adriamycin	Cytotoxicity against human A-498 cells after 7 days by MTT assay Cytotoxicity against human A-498 cells after 7 days by MTT assay	[PMID: 15730242]
A498	ED₅₀	3.2 ng/mL Compound: Adriamycin	Cytotoxicity against human A498 cells by MTT assay Cytotoxicity against human A498 cells by MTT assay	[PMID: 7714533]
A498	ED₅₀	3.66 x 10^-4 μg/mL Compound: adriamycin	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 8676130]
A498	ED₅₀	4.24 ng/mL Compound: adr	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 9461654]
A498	IC₅₀	4.9 ng/mL Compound: Adriamycin	Cytotoxicity against human A498 cells by MTT assay Cytotoxicity against human A498 cells by MTT assay	[PMID: 9644064]
A498	IC₅₀	6.1 μM Compound: DOX	Antiproliferative activity against human A498 cells after 72 hrs by MTT assay Antiproliferative activity against human A498 cells after 72 hrs by MTT assay	[PMID: 30429098]
A498	ED₅₀	6.2 ng/mL Compound: adriamycin	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 9599260]
A498	ED₅₀	6.49 ng/mL Compound: adriamycin	Cytotoxicity against human A498 cells after 7 days by MTT assay Cytotoxicity against human A498 cells after 7 days by MTT assay	[PMID: 8904848]
A549	GI₅₀	< 0.01 μM Compound: Doxorubicin	Growth inhibition of human A549 cells after 48 hrs by SRB assay Growth inhibition of human A549 cells after 48 hrs by SRB assay	10.1039/C6MD00097E
A549	GI₅₀	< 0.01 μM Compound: Doxorubicin	Growth inhibition in human A549 cells after 48 hrs by SRB assay Growth inhibition in human A549 cells after 48 hrs by SRB assay	[PMID: 31546197]
A549	GI₅₀	< 0.01 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 48 hrs by SRB assay Antiproliferative activity against human A549 cells after 48 hrs by SRB assay	[PMID: 26994690]
A549	GI₅₀	< 0.01 μM Compound: Doxorubicin	Growth inhibition of human A549 cells after 48 hrs by SRB assay Growth inhibition of human A549 cells after 48 hrs by SRB assay	[PMID: 26067381]
A549	GI₅₀	< 0.01 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 48 hrs by SRB assay Antiproliferative activity against human A549 cells after 48 hrs by SRB assay	[PMID: 25827522]
A549	IC₅₀	< 0.1 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 22330634]
A549	GI₅₀	< 0.1 μM Compound: ADR	Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 21737288]
A549	IC₅₀	< 1 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) A549 cells after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) A549 cells after 48 hr by MTT assay	10.1007/s00044-011-9884-x
A549	GI₅₀	< 1 μM Compound: DOX	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	[PMID: 31990554]
A549	IC₅₀	< 1 μM Compound: doxorubicin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 33847126]
A549	IC₅₀	> 100 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 33340938]
A549	ED₅₀	0.001 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 19783438]
A549	ED₅₀	0.001 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells by sulforhodamine B method Cytotoxicity against human A549 cells by sulforhodamine B method	[PMID: 12193011]
A549	IC₅₀	0.001 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 22951040]
A549	IC₅₀	0.0014 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by sulforhodamine B bioassay Cytotoxicity against human A549 cells by sulforhodamine B bioassay	[PMID: 25098650]
A549	IC₅₀	0.002 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 25981688]
A549	IC₅₀	0.002 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 25466198]
A549	IC₅₀	0.002 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 22483395]
A549	GI₅₀	0.003 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells by SRB assay Antiproliferative activity against human A549 cells by SRB assay	[PMID: 19394218]
A549	IC₅₀	0.004 μM Compound: Doxorubicin	Inhibitory activity against A549 cell line using MTT assay(Wild type p53) Inhibitory activity against A549 cell line using MTT assay(Wild type p53)	[PMID: 10780913]
A549	ED₅₀	0.0043 μg/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 10514307]
A549	ED₅₀	0.00622 μg/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 11087592]
A549	GI₅₀	0.007 μM Compound: Adriamycin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 19405508]
A549	IC₅₀	0.007 μM Compound: doxorubicin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 19435339]
A549	ED₅₀	0.007 μM Compound: doxorubicin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 18314958]
A549	IC₅₀	0.009 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 27010926]
A549	ED₅₀	0.01 μg/mL Compound: doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 15921415]
A549	IC₅₀	0.01 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells by sulforhodamine B assay Cytotoxicity against human A549 cells by sulforhodamine B assay	[PMID: 21684168]
A549	IC₅₀	0.01 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 20719504]
A549	ED₅₀	0.012 μg/mL Compound: doxorubicin	Cytotoxicity against human A549 cells by SRB method Cytotoxicity against human A549 cells by SRB method	[PMID: 16252909]
A549	IC₅₀	0.015 μM Compound: DOX	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27668963]
A549	GI₅₀	0.016 μM Compound: Doxorubicin	Cytostatic activity against human A549 cells after 5 days by SRB assay Cytostatic activity against human A549 cells after 5 days by SRB assay	[PMID: 21711054]
A549	ED₅₀	0.02 μg/mL Compound: doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 15730260]
A549	ED₅₀	0.02 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 11325244]
A549	IC₅₀	0.02 μg/mL Compound: doxorubicin	Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time	[PMID: 8496904]
A549	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as growth inhibition by SRB assay Cytotoxicity against human A549 cells assessed as growth inhibition by SRB assay	[PMID: 23634786]
A549	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by sulforhodamine B assay Cytotoxicity against human A549 cells by sulforhodamine B assay	[PMID: 23815260]
A549	IC₅₀	0.02 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	[PMID: 25937235]
A549	IC₅₀	0.02 μM Compound: 2	Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation	10.1016/S0960-894X(97)10122-6
A549	IC₅₀	0.021 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay Cytotoxicity against human A549 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay	[PMID: 27856237]
A549	IC₅₀	0.021 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 20594848]
A549	IC₅₀	0.022 μM Compound: doxorubicin	Cytotoxicity against human A549 cells after 3 days by SRB assay Cytotoxicity against human A549 cells after 3 days by SRB assay	[PMID: 18321715]
A549	IC₅₀	0.025 μg/mL Compound: ADR	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 18590312]
A549	IC₅₀	0.025 μM Compound: adriamycin	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 19028425]
A549	ED₅₀	0.03 μg/mL Compound: Adriamycin	Cytotoxicity against human A549 cells after 24 hrs by SRB assay Cytotoxicity against human A549 cells after 24 hrs by SRB assay	[PMID: 20850305]
A549	IC₅₀	0.03 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	[PMID: 25937235]
A549	IC₅₀	0.031 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 24 hrs by SRB method Cytotoxicity against human A549 cells after 24 hrs by SRB method	[PMID: 18429610]
A549	GI₅₀	0.04 μg/mL Compound: adriamycin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 11000028]
A549	IC₅₀	0.04 μg/mL Compound: adriamycin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 15921426]
A549	IC₅₀	0.04 μg/mL Compound: doxorubicin	Anticancer activity against human A549 cells after 72 hrs by sulforhodamine B assay Anticancer activity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 19342127]
A549	IC₅₀	0.04 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by WST-8 assay Cytotoxicity against human A549 cells after 72 hrs by WST-8 assay	[PMID: 25534608]
A549	IC₅₀	0.04 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29275232]
A549	IC₅₀	0.04 μM Compound: DOX	Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 96 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 96 hrs by MTT assay	[PMID: 35255689]
A549	IC₅₀	0.049 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 23544451]
A549	ED₅₀	0.05 μg/mL Compound: adriamycin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	10.1021/np960188t
A549	IC₅₀	0.05 μg/mL Compound: doxorubicin	Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time	[PMID: 8496904]
A549	IC₅₀	0.056 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay	[PMID: 32755677]
A549	IC₅₀	0.057 μg/mL Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as inhibition of cell viability by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell viability by MTT assay	[PMID: 32223924]
A549	GI₅₀	0.06 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human A549/ATCC cells after 48 hrs by SRB assay Cytotoxicity against human A549/ATCC cells after 48 hrs by SRB assay	[PMID: 23871905]
A549	GI₅₀	0.06 μM Compound: Doxorubicin	Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
A549	GI₅₀	0.06 μM Compound: Doxorubicin	Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
A549	GI₅₀	0.062 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 20014800]
A549	GI₅₀	0.07 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 24158013]
A549	IC₅₀	0.074 μM Compound: DOX	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31999451]
A549	IC₅₀	0.075 μM Compound: Doxorubicin	Anticancer activity against human A549 cells by sulforhodamine B assay Anticancer activity against human A549 cells by sulforhodamine B assay	[PMID: 19819696]
A549	IC₅₀	0.08 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19361894]
A549	IC₅₀	0.08 μM Compound: DOX	Antiproliferative activity against human A549 cells after 72 hrs by SRB assay Antiproliferative activity against human A549 cells after 72 hrs by SRB assay	[PMID: 30106296]
A549	IC₅₀	0.09 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 27060757]
A549	IC₅₀	0.09 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) A549 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) A549 cells after 72 hr by MTT assay	10.1007/s00044-010-9517-9
A549	IC₅₀	0.09 μM Compound: Dox	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 34116381]
A549	IC₅₀	0.092 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells incubated for 72 hrs by sulforhodamine B assay Antiproliferative activity against human A549 cells incubated for 72 hrs by sulforhodamine B assay	[PMID: 32432867]
A549	ED₅₀	0.1 μg/mL Compound: doxorubicin	Cytotoxicity against human A549 cells after 3 days by MTT assay Cytotoxicity against human A549 cells after 3 days by MTT assay	[PMID: 16252910]
A549	IC₅₀	0.1 μg/mL Compound: doxorubicin	Cytotoxicity against human A549 cells after 2 days by sulforhodamine B assay Cytotoxicity against human A549 cells after 2 days by sulforhodamine B assay	[PMID: 17067159]
A549	IC₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by CCK8 assay Cytotoxicity against human A549 cells after 72 hrs by CCK8 assay	[PMID: 28398051]
A549	IC₅₀	0.1 μM Compound: doxorubicin	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 24050254]
A549	IC₅₀	0.1 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 72 hrs by SRB assay Antiproliferative activity against human A549 cells after 72 hrs by SRB assay	[PMID: 18063366]
A549	GI₅₀	0.1 μM Compound: doxorubicin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 19007287]
A549	GI₅₀	0.1 μM Compound: doxorubicin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 17512741]
A549	IC₅₀	0.1 μM Compound: DOX	Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction) Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction)	10.1016/S0960-894X(01)81264-6
A549	IC₅₀	0.11 μM Compound: DOX	Cytotoxicity against human A549 cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human A549 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
A549	IC₅₀	0.118 μM Compound: Doxorubicin	Anticancer activity against human A549 cells after 48 hrs by SRB assay Anticancer activity against human A549 cells after 48 hrs by SRB assay	[PMID: 17070967]
A549	ED₅₀	0.12 μg/mL Compound: doxorubicin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 9392887]
A549	IC₅₀	0.12 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 27886545]
A549	IC₅₀	0.12 μM Compound: doxorubicin	Cytotoxicity against human A549 cells after 48 hrs Cytotoxicity against human A549 cells after 48 hrs	[PMID: 17673337]
A549	IC₅₀	0.124 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 25462279]
A549	IC₅₀	0.124 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 28139925]
A549	IC₅₀	0.13 μM Compound: Doxorubicin	Cytotoxicity activity against human A549 cells incubated for 48 hrs by SRB assay Cytotoxicity activity against human A549 cells incubated for 48 hrs by SRB assay	[PMID: 34119830]
A549	IC₅₀	0.13 μM Compound: DOX	Antiproliferative activity against human A549 cells after 48 hrs by SRB assay Antiproliferative activity against human A549 cells after 48 hrs by SRB assay	[PMID: 30106296]
A549	IC₅₀	0.14 μM Compound: Doxorubicin	Anticancer activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Anticancer activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 35694689]
A549	IC₅₀	0.14 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition incubated for 72 hrs by MTT assay	[PMID: 26280922]
A549	IC₅₀	0.14 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 26873414]
A549	GI₅₀	0.15 μM Compound: ADR	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 20673627]
A549	IC₅₀	0.15 μM Compound: doxorubicin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 17194596]
A549	IC₅₀	0.16 μM Compound: Adriamycin	Cytotoxicity against human A549 cells after 24 hrs by SRB assay Cytotoxicity against human A549 cells after 24 hrs by SRB assay	[PMID: 24370114]
A549	GI₅₀	0.16 μM Compound: Doxorubicin	Growth inhibition of human A549 cells after 72 hrs by SRB assay Growth inhibition of human A549 cells after 72 hrs by SRB assay	[PMID: 18585035]
A549	IC₅₀	0.16 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 20176479]
A549	IC₅₀	0.17 μM Compound: doxorubicin	Cytotoxicity against human A549 cells after 6 days by MTT method Cytotoxicity against human A549 cells after 6 days by MTT method	[PMID: 16309317]
A549	IC₅₀	0.17 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 30902399]
A549	IC₅₀	0.17 μM Compound: Adriamycin	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 20593838]
A549	IC₅₀	0.18 μM Compound: doxorubicin	Cytotoxicity against human A549 cells by SRB microtiter plate assay Cytotoxicity against human A549 cells by SRB microtiter plate assay	[PMID: 17585747]
A549	IC₅₀	0.19 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells after 3 days by MTT assay Cytotoxicity against human A549 cells after 3 days by MTT assay	[PMID: 15387653]
A549	IC₅₀	0.19 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 24 hrs by XTT assay Cytotoxicity against human A549 cells after 24 hrs by XTT assay	[PMID: 27227682]
A549	IC₅₀	0.2 μg/mL Compound: doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 18973388]
A549	IC₅₀	0.2 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT colorimetric method Cytotoxicity against human A549 cells by MTT colorimetric method	[PMID: 17125220]
A549	IC₅₀	0.2 μM Compound: adriamycin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 17190442]
A549	GI₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 29112820]
A549	ED₅₀	0.21 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 17315955]
A549	IC₅₀	0.21 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 24 hrs by MTS assay Cytotoxicity against human A549 cells after 24 hrs by MTS assay	[PMID: 30289713]
A549	IC₅₀	0.22 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 96 hrs by MTT assay Cytotoxicity against human A549 cells after 96 hrs by MTT assay	[PMID: 24852278]
A549	IC₅₀	0.22 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells by MTT reduction assay Antiproliferative activity against human A549 cells by MTT reduction assay	[PMID: 33421712]
A549	IC₅₀	0.223 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells incubated for 24 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 24 hrs by MTT assay	[PMID: 29409753]
A549	IC₅₀	0.23 μM Compound: Doxo	Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay	[PMID: 27036521]
A549	IC₅₀	0.24 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells incubated for 48 hrs by WST8 assay Antiproliferative activity against human A549 cells incubated for 48 hrs by WST8 assay	[PMID: 31679979]
A549	IC₅₀	0.258 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 25019480]
A549	IC₅₀	0.27 μg/mL Compound: Doxorubicin	Cytotoxic activity against human A549 cells by MTT assay Cytotoxic activity against human A549 cells by MTT assay	[PMID: 28366267]
A549	GI₅₀	0.27 μM Compound: Doxorubicin	Antiproliferative activity against human A549 assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human A549 assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 21875046]
A549	IC₅₀	0.29 μM Compound: DOX	Antiproliferative activity against cis-platinum-resistant human A549 cells after 48 hrs by SRB method Antiproliferative activity against cis-platinum-resistant human A549 cells after 48 hrs by SRB method	[PMID: 25061803]
A549	IC₅₀	0.29 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by XTT assay Cytotoxicity against human A549 cells after 72 hrs by XTT assay	[PMID: 19647439]
A549	IC₅₀	0.32 μM Compound: DOX	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 25737400]
A549	IC₅₀	0.33 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 20732814]
A549	IC₅₀	0.33 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 26496013]
A549	IC₅₀	0.34 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30389295]
A549	IC₅₀	0.34 μM Compound: doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 21174408]
A549	IC₅₀	0.35 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells after 3 days by MTT assay Cytotoxicity against human A549 cells after 3 days by MTT assay	[PMID: 19691312]
A549	IC₅₀	0.35 μM Compound: Doxorubicin	Anticancer activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay Anticancer activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay	[PMID: 33940466]
A549	IC₅₀	0.36 μM Compound: Doxorubicin	Anticancer activity against human A549 cells after 48 hrs by MTT assay Anticancer activity against human A549 cells after 48 hrs by MTT assay	[PMID: 21641694]
A549	IC₅₀	0.36 μM Compound: Doxorubucin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 20718475]
A549	IC₅₀	0.36 μM Compound: doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by MTT colorimetric method Cytotoxicity against human A549 cells after 72 hrs by MTT colorimetric method	[PMID: 17622129]
A549	IC₅₀	0.37 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 26397393]
A549	IC₅₀	0.37 μM Compound: DOX	Cytotoxicity against human A549 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay	[PMID: 35612499]
A549	IC₅₀	0.38 μg/mL Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) A549 cells assessed as survival after 3 days by crystal violet staining Cytotoxicity against Homo sapiens (human) A549 cells assessed as survival after 3 days by crystal violet staining	10.1007/s00044-012-0025-y
A549	IC₅₀	0.39 μg/mL Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) A549 cells after 3 days by MTT assay Cytotoxicity against Homo sapiens (human) A549 cells after 3 days by MTT assay	10.1007/s00044-011-9903-y
A549	IC₅₀	0.4 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 16724859]
A549	IC₅₀	0.4 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by Alamar Blue assay Cytotoxicity against human A549 cells by Alamar Blue assay	[PMID: 27536968]
A549	IC₅₀	0.4 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by CCK8 assay Cytotoxicity against human A549 cells after 72 hrs by CCK8 assay	[PMID: 30869892]
A549	IC₅₀	0.4 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 3 days by MTT assay Cytotoxicity against human A549 cells after 3 days by MTT assay	[PMID: 18547115]
A549	IC₅₀	0.4 μM Compound: doxorubicin	Cytotoxicity against human A549 cells after 4 days by MTT assay Cytotoxicity against human A549 cells after 4 days by MTT assay	[PMID: 19824618]
A549	IC₅₀	0.4 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 28927795]
A549	IC₅₀	0.4 μM Compound: Doxo	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 20334960]
A549	IC₅₀	0.41 μM Compound: Adriamycin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 23548547]
A549	IC₅₀	0.411 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 24231309]
A549	IC₅₀	0.414 μM Compound: Adriamycin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 25497963]
A549	IC₅₀	0.42 μg/mL Compound: doxo	Cytotoxicity against human A549 cells by MTT method Cytotoxicity against human A549 cells by MTT method	[PMID: 17417907]
A549	IC₅₀	0.42 μM Compound: DOX	Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 35818137]
A549	IC₅₀	0.43 μM Compound: DOX	Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay	[PMID: 29597166]
A549	IC₅₀	0.44 μM Compound: doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	10.1007/s00044-013-0777-z
A549	IC₅₀	0.44 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 25078311]
A549	IC₅₀	0.44 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 24836071]
A549	IC₅₀	0.45 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as cell viability after 48 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 26947606]
A549	IC₅₀	0.459 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 2 days by MTT assay Cytotoxicity against human A549 cells after 2 days by MTT assay	[PMID: 23932340]
A549	IC₅₀	0.459 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 24287557]
A549	IC₅₀	0.46 μM Compound: Doxorubicin	In vitro cytotoxicity against human A549 cells assessed as growth inhibition by MTT assay In vitro cytotoxicity against human A549 cells assessed as growth inhibition by MTT assay	[PMID: 24742385]
A549	IC₅₀	0.47 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31704206]
A549	IC₅₀	0.477 μM Compound: Dox	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 21983438]
A549	IC₅₀	0.477 μM Compound: Doxorubicin	Anticancer activity against human A549 cells by MTT assay Anticancer activity against human A549 cells by MTT assay	[PMID: 21570750]
A549	IC₅₀	0.477 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay	10.1039/C0MD00219D
A549	IC₅₀	0.48 μM Compound: DOX	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 31671309]
A549	IC₅₀	0.48 μM Compound: DOX	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay	[PMID: 30576904]
A549	IC₅₀	0.48 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay	[PMID: 30253344]
A549	IC₅₀	0.48 μM Compound: DOX	Antiproliferative activity against human A549 cells after 24 hrs by SRB assay Antiproliferative activity against human A549 cells after 24 hrs by SRB assay	[PMID: 30106296]
A549	IC₅₀	0.5 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 35526504]
A549	IC₅₀	0.5 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay	[PMID: 31148449]
A549	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27015002]
A549	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as growth inhibition by SRB assay Cytotoxicity against human A549 cells assessed as growth inhibition by SRB assay	[PMID: 23664877]
A549	IC₅₀	0.51 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 21708464]
A549	IC₅₀	0.51 μM Compound: Adriamycin	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26356746]
A549	IC₅₀	0.52 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 18590313]
A549	IC₅₀	0.52 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 21071221]
A549	IC₅₀	0.53 μM Compound: Doxorubicin	Cytotoxicity in human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity in human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 28923382]
A549	IC₅₀	0.54 μg/mL Compound: Doxorubicin	Anticancer activity against human A549 cells by MTT assay Anticancer activity against human A549 cells by MTT assay	[PMID: 31404864]
A549	IC₅₀	0.54 μM Compound: Adriamycin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 23434227]
A549	IC₅₀	0.55 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay	[PMID: 28159416]
A549	IC₅₀	0.55 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by Alamar blue assay Cytotoxicity against human A549 cells by Alamar blue assay	[PMID: 27256910]
A549	IC₅₀	0.55 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 30654238]
A549	IC₅₀	0.55 μM Compound: Dox	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30615450]
A549	IC₅₀	0.56 μM Compound: ADM	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 23639650]
A549	IC₅₀	0.58 μM Compound: DOX	Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 31820976]
A549	IC₅₀	0.59 μM Compound: Doxo	Cytotoxicity against human A549 cells after 3 days by MTT assay Cytotoxicity against human A549 cells after 3 days by MTT assay	[PMID: 21800859]
A549	IC₅₀	0.59 μM Compound: DOX	Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 33276990]
A549	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay	[PMID: 36693198]
A549	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29702447]
A549	GI₅₀	0.6 μM Compound: Dox	Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]
A549	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 29975532]
A549	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 25172418]
A549	IC₅₀	0.63 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 21106454]
A549	IC₅₀	0.63 μM Compound: DOX	Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 assay	[PMID: 29614418]
A549	IC₅₀	0.63 μM Compound: Dox	Cytotoxicity activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30031974]
A549	IC₅₀	0.63 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 31884407]
A549	GI₅₀	0.66 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 21885166]
A549	IC₅₀	0.665 μg/mL Compound: E; DOX	Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay	[PMID: 35963130]
A549	IC₅₀	0.69 μM Compound: adriamycin	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 26295905]
A549	IC₅₀	0.69 μM Compound: ADM	Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay	[PMID: 25089733]
A549	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay	[PMID: 32324401]
A549	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) A549 cells assessed as inhibition of cell growth after 3 days by MTT assay Cytotoxicity against Homo sapiens (human) A549 cells assessed as inhibition of cell growth after 3 days by MTT assay	10.1007/s00044-012-0402-6
A549	IC₅₀	0.7 μM Compound: Dox	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 28865276]
A549	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) A549 cells by MTT assay Cytotoxicity against Homo sapiens (human) A549 cells by MTT assay	10.1007/s00044-012-0370-x
A549	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 24300737]
A549	IC₅₀	0.7 μM Compound: Doxorubicine	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 22014995]
A549	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay Cytotoxicity against human A549 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay	[PMID: 36970146]
A549	IC₅₀	0.72 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19406535]
A549	IC₅₀	0.72 μM Compound: Adriamycin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 22070654]
A549	IC₅₀	0.73 μM Compound: Doxo	Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay	10.1039/C2MD20302B
A549	IC₅₀	0.73 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]
A549	IC₅₀	0.74 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 46 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 46 hrs by MTT assay	[PMID: 29138027]
A549	IC₅₀	0.74 μM Compound: doxorubicin	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 23806110]
A549	IC₅₀	0.75 μM Compound: adriamycin	Cytotoxicity against human A549 cells after 48 hrs Cytotoxicity against human A549 cells after 48 hrs	[PMID: 17583953]
A549	IC₅₀	0.76 μM Compound: Dox	Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 27397495]
A549	IC₅₀	0.766 μM Compound: Dox	Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 30599418]
A549	IC₅₀	0.79 μg/mL Compound: doxorubicin	Cytotoxicity against human A549 cells after 3 days by MTT assay Cytotoxicity against human A549 cells after 3 days by MTT assay	[PMID: 16252914]
A549	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 26252628]
A549	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 24780595]
A549	IC₅₀	0.8 μM Compound: Dox	Cytotoxicity against human A549 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 24507927]
A549	IC₅₀	0.8 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 30679134]
A549	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26551342]
A549	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 21035234]
A549	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay	[PMID: 26774921]
A549	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay	[PMID: 26646219]
A549	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 25241926]
A549	IC₅₀	0.8 μM Compound: ADM	Cytotoxicity against human A549 cells by SRB method Cytotoxicity against human A549 cells by SRB method	[PMID: 29144133]
A549	IC₅₀	0.8 μM Compound: ADM	Cytotoxic activity against human A549 cells by SRB method Cytotoxic activity against human A549 cells by SRB method	[PMID: 25611519]
A549	IC₅₀	0.82 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay	[PMID: 31404864]
A549	IC₅₀	0.837 μM Compound: doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19860383]
A549	IC₅₀	0.84 μM Compound: Doxorubicin	Antitumor activity against Homo sapiens (human) A549 cells assessed as cell growth inhibition after 48 hr by MTT assay Antitumor activity against Homo sapiens (human) A549 cells assessed as cell growth inhibition after 48 hr by MTT assay	10.1007/s00044-013-0497-4
A549	IC₅₀	0.84 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19689125]
A549	IC₅₀	0.86 μM Compound: doxorubicin	Cytotoxicity against human A549 cells after 3 days by MTT assay Cytotoxicity against human A549 cells after 3 days by MTT assay	[PMID: 18419154]
A549	IC₅₀	0.86 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by WST-8 assay Cytotoxicity against human A549 cells by WST-8 assay	[PMID: 29295796]
A549	IC₅₀	0.87 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 25419616]
A549	IC₅₀	0.89 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 4 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 4 hrs by MTT assay	[PMID: 30773423]
A549	IC₅₀	0.89 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 28554092]
A549	IC₅₀	0.9 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	10.1039/C3MD00166K
A549	IC₅₀	0.9 μM Compound: DOX	Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay	[PMID: 34323485]
A549	EC₅₀	0.9 μM Compound: doxorubicin	Cytotoxicity against human A549 cells after 72 hrs Cytotoxicity against human A549 cells after 72 hrs	[PMID: 17378530]
A549	IC₅₀	0.91 μM Compound: Dox	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 35339100]
A549	IC₅₀	0.95 μM Compound: DOXO	Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by alamar blue assay Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by alamar blue assay	[PMID: 21797280]
A549	IC₅₀	0.95 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by Alamar blue assay Cytotoxicity against human A549 cells after 48 hrs by Alamar blue assay	[PMID: 20931970]
A549	IC₅₀	0.95 μM Compound: DOX	Antiproliferative activity against human A549 cells assessed as reduction in cell growth measured after 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell growth measured after 72 hrs by CCK8 assay	[PMID: 31784322]
A549	IC₅₀	0.95 μM Compound: DOX	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27016707]
A549	IC₅₀	0.96 μM Compound: Doxorubicin	Anticancer activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Anticancer activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 32438251]
A549	GI₅₀	0.97 μM Compound: Dox	Anticancer activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Anticancer activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35533562]
A549	IC₅₀	0.97 μM Compound: Doxorubicin	Cytotoxicity activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32531682]
A549	IC₅₀	0.97 μM Compound: doxorubicin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 17827007]
A549	IC₅₀	0.97 μM Compound: Doxorubicin	Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay. Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.	[PMID: 14643344]
A549	IC₅₀	0.98 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 25747499]
A549	IC₅₀	1 μM Compound: DOX	Antiproliferative activity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 22044164]
A549	IC₅₀	1 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay	[PMID: 32915576]
A549	IC₅₀	1 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 23079527]
A549	IC₅₀	1 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 21996519]
A549	IC₅₀	1 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 24 hrs by BrdU incorporation assay Antiproliferative activity against human A549 cells after 24 hrs by BrdU incorporation assay	[PMID: 27555286]
A549	ED₅₀	1.01 ng/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 8676130]
A549	ED₅₀	1.01 x 10^-2 μg/mL Compound: Adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 7673926]
A549	IC₅₀	1.01 μM Compound: Doxorubicin	Anticancer activity against human A549 cells assessed as growth inhibition incubated for 48 hrs by MTT assay Anticancer activity against human A549 cells assessed as growth inhibition incubated for 48 hrs by MTT assay	[PMID: 34363936]
A549	IC₅₀	1.02 μM Compound: Dox	Anticancer activity against human A549 cells after 48 hrs by MTT assay Anticancer activity against human A549 cells after 48 hrs by MTT assay	[PMID: 22209733]
A549	IC₅₀	1.05 μM Compound: DOX	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35341920]
A549	IC₅₀	1.06 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 31962262]
A549	IC₅₀	1.06 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 26708114]
A549	IC₅₀	1.07 μM Compound: DOX	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 31057738]
A549	ED₅₀	1.1 ng/mL Compound: Adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 7714532]
A549	ED₅₀	1.1 ng/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days Cytotoxicity against human A549 cells after 7 days	[PMID: 8021648]
A549	IC₅₀	1.1 μM Compound: Doxorubicin	Anticancer activity against human A549 cells by MTT assay Anticancer activity against human A549 cells by MTT assay	10.1039/C4MD00219A
A549	GI₅₀	1.1 μM Compound: Dox	Antiproliferative activity against human A549 cells incubated for 72 hrs and measured by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs and measured by MTT assay	[PMID: 35973342]
A549	IC₅₀	1.11 μM Compound: DOX	Cytotoxicity against human A549 cells after 48 hrs by SRB method Cytotoxicity against human A549 cells after 48 hrs by SRB method	[PMID: 25933593]
A549	ED₅₀	1.13 ng/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 11325235]
A549	IC₅₀	1.15 μM Compound: ADM	Antiproliferative activity against human A549 cells overexpressing NQO1 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells overexpressing NQO1 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35803175]
A549	IC₅₀	1.18 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 22472043]
A549	IC₅₀	1.2 μg/mL Compound: Adriamycin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 17918910]
A549	IC₅₀	1.2 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells measured after 48 hrs in presence of NQO1 inhibitor dicoumarol by MTT assay Antiproliferative activity against human A549 cells measured after 48 hrs in presence of NQO1 inhibitor dicoumarol by MTT assay	[PMID: 32682198]
A549	IC₅₀	1.2 μM Compound: doxorubicin	Cytotoxicity against human A549 cells by SRB protein staining method Cytotoxicity against human A549 cells by SRB protein staining method	[PMID: 25781655]
A549	GI₅₀	1.21 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as growth inhibition incubated for 48 hrs by MTT assay	[PMID: 31128433]
A549	IC₅₀	1.21 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 31108261]
A549	IC₅₀	1.21 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 25172420]
A549	IC₅₀	1.21 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 24113366]
A549	IC₅₀	1.21 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 23911578]
A549	IC₅₀	1.21 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 23764302]
A549	IC₅₀	1.28 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 25703298]
A549	ED₅₀	1.3 ng/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 10395501]
A549	IC₅₀	1.3 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 24 hrs by WST assay Cytotoxicity against human A549 cells after 24 hrs by WST assay	[PMID: 25881821]
A549	IC₅₀	1.303 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 29501940]
A549	IC₅₀	1.32 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay	[PMID: 32682198]
A549	IC₅₀	1.4 μg/mL Compound: doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 22413887]
A549	IC₅₀	1.4 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 29035560]
A549	IC₅₀	1.43 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31546197]
A549	IC₅₀	1.445 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28462842]
A549	ED₅₀	1.48 ng/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days Cytotoxicity against human A549 cells after 7 days	[PMID: 8201311]
A549	ED₅₀	1.48 ng/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days Cytotoxicity against human A549 cells after 7 days	[PMID: 1593281]
A549	IC₅₀	1.495 μM Compound: Doxorubicin	Cytotoxicity activity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
A549	IC₅₀	1.5 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 33421712]
A549	IC₅₀	1.5 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 25453799]
A549	IC₅₀	1.58 μM Compound: Doxorubicin	Anticancer activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Anticancer activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 26330077]
A549	IC₅₀	1.58 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 26264845]
A549	IC₅₀	1.6 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay	[PMID: 28818768]
A549	IC₅₀	1.65 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 24418772]
A549	IC₅₀	1.68 μM Compound: II	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 29289881]
A549	ED₅₀	1.7 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 9917277]
A549	IC₅₀	1.7 μM Compound: Doxorubicin	Growth inhibition of human A549 cells by MTT assay Growth inhibition of human A549 cells by MTT assay	[PMID: 28916158]
A549	IC₅₀	1.778 μM Compound: Doxorubicin	Anti-proliferative activity against human A549 cells measured after 48 hrs by MTT assay Anti-proliferative activity against human A549 cells measured after 48 hrs by MTT assay	[PMID: 27744185]
A549	ED₅₀	1.78 ng/mL Compound: Adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 8946743]
A549	IC₅₀	1.78 μM Compound: Doxorubicin	Cytotoxic activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxic activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 25966052]
A549	IC₅₀	1.79 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 35339645]
A549	IC₅₀	1.86 μM Compound: Doxo	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 29129513]
A549	IC₅₀	1.88 μM Compound: Dox	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	10.1007/s00044-013-0584-6
A549	IC₅₀	1.9 μM Compound: DOX	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32631552]
A549	IC₅₀	1.9 μM Compound: Doxorubicin	Anticancer activity against human A549 cells after 48 hrs by MTT assay Anticancer activity against human A549 cells after 48 hrs by MTT assay	[PMID: 25615796]
A549	IC₅₀	1.9 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 19632833]
A549	IC₅₀	1.9 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as cell viability after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24012378]
A549	IC₅₀	1.9 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19394829]
A549	GI₅₀	1.9 μM Compound: Doxorubicin	Anti-proliferative activity against human A549 cells incubated for 48 hrs by SRB assay Anti-proliferative activity against human A549 cells incubated for 48 hrs by SRB assay	[PMID: 26163220]
A549	ED₅₀	1.91 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 9599260]
A549	IC₅₀	1.945 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28482219]
A549	IC₅₀	1.986 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 26301558]
A549	IC₅₀	1.99 μM Compound: Doxorubicin	Cytotoxicity against human lung carcinoma A549 cell line using MTT assay Cytotoxicity against human lung carcinoma A549 cell line using MTT assay	[PMID: 9873387]
A549	IC₅₀	10.2 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 28886509]
A549	IC₅₀	10.28 μM Compound: Dox	Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 35635947]
A549	CC₅₀	10.5 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 29792325]
A549	IC₅₀	10.55 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	10.1039/C3MD00013C
A549	IC₅₀	10.76 μM Compound: Dox	Cytotoxicity against human A549 cells assessed as cell viability measured after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability measured after 24 hrs by MTT assay	[PMID: 33183865]
A549	IC₅₀	10.83 μM Compound: DOX	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 36463726]
A549	IC₅₀	11 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 28919340]
A549	IC₅₀	11.62 μM Compound: Dox	Cytotoxicity against human A549 cells assessed as decrease in cell viability treated for 2 hrs measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as decrease in cell viability treated for 2 hrs measured after 48 hrs by MTT assay	[PMID: 28129977]
A549	GI₅₀	13.01 μM Compound: ADR	Anticancer activity against human A549 cells by SRB method Anticancer activity against human A549 cells by SRB method	[PMID: 22104151]
A549	IC₅₀	13.6 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 24681979]
A549	IC₅₀	14 μM Compound: Doxo	Cytotoxicity against human A549 cells after 48 hrs by alamar blue assay Cytotoxicity against human A549 cells after 48 hrs by alamar blue assay	[PMID: 25468043]
A549	IC₅₀	14.7 nM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay	[PMID: 31655432]
A549	IC₅₀	140 nM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay	[PMID: 35213166]
A549	IC₅₀	149 nM Compound: DX	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay	[PMID: 34592435]
A549	IC₅₀	15.07 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	10.1039/C2MD20023F
A549	IC₅₀	15.07 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 22386528]
A549	ED₅₀	152 μM Compound: doxorubicin	Antitumor activity against human A549 cells after 24 hrs by MTT assay Antitumor activity against human A549 cells after 24 hrs by MTT assay	[PMID: 17482824]
A549	IC₅₀	17 μM Compound: Doxorubicin	Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34838335]
A549	IC₅₀	172 nM Compound: DX	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay	[PMID: 33611191]
A549	IC₅₀	18.56 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28262524]
A549	IC₅₀	190 nM Compound: DX	Antiproliferative activity against human A549 cells assessed as inhibition of proliferation after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of proliferation after 72 hrs by SRB assay	[PMID: 34116158]
A549	ED₅₀	2 ng/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 8882437]
A549	IC₅₀	2.04 μM Compound: DOX	Cytotoxicity against against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30340899]
A549	IC₅₀	2.1 μM Compound: Doxo (I)	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	10.1039/C4MD00228H
A549	IC₅₀	2.1 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition by MTT assay	[PMID: 34838335]
A549	IC₅₀	2.1 μM Compound: Dox	Antiproliferative activity against human A549 cells assessed as reduction in cell viability by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability by MTT assay	[PMID: 31765156]
A549	IC₅₀	2.12 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as cell viability after 24 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 26874744]
A549	IC₅₀	2.12 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 25462233]
A549	IC₅₀	2.17 μM Compound: DOX	Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 27149641]
A549	IC₅₀	2.18 μM Compound: Doxorubicin	Anticancer activity against human A549 cells after 48 hrs by MTT assay Anticancer activity against human A549 cells after 48 hrs by MTT assay	[PMID: 22136907]
A549	IC₅₀	2.2 ng/mL Compound: Adriamycin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 9644064]
A549	IC₅₀	2.2 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 21425785]
A549	IC₅₀	2.2 μM Compound: adriamycin	Cytotoxicity against human A549 cells by rapid colorimetric assay Cytotoxicity against human A549 cells by rapid colorimetric assay	[PMID: 19585998]
A549	IC₅₀	2.23 μM Compound: DOX	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	[PMID: 20171108]
A549	IC₅₀	2.3 μM Compound: DOX	Inhibition of topoisomerase 2 in human A549 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Inhibition of topoisomerase 2 in human A549 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 30846253]
A549	IC₅₀	2.3 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29789258]
A549	IC₅₀	2.31 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 33352388]
A549	IC₅₀	2.34 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 26948541]
A549	ED₅₀	2.43 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 8904848]
A549	IC₅₀	2.48 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 24 hrs by MTT assay Antiproliferative activity against human A549 cells after 24 hrs by MTT assay	10.1039/C5MD00581G
A549	IC₅₀	2.58 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31883489]
A549	IC₅₀	2.6 x 10^-1 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by XTT assay Cytotoxicity against human A549 cells after 72 hrs by XTT assay	[PMID: 20619940]
A549	IC₅₀	2.6 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 25300819]
A549	IC₅₀	2.67 μM Compound: DOX	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs	[PMID: 32736079]
A549	IC₅₀	2.7 μM Compound: Adriamycin	Cytotoxicity against human A549 cells by MTT colorimetric method Cytotoxicity against human A549 cells by MTT colorimetric method	[PMID: 23043498]
A549	IC₅₀	2.8 μM Compound: Adriamycin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 22647719]
A549	IC₅₀	2.8 μM Compound: Adriamycin	Growth inhibition of human A549 cells by MTT assay Growth inhibition of human A549 cells by MTT assay	[PMID: 21721519]
A549	IC₅₀	2.81 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 27015609]
A549	IC₅₀	2.905 μM Compound: DOX	Growth inhibition of human A549 cells after 48 hrs by MTT assay Growth inhibition of human A549 cells after 48 hrs by MTT assay	[PMID: 29509413]
A549	ED₅₀	2.94 ng/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 9584396]
A549	ED₅₀	2.94 ng/mL Compound: Adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 7673936]
A549	IC₅₀	22 nM Compound: doxorubicin	Tested for inhibitory activity against human tumor cell line A549 (a non small, drug resistant cell line that does not produce P-glycoprotein) of lung carcinoma using sulforhodamine B assay. Tested for inhibitory activity against human tumor cell line A549 (a non small, drug resistant cell line that does not produce P-glycoprotein) of lung carcinoma using sulforhodamine B assay.	[PMID: 10956214]
A549	IC₅₀	228.2 nM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29886322]
A549	IC₅₀	24.27 μM Compound: DOX	Cytotoxicity against Homo sapiens (human) A549 cells assessed as growth inhibition after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) A549 cells assessed as growth inhibition after 48 hr by MTT assay	10.1007/s00044-012-0018-x
A549	IC₅₀	258 nM Compound: DOX; DX	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 120 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 120 hrs by MTT assay	[PMID: 31653441]
A549	IC₅₀	258 nM Compound: Doxorubicin	Antiproliferative activity against human A549 cells incubated for 72 hrs by SRB assay Antiproliferative activity against human A549 cells incubated for 72 hrs by SRB assay	[PMID: 33465696]
A549	IC₅₀	26.81 μM Compound: DOX	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 25912674]
A549	IC₅₀	3 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability by DAPI staining based assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by DAPI staining based assay	[PMID: 33461146]
A549	IC₅₀	3.03 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25594739]
A549	IC₅₀	3.08 μM Compound: DOX	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32996316]
A549	ED₅₀	3.1 x 10^-4 μg/mL Compound: Adriamycin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 7714533]
A549	IC₅₀	3.118 μg/mL Compound: ADM	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 25862199]
A549	IC₅₀	3.13 μM Compound: Dox	Antiproliferative activity against human A549 cells after 72 hrs by cell titer glo assay Antiproliferative activity against human A549 cells after 72 hrs by cell titer glo assay	[PMID: 24161704]
A549	IC₅₀	3.13 μM Compound: Doxo	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 25563891]
A549	IC₅₀	3.14 μM Compound: DOX	Cytotoxicity against human A549/CDDP cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549/CDDP cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 27149641]
A549	IC₅₀	3.16 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30500683]
A549	IC₅₀	3.19 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 33148490]
A549	IC₅₀	3.2 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	10.1039/C4MD00566J
A549	IC₅₀	3.24 μM Compound: DOX	Antiproliferative activity against human A549 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition by MTT assay	[PMID: 32631524]
A549	IC₅₀	3.28 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 22542958]
A549	IC₅₀	3.3 μM Compound: Dox	Cytotoxicity against human A549 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 27055942]
A549	IC₅₀	3.3 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	[PMID: 31546197]
A549	IC₅₀	3.35 μM Compound: DOX	Antineoplastic activity against human A549 cells measured after 36 hrs by MTT assay Antineoplastic activity against human A549 cells measured after 36 hrs by MTT assay	[PMID: 30746067]
A549	IC₅₀	3.4 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 25453802]
A549	IC₅₀	3.4 μM Compound: DOX	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30398868]
A549	ED₅₀	3.41 ng/mL Compound: Adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 7494147]
A549	IC₅₀	3.41 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by CCK8 assay Cytotoxicity against human A549 cells by CCK8 assay	[PMID: 29452840]
A549	ED₅₀	3.56 ng/mL Compound: Adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 7673935]
A549	ED₅₀	3.56 ng/mL Compound: Adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 7494150]
A549	IC₅₀	3.6 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 94 hrs by MTT assay Cytotoxicity against human A549 cells after 94 hrs by MTT assay	[PMID: 21868138]
A549	ED₅₀	3.67 ng/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 9599253]
A549	IC₅₀	3.69 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 22472043]
A549	ED₅₀	3.93 ng/mL Compound: Adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 9322367]
A549	IC₅₀	3.97 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31404864]
A549	IC₅₀	3.98 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	10.1007/s00044-013-0784-0
A549	IC₅₀	4 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 23792352]
A549	IC₅₀	4 μM Compound: doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 23748152]
A549	IC₅₀	4.11 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 24095746]
A549	IC₅₀	4.36 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 48 hrs by SRB assay Antiproliferative activity against human A549 cells after 48 hrs by SRB assay	[PMID: 30503942]
A549	ED₅₀	4.47 ng/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	10.1021/np970510f
A549	IC₅₀	4.91 μM Compound: DOX	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 6 days by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 6 days by MTT assay	[PMID: 32653698]
A549	IC₅₀	4.91 μM Compound: DOX	Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay	[PMID: 30746062]
A549	IC₅₀	4.91 μM Compound: DOX	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28427016]
A549	IC₅₀	4.91 μM Compound: DOX	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 28135634]
A549	IC₅₀	4.91 μM Compound: Dox	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27231128]
A549	IC₅₀	4.91 μM Compound: DOX	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 26720155]
A549	ED₅₀	4.99 ng/mL Compound: adr	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 9461654]
A549	ED₅₀	4.99 ng/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 9014350]
A549	IC₅₀	426 nM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by XTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by XTT assay	[PMID: 29190084]
A549	IC₅₀	459 nM Compound: DOX	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 30878835]
A549	IC₅₀	5 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	[PMID: 29072457]
A549	ED₅₀	5.04 x 10^-4 μg/mL Compound: Adriamycin	Cytotoxicity against human A549 cells after 7 days Cytotoxicity against human A549 cells after 7 days	[PMID: 1453182]
A549	ED₅₀	5.06 ng/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 8882434]
A549	IC₅₀	5.1 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 27894044]
A549	IC₅₀	5.13 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 35367708]
A549	ED₅₀	5.3 ng/mL Compound: Adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 9214729]
A549	IC₅₀	5.3 μM Compound: DOX	Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 31589431]
A549	IC₅₀	5.32 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay	[PMID: 27476117]
A549	IC₅₀	5.5 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as reduction in cell viability preincubated for 24 hrs measured after 4 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability preincubated for 24 hrs measured after 4 hrs by MTT assay	[PMID: 34223162]
A549	IC₅₀	5.58 nM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as cell viability after 5 days by cell viability analyzer Cytotoxicity against human A549 cells assessed as cell viability after 5 days by cell viability analyzer	[PMID: 26291039]
A549	IC₅₀	5.93 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay	[PMID: 32311607]
A549	ED₅₀	59.5 nM Compound: doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 17655260]
A549	IC₅₀	6.13 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as cell viability by SRB assay Cytotoxicity against human A549 cells assessed as cell viability by SRB assay	[PMID: 26022842]
A549	ED₅₀	6.22 ng/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 days by MTT assay Cytotoxicity against human A549 cells after 7 days by MTT assay	[PMID: 15730242]
A549	IC₅₀	6.22 μM Compound: Doxo	Cytotoxicity against human A549 cells measured after 24 hrs by MTT assay Cytotoxicity against human A549 cells measured after 24 hrs by MTT assay	[PMID: 31104996]
A549	IC₅₀	6.61 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 22182926]
A549	IC₅₀	69.33 μM Compound: Doxorubicin	Anticancer activity against human A549 cells by MTT assay Anticancer activity against human A549 cells by MTT assay	[PMID: 25743216]
A549	IC₅₀	7.1 μM Compound: DX	Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay	10.1039/C5MD00513B
A549	GI₅₀	7.25 μM Compound: adriamycin	Cytotoxicity against human A549 cells after 24 hrs by SRB method Cytotoxicity against human A549 cells after 24 hrs by SRB method	[PMID: 18262426]
A549	GI₅₀	7.25 μM Compound: ADR	Growth inhibition of human A549 cells after 48 hrs by SRB assay Growth inhibition of human A549 cells after 48 hrs by SRB assay	[PMID: 20031423]
A549	GI₅₀	7.25 μM Compound: ADR	Growth inhibition of human A549 cells by SRB assay Growth inhibition of human A549 cells by SRB assay	[PMID: 22361684]
A549	GI₅₀	7.25 μM Compound: ADR	Anticancer activity against human A549 cells by SRB method Anticancer activity against human A549 cells by SRB method	[PMID: 21676506]
A549	GI₅₀	7.25 μM Compound: ADR, Adriamycin	Growth inhibition of human A549 cells by SRB method Growth inhibition of human A549 cells by SRB method	[PMID: 18207392]
A549	GI₅₀	7.25 μM Compound: ADR	Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 23849207]
A549	GI₅₀	7.25 μM Compound: ADR	Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 22364746]
A549	GI₅₀	7.25 μM Compound: ADR	Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 18657979]
A549	GI₅₀	7.25 μM Compound: ADR	Cytotoxicity against human A549 cells after 24 hrs by WST-1 assay Cytotoxicity against human A549 cells after 24 hrs by WST-1 assay	[PMID: 20732817]
A549	IC₅₀	7.47 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 24607876]
A549	IC₅₀	7.52 μM Compound: Dox	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 26494582]
A549	IC₅₀	7.86 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 30108986]
A549	IC₅₀	7.88 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 18440233]
A549	IC₅₀	740 nM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 30172625]
A549	IC₅₀	8.05 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 25140752]
A549	GI₅₀	8.14 μM Compound: Doxo	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 26513642]
A549	IC₅₀	8.5 μg/mL Compound: Doxorubicin	Cytotoxicity against human A549 cells incubated for 48 hrs by SRB assay Cytotoxicity against human A549 cells incubated for 48 hrs by SRB assay	[PMID: 26048808]
A549	IC₅₀	8.5 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 33766771]
A549	IC₅₀	8.73 μM Compound: Doxorubicin	Anticancer activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Anticancer activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 36439979]
A549	ED₅₀	9.2 ng/mL Compound: adriamycin	Cytotoxicity against human A549 cells after 7 hrs by MTT assay Cytotoxicity against human A549 cells after 7 hrs by MTT assay	[PMID: 7623031]
A549	IC₅₀	9.2 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 20846862]
A549	IC₅₀	9.5 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 35526504]
A549	IC₅₀	9.7 μM Compound: Doxorubicin	Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25655719]
A549	IC₅₀	90 μM Compound: Doxorubicin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CellTiter Glo assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CellTiter Glo assay	[PMID: 33016067]
A549/CDDP	IC₅₀	4.59 μM Compound: DOX	Growth inhibition of human A549/CDDP cells after 48 hrs by MTT assay Growth inhibition of human A549/CDDP cells after 48 hrs by MTT assay	[PMID: 29509413]
A673	IC₅₀	0.1 μM Compound: DOX	Cytotoxicity against human A673 cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human A673 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
A673	IC₅₀	0.17 μM Compound: Doxorubicin	Cytotoxicity against human A673 cells after 72 hrs by resazurin/resorufin-based fluorescence assay Cytotoxicity against human A673 cells after 72 hrs by resazurin/resorufin-based fluorescence assay	[PMID: 23600925]
A673	EC₅₀	0.39 μM Compound: Doxorubicin	Induction of apoptosis in human A673 cells assessed as caspase-3 activation after 24 hrs by luminescence assay Induction of apoptosis in human A673 cells assessed as caspase-3 activation after 24 hrs by luminescence assay	[PMID: 23600925]
A704	IC₅₀	2 μM Compound: Doxorubicin	Cytotoxicity against human A704 cells after 72 hrs by MTT assay Cytotoxicity against human A704 cells after 72 hrs by MTT assay	[PMID: 19406535]
ACHN	IC₅₀	0.001 μM Compound: doxo	Antiproliferative activity against human ACHN cell line by MTT assay Antiproliferative activity against human ACHN cell line by MTT assay	[PMID: 16913700]
ACHN	IC₅₀	0.02 μM Compound: Doxorubicin	Antiproliferative activity against human ACHN cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human ACHN cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 34851111]
ACHN	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human ACHN cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay Cytotoxicity against human ACHN cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay	[PMID: 28617598]
ACHN	IC₅₀	0.04 μM Compound: Doxo	Antiproliferative activity against human ACHN cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human ACHN cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
ACHN	IC₅₀	0.04 μM Compound: Doxorubicin	Antiproliferative activity against human ACHN cells after 96 hrs by MTT assay Antiproliferative activity against human ACHN cells after 96 hrs by MTT assay	[PMID: 19053767]
ACHN	GI₅₀	0.08 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human ACHN cells after 48 hrs by SRB assay Cytotoxicity against human ACHN cells after 48 hrs by SRB assay	[PMID: 23871905]
ACHN	GI₅₀	0.08 μM Compound: ADR	Cytotoxicity against human ACHN cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human ACHN cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 30253887]
ACHN	GI₅₀	0.08 μM Compound: ADR	Cytotoxicity against human ACHN cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Cytotoxicity against human ACHN cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 28870801]
ACHN	GI₅₀	0.08 μM Compound: Doxorubicin	Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
ACHN	GI₅₀	0.08 μM Compound: Doxorubicin	Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human ACHN cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
ACHN	GI₅₀	0.088 μM Compound: ADR	Anticancer activity against human ACNH cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method Anticancer activity against human ACNH cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method	[PMID: 34500188]
ACHN	GI₅₀	0.0995 μM Compound: ADR	Cytotoxicity against human ACHN cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human ACHN cells after 72 hrs by sulforhodamine B assay	[PMID: 27096046]
ACHN	GI₅₀	0.2 μM Compound: ADR	Cytotoxicity against human ACHN cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay Cytotoxicity against human ACHN cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay	[PMID: 25953156]
ACHN	GI₅₀	0.22 μM Compound: Doxorubicin	Anticancer activity against human ACHN cells by SRB assay Anticancer activity against human ACHN cells by SRB assay	[PMID: 20732810]
ACHN	GI₅₀	0.41 μM Compound: Doxorubicin	Cytotoxicity against human ACHN cells by SRB assay Cytotoxicity against human ACHN cells by SRB assay	[PMID: 19596579]
ACHN	IC₅₀	0.79 μM Compound: Doxorubicin	Anticancer activity against human ACHN cells after 48 hrs by MTT assay Anticancer activity against human ACHN cells after 48 hrs by MTT assay	[PMID: 22136907]
ACHN	GI₅₀	1.63 μM Compound: ADR	Antiproliferative activity against human ACHN cells by SRB method Antiproliferative activity against human ACHN cells by SRB method	[PMID: 24835787]
ACHN	GI₅₀	1.63 μM Compound: ADR	Antiproliferative activity against human ACHN cells by SRB assay Antiproliferative activity against human ACHN cells by SRB assay	[PMID: 22738641]
ACHN	IC₅₀	14.2 μM Compound: doxorubicin	Cytotoxicity against multidrug-resistant human ACHN cells after 72 hrs by fluorometric microculture cytotoxicity assay Cytotoxicity against multidrug-resistant human ACHN cells after 72 hrs by fluorometric microculture cytotoxicity assay	[PMID: 16562840]
ACHN	GI₅₀	2 μM Compound: Doxorubicin	Cytotoxicity against human ACHN cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human ACHN cells after 48 hrs by sulforhodamine B assay	[PMID: 23964644]
ACHN	IC₅₀	2.08 μg/mL Compound: Doxorubicin	Cytotoxicity against human ACHN cells by MTT assay Cytotoxicity against human ACHN cells by MTT assay	10.1039/C4MD00566J
ADR5000 cell line	IC₅₀	> 10 μM Compound: Doxo	Cytotoxicity against human CEM/ADR5000 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human CEM/ADR5000 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24484281]
ADR5000 cell line	IC₅₀	> 10 μM Compound: Doxorubicin	Cytotoxicity against human CEM/ADR5000 cells after 48 hrs by MTT assay Cytotoxicity against human CEM/ADR5000 cells after 48 hrs by MTT assay	[PMID: 32496057]
ADR5000 cell line	IC₅₀	> 5.2 μM Compound: Doxorubicin	Cytotoxicity against human CEM/ADR5000 by CCK-8 assay Cytotoxicity against human CEM/ADR5000 by CCK-8 assay	[PMID: 22884578]
ADR5000 cell line	IC₅₀	> 5.2 μM Compound: doxorubicin	Cytotoxicity against human CEM/ADR5000 by XTT assay Cytotoxicity against human CEM/ADR5000 by XTT assay	[PMID: 20527917]
ADR5000 cell line	IC₅₀	0.009 μM Compound: Doxorubicin	Antiproliferative activity against human CEM/ADR5000 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human CEM/ADR5000 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 27010926]
ADR5000 cell line	IC₅₀	1.61 μM Compound: Doxorubicin	Cytotoxicity against human CEM/ADR5000 cells assessed as cell viability after 72 hrs by resazurin assay Cytotoxicity against human CEM/ADR5000 cells assessed as cell viability after 72 hrs by resazurin assay	[PMID: 26260339]
ADR5000 cell line	IC₅₀	1.61 μM Compound: Doxorubicin	Cytotoxicity against human CEM/ADR5000 cells assessed as reduction in cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human CEM/ADR5000 cells assessed as reduction in cell viability after 72 hrs by resazurin reduction assay	[PMID: 28456567]
ADR5000 cell line	IC₅₀	122.96 μM Compound: Doxorubicin	Cytotoxicity against human CEM/ADR5000 cells assessed as reduction in cell viability after 72 hrs by RRA assay Cytotoxicity against human CEM/ADR5000 cells assessed as reduction in cell viability after 72 hrs by RRA assay	[PMID: 33508467]
ADR5000 cell line	IC₅₀	23.27 μM Compound: Doxorubicin	Cytotoxicity against human multidrug-resistant CEM/ADR5000 cells expressing p-glycoprotein by resazurin assay Cytotoxicity against human multidrug-resistant CEM/ADR5000 cells expressing p-glycoprotein by resazurin assay	[PMID: 24561670]
ADR5000 cell line	EC₅₀	23.27 μM Compound: Doxorubicin	Cytotoxicity against human CEM/ADR5000 cells overexpressing P-gp assessed as reduction in cell viability after 72 hrs by resazurin dye based assay Cytotoxicity against human CEM/ADR5000 cells overexpressing P-gp assessed as reduction in cell viability after 72 hrs by resazurin dye based assay	[PMID: 29937978]
ADR5000 cell line	IC₅₀	30.07 μM Compound: Doxorubicin	Growth inhibition of human multi-drug resistant CEM/ADR5000 cells by resazurin assay Growth inhibition of human multi-drug resistant CEM/ADR5000 cells by resazurin assay	[PMID: 28121440]
ADR5000 cell line	IC₅₀	30.07 μM Compound: Doxorubicin	Antileukemic activity against human CEM/ADR5000 cells after 24 to 48 hrs by resazurin dye based fluorescence assay Antileukemic activity against human CEM/ADR5000 cells after 24 to 48 hrs by resazurin dye based fluorescence assay	[PMID: 29560715]
ADR5000 cell line	IC₅₀	30.07 μM Compound: Doxorubicin	Cytotoxicity against human CEM/ADR5000 cells assessed as reduction in cell viability after 72 hrs by resazurin dye-based fluorescence assay Cytotoxicity against human CEM/ADR5000 cells assessed as reduction in cell viability after 72 hrs by resazurin dye-based fluorescence assay	[PMID: 32663024]
ADR5000 cell line	EC₅₀	41.54 μM Compound: Doxorubicin	Cytotoxicity against human CEM/ADR5000 cells over-expressing P-gp assessed as reduction in cell viability after 72 hrs by resazurin dye based assay Cytotoxicity against human CEM/ADR5000 cells over-expressing P-gp assessed as reduction in cell viability after 72 hrs by resazurin dye based assay	[PMID: 29887512]
AGS	GI₅₀	0.01 μM Compound: Doxorubicin	Antiproliferative activity against human AGS assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human AGS assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 21875046]
AGS	GI₅₀	0.02 μM Compound: Doxorubicin	Growth inhibition of Homo sapiens (human) AGS cells after 48 hr by MTT assay Growth inhibition of Homo sapiens (human) AGS cells after 48 hr by MTT assay	10.1007/s00044-012-0232-6
AGS	IC₅₀	0.31 μM Compound: adriamycin	Cytotoxicity against human AGS cells by MTT assay Cytotoxicity against human AGS cells by MTT assay	[PMID: 17125240]
AGS	IC₅₀	1.2 μM Compound: doxorubicin	Cytotoxicity against human AGS cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human AGS cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 23806110]
AGS	IC₅₀	10.9 μM Compound: ADR	Cytotoxicity against human AGS cells after 48 hrs by MTT assay Cytotoxicity against human AGS cells after 48 hrs by MTT assay	10.1039/C2MD20270K
ARPE-19	IC₅₀	0.76 μM Compound: Doxorubicin	Cytotoxicity against human ARPE19 cells after 48 hrs by Alamar blue assay Cytotoxicity against human ARPE19 cells after 48 hrs by Alamar blue assay	[PMID: 20931970]
ASPC1	IC₅₀	< 1 μM Compound: Doxorubicin	Cytotoxicity against human ASPC1 cells assessed as reduction in cell growth by MTT assay Cytotoxicity against human ASPC1 cells assessed as reduction in cell growth by MTT assay	[PMID: 36734533]
ASPC1	IC₅₀	< 1 μM Compound: Doxorubicin	Cytotoxicity against human ASPC1 cells by SRB assay Cytotoxicity against human ASPC1 cells by SRB assay	[PMID: 33371684]
ASPC1	IC₅₀	0.86 μM Compound: Doxorubicin	Cytotoxicity against human AsPC1 cells deficit of P53 gene incubated for 72 hrs by MTS assay Cytotoxicity against human AsPC1 cells deficit of P53 gene incubated for 72 hrs by MTS assay	[PMID: 31158748]
ASPC1	IC₅₀	1.87 μM Compound: Adriamycin	Cytotoxicity against human AsPC1 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay Cytotoxicity against human AsPC1 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay	[PMID: 24717154]
AT3B-1	IC₅₀	167.5 μM Compound: 1, Dox	Tumor killing activity in AT3B1 drug-resistant cell line by MTT assay Tumor killing activity in AT3B1 drug-resistant cell line by MTT assay	[PMID: 16168650]
B16	IC₅₀	< 0.001 μg/mL Compound: 1 (doxorubicin)	In vitro cytotoxic concentration against mouse melanoma cell line (B16) using MTT coloration In vitro cytotoxic concentration against mouse melanoma cell line (B16) using MTT coloration	[PMID: 15013011]
B16	IC₅₀	< 0.1 μM Compound: Doxorubicin	Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay	[PMID: 22330634]
B16	IC₅₀	0.001 μg/mL Compound: 1 (doxorubicin)	In vitro inhibitory activity against mouse melanoma cell line (B16) using CV coloration In vitro inhibitory activity against mouse melanoma cell line (B16) using CV coloration	[PMID: 15013011]
B16	IC₅₀	0.03 μg/mL Compound: Doxorubicin	Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay	[PMID: 18586355]
B16	IC₅₀	0.03 μg/mL Compound: doxorubicin	Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay	[PMID: 17827021]
B16	IC₅₀	0.03 μg/mL Compound: doxorubicin	Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay	[PMID: 15787450]
B16	IC₅₀	0.03 μM Compound: Doxorubicin	Anticancer activity against mouse B16 cells after 48 hrs by MTT assay Anticancer activity against mouse B16 cells after 48 hrs by MTT assay	[PMID: 22668451]
B16	IC₅₀	0.1 μM Compound: doxorubicin	Cytotoxicity against murine B16 cells by MTT assay Cytotoxicity against murine B16 cells by MTT assay	[PMID: 17256903]
B16	IC₅₀	0.14 μM Compound: DOX	Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay	[PMID: 21496972]
B16	IC₅₀	0.18 μM Compound: ADM	Antiproliferative activity against mouse B16 cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against mouse B16 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 25984840]
B16	IC₅₀	0.18 μM Compound: ADM	Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay	[PMID: 25529742]
B16	IC₅₀	0.18 μM Compound: Doxorubicin	Antiproliferative activity against mouse B16 cells after 72 hrs MTT assay Antiproliferative activity against mouse B16 cells after 72 hrs MTT assay	[PMID: 25247772]
B16	IC₅₀	0.2 μM Compound: Dox	Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay	[PMID: 30659997]
B16	IC₅₀	0.43 μM Compound: Doxorubicin	Cytotoxicity against mouse B16 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against mouse B16 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 26934105]
B16	IC₅₀	1.7 μM Compound: Doxorubicin	Cytotoxicity against mouse B16 cells after 48 hrs by MTT assay Cytotoxicity against mouse B16 cells after 48 hrs by MTT assay	[PMID: 22304344]
B16	IC₅₀	17.67 μM Compound: doxorubicin	Cytotoxicity against mouse B16 cells assessed as inhibition of cell viability after 24 hrs by MTT assay Cytotoxicity against mouse B16 cells assessed as inhibition of cell viability after 24 hrs by MTT assay	[PMID: 26200396]
B16	IC₅₀	2.78 μM Compound: Doxorubicin	Cytotoxicity against mouse B16 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against mouse B16 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25594739]
B16	IC₅₀	21.5 μM Compound: Doxorubicin	Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay	[PMID: 21620529]
B16	IC₅₀	3.16 μg/mL Compound: Doxorubicin	Cytotoxicity against mouse B16 cells by MTT assay Cytotoxicity against mouse B16 cells by MTT assay	10.1039/C4MD00566J
B16	IC₅₀	670 nM Compound: Doxorubicin	Cytotoxicity against mouse B16 cells after 48 hrs by MTT assay Cytotoxicity against mouse B16 cells after 48 hrs by MTT assay	[PMID: 30172625]
B16	IC₅₀	7.6 nM Compound: Adriamycin	Inhibition of murine B16 melanoma cell proliferation measured by the MTT assay Inhibition of murine B16 melanoma cell proliferation measured by the MTT assay	[PMID: 10377224]
B16-BL6	IC₅₀	3.07 μM Compound: Doxorubicin	Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay	[PMID: 19689125]
B16-BL6	IC₅₀	8.05 μM Compound: Doxorubicin	Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay	[PMID: 18440233]
B16-F1	IC₅₀	0.23 μM Compound: Doxorubicin	Antiproliferative activity against mouse B16-F1 cells after 72 hrs by MTT reduction assay Antiproliferative activity against mouse B16-F1 cells after 72 hrs by MTT reduction assay	[PMID: 28551177]
B16-F10	IC₅₀	0.016 μM Compound: DOX	Cytotoxicity against mouse B16/F10 cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against mouse B16/F10 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
B16-F10	IC₅₀	0.072 μM Compound: Doxorubicin	Cytotoxicity against mouse B16F10 cells after 48 hrs by CCK8 assay Cytotoxicity against mouse B16F10 cells after 48 hrs by CCK8 assay	[PMID: 23777898]
B16-F10	IC₅₀	0.12 μM Compound: Adriamycin	Cytotoxicity against mouse B16F10 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay Cytotoxicity against mouse B16F10 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay	[PMID: 24717154]
B16-F10	IC₅₀	0.19 μM Compound: ADM	Antiproliferative activity against mouse B16F10 cells after 72 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells after 72 hrs by MTT assay	[PMID: 30344912]
B16-F10	IC₅₀	0.346 μM Compound: Doxorubicin	Cytotoxicity activity against mouse B16F10 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against mouse B16F10 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
B16-F10	IC₅₀	0.663 μM Compound: Dox	Cytotoxicity against mouse B16F10 cells assessed as cell killing effect after 72 hrs by MTT assay Cytotoxicity against mouse B16F10 cells assessed as cell killing effect after 72 hrs by MTT assay	[PMID: 26005543]
B16-F10	IC₅₀	2.3 μM Compound: Doxorubicin	Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay	[PMID: 27300257]
B16-F10	IC₅₀	3.28 μM Compound: Doxorubicin	Anticancer activity against mouse B16-F10 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against mouse B16-F10 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34124677]
B16-F10	IC₅₀	4.23 μM Compound: Doxorubicin	Cytotoxicity against mouse B16F10 cells after 72 hrs by alamar blue assay Cytotoxicity against mouse B16F10 cells after 72 hrs by alamar blue assay	[PMID: 24969014]
B16-F10	IC₅₀	4.33 μM Compound: Doxorubicin	Cytotoxicity against mouse B16F10 spheroid cells assessed as reduction in spheroid cell viability after 48 hrs by MTT assay Cytotoxicity against mouse B16F10 spheroid cells assessed as reduction in spheroid cell viability after 48 hrs by MTT assay	[PMID: 30433783]
B16-F10-luc2	IC₅₀	0.04 μM Compound: 1	Cytotoxicity against mouse B16-F10-Luc2 cells expressing human EGFR measured after 72 hrs by resazurin assay Cytotoxicity against mouse B16-F10-Luc2 cells expressing human EGFR measured after 72 hrs by resazurin assay	[PMID: 34411983]
B16-F10-luc2	IC₅₀	0.04 μM Compound: 1	Cytotoxicity against mouse B16-F10-Luc2 cells expressing EGFR measured after 72 hrs in absence of cetuximab by resazurin assay Cytotoxicity against mouse B16-F10-Luc2 cells expressing EGFR measured after 72 hrs in absence of cetuximab by resazurin assay	[PMID: 34411983]
B16-F10-luc2	IC₅₀	0.09 μM Compound: 1	Cytotoxicity against mouse B16-F10-Luc2 cells expressing EGFR measured after 72 hrs in presence of 3.3 uM cetuximab by resazurin assay Cytotoxicity against mouse B16-F10-Luc2 cells expressing EGFR measured after 72 hrs in presence of 3.3 uM cetuximab by resazurin assay	[PMID: 34411983]
B16-F10-luc2	IC₅₀	0.11 μM Compound: 1	Cytotoxicity against mouse B16-F10-Luc2 cells measured after 72 hrs by resazurin assay Cytotoxicity against mouse B16-F10-Luc2 cells measured after 72 hrs by resazurin assay	[PMID: 34411983]
BALB/3T3	IC₅₀	0.092 μM Compound: Doxorubicin	Cytotoxicity against mouse BALB/3T3 cells incubated for 72 hrs by sulforhodamine B assay Cytotoxicity against mouse BALB/3T3 cells incubated for 72 hrs by sulforhodamine B assay	[PMID: 32432867]
BALB/3T3	IC₅₀	0.11 μM Compound: Doxorubicin	Cytotoxicity against mouse BALB/3T3 cells after 72 hrs by SRB assay Cytotoxicity against mouse BALB/3T3 cells after 72 hrs by SRB assay	[PMID: 26639764]
BALB/3T3	IC₅₀	0.18 μM Compound: doxorubicin	Antiproliferative activity against mouse BALB/3T3 cells assessed as growth inhibition after 72 hrs by SRB method Antiproliferative activity against mouse BALB/3T3 cells assessed as growth inhibition after 72 hrs by SRB method	[PMID: 25644674]
BALB/3T3	IC₅₀	0.31 μM Compound: Doxorubicin	Antiproliferative activity against mouse BALB/3T3 cells after 72 hrs Antiproliferative activity against mouse BALB/3T3 cells after 72 hrs	[PMID: 26163197]
BALB/3T3	GI₅₀	0.6 μM Compound: Dox	Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against mouse BALB/3T3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]
BALB/3T3	GI₅₀	0.62 μM Compound: Dox	Antiproliferative activity against mouse BALB/3T3 cells incubated for 72 hrs and measured by MTT assay Antiproliferative activity against mouse BALB/3T3 cells incubated for 72 hrs and measured by MTT assay	[PMID: 35973342]
BALB/3T3	IC₅₀	1.08 μM Compound: Doxorubicin	Cytotoxicity against mouse BALB/3T3 cells assessed as cell viability after 1 hr by sulforhodamine B assay Cytotoxicity against mouse BALB/3T3 cells assessed as cell viability after 1 hr by sulforhodamine B assay	[PMID: 26496013]
BALB/3T3	IC₅₀	1.91 μM Compound: Doxorubicin	Cytotoxicity against mouse BALB/3T3 cells incubated for 72 hrs by MTT assay Cytotoxicity against mouse BALB/3T3 cells incubated for 72 hrs by MTT assay	[PMID: 23079523]
BALB/3T3	IC₅₀	166 nM Compound: DOX; DX	Antiproliferative activity against mouse BALB/3T3 cells assessed as reduction in cell viability incubated for 120 hrs by MTT assay Antiproliferative activity against mouse BALB/3T3 cells assessed as reduction in cell viability incubated for 120 hrs by MTT assay	[PMID: 31653441]
BALB/3T3	IC₅₀	166 nM Compound: Doxorubicin	Antiproliferative activity against mouse BALB/3T3 cells incubated for 72 hrs by SRB assay Antiproliferative activity against mouse BALB/3T3 cells incubated for 72 hrs by SRB assay	[PMID: 33465696]
BALB/3T3	IC₅₀	200 nM Compound: DX	Antiproliferative activity against mouse BALB/3T3 cells assessed as inhibition of proliferation after 72 hrs by SRB assay Antiproliferative activity against mouse BALB/3T3 cells assessed as inhibition of proliferation after 72 hrs by SRB assay	[PMID: 34116158]
BALB/3T3	IC₅₀	315 nM Compound: DX	Cytotoxicity against mouse BALB/3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against mouse BALB/3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 34592435]
BALB/3T3	IC₅₀	32.3 nM Compound: DX	Cytotoxicity against mouse BALB/3T3 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay Cytotoxicity against mouse BALB/3T3 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay	[PMID: 33611191]
BC	IC₅₀	0.17 μg/mL Compound: Doxorubicin	Cytotoxicity against human BC cells by colorimetric method Cytotoxicity against human BC cells by colorimetric method	[PMID: 16989536]
BC	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human BC cells by SRB assay Cytotoxicity against human BC cells by SRB assay	[PMID: 20038128]
BC	IC₅₀	2.88 x 10^-4 mM Compound: doxorubicin	Cytotoxicity against human BC cells by SRB assay Cytotoxicity against human BC cells by SRB assay	[PMID: 16933890]
Bcap37	IC₅₀	1.12 μM Compound: AMD	Cytotoxicity against human Bcap37 cells after 48 hrs by MTT assay Cytotoxicity against human Bcap37 cells after 48 hrs by MTT assay	[PMID: 26900656]
Bcap37	IC₅₀	1.19 μM Compound: AMD	Antiproliferative activity against human Bcap37 cells after 48 hrs by MTT assay Antiproliferative activity against human Bcap37 cells after 48 hrs by MTT assay	[PMID: 26807545]
Bcap37	IC₅₀	1.2 μM Compound: ADM	Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay	[PMID: 26280921]
Bcap37	IC₅₀	1.2 μM Compound: ADM	Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay	[PMID: 25874331]
Bcap37	IC₅₀	1.28 μM Compound: ADM	Antiproliferative activity against human Bcap37 cells after 72 hrs by MTT assay Antiproliferative activity against human Bcap37 cells after 72 hrs by MTT assay	[PMID: 23124210]
Bcap37	IC₅₀	1.9 μM Compound: ADM	Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay	10.1007/s00044-013-0854-3
Bcap37	IC₅₀	2 μM Compound: ADM	Antiproliferative against human Bcap37 cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative against human Bcap37 cells assessed as growth inhibition after 72 hrs by MTT assay	10.1039/C1MD00038A
Bcap37	IC₅₀	2.87 μM Compound: ADM	Cytotoxicity against human Bcap37 cells after 38 hrs by MTT assay Cytotoxicity against human Bcap37 cells after 38 hrs by MTT assay	[PMID: 25965778]
BEAS-2B	GI₅₀	0.1 μM Compound: Doxorubicin	Antiproliferative activity against human BEAS2B cells after 72 hrs by MTT assay Antiproliferative activity against human BEAS2B cells after 72 hrs by MTT assay	[PMID: 30071406]
BEAS-2B	GI₅₀	0.13 μM Compound: Doxorubicin	Cytotoxicity against human BEAS2B cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human BEAS2B cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29670691]
BEAS-2B	IC₅₀	18.6 μM Compound: Doxorubicin	Cytotoxicity against human BEAS2B cells assessed as reduction in cell viability after 70 hrs by alamar blue assay Cytotoxicity against human BEAS2B cells assessed as reduction in cell viability after 70 hrs by alamar blue assay	[PMID: 29471119]
BEAS-2B	IC₅₀	2.4 μM Compound: Doxorubicin	Antiproliferative activity against human BEAS2B cells after 70 hrs by alamar blue assay Antiproliferative activity against human BEAS2B cells after 70 hrs by alamar blue assay	[PMID: 29471119]
Bel-7402	GI₅₀	< 1 μM Compound: DOX	Antiproliferative activity against human Bel7402 cells by MTT assay Antiproliferative activity against human Bel7402 cells by MTT assay	[PMID: 31990554]
Bel-7402	IC₅₀	< 1 μM Compound: doxorubicin	Cytotoxicity against human Bel-7402 cells by SRB assay Cytotoxicity against human Bel-7402 cells by SRB assay	[PMID: 33847126]
Bel-7402	IC₅₀	> 1 μM Compound: Doxorubicin	Antiproliferative activity against human Bel-7402 cells by MTT assay Antiproliferative activity against human Bel-7402 cells by MTT assay	[PMID: 36089748]
Bel-7402	IC₅₀	0.01 μg/mL Compound: ADR	Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 18590312]
Bel-7402	IC₅₀	0.01 μg/mL Compound: ADR	Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay	[PMID: 18590312]
Bel-7402	IC₅₀	0.021 μM Compound: adriamycin	Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay	[PMID: 19028425]
Bel-7402	IC₅₀	0.049 μM Compound: Doxorubicin	Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay	[PMID: 20846862]
Bel-7402	IC₅₀	0.067 μM Compound: ADR	Cytotoxicity against human Bel7402 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human Bel7402 cells after 72 hrs by sulforhodamine B assay	[PMID: 20949916]
Bel-7402	IC₅₀	0.12 μM Compound: Adriamycin	Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay	[PMID: 20593838]
Bel-7402	IC₅₀	0.22 μM Compound: ADM	Antiproliferative activity against human Bel7402 cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human Bel7402 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 25984840]
Bel-7402	IC₅₀	0.22 μM Compound: ADM	Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 25529742]
Bel-7402	IC₅₀	0.22 μM Compound: Doxorubicin	Antiproliferative activity against human Bel7402 cells after 72 hrs MTT assay Antiproliferative activity against human Bel7402 cells after 72 hrs MTT assay	[PMID: 25247772]
Bel-7402	IC₅₀	0.53 μM Compound: Adriamycin	Cytotoxicity against human Bel7402 cells by MTT assay Cytotoxicity against human Bel7402 cells by MTT assay	[PMID: 22070654]
Bel-7402	IC₅₀	0.58 μM Compound: Doxorubicin	Antiproliferative activity human Bel7402 cells after 20 hrs by MTT assay Antiproliferative activity human Bel7402 cells after 20 hrs by MTT assay	[PMID: 20149494]
Bel-7402	IC₅₀	0.6 μM Compound: ADM	Cytotoxic activity against human Bel7402 cells by MTT method Cytotoxic activity against human Bel7402 cells by MTT method	[PMID: 25611519]
Bel-7402	IC₅₀	0.9 μM Compound: ADM	Antiproliferative activity against human Bel7402 cells after 24 hrs by MTT assay Antiproliferative activity against human Bel7402 cells after 24 hrs by MTT assay	[PMID: 20932754]
Bel-7402	IC₅₀	1 μM Compound: adriamycin	Cytotoxicity against human Bel-7402 cells by MTT assay Cytotoxicity against human Bel-7402 cells by MTT assay	[PMID: 17190442]
Bel-7402	IC₅₀	1.36 μM Compound: DOX	Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay	[PMID: 26386603]
Bel-7402	IC₅₀	5 μM Compound: Doxorubicin	Antitumor activity against human Bel7402 cells after 48 hrs by SRB assay Antitumor activity against human Bel7402 cells after 48 hrs by SRB assay	[PMID: 20884091]
Bel-7402	IC₅₀	578.2 nM Compound: Doxorubicin	Antiproliferative against human Bel7402 cells assessed as cell viability after 96 hrs by MTT assay Antiproliferative against human Bel7402 cells assessed as cell viability after 96 hrs by MTT assay	[PMID: 24211639]
BEL-7404 tumor cell line	IC₅₀	0.13 μM Compound: DOX	Cytotoxicity against human Bel7404 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human Bel7404 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27668963]
BeWo	IC₅₀	1.07 μM Compound: Doxorubicin	Antitumor activity against human Bewo cells assessed as inhibition of cell growth by MTT assay Antitumor activity against human Bewo cells assessed as inhibition of cell growth by MTT assay	[PMID: 25160837]
BeWo	IC₅₀	6.24 μg/mL Compound: (20) adriamycin	In vitro cytotoxicity of compound against Bewo, human choriocarcinoma was defined by microculture tetrazolium assay In vitro cytotoxicity of compound against Bewo, human choriocarcinoma was defined by microculture tetrazolium assay	[PMID: 12620075]
BGC-823	IC₅₀	0.35 μM Compound: adriamycin	Cytotoxicity against human BGC823 cells after 48 hrs Cytotoxicity against human BGC823 cells after 48 hrs	[PMID: 17583953]
BGC-823	IC₅₀	0.405 μM Compound: ADR	Antiproliferative activity against human BGC823 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human BGC823 cells after 72 hrs by sulforhodamine B assay	[PMID: 30241010]
BGC-823	IC₅₀	0.66 μM Compound: DOX	Antiproliferative activity against human BGC-823 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human BGC-823 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35341920]
BGC-823	IC₅₀	0.9 μM Compound: Doxorubicin	Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay	[PMID: 22749279]
BGC-823	IC₅₀	1 μM Compound: adriamycin	Cytotoxicity against human BGC-823 cells by MTT assay Cytotoxicity against human BGC-823 cells by MTT assay	[PMID: 17190442]
BGC-823	IC₅₀	1.33 μM Compound: Adriamycin	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 23434227]
BGC-823	IC₅₀	1.48 μM Compound: Adriamycin	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 24182355]
BGC-823	IC₅₀	2.6 μM Compound: ADM	Antiproliferative against human BGC823 cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative against human BGC823 cells assessed as growth inhibition after 72 hrs by MTT assay	10.1039/C1MD00038A
BGC-823	IC₅₀	4.8 μM Compound: Doxorubicin	Antitumor activity against human BGC823 cells after 48 hrs by SRB assay Antitumor activity against human BGC823 cells after 48 hrs by SRB assay	[PMID: 20884091]
BJ	IC₅₀	2.33 μM Compound: DOXO	Cytotoxicity against human BJ cells assessed as cell viability after 48 hrs by alamar blue assay Cytotoxicity against human BJ cells assessed as cell viability after 48 hrs by alamar blue assay	[PMID: 21797280]
BJ	IC₅₀	2.33 μM Compound: Doxorubicin	Cytotoxicity against human BJ cells after 48 hrs by Alamar blue assay Cytotoxicity against human BJ cells after 48 hrs by Alamar blue assay	[PMID: 20931970]
BJ	IC₅₀	2.7 μM Compound: Doxorubicin	Cytotoxicity against human BJ cells after 48 hrs by Alamar Blue assay Cytotoxicity against human BJ cells after 48 hrs by Alamar Blue assay	[PMID: 19473028]
BMDM	IC₅₀	4.6 μM Compound: Adriamycin	Cytotoxicity against mouse BMDM cells after 72 hrs by MTT assay Cytotoxicity against mouse BMDM cells after 72 hrs by MTT assay	[PMID: 22616554]
BT-474	IC₅₀	0.041 μM Compound: DOX	Antiproliferative activity against human BT474 cells after 48 hrs by CellTiter-Glo assay Antiproliferative activity against human BT474 cells after 48 hrs by CellTiter-Glo assay	[PMID: 27769032]
BT-474	IC₅₀	0.053 μM Compound: DOX	Antiproliferative activity against human BT474 cells after 24 hrs by CellTiter-Glo assay Antiproliferative activity against human BT474 cells after 24 hrs by CellTiter-Glo assay	[PMID: 27769032]
BT-474	IC₅₀	0.07 μM Compound: Dox	Cytotoxicity against human BT474 cells after 3 days by MTT assay Cytotoxicity against human BT474 cells after 3 days by MTT assay	[PMID: 21741833]
BT-474	IC₅₀	0.18 μM Compound: DOX	Antiproliferative activity against human BT474 spheroids after 3 days by CellTiter-Glo assay Antiproliferative activity against human BT474 spheroids after 3 days by CellTiter-Glo assay	[PMID: 27769032]
BT-474	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human BT474 cells assessed as reduction in cell survival after 48 hrs by MTT assay Cytotoxicity against human BT474 cells assessed as reduction in cell survival after 48 hrs by MTT assay	[PMID: 28494255]
BT-474	IC₅₀	1.9 μM Compound: DOX	Cytotoxicity against human BT474 cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human BT474 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
BT-474	IC₅₀	8.92 μg/mL Compound: doxorubicin	Cytotoxicity against human BT474 cells after 3 days by MTT assay Cytotoxicity against human BT474 cells after 3 days by MTT assay	[PMID: 19456120]
BT-549	IC₅₀	< 0.55 μg/mL Compound: Doxorubicin	Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay	[PMID: 19105653]
BT-549	IC₅₀	< 0.55 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) BT549 cells by neutral red staining Cytotoxicity against Homo sapiens (human) BT549 cells by neutral red staining	10.1007/s00044-011-9587-3
BT-549	IC₅₀	< 1.1 μg/mL Compound: Doxorubicin	Cytotoxicity against human BT549 cells after 2 to 7 days by neutral red assay Cytotoxicity against human BT549 cells after 2 to 7 days by neutral red assay	[PMID: 11374943]
BT-549	IC₅₀	0.008 μg/mL Compound: doxorubicin	Cytotoxicity against human BT549 cells after 2 to 7 days by neutral red assay Cytotoxicity against human BT549 cells after 2 to 7 days by neutral red assay	[PMID: 8984156]
BT-549	IC₅₀	0.009 μM Compound: Doxorubicin	Antiproliferative activity against human BT-549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human BT-549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 27010926]
BT-549	GI₅₀	0.01 μM Compound: Doxorubicin	Cytostatic activity against human BT549 cells after 5 days by SRB assay Cytostatic activity against human BT549 cells after 5 days by SRB assay	[PMID: 21711054]
BT-549	IC₅₀	0.01 μM Compound: Doxorubicin	Cytotoxicity against human BT549 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human BT549 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 30457333]
BT-549	IC₅₀	0.045 μM Compound: Doxorubicin	Cytotoxicity against human BT549 cells after 48 hrs by neutral red dye based assay Cytotoxicity against human BT549 cells after 48 hrs by neutral red dye based assay	[PMID: 29317147]
BT-549	IC₅₀	0.11 μM Compound: Doxorubicin	Cytotoxicity against human BT549 cells after 72 hrs by resazurin/resorufin-based fluorescence assay Cytotoxicity against human BT549 cells after 72 hrs by resazurin/resorufin-based fluorescence assay	[PMID: 23600925]
BT-549	IC₅₀	0.17 μM Compound: Doxorubicin	Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay relative to control Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay relative to control	[PMID: 25975638]
BT-549	GI₅₀	0.23 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human BT549 cells after 48 hrs by SRB assay Cytotoxicity against human BT549 cells after 48 hrs by SRB assay	[PMID: 23871905]
BT-549	GI₅₀	0.23 μM Compound: Doxorubicin	Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
BT-549	GI₅₀	0.23 μM Compound: Doxorubicin	Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human BT549 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
BT-549	IC₅₀	0.6 μg/mL Compound: doxorubicin	Cytotoxicity against human BT549 cells by neutral red assay Cytotoxicity against human BT549 cells by neutral red assay	[PMID: 17976995]
BT-549	IC₅₀	0.8 μg/mL Compound: doxorubicin	Cytotoxicity against human BT549 cells after 48 hrs by Neutral Red dye Cytotoxicity against human BT549 cells after 48 hrs by Neutral Red dye	[PMID: 20550123]
BT-549	IC₅₀	1 μg/mL Compound: Doxorubicin	Cytotoxicity against human BT549 cells after 48 hrs by neutral red staining Cytotoxicity against human BT549 cells after 48 hrs by neutral red staining	[PMID: 15165136]
BT-549	IC₅₀	1.2 μM Compound: Doxorubicin	Cytotoxicity against human BT549 cells after 48 hrs by Neutral red assay Cytotoxicity against human BT549 cells after 48 hrs by Neutral red assay	[PMID: 19658408]
BT-549	IC₅₀	1.3 μg/mL Compound: doxorubicin	Cytotoxicity against human BT549 cells after 48 hrs by neutral red dye staining Cytotoxicity against human BT549 cells after 48 hrs by neutral red dye staining	[PMID: 19928902]
BT-549	IC₅₀	1.35 μg/mL Compound: Doxorubicin	Cytotoxicity against human BT549 cells assessed as cell growth inhibition after 48 hrs by neutral red dye based assay Cytotoxicity against human BT549 cells assessed as cell growth inhibition after 48 hrs by neutral red dye based assay	[PMID: 27769668]
BT-549	IC₅₀	1.6 μM Compound: Doxorubicin	Cytotoxicity against human BT549 cells assessed as cell growth inhibition after 48 hrs by neutral red assay Cytotoxicity against human BT549 cells assessed as cell growth inhibition after 48 hrs by neutral red assay	[PMID: 26005918]
BT-549	IC₅₀	1.96 μM Compound: doxorubicin	Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay Cytotoxicity against human BT549 cells after 48 hrs by neutral red assay	[PMID: 19879765]
BT-549	IC₅₀	2.6 μM Compound: doxorubicin	Cytotoxicity against human BT549 cells assessed as viable cells by neutral red dye method Cytotoxicity against human BT549 cells assessed as viable cells by neutral red dye method	[PMID: 22530813]
BT-549	IC₅₀	3.6 μM Compound: Doxorubicin	Cytotoxicity against human BT549 cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay Cytotoxicity against human BT549 cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay	[PMID: 27618204]
BT-549	IC₅₀	3.7 μM Compound: doxorubicin	Cytotoxicity against human BT549 cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against human BT549 cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]
BXPC-3	IC₅₀	0.02 μM Compound: Doxorubicin	Antiproliferative activity against human BxPC3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method Antiproliferative activity against human BxPC3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	[PMID: 25937235]
BXPC-3	IC₅₀	0.4 μM Compound: DOX, Doxorubicin	Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay Antiproliferative activity against human BxPC3 cells after 72 hrs by MTT assay	[PMID: 24095089]
BXPC-3	IC₅₀	0.56 μM Compound: Doxorubicin	Antiproliferative activity against human BxPC3 cells after 48 hrs by MTT assay Antiproliferative activity against human BxPC3 cells after 48 hrs by MTT assay	[PMID: 28554092]
BXPC-3	IC₅₀	1.78 μM Compound: Doxorubicin	Antiproliferative activity against human BxPC3 cells assessed as growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human BxPC3 cells assessed as growth inhibition incubated for 48 hrs by MTT assay	[PMID: 26253231]
BXPC-3	IC₅₀	13 μM Compound: Doxorubicin	Cytotoxicity against human BxPC3 cells after 48 hrs by MTT assay Cytotoxicity against human BxPC3 cells after 48 hrs by MTT assay	[PMID: 27173802]
BXPC-3	IC₅₀	13.56 μM Compound: Doxorubicin	Cytotoxicity against human BxPC3 cells after 48 hrs by MTT assay Cytotoxicity against human BxPC3 cells after 48 hrs by MTT assay	[PMID: 29573910]
BXPC-3	IC₅₀	14.3 μM Compound: Doxorubicin	Cytotoxicity against human BxPC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human BxPC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28254167]
BXPC-3	IC₅₀	9.12 μM Compound: Doxorubicin	Growth inhibition of human BxPC3 cells after 48 hrs by MTT assay Growth inhibition of human BxPC3 cells after 48 hrs by MTT assay	[PMID: 30072225]
C2D cell line	IC₅₀	46.5 nM Compound: Doxorubicin	Inhibitory concentration to inhibit growth of C2D prostate cancer cell line by using MTT assay Inhibitory concentration to inhibit growth of C2D prostate cancer cell line by using MTT assay	[PMID: 14971910]
C2G cell line	IC₅₀	28.7 nM Compound: Doxorubicin	Inhibitory concentration to inhibit growth of C2G prostate cancer cell line by using MTT assay Inhibitory concentration to inhibit growth of C2G prostate cancer cell line by using MTT assay	[PMID: 14971910]
C-33-A	IC₅₀	0.28 μg/mL Compound: Doxorubicin	Cytotoxicity against human C33A cells after 48 hrs by SRB assay Cytotoxicity against human C33A cells after 48 hrs by SRB assay	[PMID: 20732814]
C-33-A	IC₅₀	0.82 μM Compound: Doxorubicin	Cytotoxicity against human C33A cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human C33A cells after 48 hrs by sulforhodamine B assay	[PMID: 21071221]
C3H	IC₅₀	0.04 μM Compound: Doxorubicin	Cytotoxicity against mouse C3H cells after 72 hrs by MTS assay Cytotoxicity against mouse C3H cells after 72 hrs by MTS assay	[PMID: 26810263]
C6	IC₅₀	0.1 μM Compound: Dox	Cytotoxicity against rat C6 cells after 72 hrs by MTT assay Cytotoxicity against rat C6 cells after 72 hrs by MTT assay	[PMID: 30659997]
C6	IC₅₀	0.5 μM Compound: Dox	Cytotoxicity against rat C6 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against rat C6 cells after 72 hrs by sulforhodamine B assay	[PMID: 28504888]
C6	IC₅₀	25.64 μM Compound: Dox	Cytotoxicity against rat C6 cells assessed as cell viability measured after 24 hrs by MTT assay Cytotoxicity against rat C6 cells assessed as cell viability measured after 24 hrs by MTT assay	[PMID: 33183865]
C8166	IC₅₀	0.02 μM Compound: doxo	Antiproliferative activity against human C8166 cell line by MTT assay Antiproliferative activity against human C8166 cell line by MTT assay	[PMID: 16913700]
Ca9-22	IC₅₀	0.09 μg/mL Compound: Doxorubicin	Cytotoxicity against human sCa9-22 cells by MTT assay Cytotoxicity against human sCa9-22 cells by MTT assay	[PMID: 18590313]
Ca9-22	IC₅₀	0.1 μg/mL Compound: doxorubicin	Cytotoxicity against human Ca9-22 cells by MTT assay Cytotoxicity against human Ca9-22 cells by MTT assay	[PMID: 18973388]
Ca9-22	IC₅₀	0.14 μg/mL Compound: Doxorubicin	Cytotoxicity against human Ca9-22 cells after 3 days by MTT assay Cytotoxicity against human Ca9-22 cells after 3 days by MTT assay	[PMID: 19691312]
Ca9-22	IC₅₀	0.26 μM Compound: Doxo	Cytotoxicity against human Ca9-22 cells after 3 days by MTT assay Cytotoxicity against human Ca9-22 cells after 3 days by MTT assay	[PMID: 21800859]
Ca9-22	IC₅₀	0.31 μg/mL Compound: doxorubicin	Cytotoxicity against human Ca9-22 cells by MTT assay Cytotoxicity against human Ca9-22 cells by MTT assay	[PMID: 22413887]
Ca9-22	CC₅₀	0.7 μM Compound: DXR	Cytotoxicity against human Ca9-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human Ca9-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31532650]
Ca9-22	IC₅₀	1.3 μM Compound: Doxo	Cytotoxicity against human Ca9-22 cells after 72 hrs by MTT assay Cytotoxicity against human Ca9-22 cells after 72 hrs by MTT assay	[PMID: 20334960]
Ca9-22	IC₅₀	14.47 μg/mL Compound: Doxorubicin	Cytotoxicity against human Ca9-22 cells by MTT assay Cytotoxicity against human Ca9-22 cells by MTT assay	[PMID: 21106454]
Caco-2	IC₅₀	0.02 μg/mL Compound: Doxorubicin	Cytotoxicity against human Caco2 cells after 72 hrs by WST-8 assay Cytotoxicity against human Caco2 cells after 72 hrs by WST-8 assay	[PMID: 25534608]
Caco-2	IC₅₀	0.05 μM Compound: Doxorubicin	Cytotoxicity against human Caco-2 cells assessed as reduction in cell viability after 48 hrs Cytotoxicity against human Caco-2 cells assessed as reduction in cell viability after 48 hrs	[PMID: 34601029]
Caco-2	IC₅₀	0.05 μM Compound: Doxorubicine	Cytotoxicity against human CaCo-2 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) Cytotoxicity against human CaCo-2 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)	[PMID: 33422908]
Caco-2	IC₅₀	0.09 μM Compound: Doxorubicin	Antiproliferative activity against human Caco2 cells after 48 hrs by Hoechst 33342 staining-based assay Antiproliferative activity against human Caco2 cells after 48 hrs by Hoechst 33342 staining-based assay	[PMID: 30655216]
Caco-2	IC₅₀	0.17 μM Compound: Doxorubicin	Toxicity in human Caco-2 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay Toxicity in human Caco-2 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay	[PMID: 31753515]
Caco-2	GI₅₀	0.32 μM Compound: Doxorubicin	Antiproliferative activity against human Caco2 cells after 2 days by sulforhodamine B assay Antiproliferative activity against human Caco2 cells after 2 days by sulforhodamine B assay	[PMID: 24184076]
Caco-2	IC₅₀	0.35 μM Compound: Doxorubicin	Antiproliferative activity against human Caco2 cells after 24 and 72 hrs by MTT assay Antiproliferative activity against human Caco2 cells after 24 and 72 hrs by MTT assay	[PMID: 24941130]
Caco-2	IC₅₀	0.6 μM Compound: Doxorubicin	Antitumor activity against human differentiated Caco2 cells after 24 to 48 hrs by MTT assay Antitumor activity against human differentiated Caco2 cells after 24 to 48 hrs by MTT assay	[PMID: 21553829]
Caco-2	IC₅₀	0.73 μM Compound: Doxorubicin	Antiproliferative activity against human Caco2 cells after 48 hrs by neutral red assay Antiproliferative activity against human Caco2 cells after 48 hrs by neutral red assay	[PMID: 29885574]
Caco-2	IC₅₀	0.96 μM Compound: Doxorubicin	Cytotoxicity against human Caco2 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human Caco2 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 26874404]
Caco-2	IC₅₀	1 μg/mL Compound: Doxorubicin	Cytotoxicity against human Caco-2 cells after 24 hrs Cytotoxicity against human Caco-2 cells after 24 hrs	[PMID: 20207452]
Caco-2	IC₅₀	1 μM Compound: Doxorubicin	Antiproliferative activity against human Caco2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human Caco2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
Caco-2	IC₅₀	2.7 μM Compound: Adriamycin	Cytotoxicity against human Caco2 cells by MTT assay Cytotoxicity against human Caco2 cells by MTT assay	[PMID: 22946634]
Caco-2	IC₅₀	21 μM Compound: 21	Cytotoxicity against human Caco2 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human Caco2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 32435401]
Caco-2	IC₅₀	26.79 μM Compound: DOX	Antiproliferative activity against human Caco2 cells by MTT assay Antiproliferative activity against human Caco2 cells by MTT assay	[PMID: 30216848]
Caco-2	IC₅₀	3 μM Compound: Doxorubicin	Antiproliferative activity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay Antiproliferative activity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 26874744]
Caco-2	IC₅₀	3.83 μM Compound: Dox	Antiproliferative activity against human Caco2 cells by MTT assay Antiproliferative activity against human Caco2 cells by MTT assay	[PMID: 28802125]
Caco-2	IC₅₀	48.1 nM Compound: DOX	Anticancer activity against human Caco-2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Anticancer activity against human Caco-2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33901898]
Caco-2	IC₅₀	5 μM Compound: Doxorubicin	Cytotoxicity against human Caco2 cells after 72 hrs by MTT assay Cytotoxicity against human Caco2 cells after 72 hrs by MTT assay	[PMID: 24099994]
Caco-2	IC₅₀	5.13 μM Compound: Doxorubicin	Antiproliferative activity against human Caco2 cells after 72 hrs by ELISA Antiproliferative activity against human Caco2 cells after 72 hrs by ELISA	[PMID: 31404864]
Caco-2	IC₅₀	6.7 μM Compound: Doxorubicin	Antitumor activity against human undifferentiated Caco2 cells after 24 to 48 hrs by MTT assay Antitumor activity against human undifferentiated Caco2 cells after 24 to 48 hrs by MTT assay	[PMID: 21553829]
Caco-2	IC₅₀	63.3 μM Compound: Doxorubicin	Cytotoxicity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 28463785]
Caco-2	IC₅₀	64.2 μg/mL Compound: Doxorubicin	Cytotoxicity against human Caco2 cells assessed as cell growth inhibition measured after 24 by MTT assay Cytotoxicity against human Caco2 cells assessed as cell growth inhibition measured after 24 by MTT assay	[PMID: 35526504]
Caco-2	IC₅₀	9.4 μM Compound: Doxorubicin	Cytotoxicity against human Caco2 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human Caco2 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27843113]
CAKI-1	GI₅₀	0.95 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human Caki1 cells after 48 hrs by SRB assay Cytotoxicity against human Caki1 cells after 48 hrs by SRB assay	[PMID: 23871905]
CAKI-1	GI₅₀	0.95 μM Compound: Doxorubicin	Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Caki1 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
CAL-27	IC₅₀	0.18 μM Compound: DOX	Antiproliferative activity against human CAL-27 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human CAL-27 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36709571]
Calu-1	GI₅₀	< 1 x 10^-2 μM Compound: Doxorubicin	Antiproliferative activity against human HTB-54 cells after 72 hrs by MTT assay Antiproliferative activity against human HTB-54 cells after 72 hrs by MTT assay	[PMID: 30071406]
Calu-1	GI₅₀	< 1 x 10^-2 μM Compound: Doxorubicin	Cytotoxicity against human HTB-54 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HTB-54 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29670691]
Calu-3	IC₅₀	0.11 μM Compound: DOX	Antiproliferative activity against human Calu3 cells after 48 hrs by CellTiter-Glo assay Antiproliferative activity against human Calu3 cells after 48 hrs by CellTiter-Glo assay	[PMID: 27769032]
Calu-3	IC₅₀	0.27 μM Compound: DOX	Antiproliferative activity against human Calu3 cells after 24 hrs by CellTiter-Glo assay Antiproliferative activity against human Calu3 cells after 24 hrs by CellTiter-Glo assay	[PMID: 27769032]
Cancer cell lines	GI₅₀	0.065 μM Compound: Doxorubicin	Growth inhibition of human gastric cancer cells after 72 hrs by sulforhodamine B assay Growth inhibition of human gastric cancer cells after 72 hrs by sulforhodamine B assay	[PMID: 20884089]
Cancer cell lines	GI₅₀	0.065 μM Compound: Doxorubicin	Growth inhibition of human lung cancer cells after 72 hrs by sulforhodamine B assay Growth inhibition of human lung cancer cells after 72 hrs by sulforhodamine B assay	[PMID: 20884089]
Cancer cell lines	GI₅₀	0.065 μM Compound: Doxorubicin	Growth inhibition of human colon cancer cells after 72 hrs by sulforhodamine B assay Growth inhibition of human colon cancer cells after 72 hrs by sulforhodamine B assay	[PMID: 20884089]
Caov-3 cell line	IC₅₀	< 0.1 μM Compound: DOX, Doxorubicin	Antiproliferative activity against human Caov3 cells after 72 hrs by MTT assay Antiproliferative activity against human Caov3 cells after 72 hrs by MTT assay	[PMID: 24095089]
CAPAN-1	IC₅₀	1.7 μM Compound: Doxorubicin	Cytotoxicity in human CAPAN-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human CAPAN-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34082225]
CAPAN-1	IC₅₀	1.7 μM Compound: Dox	Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 32428792]
CAPAN-1	IC₅₀	1.8 μM Compound: Doxorubicin	Cytotoxicity against human Capan1 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human Capan1 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
carcinoma cell line	IC₅₀	< 0.01 μM Compound: doxorubicin	Inhibitory effect against murine renal cell carcinoma cell line (RENCA cells) using a BrdU-incorporation assay Inhibitory effect against murine renal cell carcinoma cell line (RENCA cells) using a BrdU-incorporation assay	[PMID: 11454467]
CCD-841CoN	IC₅₀	1.5 μg/mL Compound: Doxorubicin	Cytotoxicity against human CCD-841CoN cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human CCD-841CoN cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 35526504]
CCRF S-180	IC₅₀	29.2 μM Compound: Doxorubicin	Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay	[PMID: 21620529]
CCRF S-180	IC₅₀	9.25 μM Compound: Doxorubicin	Antiproliferative activity against mouse S180 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against mouse S180 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25648297]
CCRF-CEM	IC₅₀	0.003 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 72 hrs by resazurin assay Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 72 hrs by resazurin assay	[PMID: 26260339]
CCRF-CEM	IC₅₀	0.003 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin reduction assay Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin reduction assay	[PMID: 28456567]
CCRF-CEM	IC₅₀	0.009 μM Compound: Doxorubicin	Antiproliferative activity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 27010926]
CCRF-CEM	IC₅₀	0.009 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-CEM cells by resazurin assay Cytotoxicity against human CCRF-CEM cells by resazurin assay	[PMID: 24561670]
CCRF-CEM	EC₅₀	0.009 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay	[PMID: 29937978]
CCRF-CEM	IC₅₀	0.01 μM Compound: Doxorubicin	Antiproliferative activity against human CCRF-CEM cells after 72 hrs by MTT assay Antiproliferative activity against human CCRF-CEM cells after 72 hrs by MTT assay	[PMID: 27808511]
CCRF-CEM	EC₅₀	0.015 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay	[PMID: 29887512]
CCRF-CEM	IC₅₀	0.017 μM Compound: Doxorubicin	Growth inhibition of human CCRF-CEM cells by resazurin assay Growth inhibition of human CCRF-CEM cells by resazurin assay	[PMID: 28121440]
CCRF-CEM	IC₅₀	0.017 μM Compound: Doxorubicin	Antileukemic activity against human CCRF-CEM cells after 24 to 48 hrs by resazurin dye based fluorescence assay Antileukemic activity against human CCRF-CEM cells after 24 to 48 hrs by resazurin dye based fluorescence assay	[PMID: 29560715]
CCRF-CEM	IC₅₀	0.02 μg/mL Compound: Doxorubicin	Cytotoxicity against human CEM cells after 72 hrs by MTT assay Cytotoxicity against human CEM cells after 72 hrs by MTT assay	[PMID: 18586355]
CCRF-CEM	IC₅₀	0.02 μg/mL Compound: doxorubicin	Cytotoxicity against human CEM cells after 72 hrs by MTT assay Cytotoxicity against human CEM cells after 72 hrs by MTT assay	[PMID: 15787450]
CCRF-CEM	GI₅₀	0.02 μM Compound: Doxorubicin	Growth inhibition of human CCRF-CEM cells after 2 days by MTT assay Growth inhibition of human CCRF-CEM cells after 2 days by MTT assay	[PMID: 20570145]
CCRF-CEM	IC₅₀	0.02 μM Compound: Doxo	Antiproliferative activity against human CCRF-CEM cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human CCRF-CEM cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
CCRF-CEM	EC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-CEM cells after 96 hrs by MTT assay Cytotoxicity against human CCRF-CEM cells after 96 hrs by MTT assay	[PMID: 26320088]
CCRF-CEM	CC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-CEM cells after 96 hrs by MTT assay Cytotoxicity against human CCRF-CEM cells after 96 hrs by MTT assay	[PMID: 26119992]
CCRF-CEM	IC₅₀	0.02 μM Compound: Doxorubicin	Antiproliferative activity against human CCRF-CEM cells after 96 hrs by MTT assay Antiproliferative activity against human CCRF-CEM cells after 96 hrs by MTT assay	[PMID: 19053767]
CCRF-CEM	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by RRA assay Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by RRA assay	[PMID: 33508467]
CCRF-CEM	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye-based fluorescence assay Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability after 72 hrs by resazurin dye-based fluorescence assay	[PMID: 32663024]
CCRF-CEM	IC₅₀	0.03 μM Compound: doxo	Antiproliferative activity against human CCRF-CEM cell line by MTT assay Antiproliferative activity against human CCRF-CEM cell line by MTT assay	[PMID: 16913700]
CCRF-CEM	IC₅₀	0.037 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-CEM cells by CCK-8 assay Cytotoxicity against human CCRF-CEM cells by CCK-8 assay	[PMID: 22884578]
CCRF-CEM	IC₅₀	0.052 μM Compound: Doxorubicin	Antiproliferative activity against human CCRF-CEM cells after 48 hrs by MTT assay Antiproliferative activity against human CCRF-CEM cells after 48 hrs by MTT assay	[PMID: 27060757]
CCRF-CEM	IC₅₀	0.06 μM Compound: 1; Dox	Antiproliferative activity against human CEM cells after 72 hrs by MTT assay Antiproliferative activity against human CEM cells after 72 hrs by MTT assay	[PMID: 26633734]
CCRF-CEM	IC₅₀	0.06 μM Compound: Dox	Cytotoxicity against human CEM cells after 72 hrs by MTT assay Cytotoxicity against human CEM cells after 72 hrs by MTT assay	[PMID: 21144624]
CCRF-CEM	IC₅₀	0.06 μM Compound: adriamycin	Cytotoxicity against drug-sensitive CCRF-CEM cells after 72 hrs Cytotoxicity against drug-sensitive CCRF-CEM cells after 72 hrs	[PMID: 17323939]
CCRF-CEM	GI₅₀	0.08 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human CCRF-CEM cells after 48 hrs by SRB assay Cytotoxicity against human CCRF-CEM cells after 48 hrs by SRB assay	[PMID: 23871905]
CCRF-CEM	GI₅₀	0.08 μM Compound: Doxorubicin	Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
CCRF-CEM	GI₅₀	0.08 μM Compound: Doxorubicin	Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
CCRF-CEM	IC₅₀	0.09 μM Compound: Doxorubicin	Antiproliferative activity against human CCRF-CEM cells assessed as cell viability after 72 hrs by MTT assay Antiproliferative activity against human CCRF-CEM cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24012378]
CCRF-CEM	IC₅₀	0.09 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay	[PMID: 19394829]
CCRF-CEM	IC₅₀	0.09 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay Cytotoxicity against human CCRF-CEM cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay	[PMID: 36691388]
CCRF-CEM	IC₅₀	0.1 mM Compound: Dox	Antiproliferative activity against human CEM cells after 72 hrs by MTT assay Antiproliferative activity against human CEM cells after 72 hrs by MTT assay	[PMID: 29459273]
CCRF-CEM	IC₅₀	0.1 μM Compound: 2	Antiproliferative activity against human CEM cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human CEM cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 33974416]
CCRF-CEM	IC₅₀	0.1 μM Compound: Dox	Antiproliferative activity in human CEM cells after 72 hrs by MTT assay Antiproliferative activity in human CEM cells after 72 hrs by MTT assay	[PMID: 30268824]
CCRF-CEM	IC₅₀	0.1 μM Compound: 5	Antiproliferative activity against human CEM cells after 72 hrs by MTT assay Antiproliferative activity against human CEM cells after 72 hrs by MTT assay	[PMID: 29137865]
CCRF-CEM	IC₅₀	0.11 μM Compound: doxorubicin	Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay	[PMID: 22582991]
CCRF-CEM	IC₅₀	0.17 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-CEM cells after 48 hrs by MTT assay Cytotoxicity against human CCRF-CEM cells after 48 hrs by MTT assay	[PMID: 32496057]
CCRF-CEM	IC₅₀	0.39 μM Compound: Doxorubicin	Cytostatic activity against human CEM/0 after 72 hrs by cell counting Cytostatic activity against human CEM/0 after 72 hrs by cell counting	[PMID: 22555152]
CCRF-CEM	EC₅₀	0.4654 μM Compound: doxorubicin	Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
CCRF-CEM	IC₅₀	0.5 μM Compound: doxorubicin	Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 25993619]
CCRF-CEM	IC₅₀	0.5 μM Compound: Doxo	Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24484281]
CCRF-CEM	IC₅₀	1.05 μM Compound: Dox	Cytotoxicity against human CCRF-CEM cells after 48 hrs by resazurin assay Cytotoxicity against human CCRF-CEM cells after 48 hrs by resazurin assay	[PMID: 29107422]
CCRF-CEM	IC₅₀	1.05 μM Compound: DOX	Antiproliferative activity against human CCRF-CEM cells after 48 hrs by resazurin dye-based fluorescence assay Antiproliferative activity against human CCRF-CEM cells after 48 hrs by resazurin dye-based fluorescence assay	[PMID: 29665526]
CCRF-CEM	IC₅₀	2.14 μM Compound: doxorubicin	Cytotoxicity against human CCRF-CEM cells by XTT assay Cytotoxicity against human CCRF-CEM cells by XTT assay	[PMID: 22663190]
CCRF-CEM	GI₅₀	3 x 10^-2 μM Compound: Doxorubicin	Antiproliferative activity against human CCRF-CEM cells after 72 hrs by MTT assay Antiproliferative activity against human CCRF-CEM cells after 72 hrs by MTT assay	[PMID: 30071406]
CCRF-CEM	EC₅₀	3.078 μM Compound: doxorubicin	Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
CCRF-CEM	IC₅₀	3.14 μM Compound: Doxorubicin	Cytotoxicity against human CEM cells after 48 hrs by alamar blue assay Cytotoxicity against human CEM cells after 48 hrs by alamar blue assay	[PMID: 22272829]
CCRF-CEM	IC₅₀	3.14 μM Compound: Doxorubicin	Cytotoxicity against human CEM cells after 48 hrs Cytotoxicity against human CEM cells after 48 hrs	[PMID: 20873721]
CCRF-CEM	GI₅₀	3.3 x 10^-2 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-CEM cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human CCRF-CEM cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29670691]
CCRF-CEM	IC₅₀	36.9 nM Compound: doxorubicin	Cytotoxicity against human CCRF-CEM by XTT assay Cytotoxicity against human CCRF-CEM by XTT assay	[PMID: 20527917]
CCRF-CEM	IC₅₀	45 nM Compound: Dox	Inhibition of cell proliferation of human CCRF-CEM cells after 96 hrs by CellTiter assay Inhibition of cell proliferation of human CCRF-CEM cells after 96 hrs by CellTiter assay	[PMID: 22276998]
CCRF-CEM	IC₅₀	55.91 μM Compound: Dox	Antiproliferative activity against human CCRF-CM cells assessed as inhibition of cell proliferation incubated for 72 hrs by CellTiter-Glo assay Antiproliferative activity against human CCRF-CM cells assessed as inhibition of cell proliferation incubated for 72 hrs by CellTiter-Glo assay	[PMID: 27687968]
CCRF-SB	EC₅₀	0.01 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-SB cells after 96 hrs by MTT assay Cytotoxicity against human CCRF-SB cells after 96 hrs by MTT assay	[PMID: 26320088]
CCRF-SB	IC₅₀	0.02 μM Compound: doxo	Antiproliferative activity against human CCRF-SB cell line by MTT assay Antiproliferative activity against human CCRF-SB cell line by MTT assay	[PMID: 16913700]
CCRF-SB	IC₅₀	0.03 μM Compound: Doxo	Antiproliferative activity against human CCRF-SB cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human CCRF-SB cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
CCRF-SB	CC₅₀	0.03 μM Compound: Doxorubicin	Cytotoxicity against human CCRF-SB cells after 96 hrs by MTT assay Cytotoxicity against human CCRF-SB cells after 96 hrs by MTT assay	[PMID: 26119992]
CCRF-SB	IC₅₀	0.03 μM Compound: Doxorubicin	Antiproliferative activity against human CCRF-SB cells after 96 hrs by MTT assay Antiproliferative activity against human CCRF-SB cells after 96 hrs by MTT assay	[PMID: 19053767]
CEM/VLB100	IC₅₀	3.71 μM Compound: adriamycin	Cytotoxicity against vinblastine-resistant CEM/VLB100 cells after 72 hrs Cytotoxicity against vinblastine-resistant CEM/VLB100 cells after 72 hrs	[PMID: 17323939]
CEM-VM1	IC₅₀	0.55 μM Compound: adriamycin	Cytotoxicity against teniposide-resistant CEM/VM1 cells after 72 hrs Cytotoxicity against teniposide-resistant CEM/VM1 cells after 72 hrs	[PMID: 17323939]
CH1	IC₅₀	0.0063 μM Compound: Doxirubicin	Concentration required to inhibit CH1-cell growth by 50% Concentration required to inhibit CH1-cell growth by 50%	[PMID: 9703471]
CHO	IC₅₀	0.08 μM Compound: Adriamycin	Cytotoxicity against CHO cells after 72 hrs by MTT assay Cytotoxicity against CHO cells after 72 hrs by MTT assay	[PMID: 21721528]
CHO	CC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against CHO cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against CHO cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 25791675]
CHO	IC₅₀	3.6 μM Compound: Doxorubicin	Cytotoxicity against Chinese hamster CHO cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against Chinese hamster CHO cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 34782182]
CHO	CC₅₀	4.65 μM Compound: Doxorubicin	Cytotoxicity against CHO cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against CHO cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 32088496]
CHO	IC₅₀	6 μM Compound: DOX	Compound was tested for the drug concentration that inhibited cell growth by 50% compared to untreated control cultures of CHO /DOX cell line Compound was tested for the drug concentration that inhibited cell growth by 50% compared to untreated control cultures of CHO /DOX cell line	[PMID: 9526570]
CHO	IC₅₀	6.0 x 10^-8 M Compound: DOX	Drug concentration that inhibit cell growth by 50% compared to untreated control cultures of CHO cells (for 6 days at 37 degree Celsius) Drug concentration that inhibit cell growth by 50% compared to untreated control cultures of CHO cells (for 6 days at 37 degree Celsius)	[PMID: 9526570]
CHO	IC₅₀	9.7 μM Compound: Adriamycin	Cytotoxicity against CHO cells selected at 1 ug/mL colchicine after 72 hrs by MTT assay Cytotoxicity against CHO cells selected at 1 ug/mL colchicine after 72 hrs by MTT assay	[PMID: 21721528]
CHO-K1	IC₅₀	4.2 μM Compound: Doxorubicin	Cytotoxicity against CHOK1 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against CHOK1 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27843113]
CNE	IC₅₀	0.22 μM Compound: DOX	Antiproliferative activity against human CNE cells after 72 hrs by CCK-8 assay Antiproliferative activity against human CNE cells after 72 hrs by CCK-8 assay	[PMID: 29614418]
CNE-2	IC₅₀	3.52 μM Compound: Doxorubicin	Cytotoxicity against human CNE2 cells by CCK8 assay Cytotoxicity against human CNE2 cells by CCK8 assay	[PMID: 29452840]
CNS cell	GI₅₀	94 μM Compound: doxorubicin	Cytotoxicity against human CNS cells after 48 hrs by SRB assay Cytotoxicity against human CNS cells after 48 hrs by SRB assay	[PMID: 19070942]
COLO 201	IC₅₀	0.8 μM Compound: Doxorubicin	Growth inhibition of human Colo-201 cells by MTT assay Growth inhibition of human Colo-201 cells by MTT assay	[PMID: 33901643]
COLO 205	GI₅₀	< 0.1 μM Compound: ADR	Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay	[PMID: 20673627]
COLO 205	GI₅₀	< 0.1 μM Compound: ADR	Cytotoxicity against human COLO205 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human COLO205 cells after 48 hrs by sulforhodamine B assay	[PMID: 21737288]
COLO 205	IC₅₀	0.02 μM Compound: Doxorubicin	Antiproliferative activity against human COLO205 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method Antiproliferative activity against human COLO205 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	[PMID: 25937235]
COLO 205	GI₅₀	0.14 μM Compound: adriamycin	Cytotoxicity against human Colo205 cells after 24 hrs by SRB method Cytotoxicity against human Colo205 cells after 24 hrs by SRB method	[PMID: 18262426]
COLO 205	GI₅₀	0.14 μM Compound: ADR	Growth inhibition of human COLO205 cells after 48 hrs by SRB assay Growth inhibition of human COLO205 cells after 48 hrs by SRB assay	[PMID: 20031423]
COLO 205	GI₅₀	0.14 μM Compound: ADR	Growth inhibition of human COLO205 cells by SRB assay Growth inhibition of human COLO205 cells by SRB assay	[PMID: 22361684]
COLO 205	GI₅₀	0.14 μM Compound: ADR	Anticancer activity against human COLO205 cells by SRB method Anticancer activity against human COLO205 cells by SRB method	[PMID: 21676506]
COLO 205	GI₅₀	0.14 μM Compound: ADR	Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay	[PMID: 23849207]
COLO 205	GI₅₀	0.14 μM Compound: ADR	Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human COLO205 cells after 48 hrs by sulforhodamine B assay	[PMID: 22364746]
COLO 205	GI₅₀	0.14 μM Compound: ADR	Cytotoxicity against human Colo205 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human Colo205 cells after 48 hrs by sulforhodamine B assay	[PMID: 18657979]
COLO 205	GI₅₀	0.14 μM Compound: ADR	Cytotoxicity against human COLO205 cells after 24 hrs by WST-1 assay Cytotoxicity against human COLO205 cells after 24 hrs by WST-1 assay	[PMID: 20732817]
COLO 205	GI₅₀	0.15 μM Compound: ADR, Adriamycin	Growth inhibition of human Colo205 cells by SRB method Growth inhibition of human Colo205 cells by SRB method	[PMID: 18207392]
COLO 205	GI₅₀	0.18 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay	[PMID: 23871905]
COLO 205	GI₅₀	0.18 μM Compound: Doxorubicin	Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
COLO 205	GI₅₀	0.18 μM Compound: Doxorubicin	Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human COLO205 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
COLO 205	IC₅₀	0.26 μM Compound: adriamycin	Cytotoxicity against human COLO205 cells after 72 hrs by MTT assay Cytotoxicity against human COLO205 cells after 72 hrs by MTT assay	[PMID: 17107806]
COLO 205	IC₅₀	0.37 μM Compound: Doxo	Cytotoxicity against human COLO205 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human COLO205 cells assessed as cell viability after 48 hrs by MTT assay	10.1039/C2MD20302B
COLO 205	IC₅₀	0.4 μM Compound: Doxorubicin	Anticancer activity against human COLO205 cells by MTT assay Anticancer activity against human COLO205 cells by MTT assay	[PMID: 21570750]
COLO 205	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human COLO205 cells by MTT assay Cytotoxicity against human COLO205 cells by MTT assay	[PMID: 24300737]
COLO 205	IC₅₀	0.52 μM Compound: DOX	Antiproliferative activity against human COLO205 cells after 72 hrs by Sulforhodamine B-stain assay Antiproliferative activity against human COLO205 cells after 72 hrs by Sulforhodamine B-stain assay	[PMID: 27484508]
COLO 205	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human COLO205 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human COLO205 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 24780595]
COLO 205	IC₅₀	0.7 μM Compound: Dox	Cytotoxicity against human COLO205 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human COLO205 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 24507927]
COLO 205	IC₅₀	1.43 μM Compound: Doxorubicin	Antiproliferative activity against human COLO205 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human COLO205 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31546197]
COLO 205	IC₅₀	1.5 μM Compound: Doxorubicin	Antitumor activity against human COLO205 cells after 24 to 48 hrs by MTT assay Antitumor activity against human COLO205 cells after 24 to 48 hrs by MTT assay	[PMID: 21553829]
COLO 205	IC₅₀	1.69 μM Compound: Dox	Anticancer activity against human COLO205 cells after 48 hrs by MTT assay Anticancer activity against human COLO205 cells after 48 hrs by MTT assay	[PMID: 22209733]
COLO 205	GI₅₀	14.7 μM Compound: ADR	Anticancer activity against human COLO205 cells by SRB method Anticancer activity against human COLO205 cells by SRB method	[PMID: 22104151]
COLO 205	IC₅₀	2 μM Compound: ADR	Cytotoxicity against human Colo205 cells by SRB assay Cytotoxicity against human Colo205 cells by SRB assay	[PMID: 18656370]
COLO 205	IC₅₀	2 μM Compound: ADR	Cytotoxicity against human Colo205 cells by sulforhodamine B assay Cytotoxicity against human Colo205 cells by sulforhodamine B assay	[PMID: 17822905]
COLO 205	IC₅₀	2.1 μM Compound: Doxorubicin	Antiproliferative activity against human COLO 205 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human COLO 205 cells assessed as cell growth inhibition by MTT assay	[PMID: 34838335]
COLO 205	IC₅₀	2.5 μM Compound: Doxorubicin	Cytotoxicity against human COLO 205 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human COLO 205 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 35293752]
COLO 205	IC₅₀	3.8 μM Compound: DOX	Cytotoxicity against human COLO205 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human COLO205 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 31589431]
COLO 320	IC₅₀	7.4 μM Compound: Doxorubicin	Cytotoxicity against human COLO 320 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human COLO 320 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 35293752]
COR-L23	IC₅₀	20.1 nM Compound: Doxorubicin	Cytotoxicity measured using the COR-L23 parental (COR-L23/P) human non small cell lung carcinoma cell line Cytotoxicity measured using the COR-L23 parental (COR-L23/P) human non small cell lung carcinoma cell line	[PMID: 11806724]
COS-7	IC₅₀	2.05 μM Compound: Doxorubicin	Cytotoxicity against African green monkey COS7 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against African green monkey COS7 cells assessed as reduction in cell viability by MTT assay	[PMID: 31404864]
COS-7	IC₅₀	3.04 μM Compound: Doxorubicin	Growth inhibition of African green monkey COS7 cells by MTT assay Growth inhibition of African green monkey COS7 cells by MTT assay	[PMID: 28147307]
CRL-7065 cell line	EC₅₀	0.9 μM Compound: Doxorubicin	Cytotoxicity against human CRL7065 cells after 96 hrs by MTT assay Cytotoxicity against human CRL7065 cells after 96 hrs by MTT assay	[PMID: 26320088]
CWR22R	IC₅₀	0.02 μM Compound: Doxorubicin	Antiproliferative activity against human 22Rv1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human 22Rv1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 34851111]
CWR22R	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human 22Rv1 cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay Cytotoxicity against human 22Rv1 cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay	[PMID: 28617598]
CWR22R	IC₅₀	6.32 μM Compound: Doxorubicin	Growth inhibition of human 22Rv1 cells after 48 hrs by MTT assay Growth inhibition of human 22Rv1 cells after 48 hrs by MTT assay	[PMID: 30072225]
DA-3 cell line	IC₅₀	4 μM Compound: DOX	Cytotoxicity against mouse DA-3 cells after 24 hrs by XTT assay Cytotoxicity against mouse DA-3 cells after 24 hrs by XTT assay	[PMID: 24900668]
Daoy	GI₅₀	0.016 μM Compound: Doxorubicin	Antiproliferative activity against human DaOY cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human DaOY cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 30360625]
Daoy	IC₅₀	0.0629 μM Compound: Doxorubicin	Antiproliferative activity against human Daoy cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human Daoy cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34325324]
Daoy	IC₅₀	8.8 nM Compound: 5; Dox	Cytotoxicity against human DaOY cells assessed as reduction in cell viability incubated for 72 hrs by AlamarBlue cell viability assay Cytotoxicity against human DaOY cells assessed as reduction in cell viability incubated for 72 hrs by AlamarBlue cell viability assay	[PMID: 31347843]
Daudi	IC₅₀	0.127 μM Compound: Dox	Antiproliferative activity against human Daudi cells after 72 hrs by MTT assay Antiproliferative activity against human Daudi cells after 72 hrs by MTT assay	[PMID: 25998504]
Daudi	IC₅₀	0.3 μM Compound: adriamycin	Cytotoxicity against human Daudi cells under deem light after 96 hrs by MTT assay Cytotoxicity against human Daudi cells under deem light after 96 hrs by MTT assay	[PMID: 17993275]
Detroit 562	IC₅₀	1.26 μM Compound: Doxorubicin	Cytotoxicity against human Detroit 562 cells assessed as reduction in cell viability after 4 hrs by MTT assay Cytotoxicity against human Detroit 562 cells assessed as reduction in cell viability after 4 hrs by MTT assay	[PMID: 30773423]
DLD-1	ED₅₀	0.1 μg/mL Compound: doxorubicin	Cytotoxicity against human DLD1 cells after 3 days by MTT assay Cytotoxicity against human DLD1 cells after 3 days by MTT assay	[PMID: 16252910]
DLD-1	IC₅₀	0.1 μM Compound: adriamycin	Antitumor activity against human DLD1 cells by methylene blue staining method Antitumor activity against human DLD1 cells by methylene blue staining method	[PMID: 17656091]
DLD-1	ED₅₀	0.57 μg/mL Compound: Doxorubicin	Cytotoxicity against human DLD1 cells by MTT assay Cytotoxicity against human DLD1 cells by MTT assay	[PMID: 15104488]
DLD-1	IC₅₀	0.84 μM Compound: Dox	Cytotoxicity against human DLD1 cells after 48 hrs by MTT assay Cytotoxicity against human DLD1 cells after 48 hrs by MTT assay	[PMID: 25247771]
DLD-1	IC₅₀	10.2 μM Compound: Doxorubicin	Anticancer activity against human DLD-1 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Anticancer activity against human DLD-1 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 30772606]
DLD-1	IC₅₀	145 nM Compound: Doxorubicin	Cytotoxicity against human DLD1 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human DLD1 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 30429975]
DLD-1	IC₅₀	2.6 μM Compound: Doxorubicin	Cytotoxicity against human DLD1 cells by Alamar Blue assay Cytotoxicity against human DLD1 cells by Alamar Blue assay	[PMID: 27536968]
DLD-1	IC₅₀	2.78 μM Compound: Doxorubicin	Cytotoxicity against human DLD1 cells after 72 hrs by alamar blue assay Cytotoxicity against human DLD1 cells after 72 hrs by alamar blue assay	[PMID: 28159416]
DLD-1	IC₅₀	2.78 μM Compound: Doxorubicin	Cytotoxicity against human DLD1 cells by Alamar blue assay Cytotoxicity against human DLD1 cells by Alamar blue assay	[PMID: 27256910]
DU-145	GI₅₀	< 0.01 μM Compound: Doxorubicin	Growth inhibition of human DU145 cells after 48 hrs by SRB assay Growth inhibition of human DU145 cells after 48 hrs by SRB assay	10.1039/C6MD00097E
DU-145	GI₅₀	< 0.01 μM Compound: Doxorubicin	Growth inhibition in human DU145 cells after 48 hrs by SRB assay Growth inhibition in human DU145 cells after 48 hrs by SRB assay	[PMID: 31546197]
DU-145	GI₅₀	< 0.1 μM Compound: ADR	Cytotoxicity against 10'5 CFU/mL human DU145 cells after 48 hrs by SRB assay Cytotoxicity against 10'5 CFU/mL human DU145 cells after 48 hrs by SRB assay	[PMID: 21794959]
DU-145	IC₅₀	< 2.94 μM Compound: Doxorubicin	Inhibition of proliferation of human DU145 cells after 72 hrs by XTT assay Inhibition of proliferation of human DU145 cells after 72 hrs by XTT assay	[PMID: 20810194]
DU-145	IC₅₀	0.01 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as cell survival after 24 hrs by XTT assay Cytotoxicity against human DU145 cells assessed as cell survival after 24 hrs by XTT assay	[PMID: 25059501]
DU-145	IC₅₀	0.02 μM Compound: Doxorubicin	Antiproliferative activity against human DU145 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method Antiproliferative activity against human DU145 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	[PMID: 25937235]
DU-145	IC₅₀	0.051 μM Compound: DOX	Cytotoxicity against human DU145 cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human DU145 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
DU-145	GI₅₀	0.06 μM Compound: Doxorubicin	Growth inhibition of human DU145 cells after 72 hrs by SRB assay Growth inhibition of human DU145 cells after 72 hrs by SRB assay	[PMID: 18585035]
DU-145	IC₅₀	0.07 μM Compound: DOX	Antiproliferative activity against human DU145 cells after 72 hrs by Sulforhodamine B-stain assay Antiproliferative activity against human DU145 cells after 72 hrs by Sulforhodamine B-stain assay	[PMID: 27484508]
DU-145	IC₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	[PMID: 19361894]
DU-145	GI₅₀	0.1081 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 31534659]
DU-145	GI₅₀	0.11 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human DU145 cells after 48 hrs by SRB assay Cytotoxicity against human DU145 cells after 48 hrs by SRB assay	[PMID: 23871905]
DU-145	GI₅₀	0.11 μM Compound: Doxorubicin	Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
DU-145	GI₅₀	0.11 μM Compound: Doxorubicin	Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human DU145 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
DU-145	IC₅₀	0.12 μM Compound: Doxorubicin	Antiproliferative activity against human DU145 cells assessed as cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human DU145 cells assessed as cell viability incubated for 72 hrs by MTT assay	[PMID: 25799376]
DU-145	IC₅₀	0.13 μM Compound: doxorubicin	Cytotoxicity against human DU145 cells by SRB microtiter plate assay Cytotoxicity against human DU145 cells by SRB microtiter plate assay	[PMID: 17585747]
DU-145	GI₅₀	0.134 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as growth inhibition measured after 48 hrs by SRB assay Cytotoxicity against human DU145 cells assessed as growth inhibition measured after 48 hrs by SRB assay	[PMID: 31059248]
DU-145	IC₅₀	0.153 μM Compound: Dox	Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 30108718]
DU-145	IC₅₀	0.2 μM Compound: DOX	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 23218718]
DU-145	IC₅₀	0.2 μM Compound: DOX, Doxorubicin	Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay	[PMID: 24095089]
DU-145	EC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells after 96 hrs by MTT assay Cytotoxicity against human DU145 cells after 96 hrs by MTT assay	[PMID: 26320088]
DU-145	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human DU-145 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay Cytotoxicity against human DU-145 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay	[PMID: 36970146]
DU-145	GI₅₀	0.35 μM Compound: Doxorubicin	Growth inhibition of human DU145 cells after 2 days by MTT assay Growth inhibition of human DU145 cells after 2 days by MTT assay	[PMID: 20138760]
DU-145	IC₅₀	0.363 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells after 24 hrs by MTT assay Cytotoxicity against human DU145 cells after 24 hrs by MTT assay	[PMID: 30654238]
DU-145	IC₅₀	0.4 μg/mL Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by SRB assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 30660827]
DU-145	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25655719]
DU-145	IC₅₀	0.52 μM Compound: adriamycin	Cytotoxicity against human DU145 cells measured on day 4 by CCK8 assay Cytotoxicity against human DU145 cells measured on day 4 by CCK8 assay	[PMID: 25936262]
DU-145	IC₅₀	0.53 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24530030]
DU-145	IC₅₀	0.534 μM Compound: 1	Cytotoxicity in human DU-145 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay Cytotoxicity in human DU-145 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay	[PMID: 33064004]
DU-145	IC₅₀	0.58 μM Compound: Doxo	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 21885273]
DU-145	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells by MTT assay Cytotoxicity against human DU145 cells by MTT assay	[PMID: 26586599]
DU-145	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells by MTT assay Cytotoxicity against human DU145 cells by MTT assay	[PMID: 25172418]
DU-145	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells by MTT assay Cytotoxicity against human DU145 cells by MTT assay	[PMID: 24300737]
DU-145	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells incubated for 24 hrs by MTT asasy Cytotoxicity against human DU145 cells incubated for 24 hrs by MTT asasy	[PMID: 28615134]
DU-145	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as cell growth inhibition by MTT assay Cytotoxicity against human DU145 cells assessed as cell growth inhibition by MTT assay	[PMID: 27187861]
DU-145	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability by MTT assay	[PMID: 26774921]
DU-145	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability by MTT assay	[PMID: 26646219]
DU-145	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells by MTT assay Cytotoxicity against human DU145 cells by MTT assay	[PMID: 25241926]
DU-145	IC₅₀	0.86 μM Compound: Adriamycin	Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay	[PMID: 25481396]
DU-145	IC₅₀	0.86 μM Compound: Adriamycin	Cytotoxicity against human DU145 cells after 2 days Cytotoxicity against human DU145 cells after 2 days	[PMID: 22318164]
DU-145	IC₅₀	0.895 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28462842]
DU-145	IC₅₀	0.95 μM Compound: Adriamycin	Cytotoxicity against human DU145 cells after 2 days by CCK8 assay Cytotoxicity against human DU145 cells after 2 days by CCK8 assay	[PMID: 26361737]
DU-145	GI₅₀	0.95 μM Compound: Doxorubicin	Anti-proliferative activity against human DU145 cells incubated for 48 hrs by SRB assay Anti-proliferative activity against human DU145 cells incubated for 48 hrs by SRB assay	[PMID: 26163220]
DU-145	IC₅₀	1 μM Compound: Adriamycin	Cytotoxicity against human DU145 cells after 2 days Cytotoxicity against human DU145 cells after 2 days	[PMID: 21601964]
DU-145	IC₅₀	1.08 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 26948541]
DU-145	IC₅₀	1.1 μM Compound: Doxorubicin	Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth incubated for 72 hrs by XTT assay Cytotoxicity against human DU-145 cells assessed as inhibition of cell growth incubated for 72 hrs by XTT assay	[PMID: 33540356]
DU-145	IC₅₀	1.1 μM Compound: Adriamycin	Cytotoxicity against human DU145 cells after 2 days by cell counting kit-8 analysis Cytotoxicity against human DU145 cells after 2 days by cell counting kit-8 analysis	[PMID: 22503656]
DU-145	IC₅₀	1.3 μM Compound: Doxorubicin	Anticancer activity against human DU145 cells after 48 hrs by MTT assay Anticancer activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 25615796]
DU-145	IC₅₀	1.38 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 26264845]
DU-145	IC₅₀	1.4 μM Compound: Doxorubicin	Anticancer activity against human DU-145 cells assessed as growth inhibition incubated for 48 hrs by MTT assay Anticancer activity against human DU-145 cells assessed as growth inhibition incubated for 48 hrs by MTT assay	[PMID: 34363936]
DU-145	IC₅₀	1.41 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 27015609]
DU-145	IC₅₀	1.428 μM Compound: Doxorubicin	Anti-proliferative activity against human DU145 cells measured after 48 hrs by MTT assay Anti-proliferative activity against human DU145 cells measured after 48 hrs by MTT assay	[PMID: 27744185]
DU-145	IC₅₀	1.57 μM Compound: ADR	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	[PMID: 22819942]
DU-145	IC₅₀	1.6 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 27496212]
DU-145	IC₅₀	1.622 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28482219]
DU-145	IC₅₀	1.75 μM Compound: Adriamycin	Cytotoxicity against human DU145 cells by MTT assay Cytotoxicity against human DU145 cells by MTT assay	[PMID: 21115246]
DU-145	IC₅₀	1.8 μM Compound: Doxorubicin	Cytotoxicity against human DU-145 cells incubated for 48 hrs by MTT assay Cytotoxicity against human DU-145 cells incubated for 48 hrs by MTT assay	[PMID: 33421712]
DU-145	IC₅₀	1.807 μM Compound: Doxorubicin	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 29501940]
DU-145	IC₅₀	1.82 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 26708114]
DU-145	IC₅₀	1.86 μM Compound: II	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 29289881]
DU-145	IC₅₀	1.9 μM Compound: Adriamycin	Cytotoxicity against human DU145 cells after 4 days by MTT assay Cytotoxicity against human DU145 cells after 4 days by MTT assay	[PMID: 21704436]
DU-145	IC₅₀	1.909 μM Compound: Doxorubicin	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 26301558]
DU-145	IC₅₀	1.91 μM Compound: Doxorubicin	Cytotoxicity in human DU145 cells incubated for 48 hrs by MTT assay Cytotoxicity in human DU145 cells incubated for 48 hrs by MTT assay	[PMID: 28923381]
DU-145	IC₅₀	1.94 μM Compound: Doxorubicin	Anticancer activity against human DU145 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Anticancer activity against human DU145 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 26330077]
DU-145	IC₅₀	10.86 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 22818039]
DU-145	IC₅₀	12.3 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 21429743]
DU-145	IC₅₀	13.24 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells after 24 hrs by MTT assay Cytotoxicity against human DU145 cells after 24 hrs by MTT assay	[PMID: 22687747]
DU-145	IC₅₀	17.67 μM Compound: Doxorubicin	Anticancer activity against human DU145 cells by MTT assay Anticancer activity against human DU145 cells by MTT assay	[PMID: 25743216]
DU-145	IC₅₀	2.13 μM Compound: Doxo	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 29129513]
DU-145	IC₅₀	2.4 μM Compound: Doxorubicin	Anticancer activity against human DU145 cells by MTT assay Anticancer activity against human DU145 cells by MTT assay	10.1039/C4MD00219A
DU-145	IC₅₀	2.4 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay	[PMID: 28818768]
DU-145	IC₅₀	2.45 μM Compound: Doxo (I)	Antiproliferative activity against human DU145 cells by MTT assay Antiproliferative activity against human DU145 cells by MTT assay	10.1039/C4MD00228H
DU-145	IC₅₀	2.49 μM Compound: Doxorubicin	Anticancer activity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay Anticancer activity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26542964]
DU-145	IC₅₀	2.54 μM Compound: DOX	Antiproliferative activity against human DU145 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32631552]
DU-145	IC₅₀	2.68 μM Compound: Adriamycin	Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay Cytotoxicity against human DU145 cells after 2 days by CCK-8 assay	[PMID: 24013413]
DU-145	IC₅₀	23.48 μM Compound: Adriamycin	Cytotoxicity against human DU145 cells after 24 hrs by MTT assay Cytotoxicity against human DU145 cells after 24 hrs by MTT assay	[PMID: 22276650]
DU-145	IC₅₀	3.11 μM Compound: Doxorubicin	Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31883489]
DU-145	IC₅₀	3.11 μM Compound: DOX	Cytotoxicity against human DU145 cells after 48 hrs by SRB method Cytotoxicity against human DU145 cells after 48 hrs by SRB method	[PMID: 25933593]
DU-145	IC₅₀	3.27 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells after 72 hrs by XTT assay Cytotoxicity against human DU145 cells after 72 hrs by XTT assay	10.1007/s00044-013-0558-8
DU-145	IC₅₀	3.9 nM Compound: doxorubicin	Anticancer activity against human DU145 cells after 72 hrs by XTT assay Anticancer activity against human DU145 cells after 72 hrs by XTT assay	[PMID: 18829316]
DU-145	IC₅₀	4.06 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 25462233]
DU-145	IC₅₀	4.75 μM Compound: Doxorubicin	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 26907155]
DU-145	IC₅₀	4.8 μM Compound: DOX	Cytotoxicity against human DU145 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 31589431]
DU-145	IC₅₀	4.88 μM Compound: Dox	Cytotoxicity against human DU145 cells after 2 days Cytotoxicity against human DU145 cells after 2 days	[PMID: 24904965]
DU-145	IC₅₀	5.3 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25594739]
DU-145	IC₅₀	5.4 μM Compound: DX	Cytotoxicity against human DU145 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human DU145 cells after 48 hrs by sulforhodamine B assay	10.1039/C5MD00513B
DU-145	IC₅₀	5.8 μM Compound: DXR	Cytotoxicity against human androgen-independent DU145 cells by MTT assay Cytotoxicity against human androgen-independent DU145 cells by MTT assay	[PMID: 22326399]
DU-145	IC₅₀	6 μM Compound: doxorubicin	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 23748152]
DU-145	IC₅₀	6.24 μM Compound: Doxo	Cytotoxicity against human DU145 cells after 24 hrs by MTT assay Cytotoxicity against human DU145 cells after 24 hrs by MTT assay	[PMID: 21885273]
DU-145	IC₅₀	8.19 μM Compound: Doxorubicin	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	[PMID: 24607876]
EA.hy 926	IC₅₀	4.2 μM Compound: Doxorubicin	Cytotoxicity against human EAhy926 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human EAhy926 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27843113]
EBC-1	IC₅₀	305.1 nM Compound: Doxorubicin	Antiproliferative activity against human EBC1 cells after 72 hrs by MTT assay Antiproliferative activity against human EBC1 cells after 72 hrs by MTT assay	[PMID: 28412159]
ECa-109 cell line	IC₅₀	2.06 μM Compound: Doxorubicin	Cytotoxicity against human ECa-109 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human ECa-109 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32866757]
Ehrlich	IC₅₀	> 10 μM Compound: doxorubicin	Cytotoxicity against mouse Ehrlich ascites carcinoma cells after 24 hrs by MTT assay Cytotoxicity against mouse Ehrlich ascites carcinoma cells after 24 hrs by MTT assay	[PMID: 18281125]
Ehrlich	IC₅₀	> 10 μM Compound: doxorubicin	Cytotoxicity against mouse EAC cells after 24 hrs by MTT assay Cytotoxicity against mouse EAC cells after 24 hrs by MTT assay	[PMID: 17400463]
Ehrlich	IC₅₀	0.35 μM Compound: Doxorubicin	Cytotoxicity against mouse EAC after 3 days by MTT assay Cytotoxicity against mouse EAC after 3 days by MTT assay	[PMID: 8350087]
Ehrlich	IC₅₀	37.4 μg/mL Compound: Doxorubicin	Cytotoxicity against mouse EAC cells assessed as cell growth inhibition measured after 2 hrs by trypan blue exclusion assay Cytotoxicity against mouse EAC cells assessed as cell growth inhibition measured after 2 hrs by trypan blue exclusion assay	[PMID: 27894044]
Ehrlich	IC₅₀	37.5 μg/mL Compound: Doxorubicin	Antitumor activity against mouse EAC cells assessed as non viable cells after 2 hrs by trypan blue exclusion test Antitumor activity against mouse EAC cells assessed as non viable cells after 2 hrs by trypan blue exclusion test	[PMID: 20149941]
Ehrlich	IC₅₀	38 μg/mL Compound: Doxorubicin	Cytotoxicity against mouse EAC assessed as non-viable cells after 2 hrs by trypan blue exclusion test Cytotoxicity against mouse EAC assessed as non-viable cells after 2 hrs by trypan blue exclusion test	[PMID: 21112675]
Ehrlich	IC₅₀	38 μg/mL Compound: doxorubicin	Cytotoxicity against mouse EAC cells after 2 hrs by trypan blue exclusion Cytotoxicity against mouse EAC cells after 2 hrs by trypan blue exclusion	[PMID: 19944497]
Ehrlich	IC₅₀	4.18 μM Compound: doxorubicin	Cytotoxicity against mouse EAC after 24 hrs by MTT assay Cytotoxicity against mouse EAC after 24 hrs by MTT assay	[PMID: 19128861]
Ehrlich	IC₅₀	5.22 μM Compound: Doxorubicin	Cytotoxicity against mouse EAC cells after 24 hrs by MTT assay Cytotoxicity against mouse EAC cells after 24 hrs by MTT assay	[PMID: 22542958]
Ehrlich	IC₅₀	52 μg/mL Compound: Doxorubicin	Antitumor activity against mouse EAC after 2 hrs by trypan blue exclusion assay Antitumor activity against mouse EAC after 2 hrs by trypan blue exclusion assay	[PMID: 19853327]
Ehrlich	IC₅₀	69.9 μM Compound: Doxorubicin	Cytotoxicity against mouse EAC cells after 2 hrs by trypan blue exclusion assay Cytotoxicity against mouse EAC cells after 2 hrs by trypan blue exclusion assay	[PMID: 20413187]
EKVX	GI₅₀	0.41 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human EKVX cells after 48 hrs by SRB assay Cytotoxicity against human EKVX cells after 48 hrs by SRB assay	[PMID: 23871905]
EKVX	GI₅₀	0.41 μM Compound: Doxorubicin	Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
EKVX	GI₅₀	0.41 μM Compound: Doxorubicin	Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human EKVX cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
EL4	IC₅₀	0.67 μg/mL Compound: (20) adriamycin	In vitro cytotoxicity of compound against EL4, mouse thymoma was defined by microculture tetrazolium assay In vitro cytotoxicity of compound against EL4, mouse thymoma was defined by microculture tetrazolium assay	[PMID: 12620075]
EMT6	ED₅₀	< 0.0001 μM Compound: Adriamycin	Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under hypoxic condition. Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under hypoxic condition.	[PMID: 7452674]
EMT6	ED₅₀	0.012 μM Compound: Adriamycin	Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under aerobic condition. Compound is measured for surviving fractions of EMT6 tumor cells treated in culture with (0.50 uM) concentration for 1 hr under aerobic condition.	[PMID: 7452674]
EOL1	IC₅₀	0.001269 μM Compound: Doxorubicin	Antiproliferative activity against human EOL1 cells assessed as inhibition of cell growth incubated for 7 days by CellTiterGlo assay Antiproliferative activity against human EOL1 cells assessed as inhibition of cell growth incubated for 7 days by CellTiterGlo assay	[PMID: 30540463]
Epithelial cell	IC₅₀	9.787 nM Compound: Doxorubicin	Cytotoxicity against albino rat epithelial rat by MTT assay Cytotoxicity against albino rat epithelial rat by MTT assay	[PMID: 34116327]
Erythrocyte	EC₅₀	> 200 μg/mL Compound: Dox	Hemolytic toxicity in mouse erythrocytes assessed as induction of cell membrane disruption incubated for 30 mins by hemoglobin release based spectrophotometry Hemolytic toxicity in mouse erythrocytes assessed as induction of cell membrane disruption incubated for 30 mins by hemoglobin release based spectrophotometry	[PMID: 25147145]
Erythrocyte	EC₅₀	> 50 μg/mL Compound: DOXO	Toxicity in mouse erythrocytes assessed as hemolytic activity after 30 mins by spectrophotometry Toxicity in mouse erythrocytes assessed as hemolytic activity after 30 mins by spectrophotometry	[PMID: 19947600]
F460pv8/eto	IC₅₀	0.02 μM Compound: Doxorubicin	Inhibitory activity against F460pv8/eto cell line using MTT assay Inhibitory activity against F460pv8/eto cell line using MTT assay	[PMID: 10780913]
FaDu	IC₅₀	0.16 μM Compound: DOX	Antiproliferative activity against human FaDu cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human FaDu cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36709571]
FaDu	IC₅₀	0.68 μM Compound: Doxorubicin	Cytotoxicity against human FADU cells assessed as reduction in cell viability after 4 hrs by MTT assay Cytotoxicity against human FADU cells assessed as reduction in cell viability after 4 hrs by MTT assay	[PMID: 30773423]
Fibroblast	IC₅₀	0.005 μM Compound: Doxorubicin	Antiproliferative activity against human fibroblast cells after 48 hrs by Hoechst 33342 staining-based assay Antiproliferative activity against human fibroblast cells after 48 hrs by Hoechst 33342 staining-based assay	[PMID: 30655216]
Fibroblast	IC₅₀	0.015 μM Compound: Doxorubicine	Cytotoxicity against human Fibroblast cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) Cytotoxicity against human Fibroblast cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)	[PMID: 33422908]
Fibroblast	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human skin fibroblast cells assessed as reduction in cell viability after 48 hrs Cytotoxicity against human skin fibroblast cells assessed as reduction in cell viability after 48 hrs	[PMID: 34601029]
Fibroblast	IC₅₀	0.03 μM Compound: Doxorubicin	Toxicity in human skin fibroblasts assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay Toxicity in human skin fibroblasts assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay	[PMID: 31753515]
Fibroblast	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity in human Fibroblast cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human Fibroblast cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34082225]
Fibroblast	IC₅₀	1.3 x 10^-11 μM Compound: Doxo	Cytotoxicity against human gingival fibroblast cells after 48 hrs by alamar blue assay Cytotoxicity against human gingival fibroblast cells after 48 hrs by alamar blue assay	[PMID: 25468043]
Fibroblast	IC₅₀	67 μM Compound: Doxorubicin	Cytotoxicity against fibroblast (unknown origin) cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay Cytotoxicity against fibroblast (unknown origin) cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay	[PMID: 36691388]
Fibroblast	IC₅₀	7.86 μM Compound: Doxorubicin	Antiproliferative activity against human dermal fibroblast cells after 72 hrs Antiproliferative activity against human dermal fibroblast cells after 72 hrs	[PMID: 25127463]
G-361	GI₅₀	< 1 x 10^-1 μM Compound: ADR	Cytotoxicity against Homo sapiens (human) G361 cells by SRB assay Cytotoxicity against Homo sapiens (human) G361 cells by SRB assay	10.1007/s00044-012-0084-0
G-361	IC₅₀	0.09 μM Compound: Doxo	Antiproliferative activity against human G-361 cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human G-361 cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
G-361	IC₅₀	0.09 μM Compound: doxo	Antiproliferative activity against human G361 cell line by MTT assay Antiproliferative activity against human G361 cell line by MTT assay	[PMID: 16913700]
GES1	IC₅₀	0.53 μM Compound: ADM	Cytotoxicity against human GES-1 cells after 48 hrs by MTT assay Cytotoxicity against human GES-1 cells after 48 hrs by MTT assay	[PMID: 25462264]
GOTO	IC₅₀	4.73 nM Compound: Doxorubicin	Cytotoxicity against human GOTO cells after 3 days by MTT assay Cytotoxicity against human GOTO cells after 3 days by MTT assay	[PMID: 20356655]
GOTO	IC₅₀	4.73 nM Compound: Doxorubicin	Cytotoxicity against human GOTO cells by MTT assay Cytotoxicity against human GOTO cells by MTT assay	[PMID: 19345581]
H22	IC₅₀	36.51 μM Compound: Doxorubicin	Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay	[PMID: 21620529]
H69AR	IC₅₀	< 1 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H69AR cells assessed as reduction in cell growth by MTT assay Cytotoxicity against human NCI-H69AR cells assessed as reduction in cell growth by MTT assay	[PMID: 36734533]
HA22T cell line	IC₅₀	0.31 μM Compound: adriamycin	Cytotoxicity against human HA22T cells after 72 hrs by MTT assay Cytotoxicity against human HA22T cells after 72 hrs by MTT assay	[PMID: 17107806]
HaCaT	GI₅₀	< 0.025 μg/mL Compound: DOX; Doxo	Cytotoxicity against human HaCaT cells after 48 hrs by SRB assay Cytotoxicity against human HaCaT cells after 48 hrs by SRB assay	[PMID: 26859070]
HaCaT	GI₅₀	< 0.046 μM Compound: Dox	Antiproliferative activity against human HaCaT cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human HaCaT cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26454648]
HaCaT	GI₅₀	< 0.046 μM Compound: Doxorubicin	Cytotoxicity against human HaCaT cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay Cytotoxicity against human HaCaT cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay	[PMID: 33214037]
HaCaT	IC₅₀	0.01 μM Compound: Doxorubicin	Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 4 days by CellTiter 96 aqueous one solution assay Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 4 days by CellTiter 96 aqueous one solution assay	[PMID: 31596585]
HaCaT	IC₅₀	0.03 μM Compound: Dox	Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30615450]
HaCaT	IC₅₀	0.03 μM Compound: Doxorubicin	Antiproliferative activity against human HaCaT cells after 48 hrs by Hoechst 33342 staining-based assay Antiproliferative activity against human HaCaT cells after 48 hrs by Hoechst 33342 staining-based assay	[PMID: 30655216]
HaCaT	GI₅₀	0.11 μg/mL Compound: DOX	Antiproliferative activity against human HaCaT cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HaCaT cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 25062010]
HaCaT	GI₅₀	0.2 μM Compound: Dox	Growth inhibition of human HaCaT cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay Growth inhibition of human HaCaT cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay	[PMID: 28505535]
HaCaT	IC₅₀	0.23 μM Compound: Doxorubicin	Cytotoxicity against human HaCaT cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HaCaT cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 31753514]
HaCaT	IC₅₀	0.235 μM Compound: Doxorubicin	Cytotoxicity against human HaCaT cells assessed as growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human HaCaT cells assessed as growth inhibition measured after 72 hrs by MTT assay	[PMID: 31383628]
HaCaT	IC₅₀	0.29 μM Compound: DOX	Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31678743]
HaCaT	IC₅₀	0.52 μM Compound: Doxorubicin	Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30389295]
HaCaT	IC₅₀	0.53 μM Compound: Doxorubicin	Cytotoxicity against human HaCaT cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human HaCaT cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 26934105]
HaCaT	GI₅₀	0.64 μM Compound: Dox	Cytotoxicity against human HaCaT cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human HaCaT cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35533562]
HaCaT	GI₅₀	0.9 μM Compound: Dox	Cytotoxicity against human HaCaT cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human HaCaT cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]
HaCaT	GI₅₀	0.9 μM Compound: Dox	Antiproliferative activity against human HaCaT cells incubated for 72 hrs and measured by MTT assay Antiproliferative activity against human HaCaT cells incubated for 72 hrs and measured by MTT assay	[PMID: 35973342]
HaCaT	IC₅₀	1.09 μM Compound: Dox	Cytotoxicity activity against human HaCaT cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity activity against human HaCaT cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30031974]
HaCaT	IC₅₀	3.26 μg/mL Compound: Doxorubicin	Cytotoxicity against human HaCaT cells assessed as cell shrinkage after 24 hrs by SRB assay Cytotoxicity against human HaCaT cells assessed as cell shrinkage after 24 hrs by SRB assay	[PMID: 24269165]
HaCaT	IC₅₀	50 μM Compound: Doxorubicin	Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay	[PMID: 35271771]
HBL-100	IC₅₀	0.08 μM Compound: Doxorubicin	Antiproliferative activity against human HBL100 cells after 70 hrs by alamar blue assay Antiproliferative activity against human HBL100 cells after 70 hrs by alamar blue assay	[PMID: 29471119]
HBL-100	IC₅₀	0.24 μM Compound: Doxorubicin	Cytotoxicity against human HBL100 cells after 72 hrs by MTT assay Cytotoxicity against human HBL100 cells after 72 hrs by MTT assay	[PMID: 19361894]
HBL-100	IC₅₀	8.5 μM Compound: Doxorubicin	Cytotoxicity against human HBL100 cells assessed as reduction in cell viability after 70 hrs by alamar blue assay Cytotoxicity against human HBL100 cells assessed as reduction in cell viability after 70 hrs by alamar blue assay	[PMID: 29471119]
HCC 2998	GI₅₀	0.26 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human HCC2998 cells after 48 hrs by SRB assay Cytotoxicity against human HCC2998 cells after 48 hrs by SRB assay	[PMID: 23871905]
HCC 2998	GI₅₀	0.26 μM Compound: Doxorubicin	Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
HCC 2998	GI₅₀	0.26 μM Compound: Doxorubicin	Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HCC2998 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
HCC1937	IC₅₀	0.44 μM Compound: Doxorubicin	Antiproliferative activity against human HCC1937 cells after 48 hrs by SRB assay Antiproliferative activity against human HCC1937 cells after 48 hrs by SRB assay	[PMID: 29407962]
HCC1954	IC₅₀	0.045 μM Compound: DOX	Cytotoxicity against human HCC1954 cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human HCC1954 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
HCC70	IC₅₀	0.05 μM Compound: Doxorubicin	Cytotoxicity against human HCC70 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human HCC70 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 30457333]
HCT-116	GI₅₀	< 1 μM Compound: DOX	Antiproliferative activity against human HCT116 cells by MTT assay Antiproliferative activity against human HCT116 cells by MTT assay	[PMID: 31990554]
HCT-116	IC₅₀	< 1 μM Compound: doxorubicin	Cytotoxicity against human HCT-116 cells by SRB assay Cytotoxicity against human HCT-116 cells by SRB assay	[PMID: 33847126]
HCT-116	IC₅₀	> 8 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 31836446]
HCT-116	IC₅₀	0.007 ug Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 48 hrs by SRB assay Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 48 hrs by SRB assay	[PMID: 27393950]
HCT-116	IC₅₀	0.007 μM Compound: DOX	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27668963]
HCT-116	IC₅₀	0.01 μM Compound: DOX	Antiproliferative activity against human HCT116 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells measured after 72 hrs by MTT assay	[PMID: 31431364]
HCT-116	GI₅₀	0.011 μM Compound: Doxorubicin	Cytostatic activity against human HCT116 cells after 5 days by SRB assay Cytostatic activity against human HCT116 cells after 5 days by SRB assay	[PMID: 21711054]
HCT-116	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	10.1039/C4MD00371C
HCT-116	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24530030]
HCT-116	IC₅₀	0.02 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method Antiproliferative activity against human HCT116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	[PMID: 25937235]
HCT-116	IC₅₀	0.023 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 31264855]
HCT-116	GI₅₀	0.023 μM Compound: Doxorubicin	Tested for in vitro concentration required to inhibit growth by 50% against HCT116 human colon cancer cell line Tested for in vitro concentration required to inhibit growth by 50% against HCT116 human colon cancer cell line	[PMID: 11755363]
HCT-116	IC₅₀	0.037 μM Compound: adriamycin	Antitumor activity against human HCT116 cells by methylene blue staining method Antitumor activity against human HCT116 cells by methylene blue staining method	[PMID: 17656091]
HCT-116	IC₅₀	0.05 μM Compound: Doxorubicine	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)	[PMID: 33422908]
HCT-116	IC₅₀	0.05 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells after 48 hrs by Hoechst 33342 staining-based assay Antiproliferative activity against human HCT116 cells after 48 hrs by Hoechst 33342 staining-based assay	[PMID: 30655216]
HCT-116	IC₅₀	0.069 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 25462279]
HCT-116	IC₅₀	0.07 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 27060757]
HCT-116	IC₅₀	0.07 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 20846862]
HCT-116	IC₅₀	0.07 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 27448912]
HCT-116	IC₅₀	0.07 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 24780599]
HCT-116	GI₅₀	0.08 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay	[PMID: 23871905]
HCT-116	GI₅₀	0.08 μM Compound: Doxorubicin	Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
HCT-116	GI₅₀	0.08 μM Compound: Doxorubicin	Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HCT116 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
HCT-116	IC₅₀	0.08 μM Compound: Doxorubicin	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs	[PMID: 34601029]
HCT-116	IC₅₀	0.09 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay	[PMID: 21215623]
HCT-116	IC₅₀	0.09 μM Compound: Doxorubicin	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay	[PMID: 32755677]
HCT-116	IC₅₀	0.1 mM Compound: Dox	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 29459273]
HCT-116	IC₅₀	0.1 μM Compound: DOX	Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth measured after 72 hrs by CCK8 assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth measured after 72 hrs by CCK8 assay	[PMID: 31784322]
HCT-116	IC₅₀	0.1 μM Compound: DOX	Cytotoxicity against human HCT116 cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human HCT116 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
HCT-116	IC₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity in human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34082225]
HCT-116	IC₅₀	0.1 μM Compound: Dox	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 30659997]
HCT-116	IC₅₀	0.1 μM Compound: 5	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 29137865]
HCT-116	IC₅₀	0.1 μM Compound: 1; Dox	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 26890118]
HCT-116	IC₅₀	0.1 μM Compound: DOX	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27016707]
HCT-116	IC₅₀	0.1 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT reduction assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT reduction assay	[PMID: 28551177]
HCT-116	IC₅₀	0.1 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method Antiproliferative activity against human HCT116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	[PMID: 25937235]
HCT-116	IC₅₀	0.11 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 31836446]
HCT-116	IC₅₀	0.11 μM Compound: 1; Dox	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 26633734]
HCT-116	IC₅₀	0.11 μM Compound: Dox	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 21144624]
HCT-116	IC₅₀	0.12 μM Compound: Doxorubicin	Toxicity in human HCT-116 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay Toxicity in human HCT-116 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay	[PMID: 31753515]
HCT-116	GI₅₀	0.13 μM Compound: Doxorubicine	Growth inhibition of human HCT116 cells after 2 days by sulforhodamine B assay Growth inhibition of human HCT116 cells after 2 days by sulforhodamine B assay	[PMID: 20045222]
HCT-116	IC₅₀	0.15 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells expressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells expressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27341379]
HCT-116	IC₅₀	0.15 μM Compound: DOXO	Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26142490]
HCT-116	GI₅₀	0.15 μM Compound: Adriamycin	Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 24686011]
HCT-116	GI₅₀	0.15 μM Compound: Adriamycin	Growth inhibition of human HCT116 cells by sulforhodamine B assay Growth inhibition of human HCT116 cells by sulforhodamine B assay	[PMID: 24650643]
HCT-116	EC₅₀	0.16 μM Compound: Doxorubicin	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35567964]
HCT-116	IC₅₀	0.16 μM Compound: Dx	Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 21444205]
HCT-116	IC₅₀	0.18 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition incubated for 72 hrs by MTT assay	[PMID: 26280922]
HCT-116	IC₅₀	0.18 μM Compound: Dox	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 25998504]
HCT-116	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxic activity against human HCT116 cells incubated for 48 hrs by MTT assay Cytotoxic activity against human HCT116 cells incubated for 48 hrs by MTT assay	[PMID: 28055219]
HCT-116	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 36044031]
HCT-116	IC₅₀	0.2 μM Compound: Dox	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 32428792]
HCT-116	IC₅₀	0.2 μM Compound: ADM	Cytotoxicity against human HCT116 cells by SRB method Cytotoxicity against human HCT116 cells by SRB method	[PMID: 29144133]
HCT-116	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells by SRB assay Cytotoxicity against human HCT116 cells by SRB assay	[PMID: 26561719]
HCT-116	IC₅₀	0.2 μM Compound: ADM	Cytotoxic activity against human HCT116 cells by SRB method Cytotoxic activity against human HCT116 cells by SRB method	[PMID: 25611519]
HCT-116	IC₅₀	0.21 μM Compound: Doxorubicin	Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 34778772]
HCT-116	IC₅₀	0.21 μM Compound: Dox	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33479619]
HCT-116	IC₅₀	0.21 μM Compound: DOX	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29660689]
HCT-116	IC₅₀	0.21 μM Compound: DOXO	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 28818447]
HCT-116	IC₅₀	0.21 μM Compound: Adriamycin	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 24370114]
HCT-116	IC₅₀	0.22 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 31836446]
HCT-116	IC₅₀	0.221 μM Compound: Dox	Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 30108718]
HCT-116	IC₅₀	0.23 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as growth inhibition by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition by MTT assay	[PMID: 24398294]
HCT-116	IC₅₀	0.24 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 48 hrs by neutral red dye based assay Cytotoxicity against human HCT116 cells after 48 hrs by neutral red dye based assay	[PMID: 29317147]
HCT-116	IC₅₀	0.25 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells incubated for 48 hrs by WST8 assay Antiproliferative activity against human HCT116 cells incubated for 48 hrs by WST8 assay	[PMID: 31679979]
HCT-116	IC₅₀	0.25 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 48 hrs by WST8 assay Cytotoxicity against human HCT116 cells after 48 hrs by WST8 assay	[PMID: 25163667]
HCT-116	IC₅₀	0.27 μM Compound: DOX	Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31999451]
HCT-116	IC₅₀	0.286 μg/mL Compound: DOX	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 20722446]
HCT-116	IC₅₀	0.29 μM Compound: DOX	Antiproliferative activity against doxorubicin sensitive human HCT-116 cells measured after 72 hrs by MTT assay Antiproliferative activity against doxorubicin sensitive human HCT-116 cells measured after 72 hrs by MTT assay	[PMID: 35612499]
HCT-116	EC₅₀	0.29 μM Compound: Doxorubicin	Induction of apoptosis in human HCT116 cells assessed as caspase activation after 48 hrs Induction of apoptosis in human HCT116 cells assessed as caspase activation after 48 hrs	[PMID: 19282188]
HCT-116	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay	[PMID: 31403289]
HCT-116	IC₅₀	0.3 μM Compound: Dox	Antiproliferative activity against human HCT-116 assessed as growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 assessed as growth inhibition measured after 72 hrs by MTT assay	[PMID: 34902732]
HCT-116	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 22749279]
HCT-116	IC₅₀	0.31 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28327308]
HCT-116	IC₅₀	0.31 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 27886545]
HCT-116	IC₅₀	0.33 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as effect on cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as effect on cell viability measured after 48 hrs by MTT assay	[PMID: 27521588]
HCT-116	IC₅₀	0.34 μM Compound: Doxorubicin	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 33261897]
HCT-116	IC₅₀	0.34 μM Compound: Doxorubicin	Antiproliferative activity against human HCT 116 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Antiproliferative activity against human HCT 116 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 31962262]
HCT-116	IC₅₀	0.34 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells expressing wild type p53 incubated for 72 hrs by MTS assay Cytotoxicity against human HCT116 cells expressing wild type p53 incubated for 72 hrs by MTS assay	[PMID: 31158748]
HCT-116	IC₅₀	0.34 μM Compound: DOXO	Antiproliferative activity against p53 expressing human HCT116 cells after 96 hrs by MTS assay Antiproliferative activity against p53 expressing human HCT116 cells after 96 hrs by MTS assay	[PMID: 26890119]
HCT-116	IC₅₀	0.34 μM Compound: Dox	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 25247771]
HCT-116	IC₅₀	0.34 μM Compound: DOX	Cytotoxicity against human HCT-116 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay	[PMID: 35612499]
HCT-116	IC₅₀	0.36 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 27080182]
HCT-116	IC₅₀	0.38 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells deficient in p53 incubated for 72 hrs by MTS assay Cytotoxicity against human HCT116 cells deficient in p53 incubated for 72 hrs by MTS assay	[PMID: 31158748]
HCT-116	IC₅₀	0.38 μM Compound: DOXO	Antiproliferative activity against p53 deficient human HCT116 cells after 96 hrs by MTS assay Antiproliferative activity against p53 deficient human HCT116 cells after 96 hrs by MTS assay	[PMID: 26890119]
HCT-116	IC₅₀	0.38 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells assessed as cell viability after 48 hrs by SRB assay Antiproliferative activity against human HCT116 cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 26947606]
HCT-116	GI₅₀	0.4 μM Compound: Doxorubicin	Growth inhibition of human HCT116 cells after 2 days by MTT assay Growth inhibition of human HCT116 cells after 2 days by MTT assay	[PMID: 20570145]
HCT-116	IC₅₀	0.4 μM Compound: DOX	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 30429098]
HCT-116	IC₅₀	0.4 μM Compound: Dox	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 21983438]
HCT-116	IC₅₀	0.4 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay	10.1039/C0MD00219D
HCT-116	IC₅₀	0.41 μM Compound: adriamycin	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 17125240]
HCT-116	IC₅₀	0.467 μM Compound: Doxorubicin	Anticancer activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT colorimetric assay Anticancer activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT colorimetric assay	[PMID: 35694689]
HCT-116	IC₅₀	0.477 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 25703298]
HCT-116	IC₅₀	0.48 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 30783501]
HCT-116	IC₅₀	0.48 μM Compound: Doxorubicin	Cytotoxicity against human HCT-116 p53+/+ cells assessed as reduction in cell viability after 72 hrs by RRA assay Cytotoxicity against human HCT-116 p53+/+ cells assessed as reduction in cell viability after 72 hrs by RRA assay	[PMID: 33508467]
HCT-116	IC₅₀	0.5 mM Compound: Dox	Antiproliferative activity against p53 knockout human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against p53 knockout human HCT116 cells after 72 hrs by MTT assay	[PMID: 29459273]
HCT-116	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as reduction in cell survival after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell survival after 48 hrs by MTT assay	[PMID: 28494255]
HCT-116	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 33668008]
HCT-116	IC₅₀	0.5 μM Compound: 5	Antiproliferative activity against p53 deficient human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against p53 deficient human HCT116 cells after 72 hrs by MTT assay	[PMID: 29137865]
HCT-116	IC₅₀	0.5 μM Compound: 1; Dox	Antiproliferative activity against p53 knockout human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against p53 knockout human HCT116 cells after 72 hrs by MTT assay	[PMID: 26890118]
HCT-116	GI₅₀	0.5 μM Compound: Dox	Antiproliferative activity against p53-deficient human HCT-116 cells incubated for 72 hrs and measured by MTT assay Antiproliferative activity against p53-deficient human HCT-116 cells incubated for 72 hrs and measured by MTT assay	[PMID: 35973342]
HCT-116	IC₅₀	0.5 μM Compound: Adriamycin	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by sulphorhodamine B assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 48 hrs by sulphorhodamine B assay	[PMID: 26222449]
HCT-116	IC₅₀	0.52 μM Compound: Dox	Cytotoxicity against human p53 knockout HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human p53 knockout HCT116 cells after 72 hrs by MTT assay	[PMID: 21144624]
HCT-116	IC₅₀	0.55 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
HCT-116	GI₅₀	0.57 μM Compound: Dox	Anticancer activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Anticancer activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35533562]
HCT-116	IC₅₀	0.579 μM Compound: 1	Cytotoxicity in human HCT-116 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay Cytotoxicity in human HCT-116 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay	[PMID: 33064004]
HCT-116	GI₅₀	0.6 μM Compound: Dox	Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]
HCT-116	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against p53 knock out human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against p53 knock out human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34082225]
HCT-116	IC₅₀	0.6 μM Compound: Dox	Cytotoxicity against p53 knockout human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against p53 knockout human HCT116 cells after 72 hrs by MTT assay	[PMID: 30659997]
HCT-116	IC₅₀	0.62 μM Compound: doxorubicin	Cytotoxicity against human HCT116 cells by SRB assay Cytotoxicity against human HCT116 cells by SRB assay	[PMID: 17194596]
HCT-116	IC₅₀	0.63 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay	[PMID: 23291120]
HCT-116	IC₅₀	0.65 μg/mL Compound: Dox	Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay	[PMID: 20399544]
HCT-116	IC₅₀	0.7 μM Compound: Dox	Antiproliferative activity against human HCT-116 cells with inactivated p53 gene assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells with inactivated p53 gene assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 32428792]
HCT-116	IC₅₀	0.74 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 26874404]
HCT-116	GI₅₀	0.76 μM Compound: Dox	Antiproliferative activity against human HCT-116 cells incubated for 72 hrs and measured by MTT assay Antiproliferative activity against human HCT-116 cells incubated for 72 hrs and measured by MTT assay	[PMID: 35973342]
HCT-116	IC₅₀	0.79 μM Compound: DOX	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay	[PMID: 29597166]
HCT-116	IC₅₀	0.8 μM Compound: Dox	Antiproliferative activity against human HCT-116p53KO subline assessed as growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human HCT-116p53KO subline assessed as growth inhibition measured after 72 hrs by MTT assay	[PMID: 34902732]
HCT-116	IC₅₀	0.87 μM Compound: DOX	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35341920]
HCT-116	IC₅₀	1.01 μM Compound: Doxorubicin	Cytotoxicity in human HCT116 cells incubated for 48 hrs by MTT assay Cytotoxicity in human HCT116 cells incubated for 48 hrs by MTT assay	[PMID: 28923381]
HCT-116	IC₅₀	1.01 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 28554092]
HCT-116	IC₅₀	1.1 μM Compound: DOX	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by MTT assay	[PMID: 34323485]
HCT-116	IC₅₀	1.19 μM Compound: Dox	Anticancer activity against Homo sapiens (human) HCT116 cells assessed as growth inhibition after 48 hr by SRB assay Anticancer activity against Homo sapiens (human) HCT116 cells assessed as growth inhibition after 48 hr by SRB assay	10.1007/s00044-012-0057-3
HCT-116	IC₅₀	1.23 μM Compound: Doxorubicin	Antiproliferative activity against p53-deficient human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against p53-deficient human HCT116 cells after 48 hrs by MTT assay	[PMID: 28554092]
HCT-116	IC₅₀	1.3 μg/mL Compound: Doxorubicin, Adriablastina	Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B method Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B method	[PMID: 21664013]
HCT-116	IC₅₀	1.38 μM Compound: Adriamycin	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 24182355]
HCT-116	IC₅₀	1.4 μM Compound: 1, DOX	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 25244612]
HCT-116	IC₅₀	1.4 μM Compound: I	Antiproliferative activity against human HCT116 cells expressing wild-type p53 after 72 hrs by MTT test Antiproliferative activity against human HCT116 cells expressing wild-type p53 after 72 hrs by MTT test	[PMID: 17276690]
HCT-116	IC₅₀	1.6 μg/mL Compound: Doxorubicin	Cytotoxicity against human HCT-116 cells by MTT assay Cytotoxicity against human HCT-116 cells by MTT assay	[PMID: 36325400]
HCT-116	IC₅₀	1.78 μM Compound: Doxorubicin	Cytotoxicity against human HCT-116 p53-/- cells assessed as reduction in cell viability after 72 hrs by RRA assay Cytotoxicity against human HCT-116 p53-/- cells assessed as reduction in cell viability after 72 hrs by RRA assay	[PMID: 33508467]
HCT-116	IC₅₀	1.878 μM Compound: Dox	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 36240546]
HCT-116	IC₅₀	1.96 μM Compound: DOX	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay	[PMID: 30245395]
HCT-116	IC₅₀	1.96 μM Compound: DOX	Antiproliferative activity against human HCT116 cells harboring PI3Kalpha H1047R mutant after 72 hrs by CCK8 assay Antiproliferative activity against human HCT116 cells harboring PI3Kalpha H1047R mutant after 72 hrs by CCK8 assay	[PMID: 30071408]
HCT-116	IC₅₀	1.96 μM Compound: DOX	Cytotoxicity against against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30340899]
HCT-116	IC₅₀	19.7 μM Compound: Doxorubicin	Antiproliferative activity against human HCT-116 cells assessed as cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as cell viability incubated for 48 hrs by MTT assay	[PMID: 32771798]
HCT-116	IC₅₀	19.9 nM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 72 hrs by cell counting Kit-8 assay Cytotoxicity against human HCT116 cells after 72 hrs by cell counting Kit-8 assay	[PMID: 25499433]
HCT-116	IC₅₀	2.05 μM Compound: DOX	Antiproliferative activity against doxorubicin resistant human HCT-116 cells measured after 72 hrs by MTT assay Antiproliferative activity against doxorubicin resistant human HCT-116 cells measured after 72 hrs by MTT assay	[PMID: 35612499]
HCT-116	IC₅₀	2.2 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 24 hrs by WST assay Cytotoxicity against human HCT116 cells after 24 hrs by WST assay	[PMID: 25881821]
HCT-116	IC₅₀	2.38 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells by WST-8 assay Cytotoxicity against human HCT116 cells by WST-8 assay	[PMID: 29295796]
HCT-116	IC₅₀	2.4 μM Compound: Doxorubicin	Anticancer activity against human HCT-116 cells by MTT assay Anticancer activity against human HCT-116 cells by MTT assay	[PMID: 33421712]
HCT-116	IC₅₀	2.56 μM Compound: doxorubicin	Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay	10.1007/s00044-013-0795-x
HCT-116	IC₅₀	2.6 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay	[PMID: 31200236]
HCT-116	GI₅₀	21.4 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTS-PMS assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTS-PMS assay	[PMID: 27614919]
HCT-116	IC₅₀	22 nM Compound: doxorubicine	Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTS assay Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTS assay	[PMID: 23072299]
HCT-116	IC₅₀	22 nM Compound: Doxorubicine	Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay	[PMID: 21142180]
HCT-116	IC₅₀	3.29 μM Compound: Doxorubicin	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs	[PMID: 34530384]
HCT-116	IC₅₀	3.3 μg/mL Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells after 24 hrs by MTS assay Antiproliferative activity against human HCT116 cells after 24 hrs by MTS assay	[PMID: 20813435]
HCT-116	IC₅₀	3.36 μg/mL Compound: Doxorubicin	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 34973507]
HCT-116	IC₅₀	3.7 μM Compound: Dox	Cytotoxicity against human HCT116 cells assessed as cell viability after 24 hrs by crystal violet staining assay Cytotoxicity against human HCT116 cells assessed as cell viability after 24 hrs by crystal violet staining assay	[PMID: 26706352]
HCT-116	IC₅₀	3.73 μg/mL Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay	[PMID: 21723735]
HCT-116	IC₅₀	366 nM Compound: DOX	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 30878835]
HCT-116	IC₅₀	4.4 μM Compound: 1, DOX	Antiproliferative activity against p53-deficient human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against p53-deficient human HCT116 cells after 72 hrs by MTT assay	[PMID: 25244612]
HCT-116	IC₅₀	4.4 μM Compound: I	Antiproliferative activity against human p53 deficient HCT116 p53-/- cells after 72 hrs by MTT test Antiproliferative activity against human p53 deficient HCT116 p53-/- cells after 72 hrs by MTT test	[PMID: 17276690]
HCT-116	IC₅₀	4.8 μM Compound: Doxorubicin	Anticancer activity against human HCT116 cells measured after 48 hrs by SRB assay Anticancer activity against human HCT116 cells measured after 48 hrs by SRB assay	[PMID: 27112448]
HCT-116	IC₅₀	49.5 μM Compound: Doxorubicin	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay	[PMID: 35271771]
HCT-116	IC₅₀	5 mM Compound: Adriamycin	Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay	[PMID: 23685942]
HCT-116	IC₅₀	5 mM Compound: Adriamycin	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 22440624]
HCT-116	IC₅₀	5.1 μM Compound: Doxorubicin	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 34530384]
HCT-116	IC₅₀	5.23 μM Compound: DOX	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 37054758]
HCT-116	IC₅₀	5.23 μM Compound: DOX	Anticancer activity against human HCT116 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Anticancer activity against human HCT116 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 32085964]
HCT-116	IC₅₀	5.23 μM Compound: DOX	Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay	[PMID: 30015070]
HCT-116	IC₅₀	5.23 μM Compound: DOX	Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 36242988]
HCT-116	IC₅₀	5.23 μM Compound: Dox	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32527460]
HCT-116	IC₅₀	5.23 μM Compound: DOX	Antiproliferative activity against human HCT-116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells after 72 hrs by MTT assay	[PMID: 35964425]
HCT-116	IC₅₀	5.23 μM Compound: Dox	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34126285]
HCT-116	IC₅₀	5.23 μM Compound: Doxorubicin	Antitumor activity against human HCT-116 cells assessed as inhibition of cell viability by MTT assay Antitumor activity against human HCT-116 cells assessed as inhibition of cell viability by MTT assay	[PMID: 33065442]
HCT-116	IC₅₀	5.23 μM Compound: DOX	Antiproliferative activity against human HCT116 cells by MTT assay Antiproliferative activity against human HCT116 cells by MTT assay	[PMID: 30216848]
HCT-116	IC₅₀	5.95 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 24 to 96 hrs by MTS assay Cytotoxicity against human HCT116 cells after 24 to 96 hrs by MTS assay	[PMID: 20303768]
HCT-116	IC₅₀	56.6 μM Compound: Doxorubicin	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by CellTiter Glo assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by CellTiter Glo assay	[PMID: 33016067]
HCT-116	IC₅₀	57.77 nM Compound: Doxorubicin	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by crystal violet staining based assay Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by crystal violet staining based assay	[PMID: 34795858]
HCT-116	IC₅₀	6 nM Compound: doxorubicin	Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay	[PMID: 19655762]
HCT-116	IC₅₀	6.3 μg/mL Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Cytotoxicity against human HCT116 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 27894044]
HCT-116	IC₅₀	6.86 μM Compound: Doxorubicin	Antitumor activity against Homo sapiens (human) HCT116 cells assessed as cell growth inhibition after 48 hr by MTT assay Antitumor activity against Homo sapiens (human) HCT116 cells assessed as cell growth inhibition after 48 hr by MTT assay	10.1007/s00044-013-0497-4
HCT-116	IC₅₀	6.86 μM Compound: DOX	Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay	[PMID: 22444025]
HCT-116	IC₅₀	6.86 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay	[PMID: 22119132]
HCT-116	IC₅₀	6.86 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HCT116 cells after 48 hrs by sulforhodamine B assay	[PMID: 22119131]
HCT-116	IC₅₀	7.41 μM Compound: Dox	Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 35635947]
HCT-116	IC₅₀	7.7 μM Compound: adriamycin	Cytotoxicity against human HCT116 cells after 4 days by MTT assay Cytotoxicity against human HCT116 cells after 4 days by MTT assay	[PMID: 17194586]
HCT-116	GI₅₀	70 nM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 24 to 72 hrs by MTS assay Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 24 to 72 hrs by MTS assay	10.1039/C0MD00179A
HCT-116	IC₅₀	761.45 nM Compound: Doxorubicin	Anticancer activity against human HCT-116 cells overexpressing MMP9/MAO-A by MTT assay Anticancer activity against human HCT-116 cells overexpressing MMP9/MAO-A by MTT assay	[PMID: 34116327]
HCT-116	IC₅₀	8.07 μM Compound: Cpd I	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 33360576]
HCT-116	IC₅₀	8.29 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 24 hrs by SRB assay Cytotoxicity against human HCT116 cells after 24 hrs by SRB assay	[PMID: 30096580]
HCT-116	IC₅₀	8.29 μM Compound: Doxorubicin	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by SRB assay	[PMID: 32361329]
HCT-116	IC₅₀	8.7 μM Compound: ADR	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	10.1039/C2MD20270K
HCT-116	IC₅₀	8.7 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 30660827]
HCT-116	IC₅₀	8.8 nM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability by SRB assay	[PMID: 30660827]
HCT-116	IC₅₀	80 nM Compound: Doxorubicin	Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay	[PMID: 35213166]
HCT-116	IC₅₀	810 nM Compound: DX	Cytotoxicity against human HCT116 cancer cell line was determined after 144 hr Cytotoxicity against human HCT116 cancer cell line was determined after 144 hr	[PMID: 15456268]
HCT-116	IC₅₀	9.4 μM Compound: Doxorubicin	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31323616]
HCT-116	IC₅₀	9.63 μM Compound: Doxorubicin	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33214036]
HCT-116	IC₅₀	9.74 μM Compound: Doxorubicin	Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay	[PMID: 28489373]
HCT-15	GI₅₀	< 10 μg/mL Compound: Doxorubicin	Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay	10.1039/C5MD00224A
HCT-15	IC₅₀	> 1000 nM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay	[PMID: 20690624]
HCT-15	ED₅₀	0.006 μg/mL Compound: Doxorubicin	Cytotoxicity against human HCT15 cells by sulforhodamine B method Cytotoxicity against human HCT15 cells by sulforhodamine B method	[PMID: 12193011]
HCT-15	IC₅₀	0.009 μM Compound: Doxorubicin	Antiproliferative activity against human HCT-15 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT-15 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 27010926]
HCT-15	IC₅₀	0.01 μg/mL Compound: Doxorubicin	Cytotoxicity against human HCT15 cells by MTT assay Cytotoxicity against human HCT15 cells by MTT assay	[PMID: 17764956]
HCT-15	IC₅₀	0.02 μg/mL Compound: doxorubicin	Anticancer activity against human HCT15 cells after 72 hrs by sulforhodamine B assay Anticancer activity against human HCT15 cells after 72 hrs by sulforhodamine B assay	[PMID: 19342127]
HCT-15	IC₅₀	0.025 μM Compound: 1 (Doxorubicin)	In vitro cytotoxic activity against human colon cancer cell line HCT15 after 72 hr of drug exposure determined by the SRB assay In vitro cytotoxic activity against human colon cancer cell line HCT15 after 72 hr of drug exposure determined by the SRB assay	[PMID: 14980672]
HCT-15	IC₅₀	0.028 μM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells by SRB assay Cytotoxicity against human HCT15 cells by SRB assay	[PMID: 20719504]
HCT-15	IC₅₀	0.035 μM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay	[PMID: 22483395]
HCT-15	IC₅₀	0.037 μM Compound: Doxorubicin	Anticancer activity against human HCT15 cells by sulforhodamine B assay Anticancer activity against human HCT15 cells by sulforhodamine B assay	[PMID: 19819696]
HCT-15	IC₅₀	0.038 μM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells by SRB assay Cytotoxicity against human HCT15 cells by SRB assay	[PMID: 20594848]
HCT-15	ED₅₀	0.04 μg/mL Compound: Doxorubicin	Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay	[PMID: 11325244]
HCT-15	ED₅₀	0.05 μg/mL Compound: doxorubicin	Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay	[PMID: 15921415]
HCT-15	IC₅₀	0.05 μg/mL Compound: Doxorubicin	Cytotoxicity against human HCT15 cells by sulforhodamine B assay Cytotoxicity against human HCT15 cells by sulforhodamine B assay	[PMID: 21684168]
HCT-15	ED₅₀	0.071 μg/mL Compound: Doxorubicin	Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay	[PMID: 19783438]
HCT-15	GI₅₀	0.076 μM Compound: ADR	Anticancer activity against human HCT-15 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method Anticancer activity against human HCT-15 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method	[PMID: 34500188]
HCT-15	GI₅₀	0.077 μM Compound: ADR	Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 30253887]
HCT-15	GI₅₀	0.077 μM Compound: ADR	Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 28870801]
HCT-15	IC₅₀	0.08 μg/mL Compound: adriamycin	Cytotoxicity against human HCT15 cells by SRB assay Cytotoxicity against human HCT15 cells by SRB assay	[PMID: 15921426]
HCT-15	IC₅₀	0.082 μM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells by SRB assay Cytotoxicity against human HCT15 cells by SRB assay	[PMID: 22951040]
HCT-15	GI₅₀	0.0854 μM Compound: ADR	Cytotoxicity against human HCT15 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human HCT15 cells after 72 hrs by sulforhodamine B assay	[PMID: 27096046]
HCT-15	IC₅₀	0.09 μM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells assessed as cell death after 48 hrs by MTT assay Cytotoxicity against human HCT15 cells assessed as cell death after 48 hrs by MTT assay	[PMID: 24215890]
HCT-15	IC₅₀	0.1 μM Compound: Doxorubicin	In vitro cytotoxic activity against HCT15 (colon cancer) cell lines by using SRB assay In vitro cytotoxic activity against HCT15 (colon cancer) cell lines by using SRB assay	[PMID: 9873661]
HCT-15	IC₅₀	0.1077 μM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells by sulforhodamine B bioassay Cytotoxicity against human HCT15 cells by sulforhodamine B bioassay	[PMID: 25098650]
HCT-15	IC₅₀	0.109 μM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 25981688]
HCT-15	IC₅₀	0.129 μM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 25466198]
HCT-15	IC₅₀	0.13 μM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells assessed as growth inhibition by SRB assay Cytotoxicity against human HCT15 cells assessed as growth inhibition by SRB assay	[PMID: 23634786]
HCT-15	IC₅₀	0.13 μM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells by sulforhodamine B assay Cytotoxicity against human HCT15 cells by sulforhodamine B assay	[PMID: 23815260]
HCT-15	IC₅₀	0.164 μM Compound: doxorubicin	Cytotoxicity against human HCT15 cells by SRB assay Cytotoxicity against human HCT15 cells by SRB assay	[PMID: 19435339]
HCT-15	ED₅₀	0.164 μM Compound: doxorubicin	Cytotoxicity against human HCT15 cells by SRB assay Cytotoxicity against human HCT15 cells by SRB assay	[PMID: 18314958]
HCT-15	GI₅₀	0.19 μM Compound: Doxorubicin	Antiproliferative activity against human HCT15 cells by SRB assay Antiproliferative activity against human HCT15 cells by SRB assay	[PMID: 19394218]
HCT-15	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 28641156]
HCT-15	IC₅₀	0.225 μM Compound: Doxorubicin	Anticancer activity against human HCT15 cells after 48 hrs by SRB assay Anticancer activity against human HCT15 cells after 48 hrs by SRB assay	[PMID: 17070967]
HCT-15	IC₅₀	0.23 μM Compound: Doxorubicine	Inhibitory activity against HCT-15 colon cell line using sulforhodamine B (SRB) protein assay Inhibitory activity against HCT-15 colon cell line using sulforhodamine B (SRB) protein assay	[PMID: 12039588]
HCT-15	IC₅₀	0.251 μM Compound: doxorubicin	Cytotoxicity against human HCT15 cells after 3 days by SRB assay Cytotoxicity against human HCT15 cells after 3 days by SRB assay	[PMID: 18321715]
HCT-15	IC₅₀	0.27 μM Compound: doxorubicin	Cytotoxicity against human HCT15 cells after 48 hrs Cytotoxicity against human HCT15 cells after 48 hrs	[PMID: 17673337]
HCT-15	ED₅₀	0.35 μg/mL Compound: doxorubicin	Cytotoxicity against human HCT15 cells by SRB method Cytotoxicity against human HCT15 cells by SRB method	[PMID: 16252909]
HCT-15	GI₅₀	0.45 μM Compound: ADR	Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay	[PMID: 25953156]
HCT-15	IC₅₀	0.6 μM Compound: Doxorubicin	Antiproliferative activity against human HCT15 cells after 72 hrs by SRB assay Antiproliferative activity against human HCT15 cells after 72 hrs by SRB assay	[PMID: 18063366]
HCT-15	IC₅₀	0.82 μM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells by SRB assay Cytotoxicity against human HCT15 cells by SRB assay	[PMID: 20176479]
HCT-15	IC₅₀	0.872 μM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay Cytotoxicity against human HCT15 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay	[PMID: 27856237]
HCT-15	IC₅₀	1.03 μM Compound: Adriamycin	Cytotoxicity against human HCT15 cells after 2 days by cell counting kit-8 analysis Cytotoxicity against human HCT15 cells after 2 days by cell counting kit-8 analysis	[PMID: 22503656]
HCT-15	IC₅₀	1.08 μM Compound: Adriamycin	Cytotoxicity against human HCT15 cells after 2 days by CCK8 assay Cytotoxicity against human HCT15 cells after 2 days by CCK8 assay	[PMID: 26361737]
HCT-15	IC₅₀	1.08 μM Compound: Adriamycin	Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay	[PMID: 25481396]
HCT-15	IC₅₀	1.13 μM Compound: DOX	Antiproliferative activity against human HCT15 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human HCT15 cells after 72 hrs by sulforhodamine B assay	[PMID: 25981689]
HCT-15	IC₅₀	1.2 μM Compound: Adriamycin	Cytotoxicity against human HCT15 cells after 2 days Cytotoxicity against human HCT15 cells after 2 days	[PMID: 21601964]
HCT-15	IC₅₀	1.23 μM Compound: adriamycin	Cytotoxicity against human HCT15 cells measured on day 4 by CCK8 assay Cytotoxicity against human HCT15 cells measured on day 4 by CCK8 assay	[PMID: 25936262]
HCT-15	IC₅₀	1.25 μM Compound: Adriamycin	Cytotoxicity against human HCT15 cells by MTT assay Cytotoxicity against human HCT15 cells by MTT assay	[PMID: 21115246]
HCT-15	IC₅₀	1.28 μM Compound: Adriamycin	Cytotoxicity against human HCT15 cells after 2 days Cytotoxicity against human HCT15 cells after 2 days	[PMID: 22318164]
HCT-15	GI₅₀	1.34 μM Compound: ADR	Antiproliferative activity against human HCT15 cells by SRB method Antiproliferative activity against human HCT15 cells by SRB method	[PMID: 24835787]
HCT-15	GI₅₀	1.34 μM Compound: ADR	Antiproliferative activity against human HCT15 cells by SRB assay Antiproliferative activity against human HCT15 cells by SRB assay	[PMID: 22738641]
HCT-15	IC₅₀	1.38 μM Compound: Adriamycin	Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay Cytotoxicity against human HCT15 cells after 2 days by CCK-8 assay	[PMID: 24013413]
HCT-15	GI₅₀	1.4 μM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HCT15 cells after 48 hrs by sulforhodamine B assay	[PMID: 23964644]
HCT-15	GI₅₀	1.64 μM Compound: Doxorubicin	Cytotoxicity against human HCT15 cells by SRB assay Cytotoxicity against human HCT15 cells by SRB assay	[PMID: 19596579]
HCT-15	IC₅₀	1.67 μM Compound: doxorubicin	Cytotoxicity against human HCT15 cells by SRB assay Cytotoxicity against human HCT15 cells by SRB assay	[PMID: 17827007]
HCT-15	IC₅₀	1.67 μM Compound: Doxorubicin	Cytotoxic activity against HCT 15 human colon tumor cell line, using sulforhodamine B (SRB) assay. Cytotoxic activity against HCT 15 human colon tumor cell line, using sulforhodamine B (SRB) assay.	[PMID: 14643344]
HCT-15	IC₅₀	1.76 μM Compound: ADR	Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay	[PMID: 22819942]
HCT-15	ED₅₀	1.8 μg/mL Compound: adriamycin	Cytotoxicity against human HCT15 cells by SRB assay Cytotoxicity against human HCT15 cells by SRB assay	10.1021/np960188t
HCT-15	IC₅₀	16.4 nM Compound: Doxorubicin	Antiproliferative activity against human HCT15 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay Antiproliferative activity against human HCT15 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay	[PMID: 31655432]
HCT-15	IC₅₀	2.2 μM Compound: DOX	Antiproliferative activity against human HCT15 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT15 cells after 72 hrs by MTT assay	[PMID: 30429098]
HCT-15	ED₅₀	2.4 μg/mL Compound: doxorubicin	Cytotoxicity against human HCT15 cells by SRB assay Cytotoxicity against human HCT15 cells by SRB assay	[PMID: 9392887]
HCT-15	IC₅₀	3.33 μM Compound: DOX	Cytotoxicity against human HCT15 cells measured after 2 days by MTT assay Cytotoxicity against human HCT15 cells measured after 2 days by MTT assay	[PMID: 26334499]
HCT-15	IC₅₀	3.76 μM Compound: Dox	Cytotoxicity against human HCT15 cells after 2 days Cytotoxicity against human HCT15 cells after 2 days	[PMID: 24904965]
HCT-15	IC₅₀	5 nM Compound: Adriamycin	Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay	[PMID: 22858298]
HCT-15	GI₅₀	6.46 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay	[PMID: 23871905]
HCT-15	GI₅₀	6.46 μM Compound: Doxorubicin	Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
HCT-15	GI₅₀	6.46 μM Compound: Doxorubicin	Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HCT15 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
HCT-15	GI₅₀	7.92 μM Compound: Doxorubicin	Antiproliferative activity against multidrug resistant human HCT15/CLO2 cells by SRB assay Antiproliferative activity against multidrug resistant human HCT15/CLO2 cells by SRB assay	[PMID: 19394218]
HCT-15	IC₅₀	81 nM Compound: doxorubicin	Cytotoxicity against human HCT15 cells after 72 hrs by MTS assay Cytotoxicity against human HCT15 cells after 72 hrs by MTS assay	[PMID: 19655762]
HCT-29	IC₅₀	2.5 μM Compound: Adriamycin	Cytotoxicity against human HCT29 cells after 4 days by MTT assay Cytotoxicity against human HCT29 cells after 4 days by MTT assay	[PMID: 21704436]
HCT-8	IC₅₀	0.01 μg/mL Compound: Dox	Cytotoxicity against Homo sapiens (human) HCT8 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) HCT8 cells after 72 hr by MTT assay	10.1007/s00044-011-9894-8
HCT-8	IC₅₀	0.02 μM Compound: Dox	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 25147145]
HCT-8	IC₅₀	0.02 μM Compound: D	Antineoplastic activity against human HCT8 cells after 72 hrs by MTT assay Antineoplastic activity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 22000949]
HCT-8	IC₅₀	0.02 μM Compound: doxorubicin	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 21381705]
HCT-8	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 20971532]
HCT-8	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 19406535]
HCT-8	IC₅₀	0.03 μM Compound: Dox	Cytotoxicity against human HCT8 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31306817]
HCT-8	IC₅₀	0.04 μg/mL Compound: Doxorubicin	Cytotoxicity against human HCT8 cells after 3 days by MTT assay Cytotoxicity against human HCT8 cells after 3 days by MTT assay	[PMID: 19159272]
HCT-8	IC₅₀	0.04 μg/mL Compound: Dox	Anticancer activity against Homo sapiens (human) HCT8 cells assessed as inhibition of cell survival after 72 hr by MTT assay Anticancer activity against Homo sapiens (human) HCT8 cells assessed as inhibition of cell survival after 72 hr by MTT assay	10.1007/s00044-012-0236-2
HCT-8	IC₅₀	0.04 μg/mL Compound: Doxorubicin	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 19084293]
HCT-8	IC₅₀	0.04 μg/mL Compound: Doxorubicin	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 18586355]
HCT-8	IC₅₀	0.04 μg/mL Compound: doxorubicin	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 17827021]
HCT-8	IC₅₀	0.04 μg/mL Compound: doxorubicin	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 15787450]
HCT-8	IC₅₀	0.05 μM Compound: Doxorubicin	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 27363939]
HCT-8	IC₅₀	0.06 μg/mL Compound: Doxo	Cytotoxicity against human HCT8 cells for 72 hrs by MTT assay Cytotoxicity against human HCT8 cells for 72 hrs by MTT assay	[PMID: 21334795]
HCT-8	IC₅₀	0.06 μM Compound: Doxorubicin	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 21115213]
HCT-8	IC₅₀	0.06 μM Compound: DOXO	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 19947600]
HCT-8	IC₅₀	0.09 μM Compound: Doxorubicin	Cytotoxicity against human HCT8 cells after 69 hrs by MTT assay Cytotoxicity against human HCT8 cells after 69 hrs by MTT assay	[PMID: 19780590]
HCT-8	IC₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity against human HCT8 cells by colorimetric method Cytotoxicity against human HCT8 cells by colorimetric method	[PMID: 24387625]
HCT-8	IC₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 22250891]
HCT-8	IC₅₀	0.13 μM Compound: Doxorubicin	Cytotoxicity against human HCT8 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24530030]
HCT-8	IC₅₀	0.19 μM Compound: DOXO	Cytotoxicity against human HCT8 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26142490]
HCT-8	IC₅₀	0.42 μM Compound: Adriamycin	Cytotoxicity against human HCT8 cells by MTT assay Cytotoxicity against human HCT8 cells by MTT assay	[PMID: 22070654]
HCT-8	IC₅₀	0.8 μM Compound: adriamycin	Cytotoxicity against human HCT8 cells by MTT assay Cytotoxicity against human HCT8 cells by MTT assay	[PMID: 17190442]
HCT-8	IC₅₀	1.17 μM Compound: DOX	Cytotoxicity against human HCT8 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HCT8 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 27149641]
HCT-8	IC₅₀	1.5 μM Compound: doxorubicine	Cytotoxic activity against human HCT8 cells after 69 hrs by MTT assay Cytotoxic activity against human HCT8 cells after 69 hrs by MTT assay	[PMID: 19788290]
HCT-8	IC₅₀	19.6 μM Compound: Dox	Cytotoxicity against human HCT8 cells under hypoxic condition after 24 hrs by crystal violet method Cytotoxicity against human HCT8 cells under hypoxic condition after 24 hrs by crystal violet method	[PMID: 25375258]
HCT-8	IC₅₀	2.4 μM Compound: Dox	Cytotoxicity against human HCT8 cells under normoxic condition after 24 hrs by crystal violet method Cytotoxicity against human HCT8 cells under normoxic condition after 24 hrs by crystal violet method	[PMID: 25375258]
HCT-8	IC₅₀	3.4 μM Compound: DOX	Antiproliferative activity against vincristine-resistant human HCT8 cells after 48 hrs by SRB method Antiproliferative activity against vincristine-resistant human HCT8 cells after 48 hrs by SRB method	[PMID: 25061803]
HCT-8	IC₅₀	7.2 μM Compound: Doxorubicin	Antiproliferative activity against human HCT8 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT8 cells after 48 hrs by MTT assay	[PMID: 30660827]
HEK293	IC₅₀	> 100 μM Compound: Doxorubicin	Cytotoxicity against HEK293 cells by MTT assay Cytotoxicity against HEK293 cells by MTT assay	[PMID: 24287557]
HEK293	IC₅₀	> 200 μM Compound: Doxorubicin	Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 4 hrs by MTT assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 4 hrs by MTT assay	[PMID: 30773423]
HEK293	IC₅₀	> 200 μM Compound: Doxorubicin	In vitro cytotoxicity against HEK293 cells assessed as growth inhibition by MTT assay In vitro cytotoxicity against HEK293 cells assessed as growth inhibition by MTT assay	[PMID: 24742385]
HEK293	IC₅₀	0.01 μM Compound: Adriamycin	Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay	[PMID: 21721528]
HEK293	IC₅₀	0.018 μM Compound: DOX	Antiproliferative activity against human HEK293 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HEK293 cells measured after 72 hrs by MTT assay	[PMID: 31431364]
HEK293	IC₅₀	0.02 μM Compound: DOX	Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30340899]
HEK293	IC₅₀	0.04 μM Compound: ADM	Cytotoxic activity against human HEK293 cells by SRB method Cytotoxic activity against human HEK293 cells by SRB method	[PMID: 25611519]
HEK293	IC₅₀	0.064 μM Compound: Doxorubicin	Cytotoxicity against HEK293 cells after 24 hrs by SRB method Cytotoxicity against HEK293 cells after 24 hrs by SRB method	[PMID: 18429610]
HEK293	IC₅₀	0.106 μM Compound: Dox	Cytotoxicity against HEK-293 cells assessed as reduction in cell viability incubated for 96 hrs by MTT method Cytotoxicity against HEK-293 cells assessed as reduction in cell viability incubated for 96 hrs by MTT method	[PMID: 34236840]
HEK293	IC₅₀	0.36 μM Compound: DX	Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 29681486]
HEK293	IC₅₀	0.42 μM Compound: Adriamycin	Cytotoxicity against human HEK293 cells transfected with plasmid expressing MDR1 after 72 hrs by MTT assay Cytotoxicity against human HEK293 cells transfected with plasmid expressing MDR1 after 72 hrs by MTT assay	[PMID: 21721528]
HEK293	IC₅₀	0.46 μM Compound: DX	Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 48 hrs by formazan dye-based EZ4U assay Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 48 hrs by formazan dye-based EZ4U assay	[PMID: 30108984]
HEK293	IC₅₀	0.46 μM Compound: Dox	Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by EZ4U Non-radioactive cell proliferation assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by EZ4U Non-radioactive cell proliferation assay	[PMID: 28372935]
HEK293	IC₅₀	0.46 μM Compound: DX	Antiproliferative activity against human HEK293 cells assessed as cell viability after 48 hrs by formazan EZ4U dye based assay Antiproliferative activity against human HEK293 cells assessed as cell viability after 48 hrs by formazan EZ4U dye based assay	[PMID: 26690914]
HEK293	IC₅₀	0.46 μM Compound: DX	Toxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by EZ4U label based assay Toxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by EZ4U label based assay	[PMID: 26052884]
HEK293	IC₅₀	0.46 μM Compound: doxorubicin	Antiproliferative activity against HEK293 cells at 0.01 to 250 uM after 48 hrs by formazan based EZ4U assay Antiproliferative activity against HEK293 cells at 0.01 to 250 uM after 48 hrs by formazan based EZ4U assay	[PMID: 25868743]
HEK293	IC₅₀	0.69 μM Compound: Doxorubicin	Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay	[PMID: 25300819]
HEK293	IC₅₀	0.7 μM Compound: Doxorubicin	Antiproliferative activity against HEK293 cells after 72 hrs by XTT assay Antiproliferative activity against HEK293 cells after 72 hrs by XTT assay	10.1039/C1MD00234A
HEK293	GI₅₀	0.8 μM Compound: Dox	Antiproliferative activity against human HEK293 cells incubated for 72 hrs and measured by MTT assay Antiproliferative activity against human HEK293 cells incubated for 72 hrs and measured by MTT assay	[PMID: 35973342]
HEK293	IC₅₀	0.9 μM Compound: doxorubicin	Cytotoxicity against transformed human HEK293 cells after 24 to 48 hrs by MTT assay Cytotoxicity against transformed human HEK293 cells after 24 to 48 hrs by MTT assay	[PMID: 21058726]
HEK293	IC₅₀	1 μg/mL Compound: Doxorubicin	Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 35526504]
HEK293	IC₅₀	1 μM Compound: ADR	Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay	[PMID: 22819942]
HEK293	IC₅₀	1.006 μM Compound: Doxorubicin	Cytotoxicity against HEK293 cells after 24 hrs by MTT assay Cytotoxicity against HEK293 cells after 24 hrs by MTT assay	10.1007/s00044-013-0784-0
HEK293	IC₅₀	1.06 μM Compound: Adriamycin	Antiproliferative activity against human HEK293 cells after 48 hrs by MTT assay Antiproliferative activity against human HEK293 cells after 48 hrs by MTT assay	[PMID: 24582982]
HEK293	IC₅₀	1.2 μM Compound: DOX	Antiproliferative activity against human HEK293 cells after 72 hrs by MTT assay Antiproliferative activity against human HEK293 cells after 72 hrs by MTT assay	[PMID: 30429098]
HEK293	IC₅₀	1.34 μM Compound: Adriamycin	Cytotoxicity against human HEK293 cells after 2 days by cell counting kit-8 analysis Cytotoxicity against human HEK293 cells after 2 days by cell counting kit-8 analysis	[PMID: 22503656]
HEK293	IC₅₀	1.65 μM Compound: Doxorubicin	Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34124677]
HEK293	IC₅₀	10 μM Compound: Doxorubicin	Cytotoxicity against HEK293 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay	[PMID: 28818768]
HEK293	IC₅₀	11.34 mM Compound: DOX	Growth inhibition of human HEK293 cells assessed as cell viability incubated for 48 hrs by MTT assay Growth inhibition of human HEK293 cells assessed as cell viability incubated for 48 hrs by MTT assay	[PMID: 31648875]
HEK293	IC₅₀	142.8 μM Compound: 12	Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay	[PMID: 29852328]
HEK293	IC₅₀	148.4 μM Compound: 21	Cytotoxicity against human HEK293 cells after 48 hrs by MTT assay Cytotoxicity against human HEK293 cells after 48 hrs by MTT assay	[PMID: 29289880]
HEK293	IC₅₀	16.7 μg/mL Compound: Doxorubicin	Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 35526504]
HEK293	IC₅₀	160 μM Compound: Doxorubicin	Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting	[PMID: 22541068]
HEK293	IC₅₀	2.1 μM Compound: Doxorubicin	Cytotoxicity in human HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity in human HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 28923382]
HEK293	IC₅₀	240 μM Compound: Doxorubicin	Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting	[PMID: 22541068]
HEK293	IC₅₀	3.07 μM Compound: Adriamycin	Cytotoxicity against HEK293 cells after 2 days by CCK-8 assay Cytotoxicity against HEK293 cells after 2 days by CCK-8 assay	[PMID: 24013413]
HEK293	IC₅₀	3.13 μM Compound: Doxorubicin	Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27816268]
HEK293	IC₅₀	3.9 μM Compound: Doxorubicin	Growth inhibition of HEK293 cells after 48 hrs by MTT assay Growth inhibition of HEK293 cells after 48 hrs by MTT assay	[PMID: 30072225]
HEK293	IC₅₀	41 μM Compound: Doxorubicin	Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting	[PMID: 22541068]
HEK293	IC₅₀	44.4 μM Compound: DOX	Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay	[PMID: 27108400]
HEK293	IC₅₀	455 nM Compound: DX	Cytotoxicity against HEK293 cells assessed as reduction of cell viability after 48 hrs by formazan dye-based EZ4U test Cytotoxicity against HEK293 cells assessed as reduction of cell viability after 48 hrs by formazan dye-based EZ4U test	[PMID: 24996140]
HEK293	IC₅₀	5.68 μM Compound: DOX	Antiproliferative activity against HEK293 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against HEK293 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 31671309]
HEK293	IC₅₀	5.68 μM Compound: DOX	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay	[PMID: 30576904]
HEK293	IC₅₀	6.1 μg/mL Compound: Doxorubicin	Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human HEK293 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 35526504]
HEK293	IC₅₀	6.1 μM Compound: Doxorubicin	Cytotoxicity against human HEK293 cells assessed as inhibition of cell growth after overnight incubation by MTT assay Cytotoxicity against human HEK293 cells assessed as inhibition of cell growth after overnight incubation by MTT assay	[PMID: 32165076]
HEK293	IC₅₀	7.2 μM Compound: Doxorubicin	Cytotoxicity against human HEK293 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against human HEK293 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 27496212]
HEK293	IC₅₀	7.41 μM Compound: Doxorubicin	Cytotoxicity against HEK293 cells after 48 hrs by MTT assay Cytotoxicity against HEK293 cells after 48 hrs by MTT assay	[PMID: 24607876]
HEK-293T	IC₅₀	0.75 μM Compound: DOX	Cytotoxicity against human HEK293T cells measured after 72 hrs by MTT assay Cytotoxicity against human HEK293T cells measured after 72 hrs by MTT assay	[PMID: 35612499]
HEK-293T	IC₅₀	0.75 μM Compound: Doxorubicin	Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay in presence of 10% FBS Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay in presence of 10% FBS	[PMID: 26298501]
HEK-293T	IC₅₀	0.84 μM Compound: Doxorubicin	Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay in absence of 10% FBS Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay in absence of 10% FBS	[PMID: 26298501]
HEK-293T	IC₅₀	1.051 μM Compound: Dox	Cytotoxicity in HEK293T cells assessed as reduction in cell viability incubated for 24 hrs under hypoxic condition by MTT assay Cytotoxicity in HEK293T cells assessed as reduction in cell viability incubated for 24 hrs under hypoxic condition by MTT assay	[PMID: 31542715]
HEK-293T	IC₅₀	1.13 μM Compound: Doxorubicin	Cytotoxicity against HEK293T cells after 48 hrs by MTT assay Cytotoxicity against HEK293T cells after 48 hrs by MTT assay	[PMID: 30170925]
HEK-293T	CC₅₀	1.13 μM Compound: Doxorubicin	Cytotoxicity against HEK293T cells after 48 hrs by MTT assay Cytotoxicity against HEK293T cells after 48 hrs by MTT assay	[PMID: 30103191]
HEK-293T	IC₅₀	1.2 μM Compound: Dox	Cytotoxicity against HEK293T cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against HEK293T cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 27055942]
HEK-293T	IC₅₀	3.1 μM Compound: Doxorubicin	Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay	[PMID: 27173802]
HEK-293T	IC₅₀	3.59 μM Compound: Doxorubicin	Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay Cytotoxicity against human HEK293T cells after 48 hrs by MTT assay	[PMID: 29573910]
HEK-293T	IC₅₀	3.77 μM Compound: Doxorubicin	Cytotoxicity against human HEK293T cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Cytotoxicity against human HEK293T cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 35367708]
HEK-293T	IC₅₀	3.77 μM Compound: Doxorubicin	Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31404864]
HEL	IC₅₀	0.42 μM Compound: Doxorubicin	Antiproliferative activity against HEL cells after 72 hrs by MTT assay Antiproliferative activity against HEL cells after 72 hrs by MTT assay	[PMID: 30500683]
HEL	IC₅₀	2.13 μM Compound: Doxorubicin	Cytotoxicity against HEL cells after 48 hrs by MTT assay Cytotoxicity against HEL cells after 48 hrs by MTT assay	[PMID: 28390228]
HeLa	GI₅₀	< 0.01 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay	[PMID: 25827522]
HeLa	GI₅₀	< 0.1 μM Compound: ADR	Cytotoxicity against human HeLa cells by SRB assay Cytotoxicity against human HeLa cells by SRB assay	10.1007/s00044-013-0855-2
HeLa	IC₅₀	< 1 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay	10.1007/s00044-011-9884-x
HeLa	IC₅₀	< 1 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 23079527]
HeLa	IC₅₀	< 1 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 21996519]
HeLa	IC₅₀	> 1 μM Compound: Doxorubicin	Cytotoxicity against oleic acid-induced human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against oleic acid-induced human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 35059132]
HeLa	IC₅₀	0.008 mM Compound: DOX	Cytotoxicity against human HeLa cells after 3 days by MTT assay Cytotoxicity against human HeLa cells after 3 days by MTT assay	[PMID: 22520152]
HeLa	IC₅₀	0.01 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as cell survival after 24 hrs by XTT assay Cytotoxicity against human HeLa cells assessed as cell survival after 24 hrs by XTT assay	[PMID: 25059501]
HeLa	IC₅₀	0.016 μM Compound: DOX	Antitumor activity against Homo sapiens (human) HeLa cells assessed as inhibition of cell proliferation after 48 hr by SRB assay Antitumor activity against Homo sapiens (human) HeLa cells assessed as inhibition of cell proliferation after 48 hr by SRB assay	10.1007/s00044-012-0051-9
HeLa	GI₅₀	0.023 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells by SRB assay Antiproliferative activity against human HeLa cells by SRB assay	[PMID: 31546197]
HeLa	IC₅₀	0.03 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell growth after 72 hrs by cell titer glo assay Cytotoxicity against human HeLa cells assessed as reduction in cell growth after 72 hrs by cell titer glo assay	[PMID: 27080175]
HeLa	GI₅₀	0.031 μM Compound: Doxorubicin	Growth inhibition of human HeLa cells after 48 hrs by SRB assay Growth inhibition of human HeLa cells after 48 hrs by SRB assay	[PMID: 26067381]
HeLa	IC₅₀	0.04 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 20207049]
HeLa	IC₅₀	0.04 μM Compound: DOX	Antitumor activity against human HeLa cells after 72 hrs by MTT assay Antitumor activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 17935309]
HeLa	IC₅₀	0.04 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 19278239]
HeLa	GI₅₀	0.05 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 27889456]
HeLa	IC₅₀	0.05 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 28257197]
HeLa	IC₅₀	0.051 μg/mL Compound: Doxorubicin	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 34973507]
HeLa	IC₅₀	0.053 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) HeLa cells after 96 hr by MTT assay Cytotoxicity against Homo sapiens (human) HeLa cells after 96 hr by MTT assay	10.1007/s00044-010-9340-3
HeLa	IC₅₀	0.06 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 22555152]
HeLa	IC₅₀	0.065 μM Compound: DOX	Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 31557614]
HeLa	IC₅₀	0.065 μM Compound: DOX	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 25259516]
HeLa	IC₅₀	0.07 μM Compound: DOX	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 6 days by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 6 days by MTT assay	[PMID: 32653698]
HeLa	IC₅₀	0.07 μM Compound: Doxorubicin	Cytotoxicity against human Hela cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human Hela cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 33340938]
HeLa	IC₅₀	0.07 μM Compound: DOX	Cytotoxicity against human HeLa cells assessed as inhibition of cell growth after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell growth after 72 hrs by MTT assay	[PMID: 30746062]
HeLa	IC₅₀	0.07 μM Compound: DOX	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28427016]
HeLa	IC₅₀	0.07 μM Compound: DOX	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 28135634]
HeLa	IC₅₀	0.07 μM Compound: Dox	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27231128]
HeLa	IC₅₀	0.07 μM Compound: DOX	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 26720155]
HeLa	IC₅₀	0.07 μM Compound: DOX	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 24021462]
HeLa	IC₅₀	0.07 μM Compound: DOX	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 20359789]
HeLa	IC₅₀	0.07 μM Compound: DOX	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 18783950]
HeLa	IC₅₀	0.07 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 96 hrs by MTT assay Antiproliferative activity against human HeLa cells after 96 hrs by MTT assay	[PMID: 19053767]
HeLa	IC₅₀	0.07 μM Compound: doxo	Antiproliferative activity against human HeLa cells by MTT assay Antiproliferative activity against human HeLa cells by MTT assay	[PMID: 16913700]
HeLa	GI₅₀	0.073 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 27209232]
HeLa	GI₅₀	0.073 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells assessed as reduction in net protein increase after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as reduction in net protein increase after 48 hrs by SRB assay	[PMID: 25462234]
HeLa	GI₅₀	0.073 μM Compound: Doxorubicin	Growth inhibition of human HeLa cells after 48 hrs by SRB assay Growth inhibition of human HeLa cells after 48 hrs by SRB assay	[PMID: 25264072]
HeLa	GI₅₀	0.083 μM Compound: Doxorubicin	Growth inhibition of human HeLa cells after 48 hrs by SRB assay Growth inhibition of human HeLa cells after 48 hrs by SRB assay	[PMID: 27964883]
HeLa	IC₅₀	0.09 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay	[PMID: 36693198]
HeLa	GI₅₀	0.09 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay	[PMID: 26994690]
HeLa	GI₅₀	0.093 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 30360625]
HeLa	ED₅₀	0.1 μg/mL Compound: doxorubicin	Cytotoxicity against human HeLa cells after 3 days by MTT assay Cytotoxicity against human HeLa cells after 3 days by MTT assay	[PMID: 16252910]
HeLa	IC₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by CCK8 assay Cytotoxicity against human HeLa cells after 72 hrs by CCK8 assay	[PMID: 28398051]
HeLa	IC₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT method Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT method	[PMID: 25932671]
HeLa	IC₅₀	0.1 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 26947606]
HeLa	IC₅₀	0.11 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30389295]
HeLa	IC₅₀	0.13 μM Compound: DOX	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 21496972]
HeLa	ED₅₀	0.14 μg/mL Compound: doxorubicin	Cytotoxicity against human HeLa cells by methylene blue staining method Cytotoxicity against human HeLa cells by methylene blue staining method	[PMID: 15921421]
HeLa	IC₅₀	0.14 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay	[PMID: 31820973]
HeLa	IC₅₀	0.14 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 24 hrs by XTT assay Cytotoxicity against human HeLa cells after 24 hrs by XTT assay	[PMID: 27227682]
HeLa	IC₅₀	0.154 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 25462279]
HeLa	IC₅₀	0.16 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 18692939]
HeLa	IC₅₀	0.163 μg/mL Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 21158422]
HeLa	IC₅₀	0.19 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 22414612]
HeLa	IC₅₀	0.19 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by XTT assay Cytotoxicity against human HeLa cells after 72 hrs by XTT assay	[PMID: 19647439]
HeLa	IC₅₀	0.2 mM Compound: Dox	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 29459273]
HeLa	IC₅₀	0.2 μM Compound: Doxo	Antiproliferative activity against human HeLa cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human HeLa cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
HeLa	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34082225]
HeLa	IC₅₀	0.2 μM Compound: 2	Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 33974416]
HeLa	IC₅₀	0.2 μM Compound: Dox	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 30659997]
HeLa	IC₅₀	0.2 μM Compound: Dox	Antiproliferative activity in human HeLa cells after 72 hrs by MTT assay Antiproliferative activity in human HeLa cells after 72 hrs by MTT assay	[PMID: 30268824]
HeLa	IC₅₀	0.2 μM Compound: 5	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 29137865]
HeLa	IC₅₀	0.2 μM Compound: 1; Dox	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 26633734]
HeLa	IC₅₀	0.2 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24012378]
HeLa	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 19394829]
HeLa	IC₅₀	0.21 μM Compound: ADM	Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 25984840]
HeLa	IC₅₀	0.21 μM Compound: ADM	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 25529742]
HeLa	IC₅₀	0.21 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 72 hrs MTT assay Antiproliferative activity against human HeLa cells after 72 hrs MTT assay	[PMID: 25247772]
HeLa	ED₅₀	0.22 μg/mL Compound: Doxorubicin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 15104488]
HeLa	IC₅₀	0.22 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by WST8 assay Cytotoxicity against human HeLa cells after 48 hrs by WST8 assay	[PMID: 25163667]
HeLa	IC₅₀	0.221 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 72 hrs by MTT reduction assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT reduction assay	[PMID: 28551177]
HeLa	IC₅₀	0.23 μM Compound: Doxorubicin	Anticancer activity against human HeLa cells after 48 hrs by MTT assay Anticancer activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 21641694]
HeLa	IC₅₀	0.24 μg/mL Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 21708464]
HeLa	IC₅₀	0.24 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells incubated for 72 hrs by MTT assay Cytotoxicity against human HeLa cells incubated for 72 hrs by MTT assay	[PMID: 32040324]
HeLa	IC₅₀	0.256 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells at 50 uM by MTT reduction assay Cytotoxicity against human HeLa cells at 50 uM by MTT reduction assay	[PMID: 33276991]
HeLa	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26972921]
HeLa	GI₅₀	0.3 μM Compound: Dox	Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]
HeLa	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 44 hrs by SRB assay Cytotoxicity against human HeLa cells after 44 hrs by SRB assay	10.1007/s00044-013-0788-9
HeLa	IC₅₀	0.32 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 28358196]
HeLa	GI₅₀	0.33 μM Compound: Doxorubicin	Growth inhibition of Homo sapiens (human) HeLa cells after 48 hr by MTT assay Growth inhibition of Homo sapiens (human) HeLa cells after 48 hr by MTT assay	10.1007/s00044-012-0232-6
HeLa	IC₅₀	0.33 μM Compound: Doxorubicin	Antitumor activity against human HeLa cells assessed as inhibition of cell growth by MTT assay Antitumor activity against human HeLa cells assessed as inhibition of cell growth by MTT assay	[PMID: 25160837]
HeLa	IC₅₀	0.33 μM Compound: DOX	Antiproliferative activity against human HeLa cells by MTT assay Antiproliferative activity against human HeLa cells by MTT assay	[PMID: 20171108]
HeLa	IC₅₀	0.337 μM Compound: Dox	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 25998504]
HeLa	IC₅₀	0.34 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 24 and 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 24 and 72 hrs by MTT assay	[PMID: 24941130]
HeLa	IC₅₀	0.36 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 4 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 4 hrs by MTT assay	[PMID: 30773423]
HeLa	IC₅₀	0.36 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
HeLa	IC₅₀	0.36 μM Compound: DOX	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 24487188]
HeLa	IC₅₀	0.36 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 25453799]
HeLa	IC₅₀	0.37 μM Compound: Doxorubicin	Anticancer activity against human HeLa cells incubated for 24 hrs by MTT assay Anticancer activity against human HeLa cells incubated for 24 hrs by MTT assay	[PMID: 28579122]
HeLa	IC₅₀	0.4 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells incubated for 48 hrs by WST8 assay Antiproliferative activity against human HeLa cells incubated for 48 hrs by WST8 assay	[PMID: 31679979]
HeLa	IC₅₀	0.41 μM Compound: adriamycin	Cytotoxicity against human HeLa cells after 1 to 11 days by MTT assay Cytotoxicity against human HeLa cells after 1 to 11 days by MTT assay	[PMID: 19072548]
HeLa	IC₅₀	0.429 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured at 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured at 48 hrs by MTT assay	[PMID: 36652792]
HeLa	IC₅₀	0.43 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay in presence of 10% FBS Cytotoxicity against human HeLa cells after 48 hrs by MTT assay in presence of 10% FBS	[PMID: 26298501]
HeLa	IC₅₀	0.45 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 25172420]
HeLa	IC₅₀	0.45 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 23911578]
HeLa	IC₅₀	0.45 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay in absence of 10% FBS Cytotoxicity against human HeLa cells after 48 hrs by MTT assay in absence of 10% FBS	[PMID: 26298501]
HeLa	IC₅₀	0.451 μM Compound: DOXO	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 29685681]
HeLa	IC₅₀	0.451 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 24113366]
HeLa	IC₅₀	0.451 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 23764302]
HeLa	IC₅₀	0.47 μM Compound: adriamycin	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 26295905]
HeLa	IC₅₀	0.47 μM Compound: ADM	Cytotoxicity against human HeLa cells assessed as inhibition of cell growth after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell growth after 72 hrs by MTT assay	[PMID: 25089733]
HeLa	IC₅₀	0.48 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 46 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 46 hrs by MTT assay	[PMID: 29138027]
HeLa	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by CCK8 assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by CCK8 assay	[PMID: 32324401]
HeLa	IC₅₀	0.5 μM Compound: doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by MTS assay Cytotoxicity against human HeLa cells after 72 hrs by MTS assay	[PMID: 25490132]
HeLa	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29702447]
HeLa	IC₅₀	0.5 μM Compound: ADM	Cytotoxic activity against human HeLa cells by MTT method Cytotoxic activity against human HeLa cells by MTT method	[PMID: 25611519]
HeLa	IC₅₀	0.5 μM Compound: ADM	Cytotoxicity against human HeLa cells by SRB method Cytotoxicity against human HeLa cells by SRB method	[PMID: 29144133]
HeLa	IC₅₀	0.509 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as growth inhibition after 2 days by MTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 2 days by MTT assay	[PMID: 23932340]
HeLa	IC₅₀	0.509 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 24287557]
HeLa	IC₅₀	0.51 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26381063]
HeLa	IC₅₀	0.51 μM Compound: Doxorubicin	In vitro cytotoxicity against human HeLa cells assessed as growth inhibition by MTT assay In vitro cytotoxicity against human HeLa cells assessed as growth inhibition by MTT assay	[PMID: 24742385]
HeLa	IC₅₀	0.52 μM Compound: DOX	Cytotoxicity against human HeLa cells measured after 2 days by MTT assay Cytotoxicity against human HeLa cells measured after 2 days by MTT assay	[PMID: 26334499]
HeLa	IC₅₀	0.54 μg/mL Compound: Doxorubicin	Anticancer activity against human HeLa cells by MTT assay Anticancer activity against human HeLa cells by MTT assay	[PMID: 31404864]
HeLa	IC₅₀	0.55 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
HeLa	IC₅₀	0.59 μM Compound: DOX	Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by CCK-8 assay	[PMID: 34978808]
HeLa	IC₅₀	0.6 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30679134]
HeLa	IC₅₀	0.6 μM Compound: DOX	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 26386603]
HeLa	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 22749279]
HeLa	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as cell growth inhibition by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition by MTT assay	[PMID: 27187861]
HeLa	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 25241926]
HeLa	IC₅₀	0.606 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 28406643]
HeLa	IC₅₀	0.62 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 19689125]
HeLa	IC₅₀	0.66 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30170925]
HeLa	CC₅₀	0.66 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30103191]
HeLa	IC₅₀	0.68 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 18440233]
HeLa	IC₅₀	0.69 μM Compound: Doxorubicin	Cytotoxicity against p53 repressed human HeLa cells asessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against p53 repressed human HeLa cells asessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 31324563]
HeLa	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells incubated for 24 hrs by MTT asasy Cytotoxicity against human HeLa cells incubated for 24 hrs by MTT asasy	[PMID: 28615134]
HeLa	GI₅₀	0.7 μM Compound: Dox	Anticancer activity against human HeLa cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Anticancer activity against human HeLa cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35533562]
HeLa	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 25172418]
HeLa	IC₅₀	0.71 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) HeLa cells by MTT assay Cytotoxicity against Homo sapiens (human) HeLa cells by MTT assay	10.1007/s00044-012-0370-x
HeLa	IC₅₀	0.71 μM Compound: Doxorubicine	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 22014995]
HeLa	IC₅₀	0.73 μM Compound: doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 19819703]
HeLa	GI₅₀	0.76 μM Compound: Dox	Antiproliferative activity against human HeLa cells incubated for 72 hrs and measured by MTT assay Antiproliferative activity against human HeLa cells incubated for 72 hrs and measured by MTT assay	[PMID: 35973342]
HeLa	IC₅₀	0.78 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 27060757]
HeLa	IC₅₀	0.8 μg/mL Compound: Adriamycin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 17918910]
HeLa	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 30654238]
HeLa	IC₅₀	0.8 μM Compound: Dox	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability by MTT assay	[PMID: 31765156]
HeLa	IC₅₀	0.82 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay	[PMID: 31404864]
HeLa	IC₅₀	0.834 μM Compound: DOX	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 26638041]
HeLa	IC₅₀	0.85 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]
HeLa	IC₅₀	0.88 μM Compound: adriamycin	Cytotoxicity against human HeLa cells measured on day 4 by CCK8 assay Cytotoxicity against human HeLa cells measured on day 4 by CCK8 assay	[PMID: 25936262]
HeLa	IC₅₀	0.9 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 25462233]
HeLa	IC₅₀	0.93 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay	10.1039/C5MD00581G
HeLa	IC₅₀	0.97 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 24182355]
HeLa	IC₅₀	1 x 10^-2 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by XTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by XTT assay	[PMID: 23470139]
HeLa	IC₅₀	1 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells after 2 days by CCK-8 assay Cytotoxicity against human HeLa cells after 2 days by CCK-8 assay	[PMID: 25481396]
HeLa	IC₅₀	1 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells incubated for 48 hrs by MTT assay	[PMID: 33421712]
HeLa	IC₅₀	1 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 19632833]
HeLa	IC₅₀	1 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells by neutral red method Cytotoxicity against human HeLa cells by neutral red method	[PMID: 26291474]
HeLa	IC₅₀	1 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells after 2 days Cytotoxicity against human HeLa cells after 2 days	[PMID: 21601964]
HeLa	IC₅₀	1.009 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 24 hrs by SRB method Cytotoxicity against human HeLa cells after 24 hrs by SRB method	[PMID: 18429610]
HeLa	IC₅₀	1.02 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells by CCK8 assay Cytotoxicity against human HeLa cells by CCK8 assay	[PMID: 29452840]
HeLa	IC₅₀	1.07 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32866757]
HeLa	IC₅₀	1.089 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28482219]
HeLa	IC₅₀	1.107 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 3 days by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 32707525]
HeLa	IC₅₀	1.1073 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells by MTT assay Antiproliferative activity against human HeLa cells by MTT assay	[PMID: 31404864]
HeLa	IC₅₀	1.12 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	10.1039/C3MD00013C
HeLa	IC₅₀	1.12 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 22182926]
HeLa	IC₅₀	1.17 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells expressing estrogen receptor after 48 hrs by MTT assay Cytotoxicity against human HeLa cells expressing estrogen receptor after 48 hrs by MTT assay	10.1039/C2MD20327H
HeLa	IC₅₀	1.17 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30108986]
HeLa	IC₅₀	1.17 μM Compound: DOX	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 25737400]
HeLa	IC₅₀	1.17 μM Compound: DOX	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 25619894]
HeLa	IC₅₀	1.17 μM Compound: DOX	Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 24148837]
HeLa	IC₅₀	1.17 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 1 hr by SRB assay Cytotoxicity against human HeLa cells after 1 hr by SRB assay	[PMID: 22770744]
HeLa	IC₅₀	1.2 μM Compound: Doxorubicin	Anticancer activity against human HeLa cells measured after 48 hrs by MTT assay Anticancer activity against human HeLa cells measured after 48 hrs by MTT assay	[PMID: 33421712]
HeLa	IC₅₀	1.2 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 26398312]
HeLa	IC₅₀	1.2 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 28886509]
HeLa	IC₅₀	1.2 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 33766771]
HeLa	IC₅₀	1.2 μM Compound: DOX	Antiproliferative activity against human HeLa cells after 72 hrs by Sulforhodamine B-stain assay Antiproliferative activity against human HeLa cells after 72 hrs by Sulforhodamine B-stain assay	[PMID: 27484508]
HeLa	IC₅₀	1.21 μM Compound: Dox	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30615450]
HeLa	IC₅₀	1.258 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 26301558]
HeLa	IC₅₀	1.28 μg/mL Compound: Doxorubicin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	10.1039/C4MD00566J
HeLa	IC₅₀	1.3 μM Compound: Doxorubicin	Cytotoxic activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxic activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 25966052]
HeLa	IC₅₀	1.31 μM Compound: Adriamycin	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 24582982]
HeLa	IC₅₀	1.43 μM Compound: DOX	Cytotoxicity against human HeLa cells after 48 hrs by SRB method Cytotoxicity against human HeLa cells after 48 hrs by SRB method	[PMID: 25933593]
HeLa	IC₅₀	1.44 μM Compound: doxo	Antiproliferative activity against human HeLa cells assessed as decrease in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as decrease in cell viability measured after 72 hrs by MTT assay	[PMID: 30763817]
HeLa	IC₅₀	1.45 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells after 2 days Cytotoxicity against human HeLa cells after 2 days	[PMID: 22318164]
HeLa	IC₅₀	1.5 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 24941129]
HeLa	IC₅₀	1.5 μM Compound: DOX	Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 22044164]
HeLa	IC₅₀	1.51 μM Compound: Doxorubicin	Anticancer activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Anticancer activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 26330077]
HeLa	IC₅₀	1.59 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 26948541]
HeLa	IC₅₀	1.6 x 10^-2 μM Compound: adriamycin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 19285863]
HeLa	IC₅₀	1.64 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 21534590]
HeLa	IC₅₀	1.68 μM Compound: Dox	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 26494582]
HeLa	IC₅₀	1.69 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 30500683]
HeLa	IC₅₀	1.73 μM Compound: Doxo	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 29129513]
HeLa	IC₅₀	1.78 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 26708114]
HeLa	IC₅₀	1.8 μM Compound: Doxorubicin	Anticancer activity against human HeLa cells by MTT assay Anticancer activity against human HeLa cells by MTT assay	[PMID: 33421712]
HeLa	IC₅₀	1.8 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells incubated for 24 hrs by MTT reduction assay Cytotoxicity against human HeLa cells incubated for 24 hrs by MTT reduction assay	[PMID: 33421712]
HeLa	IC₅₀	1.81 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells incubated for 24 hrs by MTT assay Antiproliferative activity against human HeLa cells incubated for 24 hrs by MTT assay	[PMID: 29409753]
HeLa	IC₅₀	1.82 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 29172084]
HeLa	IC₅₀	1.862 μM Compound: Doxorubicin	Anti-proliferative activity against human HeLa cells measured after 48 hrs by MTT assay Anti-proliferative activity against human HeLa cells measured after 48 hrs by MTT assay	[PMID: 27744185]
HeLa	IC₅₀	1.91 μM Compound: II	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 29289881]
HeLa	IC₅₀	1.94 μM Compound: DOX	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32631552]
HeLa	IC₅₀	1.96 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay Cytotoxicity against human HeLa cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay	[PMID: 36126331]
HeLa	IC₅₀	1.995 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 29501940]
HeLa	GI₅₀	10.7 μM Compound: DOX	Growth inhibition of human HeLa cells after 48 hrs by SRB assay Growth inhibition of human HeLa cells after 48 hrs by SRB assay	[PMID: 28433679]
HeLa	IC₅₀	10.78 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as cell viability by SRB assay Cytotoxicity against human HeLa cells assessed as cell viability by SRB assay	[PMID: 26022842]
HeLa	IC₅₀	11 μg/mL Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 11473441]
HeLa	IC₅₀	11.5 μM Compound: Doxo	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 27597408]
HeLa	IC₅₀	13 μg/mL Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 35526504]
HeLa	IC₅₀	14 μM Compound: DOX	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 31015907]
HeLa	CC₅₀	2 μg/mL Compound: doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by methylene blue staining Cytotoxicity against human HeLa cells after 72 hrs by methylene blue staining	[PMID: 20153202]
HeLa	IC₅₀	2 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31938458]
HeLa	IC₅₀	2 μM Compound: adriamycin	Cytotoxicity against human HeLa cells under deem light after 96 hrs by MTT assay Cytotoxicity against human HeLa cells under deem light after 96 hrs by MTT assay	[PMID: 17993275]
HeLa	IC₅₀	2.05 μM Compound: Doxorubicin	Growth inhibition of human HeLa cells by MTT assay Growth inhibition of human HeLa cells by MTT assay	[PMID: 28147307]
HeLa	IC₅₀	2.089 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28462842]
HeLa	IC₅₀	2.09 μM Compound: DOX	Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34700239]
HeLa	IC₅₀	2.1 μM Compound: Doxorubicin	Anticancer activity against human HeLa cells assessed as growth inhibition incubated for 48 hrs by MTT assay Anticancer activity against human HeLa cells assessed as growth inhibition incubated for 48 hrs by MTT assay	[PMID: 34363936]
HeLa	IC₅₀	2.2 μM Compound: DOX	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 23218718]
HeLa	IC₅₀	2.23 μM Compound: DOX	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29421568]
HeLa	IC₅₀	2.29 μM Compound: Doxorubicin	Anticancer activity against human HeLa cells after 48 hrs by MTT assay Anticancer activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 25615796]
HeLa	IC₅₀	2.3 μM Compound: DOX	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by Alamar blue staining based fluorescence assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by Alamar blue staining based fluorescence assay	[PMID: 28291684]
HeLa	IC₅₀	2.45 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells treated for 72 hrs by MTT assay Cytotoxicity against human HeLa cells treated for 72 hrs by MTT assay	[PMID: 35344904]
HeLa	EC₅₀	2.5 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) HeLa cells after 48 hr by MTT assay	10.1007/s00044-012-0294-5
HeLa	IC₅₀	2.57 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 27015609]
HeLa	IC₅₀	2.63 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 26264845]
HeLa	IC₅₀	2.684 μg/mL Compound: ADM	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 25862199]
HeLa	IC₅₀	2.78 μM Compound: DOX	Antiproliferative activity against human HeLa cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human HeLa cells assessed as cell growth inhibition by MTT assay	[PMID: 32631524]
HeLa	IC₅₀	2.9 x 10^-1 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 72 hrs by XTT assay Cytotoxicity against human HeLa cells after 72 hrs by XTT assay	[PMID: 20619940]
HeLa	IC₅₀	20.93 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 22818039]
HeLa	IC₅₀	21.9 μM Compound: DXR	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 24 hrs by XTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 24 hrs by XTT assay	[PMID: 26649907]
HeLa	IC₅₀	3 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability by DAPI staining based assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability by DAPI staining based assay	[PMID: 33461146]
HeLa	IC₅₀	3.24 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 23835482]
HeLa	IC₅₀	3.24 μM Compound: Doxorubicin	Cytotoxicity against human HeLa after 24 hrs by MTT assay Cytotoxicity against human HeLa after 24 hrs by MTT assay	[PMID: 20056520]
HeLa	IC₅₀	3.24 μM Compound: doxorubicin	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 19128861]
HeLa	IC₅₀	3.24 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 24 hrs incubation by MTT assay Cytotoxicity against human HeLa cells after 24 hrs incubation by MTT assay	[PMID: 24856067]
HeLa	IC₅₀	3.3 μM Compound: adriamycin	Cytotoxicity against human HeLa cells after 4 days by MTT assay Cytotoxicity against human HeLa cells after 4 days by MTT assay	[PMID: 17194586]
HeLa	IC₅₀	3.3 μM Compound: DOX	Inhibition of topoisomerase 2 in human HeLa cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Inhibition of topoisomerase 2 in human HeLa cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 30846253]
HeLa	IC₅₀	3.33 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured at 24 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured at 24 hrs by MTT assay	[PMID: 36652792]
HeLa	IC₅₀	3.55 μM Compound: DOX	Antineoplastic activity against human HeLa cells measured after 36 hrs by MTT assay Antineoplastic activity against human HeLa cells measured after 36 hrs by MTT assay	[PMID: 30746067]
HeLa	IC₅₀	3.57 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25594739]
HeLa	IC₅₀	3.64 μg/mL Compound: DOX	Antitumor activity against human HeLa cells after 48 hrs by MTT assay Antitumor activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 20599299]
HeLa	IC₅₀	3.7 μM Compound: Adriamycin	Cytotoxicity against human HeLa cells after 4 days by MTT assay Cytotoxicity against human HeLa cells after 4 days by MTT assay	[PMID: 21704436]
HeLa	IC₅₀	3.9 μM Compound: doxorubicin	Cytotoxicity against human HeLa cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]
HeLa	IC₅₀	3.92 μM Compound: Doxorubicin	Anticancer activity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay Anticancer activity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26542964]
HeLa	IC₅₀	3.97 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31404864]
HeLa	IC₅₀	3.99 μM Compound: AMD	Antiproliferative activity against human HeLa cells measured after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells measured after 48 hrs by MTT assay	[PMID: 27639364]
HeLa	IC₅₀	30.21 μM Compound: Doxorubicin	Anticancer activity against human HeLa cells after 48 hrs by SRB assay Anticancer activity against human HeLa cells after 48 hrs by SRB assay	[PMID: 24077528]
HeLa	IC₅₀	37 nM Compound: doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by WST8 assay Cytotoxicity against human HeLa cells after 48 hrs by WST8 assay	[PMID: 20180542]
HeLa	IC₅₀	4 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay	[PMID: 27618204]
HeLa	IC₅₀	4.1 μM Compound: doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 23748152]
HeLa	IC₅₀	4.16 nM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as cell viability after 5 days by cell viability analyzer Cytotoxicity against human HeLa cells assessed as cell viability after 5 days by cell viability analyzer	[PMID: 26291039]
HeLa	IC₅₀	4.61 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 35367708]
HeLa	IC₅₀	4.8 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28254167]
HeLa	IC₅₀	5 mM Compound: Adriamycin	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 23685942]
HeLa	IC₅₀	5 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 27173802]
HeLa	IC₅₀	5.17 μM Compound: Doxorubicin	Antitumor activity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Antitumor activity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 30138804]
HeLa	IC₅₀	5.2 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 27769619]
HeLa	IC₅₀	5.2 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 26252628]
HeLa	IC₅₀	5.23 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 29573910]
HeLa	IC₅₀	5.3 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 22304344]
HeLa	IC₅₀	5.57 μM Compound: DOX	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 37054758]
HeLa	IC₅₀	5.57 μM Compound: DOX	Anticancer activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Anticancer activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 32085964]
HeLa	IC₅₀	5.57 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa after 24 hrs by MTT assay Antiproliferative activity against human HeLa after 24 hrs by MTT assay	[PMID: 30826188]
HeLa	IC₅₀	5.57 μM Compound: DOX	Cytotoxicity against human HeLa cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 36242988]
HeLa	IC₅₀	5.57 μM Compound: Dox	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32527460]
HeLa	IC₅₀	5.57 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 29702448]
HeLa	IC₅₀	5.57 μM Compound: DOX	Antiproliferative activity against human HeLa cells by MTT assay Antiproliferative activity against human HeLa cells by MTT assay	[PMID: 30216848]
HeLa	IC₅₀	5.7 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability preincubated for 24 hrs measured after 4 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability preincubated for 24 hrs measured after 4 hrs by MTT assay	[PMID: 34223162]
HeLa	IC₅₀	55 nM Compound: doxorubicin	Cytotoxicity against human HeLa cells after 120 hrs by WST8 assay Cytotoxicity against human HeLa cells after 120 hrs by WST8 assay	[PMID: 20180542]
HeLa	IC₅₀	57.8 μM Compound: DOX	Antitumor activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antitumor activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 35859879]
HeLa	IC₅₀	6 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 25453802]
HeLa	IC₅₀	6.3 μM Compound: ADR	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	10.1039/C2MD20270K
HeLa	IC₅₀	6.3 μM Compound: Doxorubicin	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30660827]
HeLa	GI₅₀	6.7 μM Compound: DOX	Cytotoxicity against human HeLa cells after 48 hrs by SRB assay Cytotoxicity against human HeLa cells after 48 hrs by SRB assay	[PMID: 29316526]
HeLa	IC₅₀	6.94 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 24607876]
HeLa	IC₅₀	7.01 μM Compound: Doxo	Cytotoxicity against human HeLa cells measured after 24 hrs by MTT assay Cytotoxicity against human HeLa cells measured after 24 hrs by MTT assay	[PMID: 31104996]
HeLa	IC₅₀	7.04 μM Compound: DOX	Anticancer activity against human HeLa cells assessed as inhibition of tumor cell proliferation after 48 hrs by MTT assay Anticancer activity against human HeLa cells assessed as inhibition of tumor cell proliferation after 48 hrs by MTT assay	[PMID: 25064350]
HeLa	IC₅₀	7.18 μM Compound: Dox	Cytotoxicity against human HeLa cells assessed as decrease in cell viability treated for 2 hrs measured after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as decrease in cell viability treated for 2 hrs measured after 48 hrs by MTT assay	[PMID: 28129977]
HeLa	IC₅₀	7.2 μM Compound: DX	Cytotoxicity against human HeLa cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HeLa cells after 48 hrs by sulforhodamine B assay	10.1039/C5MD00513B
HeLa	IC₅₀	7.4 μg/mL Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 35526504]
HeLa	GI₅₀	7.51 μM Compound: Doxo	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 26513642]
HeLa	IC₅₀	7.71 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by SRB assay Cytotoxicity against human HeLa cells after 48 hrs by SRB assay	[PMID: 23994327]
HeLa	IC₅₀	7.9 μM Compound: DOX	Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 31589431]
HeLa	IC₅₀	71 nM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 28600080]
HeLa	IC₅₀	780 nM Compound: Doxorubicin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30172625]
HeLa	IC₅₀	8.1 μM Compound: Doxorubicin	Anticancer activity against human HeLa cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT based microplate ELISA reader analysis Anticancer activity against human HeLa cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT based microplate ELISA reader analysis	[PMID: 34438126]
HeLa	IC₅₀	8.3 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by trypan blue-based hemacytometer counting analysis Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by trypan blue-based hemacytometer counting analysis	[PMID: 28756265]
HeLa	IC₅₀	8.66 μM Compound: DOX	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 30398868]
HeLa	IC₅₀	8.72 μg/mL Compound: DOX	Cytotoxicity against human HeLa cells after 48 hrs by SRB assay Cytotoxicity against human HeLa cells after 48 hrs by SRB assay	[PMID: 19932530]
HeLa	IC₅₀	8.87 μM Compound: DOX	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 35964425]
HeLa	IC₅₀	8.96 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells by WST-8 assay Cytotoxicity against human HeLa cells by WST-8 assay	[PMID: 29295796]
HeLa	IC₅₀	9.03 μM Compound: Doxorubicin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 26873414]
HeLa	IC₅₀	90 nM Compound: Doxorubicin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 35059132]
HeLa S3	IC₅₀	< 0.1 μM Compound: Doxorubicin	Antiproliferative activity against human HeLaS3 cells by MTT assay Antiproliferative activity against human HeLaS3 cells by MTT assay	[PMID: 29072457]
HeLa S3	IC₅₀	0.03 μM Compound: Doxorubicin	Cytotoxicity against human HeLaS3 cells after 48 hrs by MTT assay Cytotoxicity against human HeLaS3 cells after 48 hrs by MTT assay	[PMID: 26963142]
HeLa S3	IC₅₀	0.03 μM Compound: Doxorubicin	Cytotoxicity against human HeLaS3 cells by MTT assay Cytotoxicity against human HeLaS3 cells by MTT assay	[PMID: 30719909]
HeLa S3	IC₅₀	0.12 μM Compound: Doxorubicin	Cytotoxicity in human HeLaS3 cells incubated for 72 hrs by MTT assay Cytotoxicity in human HeLaS3 cells incubated for 72 hrs by MTT assay	[PMID: 30978023]
HeLa S3	IC₅₀	0.15 μM Compound: Doxorubicin	Cytotoxicity activity against human HeLa S3 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity activity against human HeLa S3 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32627543]
Hep 3B2	IC₅₀	0.14 μM Compound: Doxorubucin	Cytotoxicity against human Hep3B cells by MTT assay Cytotoxicity against human Hep3B cells by MTT assay	[PMID: 20718475]
Hep 3B2	IC₅₀	0.2 μg/mL Compound: doxorubicin	Cytotoxicity against human Hep3B cells by MTT assay Cytotoxicity against human Hep3B cells by MTT assay	[PMID: 18973388]
Hep 3B2	IC₅₀	0.27 μg/mL Compound: Doxorubicin	Cytotoxicity against human Hep3B cells by MTT assay Cytotoxicity against human Hep3B cells by MTT assay	[PMID: 18590313]
Hep 3B2	IC₅₀	0.29 μM Compound: DOX	Cytotoxicity against human Hep3B cells measured after 48 hrs by MTT assay Cytotoxicity against human Hep3B cells measured after 48 hrs by MTT assay	[PMID: 23290052]
Hep 3B2	IC₅₀	0.31 μg/mL Compound: Doxorubicin	Cytotoxicity against human Hep3B cells after 3 days by MTT assay Cytotoxicity against human Hep3B cells after 3 days by MTT assay	[PMID: 15387653]
Hep 3B2	IC₅₀	0.41 μg/mL Compound: Doxorubicin	Cytotoxicity against human Hep3B cells after 3 days by MTT assay Cytotoxicity against human Hep3B cells after 3 days by MTT assay	[PMID: 19691312]
Hep 3B2	IC₅₀	0.42 μg/mL Compound: Doxorubicin	Cytotoxicity against human Hep3B cells by MTT assay Cytotoxicity against human Hep3B cells by MTT assay	[PMID: 21106454]
Hep 3B2	IC₅₀	0.45 μg/mL Compound: doxo	Cytotoxicity against human Hep3B cells by MTT method Cytotoxicity against human Hep3B cells by MTT method	[PMID: 17417907]
Hep 3B2	IC₅₀	0.48 μM Compound: Doxorubicin	Cytotoxicity against human Hep3B cells after 3 days by MTT assay Cytotoxicity against human Hep3B cells after 3 days by MTT assay	[PMID: 18547115]
Hep 3B2	IC₅₀	0.59 μM Compound: doxorubicin	Cytotoxicity against human Hep3B cells after 3 days by MTT assay Cytotoxicity against human Hep3B cells after 3 days by MTT assay	[PMID: 18419154]
Hep 3B2	IC₅₀	0.6 μM Compound: Doxo	Cytotoxicity against human Hep3B cells after 72 hrs by MTT assay Cytotoxicity against human Hep3B cells after 72 hrs by MTT assay	[PMID: 20334960]
Hep 3B2	IC₅₀	0.62 μM Compound: doxorubicin	Cytotoxicity against human Hep3B cells after 72 hrs by MTT colorimetric method Cytotoxicity against human Hep3B cells after 72 hrs by MTT colorimetric method	[PMID: 17622129]
Hep 3B2	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human Hep3B cells by MTT assay Cytotoxicity against human Hep3B cells by MTT assay	[PMID: 21425785]
Hep 3B2	IC₅₀	1.02 μM Compound: Doxorubicin	Cytotoxicity against human Hep3B cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human Hep3B cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34838335]
Hep 3B2	IC₅₀	1.03 μM Compound: Doxo	Cytotoxicity against human Hep3B cells after 3 days by MTT assay Cytotoxicity against human Hep3B cells after 3 days by MTT assay	[PMID: 21800859]
Hep 3B2	IC₅₀	1.15 μM Compound: Dox	Cytotoxicity against human Hep3B cells by MTT assay Cytotoxicity against human Hep3B cells by MTT assay	[PMID: 28262527]
Hep 3B2	IC₅₀	1.31 μg/mL Compound: doxorubicin	Cytotoxicity against human Hep3B cells by MTT assay Cytotoxicity against human Hep3B cells by MTT assay	[PMID: 22413887]
Hep 3B2	IC₅₀	1.8 μM Compound: Doxorubicin	Cytotoxicity against human Hep3B cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human Hep3B cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
Hep 3B2	IC₅₀	13.25 μM Compound: Dox	Antiproliferative activity against human Hep3B cells for 24 hrs by MTT assay Antiproliferative activity against human Hep3B cells for 24 hrs by MTT assay	[PMID: 24929289]
Hep 3B2	IC₅₀	16 μM Compound: DOX	Cytotoxicity against human Hep3B cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human Hep3B cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
Hep 3B2	IC₅₀	2.4 μM Compound: Doxorubicin	Growth inhibition of human Hep3B cells by MTT assay Growth inhibition of human Hep3B cells by MTT assay	[PMID: 28916158]
Hep 3B2	IC₅₀	4.5 μM Compound: Dox	Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay	[PMID: 28865276]
Hep 3B2	EC₅₀	5.6 μM Compound: doxorubicin	Cytotoxicity against human Hep3B cells deficient in p53 gene by MTT assay Cytotoxicity against human Hep3B cells deficient in p53 gene by MTT assay	[PMID: 20455578]
HEp-2	IC₅₀	0.04 μM Compound: DOX	Antitumor activity against human Hep2 cells after 72 hrs by MTT assay Antitumor activity against human Hep2 cells after 72 hrs by MTT assay	[PMID: 17935309]
HEp-2	IC₅₀	0.04 μM Compound: doxo	Antiproliferative activity against human Hep2 cell line by MTT assay Antiproliferative activity against human Hep2 cell line by MTT assay	[PMID: 16913700]
HEp-2	IC₅₀	0.4 μg/mL Compound: Doxorubicin	Cytotoxicity against human Hep2 cells after 24 hrs Cytotoxicity against human Hep2 cells after 24 hrs	[PMID: 20207452]
HEp-2	IC₅₀	0.42 μM Compound: doxorubicin	Cytotoxicity against human Hep2 cells after 24 hrs by MTT assay Cytotoxicity against human Hep2 cells after 24 hrs by MTT assay	[PMID: 18281125]
HEp-2	IC₅₀	0.42 μM Compound: doxorubicin	Cytotoxicity against human Hep2 cells after 24 hrs by MTT assay Cytotoxicity against human Hep2 cells after 24 hrs by MTT assay	[PMID: 17400463]
HEp-2	IC₅₀	0.51 μM Compound: Doxorubicin	Antiproliferative activity against human Hep2 cells after 48 hrs by neutral red assay Antiproliferative activity against human Hep2 cells after 48 hrs by neutral red assay	[PMID: 29885574]
HEp-2	IC₅₀	1.21 μM Compound: Doxorubicin	Cytotoxicity against human Hep2 cells assessed as inhibition of cell viability after 72 hrs by MTT assay Cytotoxicity against human Hep2 cells assessed as inhibition of cell viability after 72 hrs by MTT assay	[PMID: 29329071]
HEp-2	IC₅₀	1.29 μM Compound: Doxorubicin	Cytotoxicity against human Hep2 cells after 72 hrs by MTT assay Cytotoxicity against human Hep2 cells after 72 hrs by MTT assay	[PMID: 27116711]
HEp-2	IC₅₀	1.3 μM Compound: Doxorubicin	Growth inhibition of human Hep2 cells after 72 hrs by MTT assay Growth inhibition of human Hep2 cells after 72 hrs by MTT assay	[PMID: 28189083]
HEp-2	IC₅₀	1.5 μM Compound: Adriamycin	Cytotoxicity against human Hep2 cells by neutral red method Cytotoxicity against human Hep2 cells by neutral red method	[PMID: 26291474]
HEp-2	IC₅₀	1.78 μM Compound: DOX	Cytotoxicity against against human Hep2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against against human Hep2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30340899]
HEp-2	IC₅₀	6.32 μM Compound: Doxorubicin	Antiproliferative activity against human Hep2 after 24 hrs by MTT assay Antiproliferative activity against human Hep2 after 24 hrs by MTT assay	[PMID: 30826188]
HEp-2	IC₅₀	8.54 μM Compound: DOX	Antiproliferative activity against human HEp-2 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human HEp-2 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 37054758]
HEp-2	IC₅₀	8.7 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) Hep2 cells by MTT assay Cytotoxicity against Homo sapiens (human) Hep2 cells by MTT assay	10.1007/s00044-012-0370-x
HEp-2	IC₅₀	8.7 μM Compound: Doxorubicine	Cytotoxicity against human Hep2 cells by MTT assay Cytotoxicity against human Hep2 cells by MTT assay	[PMID: 22014995]
HepG2	IC₅₀	< 2.94 μM Compound: Doxorubicin	Inhibition of proliferation of human HepG2 cells after 72 hrs by XTT assay Inhibition of proliferation of human HepG2 cells after 72 hrs by XTT assay	[PMID: 20810194]
HepG2	EC₅₀	> 10 μM Compound: doxorubicin	Cytotoxicity against doxorubicin resistant human HepG2 cells expressing wild type p53 gene by MTT assay Cytotoxicity against doxorubicin resistant human HepG2 cells expressing wild type p53 gene by MTT assay	[PMID: 20455578]
HepG2	IC₅₀	> 40 μg/mL Compound: doxorubicin	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 12608856]
HepG2	IC₅₀	> 50 μM Compound: DOX	Cytotoxicity against human doxorubicin-resistant HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human doxorubicin-resistant HepG2 cells after 48 hrs by MTT assay	[PMID: 27889629]
HepG2	IC₅₀	> 75 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27843113]
HepG2	IC₅₀	0.007 ug Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 48 hrs by SRB assay Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 48 hrs by SRB assay	[PMID: 27393950]
HepG2	IC₅₀	0.009 mM Compound: DOX	Cytotoxicity against human HepG2 cells after 3 days by MTT assay Cytotoxicity against human HepG2 cells after 3 days by MTT assay	[PMID: 22520152]
HepG2	GI₅₀	0.01 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 27889456]
HepG2	IC₅₀	0.01 μM Compound: DOX	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 30826510]
HepG2	IC₅₀	0.017 g/L Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) HepG2 cells after 24 hr by MTT assay Cytotoxicity against Homo sapiens (human) HepG2 cells after 24 hr by MTT assay	10.1007/s00044-010-9433-z
HepG2	IC₅₀	0.02 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 27886545]
HepG2	CC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay	[PMID: 25282267]
HepG2	IC₅₀	0.04 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay	[PMID: 31403289]
HepG2	GI₅₀	0.04 μM Compound: Dox	Growth inhibition of human HepG2 cells by MTT assay Growth inhibition of human HepG2 cells by MTT assay	[PMID: 31330449]
HepG2	IC₅₀	0.05 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 22555152]
HepG2	CC₅₀	0.06 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 32088496]
HepG2	IC₅₀	0.06 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34782182]
HepG2	IC₅₀	0.06 μM Compound: Adriamycin	Cytotoxicity against human HepG2 cells by SRB method Cytotoxicity against human HepG2 cells by SRB method	[PMID: 18181575]
HepG2	IC₅₀	0.069 μM Compound: DOX	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31999451]
HepG2	IC₅₀	0.08 μM Compound: Dox	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 23802716]
HepG2	IC₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by CCK8 assay Cytotoxicity against human HepG2 cells after 72 hrs by CCK8 assay	[PMID: 28398051]
HepG2	IC₅₀	0.1 μM Compound: doxorubicin	Growth inhibition of human HepG2 cells after 72 hrs by MTT assay Growth inhibition of human HepG2 cells after 72 hrs by MTT assay	[PMID: 18313307]
HepG2	IC₅₀	0.16 μg/mL Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 3 days by MTT assay Cytotoxicity against human HepG2 cells after 3 days by MTT assay	[PMID: 19691312]
HepG2	IC₅₀	0.16 μM Compound: ADM; DOX	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31491611]
HepG2	IC₅₀	0.17 μg/mL Compound: Doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 18590313]
HepG2	IC₅₀	0.17 μM Compound: doxorubicin	Cytotoxicity against human HepG2 cells after 6 days by MTT method Cytotoxicity against human HepG2 cells after 6 days by MTT method	[PMID: 16309317]
HepG2	IC₅₀	0.18 μg/mL Compound: doxorubicin	Cytotoxicity against human HepG2 cells after 3 days by MTT assay Cytotoxicity against human HepG2 cells after 3 days by MTT assay	[PMID: 16252914]
HepG2	IC₅₀	0.18 μg/mL Compound: doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 22413887]
HepG2	IC₅₀	0.19 μg/mL Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 3 days by MTT assay Cytotoxicity against human HepG2 cells after 3 days by MTT assay	[PMID: 15387653]
HepG2	IC₅₀	0.19 μM Compound: DOX	Cytotoxicity against human HepG2 cells measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells measured after 48 hrs by MTT assay	[PMID: 23290052]
HepG2	GI₅₀	0.19 μM Compound: DOX	Growth inhibition of human HepG2 cells after 72 hrs by MTT assay Growth inhibition of human HepG2 cells after 72 hrs by MTT assay	[PMID: 30336023]
HepG2	GI₅₀	0.19 μM Compound: DOX	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29705710]
HepG2	IC₅₀	0.19 μM Compound: DOX	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 21496972]
HepG2	IC₅₀	0.19 μM Compound: Doxorubucin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 20718475]
HepG2	IC₅₀	0.2 μg/mL Compound: doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 18973388]
HepG2	IC₅₀	0.2 μg/mL Compound: Doxorubicin	Cytotoxicity against human Hep G2 cells by MTT colorimetric method Cytotoxicity against human Hep G2 cells by MTT colorimetric method	[PMID: 17125220]
HepG2	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28277681]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34364164]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32795774]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32652409]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32292551]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 30655943]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30092366]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 29885575]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27654395]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells measured after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells measured after 72 hrs by MTT assay	[PMID: 27155463]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 25846065]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 25791675]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 25559208]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicine	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 24946216]
HepG2	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24650715]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 24080103]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 22889559]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 22608675]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 21852132]
HepG2	CC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 21741131]
HepG2	IC₅₀	0.2 μM Compound: doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 19926173]
HepG2	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 19482476]
HepG2	IC₅₀	0.2 μM Compound: doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 17981462]
HepG2	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay Cytotoxicity against human HepG2 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay	[PMID: 36970146]
HepG2	IC₅₀	0.21 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 31836446]
HepG2	IC₅₀	0.22 μg/mL Compound: Doxorubicin	Cytotoxic activity against human HepG2 cells by MTT assay Cytotoxic activity against human HepG2 cells by MTT assay	[PMID: 28366267]
HepG2	IC₅₀	0.23 μg/mL Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as survival after 3 days by crystal violet staining Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as survival after 3 days by crystal violet staining	10.1007/s00044-012-0025-y
HepG2	IC₅₀	0.23 μg/mL Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) HepG2 cells after 3 days by MTT assay Cytotoxicity against Homo sapiens (human) HepG2 cells after 3 days by MTT assay	10.1007/s00044-011-9903-y
HepG2	IC₅₀	0.23 μg/mL Compound: Doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 21106454]
HepG2	IC₅₀	0.23 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by fluorescein diacetate dye based fluorometric microculture assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by fluorescein diacetate dye based fluorometric microculture assay	[PMID: 28038943]
HepG2	GI₅₀	0.25 μg/mL Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 26561866]
HepG2	IC₅₀	0.26 μM Compound: Dox	Cytotoxicity against human HepG2 cells after 3 days by MTT assay Cytotoxicity against human HepG2 cells after 3 days by MTT assay	[PMID: 21741833]
HepG2	IC₅₀	0.29 μM Compound: doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 21174408]
HepG2	IC₅₀	0.3 μg/mL Compound: Doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 16724859]
HepG2	IC₅₀	0.3 μM Compound: doxorubicin	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 24050254]
HepG2	IC₅₀	0.3 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	10.1039/C5MD00163C
HepG2	IC₅₀	0.3 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 19632833]
HepG2	EC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay	[PMID: 26320088]
HepG2	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 29975532]
HepG2	IC₅₀	0.36 μM Compound: doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 25314138]
HepG2	IC₅₀	0.37 μM Compound: doxorubicin	Cytotoxicity against human HepG2 cells after 4 days by MTT assay Cytotoxicity against human HepG2 cells after 4 days by MTT assay	[PMID: 19824618]
HepG2	IC₅₀	0.37 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 20846862]
HepG2	IC₅₀	0.38 μM Compound: Doxorubicin	Growth inhibition of human HepG2 cells incubated for 48 hrs by MTT assay Growth inhibition of human HepG2 cells incubated for 48 hrs by MTT assay	[PMID: 27080187]
HepG2	IC₅₀	0.39 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 36089748]
HepG2	IC₅₀	0.392 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as cell viability incubated for 72 hrs by cellTiter 96 AQueous non-radioactive cell proliferation assay Cytotoxicity against human HepG2 cells assessed as cell viability incubated for 72 hrs by cellTiter 96 AQueous non-radioactive cell proliferation assay	[PMID: 28797771]
HepG2	IC₅₀	0.4 μg/mL Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability by MTT assay	[PMID: 32223924]
HepG2	IC₅₀	0.4 μg/mL Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by neutral red-based assay Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by neutral red-based assay	[PMID: 26469557]
HepG2	IC₅₀	0.4 μM Compound: doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTS assay Cytotoxicity against human HepG2 cells after 72 hrs by MTS assay	[PMID: 25490132]
HepG2	IC₅₀	0.4 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 25747499]
HepG2	IC₅₀	0.41 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]
HepG2	IC₅₀	0.42 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by alamar blue assay Cytotoxicity against human HepG2 cells after 72 hrs by alamar blue assay	[PMID: 24969014]
HepG2	IC₅₀	0.42 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as inhibition of cell growth after 3 days by MTT assay Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as inhibition of cell growth after 3 days by MTT assay	10.1007/s00044-012-0402-6
HepG2	IC₅₀	0.425 μM Compound: DOX	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35341920]
HepG2	IC₅₀	0.45 μM Compound: Doxorubicin	Anticancer activity against human HepG2 cells by MTT assay Anticancer activity against human HepG2 cells by MTT assay	[PMID: 31404864]
HepG2	IC₅₀	0.46 μg/mL Compound: doxo	Cytotoxicity against human HepG2 cells by MTT method Cytotoxicity against human HepG2 cells by MTT method	[PMID: 17417907]
HepG2	IC₅₀	0.467 μM Compound: Doxorubicin	Anticancer activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT colorimetric assay Anticancer activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT colorimetric assay	[PMID: 35694689]
HepG2	IC₅₀	0.48 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay	[PMID: 24852278]
HepG2	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 200 uM incubated for 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 200 uM incubated for 24 hrs by MTT assay	[PMID: 31926469]
HepG2	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 25554367]
HepG2	IC₅₀	0.5 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay	[PMID: 31148449]
HepG2	IC₅₀	0.5 μM Compound: Doxorubicin	Anticancer activity against human HepG2 cells after 48 hrs by MTT assay Anticancer activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 21641694]
HepG2	IC₅₀	0.5 μM Compound: Doxo	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 20334960]
HepG2	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	10.1039/C3MD00166K
HepG2	IC₅₀	0.5 μM Compound: Adriamycin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 24182355]
HepG2	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 21425785]
HepG2	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells by SRB assay Cytotoxicity against human HepG2 cells by SRB assay	[PMID: 29035560]
HepG2	IC₅₀	0.5 μM Compound: doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTT colorimetric method Cytotoxicity against human HepG2 cells after 72 hrs by MTT colorimetric method	[PMID: 17622129]
HepG2	IC₅₀	0.52 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30389295]
HepG2	IC₅₀	0.54 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 27371926]
HepG2	IC₅₀	0.54 μM Compound: Dox	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 28262527]
HepG2	IC₅₀	0.55 μM Compound: DX	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 29681486]
HepG2	IC₅₀	0.55 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31704206]
HepG2	IC₅₀	0.57 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 26397393]
HepG2	IC₅₀	0.57 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 25019480]
HepG2	IC₅₀	0.58 μM Compound: DOX	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 26386603]
HepG2	IC₅₀	0.59 μg/mL Compound: Dox	Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine B assay	[PMID: 20399544]
HepG2	IC₅₀	0.59 μM Compound: doxorubicin	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 23806110]
HepG2	IC₅₀	0.6 μg/mL Compound: Doxorubicine	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 24177357]
HepG2	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 24300737]
HepG2	IC₅₀	0.62 μM Compound: Doxorubicin	Anticancer activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 32438251]
HepG2	IC₅₀	0.62 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells after 48 hrs by neutral red assay Antiproliferative activity against human HepG2 cells after 48 hrs by neutral red assay	[PMID: 29885574]
HepG2	IC₅₀	0.63 μM Compound: Doxo	Cytotoxicity against human HepG2 cells after 3 days by MTT assay Cytotoxicity against human HepG2 cells after 3 days by MTT assay	[PMID: 21800859]
HepG2	IC₅₀	0.64 μg/mL Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 34973507]
HepG2	IC₅₀	0.64 μM Compound: doxorubicin	Cytotoxicity against human HepG2 cells after 3 days by MTT assay Cytotoxicity against human HepG2 cells after 3 days by MTT assay	[PMID: 18419154]
HepG2	IC₅₀	0.66 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34838335]
HepG2	EC₅₀	0.67 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35567964]
HepG2	IC₅₀	0.67 μM Compound: DOX	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32996316]
HepG2	IC₅₀	0.68 μM Compound: DOX	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29421568]
HepG2	IC₅₀	0.68 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell growth after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell growth after 48 hrs by MTT assay	[PMID: 27422336]
HepG2	IC₅₀	0.69 μM Compound: DOX	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 33276990]
HepG2	IC₅₀	0.69 μM Compound: ADM	Growth inhibition of human HepG2 cells after 48 hrs by WST8 assay Growth inhibition of human HepG2 cells after 48 hrs by WST8 assay	[PMID: 16499322]
HepG2	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay	[PMID: 27300257]
HepG2	GI₅₀	0.7 μM Compound: Dox	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]
HepG2	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 22749279]
HepG2	IC₅₀	0.7 μM Compound: Dox	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability by MTT assay	[PMID: 31765156]
HepG2	IC₅₀	0.7 μM Compound: Dox	Cytotoxicity against human HepG2 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human HepG2 cells after 72 hrs by sulforhodamine B assay	[PMID: 30132670]
HepG2	IC₅₀	0.72 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay	[PMID: 31926469]
HepG2	IC₅₀	0.72 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 30654238]
HepG2	IC₅₀	0.72 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 26874404]
HepG2	IC₅₀	0.74 μM Compound: Dox	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 35339100]
HepG2	IC₅₀	0.74 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 25419616]
HepG2	CC₅₀	0.77 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 120 hrs by MTS assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 120 hrs by MTS assay	[PMID: 32590115]
HepG2	IC₅₀	0.77 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay	[PMID: 25537271]
HepG2	IC₅₀	0.79 μM Compound: doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	10.1007/s00044-013-0777-z
HepG2	IC₅₀	0.79 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 25078311]
HepG2	IC₅₀	0.79 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 24836071]
HepG2	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay	[PMID: 32324401]
HepG2	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 26586599]
HepG2	IC₅₀	0.82 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 3 days by MTT assay Cytotoxicity against human HepG2 cells after 3 days by MTT assay	[PMID: 18547115]
HepG2	IC₅₀	0.87 μM Compound: AMD	Anticancer activity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay	[PMID: 25812966]
HepG2	IC₅₀	0.877 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay	[PMID: 24231309]
HepG2	IC₅₀	0.9 μg/mL Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by neutral red Cytotoxicity against human HepG2 cells after 48 hrs by neutral red	[PMID: 23891181]
HepG2	IC₅₀	0.9 μM Compound: Dox	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28704759]
HepG2	IC₅₀	0.919 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells by SRB assay Cytotoxicity against human HepG2 cells by SRB assay	[PMID: 34128674]
HepG2	IC₅₀	0.95 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	10.1039/C3MD00013C
HepG2	IC₅₀	0.954 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 20832916]
HepG2	IC₅₀	0.99 μM Compound: Doxorubicin	Anticancer activity against human HepG2 cells by SRB assay Anticancer activity against human HepG2 cells by SRB assay	[PMID: 34128674]
HepG2	IC₅₀	1 μM Compound: Dox	Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay	[PMID: 21094049]
HepG2	IC₅₀	1 μM Compound: DOX	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 32371335]
HepG2	IC₅₀	1 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 28919340]
HepG2	IC₅₀	1 μM Compound: Doxorubicin	Cytotoxicity activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32627543]
HepG2	IC₅₀	1 μM Compound: doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by neutral red assay Cytotoxicity against human HepG2 cells after 48 hrs by neutral red assay	[PMID: 24900509]
HepG2	IC₅₀	1.01 μM Compound: DOX	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29909338]
HepG2	IC₅₀	1.02 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 23871222]
HepG2	IC₅₀	1.05 μM Compound: Doxorubicin	Anticancer activity against human HepG2 cells by MTT assay Anticancer activity against human HepG2 cells by MTT assay	[PMID: 25743216]
HepG2	IC₅₀	1.07 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 30719909]
HepG2	IC₅₀	1.08 μM Compound: Dox	Anticancer activity against Homo sapiens (human) HepG2 cells assessed as growth inhibition after 48 hr by SRB assay Anticancer activity against Homo sapiens (human) HepG2 cells assessed as growth inhibition after 48 hr by SRB assay	10.1007/s00044-012-0057-3
HepG2	IC₅₀	1.1 μM Compound: Doxorubicin	Anticancer activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT microcultured tetrazolium assay Anticancer activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT microcultured tetrazolium assay	[PMID: 25096298]
HepG2	IC₅₀	1.12 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32866757]
HepG2	IC₅₀	1.13 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells by CCK8 assay Cytotoxicity against human HepG2 cells by CCK8 assay	[PMID: 29452840]
HepG2	IC₅₀	1.15 μM Compound: Adriamycin	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 24582982]
HepG2	IC₅₀	1.18 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 3 days by microplate reader analysis Cytotoxicity against human HepG2 cells after 3 days by microplate reader analysis	[PMID: 32705864]
HepG2	IC₅₀	1.2 μM Compound: DOX	Antineoplastic activity against human HepG2 cells measured after 36 hrs by MTT assay Antineoplastic activity against human HepG2 cells measured after 36 hrs by MTT assay	[PMID: 30746067]
HepG2	IC₅₀	1.2 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by MTT assay	10.1007/s00044-011-9884-x
HepG2	IC₅₀	1.2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 27797185]
HepG2	IC₅₀	1.2 μM Compound: ADM	Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay	[PMID: 15730243]
HepG2	IC₅₀	1.2 μM Compound: ADM	Cytotoxicity against human Hep G2 by WST-8 assay Cytotoxicity against human Hep G2 by WST-8 assay	[PMID: 16933868]
HepG2	IC₅₀	1.2 μM Compound: adriamycin	Cytotoxicity against human HepG2 cells by rapid colorimetric assay Cytotoxicity against human HepG2 cells by rapid colorimetric assay	[PMID: 19585998]
HepG2	IC₅₀	1.21 μg/mL Compound: Doxorubicin	Anticancer activity against human cells HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay Anticancer activity against human cells HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 25042338]
HepG2	IC₅₀	1.21 μM Compound: DOX	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 30771605]
HepG2	IC₅₀	1.22 μM Compound: adriamycin	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 26295905]
HepG2	IC₅₀	1.22 μM Compound: ADM	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth after 72 hrs by MTT assay	[PMID: 25089733]
HepG2	IC₅₀	1.3 μM Compound: DOX	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay	[PMID: 34323485]
HepG2	IC₅₀	1.34 μM Compound: AMD	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 26900656]
HepG2	IC₅₀	1.37 μM Compound: DOX	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 31057738]
HepG2	GI₅₀	1.4 μM Compound: Doxorubicin	Anti-proliferative activity against human HepG2 cells incubated for 48 hrs by SRB assay Anti-proliferative activity against human HepG2 cells incubated for 48 hrs by SRB assay	[PMID: 26163220]
HepG2	IC₅₀	1.43 μM Compound: Doxorubicin	Cytotoxicity in human HepG2 cells incubated for 72 hrs by MTT assay Cytotoxicity in human HepG2 cells incubated for 72 hrs by MTT assay	[PMID: 30978023]
HepG2	IC₅₀	1.5 μM Compound: DOX	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 28756264]
HepG2	IC₅₀	1.51 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay	[PMID: 32682198]
HepG2	IC₅₀	1.54 μM Compound: DOXO	Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by alamar blue assay Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by alamar blue assay	[PMID: 21797280]
HepG2	IC₅₀	1.54 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by Alamar blue assay Cytotoxicity against human HepG2 cells after 48 hrs by Alamar blue assay	[PMID: 20931970]
HepG2	IC₅₀	1.54 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 26963142]
HepG2	IC₅₀	1.6 μg/mL Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 21708464]
HepG2	IC₅₀	1.6 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 19583252]
HepG2	IC₅₀	1.61 μM Compound: Doxorubicin	Anticancer activity against human HepG2 cells after 48 hrs by MTT assay Anticancer activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 25615796]
HepG2	IC₅₀	1.69 μM Compound: Dox	Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as reduction of cell survival after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as reduction of cell survival after 48 hr by MTT assay	10.1007/s00044-012-0150-7
HepG2	IC₅₀	1.7 x 10^-1 μM Compound: doxorubicin	Growth inhibition of human HepG2 cells after 72 hrs by SRB assay Growth inhibition of human HepG2 cells after 72 hrs by SRB assay	[PMID: 18512984]
HepG2	IC₅₀	1.8 μM Compound: Doxorubicin	Anticancer activity against human HepG2 cells assessed as growth inhibition incubated for 48 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as growth inhibition incubated for 48 hrs by MTT assay	[PMID: 34363936]
HepG2	IC₅₀	1.89 μM Compound: DOX	Growth inhibition of human HepG2 cells after 48 hrs by MTT assay Growth inhibition of human HepG2 cells after 48 hrs by MTT assay	[PMID: 29509413]
HepG2	CC₅₀	1.95 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 29792325]
HepG2	IC₅₀	1.969 μM Compound: DOX	Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34700239]
HepG2	IC₅₀	10 nM Compound: Dox	Anticancer activity against human HepG2 cells assessed as reduction in cell viability by MTT assay Anticancer activity against human HepG2 cells assessed as reduction in cell viability by MTT assay	[PMID: 31740054]
HepG2	IC₅₀	10 μM Compound: Doxorubicin	Antiproliferative activity against doxorubicin resistant human HepG2 cells for 24 hrs in presence of c-phycocyanin by MTT assay Antiproliferative activity against doxorubicin resistant human HepG2 cells for 24 hrs in presence of c-phycocyanin by MTT assay	[PMID: 34128674]
HepG2	IC₅₀	10.15 μM Compound: Doxorubicin	Cytotoxicity activity against human HepG2 cells by MTT assay Cytotoxicity activity against human HepG2 cells by MTT assay	[PMID: 26873414]
HepG2	IC₅₀	10.4 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31323616]
HepG2	GI₅₀	10.7 μM Compound: DOX	Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay	[PMID: 29316526]
HepG2	ED₅₀	102 μM Compound: doxorubicin	Antitumor activity against human HepG2 cells after 24 hrs by MTT assay Antitumor activity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 17482824]
HepG2	IC₅₀	12.5 μM Compound: Adriamycin	Anticancer activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24974349]
HepG2	IC₅₀	130 nM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay	[PMID: 35213166]
HepG2	IC₅₀	14.7 μM Compound: Dox	Cytotoxicity against human HepG2 Cells by MTT/Trypan Blue Exclusion Assay Cytotoxicity against human HepG2 Cells by MTT/Trypan Blue Exclusion Assay	[PMID: 31129455]
HepG2	IC₅₀	17.54 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 21620529]
HepG2	IC₅₀	18.03 μM Compound: Dox	Cytotoxicity against human HepG2 cells assessed as cell viability measured after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell viability measured after 24 hrs by MTT assay	[PMID: 33183865]
HepG2	IC₅₀	18.7 μM Compound: 12	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 29852328]
HepG2	IC₅₀	19 nM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay	[PMID: 21296467]
HepG2	IC₅₀	19 μg/mL Compound: doxorubicin	Cytotoxicity against Homo sapiens (human) HepG2 cells after 24 hr by MTT assay Cytotoxicity against Homo sapiens (human) HepG2 cells after 24 hr by MTT assay	10.1007/s00044-010-9436-9
HepG2	IC₅₀	2 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by Neutral Red assay Cytotoxicity against human HepG2 cells after 48 hrs by Neutral Red assay	10.1039/C3MD00097D
HepG2	IC₅₀	2.03 μM Compound: ADM	Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 20932754]
HepG2	IC₅₀	2.1 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 26821210]
HepG2	IC₅₀	2.1 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29702447]
HepG2	IC₅₀	2.17 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 94 hrs by MTT assay Cytotoxicity against human HepG2 cells after 94 hrs by MTT assay	[PMID: 21868138]
HepG2	IC₅₀	2.3 μM Compound: Doxorubicin	Hepatotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Hepatotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33439019]
HepG2	IC₅₀	2.32 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 33352388]
HepG2	IC₅₀	2.35 μM Compound: Doxorubicin	Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34124677]
HepG2	IC₅₀	2.41 x 10^-1 μg/mL Compound: adriamycin	Cytotoxicity against human HepG2 cells after 12 days by methylene blue colorimetric method Cytotoxicity against human HepG2 cells after 12 days by methylene blue colorimetric method	[PMID: 11473425]
HepG2	IC₅₀	2.41 x 10^-1 μg/mL Compound: Adriamycin	Cytotoxicity against human HepG2 cells after 3 days Cytotoxicity against human HepG2 cells after 3 days	[PMID: 11975482]
HepG2	IC₅₀	2.5 mM Compound: Adriamycin	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 23685942]
HepG2	IC₅₀	2.5 mM Compound: Adriamycin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 22440624]
HepG2	IC₅₀	2.5 nM Compound: Doxorubicin	Inhibition of TRK in human HepG2 cells after 48 hrs by ELISA Inhibition of TRK in human HepG2 cells after 48 hrs by ELISA	[PMID: 24013411]
HepG2	IC₅₀	2.511 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28462842]
HepG2	IC₅₀	2.594 μM Compound: Doxorubicin	Anti-proliferative activity against human HepG2 cells measured after 48 hrs by MTT assay Anti-proliferative activity against human HepG2 cells measured after 48 hrs by MTT assay	[PMID: 27744185]
HepG2	IC₅₀	2.6 μM Compound: DOX	Inhibition of topoisomerase 2 in human HepG2 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Inhibition of topoisomerase 2 in human HepG2 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 30846253]
HepG2	IC₅₀	2.67 μM Compound: AMD	Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay	[PMID: 27639364]
HepG2	IC₅₀	2.68 μM Compound: doxorubicin	Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay	10.1007/s00044-013-0795-x
HepG2	IC₅₀	2.7 μM Compound: DOX	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay	[PMID: 34450496]
HepG2	IC₅₀	2.7 μM Compound: Adriamycin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 22946634]
HepG2	IC₅₀	2.75 μM Compound: Doxorubicin	Anticancer activity against human HepG2 cells assessed as inhibition of cell growth incubated for 3 days by MTT assay Anticancer activity against human HepG2 cells assessed as inhibition of cell growth incubated for 3 days by MTT assay	[PMID: 35007724]
HepG2	IC₅₀	2.85 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay	[PMID: 31200236]
HepG2	IC₅₀	2.9 μM Compound: Dox	Inhibition of human HepG2cells assessed as inhibition of cell growth after 72 hrs by SRB method Inhibition of human HepG2cells assessed as inhibition of cell growth after 72 hrs by SRB method	[PMID: 26071861]
HepG2	IC₅₀	20.2 nM Compound: Doxorubicin	Antiproliferative against human HepG2 cells assessed as cell viability after 96 hrs by MTT assay Antiproliferative against human HepG2 cells assessed as cell viability after 96 hrs by MTT assay	[PMID: 24211639]
HepG2	IC₅₀	21.2 μM Compound: 21	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 29289880]
HepG2	IC₅₀	22 nM Compound: DOX	Anticancer activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33901898]
HepG2	IC₅₀	23.22 μM Compound: doxorubicin	Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability after 24 hrs by MTT assay	[PMID: 26200396]
HepG2	IC₅₀	240 nM Compound: doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by MTS assay Cytotoxicity against human HepG2 cells after 72 hrs by MTS assay	[PMID: 19655762]
HepG2	IC₅₀	27.11 μM Compound: Doxorubicin	Anticancer activity against human HepG2 cells after 48 hrs by SRB assay Anticancer activity against human HepG2 cells after 48 hrs by SRB assay	[PMID: 24077528]
HepG2	IC₅₀	3 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by DAPI staining based assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by DAPI staining based assay	[PMID: 33461146]
HepG2	IC₅₀	3.01 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31404864]
HepG2	IC₅₀	3.01 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 27015609]
HepG2	IC₅₀	3.1 μg/mL Compound: DOX	Cytotoxicity against human HepG2 cells by SRB assay Cytotoxicity against human HepG2 cells by SRB assay	[PMID: 23831694]
HepG2	IC₅₀	3.36 μg/mL Compound: doxorubicin	Cytotoxicity against human HepG2 cells after 3 days by MTT assay Cytotoxicity against human HepG2 cells after 3 days by MTT assay	[PMID: 19456120]
HepG2	IC₅₀	3.39 μM Compound: Doxo	Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay	[PMID: 27036521]
HepG2	IC₅₀	3.45 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells after 72 hrs by SRB assay Antiproliferative activity against human HepG2 cells after 72 hrs by SRB assay	[PMID: 25462265]
HepG2	IC₅₀	3.45 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells by sulforhodamine B assay Cytotoxicity against human HepG2 cells by sulforhodamine B assay	[PMID: 31401008]
HepG2	IC₅₀	3.5 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25655719]
HepG2	IC₅₀	3.54 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 33148490]
HepG2	IC₅₀	3.56 μM Compound: Dox	Cytotoxicity against human HepG2 cells assessed as cell viability after 24 hrs by crystal violet staining assay Cytotoxicity against human HepG2 cells assessed as cell viability after 24 hrs by crystal violet staining assay	[PMID: 26706352]
HepG2	IC₅₀	3.73 μg/mL Compound: DOX	Cytotoxicity against human HepG2 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human HepG2 cells after 72 hrs by sulforhodamine B assay	[PMID: 22370339]
HepG2	IC₅₀	3.73 μg/mL Compound: DOX	Cytotoxicity against human HepG2 by sulforhodamie B colorimetric assay Cytotoxicity against human HepG2 by sulforhodamie B colorimetric assay	[PMID: 22178093]
HepG2	IC₅₀	3.82 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 26874744]
HepG2	IC₅₀	3.82 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 25462233]
HepG2	IC₅₀	3.9 μg/mL Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay	[PMID: 24095746]
HepG2	IC₅₀	32 μM Compound: Doxorubicin	Anticancer activity against human HepG2 cells assessed as inhibition of cell proliferation at 100 uM measured after 24 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as inhibition of cell proliferation at 100 uM measured after 24 hrs by MTT assay	[PMID: 31926469]
HepG2	IC₅₀	32 μM Compound: DOX	Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by SRB assay Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by SRB assay	10.1007/s00044-011-9751-9
HepG2	IC₅₀	32 μM Compound: DOX	Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by SRB assay Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 27085944]
HepG2	GI₅₀	35.3 μM Compound: DOX	Growth inhibition of human HepG2 cells after 48 hrs by SRB assay Growth inhibition of human HepG2 cells after 48 hrs by SRB assay	[PMID: 28433679]
HepG2	IC₅₀	36.3 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as surviving fraction ratio after 48 hrs by SRB assay relative to control Cytotoxicity against human HepG2 cells assessed as surviving fraction ratio after 48 hrs by SRB assay relative to control	[PMID: 25618015]
HepG2	IC₅₀	36.74 μM Compound: doxorubicin	Growth inhibition of doxorubicin resistant human HepG2 cells after 72 hrs by MTT assay Growth inhibition of doxorubicin resistant human HepG2 cells after 72 hrs by MTT assay	[PMID: 18313307]
HepG2	IC₅₀	4 mg/mL Compound: Doxorubicin	Anticancer activity against human HepG2 cells after 48 hrs by SRB assay Anticancer activity against human HepG2 cells after 48 hrs by SRB assay	[PMID: 32631569]
HepG2	IC₅₀	4 μg/mL Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells after 48 hrs by SRB assay Antiproliferative activity against human HepG2 cells after 48 hrs by SRB assay	[PMID: 27688190]
HepG2	IC₅₀	4.1 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells after 72 hrs by ELISA Antiproliferative activity against human HepG2 cells after 72 hrs by ELISA	[PMID: 31404864]
HepG2	IC₅₀	4.1 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells after 48 hrs by SRB assay Antiproliferative activity against human HepG2 cells after 48 hrs by SRB assay	[PMID: 30503942]
HepG2	IC₅₀	4.17 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 35696863]
HepG2	IC₅₀	4.2 μg/mL Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 27894044]
HepG2	IC₅₀	4.23 μg/mL Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 28171832]
HepG2	IC₅₀	4.3 μM Compound: Doxorubicin	Antitumor activity against human HepG2 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Antitumor activity against human HepG2 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 30138804]
HepG2	IC₅₀	4.3 μM Compound: DOX	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 30398868]
HepG2	IC₅₀	4.4 μM Compound: Dox	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 28865276]
HepG2	GI₅₀	4.45 μM Compound: Doxo	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 26513642]
HepG2	IC₅₀	4.5 μM Compound: DOX	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 37054758]
HepG2	IC₅₀	4.5 μM Compound: DOX	Anticancer activity against human HepG2 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 32085964]
HepG2	IC₅₀	4.5 μM Compound: DOX	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 36242988]
HepG2	IC₅₀	4.5 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 29702448]
HepG2	IC₅₀	4.5 μM Compound: DOX	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 35964425]
HepG2	IC₅₀	4.5 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35101650]
HepG2	IC₅₀	4.5 μM Compound: Dox	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34126285]
HepG2	IC₅₀	4.5 μM Compound: Doxorubicin	Antitumor activity against human HepG2 cells assessed as inhibition of cell viability by MTT assay Antitumor activity against human HepG2 cells assessed as inhibition of cell viability by MTT assay	[PMID: 33065442]
HepG2	IC₅₀	4.56 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by RRA assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by RRA assay	[PMID: 33508467]
HepG2	IC₅₀	4.57 μg/mL Compound: DOX	Antitumor activity against human HepG2 cells after 48 hrs by MTT assay Antitumor activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 20599299]
HepG2	IC₅₀	4.89 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 72 hrs by XTT assay Cytotoxicity against human HepG2 cells after 72 hrs by XTT assay	10.1007/s00044-013-0558-8
HepG2	IC₅₀	4.93 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 28038941]
HepG2	IC₅₀	5 μM Compound: Doxorubicin	Anticancer activity against human HepG2 cells incubated for 24 hrs by MTT assay Anticancer activity against human HepG2 cells incubated for 24 hrs by MTT assay	[PMID: 28579122]
HepG2	IC₅₀	5 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 22632935]
HepG2	IC₅₀	5 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth after 72 hrs by SRB assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth after 72 hrs by SRB assay	[PMID: 28734245]
HepG2	IC₅₀	5.23 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 24 hrs by SRB assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 24 hrs by SRB assay	[PMID: 20850308]
HepG2	IC₅₀	5.23 μM Compound: Doxorubicin	Anticancer activity against Homo sapiens (human) HepG2 cells after 48 hr by SRB assay Anticancer activity against Homo sapiens (human) HepG2 cells after 48 hr by SRB assay	10.1007/s00044-011-9653-x
HepG2	IC₅₀	5.34 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells measured after 48 hrs by MTT assay	[PMID: 27476117]
HepG2	IC₅₀	5.4 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 26317881]
HepG2	IC₅₀	5.4 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells by MTT reduction assay Antiproliferative activity against human HepG2 cells by MTT reduction assay	[PMID: 33421712]
HepG2	IC₅₀	5.43 μM Compound: DOX	Antiproliferative activity against human HepG2 cells after 48 hrs by resazurin dye-based fluorescence assay Antiproliferative activity against human HepG2 cells after 48 hrs by resazurin dye-based fluorescence assay	[PMID: 29665526]
HepG2	IC₅₀	5.5 μg/mL Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine B assay	[PMID: 21723735]
HepG2	IC₅₀	5.57 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 22647723]
HepG2	IC₅₀	5.7 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells measured after 48 hrs by SRB assay Cytotoxicity against human HepG2 cells measured after 48 hrs by SRB assay	[PMID: 27112448]
HepG2	IC₅₀	5.7 μM Compound: DOX	Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay	[PMID: 22444025]
HepG2	EC₅₀	6.1 μM Compound: doxorubicin	Cytotoxicity against human HepG2 cells expressing wild type p53 gene by MTT assay Cytotoxicity against human HepG2 cells expressing wild type p53 gene by MTT assay	[PMID: 20455578]
HepG2	IC₅₀	6.11 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells incubated for 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 24 hrs by MTT assay	[PMID: 29409753]
HepG2	IC₅₀	6.91 μM Compound: DOX	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30108853]
HepG2	IC₅₀	6.91 μM Compound: DOX	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 27889629]
HepG2	IC₅₀	60.29 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as growth inhibition by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition by MTT assay	[PMID: 33243532]
HepG2	IC₅₀	630 nM Compound: DOX	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 25461322]
HepG2	IC₅₀	69 μM Compound: Doxorubicin	Cytotoxicity activity against human HepG2 cells after 24 hrs Cytotoxicity activity against human HepG2 cells after 24 hrs	[PMID: 20547797]
HepG2	IC₅₀	693.1 nM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29886322]
HepG2	IC₅₀	7.1 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 22304344]
HepG2	IC₅₀	7.3 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 33784602]
HepG2	IC₅₀	7.3 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth after overnight incubation by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth after overnight incubation by MTT assay	[PMID: 32165076]
HepG2	IC₅₀	7.36 μM Compound: Doxorubicin	Antitumor activity against Homo sapiens (human) HepG2 cells assessed as cell growth inhibition after 48 hr by MTT assay Antitumor activity against Homo sapiens (human) HepG2 cells assessed as cell growth inhibition after 48 hr by MTT assay	10.1007/s00044-013-0497-4
HepG2	IC₅₀	7.36 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay	[PMID: 23994327]
HepG2	IC₅₀	7.36 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as cell survival after 48 hrs by SRB assay Cytotoxicity against human HepG2 cells assessed as cell survival after 48 hrs by SRB assay	[PMID: 23708013]
HepG2	IC₅₀	7.36 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine B assay	[PMID: 22119132]
HepG2	IC₅₀	7.36 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine B assay	[PMID: 22119131]
HepG2	IC₅₀	7.46 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells after 24 hrs by SRB assay Cytotoxicity against human HepG2 cells after 24 hrs by SRB assay	[PMID: 30096580]
HepG2	IC₅₀	7.46 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by SRB assay	[PMID: 32361329]
HepG2	IC₅₀	7.94 μM Compound: Cpd I	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 33360576]
HepG2	IC₅₀	73.5 μM Compound: DOX	Antitumor activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antitumor activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 35859879]
HepG2	IC₅₀	8 μM Compound: Doxorubicin	Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 30772606]
HepG2	IC₅₀	8.28 μM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33214036]
HepG2	IC₅₀	8.9 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells measured after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells measured after 24 hrs by MTT assay	[PMID: 34363937]
HepG2	IC₅₀	80.9 μg/mL Compound: Doxorubicin	Antitumor activity against human HepG2 xenografted BALB/c mouse assessed as reduction in tumor growth at 30 mg/kg, ip administered for once every 3 days measured after 15 days Antitumor activity against human HepG2 xenografted BALB/c mouse assessed as reduction in tumor growth at 30 mg/kg, ip administered for once every 3 days measured after 15 days	[PMID: 34147747]
HepG2	IC₅₀	80.9 μM Compound: Doxorubicin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 36325400]
HepG2	IC₅₀	85.46 μM Compound: DOX	Cytotoxicity against human adriamycin-resistant HepG2 cells measured after 48 hrs by MTT assay Cytotoxicity against human adriamycin-resistant HepG2 cells measured after 48 hrs by MTT assay	[PMID: 23290052]
HepG2	IC₅₀	98.7 nM Compound: Doxorubicin	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 28412159]
HepG2 2.2.15	IC₅₀	4.5 x 10^-1 μg/mL Compound: adriamycin	Cytotoxicity against human HepG2(2.2.15) cells after 12 days by methylene blue colorimetric method Cytotoxicity against human HepG2(2.2.15) cells after 12 days by methylene blue colorimetric method	[PMID: 11473425]
HepG2 2.2.15	IC₅₀	4.5 x 10^-1 μg/mL Compound: Adriamycin	Cytotoxicity against human HepG2(2.2.15) cells after 3 day Cytotoxicity against human HepG2(2.2.15) cells after 3 day	[PMID: 10654411]
HepG2 2.2.15	IC₅₀	4.5 x 10^-1 μg/mL Compound: Adriamycin	Cytotoxicity against human HepG2(2.2.15) cells after 3 days Cytotoxicity against human HepG2(2.2.15) cells after 3 days	[PMID: 11975482]
HFF	CC₅₀	0.03 μM Compound: Doxorubicin	Cytotoxicity against human HFF cells after 72 hrs by MTT assay Cytotoxicity against human HFF cells after 72 hrs by MTT assay	[PMID: 21741131]
HFF	IC₅₀	0.15 μM Compound: Doxorubicin	Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34851111]
HFF	IC₅₀	0.15 μM Compound: Doxorubicin	Cytotoxicity against HFF cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay Cytotoxicity against HFF cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay	[PMID: 28617598]
HFF-1	IC₅₀	> 100 μM Compound: 21	Cytotoxicity against human HFF1 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HFF1 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 32435401]
HFF-1	GI₅₀	> 400 μM Compound: Doxorubicin	Antiproliferative activity against human HFF1 cells after 2 days by sulforhodamine B assay Antiproliferative activity against human HFF1 cells after 2 days by sulforhodamine B assay	[PMID: 24184076]
HFF-1	CC₅₀	0.53 μM Compound: Doxorubicin	Cytotoxicity against human HFF-1 cells assessed as reduction in cell viability incubated for 120 hrs by MTS assay Cytotoxicity against human HFF-1 cells assessed as reduction in cell viability incubated for 120 hrs by MTS assay	[PMID: 32590115]
HGC-27	IC₅₀	37.4 μM Compound: Doxorubicin	Cytotoxicity against HGC27 cells after 24 hrs by MTT assay Cytotoxicity against HGC27 cells after 24 hrs by MTT assay	10.1039/C5MD00515A
HL-60	IC₅₀	< 0.125 μM Compound: Dox	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 33713977]
HL-60	IC₅₀	< 0.125 μM Compound: Dox	Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth by MTT assay	[PMID: 36336315]
HL-60	IC₅₀	< 0.63 μM Compound: Doxorubicin	Growth inhibition of human HL60 cells after 48 hrs by MTT assay Growth inhibition of human HL60 cells after 48 hrs by MTT assay	[PMID: 28073673]
HL-60	IC₅₀	< 1 μM Compound: doxorubicin	Cytotoxicity against human HL-60 cells by MTT assay Cytotoxicity against human HL-60 cells by MTT assay	[PMID: 33847126]
HL-60	IC₅₀	0.003 μg/mL Compound: Doxorubicin	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 18590313]
HL-60	IC₅₀	0.0072 μM Compound: adriamycin	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 11170674]
HL-60	GI₅₀	0.0087 μM Compound: Doxorubicin	Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability measured after 72 hrs Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability measured after 72 hrs	[PMID: 31945642]
HL-60	IC₅₀	0.009 μM Compound: Doxorubicin	Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 27010926]
HL-60	IC₅₀	0.01 μM Compound: DOX	Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28531811]
HL-60	IC₅₀	0.01 μM Compound: Doxorubicin	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 27808511]
HL-60	IC₅₀	0.01 μM Compound: Doxorubicin	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 23827179]
HL-60	IC₅₀	0.01 μM Compound: Doxorubicin	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay Cytotoxicity against human HL-60 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay	[PMID: 32755677]
HL-60	IC₅₀	0.013 μM Compound: adriamycin	Cytotoxicity against HL60 cells after 72 hrs by dye exclusion assay Cytotoxicity against HL60 cells after 72 hrs by dye exclusion assay	[PMID: 17069934]
HL-60	IC₅₀	0.016 μM Compound: Adriamycin	Cytotoxicity against human HL60 cells by SRB assay Cytotoxicity against human HL60 cells by SRB assay	[PMID: 19341288]
HL-60	IC₅₀	0.017 μM Compound: Doxorubicin	Antiproliferative activity against human HL60 cells after 72 hrs by MTT reduction assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT reduction assay	[PMID: 28551177]
HL-60	IC₅₀	0.018 μM Compound: Doxorubicin	Anticancer activity against human HL60 cells by MTT assay Anticancer activity against human HL60 cells by MTT assay	[PMID: 19136263]
HL-60	GI₅₀	0.018 μM Compound: adriamycin	Antiproliferative activity against human HL60 cells by trypan blue assay Antiproliferative activity against human HL60 cells by trypan blue assay	[PMID: 18357994]
HL-60	IC₅₀	0.02 μg/mL Compound: Doxorubicin	Cytotoxicity against human HL60 cells after 3 days by MTT assay Cytotoxicity against human HL60 cells after 3 days by MTT assay	[PMID: 19159272]
HL-60	IC₅₀	0.02 μg/mL Compound: Dox	Anticancer activity against Homo sapiens (human) HL60 cells assessed as inhibition of cell survival after 72 hr by MTT assay Anticancer activity against Homo sapiens (human) HL60 cells assessed as inhibition of cell survival after 72 hr by MTT assay	10.1007/s00044-012-0236-2
HL-60	IC₅₀	0.02 μg/mL Compound: Dox	Cytotoxicity against Homo sapiens (human) HL60 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) HL60 cells after 72 hr by MTT assay	10.1007/s00044-011-9894-8
HL-60	IC₅₀	0.02 μg/mL Compound: Doxorubicin	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 20537433]
HL-60	IC₅₀	0.02 μg/mL Compound: Doxorubicin	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 19084293]
HL-60	IC₅₀	0.02 μg/mL Compound: Doxorubicin	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 18586355]
HL-60	IC₅₀	0.02 μg/mL Compound: doxorubicin	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 17827021]
HL-60	IC₅₀	0.02 μg/mL Compound: doxorubicin	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 15787450]
HL-60	IC₅₀	0.02 μg/mL Compound: Doxorubicin	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 17764956]
HL-60	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human HL60 cells assessed as growth inhibition incubated for 72 hrs by CCK8 assay Cytotoxicity against human HL60 cells assessed as growth inhibition incubated for 72 hrs by CCK8 assay	[PMID: 26280922]
HL-60	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human HL-60 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human HL-60 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 34778772]
HL-60	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human HL60 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 31836446]
HL-60	IC₅₀	0.02 μM Compound: DOX	Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29660689]
HL-60	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 27116711]
HL-60	IC₅₀	0.02 μM Compound: Adriamycin	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 24370114]
HL-60	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 17227762]
HL-60	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) HL60 cells after 48 hr by trypan blue assay Cytotoxicity against Homo sapiens (human) HL60 cells after 48 hr by trypan blue assay	10.1007/s00044-009-9222-8
HL-60	IC₅₀	0.02 μM Compound: Doxorubicin	Antiproliferative activity against human HL60 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method Antiproliferative activity against human HL60 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	[PMID: 25937235]
HL-60	IC₅₀	0.027 μM Compound: Doxorubicin	Cytotoxicity against human HL60 cells after 72 hrs by XTT assay Cytotoxicity against human HL60 cells after 72 hrs by XTT assay	[PMID: 19647439]
HL-60	IC₅₀	0.03 μg/mL Compound: DOX	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 24589485]
HL-60	IC₅₀	0.03 μg/mL Compound: Doxo	Cytotoxicity against human HL60 cells for 72 hrs by MTT assay Cytotoxicity against human HL60 cells for 72 hrs by MTT assay	[PMID: 21334795]
HL-60	IC₅₀	0.03 μM Compound: Doxorubicin	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	10.1039/C4MD00371C
HL-60	IC₅₀	0.03 μM Compound: Dox	Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31306817]
HL-60	IC₅₀	0.03 μM Compound: Doxorubicin	Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24530030]
HL-60	IC₅₀	0.03 μM Compound: Doxorubicin	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 21115213]
HL-60	IC₅₀	0.03 μM Compound: DOXO	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 19947600]
HL-60	IC₅₀	0.03 μM Compound: Doxorubicin	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 27363939]
HL-60	IC₅₀	0.03 μM Compound: Doxorubicin	Cytotoxicity against human HL60 cells assessed as LDH release after 72 hrs Cytotoxicity against human HL60 cells assessed as LDH release after 72 hrs	[PMID: 17227762]
HL-60	IC₅₀	0.031 μM Compound: Doxorubicin	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 28139925]
HL-60	IC₅₀	0.037 μM Compound: Doxorubicin	Cytotoxicity against human HL60 cells assessed as growth inhibition by MTT assay Cytotoxicity against human HL60 cells assessed as growth inhibition by MTT assay	[PMID: 24398294]
HL-60	IC₅₀	0.04 μM Compound: Doxorubicin	Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay	[PMID: 31403289]
HL-60	IC₅₀	0.04 μM Compound: doxorubicin	Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay	[PMID: 22582991]
HL-60	IC₅₀	0.04 μM Compound: Dox	Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32551011]
HL-60	IC₅₀	0.04 μM Compound: doxorubicin	Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 25644674]
HL-60	IC₅₀	0.04 μM Compound: Dox	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 25147145]
HL-60	IC₅₀	0.04 μM Compound: D	Antineoplastic activity against human HL60 cells after 72 hrs by MTT assay Antineoplastic activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 22000949]
HL-60	IC₅₀	0.04 μM Compound: doxorubicin	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 21381705]
HL-60	IC₅₀	0.04 μM Compound: Doxorubicin	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 20971532]
HL-60	IC₅₀	0.04 μM Compound: Adriamycin	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 20593838]
HL-60	IC₅₀	0.04 μM Compound: Doxorubicin	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 19406535]
HL-60	IC₅₀	0.04 μM Compound: doxorubicin	Cytotoxicity against human HL60 cells by SRB assay Cytotoxicity against human HL60 cells by SRB assay	[PMID: 17194596]
HL-60	IC₅₀	0.044 μM Compound: doxorubicin	Cytotoxicity against human HL60 cells after 3 days by SRB assay Cytotoxicity against human HL60 cells after 3 days by SRB assay	[PMID: 18321715]
HL-60	IC₅₀	0.05 μM Compound: Doxorubicin	Cytotoxicity against human HL60 cells by colorimetric method Cytotoxicity against human HL60 cells by colorimetric method	[PMID: 24387625]
HL-60	IC₅₀	0.05 μM Compound: Doxorubicin	Cytotoxicity against human HL60 cells after 69 hrs by MTT assay Cytotoxicity against human HL60 cells after 69 hrs by MTT assay	[PMID: 19780590]
HL-60	IC₅₀	0.05 μM Compound: DOX	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 29970309]
HL-60	IC₅₀	0.05 μM Compound: DOX	Cytotoxicity against human HL60 cells after 18 hrs by annexin-V labeling-based flow cytometry Cytotoxicity against human HL60 cells after 18 hrs by annexin-V labeling-based flow cytometry	[PMID: 22985027]
HL-60	IC₅₀	0.051 μM Compound: Dox	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 27089210]
HL-60	IC₅₀	0.058 μM Compound: doxorubicin	Cytotoxicity against human HL60 cells by MTT method Cytotoxicity against human HL60 cells by MTT method	[PMID: 25781655]
HL-60	IC₅₀	0.06 μM Compound: Dox	Cytotoxicity against human HL-60 assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HL-60 assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33065435]
HL-60	IC₅₀	0.06 μM Compound: Doxorubicin	Cytotoxicity against NQO1-deficient human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against NQO1-deficient human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27341379]
HL-60	IC₅₀	0.06 μM Compound: DOXO	Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26142490]
HL-60	IC₅₀	0.06 μM Compound: Doxorubicin	Cytotoxicity against human HL60 cells incubated for 72 hrs by MTT assay Cytotoxicity against human HL60 cells incubated for 72 hrs by MTT assay	[PMID: 23079523]
HL-60	IC₅₀	0.07 μM Compound: doxorubicine	Cytotoxic activity against human HL60 cells after 69 hrs by MTT assay Cytotoxic activity against human HL60 cells after 69 hrs by MTT assay	[PMID: 19788290]
HL-60	IC₅₀	0.07 μM Compound: DOX	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 24095093]
HL-60	IC₅₀	0.082 μM Compound: Doxorubicin	Cytotoxicity against human HL60 cells assessed as growth inhibition by MTT assay Cytotoxicity against human HL60 cells assessed as growth inhibition by MTT assay	[PMID: 23664877]
HL-60	IC₅₀	0.1 μM Compound: Dox	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 30659997]
HL-60	IC₅₀	0.1 μM Compound: Doxrubicin	Growth inhibition of human HL60 cells after 3 days Growth inhibition of human HL60 cells after 3 days	[PMID: 18375126]
HL-60	IC₅₀	0.11 μM Compound: Dox	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HL-60 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 33852973]
HL-60	IC₅₀	0.11 μM Compound: Doxorubicin	Cytotoxicity against human HL60 cells assessed as inhibition of metabolic activity after 48 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as inhibition of metabolic activity after 48 hrs by MTT assay	[PMID: 27187858]
HL-60	IC₅₀	0.12 μM Compound: DXR	Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 34808062]
HL-60	IC₅₀	0.12 μM Compound: Adriamycin	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 23548547]
HL-60	IC₅₀	0.123 μM Compound: Adriamycin	Cytotoxicity against human HL60 cells by SRB assay Cytotoxicity against human HL60 cells by SRB assay	[PMID: 25497963]
HL-60	IC₅₀	0.14 μM Compound: Doxorubicin	Cytotoxicity against human HL60 cells after 24 hrs by MTT assay Cytotoxicity against human HL60 cells after 24 hrs by MTT assay	[PMID: 25353976]
HL-60	IC₅₀	0.17 μM Compound: ADM	Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 25984840]
HL-60	IC₅₀	0.17 μM Compound: ADM	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 25529742]
HL-60	IC₅₀	0.17 μM Compound: Doxorubicin	Antiproliferative activity against human HL60 cells after 72 hrs MTT assay Antiproliferative activity against human HL60 cells after 72 hrs MTT assay	[PMID: 25247772]
HL-60	IC₅₀	0.19 μM Compound: Doxorubicin	Cytotoxicity against human HL60 cells assessed as inhibition of cell viability after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as inhibition of cell viability after 72 hrs by MTT assay	[PMID: 29329071]
HL-60	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HL60 cells after 72 hrs by CCK8 assay Cytotoxicity against human HL60 cells after 72 hrs by CCK8 assay	[PMID: 30869892]
HL-60	IC₅₀	0.2 μM Compound: DOX	Cytotoxicity against human HL60 cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human HL60 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
HL-60	IC₅₀	0.2 μM Compound: doxorubicin	Cytotoxicity against human HL60 cells after 72 hrs by MTS assay Cytotoxicity against human HL60 cells after 72 hrs by MTS assay	[PMID: 25490132]
HL-60	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HL-60 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human HL-60 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 35526504]
HL-60	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity in human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34082225]
HL-60	IC₅₀	0.2 μM Compound: Dox	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HL-60 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33479619]
HL-60	IC₅₀	0.2 μM Compound: Dox	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 32428792]
HL-60	IC₅₀	0.2 μM Compound: Doxorubicin	Growth inhibition of human HL60 cells after 72 hrs by MTT assay Growth inhibition of human HL60 cells after 72 hrs by MTT assay	[PMID: 28189083]
HL-60	IC₅₀	0.2 μM Compound: ADM	Cytotoxicity against human HL60 cells by MTT method Cytotoxicity against human HL60 cells by MTT method	[PMID: 29144133]
HL-60	IC₅₀	0.2 μM Compound: doxorubicin	Cytotoxicity against human HL60 cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against human HL60 cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]
HL-60	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 27371926]
HL-60	IC₅₀	0.31 μM Compound: Doxorubicin	Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]
HL-60	IC₅₀	0.33 μM Compound: Doxorubicin	Antiproliferative activity against human HL60 cells after 24 and 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 24 and 72 hrs by MTT assay	[PMID: 24941130]
HL-60	IC₅₀	0.4 μM Compound: DOX	Antiproliferative activity against human HL60 cells after 72 hrs by Sulforhodamine B-stain assay Antiproliferative activity against human HL60 cells after 72 hrs by Sulforhodamine B-stain assay	[PMID: 27484508]
HL-60	IC₅₀	0.42 μM Compound: Doxorubicin	Antitumor activity against human HL60 cells assessed as inhibition of cell growth by MTT assay Antitumor activity against human HL60 cells assessed as inhibition of cell growth by MTT assay	[PMID: 25160837]
HL-60	IC₅₀	0.457 μg/mL Compound: DOX	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 20722446]
HL-60	IC₅₀	0.532 μM Compound: Doxorubicin	Antiproliferative activity against human HL60 cells after 48 hrs by EZ-Cytox cell viability assay Antiproliferative activity against human HL60 cells after 48 hrs by EZ-Cytox cell viability assay	[PMID: 28406643]
HL-60	IC₅₀	0.55 μM Compound: 49	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 23932070]
HL-60	IC₅₀	0.7 μM Compound: Doxorubicin	Antiproliferative activity against human HL-60 cells assessed as reduction in cell growth after 24 hrs by MTS assay Antiproliferative activity against human HL-60 cells assessed as reduction in cell growth after 24 hrs by MTS assay	[PMID: 25300820]
HL-60	IC₅₀	0.7 μM Compound: Adriamycin	Cytotoxicity against human HL60 cells after 2 days Cytotoxicity against human HL60 cells after 2 days	[PMID: 21601964]
HL-60	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay	[PMID: 27300257]
HL-60	IC₅₀	0.8 μM Compound: Adriamycin	Cytotoxicity against human HL60 cells after 4 days by MTT assay Cytotoxicity against human HL60 cells after 4 days by MTT assay	[PMID: 21704436]
HL-60	IC₅₀	0.9 μM Compound: ADM	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 23639650]
HL-60	IC₅₀	0.91 μM Compound: Doxorubicin	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 28919340]
HL-60	IC₅₀	0.92 μM Compound: DOX	Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability measured after 6 days by MTT assay Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability measured after 6 days by MTT assay	[PMID: 32653698]
HL-60	IC₅₀	0.92 μM Compound: DOX	Antiproliferative activity against human HL60 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HL60 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 31557614]
HL-60	IC₅₀	0.92 μM Compound: DOX	Cytotoxicity against human HL60 cells assessed as inhibition of cell growth after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as inhibition of cell growth after 72 hrs by MTT assay	[PMID: 30746062]
HL-60	IC₅₀	0.92 μM Compound: DOX	Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28427016]
HL-60	IC₅₀	0.92 μM Compound: DOX	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 28135634]
HL-60	IC₅₀	0.92 μM Compound: Dox	Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27231128]
HL-60	IC₅₀	0.92 μM Compound: DOX	Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 26720155]
HL-60	IC₅₀	0.92 μM Compound: DOX	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 25259516]
HL-60	IC₅₀	0.92 μM Compound: DOX	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 24021462]
HL-60	IC₅₀	0.92 μM Compound: DOX	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 20359789]
HL-60	IC₅₀	0.92 μM Compound: DOX	Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay	[PMID: 18783950]
HL-60	IC₅₀	1.13 nM Compound: Doxorubicin	Cytotoxicity against human HL60 cells after 3 days by MTT assay Cytotoxicity against human HL60 cells after 3 days by MTT assay	[PMID: 20356655]
HL-60	IC₅₀	1.13 nM Compound: Doxorubicin	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 19345581]
HL-60	IC₅₀	1.2 μM Compound: Doxorubicin	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HL-60 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32975117]
HL-60	IC₅₀	1.2 μM Compound: Doxorubicin	Cytotoxicity against human HL60 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
HL-60	GI₅₀	1.45 mM Compound: Doxorubicin	Photocytotoxicity against human HL60 cells irradiated with 2.5 J cm^-2 ultraviolet radiation after 72 hrs by MTT assay Photocytotoxicity against human HL60 cells irradiated with 2.5 J cm^-2 ultraviolet radiation after 72 hrs by MTT assay	[PMID: 18023182]
HL-60	EC₅₀	1.508 μM Compound: doxorubicin	Cytotoxicity against human HL60 cells after 48 hrs by cell titer-blue assay Cytotoxicity against human HL60 cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
HL-60	IC₅₀	1.53 μM Compound: Doxorubicin	Cytotoxicity against human HL60 cells after 72 hrs by alamar blue assay Cytotoxicity against human HL60 cells after 72 hrs by alamar blue assay	[PMID: 24969014]
HL-60	IC₅₀	1.6 μM Compound: Dox	Cytotoxicity against human HL60 cells after 24 hrs by MTT assay Cytotoxicity against human HL60 cells after 24 hrs by MTT assay	[PMID: 29398445]
HL-60	IC₅₀	1.73 μM Compound: Doxorubicin	Antiproliferative activity against human HL60 cells after 24 hrs by MTT assay Antiproliferative activity against human HL60 cells after 24 hrs by MTT assay	10.1039/C5MD00581G
HL-60	IC₅₀	13 nM Compound: doxorubicin	Cytotoxicity against human HL60 cells after 72 hrs by MTS assay Cytotoxicity against human HL60 cells after 72 hrs by MTS assay	[PMID: 19655762]
HL-60	IC₅₀	2.05 μM Compound: Doxorubicin	Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability by MTT assay Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability by MTT assay	[PMID: 34715305]
HL-60	GI₅₀	2.36 mM Compound: Doxorubicin	Photocytotoxicity against human HL60 cells irradiated with 1.25 J cm^-2 ultraviolet radiation after 72 hrs by MTT assay Photocytotoxicity against human HL60 cells irradiated with 1.25 J cm^-2 ultraviolet radiation after 72 hrs by MTT assay	[PMID: 18023182]
HL-60	EC₅₀	2.5 μM Compound: Doxorubicin	Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 24 hrs by MTT assay relative to control Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 24 hrs by MTT assay relative to control	[PMID: 21882827]
HL-60	GI₅₀	28 nM Compound: Doxorubicin	Cytotoxicity against human HL60 cells after 48 hrs by SRB assay Cytotoxicity against human HL60 cells after 48 hrs by SRB assay	[PMID: 24113365]
HL-60	GI₅₀	28 nM Compound: Doxorubicin	Growth inhibition of human HL60 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HL60 cells after 48 hrs by sulforhodamine B assay	[PMID: 23623253]
HL-60	IC₅₀	3.137 μM Compound: Doxorubicin	Cytotoxicity against human HL60 cells after 94 hrs by MTT assay Cytotoxicity against human HL60 cells after 94 hrs by MTT assay	[PMID: 21868138]
HL-60	IC₅₀	3.6 μM Compound: Doxorubicin	Antiproliferative activity against human HL60 cells after 24 to 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 24 to 72 hrs by MTT assay	[PMID: 30660827]
HL-60	IC₅₀	30 nM Compound: doxorubicine	Cytotoxicity against human HL60 cells incubated for 72 hrs by MTS assay Cytotoxicity against human HL60 cells incubated for 72 hrs by MTS assay	[PMID: 23072299]
HL-60	IC₅₀	30 nM Compound: Doxorubicine	Cytotoxicity against human HL60 cells after 72 hrs by MTS assay Cytotoxicity against human HL60 cells after 72 hrs by MTS assay	[PMID: 21142180]
HL-60	IC₅₀	46 nM Compound: Doxorubicin	Cytotoxicity against human HL60 cells incubated for 72 hrs by MTT assay Cytotoxicity against human HL60 cells incubated for 72 hrs by MTT assay	[PMID: 32040324]
HL-60	IC₅₀	5.5 μM Compound: DOX	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 27108400]
HL-60	IC₅₀	53.3 μM Compound: Doxorubicin	Antitumor activity against human HL60 cells after 48 hrs by MTT assay Antitumor activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 20884091]
HL-60	IC₅₀	8.91 μM Compound: Doxorubicin	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 29547830]
HL-60	IC₅₀	81 nM Compound: Doxorubicin	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 20690624]
HL-60	IC₅₀	990 nM Compound: Doxorubicine	Cytotoxicity against human HL60R cells after 72 hrs by MTS assay Cytotoxicity against human HL60R cells after 72 hrs by MTS assay	[PMID: 21142180]
HL-60(TB)	GI₅₀	0.12 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human HL-60(TB) cells after 48 hrs by SRB assay Cytotoxicity against human HL-60(TB) cells after 48 hrs by SRB assay	[PMID: 23871905]
HL-60(TB)	GI₅₀	0.12 μM Compound: Doxorubicin	Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
HL-60(TB)	GI₅₀	0.12 μM Compound: Doxorubicin	Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HL-60(TB) cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
HL60/ADR	IC₅₀	2 μM Compound: adriamycin	Cytotoxicity against adriamycin-resistant HL60/ADR cells expressing MRP1 after 72 hrs by dye exclusion assay Cytotoxicity against adriamycin-resistant HL60/ADR cells expressing MRP1 after 72 hrs by dye exclusion assay	[PMID: 17069934]
HL60/ADR	IC₅₀	8.8 μM Compound: Dox	Antiproliferative activity against human HL60/ADR cells after 72 hrs by MTT assay Antiproliferative activity against human HL60/ADR cells after 72 hrs by MTT assay	[PMID: 27089210]
HL60/MX2	EC₅₀	8.046 μM Compound: doxorubicin	Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
HMEC	GI₅₀	276 nM Compound: Doxorubicin	Antiproliferative activity against HMEC assessed as growth inhibition after 24 to 72 hrs by MTS assay Antiproliferative activity against HMEC assessed as growth inhibition after 24 to 72 hrs by MTS assay	10.1039/C0MD00179A
HMEC-1	IC₅₀	0.06 μM Compound: Adriamycin	Cytotoxicity against human HMEC1 cells after 72 hrs by MTT assay Cytotoxicity against human HMEC1 cells after 72 hrs by MTT assay	[PMID: 22616554]
HMEC-1	IC₅₀	0.1 μM Compound: 2	Cytotoxicity against human HMEC-1 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HMEC-1 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 33974416]
HMEC-1	IC₅₀	0.36 μM Compound: Doxorubicin	Cytotoxicity against HMEC1 cells after 48 hrs by Alamar blue assay Cytotoxicity against HMEC1 cells after 48 hrs by Alamar blue assay	[PMID: 20931970]
HMLE	IC₅₀	0.01 μM Compound: Doxorubicin	Antiproliferative activity against human shGFP-fused HMLE cells after 72 hrs by MTT assay Antiproliferative activity against human shGFP-fused HMLE cells after 72 hrs by MTT assay	[PMID: 27448912]
HOP-62	IC₅₀	0.004 μM Compound: Doxorubicin	In vitro cytotoxic activity against HOP62 (lung cancer) cell lines by using SRB assay In vitro cytotoxic activity against HOP62 (lung cancer) cell lines by using SRB assay	[PMID: 9873661]
HOP-62	IC₅₀	0.02 μM Compound: Doxorubicin	Antiproliferative activity against human HOP62 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method Antiproliferative activity against human HOP62 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	[PMID: 25937235]
HOP-62	GI₅₀	0.07 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay	[PMID: 23871905]
HOP-62	GI₅₀	0.07 μM Compound: Doxorubicin	Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
HOP-62	GI₅₀	0.07 μM Compound: Doxorubicin	Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HOP62 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
HOP-62	GI₅₀	0.14 μM Compound: ADR	Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay	[PMID: 20673627]
HOP-62	GI₅₀	0.14 μM Compound: ADR	Growth inhibition of human HOP62 cells after 48 hrs by SRB assay Growth inhibition of human HOP62 cells after 48 hrs by SRB assay	[PMID: 20031423]
HOP-62	GI₅₀	0.14 μM Compound: ADR	Growth inhibition of human HOP62 cells by SRB assay Growth inhibition of human HOP62 cells by SRB assay	[PMID: 22361684]
HOP-62	GI₅₀	0.14 μM Compound: ADR	Anticancer activity against human HOP62 cells by SRB method Anticancer activity against human HOP62 cells by SRB method	[PMID: 21676506]
HOP-62	GI₅₀	0.14 μM Compound: ADR	Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay	[PMID: 23849207]
HOP-62	GI₅₀	0.14 μM Compound: ADR	Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HOP62 cells after 48 hrs by sulforhodamine B assay	[PMID: 22364746]
HOP-62	GI₅₀	0.14 μM Compound: ADR	Cytotoxicity against human HOP62 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HOP62 cells after 48 hrs by sulforhodamine B assay	[PMID: 18657979]
HOP-62	GI₅₀	0.14 μM Compound: ADR	Cytotoxicity against human HOP62 cells after 24 hrs by WST-1 assay Cytotoxicity against human HOP62 cells after 24 hrs by WST-1 assay	[PMID: 20732817]
HOP-62	GI₅₀	0.15 μM Compound: ADR	Cytotoxicity against human HOP62 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HOP62 cells after 48 hrs by sulforhodamine B assay	[PMID: 21737288]
HOP-62	IC₅₀	1 μM Compound: ADR	Cytotoxicity against human Hop62 cells by SRB assay Cytotoxicity against human Hop62 cells by SRB assay	[PMID: 18656370]
HOP-62	IC₅₀	1 μM Compound: ADR	Cytotoxicity against human Hop62 cells by sulforhodamine B assay Cytotoxicity against human Hop62 cells by sulforhodamine B assay	[PMID: 17822905]
HOP-92	GI₅₀	0.1 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human HOP92 cells after 48 hrs by SRB assay Cytotoxicity against human HOP92 cells after 48 hrs by SRB assay	[PMID: 23871905]
HOP-92	GI₅₀	0.1 μM Compound: Doxorubicin	Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
HOP-92	GI₅₀	0.1 μM Compound: Doxorubicin	Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HOP92 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
HOS-TE85	IC₅₀	0.59 μM Compound: Doxorubicin	Cytotoxicity against human MNNG-HOS cells after 72 hrs by resazurin/resorufin-based fluorescence assay Cytotoxicity against human MNNG-HOS cells after 72 hrs by resazurin/resorufin-based fluorescence assay	[PMID: 23600925]
Hs-578T	GI₅₀	0.33 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human Hs578T cells after 48 hrs by SRB assay Cytotoxicity against human Hs578T cells after 48 hrs by SRB assay	[PMID: 23871905]
Hs-578T	GI₅₀	0.33 μM Compound: Doxorubicin	Growth inhibition of human Hs 578T cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Hs 578T cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
Hs-578T	GI₅₀	0.33 μM Compound: Doxorubicin	Growth inhibition of human Hs578T cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Hs578T cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
Hs-578T	IC₅₀	0.37 μM Compound: Doxorubicin	Cytotoxicity against human Hs578T cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human Hs578T cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24530030]
Hs-578T	IC₅₀	0.52 μM Compound: Doxorubicin	Anticancer activity against human Hs 578T cells after 72 hrs by sulforhodamine B assay Anticancer activity against human Hs 578T cells after 72 hrs by sulforhodamine B assay	[PMID: 30081238]
Hs-578T	IC₅₀	0.546 μM Compound: doxorubicin	Cytotoxicity against human Hs578T cells after 72 hrs by CellTiter-Glo assay Cytotoxicity against human Hs578T cells after 72 hrs by CellTiter-Glo assay	[PMID: 22316168]
Hs-578T	IC₅₀	0.75 μM Compound: Dox	Cytotoxicity against human Hs578T cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human Hs578T cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31306817]
Hs-578T	IC₅₀	0.83 μM Compound: Dox	Cytotoxicity against human Hs 578T cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human Hs 578T cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31306817]
Hs-578T	IC₅₀	98.32 μM Compound: doxorubicin	Cytotoxicity against human Hs578T cells at 40 uM after 72 hrs by CellTiter-Glo assay relative to untreated control Cytotoxicity against human Hs578T cells at 40 uM after 72 hrs by CellTiter-Glo assay relative to untreated control	[PMID: 22316168]
HSC-2	CC₅₀	0.2 μM Compound: DXR	Cytotoxicity against human HSC-2 cells incubated for 48 hrs by MTT assay Cytotoxicity against human HSC-2 cells incubated for 48 hrs by MTT assay	[PMID: 33744685]
HSC-2	CC₅₀	0.2 μM Compound: DXR	Cytotoxicity against human HSC2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HSC2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31532650]
HSC-2	IC₅₀	2.5 μg/mL Compound: doxorubicin	Cytotoxicity against human HSC2 cells after 24 hrs by MTT assay Cytotoxicity against human HSC2 cells after 24 hrs by MTT assay	[PMID: 12608856]
HSC-4	CC₅₀	0.1 μM Compound: DXR	Cytotoxicity against human HSC4 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HSC4 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31532650]
HT-1080	IC₅₀	0.0058 μM Compound: Doxorubicin	Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 29705708]
HT-1080	IC₅₀	0.017 μM Compound: Doxorubicin	Cytotoxic activity in human HT1080 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Cytotoxic activity in human HT1080 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 28395220]
HT-1080	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) HT1080 cells assessed as growth inhibition after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) HT1080 cells assessed as growth inhibition after 72 hr by MTT assay	10.1007/s00044-012-0428-9
HT-1080	IC₅₀	0.022 μM Compound: doxorubicin	Cytotoxicity against human HT1080 cells by MTT assay Cytotoxicity against human HT1080 cells by MTT assay	[PMID: 17141923]
HT-1080	IC₅₀	0.022 μM Compound: doxorubicin	Cytotoxicity against human HT1080 cells after 3 days by SRB assay Cytotoxicity against human HT1080 cells after 3 days by SRB assay	[PMID: 18321715]
HT-1080	IC₅₀	0.06 μM Compound: doxorubicin	Cytotoxicity against human HT1080 cells by SRB assay Cytotoxicity against human HT1080 cells by SRB assay	[PMID: 17194596]
HT-1080	IC₅₀	0.1 μM Compound: Doxorubicin	Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 19632833]
HT-1080	IC₅₀	0.17 μg/mL Compound: 1 (doxorubicin)	In vitro inhibitory activity against human fibrosarcoma cell line (HT1080) using CV coloration In vitro inhibitory activity against human fibrosarcoma cell line (HT1080) using CV coloration	[PMID: 15013011]
HT-1080	IC₅₀	0.31 μg/mL Compound: 1 (doxorubicin)	In vitro cytotoxic concentration against human fibrosarcoma cell line (HT1080) using MTT coloration In vitro cytotoxic concentration against human fibrosarcoma cell line (HT1080) using MTT coloration	[PMID: 15013011]
HT-1080	IC₅₀	0.41 μM Compound: Doxorubicin	Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 19689125]
HT-1080	IC₅₀	0.53 μM Compound: Doxorubicin	Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 19919052]
HT-1080	IC₅₀	0.93 μM Compound: DOX	Cytotoxicity against human HT-1080 cells assessed as reduction in cell viability incubated for 48 hrs Cytotoxicity against human HT-1080 cells assessed as reduction in cell viability incubated for 48 hrs	[PMID: 32736079]
HT-1080	IC₅₀	15.4 μM Compound: Doxorubicin	Cytotoxicity against human HT1080 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HT1080 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 24681979]
HT-1080	IC₅₀	19.22 μM Compound: Doxorubicin	Anticancer activity against human HT1080 cells after 48 hrs by SRB assay Anticancer activity against human HT1080 cells after 48 hrs by SRB assay	[PMID: 24077528]
HT-1080	IC₅₀	59 nM Compound: doxorubicin	Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 14640513]
HT-1080	IC₅₀	9.32 μM Compound: Doxorubicin	Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 18440233]
HT-29	ED₅₀	> 0 μg/mL Compound: Adriamycin	Cytotoxicity against human HT-29 cells after 24 hrs by SRB assay Cytotoxicity against human HT-29 cells after 24 hrs by SRB assay	[PMID: 20850305]
HT-29	EC₅₀	> 30 μM Compound: DR	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32956968]
HT-29	IC₅₀	0.002 μM Compound: Doxorubicin	Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay	[PMID: 19053767]
HT-29	IC₅₀	0.015 μM Compound: Doxorubicin	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31546197]
HT-29	ED₅₀	0.0168 μg/mL Compound: adriamycin	Cytotoxicity against human HT-29 cells after 7 days by MTT assay Cytotoxicity against human HT-29 cells after 7 days by MTT assay	[PMID: 10514307]
HT-29	IC₅₀	0.018 μM Compound: adriamycin	Cytotoxicity against human HT-29 cells after 72 hrs by SRB assay Cytotoxicity against human HT-29 cells after 72 hrs by SRB assay	[PMID: 19028425]
HT-29	IC₅₀	0.02 μg/mL Compound: doxorubicin	Growth inhibition of HT 29 cell line by MTT reduction for 7 days of incubation time Growth inhibition of HT 29 cell line by MTT reduction for 7 days of incubation time	[PMID: 8496904]
HT-29	IC₅₀	0.02 μM Compound: 2	Compound was evaluated for the cytotoxicity against HT-29 tumor cell line after 3 days of incubation Compound was evaluated for the cytotoxicity against HT-29 tumor cell line after 3 days of incubation	10.1016/S0960-894X(97)10122-6
HT-29	IC₅₀	0.026 μM Compound: DX	Concentration required to inhibit cell growth by 50% in vitro against Human colon adenocarcinoma cell line Concentration required to inhibit cell growth by 50% in vitro against Human colon adenocarcinoma cell line	[PMID: 11563932]
HT-29	ED₅₀	0.0287 μg/mL Compound: adriamycin	Cytotoxicity against human HT29 cells after 7 days by MTT assay Cytotoxicity against human HT29 cells after 7 days by MTT assay	[PMID: 11087592]
HT-29	GI₅₀	0.05 μM Compound: Dox	Growth inhibition of human HT-29 cells by MTT assay Growth inhibition of human HT-29 cells by MTT assay	[PMID: 31330449]
HT-29	GI₅₀	0.056 μM Compound: Doxorubicin	Tested for in vitro concentration required to inhibit growth by 50% against HT-29 human colon cancer cell line Tested for in vitro concentration required to inhibit growth by 50% against HT-29 human colon cancer cell line	[PMID: 11755363]
HT-29	GI₅₀	0.06 μg/mL Compound: adriamycin	Cytotoxicity against human HT29 cells by MTT assay Cytotoxicity against human HT29 cells by MTT assay	[PMID: 11000028]
HT-29	IC₅₀	0.06 μg/mL Compound: doxorubicin	Growth inhibition of HT 29 cell line by MTT reduction for 3 days of incubation time Growth inhibition of HT 29 cell line by MTT reduction for 3 days of incubation time	[PMID: 8496904]
HT-29	GI₅₀	0.06 μM Compound: Adriamycin	Cytotoxicity against human HT-29 cells by MTT assay Cytotoxicity against human HT-29 cells by MTT assay	[PMID: 19405508]
HT-29	GI₅₀	0.066 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells after 72 hrs by SRB assay Cytotoxicity against human HT-29 cells after 72 hrs by SRB assay	[PMID: 20014800]
HT-29	GI₅₀	0.07 μg/mL Compound: DOX	Growth inhibition of human HT-29 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HT-29 cells after 48 hrs by sulforhodamine B assay	[PMID: 21041092]
HT-29	IC₅₀	0.07 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) HT-29 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) HT-29 cells after 72 hr by MTT assay	10.1007/s00044-010-9517-9
HT-29	IC₅₀	0.082 μM Compound: Doxorubicin	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31883489]
HT-29	IC₅₀	0.092 μM Compound: ADR	Cytotoxicity against human HT-29 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 72 hrs by sulforhodamine B assay	[PMID: 20949916]
HT-29	IC₅₀	0.1 μg/mL Compound: (20) adriamycin	In vitro cytotoxicity of compound against HT29, human colorectal adenocarcinoma was defined by microculture tetrazolium assay In vitro cytotoxicity of compound against HT29, human colorectal adenocarcinoma was defined by microculture tetrazolium assay	[PMID: 12620075]
HT-29	IC₅₀	0.1 μM Compound: Dox	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 26494582]
HT-29	GI₅₀	0.1 μM Compound: Doxorubicin	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 30071406]
HT-29	GI₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29670691]
HT-29	GI₅₀	0.1 μM Compound: doxorubicin	Cytotoxicity against human HT-29 cells by SRB assay Cytotoxicity against human HT-29 cells by SRB assay	[PMID: 19007287]
HT-29	GI₅₀	0.1 μM Compound: doxorubicin	Cytotoxicity against human HT29 cells by SRB assay Cytotoxicity against human HT29 cells by SRB assay	[PMID: 17512741]
HT-29	GI₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 48 hrs by sulforhodamine B assay	[PMID: 24158013]
HT-29	GI₅₀	0.12 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human HT-29 cells after 48 hrs by SRB assay Cytotoxicity against human HT-29 cells after 48 hrs by SRB assay	[PMID: 23871905]
HT-29	GI₅₀	0.12 μM Compound: Doxorubicin	Antiproliferative activity against human HT-29 assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human HT-29 assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 21875046]
HT-29	IC₅₀	0.12 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay	[PMID: 36691388]
HT-29	GI₅₀	0.12 μM Compound: Doxorubicin	Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
HT-29	GI₅₀	0.12 μM Compound: Doxorubicin	Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
HT-29	IC₅₀	0.12 μM Compound: DOX	Compound was tested for cytotoxicity on HT-29 colon cancer cell line using a proliferation assay (MTT reduction) Compound was tested for cytotoxicity on HT-29 colon cancer cell line using a proliferation assay (MTT reduction)	10.1016/S0960-894X(01)81264-6
HT-29	GI₅₀	0.13 μg/mL Compound: DOX; Doxo	Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay	[PMID: 26859070]
HT-29	IC₅₀	0.15 μM Compound: Doxo	Antiproliferative activity against human HT-29 cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human HT-29 cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
HT-29	IC₅₀	0.15 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 33340938]
HT-29	IC₅₀	0.15 μM Compound: DOX	Antiproliferative activity against human HT-29 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 31557614]
HT-29	IC₅₀	0.15 μM Compound: doxo	Antiproliferative activity against human HT29 cell line by MTT assay Antiproliferative activity against human HT29 cell line by MTT assay	[PMID: 16913700]
HT-29	IC₅₀	0.15 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth after 48 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth after 48 hrs by SRB assay	[PMID: 34077833]
HT-29	IC₅₀	0.153 μM Compound: Dx	Antiproliferative activity against HT29 cells by MTT assay after 72 hrs Antiproliferative activity against HT29 cells by MTT assay after 72 hrs	[PMID: 16824751]
HT-29	IC₅₀	0.164 μM Compound: Doxorubicin	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation after 3 days by MTS assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation after 3 days by MTS assay	10.1039/C1MD00155H
HT-29	GI₅₀	0.18 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells by sulforhodamine B assay Cytotoxicity against human HT-29 cells by sulforhodamine B assay	[PMID: 20413188]
HT-29	GI₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 23831811]
HT-29	GI₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 21115210]
HT-29	GI₅₀	0.21 μM Compound: Doxorubicin	Growth inhibition of human HT29 cells after 72 hrs by SRB assay Growth inhibition of human HT29 cells after 72 hrs by SRB assay	[PMID: 18585035]
HT-29	GI₅₀	0.23 μM Compound: Dox	Growth inhibition of human HT-29 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay Growth inhibition of human HT-29 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay	[PMID: 28505535]
HT-29	IC₅₀	0.24 μM Compound: DOX	Cytotoxicity against human HT-29 cells after 96 hrs under normoxic condition by MTT assay Cytotoxicity against human HT-29 cells after 96 hrs under normoxic condition by MTT assay	[PMID: 29649740]
HT-29	IC₅₀	0.24 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay	[PMID: 19647439]
HT-29	IC₅₀	0.25 μM Compound: DOX	Cytotoxicity against human HT-29 cells after 96 hrs under hypoxic condition by MTT assay Cytotoxicity against human HT-29 cells after 96 hrs under hypoxic condition by MTT assay	[PMID: 29649740]
HT-29	IC₅₀	0.26 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 26963142]
HT-29	GI₅₀	0.26 μM Compound: Doxorubicin	Anticancer activity against human HT-29 cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay Anticancer activity against human HT-29 cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay	[PMID: 33214037]
HT-29	GI₅₀	0.27 μg/mL Compound: Doxorubicin	Growth inhibition of human HT-29 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HT-29 cells after 48 hrs by sulforhodamine B assay	[PMID: 22410248]
HT-29	GI₅₀	0.27 μg/mL Compound: Doxorubicin	Cytotoxicity against human HT-29 cells by sulforhodamine B assay Cytotoxicity against human HT-29 cells by sulforhodamine B assay	[PMID: 26913941]
HT-29	GI₅₀	0.28 μM Compound: Doxorubicin	Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 33477019]
HT-29	IC₅₀	0.28 μM Compound: Doxorubicin	Inhibitory concentration that reduced the viability of HT 29 cell population by 50%. Inhibitory concentration that reduced the viability of HT 29 cell population by 50%.	[PMID: 9003520]
HT-29	IC₅₀	0.3 μM Compound: Doxorubicin	Growth inhibition of human HT-29 cells incubated for 48 hrs by MTT assay Growth inhibition of human HT-29 cells incubated for 48 hrs by MTT assay	[PMID: 27080187]
HT-29	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells assessed as growth inhibition by MTT assay Cytotoxicity against human HT-29 cells assessed as growth inhibition by MTT assay	[PMID: 25765907]
HT-29	GI₅₀	0.3 μM Compound: Dox	Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26454648]
HT-29	GI₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 48 hrs by sulforhodamine B assay	[PMID: 29112820]
HT-29	IC₅₀	0.31 μM Compound: Doxorubicin	Antiproliferative activity against human HT-29 cells after 24 and 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 24 and 72 hrs by MTT assay	[PMID: 24941130]
HT-29	IC₅₀	0.32 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells expressing estrogen receptor after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells expressing estrogen receptor after 48 hrs by MTT assay	10.1039/C2MD20327H
HT-29	IC₅₀	0.32 μM Compound: Doxorubicin	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 30108986]
HT-29	IC₅₀	0.32 μM Compound: DOX	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 24148837]
HT-29	IC₅₀	0.32 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells after 1 hr by SRB assay Cytotoxicity against human HT-29 cells after 1 hr by SRB assay	[PMID: 22770744]
HT-29	IC₅₀	0.33 μM Compound: Adriamycin	Cytotoxicity against human HT-29 cells by SRB assay Cytotoxicity against human HT-29 cells by SRB assay	[PMID: 19341288]
HT-29	IC₅₀	0.34 μM Compound: Doxorubicin	Cytotoxicity in human HT-29 cells incubated for 72 hrs by MTT assay Cytotoxicity in human HT-29 cells incubated for 72 hrs by MTT assay	[PMID: 30978023]
HT-29	IC₅₀	0.34 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells by MTT assay Cytotoxicity against human HT-29 cells by MTT assay	[PMID: 30719909]
HT-29	IC₅₀	0.35 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) HT-29 cells assessed as growth inhibition after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) HT-29 cells assessed as growth inhibition after 72 hr by MTT assay	10.1007/s00044-012-0428-9
HT-29	IC₅₀	0.35 μM Compound: doxorubicin	Cytotoxicity against human HT29 cells by MTT assay Cytotoxicity against human HT29 cells by MTT assay	[PMID: 17141923]
HT-29	IC₅₀	0.36 μM Compound: DOX	Antiproliferative activity against human HT-29 cells after 72 hrs by Sulforhodamine B-stain assay Antiproliferative activity against human HT-29 cells after 72 hrs by Sulforhodamine B-stain assay	[PMID: 27484508]
HT-29	IC₅₀	0.4 μM Compound: Doxorubicin	Antiproliferative activity against human HT-29 cells by MTT assay Antiproliferative activity against human HT-29 cells by MTT assay	[PMID: 29072457]
HT-29	IC₅₀	0.4 μM Compound: Doxorubicin	Anticancer activity against human HT-29 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay Anticancer activity against human HT-29 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay	[PMID: 33940466]
HT-29	IC₅₀	0.44 μM Compound: DOX	Cytotoxicity against human HT-29 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 48 hrs by sulforhodamine B assay	[PMID: 23810282]
HT-29	IC₅₀	0.59 μM Compound: Doxorubicin	Cytotoxicity activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32627543]
HT-29	IC₅₀	0.6 μM Compound: Dox	Cytotoxicity against human HT-29 cells after 24 hrs by MTS assay Cytotoxicity against human HT-29 cells after 24 hrs by MTS assay	[PMID: 21094049]
HT-29	IC₅₀	0.68 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 26398312]
HT-29	IC₅₀	0.69 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 72 hrs by MTT assay	[PMID: 29329071]
HT-29	IC₅₀	0.82 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells after 2 days by MTT assay Cytotoxicity against human HT-29 cells after 2 days by MTT assay	[PMID: 21353544]
HT-29	IC₅₀	0.82 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability by MTT assay	[PMID: 31404864]
HT-29	GI₅₀	0.85 μg/mL Compound: Doxorubicin	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 26561866]
HT-29	GI₅₀	0.85 μM Compound: Doxorubicin	Growth inhibition of human HT-29 cells after 2 days by MTT assay Growth inhibition of human HT-29 cells after 2 days by MTT assay	[PMID: 20138760]
HT-29	IC₅₀	0.87 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells after 72 hrs by alamar blue assay Cytotoxicity against human HT-29 cells after 72 hrs by alamar blue assay	[PMID: 28159416]
HT-29	IC₅₀	0.87 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells by Alamar blue assay Cytotoxicity against human HT-29 cells by Alamar blue assay	[PMID: 27256910]
HT-29	IC₅₀	0.89 μM Compound: doxorubicin	Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 72 hrs by SRB method Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 72 hrs by SRB method	[PMID: 25644674]
HT-29	IC₅₀	0.9 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability by MTT assay	[PMID: 31820973]
HT-29	EC₅₀	0.9 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 33049606]
HT-29	IC₅₀	0.9 μM Compound: DX	Cytotoxicity against human HT29 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human HT29 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32422522]
HT-29	IC₅₀	0.93 μM Compound: Doxorubicin	Anticancer activity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Anticancer activity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 26330077]
HT-29	ED₅₀	1 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human HT29 cells after 7 days by MTT assay Cytotoxicity against human HT29 cells after 7 days by MTT assay	[PMID: 10395501]
HT-29	IC₅₀	1 μM Compound: DOX	Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 22044164]
HT-29	GI₅₀	1.01 μM Compound: Doxorubicin	Antiproliferative activity against human HT-29 cells assessed as growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as growth inhibition incubated for 48 hrs by MTT assay	[PMID: 31128433]
HT-29	IC₅₀	1.01 μM Compound: Doxorubicin	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 31108261]
HT-29	IC₅₀	1.06 μM Compound: Doxorubicin	Anticancer activity against human HT-29 cells after 48 hrs by MTT assay Anticancer activity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 22136907]
HT-29	IC₅₀	1.1 μM Compound: Doxorubicin	Antitumor activity against human HT-29 cells after 24 to 48 hrs by MTT assay Antitumor activity against human HT-29 cells after 24 to 48 hrs by MTT assay	[PMID: 21553829]
HT-29	IC₅₀	1.13 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 33352388]
HT-29	IC₅₀	1.13 μM Compound: ADM	Antiproliferative activity against human HT-29 cells overexpressing NQO1 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells overexpressing NQO1 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35803175]
HT-29	GI₅₀	1.13 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells after 72 hrs by SRB assay Cytotoxicity against human HT-29 cells after 72 hrs by SRB assay	[PMID: 21885166]
HT-29	IC₅₀	1.15 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells after 48 hrs by Alamar Blue assay Cytotoxicity against human HT-29 cells after 48 hrs by Alamar Blue assay	[PMID: 19473028]
HT-29	ED₅₀	1.16 x 10^-2 μg/mL Compound: Adriamycin	Cytotoxicity against human HT-29 cells after 7 days by MTT assay Cytotoxicity against human HT-29 cells after 7 days by MTT assay	[PMID: 7494147]
HT-29	IC₅₀	1.16 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 26708114]
HT-29	IC₅₀	1.23 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells after 48 hrs by Alamar blue assay Cytotoxicity against human HT-29 cells after 48 hrs by Alamar blue assay	[PMID: 20931970]
HT-29	ED₅₀	1.28 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human HT-29 cells after 7 days by MTT assay Cytotoxicity against human HT-29 cells after 7 days by MTT assay	[PMID: 11325235]
HT-29	IC₅₀	1.3 μM Compound: Doxorubicin	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 19632833]
HT-29	IC₅₀	1.4 μM Compound: Doxorubicin	Antiproliferative activity against human HT-29 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay	[PMID: 33744686]
HT-29	IC₅₀	1.41 μM Compound: II	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 29289881]
HT-29	IC₅₀	1.48 μM Compound: Doxorubicin	Cytotoxicity activity against human HT-29 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Cytotoxicity activity against human HT-29 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 32531682]
HT-29	IC₅₀	1.57 μM Compound: Doxorubicin	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33477020]
HT-29	ED₅₀	1.62 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human HT-29 cells after 7 days by MTT assay Cytotoxicity against human HT-29 cells after 7 days by MTT assay	10.1021/np970510f
HT-29	IC₅₀	1.64 μM Compound: Doxorubicin	Cytotoxicity against human HT29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HT29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33823396]
HT-29	IC₅₀	1.7 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay	[PMID: 26252628]
HT-29	IC₅₀	1.7 μM Compound: Doxorubicin	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	10.1039/C5MD00163C
HT-29	IC₅₀	1.76 μM Compound: Dox	Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay	10.1007/s00044-013-0584-6
HT-29	IC₅₀	1.76 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
HT-29	IC₅₀	1.76 μM Compound: DOX	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 24487188]
HT-29	IC₅₀	12.94 μM Compound: Dox	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CellTiter-Glo assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CellTiter-Glo assay	[PMID: 27687968]
HT-29	IC₅₀	16 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 24681979]
HT-29	IC₅₀	16.32 μM Compound: Dox	Cytotoxicity against human HT-29 cells assessed as cell viability measured after 24 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as cell viability measured after 24 hrs by MTT assay	[PMID: 33183865]
HT-29	IC₅₀	19.3 μM Compound: Doxorubicin	Anticancer activity against human HT-29 cells after 48 hrs by MTT assay Anticancer activity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 22668451]
HT-29	ED₅₀	2 x 10^-2 μg/mL Compound: Adriamycin	Cytotoxicity against human HT-29 cells after 7 days by MTT assay Cytotoxicity against human HT-29 cells after 7 days by MTT assay	[PMID: 9214729]
HT-29	IC₅₀	2.05 μM Compound: doxorubicin	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 20405844]
HT-29	IC₅₀	2.24 μM Compound: Doxorubicin	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 31200236]
HT-29	EC₅₀	2.5 μM Compound: Doxorubicin	Compound was tested in vitro to inhibit 50% colon carcinoma HT-29 cell growth after 72 h Compound was tested in vitro to inhibit 50% colon carcinoma HT-29 cell growth after 72 h	10.1016/S0960-894X(96)00243-0
HT-29	GI₅₀	2.58 μM Compound: DOXO	Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 31247374]
HT-29	ED₅₀	2.62 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human HT-29 cells after 7 days by MTT assay Cytotoxicity against human HT-29 cells after 7 days by MTT assay	[PMID: 8676130]
HT-29	ED₅₀	2.7 ng/mL Compound: Adriamycin	Cytotoxicity against human HT-29 cells after 7 days by MTT assay Cytotoxicity against human HT-29 cells after 7 days by MTT assay	[PMID: 7714532]
HT-29	ED₅₀	2.75 x 10^-2 μg/mL Compound: Adriamycin	Cytotoxicity against human HT-29 cells after 7 days by MTT assay Cytotoxicity against human HT-29 cells after 7 days by MTT assay	[PMID: 7673926]
HT-29	IC₅₀	2.75 μM Compound: Dox	Antiproliferative activity against human HT-29 cells after 72 hrs by cell titer glo assay Antiproliferative activity against human HT-29 cells after 72 hrs by cell titer glo assay	[PMID: 24161704]
HT-29	ED₅₀	2.78 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human HT-29 cells after 7 days by MTT assay Cytotoxicity against human HT-29 cells after 7 days by MTT assay	[PMID: 9599260]
HT-29	ED₅₀	2.79 ng/mL Compound: adriamycin	Cytotoxicity against human HT-29 cells after 7 days Cytotoxicity against human HT-29 cells after 7 days	[PMID: 8021648]
HT-29	IC₅₀	2.8 x 10^-1 μM Compound: Doxorubucin	Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay	[PMID: 20538470]
HT-29	ED₅₀	2.87 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human HT-29 cells after 7 days by MTT assay Cytotoxicity against human HT-29 cells after 7 days by MTT assay	[PMID: 15730242]
HT-29	ED₅₀	274 μM Compound: doxorubicin	Antitumor activity against human HT29 cells after 24 hrs by MTT assay Antitumor activity against human HT29 cells after 24 hrs by MTT assay	[PMID: 17482824]
HT-29	IC₅₀	3 x 10^-1 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay	[PMID: 20619940]
HT-29	ED₅₀	3.01 x 10^-2 μg/mL Compound: Adriamycin	Cytotoxicity against human HT-29 cells after 7 days by MTT assay Cytotoxicity against human HT-29 cells after 7 days by MTT assay	[PMID: 7673935]
HT-29	ED₅₀	3.01 x 10^-2 μg/mL Compound: Adriamycin	Cytotoxicity against human HT-29 cells after 7 days by MTT assay Cytotoxicity against human HT-29 cells after 7 days by MTT assay	[PMID: 7494150]
HT-29	ED₅₀	3.1 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human HT-29 cells by MTT assay Cytotoxicity against human HT-29 cells by MTT assay	[PMID: 9917277]
HT-29	ED₅₀	3.46 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human HT29 cells after 7 days by MTT assay Cytotoxicity against human HT29 cells after 7 days by MTT assay	[PMID: 8904848]
HT-29	ED₅₀	3.48 x 10^-2 μg/mL Compound: Adriamycin	Cytotoxicity against human HT-29 cells after 7 days by MTT assay Cytotoxicity against human HT-29 cells after 7 days by MTT assay	[PMID: 7673936]
HT-29	ED₅₀	3.51 x 10^-2 μg/mL Compound: adr	Cytotoxicity against human HT-29 cells after 7 days by MTT assay Cytotoxicity against human HT-29 cells after 7 days by MTT assay	[PMID: 9461654]
HT-29	ED₅₀	3.57 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human HT-29 cells after 7 days by MTT assay Cytotoxicity against human HT-29 cells after 7 days by MTT assay	[PMID: 9014350]
HT-29	ED₅₀	3.81 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human HT-29 cells after 7 days by MTT assay Cytotoxicity against human HT-29 cells after 7 days by MTT assay	[PMID: 9584396]
HT-29	ED₅₀	3.92 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human HT-29 cells after 7 hrs by MTT assay Cytotoxicity against human HT-29 cells after 7 hrs by MTT assay	[PMID: 7623031]
HT-29	IC₅₀	330 nM Compound: Doxorubicin	Human tumor cell cytotoxicity assay was performed using MTT (HT-29 cell line ) Human tumor cell cytotoxicity assay was performed using MTT (HT-29 cell line )	[PMID: 8576914]
HT-29	IC₅₀	331 nM Compound: Doxorubicin	Cytotoxicity was determined in vitro in HT-29 cells(colon) of human tumor cell lines by using MTT assay Cytotoxicity was determined in vitro in HT-29 cells(colon) of human tumor cell lines by using MTT assay	[PMID: 7853331]
HT-29	IC₅₀	37 nM Compound: Adriamycin	Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay	[PMID: 2778449]
HT-29	ED₅₀	4 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human HT29 cells after 7 days by MTT assay Cytotoxicity against human HT29 cells after 7 days by MTT assay	[PMID: 8882437]
HT-29	ED₅₀	4.28 ng/mL Compound: Adriamycin	Cytotoxicity against human HT29 cells after 7 days by MTT assay Cytotoxicity against human HT29 cells after 7 days by MTT assay	[PMID: 8946743]
HT-29	ED₅₀	4.37 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human HT29 cells after 7 days by MTT assay Cytotoxicity against human HT29 cells after 7 days by MTT assay	[PMID: 8882434]
HT-29	ED₅₀	4.45 ng/mL Compound: Adriamycin	Cytotoxicity against human HT-29 cells after 7 days Cytotoxicity against human HT-29 cells after 7 days	[PMID: 1453182]
HT-29	IC₅₀	5.3 ng/mL Compound: Adriamycin	Cytotoxicity against human HT-29 cells by MTT assay Cytotoxicity against human HT-29 cells by MTT assay	[PMID: 9644064]
HT-29	IC₅₀	5.38 μM Compound: Dox	Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs under hypoxic condition by MTT assay Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs under hypoxic condition by MTT assay	[PMID: 31542715]
HT-29	ED₅₀	5.6 x 10^-4 μg/mL Compound: Adriamycin	Cytotoxicity against human HT-29 cells by MTT assay Cytotoxicity against human HT-29 cells by MTT assay	[PMID: 7714533]
HT-29	IC₅₀	5.92 μM Compound: DOX	Antiproliferative activity against human HT29 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HT29 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32996316]
HT-29	IC₅₀	6.04 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells after 48 hrs by alamar blue assay Cytotoxicity against human HT-29 cells after 48 hrs by alamar blue assay	[PMID: 22272829]
HT-29	IC₅₀	6.4 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells after 48 hrs Cytotoxicity against human HT-29 cells after 48 hrs	[PMID: 20873721]
HT-29	ED₅₀	6.69 ng/mL Compound: adriamycin	Cytotoxicity against human HT-29 cells after 7 days Cytotoxicity against human HT-29 cells after 7 days	[PMID: 8201311]
HT-29	ED₅₀	6.69 ng/mL Compound: adriamycin	Cytotoxicity against human HT-29 cells after 7 days Cytotoxicity against human HT-29 cells after 7 days	[PMID: 1593281]
HT-29	ED₅₀	7.25 x 10^-1 μg/mL Compound: Adriamycin	Cytotoxicity against human HT29 cells after 7 days by MTT assay Cytotoxicity against human HT29 cells after 7 days by MTT assay	[PMID: 9322367]
HT-29	IC₅₀	7.4 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27843113]
HT-29	IC₅₀	7.7 μM Compound: Doxorubicin	Antiproliferative activity against human HT-29 cells after 72 hrs by SRB assay Antiproliferative activity against human HT-29 cells after 72 hrs by SRB assay	[PMID: 25462265]
HT-29	IC₅₀	7.7 μM Compound: Doxorubicin	Cytotoxicity against human HT-29 cells by sulforhodamine B assay Cytotoxicity against human HT-29 cells by sulforhodamine B assay	[PMID: 31401008]
HT-29	IC₅₀	7.86 μM Compound: DOX	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 25737400]
HT-29	ED₅₀	9.66 ng/mL Compound: adriamycin	Cytotoxicity against human HT-29 cells after 7 days by MTT assay Cytotoxicity against human HT-29 cells after 7 days by MTT assay	[PMID: 9599253]
hTERT-BJ	IC₅₀	< 6.25 μM Compound: DOX	Cytotoxicity against hTERT-BJ cells after 48 hrs by resazurin dye-based fluorescence assay Cytotoxicity against hTERT-BJ cells after 48 hrs by resazurin dye-based fluorescence assay	[PMID: 29665526]
HuCC-A1	IC₅₀	0.239 μM Compound: Doxorubicin	Cytotoxicity against human HuCCa1 cells after 48 hrs by MTT assay Cytotoxicity against human HuCCa1 cells after 48 hrs by MTT assay	[PMID: 25019480]
HuCC-A1	IC₅₀	0.33 μg/mL Compound: Doxorubicin	Cytotoxic activity against human HuCCa1 cells by MTT assay Cytotoxic activity against human HuCCa1 cells by MTT assay	[PMID: 28366267]
HuCC-A1	IC₅₀	0.35 μg/mL Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) HuCCa1 cells assessed as survival after 3 days by crystal violet staining Cytotoxicity against Homo sapiens (human) HuCCa1 cells assessed as survival after 3 days by crystal violet staining	10.1007/s00044-012-0025-y
HuCC-A1	IC₅₀	0.42 μM Compound: Doxorubicin	Cytotoxicity against HuCCa1 cells after 48 hrs by MTT assay Cytotoxicity against HuCCa1 cells after 48 hrs by MTT assay	[PMID: 26397393]
HuCC-A1	IC₅₀	0.45 μg/mL Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) HuCCa1 cells after 3 days by crystal violet staining Cytotoxicity against Homo sapiens (human) HuCCa1 cells after 3 days by crystal violet staining	10.1007/s00044-011-9903-y
HuCC-A1	IC₅₀	0.64 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) HuCCa1 cells assessed as inhibition of cell growth after 3 days by crystal violet staining Cytotoxicity against Homo sapiens (human) HuCCa1 cells assessed as inhibition of cell growth after 3 days by crystal violet staining	10.1007/s00044-012-0402-6
HuCC-A1	IC₅₀	0.64 μM Compound: doxorubicin	Cytotoxicity against HuCCa1 cells after 4 days by MTT assay Cytotoxicity against HuCCa1 cells after 4 days by MTT assay	[PMID: 19824618]
HuCC-A1	IC₅₀	0.67 μM Compound: doxorubicin	Cytotoxicity against human HuCCA1 cells by MTT assay Cytotoxicity against human HuCCA1 cells by MTT assay	[PMID: 21174408]
HuCC-A1	IC₅₀	0.83 μM Compound: doxorubicin	Cytotoxicity against human HuCCa1 cells after 48 hrs by MTT assay Cytotoxicity against human HuCCa1 cells after 48 hrs by MTT assay	10.1007/s00044-013-0777-z
HuCC-A1	IC₅₀	0.83 μM Compound: Doxorubicin	Cytotoxicity against human HuCCa1 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HuCCa1 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 25078311]
HuCC-A1	IC₅₀	0.83 μM Compound: Doxorubicin	Cytotoxicity against human HuCCa1 cells after 48 hrs by MTT assay Cytotoxicity against human HuCCa1 cells after 48 hrs by MTT assay	[PMID: 24836071]
HuCC-A1	IC₅₀	1.1 μM Compound: Doxorubicin	Cytotoxicity against human HuCCa1 cells by MTT assay Cytotoxicity against human HuCCa1 cells by MTT assay	10.1039/C3MD00166K
HuCC-A1	IC₅₀	1.13 μM Compound: Doxorubicin	Antiproliferative activity against human HuCCa1 cells assessed as reduction in cell viability after 48 hrs by XTT assay Antiproliferative activity against human HuCCa1 cells assessed as reduction in cell viability after 48 hrs by XTT assay	[PMID: 31704206]
HuCC-A1	IC₅₀	2.39 μM Compound: Doxorubicin	Cytotoxicity against human HuCCa1 cells by MTT assay Cytotoxicity against human HuCCa1 cells by MTT assay	[PMID: 25747499]
HuCCT-1	IC₅₀	0.048 μM Compound: DOX	Cytotoxicity against human HuCCT1 cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human HuCCT1 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
Huh-7	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability after 48 hrs Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability after 48 hrs	[PMID: 34601029]
Huh-7	IC₅₀	0.03 μM Compound: Doxorubicin	Toxicity in human Huh-7 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay Toxicity in human Huh-7 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay	[PMID: 31753515]
Huh-7	IC₅₀	0.03 μM Compound: Doxorubicin	Antiproliferative activity against human HuH7 cells after 48 hrs by Hoechst 33342 staining-based assay Antiproliferative activity against human HuH7 cells after 48 hrs by Hoechst 33342 staining-based assay	[PMID: 30655216]
Huh-7	IC₅₀	0.036 μM Compound: Doxorubicine	Cytotoxicity against human HuH-7 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) Cytotoxicity against human HuH-7 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)	[PMID: 33422908]
Huh-7	IC₅₀	0.22 μM Compound: Doxorubicin	Antiproliferative activity against human HuH7 cells incubated for 48 hrs by WST8 assay Antiproliferative activity against human HuH7 cells incubated for 48 hrs by WST8 assay	[PMID: 31679979]
Huh-7	IC₅₀	0.22 μM Compound: Doxorubicin	Cytotoxicity against human HuH7 cells after 48 hrs by WST8 assay Cytotoxicity against human HuH7 cells after 48 hrs by WST8 assay	[PMID: 25163667]
Huh-7	IC₅₀	0.24 μM Compound: Doxorubicin	Cytotoxicity against human HuH7 cells assessed as reduction in cell growth after 48 hrs by MTT assay Cytotoxicity against human HuH7 cells assessed as reduction in cell growth after 48 hrs by MTT assay	[PMID: 27422336]
Huh-7	IC₅₀	0.36 μM Compound: Doxorubicin	Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 72 hrs by WST1 assay Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 72 hrs by WST1 assay	[PMID: 28189419]
Huh-7	IC₅₀	0.36 μM Compound: Doxorubicin	Cytotoxicity against human HuH7 cells assessed as cell viability after 72 hrs by WST-1 assay Cytotoxicity against human HuH7 cells assessed as cell viability after 72 hrs by WST-1 assay	[PMID: 26711144]
Huh-7	IC₅₀	0.36 μM Compound: doxorubicin	Cytotoxicity against human HuH7 cells after 72 hrs by WST1 assay Cytotoxicity against human HuH7 cells after 72 hrs by WST1 assay	[PMID: 26083682]
Huh-7	IC₅₀	0.4 μM Compound: Doxorubicin	Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 72 hrs by WST-1 assay Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 72 hrs by WST-1 assay	[PMID: 27035556]
Huh-7	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human HuH7 cells after 24 hrs by MTT assay Cytotoxicity against human HuH7 cells after 24 hrs by MTT assay	[PMID: 25554367]
Huh-7	IC₅₀	1.11 μM Compound: Doxorubicin	Antiproliferative activity against human HuH7 cells assessed as growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human HuH7 cells assessed as growth inhibition incubated for 48 hrs by MTT assay	[PMID: 26253231]
Huh-7	IC₅₀	5.43 μM Compound: Dox	Cytotoxicity against human HuH7 cells after 48 hrs by resazurin assay Cytotoxicity against human HuH7 cells after 48 hrs by resazurin assay	[PMID: 29107422]
HuTu80	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human HuTu80 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay Cytotoxicity against human HuTu80 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay	[PMID: 36970146]
HUVEC	GI₅₀	0.0268 μM Compound: Doxorubicin	Cytotoxicity against HUVEC cells after 48 hrs by SRB assay Cytotoxicity against HUVEC cells after 48 hrs by SRB assay	[PMID: 26462052]
HUVEC	IC₅₀	0.0807 μM Compound: Doxorubicin	Cytotoxicity against HUVEC assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against HUVEC assessed as cell viability after 48 hrs by MTT assay	[PMID: 24012378]
HUVEC	GI₅₀	0.1 μg/mL Compound: doxorubicin	Antiproliferative activity against HUVEC after 72 hrs by resazurin dye reduction assay Antiproliferative activity against HUVEC after 72 hrs by resazurin dye reduction assay	[PMID: 20153202]
HUVEC	IC₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity against human HUVEC cells assessed as inhibition of cell growth after 48 hrs by SRB assay Cytotoxicity against human HUVEC cells assessed as inhibition of cell growth after 48 hrs by SRB assay	[PMID: 34077833]
HUVEC	IC₅₀	0.15 μM Compound: Doxorubicin	Antiproliferative activity against HUVEC after 70 hrs by alamar blue assay Antiproliferative activity against HUVEC after 70 hrs by alamar blue assay	[PMID: 29471119]
HUVEC	IC₅₀	0.4 μM Compound: Doxorubicin	Cytotoxicity against HUVEC cells after 48 hrs by WST8 assay Cytotoxicity against HUVEC cells after 48 hrs by WST8 assay	[PMID: 25163667]
HUVEC	IC₅₀	0.48 μM Compound: Doxorubicin	Cytotoxicity against HUVEC assessed as reduction in cell viability after 70 hrs by alamar blue assay Cytotoxicity against HUVEC assessed as reduction in cell viability after 70 hrs by alamar blue assay	[PMID: 29471119]
HUVEC	IC₅₀	1.1 μM Compound: Dox	Cytotoxicity against human HUVEC cells after 48 hrs by MTT assay Cytotoxicity against human HUVEC cells after 48 hrs by MTT assay	[PMID: 24028446]
HUVEC	IC₅₀	1.4 μM Compound: DXR	Cytotoxicity against HUVEC cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Cytotoxicity against HUVEC cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 34808062]
HUVEC	IC₅₀	1.4 μM Compound: Doxorubicin	Cytotoxicity against HUVEC assessed as inhibition of metabolic activity after 48 hrs by MTT assay Cytotoxicity against HUVEC assessed as inhibition of metabolic activity after 48 hrs by MTT assay	[PMID: 27187858]
HUVEC	GI₅₀	109 nM Compound: Doxorubicin	Antiproliferative activity against HUVEC assessed as growth inhibition after 24 to 72 hrs by MTS assay Antiproliferative activity against HUVEC assessed as growth inhibition after 24 to 72 hrs by MTS assay	10.1039/C0MD00179A
HUVEC	IC₅₀	23.34 μg/mL Compound: Doxorubicin	Cytotoxicity against human HUVEC cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Cytotoxicity against human HUVEC cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 34973507]
HUVEC	IC₅₀	3.8 μM Compound: Dox	Cytotoxicity against human HUVEC cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HUVEC cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 33852973]
HUVEC	IC₅₀	30.3 nM Compound: Doxorubicin	Antiproliferative activity against human HUVEC cells after 96 hrs by MTT assay Antiproliferative activity against human HUVEC cells after 96 hrs by MTT assay	[PMID: 21296467]
HUVEC	IC₅₀	4.4 μM Compound: DOX	Cytotoxicity against HUVEC measured after 36 hrs by MTT assay Cytotoxicity against HUVEC measured after 36 hrs by MTT assay	[PMID: 30746067]
HUVEC	IC₅₀	6.3 μM Compound: Doxorubicin	Cytotoxicity against human HUVEC after 24 hrs by MTT assay Cytotoxicity against human HUVEC after 24 hrs by MTT assay	[PMID: 26252628]
HUVEC	IC₅₀	79.6 μM Compound: Doxorubicin	Cytotoxicity against HUVEC assessed as reduction in cell viability by MTT assay Cytotoxicity against HUVEC assessed as reduction in cell viability by MTT assay	[PMID: 26774921]
HUVEC	IC₅₀	8.65 μM Compound: DOX	Cytotoxicity against HUVEC assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against HUVEC assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28355069]
IEC-6	IC₅₀	2.6 μg/mL Compound: Doxorubicin	Cytotoxicity against rat IEC-6 cells by MTT assay Cytotoxicity against rat IEC-6 cells by MTT assay	10.1039/C4MD00566J
IGROV-1	GI₅₀	0.17 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human IGROV1 cells after 48 hrs by SRB assay Cytotoxicity against human IGROV1 cells after 48 hrs by SRB assay	[PMID: 23871905]
IGROV-1	GI₅₀	0.17 μM Compound: Doxorubicin	Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
IGROV-1	GI₅₀	0.17 μM Compound: Doxorubicin	Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human IGROV1 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
IGROV-1	IC₅₀	4.36 μM Compound: Doxorubicin	Antiproliferative activity against human IGROV1 cells after 48 hrs by MTT assay Antiproliferative activity against human IGROV1 cells after 48 hrs by MTT assay	[PMID: 29547830]
IMR-32	GI₅₀	< 0.01 μM Compound: Doxorubicin	Growth inhibition of human IMR32 cells after 48 hrs by SRB assay Growth inhibition of human IMR32 cells after 48 hrs by SRB assay	10.1039/C6MD00097E
IMR-32	GI₅₀	< 0.01 μM Compound: Doxorubicin	Growth inhibition in human IMR32 cells after 48 hrs by SRB assay Growth inhibition in human IMR32 cells after 48 hrs by SRB assay	[PMID: 31546197]
IMR-32	IC₅₀	0.0051 μM Compound: DX	Antiproliferative activity against human IMR32 cells assessed as cell viability after 48 hrs by formazan EZ4U dye based assay Antiproliferative activity against human IMR32 cells assessed as cell viability after 48 hrs by formazan EZ4U dye based assay	[PMID: 26690914]
IMR-32	GI₅₀	0.023 μM Compound: Doxorubicin	Antiproliferative activity against human IMR32 cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human IMR32 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 27209232]
IMR-32	GI₅₀	0.023 μM Compound: Doxorubicin	Antiproliferative activity against human IMR32 cells assessed as reduction in net protein increase after 48 hrs by SRB assay Antiproliferative activity against human IMR32 cells assessed as reduction in net protein increase after 48 hrs by SRB assay	[PMID: 25462234]
IMR-32	GI₅₀	0.023 μM Compound: Doxorubicin	Growth inhibition of human IMR32 cells after 48 hrs by SRB assay Growth inhibition of human IMR32 cells after 48 hrs by SRB assay	[PMID: 25264072]
IMR-32	GI₅₀	0.023 μM Compound: Doxorubicin	Antiproliferative activity against human IMR32 cells by SRB assay Antiproliferative activity against human IMR32 cells by SRB assay	[PMID: 31546197]
IMR-32	GI₅₀	0.025 μM Compound: Doxorubicin	Growth inhibition of human IMR32 cells after 48 hrs by SRB assay Growth inhibition of human IMR32 cells after 48 hrs by SRB assay	[PMID: 27964883]
IMR-32	IC₅₀	0.05 μM Compound: DX	Cytotoxicity against human IMR32 cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human IMR32 cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 29681486]
IMR-32	IC₅₀	0.08 μM Compound: Doxorubicin	Antiproliferative activity against human IMR32 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human IMR32 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31546197]
IMR-32	IC₅₀	0.8 μg/mL Compound: Doxorubicine	Cytotoxicity against human IMR32 cells after 24 hrs by MTT assay Cytotoxicity against human IMR32 cells after 24 hrs by MTT assay	[PMID: 24177357]
IMR-32	IC₅₀	1.7 μM Compound: adriamycin	Growth inhibition of human IMR32 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human IMR32 cells after 48 hrs by sulforhodamine B assay	[PMID: 19939522]
IMR-32	IC₅₀	2.3 μM Compound: Doxorubicin	Cytotoxicity against human IMR32 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay Cytotoxicity against human IMR32 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay	[PMID: 28818768]
IMR-32	IC₅₀	3.2 μM Compound: Doxorubicin	Antiproliferative activity against human IMR32 cells after 48 hrs by SRB assay Antiproliferative activity against human IMR32 cells after 48 hrs by SRB assay	[PMID: 28419927]
IMR-32	IC₅₀	44.4 μM Compound: Doxorubicin	Anticancer activity against human IMR32 cells by MTT assay Anticancer activity against human IMR32 cells by MTT assay	[PMID: 25743216]
IMR-32	IC₅₀	5.1 nM Compound: Dox	Cytotoxicity against human IMR32 cells assessed as reduction in cell viability after 48 hrs by EZ4U Non-radioactive cell proliferation assay Cytotoxicity against human IMR32 cells assessed as reduction in cell viability after 48 hrs by EZ4U Non-radioactive cell proliferation assay	[PMID: 28372935]
IMR-32	IC₅₀	5.1 nM Compound: DX	Antiproliferative activity against human IMR32 cells assessed as inhibition of cell viability after 48 hrs Antiproliferative activity against human IMR32 cells assessed as inhibition of cell viability after 48 hrs	[PMID: 26360048]
IMR-32	IC₅₀	5.1 nM Compound: DX	Cytotoxicity against human IMR32 cells assessed as cell viability after 48 hrs by formazan dye-based EZ4U test Cytotoxicity against human IMR32 cells assessed as cell viability after 48 hrs by formazan dye-based EZ4U test	[PMID: 24996140]
IMR-32	IC₅₀	8.49 μM Compound: Doxorubicin	Cytotoxicity against human IMR32 cells after 48 hrs by SRB assay Cytotoxicity against human IMR32 cells after 48 hrs by SRB assay	[PMID: 28318941]
IMR-90	IC₅₀	0.59 μM Compound: Doxorubicin	Cytotoxicity against human IMR90 cells after 24 hrs by MTT assay Cytotoxicity against human IMR90 cells after 24 hrs by MTT assay	[PMID: 21215623]
IMR-90	IC₅₀	1 μM Compound: Doxorubicin	Antiproliferative activity against human IMR90 cells after 72 hrs by MTT assay Antiproliferative activity against human IMR90 cells after 72 hrs by MTT assay	[PMID: 19632833]
IMR-90	IC₅₀	21.3 μM Compound: Doxorubicin	Cytotoxicity against human IMR90 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human IMR90 cells assessed as reduction in cell viability by MTT assay	[PMID: 26646219]
Ishikawa	IC₅₀	0.1 μM Compound: Dox	Antiproliferative activity against human Ishikawa cells after 72 hrs by MTT assay Antiproliferative activity against human Ishikawa cells after 72 hrs by MTT assay	[PMID: 25998504]
Ishikawa	IC₅₀	9.02 μM Compound: DOX	Anticancer activity against human Ishikawa cells assessed as inhibition of tumor cell proliferation after 48 hrs by MTT assay Anticancer activity against human Ishikawa cells assessed as inhibition of tumor cell proliferation after 48 hrs by MTT assay	[PMID: 25064350]
J774.1	CC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against mouse J774.1 cells after 72 hrs by MTT assay Cytotoxicity against mouse J774.1 cells after 72 hrs by MTT assay	[PMID: 24080103]
J774.1	IC₅₀	0.06 μM Compound: Doxorubicin	Cytotoxicity against mouse J774A.1 cells after 72 hrs by MTT assay Cytotoxicity against mouse J774A.1 cells after 72 hrs by MTT assay	[PMID: 25846065]
J774.A1	CC₅₀	0.01 μM Compound: Doxorubicin	Cytotoxicity against mouse J774A1 cells incubated for 72 hrs by MTT assay Cytotoxicity against mouse J774A1 cells incubated for 72 hrs by MTT assay	[PMID: 25282267]
J774.A1	CC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against mouse J774A1 cells after 72 hrs by MTT assay Cytotoxicity against mouse J774A1 cells after 72 hrs by MTT assay	[PMID: 22608675]
J774.A1	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxic activity against mouse J774A1 cells after 72 hrs by MTT assay Cytotoxic activity against mouse J774A1 cells after 72 hrs by MTT assay	[PMID: 21555166]
JeKo-1	IC₅₀	0.18 μM Compound: Doxorubicin	Cytotoxicity activity against human JeKo1 cells assessed as reduction in cell viability after 48 hrs by CCK-8 assay Cytotoxicity activity against human JeKo1 cells assessed as reduction in cell viability after 48 hrs by CCK-8 assay	[PMID: 29288944]
JIMT-1	IC₅₀	0.37 μM Compound: ADM	Antiproliferative activity against human JIMT-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human JIMT-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 36332551]
JIMT-1	IC₅₀	0.59 μM Compound: DX	Antiproliferative activity against human JIMT1 cells after 72 hrs by SRB assay Antiproliferative activity against human JIMT1 cells after 72 hrs by SRB assay	[PMID: 30025346]
Jurkat	GI₅₀	< 1 μM Compound: DOX	Antiproliferative activity against human Jurkat cells by MTT assay Antiproliferative activity against human Jurkat cells by MTT assay	[PMID: 31990554]
Jurkat	IC₅₀	0.009 μM Compound: Doxorubicin	Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 27010926]
Jurkat	IC₅₀	0.012 μM Compound: DOX	Cytotoxicity against human Jurkat cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human Jurkat cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 26638041]
Jurkat	IC₅₀	0.02 μM Compound: DOX	Cytotoxicity against human Jurkat cell viability after 72 hrs by MTT assay Cytotoxicity against human Jurkat cell viability after 72 hrs by MTT assay	[PMID: 29660689]
Jurkat	IC₅₀	0.03 μM Compound: DOX	Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability measured after 6 days by MTT assay Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability measured after 6 days by MTT assay	[PMID: 32653698]
Jurkat	IC₅₀	0.03 μM Compound: DOX	Antiproliferative activity against human Jurkat cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human Jurkat cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 31557614]
Jurkat	IC₅₀	0.03 μM Compound: DOX	Cytotoxicity against human Jurkat cells assessed as inhibition of cell growth after 72 hrs by MTT assay Cytotoxicity against human Jurkat cells assessed as inhibition of cell growth after 72 hrs by MTT assay	[PMID: 30746062]
Jurkat	IC₅₀	0.03 μM Compound: DOX	Cytotoxicity against human Jurkat cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human Jurkat cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28427016]
Jurkat	IC₅₀	0.03 μM Compound: DOX	Antiproliferative activity against human Jurkat cells after 72 hrs by MTT assay Antiproliferative activity against human Jurkat cells after 72 hrs by MTT assay	[PMID: 28135634]
Jurkat	IC₅₀	0.03 μM Compound: Dox	Cytotoxicity against human Jurkat cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human Jurkat cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27231128]
Jurkat	IC₅₀	0.03 μM Compound: DOX	Cytotoxicity against human Jurkat T cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human Jurkat T cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 26720155]
Jurkat	IC₅₀	0.03 μM Compound: DOX	Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay	[PMID: 25259516]
Jurkat	IC₅₀	0.03 μM Compound: DOX	Antiproliferative activity against human Jurkat cells after 72 hrs by MTT assay Antiproliferative activity against human Jurkat cells after 72 hrs by MTT assay	[PMID: 24021462]
Jurkat	IC₅₀	0.03 μM Compound: DOX	Antiproliferative activity against human Jurkat cells after 72 hrs by MTT assay Antiproliferative activity against human Jurkat cells after 72 hrs by MTT assay	[PMID: 20359789]
Jurkat	IC₅₀	0.03 μM Compound: DOX	Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay	[PMID: 18783950]
Jurkat	IC₅₀	0.05 μM Compound: Doxorubicin	Cytotoxicity against human Jurkat cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human Jurkat cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 33668008]
Jurkat	IC₅₀	0.078 μM Compound: Doxorubicin	Antiproliferative activity against human Jurkat cells assessed as cell viability after 72 hrs by MTT assay Antiproliferative activity against human Jurkat cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24012378]
Jurkat	IC₅₀	0.078 μM Compound: Doxorubicin	Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay	[PMID: 19394829]
Jurkat	IC₅₀	0.09 μM Compound: Doxorubicin	Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay	[PMID: 17227762]
Jurkat	IC₅₀	0.1 μM Compound: Dox	Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay	[PMID: 30659997]
Jurkat	IC₅₀	0.11 μM Compound: DOX	Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay	[PMID: 29970309]
Jurkat	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human Jurkat cells assessed as reduction in cell viability measured after 48 hrs MTT assay Cytotoxicity against human Jurkat cells assessed as reduction in cell viability measured after 48 hrs MTT assay	[PMID: 33668008]
Jurkat	IC₅₀	0.23 μM Compound: Doxorubicin	Cytotoxicity against human Jurkat cells assessed as effect on cell viability measured after 48 hrs by MTT assay Cytotoxicity against human Jurkat cells assessed as effect on cell viability measured after 48 hrs by MTT assay	[PMID: 27521588]
Jurkat	IC₅₀	0.26 μM Compound: Doxorubicin	Cytotoxicity against human Jurkat cells assessed as reduction in cell survival after 48 hrs by MTT assay Cytotoxicity against human Jurkat cells assessed as reduction in cell survival after 48 hrs by MTT assay	[PMID: 28494255]
Jurkat	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human Jurkat cells assessed as cell growth inhibition measured after 45 hrs Cytotoxicity against human Jurkat cells assessed as cell growth inhibition measured after 45 hrs	[PMID: 35526504]
Jurkat	GI₅₀	0.43 μM Compound: Dox	Anticancer activity against human Jurkat cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Anticancer activity against human Jurkat cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35533562]
Jurkat	GI₅₀	0.65 μM Compound: Dox	Antiproliferative activity against human Jurkat cells incubated for 72 hrs and measured by MTT assay Antiproliferative activity against human Jurkat cells incubated for 72 hrs and measured by MTT assay	[PMID: 35973342]
Jurkat	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human Jurkat cells assessed as reduction in cell viability measured after 24 hrs MTT assay Cytotoxicity against human Jurkat cells assessed as reduction in cell viability measured after 24 hrs MTT assay	[PMID: 33668008]
Jurkat	IC₅₀	1 μM Compound: Doxorubicin	Cytotoxicity against human Jurkat cells assessed as cell growth inhibition measured after 24 hrs Cytotoxicity against human Jurkat cells assessed as cell growth inhibition measured after 24 hrs	[PMID: 35526504]
Jurkat	IC₅₀	1.8 μM Compound: Doxorubicin	Cytotoxicity against human Jurkat cells assessed as cell growth inhibition measured after 18 hrs Cytotoxicity against human Jurkat cells assessed as cell growth inhibition measured after 18 hrs	[PMID: 35526504]
Jurkat	IC₅₀	2.35 μM Compound: doxo	Antiproliferative activity against human Jurkat T cells assessed as decrease in cell viability measured after 24 to 72 hrs by MTT assay Antiproliferative activity against human Jurkat T cells assessed as decrease in cell viability measured after 24 to 72 hrs by MTT assay	[PMID: 30763817]
Jurkat	IC₅₀	37.5 nM Compound: Doxorubicin	Antiproliferative activity against human Jurkat cells after 96 hrs by MTT assay Antiproliferative activity against human Jurkat cells after 96 hrs by MTT assay	[PMID: 21296467]
Jurkat E6.1	IC₅₀	1.03 μM Compound: Dox	Cytotoxicity against human Jurkat E6-1 cells after 24 hrs by MTT assay Cytotoxicity against human Jurkat E6-1 cells after 24 hrs by MTT assay	[PMID: 29398445]
K562	GI₅₀	< 0.046 μM Compound: Dox	Antiproliferative activity against human K562 cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human K562 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26454648]
K562	IC₅₀	< 1 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells assessed as reduction in cell growth by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell growth by MTT assay	[PMID: 36734533]
K562	IC₅₀	< 1 μM Compound: doxorubicin	Cytotoxicity against human K562 cells by MTT assay Cytotoxicity against human K562 cells by MTT assay	[PMID: 33847126]
K562	IC₅₀	< 1 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells by MTT assay Cytotoxicity against human K562 cells by MTT assay	[PMID: 33371684]
K562	GI₅₀	< 1 μM Compound: DOX	Antiproliferative activity against human K562 cells by MTT assay Antiproliferative activity against human K562 cells by MTT assay	[PMID: 31990554]
K562	GI₅₀	> 150 nM Compound: Doxorubicin	Inhibition of P-gp in doxorubicin resistant human K562 cells assessed as reduction in cell viability measured after 48 hrs by Presto blue assay Inhibition of P-gp in doxorubicin resistant human K562 cells assessed as reduction in cell viability measured after 48 hrs by Presto blue assay	[PMID: 27908756]
K562	IC₅₀	> 167.6 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32531682]
K562	IC₅₀	0.006 μM Compound: Dox	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 27423028]
K562	IC₅₀	0.01 μM Compound: ADR	Antiproliferative activity against human K562 cells after 48 hrs by hemocytometer Antiproliferative activity against human K562 cells after 48 hrs by hemocytometer	[PMID: 21705223]
K562	IC₅₀	0.01 μM Compound: Adriamycin	Antiproliferative activity against human K562 cells after 48 hrs by hemocytometric analysis Antiproliferative activity against human K562 cells after 48 hrs by hemocytometric analysis	[PMID: 21563750]
K562	IC₅₀	0.01 μM Compound: adriamycin	Antiproliferative activity against human K562 cells after 48 hrs Antiproliferative activity against human K562 cells after 48 hrs	[PMID: 19220018]
K562	IC₅₀	0.011 μg/mL Compound: ADR	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 18590312]
K562	IC₅₀	0.011 μg/mL Compound: ADR	Cytotoxicity against human K562 cells after 72 hrs by SRB assay Cytotoxicity against human K562 cells after 72 hrs by SRB assay	[PMID: 18590312]
K562	IC₅₀	0.018 μM Compound: Doxorubicin	Antiproliferative activity against human K562 cells after 72 hrs by MTT reduction assay Antiproliferative activity against human K562 cells after 72 hrs by MTT reduction assay	[PMID: 28551177]
K562	IC₅₀	0.019 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against human K562 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 33261897]
K562	IC₅₀	0.021 μM Compound: DOX	Cytotoxicity against human K562 cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human K562 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
K562	IC₅₀	0.03 μM Compound: Doxo	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 23245571]
K562	GI₅₀	0.03 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells by sulforhodamine B assay Cytotoxicity against human K562 cells by sulforhodamine B assay	[PMID: 20413188]
K562	IC₅₀	0.032 μM Compound: DOX	Cytotoxicity against human doxorubicin-sensitive K562 cells after 72 hrs by MTT assay Cytotoxicity against human doxorubicin-sensitive K562 cells after 72 hrs by MTT assay	[PMID: 19140665]
K562	IC₅₀	0.033 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells after 72 hrs by MTS assay Cytotoxicity against human K562 cells after 72 hrs by MTS assay	[PMID: 20471276]
K562	IC₅₀	0.035 μg/mL Compound: doxorubicin	Cytotoxicity against human K562 cells after 2 to 7 days by neutral red assay Cytotoxicity against human K562 cells after 2 to 7 days by neutral red assay	[PMID: 8984156]
K562	IC₅₀	0.047 μM Compound: Dox	Cytotoxicity against human K562 cells incubated for 72 hrs by CellTiter 96 aqueous one solution reagent based assay Cytotoxicity against human K562 cells incubated for 72 hrs by CellTiter 96 aqueous one solution reagent based assay	[PMID: 27753480]
K562	IC₅₀	0.06 μM Compound: doxorubicin	Cytotoxicity against human K562 cells after 72 hrs by flow cytometry Cytotoxicity against human K562 cells after 72 hrs by flow cytometry	[PMID: 19926173]
K562	IC₅₀	0.06 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells after 72 hrs by flow cytometry Cytotoxicity against human K562 cells after 72 hrs by flow cytometry	[PMID: 19482476]
K562	GI₅₀	0.06 μM Compound: Doxorubicin	Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay	[PMID: 33214037]
K562	IC₅₀	0.07 μM Compound: Doxorubicin	Anticancer activity against human K562 cells incubated for 24 hrs by MTT assay Anticancer activity against human K562 cells incubated for 24 hrs by MTT assay	[PMID: 28579122]
K562	IC₅₀	0.08 μM Compound: Doxorubicin	Growth inhibition of human K562 cells after 72 hrs by MTS method Growth inhibition of human K562 cells after 72 hrs by MTS method	[PMID: 18258442]
K562	IC₅₀	0.09 μM Compound: Adriamycin	Cytotoxicity against human K562 cells by SRB method Cytotoxicity against human K562 cells by SRB method	[PMID: 18181575]
K562	IC₅₀	0.1 mM Compound: Dox	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 29459273]
K562	IC₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity in human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34082225]
K562	IC₅₀	0.1 μM Compound: Dox	Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 32428792]
K562	IC₅₀	0.1 μM Compound: Dox	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 30659997]
K562	IC₅₀	0.1 μM Compound: 5	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 29137865]
K562	IC₅₀	0.1 μM Compound: 1; Dox	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 26890118]
K562	GI₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 21115210]
K562	IC₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 19361894]
K562	GI₅₀	0.1 μM Compound: adriamycin	Antitumor activity against human K562 cells after 48 hrs by sulforhodamine B protein assay Antitumor activity against human K562 cells after 48 hrs by sulforhodamine B protein assay	[PMID: 17448574]
K562	IC₅₀	0.12 μM Compound: 1; Dox	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 26633734]
K562	IC₅₀	0.12 μM Compound: Dox	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 21144624]
K562	IC₅₀	0.14 μg/mL Compound: Doxorubicin	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 18586355]
K562	IC₅₀	0.14 μM Compound: Doxorubicin	Cytotoxicity against p53 null human K562 cells asessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against p53 null human K562 cells asessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 31324563]
K562	IC₅₀	0.14 μM Compound: DOX	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 29970309]
K562	IC₅₀	0.14 μM Compound: I	Antiproliferative activity against human K562 cells after 72 hrs by MTT test Antiproliferative activity against human K562 cells after 72 hrs by MTT test	[PMID: 17276690]
K562	IC₅₀	0.157 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells at 50 uM by MTT reduction assay Cytotoxicity against human K562 cells at 50 uM by MTT reduction assay	[PMID: 33276991]
K562	IC₅₀	0.17 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 22537362]
K562	IC₅₀	0.17 μM Compound: doxorubicin	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 21087017]
K562	GI₅₀	0.19 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human K562 cells after 48 hrs by SRB assay Cytotoxicity against human K562 cells after 48 hrs by SRB assay	[PMID: 23871905]
K562	GI₅₀	0.19 μM Compound: Doxorubicin	Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
K562	GI₅₀	0.19 μM Compound: Doxorubicin	Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
K562	IC₅₀	0.198 μM Compound: Doxorubicin	Anticancer activity against human K562 cells by MTT assay Anticancer activity against human K562 cells by MTT assay	[PMID: 21570750]
K562	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT method Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT method	[PMID: 25932671]
K562	IC₅₀	0.21 μM Compound: Doxorubicin	Antiproliferative activity against human K562 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human K562 cells incubated for 48 hrs by MTT assay	[PMID: 32035399]
K562	IC₅₀	0.22 μM Compound: Doxorubicin	Antiproliferative activity against human K562 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human K562 cells incubated for 72 hrs by CCK8 assay	[PMID: 32992133]
K562	IC₅₀	0.22 μM Compound: Doxorubicin	Antiproliferative activity against human K562 cells measured after 72 hrs by CCK8 assay Antiproliferative activity against human K562 cells measured after 72 hrs by CCK8 assay	[PMID: 27484511]
K562	IC₅₀	0.24 μM Compound: doxorubicin	Growth inhibition of human K562 cells after 72 hrs by SRB assay Growth inhibition of human K562 cells after 72 hrs by SRB assay	[PMID: 18313307]
K562	IC₅₀	0.25 μM Compound: DOX	Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured after 6 days by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured after 6 days by MTT assay	[PMID: 32653698]
K562	IC₅₀	0.25 μM Compound: DOX	Antiproliferative activity against human K562 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 31557614]
K562	IC₅₀	0.25 μM Compound: DOX	Cytotoxicity against human K562 cells assessed as inhibition of cell growth after 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as inhibition of cell growth after 72 hrs by MTT assay	[PMID: 30746062]
K562	IC₅₀	0.25 μM Compound: DOX	Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28427016]
K562	IC₅₀	0.25 μM Compound: DOX	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 28135634]
K562	IC₅₀	0.25 μM Compound: Dox	Cytotoxicity against human K562 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27231128]
K562	IC₅₀	0.25 μM Compound: DOX	Cytotoxicity against human K562 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 26720155]
K562	IC₅₀	0.25 μM Compound: DOX	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 25259516]
K562	IC₅₀	0.25 μM Compound: Adriamycin	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 24370114]
K562	IC₅₀	0.25 μM Compound: DOX	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 24021462]
K562	IC₅₀	0.25 μM Compound: DOX	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 20359789]
K562	IC₅₀	0.26 μg/mL Compound: DOX	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 24589485]
K562	IC₅₀	0.28 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27623548]
K562	IC₅₀	0.28 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells by MTT assay Cytotoxicity against human K562 cells by MTT assay	[PMID: 23544451]
K562	IC₅₀	0.28 μM Compound: Adriamycin	Cytotoxicity against human K-562 cells after 48 hrs by SRB assay Cytotoxicity against human K-562 cells after 48 hrs by SRB assay	[PMID: 17125233]
K562	IC₅₀	0.28 μM Compound: Doxorubicine	Iinhibitory activity against K562 leukemia cell line using sulforhodamine B (SRB) protein assay Iinhibitory activity against K562 leukemia cell line using sulforhodamine B (SRB) protein assay	[PMID: 12039588]
K562	IC₅₀	0.3 μM Compound: doxorubicin	Growth inhibition of human K562 cells by MTS method Growth inhibition of human K562 cells by MTS method	[PMID: 19457675]
K562	IC₅₀	0.32 μM Compound: adriamycin	Cytotoxicity against human K562 cells by MTT assay Cytotoxicity against human K562 cells by MTT assay	[PMID: 19422203]
K562	IC₅₀	0.33 μM Compound: DOX	Cytotoxicity against human K562 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Cytotoxicity against human K562 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 31820976]
K562	IC₅₀	0.36 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells expressing estrogen receptor after 48 hrs by MTT assay Cytotoxicity against human K562 cells expressing estrogen receptor after 48 hrs by MTT assay	10.1039/C2MD20327H
K562	IC₅₀	0.361 μM Compound: 1	Cytotoxicity in human K562 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay Cytotoxicity in human K562 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay	[PMID: 33064004]
K562	GI₅₀	0.4 μg/mL Compound: DOX	Growth inhibition of human K562 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human K562 cells after 48 hrs by sulforhodamine B assay	[PMID: 21041092]
K562	IC₅₀	0.424 μM Compound: Dox	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 26494582]
K562	IC₅₀	0.425 μM Compound: Adriamycin	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 21843940]
K562	IC₅₀	0.43 μM Compound: ADR	Antiproliferative activity against human K562 cells after 72 hrs by MTS assay Antiproliferative activity against human K562 cells after 72 hrs by MTS assay	[PMID: 22450134]
K562	IC₅₀	0.43 μM Compound: ADR	Cytotoxicity against human K562 cells after 72 hrs by MTS assay Cytotoxicity against human K562 cells after 72 hrs by MTS assay	[PMID: 22405646]
K562	IC₅₀	0.43 μM Compound: ADR	Cytotoxicity against human K562 cells after 72 hrs by sulforhodamine B and MTT assay Cytotoxicity against human K562 cells after 72 hrs by sulforhodamine B and MTT assay	[PMID: 22119124]
K562	IC₅₀	0.44 μM Compound: doxorubicin	Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay	[PMID: 22582991]
K562	IC₅₀	0.45 μM Compound: ADM	Anticancer activity against human K562 cells after 48 hrs by MTT assay Anticancer activity against human K562 cells after 48 hrs by MTT assay	[PMID: 25462264]
K562	IC₅₀	0.46 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 31836446]
K562	IC₅₀	0.49 μM Compound: Dox	Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33479619]
K562	IC₅₀	0.5 μM Compound: Doxorubicin	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 27808511]
K562	IC₅₀	0.51 μM Compound: DOX	Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31202598]
K562	IC₅₀	0.51 μM Compound: DOX	Antiproliferative activity against human K562 cells after 72 hrs by Sulforhodamine B-stain assay Antiproliferative activity against human K562 cells after 72 hrs by Sulforhodamine B-stain assay	[PMID: 27484508]
K562	IC₅₀	0.54 μg/mL Compound: Doxorubicin	Anticancer activity against human K562 cells by MTT assay Anticancer activity against human K562 cells by MTT assay	[PMID: 31404864]
K562	IC₅₀	0.55 μM Compound: Adriamycin	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 25686590]
K562	IC₅₀	0.58 μM Compound: adriamycin	Cytotoxicity against human K562 cells after 48 hrs Cytotoxicity against human K562 cells after 48 hrs	[PMID: 17583953]
K562	IC₅₀	0.6 μM Compound: ADM	Cytotoxicity against human K562 cells by MTT method Cytotoxicity against human K562 cells by MTT method	[PMID: 29144133]
K562	IC₅₀	0.62 μM Compound: DOX	Cytotoxicity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28355069]
K562	IC₅₀	0.65 μM Compound: Doxorubicin	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 30500683]
K562	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue assay	[PMID: 27300257]
K562	GI₅₀	0.7 μM Compound: Dox	Antiproliferative activity against human K562 cells incubated for 72 hrs and measured by MTT assay Antiproliferative activity against human K562 cells incubated for 72 hrs and measured by MTT assay	[PMID: 35973342]
K562	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27015002]
K562	IC₅₀	0.8 μM Compound: 1, DOX	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 25244612]
K562	IC₅₀	0.89 μM Compound: Doxorubicin	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 29172084]
K562	GI₅₀	0.93 μM Compound: Dox	Growth inhibition of human K562 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay Growth inhibition of human K562 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay	[PMID: 28505535]
K562	IC₅₀	0.94 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells after 72 hrs by alamar blue assay Cytotoxicity against human K562 cells after 72 hrs by alamar blue assay	[PMID: 28159416]
K562	IC₅₀	0.94 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells by Alamar blue assay Cytotoxicity against human K562 cells by Alamar blue assay	[PMID: 27256910]
K562	GI₅₀	1 μg/mL Compound: doxorubicin	Antiproliferative activity against human K562 cells after 72 hrs by resazurin dye reduction assay Antiproliferative activity against human K562 cells after 72 hrs by resazurin dye reduction assay	[PMID: 20153202]
K562	IC₅₀	1 μM Compound: Doxorubicin	Antiproliferative activity against human K562 cells assessed as inhibition of cell survival after 48 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as inhibition of cell survival after 48 hrs by MTT assay	[PMID: 27265687]
K562	IC₅₀	1 μM Compound: adriamycin	Cytotoxicity against human K562 cells under deem light after 96 hrs by MTT assay Cytotoxicity against human K562 cells under deem light after 96 hrs by MTT assay	[PMID: 17993275]
K562	IC₅₀	1.1 μM Compound: Adriamycin	Cytotoxicity against human K562 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26356746]
K562	GI₅₀	1.11 μM Compound: DOXO	Antiproliferative activity against human K562 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human K562 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 31247374]
K562	IC₅₀	1.25 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells after 72 hrs by alamar blue assay Cytotoxicity against human K562 cells after 72 hrs by alamar blue assay	[PMID: 24969014]
K562	IC₅₀	1.33 μM Compound: Adriamycin	Cytotoxicity against human K562 cells by MTT assay Cytotoxicity against human K562 cells by MTT assay	[PMID: 21115246]
K562	IC₅₀	1.38 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells assessed as inhibition of cell viability after 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as inhibition of cell viability after 72 hrs by MTT assay	[PMID: 29329071]
K562	IC₅₀	1.4 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 32496057]
K562	IC₅₀	1.41 μg/mL Compound: Adriamycin	Cytotoxicity against human K562 cells by MTT assay Cytotoxicity against human K562 cells by MTT assay	[PMID: 17918910]
K562	IC₅₀	1.41 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 22677031]
K562	IC₅₀	1.43 μM Compound: Doxorubicin	Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31546197]
K562	IC₅₀	1.514 μM Compound: DOXO	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 29685681]
K562	IC₅₀	1.58 μM Compound: DOX	Cytotoxicity against human K562 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29421568]
K562	IC₅₀	1.6 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26551342]
K562	IC₅₀	1.67 μM Compound: D	Antineoplastic activity against human K562 cells after 72 hrs by MTT assay Antineoplastic activity against human K562 cells after 72 hrs by MTT assay	[PMID: 22000949]
K562	IC₅₀	1.77 μM Compound: Doxorubicin	Cytotoxicity against human chronic myelogenous leukemia (K562) cell line using MTT assay Cytotoxicity against human chronic myelogenous leukemia (K562) cell line using MTT assay	[PMID: 9873387]
K562	IC₅₀	10.9 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Cytotoxicity against human K562 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 26317881]
K562	GI₅₀	11.62 μM Compound: Doxorubicin	Inhibition of P-gp in doxorubicin resistant human K562 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay Inhibition of P-gp in doxorubicin resistant human K562 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay	[PMID: 27908756]
K562	IC₅₀	13.53 μM Compound: Doxo	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 27597408]
K562	IC₅₀	13.6 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells by spectrophotometric analysis Cytotoxicity against human K562 cells by spectrophotometric analysis	[PMID: 22148280]
K562	IC₅₀	14 nM Compound: Adriamycin	Cytotoxicity against human K562 cells after 48 hrs by SRB assay Cytotoxicity against human K562 cells after 48 hrs by SRB assay	[PMID: 22858298]
K562	IC₅₀	16.31 μM Compound: Doxorubicin	Antiproliferative activity against drug resistant human K562 cells incubated for 48 hrs by MTT assay Antiproliferative activity against drug resistant human K562 cells incubated for 48 hrs by MTT assay	[PMID: 32035399]
K562	IC₅₀	17.23 μM Compound: Doxorubicin	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 21620529]
K562	GI₅₀	2 x 10^-2 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29670691]
K562	IC₅₀	2 μM Compound: Doxorubicin	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 30179747]
K562	IC₅₀	2.41 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 28390228]
K562	IC₅₀	2.5 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human K562 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 35526504]
K562	IC₅₀	2.5 μM Compound: adriamycin	Cytotoxicity against human K562 cells by rapid colorimetric assay Cytotoxicity against human K562 cells by rapid colorimetric assay	[PMID: 19585998]
K562	IC₅₀	2.84 μM Compound: Doxo	Cytotoxicity against human doxorubicin-resistant K562 cells after 72 hrs by MTT assay Cytotoxicity against human doxorubicin-resistant K562 cells after 72 hrs by MTT assay	[PMID: 23245571]
K562	IC₅₀	2.84 μM Compound: DOX	Cytotoxicity against human doxorubicin-resistant K562 cells expressing Pgp after 72 hrs by MTT assay Cytotoxicity against human doxorubicin-resistant K562 cells expressing Pgp after 72 hrs by MTT assay	[PMID: 19140665]
K562	IC₅₀	2.85 μM Compound: Adriamycin	Cytotoxicity against human K562 cells after 2 days Cytotoxicity against human K562 cells after 2 days	[PMID: 22318164]
K562	IC₅₀	2.96 μM Compound: Doxorubicin	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 28038941]
K562	IC₅₀	220 nM Compound: Doxorubicin	Cytotoxicity against human K562 cells incubated for 72 hrs by CCK8 assay Cytotoxicity against human K562 cells incubated for 72 hrs by CCK8 assay	[PMID: 32992133]
K562	IC₅₀	24.14 μM Compound: doxorubicin	Growth inhibition of doxorubicin-resistant human K562 cells after 72 hrs by SRB assay Growth inhibition of doxorubicin-resistant human K562 cells after 72 hrs by SRB assay	[PMID: 18313307]
K562	IC₅₀	3.79 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells after 24 hrs by MTT assay Cytotoxicity against human K562 cells after 24 hrs by MTT assay	[PMID: 22687747]
K562	IC₅₀	4.49 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) K562 cells assessed as inhibition of cell proliferation after 24 hr by MTT assay Cytotoxicity against Homo sapiens (human) K562 cells assessed as inhibition of cell proliferation after 24 hr by MTT assay	10.1007/s00044-012-0436-9
K562	IC₅₀	46.69 μM Compound: ADR	Cytotoxicity against human K562 cells after 72 hrs by MTS assay Cytotoxicity against human K562 cells after 72 hrs by MTS assay	[PMID: 22429509]
K562	IC₅₀	5.23 μM Compound: Doxorubicin	Cytotoxicity against human K562 cells incubated for 72 hrs by Sulphorhodamine assay Cytotoxicity against human K562 cells incubated for 72 hrs by Sulphorhodamine assay	[PMID: 37146520]
K562	IC₅₀	56.83 μM Compound: ADR	Cytotoxicity against adriamycin-selected multi drug-resistant human K562 cells after 72 hrs by sulforhodamine B and MTT assay Cytotoxicity against adriamycin-selected multi drug-resistant human K562 cells after 72 hrs by sulforhodamine B and MTT assay	[PMID: 22119124]
K562	ED₅₀	59.5 nM Compound: doxorubicin	Cytotoxicity against human K562 cells by MTT assay Cytotoxicity against human K562 cells by MTT assay	[PMID: 17655260]
K562	IC₅₀	6.12 nM Compound: Doxorubicin	Cytotoxicity against human K562 cells after 3 days by MTT assay Cytotoxicity against human K562 cells after 3 days by MTT assay	[PMID: 20356655]
K562	IC₅₀	6.25 μM Compound: DOX	Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28531811]
K562	IC₅₀	6.66 nM Compound: Doxorubicin	Cytotoxicity against human K562 cells by MTT assay Cytotoxicity against human K562 cells by MTT assay	[PMID: 19345581]
K562	GI₅₀	65 nM Compound: Doxorubicin	Antiproliferative activity against human K562 cells measured after 48 hrs by Presto blue assay Antiproliferative activity against human K562 cells measured after 48 hrs by Presto blue assay	[PMID: 27908756]
K562	IC₅₀	8.5 μM Compound: doxorubicin	Cytotoxicity against human K562 cells assessed as viable cells after 72 hrs by MTS/PMS assay Cytotoxicity against human K562 cells assessed as viable cells after 72 hrs by MTS/PMS assay	[PMID: 20055495]
K562/A02	IC₅₀	0.43 μM Compound: ADR	Cytotoxicity against human K562/A02 cells overexpress P-gp after 72 hrs by MTS assay Cytotoxicity against human K562/A02 cells overexpress P-gp after 72 hrs by MTS assay	[PMID: 22429509]
K562/A02	GI₅₀	14.28 μM Compound: Doxorubicin	Cytotoxicity against human K562/A02 cells by SRB assay Cytotoxicity against human K562/A02 cells by SRB assay	[PMID: 32992133]
K562/A02	IC₅₀	17.84 μM Compound: Adriamycin	Cytotoxicity against adriamycin-resistant human K562/A02 cells after 48 hrs by MTT assay Cytotoxicity against adriamycin-resistant human K562/A02 cells after 48 hrs by MTT assay	[PMID: 21843940]
K562/A02	IC₅₀	46.69 μM Compound: ADR	Antiproliferative activity against multidrug-resistant human K562/A02 cells overexpressing p-glycoprotein after 72 hrs by MTS assay Antiproliferative activity against multidrug-resistant human K562/A02 cells overexpressing p-glycoprotein after 72 hrs by MTS assay	[PMID: 22450134]
K562/A02	IC₅₀	46.69 μM Compound: ADR	Cytotoxicity against human K562/A02 cells expressing p-glycoprotein after 72 hrs by MTS assay Cytotoxicity against human K562/A02 cells expressing p-glycoprotein after 72 hrs by MTS assay	[PMID: 22405646]
K562/A02	IC₅₀	5.961 μM Compound: Dox	Antiproliferative activity against human K562/A02 cells after 72 hrs by MTT assay Antiproliferative activity against human K562/A02 cells after 72 hrs by MTT assay	[PMID: 27423028]
K562/A02	IC₅₀	55.47 μM Compound: DOX	Cytotoxicity against human K562/A02 cells overexpressing P-gp assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human K562/A02 cells overexpressing P-gp assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31202598]
K562/A02	IC₅₀	89.8 μM Compound: DOX	Cytotoxicity against human K562/A02 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human K562/A02 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28355069]
K562/Adr	IC₅₀	18.779 μM Compound: Doxorubicin	Antiproliferative activity against human K562/ADR cells measured after 72 hrs by CCK8 assay Antiproliferative activity against human K562/ADR cells measured after 72 hrs by CCK8 assay	[PMID: 27484511]
K562/Adr	IC₅₀	18.799 μM Compound: Doxorubicin	Antiproliferative activity against human K562/ADR cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human K562/ADR cells incubated for 72 hrs by CCK8 assay	[PMID: 32992133]
K562/Adr	IC₅₀	220 nM Compound: Doxorubicin	Cytotoxicity against human K562/ADR cells incubated for 72 hrs by CCK8 assay Cytotoxicity against human K562/ADR cells incubated for 72 hrs by CCK8 assay	[PMID: 32992133]
K562/Adr	IC₅₀	67.6 μM Compound: ADM	Anticancer activity against human K562/ADR cells after 48 hrs by MTT assay Anticancer activity against human K562/ADR cells after 48 hrs by MTT assay	[PMID: 25462264]
K562-Lucena 1	IC₅₀	> 10 μM Compound: Doxorubicin	Cytotoxicity against human K562-Lucena 1 cells after 48 hrs by MTT assay Cytotoxicity against human K562-Lucena 1 cells after 48 hrs by MTT assay	[PMID: 32496057]
K-562R	IC₅₀	35 μM Compound: Dox	Cytotoxicity against doxorubicin-resistant human K562R cells incubated for 72 hrs by CellTiter 96 aqueous one solution reagent based assay Cytotoxicity against doxorubicin-resistant human K562R cells incubated for 72 hrs by CellTiter 96 aqueous one solution reagent based assay	[PMID: 27753480]
KARPAS-299	IC₅₀	0.38 μM Compound: DOX	Cytotoxicity against human KARPAS299 cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human KARPAS299 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
KB	IC₅₀	< 0.55 μg/mL Compound: Doxorubicin	Cytotoxicity against human KB cells after 48 hrs by neutral red assay Cytotoxicity against human KB cells after 48 hrs by neutral red assay	[PMID: 19105653]
KB	IC₅₀	< 0.55 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) KB cells by neutral red staining Cytotoxicity against Homo sapiens (human) KB cells by neutral red staining	10.1007/s00044-011-9587-3
KB	IC₅₀	< 1.1 μg/mL Compound: Doxorubicin	Cytotoxicity against human KB cells after 2 to 7 days by neutral red assay Cytotoxicity against human KB cells after 2 to 7 days by neutral red assay	[PMID: 11374943]
KB	IC₅₀	> 400 μM Compound: Adriamycin	Cytotoxicity against human KB cells by SRB method Cytotoxicity against human KB cells by SRB method	[PMID: 18181575]
KB	IC₅₀	0.009 μM Compound: Doxorubicin	Antiproliferative activity against human KB cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human KB cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 27010926]
KB	IC₅₀	0.01 μM Compound: Doxorubicin	Cytotoxicity in human KB cells incubated for 72 hrs by MTT assay Cytotoxicity in human KB cells incubated for 72 hrs by MTT assay	[PMID: 30978023]
KB	IC₅₀	0.012 μM Compound: Doxorubicin	Cytotoxicity against human KB cells after 48 hrs by MTT assay Cytotoxicity against human KB cells after 48 hrs by MTT assay	[PMID: 22537362]
KB	IC₅₀	0.012 μM Compound: doxorubicin	Cytotoxicity against human KB cells after 48 hrs by MTT assay Cytotoxicity against human KB cells after 48 hrs by MTT assay	[PMID: 21087017]
KB	IC₅₀	0.015 μM Compound: Doxorubicin	Inhibitory concentration that reduced the viability of KB cell population by 50%. Inhibitory concentration that reduced the viability of KB cell population by 50%.	[PMID: 9003520]
KB	IC₅₀	0.02 μg/mL Compound: adriamycin	In vitro reduction in viability of KB cells by modified crystal violet assay. In vitro reduction in viability of KB cells by modified crystal violet assay.	[PMID: 8277498]
KB	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity activity against human KB cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity activity against human KB cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32627543]
KB	IC₅₀	0.024 μM Compound: Doxorubicin	Cytotoxicity against human KB cells after 48 hrs by neutral red dye based assay Cytotoxicity against human KB cells after 48 hrs by neutral red dye based assay	[PMID: 29317147]
KB	IC₅₀	0.028 μM Compound: Doxorubicin	Cytotoxicity against human KB cells after 44 hrs by SRB assay Cytotoxicity against human KB cells after 44 hrs by SRB assay	10.1007/s00044-013-0788-9
KB	ED₅₀	0.058 μg/mL Compound: Doxorubicin	Cytotoxicity against human KB cells after 72 hrs by neutral red staining Cytotoxicity against human KB cells after 72 hrs by neutral red staining	[PMID: 11374944]
KB	IC₅₀	0.06 μM Compound: Doxorubicin	Concentration required to reduce proliferation of KB human nasopharyngeal carcinoma (KBWT) cell line by 50% as determined by the MTT method Concentration required to reduce proliferation of KB human nasopharyngeal carcinoma (KBWT) cell line by 50% as determined by the MTT method	[PMID: 14761187]
KB	IC₅₀	0.06 μM Compound: doxorubicin	Compound concentration required to reduce the cell proliferation of Wild type and Drug- resistant human nasopharyngeal carcinoma KB cells by 50% Compound concentration required to reduce the cell proliferation of Wild type and Drug- resistant human nasopharyngeal carcinoma KB cells by 50%	[PMID: 12431048]
KB	IC₅₀	0.09 μM Compound: Doxorubicin	Cytotoxicity against human KB cells after 48 hrs by MTT assay Cytotoxicity against human KB cells after 48 hrs by MTT assay	[PMID: 26963142]
KB	ED₅₀	0.1 μg/mL Compound: doxorubicin	Cytotoxicity against human KB cells after 3 days by MTT assay Cytotoxicity against human KB cells after 3 days by MTT assay	[PMID: 16252910]
KB	IC₅₀	0.1 μg/mL Compound: doxorubicin	Cytotoxicity against human KB cells after 2 days by sulforhodamine B assay Cytotoxicity against human KB cells after 2 days by sulforhodamine B assay	[PMID: 17067159]
KB	GI₅₀	0.11 μM Compound: ADR	Cytotoxicity against human KB cells after 48 hrs by SRB assay Cytotoxicity against human KB cells after 48 hrs by SRB assay	[PMID: 20673627]
KB	IC₅₀	0.12 μg/mL Compound: doxorubicin	Cytotoxicity against human KB cells after 2 to 7 days by neutral red assay Cytotoxicity against human KB cells after 2 to 7 days by neutral red assay	[PMID: 8984156]
KB	IC₅₀	0.12 μg/mL Compound: Doxorubicin	Cytotoxicity against human KB cells after 48 hrs by SRB assay Cytotoxicity against human KB cells after 48 hrs by SRB assay	[PMID: 20732814]
KB	IC₅₀	0.12 μg/mL Compound: doxorubicin	Cytotoxicity against human KB cells by sulforhodamine B assay Cytotoxicity against human KB cells by sulforhodamine B assay	[PMID: 19555123]
KB	IC₅₀	0.13 μg/mL Compound: doxorubicin	Cytotoxicity against human KB cells by SRB assay Cytotoxicity against human KB cells by SRB assay	[PMID: 19778068]
KB	IC₅₀	0.13 μM Compound: DOX	Cytotoxicity against human KB cells after 48 hrs by MTT assay Cytotoxicity against human KB cells after 48 hrs by MTT assay	[PMID: 26386603]
KB	IC₅₀	0.13 μM Compound: Doxorubicin	Cytotoxicity against human KB cells by MTT assay Cytotoxicity against human KB cells by MTT assay	[PMID: 30719909]
KB	IC₅₀	0.141 μM Compound: Dox	Antiproliferative activity against human KB cells after 72 hrs by MTT assay Antiproliferative activity against human KB cells after 72 hrs by MTT assay	[PMID: 27423028]
KB	IC₅₀	0.144 μg/mL Compound: Doxorubicin	Cytotoxicity against human KB cells by resazurin microplate assay Cytotoxicity against human KB cells by resazurin microplate assay	[PMID: 19456117]
KB	ED₅₀	0.15 μg/mL Compound: doxorubicin	Cytotoxicity against human KB cells by methylene blue staining method Cytotoxicity against human KB cells by methylene blue staining method	[PMID: 15921421]
KB	IC₅₀	0.15 μM Compound: doxo	Antiproliferative activity against human KB cell line by MTT assay Antiproliferative activity against human KB cell line by MTT assay	[PMID: 16913700]
KB	GI₅₀	0.16 μM Compound: ADR	Anticancer activity against human KB cells by SRB method Anticancer activity against human KB cells by SRB method	[PMID: 22104151]
KB	GI₅₀	0.17 μM Compound: adriamycin	Cytotoxicity against human KB cells after 24 hrs by SRB method Cytotoxicity against human KB cells after 24 hrs by SRB method	[PMID: 18262426]
KB	GI₅₀	0.17 μM Compound: ADR	Growth inhibition of human KB cells after 48 hrs by SRB assay Growth inhibition of human KB cells after 48 hrs by SRB assay	[PMID: 20031423]
KB	GI₅₀	0.17 μM Compound: ADR	Growth inhibition of human KB cells by SRB assay Growth inhibition of human KB cells by SRB assay	[PMID: 22361684]
KB	GI₅₀	0.17 μM Compound: ADR	Anticancer activity against human KB cells by SRB method Anticancer activity against human KB cells by SRB method	[PMID: 21676506]
KB	GI₅₀	0.17 μM Compound: ADR, Adriamycin	Growth inhibition of human KB cells by SRB method Growth inhibition of human KB cells by SRB method	[PMID: 18207392]
KB	GI₅₀	0.17 μM Compound: ADR	Growth inhibition of human KB cells after 48 hrs by sulforhodamine B assay Growth inhibition of human KB cells after 48 hrs by sulforhodamine B assay	[PMID: 23849207]
KB	GI₅₀	0.17 μM Compound: ADR	Growth inhibition of human KB cells after 48 hrs by sulforhodamine B assay Growth inhibition of human KB cells after 48 hrs by sulforhodamine B assay	[PMID: 22364746]
KB	GI₅₀	0.17 μM Compound: ADR	Cytotoxicity against human KB cells after 24 hrs by WST-1 assay Cytotoxicity against human KB cells after 24 hrs by WST-1 assay	[PMID: 20732817]
KB	IC₅₀	0.18 μM Compound: doxorubicin	Cytotoxicity against human KB cells by SRB microtiter plate assay Cytotoxicity against human KB cells by SRB microtiter plate assay	[PMID: 17585747]
KB	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human KB cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human KB cells assessed as reduction in cell viability by MTT assay	[PMID: 31820973]
KB	IC₅₀	0.22 μM Compound: Doxorubicin	Cytotoxicity against human KB cells after 48 hrs by neutral red assay relative to control Cytotoxicity against human KB cells after 48 hrs by neutral red assay relative to control	[PMID: 25975638]
KB	IC₅₀	0.22 μM Compound: DOX	Antiproliferative activity against human KB cells after 72 hrs by SRB assay Antiproliferative activity against human KB cells after 72 hrs by SRB assay	[PMID: 30106296]
KB	IC₅₀	0.22 μM Compound: Doxorubicin	Cytotoxicity against human KB cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human KB cells after 48 hrs by sulforhodamine B assay	[PMID: 21071221]
KB	IC₅₀	0.23 nM Compound: Doxorubicin	Antiproliferative activity against human KB cells after 72 hrs by methylene blue staining Antiproliferative activity against human KB cells after 72 hrs by methylene blue staining	[PMID: 21067930]
KB	IC₅₀	0.24 μM Compound: Doxorubicin	Cytotoxicity against human KB cells by SRB assay Cytotoxicity against human KB cells by SRB assay	[PMID: 20038128]
KB	ED₅₀	0.25 μg/mL Compound: Doxorubicin	Cytotoxicity against human KB cells by MTT assay Cytotoxicity against human KB cells by MTT assay	[PMID: 15104488]
KB	IC₅₀	0.25 μg/mL Compound: doxorubicin	Cytotoxicity against human KB cells by resazurin microplate assay Cytotoxicity against human KB cells by resazurin microplate assay	[PMID: 20329738]
KB	EC₅₀	0.25 μM Compound: Doxorubicin	Cytotoxicity against human KB/HeLa cells after 48 hrs by resazurin dye assay Cytotoxicity against human KB/HeLa cells after 48 hrs by resazurin dye assay	[PMID: 23988351]
KB	IC₅₀	0.27 μg/mL Compound: Doxorubicin	Cytotoxicity against human KB cells by colorimetric method Cytotoxicity against human KB cells by colorimetric method	[PMID: 16989536]
KB	IC₅₀	0.27 μM Compound: adriamycin	Cytotoxicity against human KB cells after 72 hrs Cytotoxicity against human KB cells after 72 hrs	[PMID: 15921436]
KB	IC₅₀	0.28 μM Compound: Doxorubicin	Cytotoxicity against human KB cells by resazurin microplate assay Cytotoxicity against human KB cells by resazurin microplate assay	[PMID: 19739600]
KB	ED₅₀	0.3 μg/mL Compound: Doxourbicine	Cytotoxicity against human KB cells by MTT assay Cytotoxicity against human KB cells by MTT assay	[PMID: 12502336]
KB	IC₅₀	0.3 μM Compound: Doxorubicin	Antiproliferative activity against human KB cells after 72 hrs by MTT assay Antiproliferative activity against human KB cells after 72 hrs by MTT assay	[PMID: 19632833]
KB	IC₅₀	0.33 μM Compound: DOX	Cytotoxicity against human KB cells after 48 hrs by MTT assay Cytotoxicity against human KB cells after 48 hrs by MTT assay	[PMID: 23218718]
KB	IC₅₀	0.33 μM Compound: doxorubicin	Cytotoxicity against human KB cells by SRB assay Cytotoxicity against human KB cells by SRB assay	[PMID: 22004007]
KB	IC₅₀	0.34 μM Compound: DOX	Antiproliferative activity against human KB cells after 48 hrs by SRB assay Antiproliferative activity against human KB cells after 48 hrs by SRB assay	[PMID: 30106296]
KB	IC₅₀	0.37 μM Compound: Doxorubicin	Cytotoxicity against human KB cells by resazurin microplate assay Cytotoxicity against human KB cells by resazurin microplate assay	[PMID: 21090800]
KB	IC₅₀	0.38 μM Compound: doxorubicin	Cytotoxicity against human KB cells by colorimetric method Cytotoxicity against human KB cells by colorimetric method	[PMID: 23795891]
KB	IC₅₀	0.4 μM Compound: Doxorubicin	Cytotoxicity against human KB cells after 72 hrs by MTS assay Cytotoxicity against human KB cells after 72 hrs by MTS assay	[PMID: 23148652]
KB	IC₅₀	0.4 μM Compound: Doxorubicin	Concentration required to reduce proliferation of KB subclones passaged in the presence of vincristine 0.02 uM (KB7D) cell line by 50% as determined by the MTT method Concentration required to reduce proliferation of KB subclones passaged in the presence of vincristine 0.02 uM (KB7D) cell line by 50% as determined by the MTT method	[PMID: 14761187]
KB	EC₅₀	0.4 μM Compound: doxorubicin	Cytotoxicity against human KB cells after 72 hrs Cytotoxicity against human KB cells after 72 hrs	[PMID: 17378530]
KB	IC₅₀	0.55 μM Compound: doxorubicin	Cytotoxicity against human KB cells by resazurin assay Cytotoxicity against human KB cells by resazurin assay	[PMID: 23806072]
KB	IC₅₀	0.56 μM Compound: Doxorubicin	Cytotoxicity against human KB cells by SRB assay Cytotoxicity against human KB cells by SRB assay	[PMID: 23806014]
KB	IC₅₀	0.82 μM Compound: DOX	Antiproliferative activity against human KB cells after 24 hrs by SRB assay Antiproliferative activity against human KB cells after 24 hrs by SRB assay	[PMID: 30106296]
KB	IC₅₀	0.84 μM Compound: Doxorubicin	Antiproliferative activity against human KB cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human KB cells after 72 hrs by sulforhodamine B assay	[PMID: 26496013]
KB	IC₅₀	0.9 μg/mL Compound: doxorubicin	Cytotoxicity against human KB cells after 48 hrs by neutral red dye staining Cytotoxicity against human KB cells after 48 hrs by neutral red dye staining	[PMID: 19928902]
KB	IC₅₀	0.9 μg/mL Compound: doxorubicin	Cytotoxicity against human KB cells by neutral red assay Cytotoxicity against human KB cells by neutral red assay	[PMID: 17976995]
KB	IC₅₀	0.9 μM Compound: Doxorubicin	Cytotoxicity against human KB cells after 3 days by resazurin microplate assay Cytotoxicity against human KB cells after 3 days by resazurin microplate assay	[PMID: 22280818]
KB	IC₅₀	0.91 μM Compound: doxorubicin	Antiproliferative activity against human KB cells assessed as reduction in cell growth incubated at 37 degC for 3 days by resazurin microplate assay Antiproliferative activity against human KB cells assessed as reduction in cell growth incubated at 37 degC for 3 days by resazurin microplate assay	[PMID: 25734623]
KB	IC₅₀	0.96 μM Compound: Doxorubicin	Cytotoxicity against human KB cells after 3 days by resazurin microplate assay Cytotoxicity against human KB cells after 3 days by resazurin microplate assay	[PMID: 23313636]
KB	IC₅₀	1 nM Compound: doxorubicin	Cytotoxicity against human KB cells after 72 hrs by MTS assay Cytotoxicity against human KB cells after 72 hrs by MTS assay	[PMID: 19655762]
KB	IC₅₀	1 μM Compound: Doxorubicin	Cytotoxicity against human KB cells by sulforhodamine B assay Cytotoxicity against human KB cells by sulforhodamine B assay	[PMID: 26928423]
KB	IC₅₀	1.06 μM Compound: Doxorubicin	Cytotoxicity against human KB cells assessed as reduction in cell viability by resazurin microplate assay Cytotoxicity against human KB cells assessed as reduction in cell viability by resazurin microplate assay	[PMID: 27311894]
KB	IC₅₀	1.19 μM Compound: Doxorubicin	Cytotoxicity against human KB cells by resazurin microplate assay Cytotoxicity against human KB cells by resazurin microplate assay	[PMID: 27228159]
KB	IC₅₀	1.2 μM Compound: Doxorubicin	Cytotoxicity against human KB cells assessed as reduction in cell viability by resazurin based fluorescence assay Cytotoxicity against human KB cells assessed as reduction in cell viability by resazurin based fluorescence assay	[PMID: 33852304]
KB	IC₅₀	1.35 μg/mL Compound: doxorubicin	Cytotoxicity against human KB cells after 48 hrs by Neutral Red dye Cytotoxicity against human KB cells after 48 hrs by Neutral Red dye	[PMID: 20550123]
KB	IC₅₀	1.35 μM Compound: Doxorubicin	Cytotoxicity against human KB cells after 72 hrs by resazurin based fluorescence assay Cytotoxicity against human KB cells after 72 hrs by resazurin based fluorescence assay	[PMID: 28927795]
KB	IC₅₀	1.4 μM Compound: Doxorubicin	Cytotoxicity against human KB cells after 48 hrs by MTT assay Cytotoxicity against human KB cells after 48 hrs by MTT assay	[PMID: 26398312]
KB	IC₅₀	1.59 μg/mL Compound: Doxorubicin	Cytotoxicity against human KB cells assessed as cell growth inhibition after 48 hrs by neutral red dye based assay Cytotoxicity against human KB cells assessed as cell growth inhibition after 48 hrs by neutral red dye based assay	[PMID: 27769668]
KB	IC₅₀	1.7 μg/mL Compound: Doxorubicin	Cytotoxicity against human KB cells after 48 hrs by neutral red staining Cytotoxicity against human KB cells after 48 hrs by neutral red staining	[PMID: 15165136]
KB	IC₅₀	1.7 μM Compound: doxorubicin	Cytotoxicity against human KB cells by resazurin reduction assay Cytotoxicity against human KB cells by resazurin reduction assay	[PMID: 22482432]
KB	GI₅₀	1.72 μM Compound: ADR	Cytotoxicity against human KB cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human KB cells after 48 hrs by sulforhodamine B assay	[PMID: 18657979]
KB	IC₅₀	1.8 μM Compound: Doxorubicin	Concentration required to reduce proliferation of KB subclones passaged in the presence of doxorubicin 0.09 uM (KBMDR) cell line by 50% as determined by the MTT method Concentration required to reduce proliferation of KB subclones passaged in the presence of doxorubicin 0.09 uM (KBMDR) cell line by 50% as determined by the MTT method	[PMID: 14761187]
KB	IC₅₀	2.01 μM Compound: Dox	Cytotoxicity against human KB cells after 3 days by MTT assay Cytotoxicity against human KB cells after 3 days by MTT assay	[PMID: 21741833]
KB	IC₅₀	2.04 μM Compound: doxorubicin	Cytotoxicity against human KB cells after 48 hrs by neutral red assay Cytotoxicity against human KB cells after 48 hrs by neutral red assay	[PMID: 19879765]
KB	IC₅₀	2.19 x 10^-4 mM Compound: doxorubicin	Cytotoxicity against human KB cells by SRB assay Cytotoxicity against human KB cells by SRB assay	[PMID: 16933890]
KB	IC₅₀	2.6 μM Compound: Doxorubicin	Cytotoxicity against human KB cells assessed as cell growth inhibition after 48 hrs by neutral red assay Cytotoxicity against human KB cells assessed as cell growth inhibition after 48 hrs by neutral red assay	[PMID: 26005918]
KB	IC₅₀	2.6 μM Compound: doxorubicin	Cytotoxicity against human KB cells assessed as viable cells by neutral red dye method Cytotoxicity against human KB cells assessed as viable cells by neutral red dye method	[PMID: 22530813]
KB	IC₅₀	2.7 μg/mL Compound: doxorubicin	Cytotoxicity against multidrug-resistant human KB-VCR cells after 2 days by sulforhodamine B assay Cytotoxicity against multidrug-resistant human KB-VCR cells after 2 days by sulforhodamine B assay	[PMID: 17067159]
KB	IC₅₀	3 μM Compound: Doxorubicin	Concentration required to reduce proliferation of KB subclones passaged in the presence of etoposide 7 uM (KB7D) cell line by 50% as determined by the MTT method Concentration required to reduce proliferation of KB subclones passaged in the presence of etoposide 7 uM (KB7D) cell line by 50% as determined by the MTT method	[PMID: 14761187]
KB	IC₅₀	3 μM Compound: Doxorubicin	Cytotoxicity against human KB cells after 72 hrs by MTT assay Cytotoxicity against human KB cells after 72 hrs by MTT assay	[PMID: 19361894]
KB	IC₅₀	3.8 μM Compound: Doxorubicin	Cytotoxicity against human KB cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay Cytotoxicity against human KB cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay	[PMID: 27618204]
KB	IC₅₀	3.8 μM Compound: doxorubicin	Cytotoxicity against human KB cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against human KB cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]
KB	IC₅₀	300 nM Compound: Doxorubicin	Antiproliferative activity against human KB cells assessed as inhibition of cell viability after 72 hrs by MTT assay Antiproliferative activity against human KB cells assessed as inhibition of cell viability after 72 hrs by MTT assay	[PMID: 23360521]
KB	IC₅₀	4.3 μM Compound: Doxorubicin	Cytotoxicity against human KB cells after 24 hrs by WST assay Cytotoxicity against human KB cells after 24 hrs by WST assay	[PMID: 25881821]
KB	IC₅₀	40 nM Compound: doxorubicine	Cytotoxicity against human KB cells incubated for 72 hrs by MTS assay Cytotoxicity against human KB cells incubated for 72 hrs by MTS assay	[PMID: 23072299]
KB	IC₅₀	40 nM Compound: Doxorubicine	Cytotoxicity against human KB cells after 72 hrs by MTS assay Cytotoxicity against human KB cells after 72 hrs by MTS assay	[PMID: 21142180]
KB	IC₅₀	5.8 μM Compound: Doxorubicin	Antitumor activity against human KB cells after 48 hrs by SRB assay Antitumor activity against human KB cells after 48 hrs by SRB assay	[PMID: 20884091]
KB	IC₅₀	7.01 μM Compound: ADR (Adriamycin)	In vitro cytotoxicity using human epidermoid carcinoma (KB-A1) cells In vitro cytotoxicity using human epidermoid carcinoma (KB-A1) cells	10.1016/0960-894X(96)00457-X
KB	IC₅₀	7.01 μM Compound: Adriamycin (ADR)	In vitro cytotoxic activity was evaluated using the KB-3-1 resistant to adriamycin (ADR) subline KB-A1 In vitro cytotoxic activity was evaluated using the KB-3-1 resistant to adriamycin (ADR) subline KB-A1	[PMID: 12443763]
KB 3-1	IC₅₀	0.0004 μM Compound: Doxorubicin	Antiproliferative activity against human KB 3.1 cells after 72 hrs by MTT assay Antiproliferative activity against human KB 3.1 cells after 72 hrs by MTT assay	[PMID: 17949859]
KB 3-1	IC₅₀	0.01 μM Compound: Doxorubicin	Antiproliferative activity against human KB 3.1 cells after 24 hrs by MTT assay Antiproliferative activity against human KB 3.1 cells after 24 hrs by MTT assay	[PMID: 17949859]
KB 3-1	IC₅₀	0.02 μM Compound: Adriamycin	Cytotoxicity against human KB-3-1 cells after 72 hrs by MTT assay Cytotoxicity against human KB-3-1 cells after 72 hrs by MTT assay	[PMID: 21721528]
KB 3-1	IC₅₀	0.021 μM Compound: ADR (Adriamycin)	In vitro cytotoxicity using human epidermoid carcinoma (KB-3-1) cells In vitro cytotoxicity using human epidermoid carcinoma (KB-3-1) cells	10.1016/0960-894X(96)00457-X
KB 3-1	IC₅₀	0.021 μM Compound: Adriamycin (ADR)	In vitro cytotoxic activity was evaluated using the human epidermoid carcinoma cell line KB-3-1 In vitro cytotoxic activity was evaluated using the human epidermoid carcinoma cell line KB-3-1	[PMID: 12443763]
KB 3-1	IC₅₀	0.18 μM Compound: doxorubicin	Growth inhibition of human KB3-1 cells after 72 hrs by MTT assay Growth inhibition of human KB3-1 cells after 72 hrs by MTT assay	[PMID: 18313307]
KB 3-1	IC₅₀	0.37 μM Compound: Doxorubicin	Cytotoxicity against human KB-3-1 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human KB-3-1 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29501942]
KB 3-1	GI₅₀	0.74 μM Compound: Dox	Antiproliferative activity against human KB 3-1 cells incubated for 72 hrs and measured by MTT assay Antiproliferative activity against human KB 3-1 cells incubated for 72 hrs and measured by MTT assay	[PMID: 35973342]
KB 3-1	GI₅₀	0.98 μM Compound: Dox	Anticancer activity against human KB 3-1 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Anticancer activity against human KB 3-1 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35533562]
KB 3-1	IC₅₀	1.2 μM Compound: Doxorubicin	Cytotoxicity against human KB3-1 cells after 72 hrs by MTT assay Cytotoxicity against human KB3-1 cells after 72 hrs by MTT assay	[PMID: 21035234]
KB 3-1	GI₅₀	676.08 nM Compound: 21	Cytotoxicity against human KB 3.1 cells after 72 hrs by MTT assay Cytotoxicity against human KB 3.1 cells after 72 hrs by MTT assay	[PMID: 24502276]
KB-V1	GI₅₀	> 1000 nM Compound: 21	Cytotoxicity against vinblastine-resistant human KBV1 cells after 72 hrs by MTT assay Cytotoxicity against vinblastine-resistant human KBV1 cells after 72 hrs by MTT assay	[PMID: 24502276]
KB-V1	IC₅₀	31.98 μM Compound: doxorubicin	Growth inhibition of human KB V1 cells after 72 hrs by MTT assay Growth inhibition of human KB V1 cells after 72 hrs by MTT assay	[PMID: 18313307]
KB-V1	IC₅₀	4.7 μM Compound: Adriamycin	Cytotoxicity against vinblastine-selected human KBV1 cells after 72 hrs by MTT assay Cytotoxicity against vinblastine-selected human KBV1 cells after 72 hrs by MTT assay	[PMID: 21721528]
KCL-22	IC₅₀	1.8 μM Compound: Doxorubicin	Antiproliferative activity against human KCL22 cells after 48 hrs by MTT assay Antiproliferative activity against human KCL22 cells after 48 hrs by MTT assay	[PMID: 24941129]
Kelly	IC₅₀	0.18 μM Compound: Doxorubicin	Antiproliferative activity against human Kelly cells after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human Kelly cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 28273560]
Kelly	IC₅₀	6.57 μM Compound: Doxorubicin	Antiproliferative activity against human adriamycin-resistant Kelly cells after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human adriamycin-resistant Kelly cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 28273560]
KG-1a	IC₅₀	0.65 μg/mL Compound: DOX	Cytotoxicity against human KG1a cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human KG1a cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29274817]
KM12	IC₅₀	0.02 μM Compound: Doxorubicin	Antiproliferative activity against human KM12 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method Antiproliferative activity against human KM12 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	[PMID: 25937235]
KM12	ED₅₀	0.11 μg/mL Compound: adriamycin	Cytotoxicity against human KM12 cells after 48 hrs by SRB assay Cytotoxicity against human KM12 cells after 48 hrs by SRB assay	10.1021/np50124a024
KM12	GI₅₀	0.27 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human KM12 cells after 48 hrs by SRB assay Cytotoxicity against human KM12 cells after 48 hrs by SRB assay	[PMID: 23871905]
KM12	GI₅₀	0.27 μM Compound: Doxorubicin	Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
KM12	GI₅₀	0.27 μM Compound: Doxorubicin	Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
L02	IC₅₀	< 1 μM Compound: Doxorubicin	Cytotoxicity against human L02 cells assessed as reduction in cell growth by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell growth by MTT assay	[PMID: 36734533]
L02	IC₅₀	< 1 μM Compound: doxorubicin	Cytotoxicity against human L02 cells by SRB assay Cytotoxicity against human L02 cells by SRB assay	[PMID: 33847126]
L02	IC₅₀	< 1 μM Compound: Doxorubicin	Cytotoxicity against human L02 cells by SRB assay Cytotoxicity against human L02 cells by SRB assay	[PMID: 33371684]
L02	IC₅₀	> 100 μM Compound: Doxorubicin	Cytotoxicity against human L02 cells incubated for 48 hrs by MTT assay Cytotoxicity against human L02 cells incubated for 48 hrs by MTT assay	[PMID: 35367708]
L02	IC₅₀	> 50 μg/mL Compound: Doxorubicin	Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 34973507]
L02	IC₅₀	0.11 μM Compound: Doxorubicin	Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29702447]
L02	IC₅₀	0.14 μM Compound: ADM; DOX	Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31491611]
L02	IC₅₀	0.18 μM Compound: Dox	Antiproliferative activity against human L02 cells after 48 hrs by MTT assay Antiproliferative activity against human L02 cells after 48 hrs by MTT assay	[PMID: 35339100]
L02	IC₅₀	0.18 μM Compound: DOX	Cytotoxicity against human L02 cells measured after 72 hrs by MTT assay Cytotoxicity against human L02 cells measured after 72 hrs by MTT assay	[PMID: 35612499]
L02	IC₅₀	0.256 μM Compound: Dox	Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 96 hrs by MTT method Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 96 hrs by MTT method	[PMID: 34236840]
L02	IC₅₀	0.351 μM Compound: DOX	Cytotoxicity against human HL7702 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human HL7702 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34700239]
L02	IC₅₀	0.59 μM Compound: Doxorubicin	Cytotoxicity against human L02 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32438251]
L02	IC₅₀	0.7 μM Compound: DOX	Cytotoxicity against human LO2 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human LO2 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 31820976]
L02	IC₅₀	0.85 μM Compound: DOX	Antiproliferative activity against human L02 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human L02 cells after 72 hrs by CCK-8 assay	[PMID: 29597166]
L02	IC₅₀	0.88 μM Compound: DOX	Antiproliferative activity against human L02 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human L02 cells after 72 hrs by CCK-8 assay	[PMID: 29614418]
L02	IC₅₀	0.9 μM Compound: Doxorubicin	Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29789258]
L02	IC₅₀	0.94 μM Compound: Doxorubicin	Cytotoxicity against human HL7702 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HL7702 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32866757]
L02	IC₅₀	1.09 μM Compound: Doxorubicin	Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 35367708]
L02	IC₅₀	1.09 μM Compound: Doxorubicin	Cytotoxicity against human L02 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31404864]
L02	IC₅₀	1.1 μM Compound: Doxorubicin	Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay	[PMID: 32324401]
L02	IC₅₀	10.36 μM Compound: DOX	Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 30771605]
L02	IC₅₀	10.4 μM Compound: DOX	Cytotoxicity against human HL-7702 cells after 48 hrs by MTT assay Cytotoxicity against human HL-7702 cells after 48 hrs by MTT assay	[PMID: 28756264]
L02	IC₅₀	10.44 μM Compound: DOX	Cytotoxicity against human HL-7702 cells after 48 hrs by MTT assay Cytotoxicity against human HL-7702 cells after 48 hrs by MTT assay	[PMID: 31057738]
L02	IC₅₀	12.23 μM Compound: DOX	Cytotoxicity against human HL-7702 cells after 48 hrs by MTT assay Cytotoxicity against human HL-7702 cells after 48 hrs by MTT assay	[PMID: 27889629]
L02	IC₅₀	13.25 μM Compound: Doxorubicin	Cytotoxicity against human L02 cells by CCK8 assay Cytotoxicity against human L02 cells by CCK8 assay	[PMID: 29452840]
L02	IC₅₀	13.8 μM Compound: DOX	Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 32371335]
L02	IC₅₀	2.18 μM Compound: Doxorubicin	Cytotoxicity against human L02 cells measured after 48 hrs by MTT assay Cytotoxicity against human L02 cells measured after 48 hrs by MTT assay	[PMID: 32682198]
L02	IC₅₀	2.19 μM Compound: DOX	Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35341920]
L02	IC₅₀	2.24 μM Compound: DOX	Antiproliferative activity against human L02 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human L02 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32996316]
L02	IC₅₀	3.5 μM Compound: DOX	Cytotoxicity against human L02 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human L02 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 30846253]
L02	IC₅₀	3.6 μM Compound: DOX	Antiproliferative activity against human L02 cells after 72 hrs by MTT assay Antiproliferative activity against human L02 cells after 72 hrs by MTT assay	[PMID: 30398868]
L02	IC₅₀	53.3 nM Compound: Doxorubicin	Cytotoxicity against human L02 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human L02 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29886322]
L02	IC₅₀	6.93 μM Compound: DOX	Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29421568]
L02	IC₅₀	7.87 μM Compound: DOX	Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29909338]
L02	IC₅₀	8.6 μM Compound: Dox	Cytotoxicity against human L02 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability by MTT assay	[PMID: 31765156]
L1210	IC₅₀	< 0.1 μg/mL Compound: doxorubicin	Cytotoxicity against mouse L1210 cells assessed as cell viability by trypan blue assay Cytotoxicity against mouse L1210 cells assessed as cell viability by trypan blue assay	[PMID: 9051915]
L1210	IC₅₀	0.02 μg/mL Compound: doxorubicin	Growth inhibition of L1210 murine leukemia cells after 1 hr exposure in stem cell assay Growth inhibition of L1210 murine leukemia cells after 1 hr exposure in stem cell assay	[PMID: 8496904]
L1210	IC₅₀	0.025 μM Compound: Adriamycin (ADR)	In vitro cytotoxic activity was evaluated using the murine leukemia L1210 cell line In vitro cytotoxic activity was evaluated using the murine leukemia L1210 cell line	[PMID: 12443763]
L1210	IC₅₀	0.03 μM Compound: doxorubicine	Cytotoxicity against mouse L1210 cells after 48 hrs by MTT method Cytotoxicity against mouse L1210 cells after 48 hrs by MTT method	[PMID: 7561901]
L1210	IC₅₀	0.033 μM Compound: ADR (Adriamycin)	In vitro cytotoxicity using murine leukemia L1210 cells from american type culture collection. In vitro cytotoxicity using murine leukemia L1210 cells from american type culture collection.	10.1016/0960-894X(96)00457-X
L1210	IC₅₀	0.04 μg/mL Compound: doxorubicin	Growth inhibition of L1210 murine leukemia cells after 1 hr exposure in untreated control culture Growth inhibition of L1210 murine leukemia cells after 1 hr exposure in untreated control culture	[PMID: 8496904]
L1210	IC₅₀	0.04 μM Compound: DOX	Compound was tested for cytotoxicity on L1210 leukemia cell line using a proliferation assay (MTT reduction) Compound was tested for cytotoxicity on L1210 leukemia cell line using a proliferation assay (MTT reduction)	10.1016/S0960-894X(01)81264-6
L1210	IC₅₀	0.05 μM Compound: doxorubicin	Tested in vitro for inhibition after 48 hr exposure against murine leukemia cell line L1210 Tested in vitro for inhibition after 48 hr exposure against murine leukemia cell line L1210	[PMID: 7996544]
L1210	IC₅₀	0.06 μM Compound: doxorubicin	Tested in vitro for inhibition after 48 hr exposure against murine leukemia cell line L1210/L-PAM resistant to melphalan (L-PAM) Tested in vitro for inhibition after 48 hr exposure against murine leukemia cell line L1210/L-PAM resistant to melphalan (L-PAM)	[PMID: 7996544]
L1210	IC₅₀	0.2 μg/mL Compound: doxorubicin	Cytotoxicity against mouse L1210 cells by MTT assay Cytotoxicity against mouse L1210 cells by MTT assay	[PMID: 9051915]
L1210	IC₅₀	0.37 μM Compound: 1; Dox	Antiproliferative activity against mouse L1210 cells after 48 hrs by MTT assay Antiproliferative activity against mouse L1210 cells after 48 hrs by MTT assay	[PMID: 26633734]
L1210	IC₅₀	0.37 μM Compound: Dox	Cytotoxicity against mouse L1210 cells after 48 hrs by MTT assay Cytotoxicity against mouse L1210 cells after 48 hrs by MTT assay	[PMID: 21144624]
L1210	IC₅₀	0.4 mM Compound: Dox	Antiproliferative activity against mouse L1210 cells after 48 hrs by MTT assay Antiproliferative activity against mouse L1210 cells after 48 hrs by MTT assay	[PMID: 29459273]
L1210	IC₅₀	0.4 μM Compound: Dox	Antiproliferative activity in mouse L1210 cells after 48 hrs by MTT assay Antiproliferative activity in mouse L1210 cells after 48 hrs by MTT assay	[PMID: 30268824]
L1210	IC₅₀	0.4 μM Compound: 1; Dox	Antiproliferative activity against mouse L1210 cells after 48 hrs by MTT assay Antiproliferative activity against mouse L1210 cells after 48 hrs by MTT assay	[PMID: 26890118]
L1210	IC₅₀	0.4 μM Compound: 2	Antiproliferative activity against mouse L1210 cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against mouse L1210 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 33974416]
L1210	IC₅₀	0.4 μM Compound: 5	Antiproliferative activity against mouse L1210 cells after 72 hrs by MTT assay Antiproliferative activity against mouse L1210 cells after 72 hrs by MTT assay	[PMID: 29137865]
L1210	ED₅₀	0.58 μM Compound: 1	Concentration of drug necessary to reduce by 50% the incorporation of tritiated uridine in the RNA of actively growing L1210 cells. Concentration of drug necessary to reduce by 50% the incorporation of tritiated uridine in the RNA of actively growing L1210 cells.	[PMID: 7086816]
L1210	ED₅₀	0.67 μM Compound: Adriamycin	Inhibition of RNA synthesis in mouse L1210 cells after 3 hrs by [3H]uridine incorporation assay Inhibition of RNA synthesis in mouse L1210 cells after 3 hrs by [3H]uridine incorporation assay	[PMID: 915894]
L1210	ED₅₀	0.8 μM Compound: Adriamycin	Inhibition of DNA synthesis in mouse L1210 cells preincubated for 3 hrs followed by [3H]-thymidine addition measured after 1 hr by scintillation spectrometric analysis Inhibition of DNA synthesis in mouse L1210 cells preincubated for 3 hrs followed by [3H]-thymidine addition measured after 1 hr by scintillation spectrometric analysis	[PMID: 176359]
L1210	IC₅₀	0.9 μg/mL Compound: doxorubicin	Growth inhibition of L1210/ADM murine leukemia cells after 3 hr exposure in MTT assay Growth inhibition of L1210/ADM murine leukemia cells after 3 hr exposure in MTT assay	[PMID: 8496904]
L1210	ED₅₀	0.9 μM Compound: Adriamycin	Inhibition of RNA synthesis in mouse L1210 cells preincubated for 3 hrs followed by [3H]-uridine addition measured after 1 hr by scintillation spectrometric analysis Inhibition of RNA synthesis in mouse L1210 cells preincubated for 3 hrs followed by [3H]-uridine addition measured after 1 hr by scintillation spectrometric analysis	[PMID: 176359]
L1210	IC₅₀	1.2 μM Compound: Doxorubicin	Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
L1210	ED₅₀	1.5 μM Compound: Adriamycin	Inhibition of DNA synthesis in mouse L1210 cells after 3 hrs by [3H]thymidine incorporation assay Inhibition of DNA synthesis in mouse L1210 cells after 3 hrs by [3H]thymidine incorporation assay	[PMID: 915894]
L1210	ED₅₀	1.5 μM Compound: 1	Concentration of drug necessary to reduce by 50% the incorporation of tritiated thymidine in the DNA of actively growing L1210 cells Concentration of drug necessary to reduce by 50% the incorporation of tritiated thymidine in the DNA of actively growing L1210 cells	[PMID: 7086816]
L1210	IC₅₀	1.7 μM Compound: Doxorubicin	Antiproliferative activity against mouse L1210 cells after 24 to 72 hrs by MTT assay Antiproliferative activity against mouse L1210 cells after 24 to 72 hrs by MTT assay	[PMID: 30660827]
L1210	IC₅₀	182 nM Compound: doxorubicin	Antitumor activity against mouse L1210 cells assessed as inhibition of [3H]thymidine uptake after 48 hrs Antitumor activity against mouse L1210 cells assessed as inhibition of [3H]thymidine uptake after 48 hrs	[PMID: 18508273]
L1210	IC₅₀	34.3 nM Compound: Adriamycin	Inhibition of murine L1210 leukemia cell proliferation measured by the MTT assay Inhibition of murine L1210 leukemia cell proliferation measured by the MTT assay	[PMID: 10377224]
L1210	IC₅₀	35 nM Compound: Doxorubicin	Anti-tumor activity against murine L1210 sensitive cell line by using MTT assay Anti-tumor activity against murine L1210 sensitive cell line by using MTT assay	[PMID: 7699715]
L1210	IC₅₀	35 nM Compound: doxorubicin	Tested for inhibitory activity against murine cell line L12110, a strain sensitive to doxorubicin using MTT assay. Tested for inhibitory activity against murine cell line L12110, a strain sensitive to doxorubicin using MTT assay.	[PMID: 10956214]
L1210	IC₅₀	37.84 nM Compound: doxorubicin	Cytotoxicity was determined after 48 hr of continuous exposure against L1210 murine leukemia cells Cytotoxicity was determined after 48 hr of continuous exposure against L1210 murine leukemia cells	[PMID: 15115402]
L1210	IC₅₀	3884 nM Compound: Doxorubicin	Antitumor activity against murine L1210 resistant cell line by using MTT assay Antitumor activity against murine L1210 resistant cell line by using MTT assay	[PMID: 7699715]
L1210	IC₅₀	3884 nM Compound: doxorubicin	Tested for inhibitory activity against murine cell line L12110, a strain resistant to doxorubicin using MTT assay. Tested for inhibitory activity against murine cell line L12110, a strain resistant to doxorubicin using MTT assay.	[PMID: 10956214]
L1210	IC₅₀	39.56 nM Compound: doxorubicin	Cytotoxicity was determined after 48 hr of continuous exposure against L1210 murine leukemia cells,(cells resistant to melphalan (L-PAM) Cytotoxicity was determined after 48 hr of continuous exposure against L1210 murine leukemia cells,(cells resistant to melphalan (L-PAM)	[PMID: 15115402]
L1210	IC₅₀	4.2 μM Compound: Doxorubicin	Antiproliferative activity against mouse L1210 cells by MTT assay Antiproliferative activity against mouse L1210 cells by MTT assay	[PMID: 30660827]
L132	IC₅₀	0.01 μM Compound: Doxorubicin	Cytotoxicity against human L132 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human L132 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31883489]
L5178Y	IC₅₀	4.6 μM Compound: Doxorubicin	Cytotoxicity against mouse L5178Y cells by MTT assay Cytotoxicity against mouse L5178Y cells by MTT assay	[PMID: 30015071]
L929	IC₅₀	0.16 μM Compound: Doxorubicin	Cytotoxicity against mouse L929 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against mouse L929 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24530030]
L929	IC₅₀	0.22 μM Compound: DOXO	Antiproliferative activity against mouse L929 cells after 72 hrs by MTT assay Antiproliferative activity against mouse L929 cells after 72 hrs by MTT assay	[PMID: 28818447]
L929	IC₅₀	0.23 μM Compound: Doxorubicin	Cytotoxicity against NQO1-deficient mouse L929 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against NQO1-deficient mouse L929 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27341379]
L929	IC₅₀	0.23 μM Compound: DOXO	Cytotoxicity against mouse L929 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against mouse L929 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26142490]
L929	IC₅₀	0.66 μM Compound: Doxorubicin	Cytotoxicity against mouse L929 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against mouse L929 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 31836446]
L929	IC₅₀	1.72 μM Compound: Doxorubicin	Cytotoxicity against mouse L929 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against mouse L929 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 34778772]
L929	IC₅₀	1.72 μM Compound: DOX	Cytotoxicity against mouse L929 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against mouse L929 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29660689]
L929	IC₅₀	161 nM Compound: Doxorubicin	Antiproliferative activity against mouse L929 cells assessed as inhibition of cell viability after 72 hrs by XTT assay Antiproliferative activity against mouse L929 cells assessed as inhibition of cell viability after 72 hrs by XTT assay	[PMID: 23360521]
L929	IC₅₀	20 μM Compound: Dox	Cytotoxicity against mouse L929 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against mouse L929 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33479619]
L929	IC₅₀	325.9 μM Compound: DOX	Cytotoxicity against mouse L929 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Cytotoxicity against mouse L929 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 35859879]
L929	IC₅₀	7.5 μM Compound: Doxorubicin	Cytotoxicity against mouse L929 cells by MTT assay Cytotoxicity against mouse L929 cells by MTT assay	[PMID: 33766771]
LAMA-84	IC₅₀	0.74 μM Compound: DOXO	Cytotoxicity against human LAMA-84 cells assessed as cell viability after 48 hrs by alamar blue assay Cytotoxicity against human LAMA-84 cells assessed as cell viability after 48 hrs by alamar blue assay	[PMID: 21797280]
LAMA-84	IC₅₀	0.74 μM Compound: Doxorubicin	Cytotoxicity against human LAMA-84 cells after 48 hrs by Alamar blue assay Cytotoxicity against human LAMA-84 cells after 48 hrs by Alamar blue assay	[PMID: 20931970]
LAMA-84	IC₅₀	0.76 μM Compound: Doxorubicin	Cytotoxicity against human LAMA-84 cells after 48 hrs by Alamar Blue assay Cytotoxicity against human LAMA-84 cells after 48 hrs by Alamar Blue assay	[PMID: 19473028]
Lewis lung carcinoma cell line	ED₅₀	0.14 μg/mL Compound: Adriamycin	Cytotoxicity against mouse LLC cells after 48 hrs by SRB assay Cytotoxicity against mouse LLC cells after 48 hrs by SRB assay	[PMID: 14738384]
Lewis lung carcinoma cell line	IC₅₀	2.942 μM Compound: Doxorubicin	Cytotoxicity activity against mouse LLC cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against mouse LLC cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
Lewis lung carcinoma cell line	IC₅₀	207 nM Compound: doxorubicin	Antiproliferative activity against mouse LLC cells after 48 hrs by XTT assay Antiproliferative activity against mouse LLC cells after 48 hrs by XTT assay	[PMID: 22515366]
Lewis lung carcinoma cell line	IC₅₀	3.7 μg/mL Compound: Doxorubicin	Antiproliferative activity against mouse LLC cells after 24 hrs by MTS assay Antiproliferative activity against mouse LLC cells after 24 hrs by MTS assay	[PMID: 20813435]
Lewis lung carcinoma cell line	IC₅₀	8.04 μM Compound: Doxorubicin	Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay	[PMID: 18440233]
LLC-PK1	IC₅₀	< 0.55 μg/mL Compound: Doxorubicin	Cytotoxicity against pig LLC-PK1 cells after 48 hrs by neutral red assay Cytotoxicity against pig LLC-PK1 cells after 48 hrs by neutral red assay	[PMID: 19105653]
LLC-PK1	IC₅₀	< 1 μM Compound: Doxorubicin	Cytotoxicity against a pig LLC-PK1 cells after 48 hrs by Neutral Red assay Cytotoxicity against a pig LLC-PK1 cells after 48 hrs by Neutral Red assay	10.1039/C3MD00097D
LLC-PK1	IC₅₀	0.2 μM Compound: Adriamycin	Cytotoxicity against pig LLC-PK1 cells transfected with empty vector after 72 hrs by MTT assay Cytotoxicity against pig LLC-PK1 cells transfected with empty vector after 72 hrs by MTT assay	[PMID: 21721528]
LLC-PK1	IC₅₀	0.4 μg/mL Compound: Doxorubicin	Cytotoxicity against pig LLC-PK1 cells assessed as reduction in cell viability incubated for 48 hrs by neutral red based assay Cytotoxicity against pig LLC-PK1 cells assessed as reduction in cell viability incubated for 48 hrs by neutral red based assay	[PMID: 26371504]
LLC-PK1	IC₅₀	0.5 μg/mL Compound: Doxorubicin	Cytotoxicity against pig LLC-PK1 cells assessed as cell viability after 48 hrs by neutral red-based assay Cytotoxicity against pig LLC-PK1 cells assessed as cell viability after 48 hrs by neutral red-based assay	[PMID: 26469557]
LLC-PK1	IC₅₀	0.65 μg/mL Compound: DOX	Cytotoxicity against LLC-PK1 cells by neutral red method Cytotoxicity against LLC-PK1 cells by neutral red method	[PMID: 17181171]
LLC-PK1	IC₅₀	0.65 μg/mL Compound: doxorubicin	Cytotoxicity against LLC-PK1 cells by neutral red assay Cytotoxicity against LLC-PK1 cells by neutral red assay	[PMID: 17070063]
LLC-PK1	IC₅₀	0.75 μM Compound: Doxorubicin	Cytotoxicity against Sus scrofa (pig) LLC-PK1 cells by neutral red staining Cytotoxicity against Sus scrofa (pig) LLC-PK1 cells by neutral red staining	10.1007/s00044-011-9587-3
LLC-PK1	IC₅₀	1.3 μg/mL Compound: Doxorubicin	Cytotoxicity against pig LLC-PK1 cells assessed as reduction in viable cells measured after 48 hrs by neutral red dye-based method Cytotoxicity against pig LLC-PK1 cells assessed as reduction in viable cells measured after 48 hrs by neutral red dye-based method	[PMID: 27584935]
LLC-PK1	IC₅₀	1.6 μM Compound: doxorubicin	Cytotoxicity against pig LLC-PK1 cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against pig LLC-PK1 cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]
LLC-PK1	IC₅₀	17 μM Compound: Doxorubicin	Cytotoxicity against pig LLC-PK1 cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay Cytotoxicity against pig LLC-PK1 cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay	[PMID: 27618204]
LLC-PK1	IC₅₀	19.72 μM Compound: Adriamycin	Cytotoxicity against pig LLC-PK1 cells after 72 hrs by MTT assay Cytotoxicity against pig LLC-PK1 cells after 72 hrs by MTT assay	[PMID: 21721528]
LLC-PK1	IC₅₀	2.6 μM Compound: Doxorubicin	Cytotoxicity against pig LLC-PK1 cells assessed as cell growth inhibition after 48 hrs by neutral red assay Cytotoxicity against pig LLC-PK1 cells assessed as cell growth inhibition after 48 hrs by neutral red assay	[PMID: 26005918]
LN-18	IC₅₀	68.9 μM Compound: DOX	Antiproliferative activity against human LN18 cells after 48 hrs by MTT assay Antiproliferative activity against human LN18 cells after 48 hrs by MTT assay	[PMID: 27108400]
LN-229	IC₅₀	0.17 μM Compound: DOX	Antiproliferative activity against human LN-229 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Antiproliferative activity against human LN-229 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 34968902]
LN-229	IC₅₀	2 μg/mL Compound: Doxorubicin	Cytotoxicity against human LN-229 cells assessed as cell growth inhibition measured after 48 hrs Cytotoxicity against human LN-229 cells assessed as cell growth inhibition measured after 48 hrs	[PMID: 35526504]
LN-229	IC₅₀	2.25 μM Compound: Doxorubicin	Antiproliferative activity against human LN229 cells assessed as growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human LN229 cells assessed as growth inhibition incubated for 48 hrs by MTT assay	[PMID: 26253231]
LNCaP	IC₅₀	0.02 μM Compound: Doxorubicin	Antiproliferative activity against human LNCaP cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human LNCaP cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 34851111]
LNCaP	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay	[PMID: 28617598]
LNCaP	IC₅₀	0.154 μM Compound: Doxorubicin	Antiproliferative activity against human LNCAP cells assessed as inhibition of cell proliferation after 3 days by MTS assay Antiproliferative activity against human LNCAP cells assessed as inhibition of cell proliferation after 3 days by MTS assay	10.1039/C1MD00155H
LNCaP	IC₅₀	0.2 μM Compound: Doxorubicin	Antiproliferative activity against human LNCAP cells assessed as reduction in cell growth after 24 hrs by MTS assay Antiproliferative activity against human LNCAP cells assessed as reduction in cell growth after 24 hrs by MTS assay	[PMID: 25300820]
LNCaP	IC₅₀	0.2 μM Compound: DOX, Doxorubicin	Antiproliferative activity against human LNCAP cells after 72 hrs by MTT assay Antiproliferative activity against human LNCAP cells after 72 hrs by MTT assay	[PMID: 24095089]
LNCaP	IC₅₀	1.4 μM Compound: Doxorubicin	Cytotoxicity against human LNCAP cells by Alamar Blue assay Cytotoxicity against human LNCAP cells by Alamar Blue assay	[PMID: 27536968]
LNCaP	IC₅₀	1.66 μM Compound: Doxo	Cytotoxicity against androgen receptor-positive human LNCAP cells after 48 hrs by MTT assay Cytotoxicity against androgen receptor-positive human LNCAP cells after 48 hrs by MTT assay	[PMID: 21885273]
LNCaP	CC₅₀	106.6 nM Compound: Dox	Cytotoxicity against PSMA-positive human LNCAP cells by MTT assay Cytotoxicity against PSMA-positive human LNCAP cells by MTT assay	[PMID: 30904185]
LNCaP	IC₅₀	13.52 nM Compound: Doxorubicin	Cytotoxicity against human LNCAP cells after 72 hrs by Alamar Blue assay Cytotoxicity against human LNCAP cells after 72 hrs by Alamar Blue assay	[PMID: 24973030]
LNCaP	IC₅₀	16.02 μM Compound: Adriamycin	Cytotoxicity against human LNCAP cells after 24 hrs by MTT assay Cytotoxicity against human LNCAP cells after 24 hrs by MTT assay	[PMID: 22276650]
LNCaP	IC₅₀	2.76 μM Compound: Doxorubicin	Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay	[PMID: 22818039]
LNCaP	IC₅₀	4.6 μM Compound: adriamycin	Cytotoxicity against human LnCap cells after 4 days by MTT assay Cytotoxicity against human LnCap cells after 4 days by MTT assay	[PMID: 17194586]
LNCaP	GI₅₀	45.3 nM Compound: Doxorubicin	Cytotoxicity against human LNCaP cells assessed as inhibition of cell growth measured for 72 hrs by MTT assay Cytotoxicity against human LNCaP cells assessed as inhibition of cell growth measured for 72 hrs by MTT assay	[PMID: 31945642]
LNCaP	GI₅₀	45.3 nM Compound: DOX	Growth inhibition of human LNCaP cells after 72 hrs by MTT assay Growth inhibition of human LNCaP cells after 72 hrs by MTT assay	[PMID: 17181166]
LNCaP	IC₅₀	5.28 μg/mL Compound: Doxorubicin	Cytotoxicity against human LNCAP cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human LNCAP cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 28171832]
LNCaP	IC₅₀	6.3 μM Compound: Doxorubicin	Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay	[PMID: 21429743]
LNCaP	IC₅₀	6.46 μM Compound: Doxorubicin	Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay in absence of 10% FBS Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay in absence of 10% FBS	[PMID: 26298501]
LNCaP	IC₅₀	7.4 μM Compound: Doxorubicin	Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay in presence of 10% FBS Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay in presence of 10% FBS	[PMID: 26298501]
LNCaP	IC₅₀	7.42 μM Compound: Doxo	Cytotoxicity against androgen receptor-positive human LNCAP cells after 24 hrs by MTT assay Cytotoxicity against androgen receptor-positive human LNCAP cells after 24 hrs by MTT assay	[PMID: 21885273]
LNCaP C4-2	IC₅₀	> 32 nM Compound: Dox	Cytotoxicity against PSMA-positive human C4-2 cells by cellTiter 96 aqueous cell proliferation assay Cytotoxicity against PSMA-positive human C4-2 cells by cellTiter 96 aqueous cell proliferation assay	[PMID: 30904185]
LNCaP C4-2	IC₅₀	0.57 μM Compound: Doxorubicin	Cytotoxicity against human castration-resistant C4-2 cells after 48 hrs by MTT assay in presence of 10% FBS Cytotoxicity against human castration-resistant C4-2 cells after 48 hrs by MTT assay in presence of 10% FBS	[PMID: 26298501]
LNCaP C4-2	IC₅₀	1.02 μM Compound: Doxorubicin	Cytotoxicity against human castration-resistant C4-2 cells after 48 hrs by MTT assay in absence of 10% FBS Cytotoxicity against human castration-resistant C4-2 cells after 48 hrs by MTT assay in absence of 10% FBS	[PMID: 26298501]
LNCaP C4-2	IC₅₀	1.85 μM Compound: Doxorubicin	Cytotoxicity against human C4-2 cells after 48 hrs by MTT assay Cytotoxicity against human C4-2 cells after 48 hrs by MTT assay	[PMID: 27173802]
LNCaP C4-2	IC₅₀	2.5 μM Compound: Doxorubicin	Cytotoxicity against human C4-2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human C4-2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28254167]
LNCaP C4-2	IC₅₀	3.2 μM Compound: Doxorubicin	Cytotoxicity against human C4-2 cells after 48 hrs by MTT assay Cytotoxicity against human C4-2 cells after 48 hrs by MTT assay	[PMID: 29573910]
LNCaP C4-2	IC₅₀	3.25 μM Compound: Doxorubicin	Growth inhibition of human C4-2 cells after 48 hrs by MTT assay Growth inhibition of human C4-2 cells after 48 hrs by MTT assay	[PMID: 30072225]
LoVo	IC₅₀	> 400 μM Compound: Adriamycin	Cytotoxicity against human LoVo cells by SRB method Cytotoxicity against human LoVo cells by SRB method	[PMID: 18181575]
LoVo	IC₅₀	0.024 μM Compound: Doxorubicin (Dx)	Cytotoxicity activity on LoVo human adenocarcinoma cell line after 144 hr of drug exposure Cytotoxicity activity on LoVo human adenocarcinoma cell line after 144 hr of drug exposure	[PMID: 11806721]
LoVo	IC₅₀	0.04 μM Compound: Doxorubicin	Antiproliferative activity against human LoVo cells after 72 hrs by SRB assay Antiproliferative activity against human LoVo cells after 72 hrs by SRB assay	[PMID: 22944121]
LoVo	IC₅₀	0.057 μM Compound: doxorubicin	Tested in vitro for inhibition after 144 hr exposure against human colon carcinoma LoVo cell line Tested in vitro for inhibition after 144 hr exposure against human colon carcinoma LoVo cell line	[PMID: 7996544]
LoVo	IC₅₀	0.09 μM Compound: Doxorubicin	Cytotoxicity against human LoVo cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human LoVo cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 24858544]
LoVo	IC₅₀	0.09 μM Compound: Doxorubicin	Antiproliferative activity against human LoVo cells after 72 hrs Antiproliferative activity against human LoVo cells after 72 hrs	[PMID: 26163197]
LoVo	IC₅₀	0.092 μM Compound: Doxorubicin	Antiproliferative activity against human LoVo cells incubated for 72 hrs by sulforhodamine B assay Antiproliferative activity against human LoVo cells incubated for 72 hrs by sulforhodamine B assay	[PMID: 32432867]
LoVo	IC₅₀	0.11 μM Compound: Doxorubicin	Antiproliferative activity against human LoVo cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human LoVo cells after 72 hrs by sulforhodamine B assay	[PMID: 26496013]
LoVo	GI₅₀	0.12 μM Compound: Doxorubicin	Cytotoxicity against human LoVo cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human LoVo cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 25317694]
LoVo	IC₅₀	0.12 μM Compound: Doxorubicin	Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay	[PMID: 22027100]
LoVo	IC₅₀	0.15 μM Compound: Doxorubicin	Antiproliferative activity against human LoVo cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human LoVo cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 26639764]
LoVo	IC₅₀	0.15 μM Compound: doxorubicin	Antiproliferative activity against human LoVo cells assessed as growth inhibition after 72 hrs by SRB method Antiproliferative activity against human LoVo cells assessed as growth inhibition after 72 hrs by SRB method	[PMID: 25644674]
LoVo	IC₅₀	0.24 μM Compound: DX	Antiproliferative activity against human LoVo cells after 72 hrs by SRB assay Antiproliferative activity against human LoVo cells after 72 hrs by SRB assay	[PMID: 30025346]
LoVo	IC₅₀	0.3 μM Compound: Doxo	Antiproliferative activity against human LoVo cells after 72 hrs by SRB assay Antiproliferative activity against human LoVo cells after 72 hrs by SRB assay	[PMID: 29945793]
LoVo	IC₅₀	0.3 μM Compound: DOXO	Cytotoxicity against human LoVo cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human LoVo cells after 72 hrs by sulforhodamine B assay	[PMID: 28342398]
LoVo	IC₅₀	0.31 μM Compound: Doxorubicin	Cytostatic activity against human LoVo cells after 72 hrs by SRB assay Cytostatic activity against human LoVo cells after 72 hrs by SRB assay	[PMID: 21704523]
LoVo	IC₅₀	0.38 μM Compound: Doxorubicin	Cytotoxicity against human LoVo cells incubated for 72 hrs by MTT assay Cytotoxicity against human LoVo cells incubated for 72 hrs by MTT assay	[PMID: 23079523]
LoVo	IC₅₀	0.86 μM Compound: Doxorubicin (Dx)	Cytotoxicity activity on LoVo human adenocarcinoma cell line after 1 hr of drug exposure Cytotoxicity activity on LoVo human adenocarcinoma cell line after 1 hr of drug exposure	[PMID: 11806721]
LoVo	IC₅₀	1.46 μM Compound: doxorubicin	Cytotoxicity against human LoVo cells after 48 hrs by MTT assay Cytotoxicity against human LoVo cells after 48 hrs by MTT assay	[PMID: 18251492]
LoVo	IC₅₀	12.2 μM Compound: Doxorubicin	Cytostatic activity against doxorubicin-resistant human LoVo cells after 72 hrs by SRB assay Cytostatic activity against doxorubicin-resistant human LoVo cells after 72 hrs by SRB assay	[PMID: 21704523]
LoVo	IC₅₀	120 nM Compound: Doxorubicin	Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay	[PMID: 23117171]
LoVo	IC₅₀	120 nM Compound: doxorubicin	Antiproliferative activity against human LoVo cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human LoVo cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 21663319]
LoVo	IC₅₀	13.1 μM Compound: Doxorubicin	Antiproliferative activity against doxorubicin-resistant human LoVo cells after 72 hrs by MTT assay Antiproliferative activity against doxorubicin-resistant human LoVo cells after 72 hrs by MTT assay	[PMID: 22027100]
LoVo	IC₅₀	13150 nM Compound: doxorubicin	Antiproliferative activity against human doxorubicin-resistant LoVo cells overexpressing P-gp assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human doxorubicin-resistant LoVo cells overexpressing P-gp assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 21663319]
LoVo	IC₅₀	160 nM Compound: DX	Antiproliferative activity against human LoVo cells assessed as inhibition of proliferation after 72 hrs by SRB assay Antiproliferative activity against human LoVo cells assessed as inhibition of proliferation after 72 hrs by SRB assay	[PMID: 34116158]
LoVo	IC₅₀	2.4 μM Compound: Doxorubicin (Dx)	Cytotoxicity activity on LoVo/Dx human adenocarcinoma cell line after 144 hr of drug exposure Cytotoxicity activity on LoVo/Dx human adenocarcinoma cell line after 144 hr of drug exposure	[PMID: 11806721]
LoVo	IC₅₀	2.7 μM Compound: Adriamycin	Cytotoxicity against human LoVo cells by MTT colorimetric method Cytotoxicity against human LoVo cells by MTT colorimetric method	[PMID: 23043498]
LoVo	IC₅₀	22 nM Compound: DX	Cytotoxicity against human LoVo cancer cell line was determined after 1 hr Cytotoxicity against human LoVo cancer cell line was determined after 1 hr	[PMID: 15456268]
LoVo	IC₅₀	24.33 μM Compound: Doxorubicin	Anticancer activity against human LoVo cells after 48 hrs by SRB assay Anticancer activity against human LoVo cells after 48 hrs by SRB assay	[PMID: 24077528]
LoVo	IC₅₀	44.89 μM Compound: doxorubicin	Cytotoxicity against human multidrug resistant LoVo cells after 48 hrs by MTT assay Cytotoxicity against human multidrug resistant LoVo cells after 48 hrs by MTT assay	[PMID: 18251492]
LoVo	GI₅₀	5.48 mM Compound: Doxorubicin	Photocytotoxicity against human LoVo cells irradiated with 2.5 J cm^-2 ultraviolet radiation after 72 hrs by MTT assay Photocytotoxicity against human LoVo cells irradiated with 2.5 J cm^-2 ultraviolet radiation after 72 hrs by MTT assay	[PMID: 18023182]
LoVo	IC₅₀	7.6 μM Compound: doxorubicin	Tested in vitro for inhibition after 144 hr against human colon carcinoma LoVo/DX cell line resistant to Doxorubicin (DX) Tested in vitro for inhibition after 144 hr against human colon carcinoma LoVo/DX cell line resistant to Doxorubicin (DX)	[PMID: 7996544]
LoVo	IC₅₀	71 nM Compound: DX	Antiproliferative activity against human LoVo cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay Antiproliferative activity against human LoVo cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay	[PMID: 34592435]
LoVo	IC₅₀	78.3 nM Compound: Doxorubicin	Cytotoxicity against human LoVo cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human LoVo cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 30429975]
LoVo	GI₅₀	8.54 mM Compound: Doxorubicin	Photocytotoxicity against human LoVo cells irradiated with 1.25 J cm^-2 ultraviolet radiation after 72 hrs by MTT assay Photocytotoxicity against human LoVo cells irradiated with 1.25 J cm^-2 ultraviolet radiation after 72 hrs by MTT assay	[PMID: 18023182]
LoVo	IC₅₀	83.2 nM Compound: DX	Antiproliferative activity against human LoVo cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay Antiproliferative activity against human LoVo cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay	[PMID: 33611191]
LoVo	IC₅₀	9.7 μM Compound: Doxorubicin (Dx)	Cytotoxicity activity on LoVo/Dx human adenocarcinoma cell line after 1 hr of drug exposure Cytotoxicity activity on LoVo/Dx human adenocarcinoma cell line after 1 hr of drug exposure	[PMID: 11806721]
LoVo	IC₅₀	92 nM Compound: DOX; DX	Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 120 hrs by MTT assay Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 120 hrs by MTT assay	[PMID: 31653441]
LoVo	IC₅₀	92 nM Compound: Doxorubicin	Antiproliferative activity against human LoVo cells incubated for 72 hrs by SRB assay Antiproliferative activity against human LoVo cells incubated for 72 hrs by SRB assay	[PMID: 33465696]
LoVo	IC₅₀	95.6 nM Compound: Doxorubicin	Growth inhibition of human LoVo cells after 72 hrs by MTT assay Growth inhibition of human LoVo cells after 72 hrs by MTT assay	[PMID: 25025853]
LoVo	IC₅₀	95.6 nM Compound: doxorubicin	Cytotoxicity against human LoVo cells after 72 hrs by MTT assay Cytotoxicity against human LoVo cells after 72 hrs by MTT assay	[PMID: 23445496]
LOX IMVI	ED₅₀	0.001 μg/mL Compound: Doxorubicin	Cytotoxicity against human LOXIMVI cells by sulforhodamine B method Cytotoxicity against human LOXIMVI cells by sulforhodamine B method	[PMID: 12193011]
LOX IMVI	GI₅₀	0.07 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human LOXIMVI cells after 48 hrs by SRB assay Cytotoxicity against human LOXIMVI cells after 48 hrs by SRB assay	[PMID: 23871905]
LOX IMVI	GI₅₀	0.07 μM Compound: Doxorubicin	Growth inhibition of human LOXIMVI cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human LOXIMVI cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
LOX IMVI	GI₅₀	0.07 μM Compound: Doxorubicin	Growth inhibition of human LOXIMVI cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human LOXIMVI cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
LOX IMVI	ED₅₀	0.13 μg/mL Compound: adriamycin	Cytotoxicity against human LOXIMVI cells after 48 hrs by SRB assay Cytotoxicity against human LOXIMVI cells after 48 hrs by SRB assay	10.1021/np50124a024
LOX IMVI	IC₅₀	42 nM Compound: Doxorubicin	Cytotoxicity was determined in vitro in LOX cells (melanoma) of human tumor cell lines by using MTT assay Cytotoxicity was determined in vitro in LOX cells (melanoma) of human tumor cell lines by using MTT assay	[PMID: 7853331]
LS180	IC₅₀	0.04 μM Compound: Doxorubicin	Cytotoxicity against human LS180 cells after 72 hrs by MTT assay Cytotoxicity against human LS180 cells after 72 hrs by MTT assay	[PMID: 23827179]
LS180	IC₅₀	0.09 μM Compound: doxorubicin	Antiproliferative activity against human LS180 cells assessed as growth inhibition after 72 hrs by SRB method Antiproliferative activity against human LS180 cells assessed as growth inhibition after 72 hrs by SRB method	[PMID: 25644674]
LS180	IC₅₀	0.13 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) LS180 cells after 96 hr by MTT assay Cytotoxicity against Homo sapiens (human) LS180 cells after 96 hr by MTT assay	10.1007/s00044-010-9340-3
LS180	IC₅₀	0.18 μM Compound: Doxorubicin	Cytotoxicity against human LS180 cells at 50 uM by MTT reduction assay Cytotoxicity against human LS180 cells at 50 uM by MTT reduction assay	[PMID: 33276991]
LS180	IC₅₀	0.84 μM Compound: Doxorubicin	Cytotoxicity against human LS180 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human LS180 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 27371926]
LXFL 529	IC₅₀	< 0.052 μM Compound: adriamycin	Cytotoxicity against human LXFL529 cells after 24 hrs by CellTiter-BlueCell viability assay Cytotoxicity against human LXFL529 cells after 24 hrs by CellTiter-BlueCell viability assay	[PMID: 20545334]
LXFL 529	IC₅₀	0.04 μM Compound: Doxorubicin	Antiproliferative activity assessed in the LXFL529 human lung carcinoma using the BrdU Antiproliferative activity assessed in the LXFL529 human lung carcinoma using the BrdU	[PMID: 12459020]
Lymphocyte	GI₅₀	0.5 μM Compound: Dox	Cytotoxicity against mitogen activated human peripheral blood lymphocytes assessed as cell growth inhibition incubated for 48 hrs by MTT assay Cytotoxicity against mitogen activated human peripheral blood lymphocytes assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 35533562]
Lymphocyte	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human lymphocytes by colorimetric method Cytotoxicity against human lymphocytes by colorimetric method	[PMID: 24387625]
Lymphocyte	GI₅₀	2.9 μM Compound: Dox	Cytotoxicity against mitogen activated human peripheral blood lymphocytes assessed as cell growth inhibition incubated for 24 hrs by MTT assay Cytotoxicity against mitogen activated human peripheral blood lymphocytes assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 35533562]
Lymphocyte	IC₅₀	4.36 μM Compound: Dox	Cytotoxicity against human lymphocytes after 24 to 48 hrs by MTT assay Cytotoxicity against human lymphocytes after 24 to 48 hrs by MTT assay	[PMID: 29398445]
Lymphocyte	IC₅₀	9 μM Compound: Dox	Cytotoxicity against human lymphocytes after 72 hrs by MTT assay Cytotoxicity against human lymphocytes after 72 hrs by MTT assay	[PMID: 30659997]
M059J	IC₅₀	6.9 μM Compound: DXR	Cytotoxicity against human M059J cells assessed as cell growth inhibition after 24 hrs by XTT assay Cytotoxicity against human M059J cells assessed as cell growth inhibition after 24 hrs by XTT assay	[PMID: 26649907]
M14	IC₅₀	0.09 μM Compound: Doxorubicin	Antiproliferative activity against human M14 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human M14 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 34851111]
M14	IC₅₀	0.09 μM Compound: Doxorubicin	Cytotoxicity against human M14 cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay Cytotoxicity against human M14 cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay	[PMID: 28617598]
M14	GI₅₀	0.18 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human M14 cells after 48 hrs by SRB assay Cytotoxicity against human M14 cells after 48 hrs by SRB assay	[PMID: 23871905]
M14	GI₅₀	0.18 μM Compound: Doxorubicin	Growth inhibition of human M14 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human M14 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
M14	GI₅₀	0.18 μM Compound: Doxorubicin	Growth inhibition of human M14 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human M14 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
M14	IC₅₀	0.82 μM Compound: Doxorubicin	Cytotoxicity against human M14 cells after 24 hrs by SRB method Cytotoxicity against human M14 cells after 24 hrs by SRB method	[PMID: 18429610]
M14	IC₅₀	1 μM Compound: doxorubicin	Cytotoxicity against human M14 cells after 24 to 48 hrs by MTT assay Cytotoxicity against human M14 cells after 24 to 48 hrs by MTT assay	[PMID: 21058726]
M14	IC₅₀	3.4 μM Compound: DOX	Antiproliferative activity against human M14 cells after 72 hrs by MTT assay Antiproliferative activity against human M14 cells after 72 hrs by MTT assay	[PMID: 30429098]
Malme-3M	GI₅₀	0.1 μg/mL Compound: adriamycin	Cytotoxicity against human MALME-3M cells by MTT assay Cytotoxicity against human MALME-3M cells by MTT assay	[PMID: 11000028]
Malme-3M	GI₅₀	0.12 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human MALME-3M cells after 48 hrs by SRB assay Cytotoxicity against human MALME-3M cells after 48 hrs by SRB assay	[PMID: 23871905]
Malme-3M	GI₅₀	0.12 μM Compound: Doxorubicin	Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
Malme-3M	GI₅₀	0.12 μM Compound: Doxorubicin	Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MALME-3M cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
Malme-3M	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human MALME-3M cells after 72 hrs by MTT assay Cytotoxicity against human MALME-3M cells after 72 hrs by MTT assay	[PMID: 30783501]
MC-38	IC₅₀	10 nM Compound: adriamycin	Tested for cytotoxicity against C38 cell lines measured by MAT assay Tested for cytotoxicity against C38 cell lines measured by MAT assay	[PMID: 8057291]
MCF10	IC₅₀	0.16 μM Compound: Doxorubicin	Cytotoxicity against human MCF10 cells assessed as reduction in cell growth after 72 hrs by cell titer glo assay Cytotoxicity against human MCF10 cells assessed as reduction in cell growth after 72 hrs by cell titer glo assay	[PMID: 27080175]
MCF-10A	GI₅₀	> 5 μM Compound: Doxorubicin	Growth inhibition of human MCF10A cells after 72 hrs by celltiter-blue viability assay Growth inhibition of human MCF10A cells after 72 hrs by celltiter-blue viability assay	[PMID: 21348461]
MCF-10A	IC₅₀	0.033 μM Compound: Dox	Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability incubated for 96 hrs by MTT method Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability incubated for 96 hrs by MTT method	[PMID: 34236840]
MCF-10A	IC₅₀	0.047 μM Compound: Dox	Cytotoxicity against human MCF-10A assessed as cell viability under normoxia conditions measured after 72 hrs by MTT assay Cytotoxicity against human MCF-10A assessed as cell viability under normoxia conditions measured after 72 hrs by MTT assay	[PMID: 34902732]
MCF-10A	IC₅₀	0.051 μM Compound: Dox	Cytotoxicity against human MCF-10A assessed as cell viability under hypoxia conditions measured after 72 hrs by MTT assay Cytotoxicity against human MCF-10A assessed as cell viability under hypoxia conditions measured after 72 hrs by MTT assay	[PMID: 34902732]
MCF-10A	IC₅₀	0.06 μM Compound: Doxorubicin	Cytotoxicity against human MCF10A cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF10A cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28327308]
MCF-10A	IC₅₀	0.15 μM Compound: DOX	Antiproliferative activity against human MCF10A cells after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human MCF10A cells after 72 hrs by CellTiter-Glo assay	[PMID: 27769032]
MCF-10A	IC₅₀	0.18 μM Compound: Doxorubicin	Cytotoxicity against human MCF10A cells after 48 hrs by MTT assay Cytotoxicity against human MCF10A cells after 48 hrs by MTT assay	[PMID: 20064676]
MCF-10A	IC₅₀	0.31 μM Compound: Doxorubicin	Cytotoxicity against human MCF-10A cells after 3 days by microplate reader analysis Cytotoxicity against human MCF-10A cells after 3 days by microplate reader analysis	[PMID: 32705864]
MCF-10A	IC₅₀	0.4 μM Compound: Doxorubicin	Cytotoxicity against human MCF10A cells after 24 hrs by XTT assay Cytotoxicity against human MCF10A cells after 24 hrs by XTT assay	[PMID: 27227682]
MCF-10A	IC₅₀	0.49 μM Compound: Doxorubicin	Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 34315044]
MCF-10A	IC₅₀	0.58 μM Compound: DX	Antiproliferative activity against human MCF10A cells after 72 hrs by SRB assay Antiproliferative activity against human MCF10A cells after 72 hrs by SRB assay	[PMID: 30025346]
MCF-10A	IC₅₀	0.75 μM Compound: Doxorubicin	Cytotoxicity against human MCF10A cells after 24 hrs by MTT assay Cytotoxicity against human MCF10A cells after 24 hrs by MTT assay	[PMID: 20064676]
MCF-10A	IC₅₀	0.93 μM Compound: Dox	Cytotoxicity against human MCF10A cells after 2 days Cytotoxicity against human MCF10A cells after 2 days	[PMID: 24904965]
MCF-10A	IC₅₀	1.2 μM Compound: Doxorubicin	Cytotoxicity against human MCF10A cells assessed as inhibition of metabolic activity after 48 hrs by MTT assay Cytotoxicity against human MCF10A cells assessed as inhibition of metabolic activity after 48 hrs by MTT assay	[PMID: 27187858]
MCF-10A	IC₅₀	1.2 μM Compound: Dox	Cytotoxicity against human MCF10A cells after 48 hrs by MTT assay Cytotoxicity against human MCF10A cells after 48 hrs by MTT assay	[PMID: 24028446]
MCF-10A	IC₅₀	1.23 μM Compound: Adriamycin	Cytotoxicity against human MCF10A cells after 2 days by CCK8 assay Cytotoxicity against human MCF10A cells after 2 days by CCK8 assay	[PMID: 26361737]
MCF-10A	IC₅₀	1.37 μM Compound: Dox	Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 33852973]
MCF-10A	IC₅₀	1.54 μM Compound: Doxorubicin	Cytotoxicity against human MCF10A cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MCF10A cells after 72 hrs by sulforhodamine B assay	[PMID: 30081238]
MCF-10A	IC₅₀	12.51 μM Compound: Dox	Cytotoxicity against human MCF10A after 72 hrs by MTT assay Cytotoxicity against human MCF10A after 72 hrs by MTT assay	[PMID: 28549734]
MCF-10A	CC₅₀	13.9 μM Compound: Doxorubicin	Cytotoxicity against human MCF10A cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MCF10A cells assessed as reduction in cell viability by MTT assay	[PMID: 33784602]
MCF-10A	IC₅₀	19 μM Compound: Doxorubicin	Cytotoxicity against human MCF10A cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human MCF10A cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 34791873]
MCF-10A	IC₅₀	2.64 μM Compound: Dox	Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 33713977]
MCF-10A	IC₅₀	2.8 μM Compound: Doxorubicin	Cytotoxicity against human MCF10A cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF10A cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 24044895]
MCF-10A	IC₅₀	24 μM Compound: Doxo	Cytotoxicity against human MCF10A cells after 48 hrs by MTT assay Cytotoxicity against human MCF10A cells after 48 hrs by MTT assay	[PMID: 25563891]
MCF-10A	IC₅₀	31 μM Compound: Doxo	Cytotoxicity against human MCF10A cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF10A cells assessed as cell viability after 48 hrs by MTT assay	10.1039/C2MD20302B
MCF7	GI₅₀	< 0.025 μg/mL Compound: DOX; Doxo	Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 26859070]
MCF7	GI₅₀	< 0.046 μM Compound: Dox	Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26454648]
MCF7	GI₅₀	< 0.046 μM Compound: Doxorubicin	Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay	[PMID: 33214037]
MCF7	GI₅₀	< 0.1 μM Compound: ADR	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 20673627]
MCF7	GI₅₀	< 0.1 μM Compound: ADR	Cytotoxicity against human MCF7 cells by SRB assay Cytotoxicity against human MCF7 cells by SRB assay	10.1007/s00044-013-0855-2
MCF7	GI₅₀	< 0.1 μM Compound: ADR	Anticancer activity against human MCF7 cells by SRB method Anticancer activity against human MCF7 cells by SRB method	[PMID: 22104151]
MCF7	IC₅₀	< 0.26 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 96 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 96 hrs by SRB assay	[PMID: 33276991]
MCF7	IC₅₀	< 1 μM Compound: doxorubicin	Cytotoxicity against human MCF7 cells by SRB assay Cytotoxicity against human MCF7 cells by SRB assay	[PMID: 33847126]
MCF7	IC₅₀	> 10 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth after 24 hrs by MTS assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth after 24 hrs by MTS assay	[PMID: 25300820]
MCF7	IC₅₀	> 100 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell proliferation after 24 hr by MTT assay Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell proliferation after 24 hr by MTT assay	10.1007/s00044-012-0436-9
MCF7	IC₅₀	> 20 μM Compound: DOX	Cytotoxicity against human MCF7 cells after 24 hrs by XTT assay Cytotoxicity against human MCF7 cells after 24 hrs by XTT assay	[PMID: 24900344]
MCF7	GI₅₀	> 5 μM Compound: Doxorubicin	Growth inhibition of human MCF7 cells after 72 hrs by celltiter-blue viability assay Growth inhibition of human MCF7 cells after 72 hrs by celltiter-blue viability assay	[PMID: 21348461]
MCF7	IC₅₀	> 60 μM Compound: DOX	Cytotoxicity against human MCF7 cells after 24 hrs by XTT assay Cytotoxicity against human MCF7 cells after 24 hrs by XTT assay	[PMID: 24900668]
MCF7	IC₅₀	0.0007 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 17949859]
MCF7	IC₅₀	0.0039 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 24 hrs by MTS assay Cytotoxicity against human MCF7 cells after 24 hrs by MTS assay	[PMID: 30289713]
MCF7	IC₅₀	0.005 ug Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 48 hrs by SRB assay	[PMID: 27393950]
MCF7	IC₅₀	0.009 mM Compound: DOX	Cytotoxicity against human MCF7 cells after 3 days by MTT assay Cytotoxicity against human MCF7 cells after 3 days by MTT assay	[PMID: 22520152]
MCF7	IC₅₀	0.009 μM Compound: ADR	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 96 hrs by SRB assay	[PMID: 25817774]
MCF7	IC₅₀	0.0093 μM Compound: Doxorubicin	Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 33940466]
MCF7	IC₅₀	0.01 μM Compound: DOX	Antiproliferative activity against human MCF7 cells measured after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells measured after 72 hrs by MTT assay	[PMID: 31431364]
MCF7	IC₅₀	0.01 μM Compound: Doxorubicin	Inhibitory activity against MCF-7 wt cell line using MTT assay (ER+,pgR+,wildtype p53) Inhibitory activity against MCF-7 wt cell line using MTT assay (ER+,pgR+,wildtype p53)	[PMID: 10780913]
MCF7	GI₅₀	0.013 μM Compound: Doxorubicin	Tested for in vitro concentration required to inhibit growth by 50% against MCF-7 human breast cancer cell line cell line Tested for in vitro concentration required to inhibit growth by 50% against MCF-7 human breast cancer cell line cell line	[PMID: 11755363]
MCF7	IC₅₀	0.015 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31546197]
MCF7	IC₅₀	0.018 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 17949859]
MCF7	IC₅₀	0.02 μM Compound: Dox	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 23802716]
MCF7	GI₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 20675130]
MCF7	GI₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 27889456]
MCF7	IC₅₀	0.02 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 27448912]
MCF7	IC₅₀	0.02 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 24780599]
MCF7	GI₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 23831811]
MCF7	GI₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 21115210]
MCF7	IC₅₀	0.022 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 24 hrs by SRB method Cytotoxicity against human MCF7 cells after 24 hrs by SRB method	[PMID: 18429610]
MCF7	IC₅₀	0.0234 μM Compound: DOX	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 30826510]
MCF7	ED₅₀	0.03 μg/mL Compound: Adriamycin	Cytotoxicity against human MCF7 cells after 24 hrs by SRB assay Cytotoxicity against human MCF7 cells after 24 hrs by SRB assay	[PMID: 20850305]
MCF7	GI₅₀	0.03 μg/mL Compound: DOX	Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 21041092]
MCF7	GI₅₀	0.03 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 23871905]
MCF7	IC₅₀	0.031 μM Compound: DOX	Antitumor activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antitumor activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 34319100]
MCF7	IC₅₀	0.035 μM Compound: DOX	Cytotoxicity against human MCF-7 assessed as reduction in cell viability by SRB assay Cytotoxicity against human MCF-7 assessed as reduction in cell viability by SRB assay	[PMID: 33130288]
MCF7	GI₅₀	0.038 μg/mL Compound: DOX	Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 25062010]
MCF7	IC₅₀	0.038 μM Compound: Dox	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 34116381]
MCF7	IC₅₀	0.04 ug/L Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by SRB assay	[PMID: 26420384]
MCF7	IC₅₀	0.04 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 20207049]
MCF7	IC₅₀	0.04 μM Compound: DOX	Antitumor activity against human MCF7 cells after 72 hrs by MTT assay Antitumor activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 17935309]
MCF7	GI₅₀	0.04 μM Compound: doxorubicin	Growth inhibition of Homo sapiens (human) MCF7 cells after 48 hr by SRB assay Growth inhibition of Homo sapiens (human) MCF7 cells after 48 hr by SRB assay	10.1007/s00044-012-0213-9
MCF7	GI₅₀	0.04 μM Compound: Doxorubicin	Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
MCF7	GI₅₀	0.04 μM Compound: Doxorubicin	Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
MCF7	IC₅₀	0.04 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	10.1007/s00044-013-0712-3
MCF7	IC₅₀	0.04 μM Compound: DOX	Antiproliferative activity against human MCF7 cells after 72 hrs by Sulforhodamine B-stain assay Antiproliferative activity against human MCF7 cells after 72 hrs by Sulforhodamine B-stain assay	[PMID: 27484508]
MCF7	GI₅₀	0.04 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by sulforhodamine B assay Cytotoxicity against human MCF7 cells by sulforhodamine B assay	[PMID: 20413188]
MCF7	IC₅₀	0.04 μM Compound: Doxorubicin	Antiproliferative activity assessed in the MCF-7 human mamma carcinoma using the BrdU Antiproliferative activity assessed in the MCF-7 human mamma carcinoma using the BrdU	[PMID: 12459020]
MCF7	IC₅₀	0.042 μg/mL Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 34973507]
MCF7	GI₅₀	0.0428 μM Compound: Doxorubicin	Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 21435889]
MCF7	GI₅₀	0.043 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 15620248]
MCF7	IC₅₀	0.05 μM Compound: Doxo	Antiproliferative activity against human MCF7 cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
MCF7	IC₅₀	0.05 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay	[PMID: 19053767]
MCF7	IC₅₀	0.05 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by neutral red dye based assay Cytotoxicity against human MCF7 cells after 48 hrs by neutral red dye based assay	[PMID: 29317147]
MCF7	IC₅₀	0.06 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 22414612]
MCF7	IC₅₀	0.06 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition incubated for 72 hrs by MTT assay	[PMID: 26280922]
MCF7	IC₅₀	0.06 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 22555152]
MCF7	IC₅₀	0.06 μM Compound: doxorubicin	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 18164206]
MCF7	IC₅₀	0.06 μM Compound: Doxorubicin	Cytotoxicity activity against human MCF7 cells incubated for 48 hrs by SRB assay Cytotoxicity activity against human MCF7 cells incubated for 48 hrs by SRB assay	[PMID: 34119830]
MCF7	IC₅₀	0.063 mM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by neutral red assay Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by neutral red assay	10.1007/s00044-011-9761-7
MCF7	IC₅₀	0.065 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by CCK8 assay Cytotoxicity against human MCF7 cells after 48 hrs by CCK8 assay	[PMID: 23777898]
MCF7	GI₅₀	0.07 μg/mL Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 26561866]
MCF7	IC₅₀	0.07 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 17190470]
MCF7	IC₅₀	0.07 μM Compound: doxorubicin	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 17286429]
MCF7	IC₅₀	0.07 μM Compound: doxorubicin	Antiproliferative activity against human MCF7 cells by MTT assay Antiproliferative activity against human MCF7 cells by MTT assay	[PMID: 18247573]
MCF7	IC₅₀	0.07 μM Compound: doxorubicin	Antiproliferative activity against human MCF7 cells by MTT assay Antiproliferative activity against human MCF7 cells by MTT assay	[PMID: 18052326]
MCF7	IC₅₀	0.07 μM Compound: doxorubicin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 15921417]
MCF7	IC₅₀	0.07 μM Compound: doxorubicin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 15620238]
MCF7	IC₅₀	0.07 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells assessed as cell viability after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as cell viability after 48 hrs by SRB assay	[PMID: 26947606]
MCF7	IC₅₀	0.07 μM Compound: Doxorubicine	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)	[PMID: 33422908]
MCF7	GI₅₀	0.07 μM Compound: Dox	Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay	[PMID: 28505535]
MCF7	GI₅₀	0.073 μM Compound: DOXO	Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 31247374]
MCF7	IC₅₀	0.077 μM Compound: Adriamycin	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 24684844]
MCF7	IC₅₀	0.0795 μM Compound: Dox	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by MTT method Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by MTT method	[PMID: 34236840]
MCF7	IC₅₀	0.09 μM Compound: Doxorubicin	Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33477020]
MCF7	IC₅₀	0.092 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by sulforhodamine B assay	[PMID: 32432867]
MCF7	IC₅₀	0.097 μM Compound: DOX	Cytotoxicity against human MCF7 cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human MCF7 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
MCF7	ED₅₀	0.1 μg/mL Compound: doxorubicin	Cytotoxicity against human MCF7 cells after 3 days by MTT assay Cytotoxicity against human MCF7 cells after 3 days by MTT assay	[PMID: 16252910]
MCF7	IC₅₀	0.1 μM Compound: Doxo	Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay	10.1039/C2MD20302B
MCF7	IC₅₀	0.1 μM Compound: Dox	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30659997]
MCF7	GI₅₀	0.1 μM Compound: Adriamycin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 19405508]
MCF7	IC₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs	[PMID: 34601029]
MCF7	IC₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as intracellular ATP level after 72 hrs by luminometry Cytotoxicity against human MCF7 cells assessed as intracellular ATP level after 72 hrs by luminometry	[PMID: 21354800]
MCF7	IC₅₀	0.112 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 26840362]
MCF7	ED₅₀	0.12 μg/mL Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 17315955]
MCF7	IC₅₀	0.12 μg/mL Compound: (20) adriamycin	In vitro cytotoxicity of compound against MCF7, human breast cancer was defined by microculture tetrazolium assay In vitro cytotoxicity of compound against MCF7, human breast cancer was defined by microculture tetrazolium assay	[PMID: 12620075]
MCF7	IC₅₀	0.12 μM Compound: DOX	Antiproliferative activity against ER positive human MCF7 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Antiproliferative activity against ER positive human MCF7 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 25737400]
MCF7	IC₅₀	0.12 μM Compound: Doxo	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 25563891]
MCF7	IC₅₀	0.12 μM Compound: Adriamycin	Cytotoxicity against human MCF7 cells by SRB assay Cytotoxicity against human MCF7 cells by SRB assay	[PMID: 19341288]
MCF7	IC₅₀	0.12 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 24 hrs by XTT assay Cytotoxicity against human MCF7 cells after 24 hrs by XTT assay	[PMID: 27227682]
MCF7	IC₅₀	0.12 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay	[PMID: 32755677]
MCF7	ED₅₀	0.129 μg/mL Compound: adriamycin	Cytotoxicity against human MCF7 cells after 7 days by MTT assay Cytotoxicity against human MCF7 cells after 7 days by MTT assay	[PMID: 10514307]
MCF7	IC₅₀	0.13 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 27496212]
MCF7	IC₅₀	0.13 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells assessed as growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as growth inhibition incubated for 48 hrs by MTT assay	[PMID: 26253231]
MCF7	IC₅₀	0.13 μM Compound: Doxorubicin	Growth inhibition of human MCF7 cells incubated for 48 hrs by MTT assay Growth inhibition of human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 27080187]
MCF7	IC₅₀	0.13 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24530030]
MCF7	IC₅₀	0.13 μM Compound: doxorubicin	Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay	[PMID: 18513976]
MCF7	GI₅₀	0.13 μM Compound: ADR	Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 21737288]
MCF7	IC₅₀	0.137 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells at 50 uM by MTT reduction assay Cytotoxicity against human MCF7 cells at 50 uM by MTT reduction assay	[PMID: 33276991]
MCF7	IC₅₀	0.14 μM Compound: DOX	Cytotoxicity against against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30340899]
MCF7	IC₅₀	0.14 μM Compound: Dox	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 27423028]
MCF7	IC₅₀	0.14 μM Compound: Doxorubicine	Inhibitory activity against MCF-7 breast cell line using sulforhodamine B (SRB) protein assay Inhibitory activity against MCF-7 breast cell line using sulforhodamine B (SRB) protein assay	[PMID: 12039588]
MCF7	IC₅₀	0.142 μM Compound: DOX	Cytotoxicity against human MCF7 cells after 24 to 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 to 72 hrs by MTT assay	[PMID: 29032034]
MCF7	IC₅₀	0.15 μg/mL Compound: Doxorubicin	In vitro cytotoxic activity against human breast cancer cells (MCF-7) by using SRB assay after 72 hr of drug exposure In vitro cytotoxic activity against human breast cancer cells (MCF-7) by using SRB assay after 72 hr of drug exposure	10.1016/0960-894X(96)00156-4
MCF7	GI₅₀	0.15 μM Compound: DOX	Growth inhibition of human MCF7 cells incubated for 72 hrs by MTT assay Growth inhibition of human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 31176097]
MCF7	IC₅₀	0.15 μM Compound: ADM	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30344912]
MCF7	GI₅₀	0.15 μM Compound: DOX	Growth inhibition of human MCF7 cells after 72 hrs by MTT assay Growth inhibition of human MCF7 cells after 72 hrs by MTT assay	[PMID: 30336023]
MCF7	GI₅₀	0.15 μM Compound: DOX	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29705710]
MCF7	IC₅₀	0.15 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28782948]
MCF7	IC₅₀	0.16 μg/mL Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 21708464]
MCF7	IC₅₀	0.16 μg/mL Compound: adriamycin	Cytotoxicity against human MCF7 cells by SRB assay Cytotoxicity against human MCF7 cells by SRB assay	[PMID: 17981473]
MCF7	IC₅₀	0.16 μM Compound: DOX	Antiproliferative activity against human MCF7 cells after 48 hrs by CellTiter-Glo assay Antiproliferative activity against human MCF7 cells after 48 hrs by CellTiter-Glo assay	[PMID: 27769032]
MCF7	IC₅₀	0.16 μM Compound: DOX	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 26386603]
MCF7	IC₅₀	0.16 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth after 48 hrs by SRB assay	[PMID: 34077833]
MCF7	IC₅₀	0.16 μM Compound: Doxorubicin	Toxicity in human MCF7 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay Toxicity in human MCF7 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay	[PMID: 31753515]
MCF7	IC₅₀	0.17 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 31836446]
MCF7	GI₅₀	0.17 μM Compound: ADR	Growth inhibition of human MCF7 cells after 48 hrs by SRB assay Growth inhibition of human MCF7 cells after 48 hrs by SRB assay	[PMID: 20031423]
MCF7	GI₅₀	0.17 μM Compound: ADR	Growth inhibition of human MCF7 cells by SRB assay Growth inhibition of human MCF7 cells by SRB assay	[PMID: 22361684]
MCF7	GI₅₀	0.17 μM Compound: ADR	Anticancer activity against human MCF7 cells by SRB method Anticancer activity against human MCF7 cells by SRB method	[PMID: 21676506]
MCF7	GI₅₀	0.17 μM Compound: ADR	Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 23849207]
MCF7	GI₅₀	0.17 μM Compound: ADR	Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 22364746]
MCF7	GI₅₀	0.17 μM Compound: ADR	Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 18657979]
MCF7	GI₅₀	0.17 μM Compound: ADR	Cytotoxicity against human MCF7 cells after 24 hrs by WST-1 assay Cytotoxicity against human MCF7 cells after 24 hrs by WST-1 assay	[PMID: 20732817]
MCF7	IC₅₀	0.18 μg/mL Compound: DOX	Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 24 to 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 24 to 48 hrs by SRB assay	[PMID: 24012683]
MCF7	IC₅₀	0.18 μM Compound: ADM; DOX	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31491611]
MCF7	GI₅₀	0.18 μM Compound: adriamycin	Cytotoxicity against human MCF7 cells after 24 hrs by SRB method Cytotoxicity against human MCF7 cells after 24 hrs by SRB method	[PMID: 18262426]
MCF7	GI₅₀	0.18 μM Compound: ADR, Adriamycin	Growth inhibition of human MCF7 cells by SRB method Growth inhibition of human MCF7 cells by SRB method	[PMID: 18207392]
MCF7	IC₅₀	0.18 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by resazurin dye-based fluorescence assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by resazurin dye-based fluorescence assay	[PMID: 32663024]
MCF7	IC₅₀	0.19 μM Compound: DOX	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 21496972]
MCF7	IC₅₀	0.19 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 44 hrs by SRB assay Cytotoxicity against human MCF7 cells after 44 hrs by SRB assay	10.1007/s00044-013-0788-9
MCF7	IC₅₀	0.2 μg/mL Compound: doxorubicin	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 15787450]
MCF7	IC₅₀	0.2 μg/mL Compound: doxorubicin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 18973388]
MCF7	GI₅₀	0.2 μg/mL Compound: adriamycin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 11000028]
MCF7	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 26963142]
MCF7	IC₅₀	0.2 μM Compound: DOX	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 6 days by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 6 days by MTT assay	[PMID: 32653698]
MCF7	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity activity against human MCF7 assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity activity against human MCF7 assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 33340938]
MCF7	IC₅₀	0.2 μM Compound: DOX	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth after 72 hrs by MTT assay	[PMID: 30746062]
MCF7	IC₅₀	0.2 μM Compound: DOX	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28427016]
MCF7	IC₅₀	0.2 μM Compound: DOX	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 28135634]
MCF7	IC₅₀	0.2 μM Compound: Dox	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27231128]
MCF7	IC₅₀	0.2 μM Compound: DOX	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 26720155]
MCF7	IC₅₀	0.2 μM Compound: DOX	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 25259516]
MCF7	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 23827179]
MCF7	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 34332400]
MCF7	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 28641156]
MCF7	EC₅₀	0.2 μM Compound: doxorubicin	Cytotoxicity against human MCF7 cells after 72 hrs Cytotoxicity against human MCF7 cells after 72 hrs	[PMID: 17378530]
MCF7	IC₅₀	0.211 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) MCF7 cells after 96 hr by MTT assay Cytotoxicity against Homo sapiens (human) MCF7 cells after 96 hr by MTT assay	10.1007/s00044-010-9340-3
MCF7	IC₅₀	0.22 μM Compound: DOX	Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 30106296]
MCF7	IC₅₀	0.22 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT reduction assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT reduction assay	[PMID: 28551177]
MCF7	IC₅₀	0.23 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 4 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 4 hrs by MTT assay	[PMID: 30773423]
MCF7	IC₅₀	0.24 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 72 hrs by resazurin/resorufin-based fluorescence assay Cytotoxicity against human MCF7 cells after 72 hrs by resazurin/resorufin-based fluorescence assay	[PMID: 23600925]
MCF7	IC₅₀	0.25 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36242992]
MCF7	IC₅₀	0.25 μM Compound: 1, Dox	Tumor killing activity in MCF7 breast cancer cells by MTT assay Tumor killing activity in MCF7 breast cancer cells by MTT assay	[PMID: 16168650]
MCF7	IC₅₀	0.25 μM Compound: ADR, ADM	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 21761866]
MCF7	GI₅₀	0.25 μM Compound: Doxorubicin	Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 33477019]
MCF7	IC₅₀	0.26 μM Compound: DX	Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 30025346]
MCF7	IC₅₀	0.27 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay	[PMID: 36691388]
MCF7	IC₅₀	0.29 μM Compound: Dox	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 26494582]
MCF7	IC₅₀	0.294 nM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as cell viability after 5 days by cell viability analyzer Cytotoxicity against human MCF7 cells assessed as cell viability after 5 days by cell viability analyzer	[PMID: 26291039]
MCF7	IC₅₀	0.3 μg/mL Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by MTT colorimetric method Cytotoxicity against human MCF7 cells by MTT colorimetric method	[PMID: 17125220]
MCF7	IC₅₀	0.3 μM Compound: DOX	Antiproliferative activity against human MCF7 cells after 24 hrs by CellTiter-Glo assay Antiproliferative activity against human MCF7 cells after 24 hrs by CellTiter-Glo assay	[PMID: 27769032]
MCF7	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 to 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 to 72 hrs by MTT assay	[PMID: 33586438]
MCF7	IC₅₀	0.3 μM Compound: DOX	Antiproliferative activity against wild type human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against wild type human MCF7 cells after 72 hrs by MTT assay	[PMID: 17964170]
MCF7	EC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay	[PMID: 26320088]
MCF7	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by resazurin dye based AlamarBlue assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by resazurin dye based AlamarBlue assay	[PMID: 34495663]
MCF7	IC₅₀	0.31 μM Compound: Dox	Antiproliferative activity against human MCF7 cells assessed as growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as growth inhibition measured after 72 hrs by MTT assay	[PMID: 34902732]
MCF7	IC₅₀	0.31 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 22677031]
MCF7	IC₅₀	0.31 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 18692939]
MCF7	GI₅₀	0.31 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 2 days by sulforhodamine B assay Antiproliferative activity against human MCF7 cells after 2 days by sulforhodamine B assay	[PMID: 24184076]
MCF7	IC₅₀	0.32 μg/mL Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 18590313]
MCF7	IC₅₀	0.32 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 72 hrs by resazurin-based colorimetric assay Cytotoxicity against human MCF7 cells after 72 hrs by resazurin-based colorimetric assay	[PMID: 27071003]
MCF7	IC₅₀	0.32 μM Compound: doxorubicin	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay	[PMID: 26305181]
MCF7	IC₅₀	0.32 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 72 hrs Antiproliferative activity against human MCF7 cells after 72 hrs	[PMID: 25127463]
MCF7	IC₅₀	0.34 μg/mL Compound: DOX	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 24589485]
MCF7	IC₅₀	0.34 μg/mL Compound: doxo	Cytotoxicity against human MCF7 cells by MTT method Cytotoxicity against human MCF7 cells by MTT method	[PMID: 17417907]
MCF7	IC₅₀	0.35 μg/mL Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 21106454]
MCF7	IC₅₀	0.35 μM Compound: doxorubicin	Cytotoxicity against human MCF7 cells after 72 hrs by Alamar Blue assay Cytotoxicity against human MCF7 cells after 72 hrs by Alamar Blue assay	[PMID: 24251417]
MCF7	IC₅₀	0.35 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 24 and 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 and 72 hrs by MTT assay	[PMID: 24941130]
MCF7	IC₅₀	0.35 μM Compound: DOX	Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 30106296]
MCF7	IC₅₀	0.36 μg/mL Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay	[PMID: 22658083]
MCF7	IC₅₀	0.36 μM Compound: ADM	Anticancer activity against human MCF7 cells after 48 hrs by MTT assay Anticancer activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 25462264]
MCF7	IC₅₀	0.37 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30170925]
MCF7	CC₅₀	0.37 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30103191]
MCF7	IC₅₀	0.37 μM Compound: DOX	Cytotoxicity against human MCF7 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay	[PMID: 35612499]
MCF7	IC₅₀	0.37 μM Compound: Dox	Antiproliferative activity against human MCF7 cells assessed as growth inhibition under hypoxia conditions measured after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as growth inhibition under hypoxia conditions measured after 72 hrs by MTT assay	[PMID: 34902732]
MCF7	IC₅₀	0.37 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells under hypoxic condition by MTT assay Cytotoxicity against human MCF7 cells under hypoxic condition by MTT assay	[PMID: 29684705]
MCF7	IC₅₀	0.38 μM Compound: DOX	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35341920]
MCF7	IC₅₀	0.38 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 27080182]
MCF7	IC₅₀	0.38 μM Compound: Doxorubicin	Cytotoxicity against ER-positive human MCF7 cells assessed as redution in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against ER-positive human MCF7 cells assessed as redution in cell viability incubated for 72 hrs by SRB assay	[PMID: 31810778]
MCF7	IC₅₀	0.39 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 48 hrs by MTT assay	[PMID: 28494255]
MCF7	IC₅₀	0.4 μg/mL Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 16724859]
MCF7	IC₅₀	0.4 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 72 hrs by Alamar blue assay Cytotoxicity against human MCF7 cells after 72 hrs by Alamar blue assay	[PMID: 21999655]
MCF7	IC₅₀	0.4 μM Compound: Adriamycin	Cytotoxicity against human MCF7 cells after 2 days by CCK-8 assay Cytotoxicity against human MCF7 cells after 2 days by CCK-8 assay	[PMID: 25481396]
MCF7	IC₅₀	0.4 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay	[PMID: 32324401]
MCF7	IC₅₀	0.4 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30179747]
MCF7	IC₅₀	0.4 μM Compound: DOX	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 35818137]
MCF7	GI₅₀	0.4 μM Compound: Dox	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]
MCF7	IC₅₀	0.4 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay Cytotoxicity against human MCF7 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay	[PMID: 36970146]
MCF7	IC₅₀	0.4 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by resazurin dye based Alamar blue assay Cytotoxicity against human MCF7 cells by resazurin dye based Alamar blue assay	[PMID: 29373790]
MCF7	IC₅₀	0.405 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 33261897]
MCF7	IC₅₀	0.41 μM Compound: Doxorubicin	Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 31962262]
MCF7	IC₅₀	0.41 μM Compound: Doxorubicin	Anticancer activity against human MCF7 cells incubated for 24 hrs by MTT assay Anticancer activity against human MCF7 cells incubated for 24 hrs by MTT assay	[PMID: 28579122]
MCF7	IC₅₀	0.41 μM Compound: DOX	Cytotoxicity against human MCF7 cells after 48 hrs by [3H]hypoxanthine incorporation assay Cytotoxicity against human MCF7 cells after 48 hrs by [3H]hypoxanthine incorporation assay	[PMID: 20362359]
MCF7	IC₅₀	0.42 μM Compound: doxorubicin	Cytotoxicity against human MCF7 cells after 72 hrs by Alamar blue assay Cytotoxicity against human MCF7 cells after 72 hrs by Alamar blue assay	[PMID: 22264149]
MCF7	IC₅₀	0.42 μM Compound: Doxorubicin	Growth inhibition of human MCF7 cells after 72 hrs by MTT assay Growth inhibition of human MCF7 cells after 72 hrs by MTT assay	[PMID: 30471828]
MCF7	IC₅₀	0.42 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 72 hrs by resazurin/AlamarBlue dye-based fluorescence assay Cytotoxicity against human MCF7 cells after 72 hrs by resazurin/AlamarBlue dye-based fluorescence assay	[PMID: 28139929]
MCF7	IC₅₀	0.43 μg/mL Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 3 days by MTT assay Cytotoxicity against human MCF7 cells after 3 days by MTT assay	[PMID: 19691312]
MCF7	IC₅₀	0.43 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells incubated for 48 hrs by CCK-8 assay	[PMID: 33725657]
MCF7	IC₅₀	0.43 μM Compound: adriamycin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 17125240]
MCF7	IC₅₀	0.44 μM Compound: Doxorubicin	Cytotoxicity against estrogen receptor-positive human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against estrogen receptor-positive human MCF7 cells after 24 hrs by MTT assay	[PMID: 24513041]
MCF7	IC₅₀	0.44 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7 cells after 72 hrs by sulforhodamine B assay	[PMID: 26496013]
MCF7	IC₅₀	0.45 μg/mL Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 20732814]
MCF7	IC₅₀	0.46 μM Compound: doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 25314138]
MCF7	IC₅₀	0.467 μM Compound: Doxorubicin	Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT colorimetric assay Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT colorimetric assay	[PMID: 35694689]
MCF7	IC₅₀	0.48 μM Compound: DOX	Antiproliferative activity against human MCF7 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells after 72 hrs by CCK-8 assay	[PMID: 29614418]
MCF7	IC₅₀	0.49 μM Compound: ADR	Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28754470]
MCF7	IC₅₀	0.49 μM Compound: Doxorubicin	Cytotoxicity in human MCF7 cells incubated for 72 hrs by MTT assay Cytotoxicity in human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 30978023]
MCF7	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 21215623]
MCF7	IC₅₀	0.5 μM Compound: Dox	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 30599418]
MCF7	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 36044031]
MCF7	IC₅₀	0.5 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24012378]
MCF7	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 19394829]
MCF7	IC₅₀	0.5 μM Compound: ADR	Cytotoxicity against human MCF7 cells by SRB assay Cytotoxicity against human MCF7 cells by SRB assay	[PMID: 18656370]
MCF7	IC₅₀	0.5 μM Compound: Adriamycin	Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 24910974]
MCF7	IC₅₀	0.5 μM Compound: Adriamycin	Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 23501113]
MCF7	IC₅₀	0.5 μM Compound: ADR	Cytotoxicity against human MCF7 cells by sulforhodamine B assay Cytotoxicity against human MCF7 cells by sulforhodamine B assay	[PMID: 17822905]
MCF7	IC₅₀	0.51 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 34315044]
MCF7	IC₅₀	0.53 μM Compound: ADR	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 19523827]
MCF7	IC₅₀	0.54 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 22537362]
MCF7	IC₅₀	0.54 μM Compound: doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 21087017]
MCF7	IC₅₀	0.55 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 27116711]
MCF7	IC₅₀	0.56 μg/mL Compound: doxorubicin	Cytotoxicity against human MCF7 cells after 3 days by MTT assay Cytotoxicity against human MCF7 cells after 3 days by MTT assay	[PMID: 16252914]
MCF7	IC₅₀	0.56 μM Compound: Doxorubicin	Cytotoxicity in human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity in human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 28923382]
MCF7	IC₅₀	0.57 μg/mL Compound: doxorubicin	Cytotoxicity against human MCF7 cells by resazurin microplate assay Cytotoxicity against human MCF7 cells by resazurin microplate assay	[PMID: 20329738]
MCF7	IC₅₀	0.59 μM Compound: Doxorubucin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 20718475]
MCF7	IC₅₀	0.6 μM Compound: Doxorubicin	Anticancer activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 32438251]
MCF7	IC₅₀	0.6 μM Compound: Doxorubicin	Growth inhibition of human MCF7 cells after 72 hrs by MTT assay Growth inhibition of human MCF7 cells after 72 hrs by MTT assay	[PMID: 28189083]
MCF7	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 25172418]
MCF7	IC₅₀	0.6 μM Compound: ADM	Cytotoxicity against human MCF7 cells by SRB method Cytotoxicity against human MCF7 cells by SRB method	[PMID: 29144133]
MCF7	IC₅₀	0.61 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 30719909]
MCF7	IC₅₀	0.61 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 21071221]
MCF7	IC₅₀	0.62 μM Compound: DOX	Antiproliferative activity against human MCF7 cells after 3 days by MTT assay Antiproliferative activity against human MCF7 cells after 3 days by MTT assay	[PMID: 28291685]
MCF7	IC₅₀	0.62 μM Compound: Dox	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 26494582]
MCF7	IC₅₀	0.62 μM Compound: DOX	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 31820976]
MCF7	IC₅₀	0.629 μM Compound: DOX	Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 23123017]
MCF7	IC₅₀	0.63 μM Compound: Doxorubicin	Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 26330077]
MCF7	IC₅₀	0.63 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 28886509]
MCF7	IC₅₀	0.64 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay	[PMID: 24852278]
MCF7	IC₅₀	0.65 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 3 days by MTT assay Cytotoxicity against human MCF7 cells after 3 days by MTT assay	[PMID: 18547115]
MCF7	IC₅₀	0.66 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 32035399]
MCF7	IC₅₀	0.66 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as cell survival after 24 hrs by XTT assay Cytotoxicity against human MCF7 cells assessed as cell survival after 24 hrs by XTT assay	[PMID: 25059501]
MCF7	IC₅₀	0.67 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 28554092]
MCF7	IC₅₀	0.7 μg/mL Compound: Dox	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 19540022]
MCF7	IC₅₀	0.7 μM Compound: DOX	Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 30860373]
MCF7	IC₅₀	0.7 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30679134]
MCF7	IC₅₀	0.7 μM Compound: DOX	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 28756264]
MCF7	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 24044895]
MCF7	IC₅₀	0.7 μM Compound: Doxo	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 20334960]
MCF7	IC₅₀	0.7 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 19632833]
MCF7	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 25241926]
MCF7	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by SRB assay Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by SRB assay	10.1007/s00044-012-0272-y
MCF7	IC₅₀	0.707 μM Compound: DOXO	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29685681]
MCF7	IC₅₀	0.72 μg/mL Compound: Dox	Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 20399544]
MCF7	IC₅₀	0.72 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29275232]
MCF7	IC₅₀	0.72 μM Compound: DOX	Antiproliferative activity against human MCF7 cells after 24 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 24 hrs by SRB assay	[PMID: 30106296]
MCF7	IC₅₀	0.74 μM Compound: doxorubicin	Cytotoxicity against human MCF7 cells after 72 hrs by MTT colorimetric method Cytotoxicity against human MCF7 cells after 72 hrs by MTT colorimetric method	[PMID: 17622129]
MCF7	IC₅₀	0.75 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay	10.1039/C2MD20327H
MCF7	IC₅₀	0.75 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30108986]
MCF7	IC₅₀	0.75 μM Compound: DOX	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 25619894]
MCF7	IC₅₀	0.75 μM Compound: DOX	Cytotoxicity against ER-positive human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against ER-positive human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 24148837]
MCF7	IC₅₀	0.75 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 20846862]
MCF7	GI₅₀	0.75 μM Compound: Dox	Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35533562]
MCF7	IC₅₀	0.75 μM Compound: Doxorubicin	Cytotoxicity against ER-positive human MCF7 cells after 1 hr by SRB assay Cytotoxicity against ER-positive human MCF7 cells after 1 hr by SRB assay	[PMID: 22770744]
MCF7	IC₅₀	0.77 μM Compound: Doxo	Cytotoxicity against human MCF7 cells after 3 days by MTT assay Cytotoxicity against human MCF7 cells after 3 days by MTT assay	[PMID: 21800859]
MCF7	IC₅₀	0.8 μg/mL Compound: doxorubicin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 22413887]
MCF7	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29702447]
MCF7	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25655719]
MCF7	IC₅₀	0.8 μM Compound: Dox	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability by MTT assay	[PMID: 31765156]
MCF7	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition by MTT assay	[PMID: 27187861]
MCF7	IC₅₀	0.81 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 27060757]
MCF7	IC₅₀	0.812 μM Compound: DOX	Growth inhibition of human MCF7 cells after 24 hrs by MTT assay Growth inhibition of human MCF7 cells after 24 hrs by MTT assay	[PMID: 28094220]
MCF7	GI₅₀	0.82 μM Compound: Dox	Antiproliferative activity against human MCF7 cells incubated for 72 hrs and measured by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs and measured by MTT assay	[PMID: 35973342]
MCF7	IC₅₀	0.82 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay	[PMID: 31404864]
MCF7	IC₅₀	0.83 μM Compound: Dox	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 27397495]
MCF7	IC₅₀	0.83 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 26398312]
MCF7	IC₅₀	0.85 μM Compound: DOXO	Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by alamar blue assay Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by alamar blue assay	[PMID: 21797280]
MCF7	IC₅₀	0.85 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by Alamar blue assay Cytotoxicity against human MCF7 cells after 48 hrs by Alamar blue assay	[PMID: 20931970]
MCF7	IC₅₀	0.87 μg/mL Compound: Doxorubicine	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 24177357]
MCF7	IC₅₀	0.89 μM Compound: Dox	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 33852973]
MCF7	IC₅₀	0.89 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as inhibition of metabolic activity after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of metabolic activity after 48 hrs by MTT assay	[PMID: 27187858]
MCF7	IC₅₀	0.899 μg/mL Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by resazurin microplate assay Cytotoxicity against human MCF7 cells by resazurin microplate assay	[PMID: 19456117]
MCF7	IC₅₀	0.9 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human MCF7 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 28273560]
MCF7	IC₅₀	0.9 μM Compound: doxorubicin	Cytotoxicity against human MCF7 cells after 3 days by MTT assay Cytotoxicity against human MCF7 cells after 3 days by MTT assay	[PMID: 18419154]
MCF7	IC₅₀	0.9 μM Compound: DXR	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 34808062]
MCF7	GI₅₀	0.9 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells assessed as growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as growth inhibition incubated for 48 hrs by MTT assay	[PMID: 31128433]
MCF7	IC₅₀	0.9 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 31108261]
MCF7	IC₅₀	0.9 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay	[PMID: 26774921]
MCF7	IC₅₀	0.9 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay	[PMID: 26646219]
MCF7	IC₅₀	0.92 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay	[PMID: 33744686]
MCF7	IC₅₀	0.92 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 19795842]
MCF7	IC₅₀	0.92 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26381063]
MCF7	IC₅₀	0.924 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26972921]
MCF7	IC₅₀	0.93 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells assessed as cell viability after 48 hrs MTT assay Antiproliferative activity against human MCF7 cells assessed as cell viability after 48 hrs MTT assay	[PMID: 33039723]
MCF7	IC₅₀	0.94 μM Compound: doxorubicin	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 23806110]
MCF7	ED₅₀	0.953 μg/mL Compound: adriamycin	Cytotoxicity against human MCF7 cells after 7 days by MTT assay Cytotoxicity against human MCF7 cells after 7 days by MTT assay	[PMID: 11087592]
MCF7	IC₅₀	0.96 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 26264845]
MCF7	IC₅₀	0.97 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay	[PMID: 36693198]
MCF7	IC₅₀	0.99 μM Compound: Doxorubicin	Anticancer activity against human MCF7 cells after 48 hrs by MTT assay Anticancer activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 25615796]
MCF7	IC₅₀	1 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	10.1039/C3MD00013C
MCF7	IC₅₀	1 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 33743356]
MCF7	IC₅₀	1 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
MCF7	IC₅₀	1 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29789258]
MCF7	IC₅₀	1 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 27797185]
MCF7	IC₅₀	1 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 23079527]
MCF7	IC₅₀	1 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 21996519]
MCF7	IC₅₀	1 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) MCF7 cells by tetrazolium-reduction assay Cytotoxicity against Homo sapiens (human) MCF7 cells by tetrazolium-reduction assay	10.1007/s00044-012-0450-y
MCF7	IC₅₀	1.02 μM Compound: DOX	Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 27149641]
MCF7	IC₅₀	1.02 μM Compound: Dox	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28704759]
MCF7	ED₅₀	1.03 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human MCF7 cells after 7 days by MTT assay Cytotoxicity against human MCF7 cells after 7 days by MTT assay	[PMID: 8676130]
MCF7	IC₅₀	1.03 μM Compound: doxorubicin	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 19819703]
MCF7	IC₅₀	1.05 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 25172420]
MCF7	IC₅₀	1.05 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 24113366]
MCF7	IC₅₀	1.05 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 23911578]
MCF7	IC₅₀	1.05 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 23764302]
MCF7	IC₅₀	1.05 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by resazurin microplate assay Cytotoxicity against human MCF7 cells by resazurin microplate assay	[PMID: 32193929]
MCF7	IC₅₀	1.054 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 26301558]
MCF7	ED₅₀	1.06 x 10^-1 μg/mL Compound: Adriamycin	Cytotoxicity against human MCF7 cells after 7 days by MTT assay Cytotoxicity against human MCF7 cells after 7 days by MTT assay	[PMID: 7673936]
MCF7	IC₅₀	1.07 μM Compound: Doxorubicin	In vitro cytotoxicity against human MCF7 cells assessed as growth inhibition by MTT assay In vitro cytotoxicity against human MCF7 cells assessed as growth inhibition by MTT assay	[PMID: 24742385]
MCF7	IC₅₀	1.07 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 24287557]
MCF7	IC₅₀	1.08 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31404864]
MCF7	IC₅₀	1.08 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26433616]
MCF7	IC₅₀	1.08 μM Compound: Dox	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30615450]
MCF7	IC₅₀	1.08 μM Compound: Doxorubicin	Growth inhibition of human MCF7 cells by MTT assay Growth inhibition of human MCF7 cells by MTT assay	[PMID: 33901643]
MCF7	IC₅₀	1.09 μg/mL Compound: Doxorubicin	Anticancer activity against human cells MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay Anticancer activity against human cells MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 25042338]
MCF7	EC₅₀	1.1 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 33049606]
MCF7	EC₅₀	1.1 μM Compound: DR	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32956968]
MCF7	IC₅₀	1.1 μM Compound: DX	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32422522]
MCF7	IC₅₀	1.1 μM Compound: Doxorubicin	Cytotoxicity against human tamoxifen-resistant MCF7 cells by WST-1 assay Cytotoxicity against human tamoxifen-resistant MCF7 cells by WST-1 assay	[PMID: 22197145]
MCF7	IC₅₀	1.117 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28482219]
MCF7	IC₅₀	1.12 μM Compound: Dox	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 26494582]
MCF7	IC₅₀	1.13 μM Compound: Doxorubicin	Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 3 days by MTT assay Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 3 days by MTT assay	[PMID: 35007724]
MCF7	IC₅₀	1.13 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 27015609]
MCF7	IC₅₀	1.17 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell growth after 72 hrs by cell titer glo assay Cytotoxicity against human MCF7 cells assessed as reduction in cell growth after 72 hrs by cell titer glo assay	[PMID: 27080175]
MCF7	IC₅₀	1.17 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition and measured after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition and measured after 72 hrs by SRB assay	[PMID: 34000484]
MCF7	IC₅₀	1.17 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 25462265]
MCF7	IC₅₀	1.172 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	10.1039/C5MD00127G
MCF7	IC₅₀	1.172 μM Compound: Doxorubicin	Anticancer against human MCF7 cells assessed as tumor growth inhibition after 72 hrs by SRB assay Anticancer against human MCF7 cells assessed as tumor growth inhibition after 72 hrs by SRB assay	[PMID: 26256032]
MCF7	IC₅₀	1.172 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 24231309]
MCF7	IC₅₀	1.18 μM Compound: Doxorubicin	Antiproliferative activity against human cells MCF-7 assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human cells MCF-7 assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33477020]
MCF7	IC₅₀	1.2 μM Compound: Dox	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 24028446]
MCF7	IC₅₀	1.2 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 21425785]
MCF7	IC₅₀	1.21 μg/mL Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 3 days by MTT assay Cytotoxicity against human MCF7 cells after 3 days by MTT assay	[PMID: 15387653]
MCF7	IC₅₀	1.227 μM Compound: DOX	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34700239]
MCF7	ED₅₀	1.24 x 10^-1 μg/mL Compound: adriamycin	Cytotoxicity against human MCF7 cells after 7 days by MTT assay Cytotoxicity against human MCF7 cells after 7 days by MTT assay	[PMID: 9584396]
MCF7	ED₅₀	1.26 x 10^-1 μg/mL Compound: Adriamycin	Cytotoxicity against human MCF7 cells after 7 days by MTT assay Cytotoxicity against human MCF7 cells after 7 days by MTT assay	[PMID: 7673926]
MCF7	IC₅₀	1.28 μM Compound: Dox	Anticancer activity against Homo sapiens (human) MCF7 cells assessed as growth inhibition after 48 hr by SRB assay Anticancer activity against Homo sapiens (human) MCF7 cells assessed as growth inhibition after 48 hr by SRB assay	10.1007/s00044-012-0057-3
MCF7	IC₅₀	1.29 μM Compound: Doxorubicin	Cytotoxicity activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32627543]
MCF7	IC₅₀	1.32 μM Compound: Doxorubicin	Anticancer activity against human MCF7 cells after 72 hrs by sulforhodamine B assay Anticancer activity against human MCF7 cells after 72 hrs by sulforhodamine B assay	[PMID: 30081238]
MCF7	IC₅₀	1.33 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 26948541]
MCF7	IC₅₀	1.35 μM Compound: ADM	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 26280921]
MCF7	IC₅₀	1.35 μM Compound: ADM	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 25874331]
MCF7	IC₅₀	1.37 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 22687747]
MCF7	IC₅₀	1.4 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28277681]
MCF7	IC₅₀	1.4 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 33421712]
MCF7	IC₅₀	1.4 μM Compound: DOX	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30429098]
MCF7	IC₅₀	1.4 μM Compound: DOX	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay	[PMID: 34323485]
MCF7	ED₅₀	1.42 x 10^-1 μg/mL Compound: Adriamycin	Cytotoxicity against human MCF7 cells after 7 days by MTT assay Cytotoxicity against human MCF7 cells after 7 days by MTT assay	[PMID: 7673935]
MCF7	ED₅₀	1.42 x 10^-1 μg/mL Compound: Adriamycin	Cytotoxicity against human MCF7 cells after 7 days by MTT assay Cytotoxicity against human MCF7 cells after 7 days by MTT assay	[PMID: 7494150]
MCF7	IC₅₀	1.43 μM Compound: DOX	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 32435420]
MCF7	ED₅₀	1.47 x 10^-1 μg/mL Compound: adriamycin	Cytotoxicity against human MCF7 cells after 7 days Cytotoxicity against human MCF7 cells after 7 days	[PMID: 8201311]
MCF7	ED₅₀	1.47 x 10^-1 μg/mL Compound: adriamycin	Cytotoxicity against human MCF7 cells after 7 days Cytotoxicity against human MCF7 cells after 7 days	[PMID: 1593281]
MCF7	IC₅₀	1.5 μM Compound: DOX	Inhibition of topoisomerase 2 in human MCF7 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Inhibition of topoisomerase 2 in human MCF7 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 30846253]
MCF7	IC₅₀	1.5 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by resazurin microplate assay Cytotoxicity against human MCF7 cells by resazurin microplate assay	[PMID: 19739600]
MCF7	IC₅₀	1.51 μM Compound: Doxo	Cytotoxicity against estrogen receptor-positive human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against estrogen receptor-positive human MCF7 cells after 48 hrs by MTT assay	[PMID: 21885273]
MCF7	IC₅₀	1.51 μM Compound: Doxorubicin	Cytotoxicity activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32531682]
MCF7	ED₅₀	1.52 x 10^-1 μg/mL Compound: adriamycin	Cytotoxicity against human MCF7 cells after 7 days by MTT assay Cytotoxicity against human MCF7 cells after 7 days by MTT assay	[PMID: 8882434]
MCF7	IC₅₀	1.54 μM Compound: doxorubicin	Cytotoxicity against human MCF7 cells after 72 hrs by CellTiter-Glo assay Cytotoxicity against human MCF7 cells after 72 hrs by CellTiter-Glo assay	[PMID: 22316168]
MCF7	IC₅₀	1.6 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay	[PMID: 31403289]
MCF7	GI₅₀	1.6 μM Compound: Doxorubicin	Anti-proliferative activity against human MCF7 cells incubated for 48 hrs by SRB assay Anti-proliferative activity against human MCF7 cells incubated for 48 hrs by SRB assay	[PMID: 26163220]
MCF7	IC₅₀	1.65 μM Compound: Adriamycin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 23434227]
MCF7	IC₅₀	1.659 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28462842]
MCF7	IC₅₀	1.69 μM Compound: Adriamycin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 21115246]
MCF7	ED₅₀	1.7 x 10^-1 μg/mL Compound: Adriamycin	Cytotoxicity against human MCF7 cells after 7 days by MTT assay Cytotoxicity against human MCF7 cells after 7 days by MTT assay	[PMID: 8946743]
MCF7	IC₅₀	1.7 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32975117]
MCF7	IC₅₀	1.7 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by WST-1 assay Cytotoxicity against human MCF7 cells by WST-1 assay	[PMID: 22197145]
MCF7	IC₅₀	1.738 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29501940]
MCF7	IC₅₀	1.74 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30500683]
MCF7	IC₅₀	1.77 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 33352388]
MCF7	ED₅₀	1.79 x 10^-1 μg/mL Compound: adriamycin	Cytotoxicity against human MCF7 cells after 7 days by MTT assay Cytotoxicity against human MCF7 cells after 7 days by MTT assay	[PMID: 9599260]
MCF7	ED₅₀	1.8 ng/mL Compound: adriamycin	Cytotoxicity against human MCF7 cells after 6 days by BCA assay Cytotoxicity against human MCF7 cells after 6 days by BCA assay	[PMID: 8984151]
MCF7	IC₅₀	1.819 μM Compound: Doxorubicin	Anti-proliferative activity against human MCF7 cells measured after 48 hrs by MTT assay Anti-proliferative activity against human MCF7 cells measured after 48 hrs by MTT assay	[PMID: 27744185]
MCF7	ED₅₀	1.82 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human MCF7 cells after 7 days by MTT assay Cytotoxicity against human MCF7 cells after 7 days by MTT assay	[PMID: 11325235]
MCF7	IC₅₀	1.83 μM Compound: DOX	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs	[PMID: 32736079]
MCF7	IC₅₀	1.88 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 33784602]
MCF7	ED₅₀	1.89 x 10^-1 μg/mL Compound: adriamycin	Cytotoxicity against human MCF7 cells after 7 days by MTT assay Cytotoxicity against human MCF7 cells after 7 days by MTT assay	[PMID: 9014350]
MCF7	IC₅₀	1.9 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 33668008]
MCF7	IC₅₀	1.93 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 34791873]
MCF7	IC₅₀	1.94 μM Compound: Doxo	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay	[PMID: 27036521]
MCF7	IC₅₀	10.6 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 29133058]
MCF7	IC₅₀	10.9 μM Compound: Dox	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	10.1007/s00044-013-0584-6
MCF7	IC₅₀	10.9 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
MCF7	IC₅₀	10.9 μM Compound: DOX	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 24487188]
MCF7	IC₅₀	107.11 μM Compound: Doxorubicin	Antiproliferative activity against drug-resistant human MCF7 cells incubated for 48 hrs by MTT assay Antiproliferative activity against drug-resistant human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 32035399]
MCF7	IC₅₀	11.1 μg/mL Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 35526504]
MCF7	IC₅₀	11.52 μM Compound: doxorubicin	Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated at 37 degC for 3 days by resazurin microplate assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated at 37 degC for 3 days by resazurin microplate assay	[PMID: 25734623]
MCF7	IC₅₀	1172 nM Compound: doxorubicin	Tested for inhibitory activity against human tumor cell line D40, a strain resistant to doxorubicin of breast carcinoma using sulforhodamine B assay. Tested for inhibitory activity against human tumor cell line D40, a strain resistant to doxorubicin of breast carcinoma using sulforhodamine B assay.	[PMID: 10956214]
MCF7	IC₅₀	12 nM Compound: doxorubicin	Cytotoxicity against human MCF7 cells after 72 hrs by MTS assay Cytotoxicity against human MCF7 cells after 72 hrs by MTS assay	[PMID: 19655762]
MCF7	IC₅₀	12.34 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as cell viability by SRB assay Cytotoxicity against human MCF7 cells assessed as cell viability by SRB assay	[PMID: 26022842]
MCF7	IC₅₀	13.51 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 2 days by MTT assay Cytotoxicity against human MCF7 cells after 2 days by MTT assay	[PMID: 23932340]
MCF7	IC₅₀	13.97 μM Compound: doxo	Antiproliferative activity against human MCF7 cells assessed as decrease in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as decrease in cell viability measured after 72 hrs by MTT assay	[PMID: 30763817]
MCF7	IC₅₀	130 μM Compound: Dox	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 35339100]
MCF7	IC₅₀	131.5 nM Compound: DX	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay	[PMID: 33611191]
MCF7	IC₅₀	14 μM Compound: DOX	Antineoplastic activity against human MCF7 cells measured after 36 hrs by MTT assay Antineoplastic activity against human MCF7 cells measured after 36 hrs by MTT assay	[PMID: 30746067]
MCF7	IC₅₀	14.1 μg/mL Compound: DOX	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 24090920]
MCF7	IC₅₀	146 nM Compound: DX	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay	[PMID: 34592435]
MCF7	IC₅₀	15 μM Compound: DOX	Antiproliferative activity against doxorubicin-resistant human MCF7 cells after 48 hrs by SRB method Antiproliferative activity against doxorubicin-resistant human MCF7 cells after 48 hrs by SRB method	[PMID: 25061803]
MCF7	IC₅₀	15.12 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28262524]
MCF7	IC₅₀	15.2 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin based fluorescence assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin based fluorescence assay	[PMID: 33852304]
MCF7	EC₅₀	15.3 μM Compound: 12	Dark toxicity in human MCF7 cells assessed as decrease in cell viability after 24 hrs by MTT assay Dark toxicity in human MCF7 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 29172528]
MCF7	IC₅₀	15.69 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin microplate assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin microplate assay	[PMID: 27311894]
MCF7	IC₅₀	15.88 μM Compound: doxorubicin	Cytotoxicity against human MCF7 cells by colorimetric method Cytotoxicity against human MCF7 cells by colorimetric method	[PMID: 23795891]
MCF7	IC₅₀	16 μM Compound: Doxorubicin	Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34838335]
MCF7	IC₅₀	16.8 μM Compound: Dox	Cytotoxicity against human MCF7 cells after 24 hrs by MTS assay Cytotoxicity against human MCF7 cells after 24 hrs by MTS assay	[PMID: 21094049]
MCF7	IC₅₀	16.8 μM Compound: doxorubicin	Cytotoxicity against human MCF7 cells by resazurin reduction assay Cytotoxicity against human MCF7 cells by resazurin reduction assay	[PMID: 22482432]
MCF7	IC₅₀	16.9 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 24681979]
MCF7	IC₅₀	17.67 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 22647723]
MCF7	IC₅₀	17.9 nM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay	[PMID: 21296467]
MCF7	IC₅₀	17.9 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 3 days by resazurin microplate assay Cytotoxicity against human MCF7 cells after 3 days by resazurin microplate assay	[PMID: 22280818]
MCF7	IC₅₀	18 μg/mL Compound: DOX	Anticancer activity against Homo sapiens (human) MCF-7 cells assessed as inhibition of cell survival after 24 hr by MTT assay Anticancer activity against Homo sapiens (human) MCF-7 cells assessed as inhibition of cell survival after 24 hr by MTT assay	10.1007/s00044-012-0071-5
MCF7	IC₅₀	18.5 μM Compound: 21	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29289880]
MCF7	IC₅₀	18.6 mM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32631569]
MCF7	IC₅₀	19 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay	10.1007/s00044-013-0586-4
MCF7	GI₅₀	2 nM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30071406]
MCF7	GI₅₀	2 nM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29670691]
MCF7	ED₅₀	2 x 10^-1 μg/mL Compound: Adriamycin	Cytotoxicity against human MCF7 cells after 7 days by MTT assay Cytotoxicity against human MCF7 cells after 7 days by MTT assay	[PMID: 9214729]
MCF7	ED₅₀	2 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human MCF7 cells after 7 days by MTT assay Cytotoxicity against human MCF7 cells after 7 days by MTT assay	[PMID: 8882437]
MCF7	ED₅₀	2 x 10^-2 μg/mL Compound: Adriamycin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 7714533]
MCF7	IC₅₀	2 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 30654238]
MCF7	IC₅₀	2.02 μM Compound: Doxorubicin	Anticancer activity against human MCF-7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human MCF-7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34124677]
MCF7	IC₅₀	2.02 μM Compound: Doxorubicin	Anticancer activity against human MCF7 cells after 48 hrs by MTT assay Anticancer activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 22136907]
MCF7	IC₅₀	2.08 μM Compound: Doxorubicin	Growth inhibition of human MCF7 cells by MTT assay Growth inhibition of human MCF7 cells by MTT assay	[PMID: 28462836]
MCF7	ED₅₀	2.09 x 10^-1 μg/mL Compound: adriamycin	Cytotoxicity against human MCF7 cells after 7 days by MTT assay Cytotoxicity against human MCF7 cells after 7 days by MTT assay	[PMID: 8904848]
MCF7	ED₅₀	2.1 ng/mL Compound: adriamycin	Cytotoxicity against human MCF7 cells after 6 days by coulter counted assay Cytotoxicity against human MCF7 cells after 6 days by coulter counted assay	[PMID: 8984151]
MCF7	ED₅₀	2.1 x 10^-1 μg/mL Compound: adriamycin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 9917277]
MCF7	IC₅₀	2.1 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33823396]
MCF7	IC₅₀	2.1 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition by MTT assay	[PMID: 34838335]
MCF7	ED₅₀	2.12 x 10^-1 μg/mL Compound: adriamycin	Cytotoxicity against human MCF7 cells after 7 days by MTT assay Cytotoxicity against human MCF7 cells after 7 days by MTT assay	[PMID: 9599253]
MCF7	IC₅₀	2.18 μM Compound: Doxo	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29129513]
MCF7	IC₅₀	2.2 μg/mL Compound: doxorubicin	Cytotoxicity against human MCF7 cells by SRB assay Cytotoxicity against human MCF7 cells by SRB assay	[PMID: 19778068]
MCF7	IC₅₀	2.24 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 25594739]
MCF7	ED₅₀	2.28 x 10^-2 μg/mL Compound: Adriamycin	Cytotoxicity against human MCF7 cells after 7 days by MTT assay Cytotoxicity against human MCF7 cells after 7 days by MTT assay	[PMID: 7714532]
MCF7	ED₅₀	2.28 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human MCF7 cells after 7 days Cytotoxicity against human MCF7 cells after 7 days	[PMID: 8021648]
MCF7	IC₅₀	2.29 μM Compound: doxorubicin	Cytotoxicity against human MCF7 cells by SRB assay Cytotoxicity against human MCF7 cells by SRB assay	[PMID: 22004007]
MCF7	ED₅₀	2.3 x 10^-1 μg/mL Compound: adriamycin	Cytotoxicity against human MCF7 cells after 7 hrs by MTT assay Cytotoxicity against human MCF7 cells after 7 hrs by MTT assay	[PMID: 7623031]
MCF7	IC₅₀	2.3 μM Compound: Doxorubicin	Growth inhibition of human MCF7 cells by MTT assay Growth inhibition of human MCF7 cells by MTT assay	[PMID: 28916158]
MCF7	IC₅₀	2.3 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by resazurin microplate assay Cytotoxicity against human MCF7 cells by resazurin microplate assay	[PMID: 21090800]
MCF7	ED₅₀	2.31 x 10^-1 μg/mL Compound: Adriamycin	Cytotoxicity against human MCF7 cells after 7 days Cytotoxicity against human MCF7 cells after 7 days	[PMID: 1453182]
MCF7	IC₅₀	2.31 μM Compound: DOX	Cytotoxicity against human MCF7 cells after 48 hrs by SRB method Cytotoxicity against human MCF7 cells after 48 hrs by SRB method	[PMID: 25933593]
MCF7	IC₅₀	2.36 μM Compound: Dox	Antiproliferative activity against human MCF7 cells measured after 48 hrs under normoxia condition by MTT assay Antiproliferative activity against human MCF7 cells measured after 48 hrs under normoxia condition by MTT assay	[PMID: 31276899]
MCF7	IC₅₀	2.37 μM Compound: Dox	Antiproliferative activity against human MCF7 cells by MTT assay Antiproliferative activity against human MCF7 cells by MTT assay	[PMID: 28802125]
MCF7	IC₅₀	2.4 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 20832916]
MCF7	IC₅₀	2.44 μM Compound: doxorubicin	Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay	10.1007/s00044-013-0795-x
MCF7	IC₅₀	2.5 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by alamar blue assay Cytotoxicity against human MCF7 cells after 48 hrs by alamar blue assay	[PMID: 22272829]
MCF7	ED₅₀	2.53 x 10^-1 μg/mL Compound: adr	Cytotoxicity against human MCF7 cells after 7 days by MTT assay Cytotoxicity against human MCF7 cells after 7 days by MTT assay	[PMID: 9461654]
MCF7	IC₅₀	2.57 μM Compound: Dox	Cytotoxicity against human MCF7 cells assessed as cell viability after 24 hrs by crystal violet staining assay Cytotoxicity against human MCF7 cells assessed as cell viability after 24 hrs by crystal violet staining assay	[PMID: 26706352]
MCF7	IC₅₀	2.57 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs Cytotoxicity against human MCF7 cells after 48 hrs	[PMID: 20873721]
MCF7	IC₅₀	2.58 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells incubated for 72 hrs by Sulphorhodamine assay Cytotoxicity against human MCF7 cells incubated for 72 hrs by Sulphorhodamine assay	[PMID: 37146520]
MCF7	IC₅₀	2.6 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 30503942]
MCF7	IC₅₀	2.62 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 after 24 hrs by MTT assay Cytotoxicity against human MCF7 after 24 hrs by MTT assay	[PMID: 20056520]
MCF7	IC₅₀	2.63 μM Compound: Doxorubicin	Anticancer activity against human MCF7 cells by MTT assay Anticancer activity against human MCF7 cells by MTT assay	[PMID: 25743216]
MCF7	IC₅₀	2.67 μM Compound: Dox	Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as reduction of cell survival after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as reduction of cell survival after 48 hr by MTT assay	10.1007/s00044-012-0150-7
MCF7	IC₅₀	2.71 μM Compound: DOX	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28531811]
MCF7	IC₅₀	2.78 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells assessed as cell viability after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 26874744]
MCF7	IC₅₀	2.78 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 25462233]
MCF7	IC₅₀	2.8 μg/mL Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 24095746]
MCF7	IC₅₀	2.8 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 19583252]
MCF7	IC₅₀	2.82 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 22542958]
MCF7	IC₅₀	2.9 μM Compound: Doxorubicin	Anticancer activity against Homo sapiens (human) MCF-7 cells assessed as inhibition of cell viability after 72 hr by SRB assay Anticancer activity against Homo sapiens (human) MCF-7 cells assessed as inhibition of cell viability after 72 hr by SRB assay	10.1007/s00044-012-0098-7
MCF7	IC₅₀	2.9 μM Compound: Dox	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 22000946]
MCF7	IC₅₀	2.9 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 4 hrs under normoxia condition by MTT colorimetric assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 4 hrs under normoxia condition by MTT colorimetric assay	[PMID: 35551035]
MCF7	IC₅₀	2.96 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	10.1039/C5MD00581G
MCF7	IC₅₀	2.97 μg/mL Compound: DOX	Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by SRB assay Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by SRB assay	10.1007/s00044-011-9636-y
MCF7	IC₅₀	2.97 μg/mL Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by Sulforhodamine B assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by Sulforhodamine B assay	[PMID: 21429629]
MCF7	IC₅₀	2.97 μg/mL Compound: DOX	Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay	[PMID: 22370339]
MCF7	IC₅₀	2.97 μM Compound: Doxorubicin	Antiproliferative activity against Homo sapiens (human) MCF7 cells after 72 hr by SRB assay Antiproliferative activity against Homo sapiens (human) MCF7 cells after 72 hr by SRB assay	10.1007/s00044-011-9874-z
MCF7	IC₅₀	2.99 μM Compound: Dox	Cytotoxicity against human MCF-7 assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human MCF-7 assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33065435]
MCF7	IC₅₀	20.2 μM Compound: 12	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29852328]
MCF7	IC₅₀	22 nM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 25937236]
MCF7	IC₅₀	22.6 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells assessed as cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell viability incubated for 48 hrs by MTT assay	[PMID: 32771798]
MCF7	IC₅₀	23.4 nM Compound: Dox	Anticancer activity against human MCF7 cells assessed as reduction in cell viability by MTT assay Anticancer activity against human MCF7 cells assessed as reduction in cell viability by MTT assay	[PMID: 31740054]
MCF7	IC₅₀	240 nM Compound: DX	Antiproliferative activity against human MCF-7 cells assessed as inhibition of proliferation after 72 hrs by SRB assay Antiproliferative activity against human MCF-7 cells assessed as inhibition of proliferation after 72 hrs by SRB assay	[PMID: 34116158]
MCF7	IC₅₀	26.1 μg/mL Compound: Doxorubicin	Growth inhibition of human MCF7 cells after 48 hrs by MTT assay Growth inhibition of human MCF7 cells after 48 hrs by MTT assay	[PMID: 29793751]
MCF7	IC₅₀	26.7 μM Compound: Doxorubicine	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin microplate assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin microplate assay	[PMID: 34748348]
MCF7	IC₅₀	26.9 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31323616]
MCF7	IC₅₀	28 nM Compound: doxorubicin	Tested for inhibitory activity against human tumor cell line MCF7, a strain resistant to mitoxantrone of breast carcinoma using sulforhodamine B assay. Tested for inhibitory activity against human tumor cell line MCF7, a strain resistant to mitoxantrone of breast carcinoma using sulforhodamine B assay.	[PMID: 10956214]
MCF7	IC₅₀	28 nM Compound: doxorubicin	Tested for inhibitory activity against human tumor cell line MCF7, a strain sensitive to doxorubicin of breast carcinoma using sulforhodamine B assay. Tested for inhibitory activity against human tumor cell line MCF7, a strain sensitive to doxorubicin of breast carcinoma using sulforhodamine B assay.	[PMID: 10956214]
MCF7	IC₅₀	3 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by DAPI staining-based fluorescence assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by DAPI staining-based fluorescence assay	[PMID: 32786882]
MCF7	IC₅₀	3 μM Compound: Doxorubicin	Anticancer activity against human MCF7 cells assessed as cell viability after 48 hrs by MTT microcultured tetrazolium assay Anticancer activity against human MCF7 cells assessed as cell viability after 48 hrs by MTT microcultured tetrazolium assay	[PMID: 25096298]
MCF7	IC₅₀	3 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by DAPI staining based assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by DAPI staining based assay	[PMID: 33461146]
MCF7	IC₅₀	3 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells by fluorescence based viable cell counting method Antiproliferative activity against human MCF7 cells by fluorescence based viable cell counting method	[PMID: 31610378]
MCF7	IC₅₀	3.04 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 4 hrs under hypoxia condition by MTT colorimetric assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 4 hrs under hypoxia condition by MTT colorimetric assay	[PMID: 35551035]
MCF7	IC₅₀	3.05 μM Compound: Doxorubicin	Antiproliferative activity against human cells MCF-7 assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human cells MCF-7 assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33477020]
MCF7	IC₅₀	3.09 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 33744443]
MCF7	IC₅₀	3.12 μM Compound: Doxo (I)	Antiproliferative activity against human MCF7 cells by MTT assay Antiproliferative activity against human MCF7 cells by MTT assay	10.1039/C4MD00228H
MCF7	IC₅₀	3.15 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK-8 assay	[PMID: 34365102]
MCF7	IC₅₀	3.18 μM Compound: Doxorubicin	Anticancer activity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26542964]
MCF7	IC₅₀	3.19 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by CCK8 assay Cytotoxicity against human MCF7 cells by CCK8 assay	[PMID: 29452840]
MCF7	IC₅₀	3.2 nM Compound: Doxorubicin	Inhibition of TRK in human MCF7 cells after 48 hrs by ELISA Inhibition of TRK in human MCF7 cells after 48 hrs by ELISA	[PMID: 24013411]
MCF7	IC₅₀	3.22 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 24 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 24 hrs by SRB assay	[PMID: 20850308]
MCF7	IC₅₀	3.22 μM Compound: Doxorubicin	Anticancer activity against Homo sapiens (human) MCF7 cells after 48 hr by SRB assay Anticancer activity against Homo sapiens (human) MCF7 cells after 48 hr by SRB assay	10.1007/s00044-011-9653-x
MCF7	IC₅₀	3.24 x 10^-1 μM Compound: Doxorubucin	Cytotoxicity against human MCF7 cells after 72 hrs by XTT assay Cytotoxicity against human MCF7 cells after 72 hrs by XTT assay	[PMID: 20538470]
MCF7	IC₅₀	3.28 μM Compound: DOX	Antiproliferative activity against human MCF7 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells after 72 hrs by CCK-8 assay	[PMID: 30245395]
MCF7	IC₅₀	3.28 μM Compound: DOX	Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay	[PMID: 30071408]
MCF7	IC₅₀	3.28 μM Compound: DOX	Antiproliferative activity against human MCF-7 cells measured by MTT assay Antiproliferative activity against human MCF-7 cells measured by MTT assay	[PMID: 33860662]
MCF7	IC₅₀	3.28 μM Compound: DOX	Cytotoxicity against human MCF-7 cells measured by MTT assay Cytotoxicity against human MCF-7 cells measured by MTT assay	[PMID: 33860662]
MCF7	ED₅₀	3.29 x 10^-1 μg/mL Compound: Adriamycin	Cytotoxicity against human MCF7 cells after 7 days by MTT assay Cytotoxicity against human MCF7 cells after 7 days by MTT assay	[PMID: 7494147]
MCF7	IC₅₀	3.3 μM Compound: Doxorubicin	Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 34838335]
MCF7	IC₅₀	3.51 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 24418772]
MCF7	IC₅₀	3.62 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells treated for 72 hrs by MTT assay Cytotoxicity against human MCF7 cells treated for 72 hrs by MTT assay	[PMID: 35344904]
MCF7	ED₅₀	3.69 x 10^-1 μg/mL Compound: Adriamycin	Cytotoxicity against human MCF7 cells after 7 days by MTT assay Cytotoxicity against human MCF7 cells after 7 days by MTT assay	[PMID: 9322367]
MCF7	IC₅₀	3.69 μM Compound: Adriamycin	Cytotoxicity against human MCF7 cells after 2 days Cytotoxicity against human MCF7 cells after 2 days	[PMID: 22318164]
MCF7	IC₅₀	3.7 μM Compound: DOX	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition by MTT assay	[PMID: 32631524]
MCF7	IC₅₀	3.76 μg/mL Compound: DOX	Antitumor activity against human MCF7 cells after 48 hrs by MTT assay Antitumor activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 20599299]
MCF7	IC₅₀	3.83 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 27769619]
MCF7	IC₅₀	3.89 μM Compound: Doxorubicin	Antiproliferative activity against human MCF-7 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Antiproliferative activity against human MCF-7 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 31884407]
MCF7	IC₅₀	3.97 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 35367708]
MCF7	IC₅₀	3.97 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31404864]
MCF7	IC₅₀	3.97 μM Compound: Doxorubicin	Antitumor activity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Antitumor activity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 30138804]
MCF7	IC₅₀	32 μM Compound: DOX	Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 22583778]
MCF7	IC₅₀	32.02 μM Compound: DOX	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 21093116]
MCF7	IC₅₀	33.13 μM Compound: DOX	Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay	[PMID: 25912674]
MCF7	IC₅₀	33.48 μM Compound: Dox	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CellTiter-Glo assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CellTiter-Glo assay	[PMID: 27687968]
MCF7	IC₅₀	34.52 μM Compound: doxorubicin	Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 24 hrs by MTT assay	[PMID: 26200396]
MCF7	IC₅₀	37.57 μg/mL Compound: Doxorubicin	In vitro cytotoxic activity against subline resistant to doxorubicin (MCF-7/R) by using SRB assay after 72 hr of drug exposure In vitro cytotoxic activity against subline resistant to doxorubicin (MCF-7/R) by using SRB assay after 72 hr of drug exposure	10.1016/0960-894X(96)00156-4
MCF7	IC₅₀	386 nM Compound: DOX; DX	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 120 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 120 hrs by MTT assay	[PMID: 31653441]
MCF7	IC₅₀	386 nM Compound: Doxorubicin	Antiproliferative activity against human MCF-7 cells incubated for 72 hrs by SRB assay Antiproliferative activity against human MCF-7 cells incubated for 72 hrs by SRB assay	[PMID: 33465696]
MCF7	IC₅₀	4 μg/mL Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 27688190]
MCF7	IC₅₀	4.12 μg/mL Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as cell viability after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as cell viability after 48 hr by MTT assay	10.1007/s00044-012-0168-x
MCF7	IC₅₀	4.17 μM Compound: DOX	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 37054758]
MCF7	IC₅₀	4.17 μM Compound: DOX	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 32307260]
MCF7	IC₅₀	4.17 μM Compound: DOX	Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 32085964]
MCF7	IC₅₀	4.17 μM Compound: DOX	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 30015070]
MCF7	IC₅₀	4.17 μM Compound: DOX	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 36242988]
MCF7	IC₅₀	4.17 μM Compound: Dox	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32527460]
MCF7	IC₅₀	4.17 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 29702448]
MCF7	IC₅₀	4.17 μM Compound: DOX	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 35964425]
MCF7	IC₅₀	4.17 μM Compound: Dox	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34126285]
MCF7	IC₅₀	4.17 μM Compound: Doxorubicin	Antitumor activity against human MCF7 cells assessed as inhibition of cell viability by MTT assay Antitumor activity against human MCF7 cells assessed as inhibition of cell viability by MTT assay	[PMID: 33065442]
MCF7	IC₅₀	4.17 μM Compound: DOX	Antiproliferative activity against human MCF7 cells by MTT assay Antiproliferative activity against human MCF7 cells by MTT assay	[PMID: 30216848]
MCF7	IC₅₀	4.24 μg/mL Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 28171832]
MCF7	IC₅₀	4.302 μg/mL Compound: Doxo	Cytotoxicity against human MCF7 cells after 48 hrs by alamar blue assay Cytotoxicity against human MCF7 cells after 48 hrs by alamar blue assay	[PMID: 25468043]
MCF7	IC₅₀	4.33 μM Compound: DOX	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 36252396]
MCF7	IC₅₀	4.39 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 33148490]
MCF7	IC₅₀	4.39 μM Compound: Dox	Cytotoxicity against human MCF7 cells assessed as decrease in cell viability treated for 2 hrs measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as decrease in cell viability treated for 2 hrs measured after 48 hrs by MTT assay	[PMID: 28129977]
MCF7	IC₅₀	4.4 μg/mL Compound: DOX	Cytotoxicity against human MCF7 cells by SRB assay Cytotoxicity against human MCF7 cells by SRB assay	[PMID: 23831694]
MCF7	IC₅₀	4.4 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 28919340]
MCF7	IC₅₀	4.5 μg/mL Compound: doxorubicin	Cytotoxicity against human MCF7 cells assessed as [3H]hypoxanthin incorporation after 24 to 72 hrs Cytotoxicity against human MCF7 cells assessed as [3H]hypoxanthin incorporation after 24 to 72 hrs	[PMID: 19296616]
MCF7	IC₅₀	4.5 μM Compound: adriamycin	Cytotoxicity against human MCF7 cells after 4 days by MTT assay Cytotoxicity against human MCF7 cells after 4 days by MTT assay	[PMID: 17194586]
MCF7	IC₅₀	4.5 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 35696863]
MCF7	IC₅₀	4.5 μM Compound: Dox	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 22000946]
MCF7	IC₅₀	4.56 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 24 hrs by SRB assay Cytotoxicity against human MCF7 cells after 24 hrs by SRB assay	[PMID: 30096580]
MCF7	IC₅₀	4.56 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by SRB assay	[PMID: 32361329]
MCF7	IC₅₀	4.6 μg/mL Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 35526504]
MCF7	IC₅₀	4.6 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 33766771]
MCF7	IC₅₀	4.63 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34838335]
MCF7	IC₅₀	4.7 μg/mL Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay	[PMID: 27894044]
MCF7	IC₅₀	4.9 x 10^-2 μM Compound: adriamycin	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 19285863]
MCF7	IC₅₀	41.9 nM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay	[PMID: 31655432]
MCF7	IC₅₀	42.52 μM Compound: Dox	Cytotoxicity against human MCF7 cells after 3 days by MTT assay Cytotoxicity against human MCF7 cells after 3 days by MTT assay	[PMID: 21741833]
MCF7	GI₅₀	42.8 nM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 15270581]
MCF7	GI₅₀	42.8 nM Compound: Doxorubicin	Antitumor activity against human MCF7 cells expressing estrogen receptor assessed as inhibition of growth after 48 hrs using sulforhodamine B dye Antitumor activity against human MCF7 cells expressing estrogen receptor assessed as inhibition of growth after 48 hrs using sulforhodamine B dye	[PMID: 19428155]
MCF7	GI₅₀	42.8 nM Compound: doxorubicin	Antitumor activity against human MCF7 cells after 48 hrs Antitumor activity against human MCF7 cells after 48 hrs	[PMID: 18439831]
MCF7	GI₅₀	42.8 nM Compound: doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs Cytotoxicity against human MCF7 cells after 48 hrs	[PMID: 17964791]
MCF7	GI₅₀	42.8 nM Compound: doxorubicin	Growth inhibition of human MCF7 cells after 48 hrs Growth inhibition of human MCF7 cells after 48 hrs	[PMID: 17692432]
MCF7	GI₅₀	42.8 μM Compound: doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 19070942]
MCF7	GI₅₀	42.8 μM Compound: Doxorubicin	Growth inhibition of human MCF7 cells after 48 hrs by SRB assay Growth inhibition of human MCF7 cells after 48 hrs by SRB assay	[PMID: 15165162]
MCF7	GI₅₀	42.8 μM Compound: Doxorubicin	Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 21504224]
MCF7	GI₅₀	43.3 nM Compound: Doxorubucin	Growth inhibition of human MCF7 cells after 48 hrs by SRB assay Growth inhibition of human MCF7 cells after 48 hrs by SRB assay	[PMID: 21138784]
MCF7	GI₅₀	43.3 nM Compound: doxorubicin	Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 20934235]
MCF7	IC₅₀	43.44 μM Compound: ADR, ADM	Cytotoxicity against adriyamycin-resistant human MCF7 cells over expressing P-glycoprotein after 72 hrs by SRB assay Cytotoxicity against adriyamycin-resistant human MCF7 cells over expressing P-glycoprotein after 72 hrs by SRB assay	[PMID: 21761866]
MCF7	IC₅₀	44 μM Compound: 21	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 32435401]
MCF7	IC₅₀	47.8 μM Compound: DOX	Antiproliferative activity against adriamycin resistant human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against adriamycin resistant human MCF7 cells after 72 hrs by MTT assay	[PMID: 17964170]
MCF7	IC₅₀	5 ug Compound: Doxorubicin	Anticancer activity against human MCF7 cells after 48 hrs by MTT assay Anticancer activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 28372908]
MCF7	IC₅₀	5 μg/mL Compound: adriamycin	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 19700322]
MCF7	IC₅₀	5 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs under hypoxic condition by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs under hypoxic condition by MTT assay	[PMID: 31972093]
MCF7	IC₅₀	5.17 μM Compound: Dox	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 35635947]
MCF7	IC₅₀	5.3 μM Compound: DXR	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 24 hrs by XTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 24 hrs by XTT assay	[PMID: 26649907]
MCF7	IC₅₀	5.4 nM Compound: Dox	Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 48 hrs by SRB assay	[PMID: 23085106]
MCF7	IC₅₀	5.46 μM Compound: Doxorubicin	Antitumor activity against Homo sapiens (human) MCF7 cells assessed as cell growth inhibition after 48 hr by MTT assay Antitumor activity against Homo sapiens (human) MCF7 cells assessed as cell growth inhibition after 48 hr by MTT assay	10.1007/s00044-013-0497-4
MCF7	IC₅₀	5.46 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as cell survival after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as cell survival after 48 hrs by SRB assay	[PMID: 23708013]
MCF7	IC₅₀	5.46 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 22119132]
MCF7	IC₅₀	5.46 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 22119131]
MCF7	IC₅₀	5.49 mM Compound: doxorubicin	Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 24583357]
MCF7	GI₅₀	5.5 x 10^-2 μM Compound: doxorubicin	Cytotoxicity against human MCF7 cells by SRB assay Cytotoxicity against human MCF7 cells by SRB assay	[PMID: 11678649]
MCF7	IC₅₀	5.5 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth after overnight incubation by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth after overnight incubation by MTT assay	[PMID: 32165076]
MCF7	IC₅₀	5.51 μM Compound: Dox	Cytotoxicity against human MCF7 cells assessed as cell viability measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell viability measured after 24 hrs by MTT assay	[PMID: 33183865]
MCF7	GI₅₀	5.7 μM Compound: ADR	Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 28754470]
MCF7	IC₅₀	5.73 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 26873414]
MCF7	IC₅₀	5.9 μM Compound: Doxorubicin	Anticancer activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT based microplate ELISA reader analysis Anticancer activity against human MCF7 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT based microplate ELISA reader analysis	[PMID: 34438126]
MCF7	IC₅₀	5300 nM Compound: Doxorubicin	Antiproliferative activity against human doxorubicin-resistant MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human doxorubicin-resistant MCF7 cells after 48 hrs by MTT assay	[PMID: 25937236]
MCF7	IC₅₀	58 nM Compound: doxorubicin	Cytotoxicity against human MCF7 cells expressing P-glycoprotein after 72 hrs by MTS assay Cytotoxicity against human MCF7 cells expressing P-glycoprotein after 72 hrs by MTS assay	[PMID: 19655762]
MCF7	IC₅₀	580 nM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30172625]
MCF7	GI₅₀	59.77 nM Compound: Doxorubicin	Growth inhibition of human MCF7 cells after 48 hrs by SRB assay Growth inhibition of human MCF7 cells after 48 hrs by SRB assay	[PMID: 24411197]
MCF7	IC₅₀	6.1 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as surviving fraction after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as surviving fraction after 48 hrs by SRB assay	[PMID: 24686014]
MCF7	IC₅₀	6.1 μM Compound: DX	Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay	10.1039/C5MD00513B
MCF7	IC₅₀	6.2 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 26317881]
MCF7	IC₅₀	6.3 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells by MTT reduction assay Antiproliferative activity against human MCF7 cells by MTT reduction assay	[PMID: 33421712]
MCF7	IC₅₀	6.32 μM Compound: Dox	Antiproliferative activity against human MCF7 cells after 48 hrs under hypoxic condition by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs under hypoxic condition by MTT assay	[PMID: 30445264]
MCF7	IC₅₀	6.71 μg/mL Compound: DOX	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 19932530]
MCF7	IC₅₀	6.75 μM Compound: DOX	Anticancer activity against human MCF7 cells assessed as inhibition of tumor cell proliferation after 48 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as inhibition of tumor cell proliferation after 48 hrs by MTT assay	[PMID: 25064350]
MCF7	IC₅₀	6.75 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by resazurin microplate assay Cytotoxicity against human MCF7 cells by resazurin microplate assay	[PMID: 27228159]
MCF7	IC₅₀	6.9 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 22304344]
MCF7	GI₅₀	65.4 nM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 24113365]
MCF7	GI₅₀	65.4 nM Compound: Doxorubicin	Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 23623253]
MCF7	IC₅₀	65.6 μg/mL Compound: Doxorubicin	Antitumor activity against human MCF7 xenografted BALB/c mouse assessed as reduction in tumor growth at 30 mg/kg, ip administered for once every 3 days measured after 15 days Antitumor activity against human MCF7 xenografted BALB/c mouse assessed as reduction in tumor growth at 30 mg/kg, ip administered for once every 3 days measured after 15 days	[PMID: 34147747]
MCF7	IC₅₀	65.6 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 36325400]
MCF7	IC₅₀	65.6 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by SRB assay Cytotoxicity against human MCF7 cells by SRB assay	[PMID: 36325400]
MCF7	IC₅₀	66.2 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 21429743]
MCF7	GI₅₀	68.8 nM Compound: Doxorubicin	Growth inhibition of human MCF7 cells after 48 hrs by SRB assay Growth inhibition of human MCF7 cells after 48 hrs by SRB assay	[PMID: 22177409]
MCF7	CC₅₀	7 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 29792325]
MCF7	IC₅₀	7.2 μM Compound: Dox	Growth inhibition of Homo sapiens (human) MCF7 cells after 48 hr by MTT assay Growth inhibition of Homo sapiens (human) MCF7 cells after 48 hr by MTT assay	10.1007/s00044-013-0534-3
MCF7	IC₅₀	7.66 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells by SRB assay Cytotoxicity against human MCF7 cells by SRB assay	[PMID: 23806014]
MCF7	IC₅₀	7.67 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33214036]
MCF7	IC₅₀	7.86 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells incubated for 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 24 hrs by MTT assay	[PMID: 29409753]
MCF7	IC₅₀	71.8 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) MCF-7 cells after 48 hr by SRB assay relative to control Cytotoxicity against Homo sapiens (human) MCF-7 cells after 48 hr by SRB assay relative to control	10.1007/s00044-010-9332-3
MCF7	IC₅₀	71.8 μM Compound: Doxorubicin	Anticancer activity against human MCF7 cells assessed as viable cells after 48 hrs by SRB assay Anticancer activity against human MCF7 cells assessed as viable cells after 48 hrs by SRB assay	[PMID: 21890248]
MCF7	IC₅₀	71.8 μM Compound: Doxorubicin	Anticancer activity against human MCF7 cells assessed as survival fraction after 48 hrs by SRB assay Anticancer activity against human MCF7 cells assessed as survival fraction after 48 hrs by SRB assay	[PMID: 20684857]
MCF7	IC₅₀	75.6 nM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29886322]
MCF7	IC₅₀	792 nM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTS assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTS assay	[PMID: 35737669]
MCF7	ED₅₀	8 μM Compound: doxorubicin	Antitumor activity against human MCF7 cells after 24 hrs by MTT assay Antitumor activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 17482824]
MCF7	IC₅₀	8.02 nM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine-B assay Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine-B assay	[PMID: 25255434]
MCF7	IC₅₀	8.02 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 26907155]
MCF7	IC₅₀	8.02 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 48 hrs by MTT assay	[PMID: 24878360]
MCF7	IC₅₀	8.09 μM Compound: DOX	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 22444025]
MCF7	IC₅₀	8.1 x 10^-2 μg/mL Compound: Adriamycin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 9644064]
MCF7	IC₅₀	8.3 μM Compound: DOX	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 19329312]
MCF7	IC₅₀	8.39 μM Compound: Dox	Antiproliferative activity against human MCF7 cells measured after 48 hrs under hypoxia condition by MTT assay Antiproliferative activity against human MCF7 cells measured after 48 hrs under hypoxia condition by MTT assay	[PMID: 31276899]
MCF7	IC₅₀	8.4 nM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by SRB assay	[PMID: 30660827]
MCF7	IC₅₀	8.4 μg/mL Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 35526504]
MCF7	GI₅₀	8.4 μM Compound: Dox	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 29407991]
MCF7	GI₅₀	8.4 μM Compound: DOX	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 29316526]
MCF7	GI₅₀	8.4 μM Compound: DOX	Growth inhibition of human MCF7 cells after 48 hrs by SRB assay Growth inhibition of human MCF7 cells after 48 hrs by SRB assay	[PMID: 28433679]
MCF7	IC₅₀	8.62 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 22818039]
MCF7	IC₅₀	8.81 μM Compound: Doxo	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 27597408]
MCF7	IC₅₀	8.94 μM Compound: Doxo	Cytotoxicity against estrogen receptor-positive human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against estrogen receptor-positive human MCF7 cells after 24 hrs by MTT assay	[PMID: 21885273]
MCF7	ED₅₀	8.97 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human MCF7 cells after 7 days by MTT assay Cytotoxicity against human MCF7 cells after 7 days by MTT assay	10.1021/np970510f
MCF7	IC₅₀	8.98 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells after 72 hrs by resazurin based fluorescence assay Cytotoxicity against human MCF7 cells after 72 hrs by resazurin based fluorescence assay	[PMID: 28927795]
MCF7	IC₅₀	879 nM Compound: Doxorubicin	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29795767]
MCF7	ED₅₀	9 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human MCF7 cells after 7 days by MTT assay Cytotoxicity against human MCF7 cells after 7 days by MTT assay	[PMID: 10395501]
MCF7	IC₅₀	9.11 μM Compound: Dox	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28549734]
MCF7	IC₅₀	9.34 μM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells measured after 24 hrs by MTT assay	[PMID: 34363937]
MCF7	ED₅₀	9.53 x 10^-1 μg/mL Compound: adriamycin	Cytotoxicity against human MCF7 cells after 7 days by MTT assay Cytotoxicity against human MCF7 cells after 7 days by MTT assay	[PMID: 15730242]
MCF7	IC₅₀	9.84 nM Compound: Doxorubicin	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 30429975]
MCF7	IC₅₀	9.86 μM Compound: Doxo	Cytotoxicity against human MCF7 cells measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells measured after 24 hrs by MTT assay	[PMID: 31104996]
MCF7-DOX	IC₅₀	3.8 μM Compound: Dox	Cytotoxicity against human MCF7/Dox cells after 72 hrs by MTT assay Cytotoxicity against human MCF7/Dox cells after 72 hrs by MTT assay	[PMID: 30659997]
MDA-MB-231	GI₅₀	< 0.01 μM Compound: Doxorubicin	Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay	10.1039/C6MD00097E
MDA-MB-231	GI₅₀	< 0.01 μM Compound: Doxorubicin	Growth inhibition in human MDA-MB-231 cells after 48 hrs by SRB assay Growth inhibition in human MDA-MB-231 cells after 48 hrs by SRB assay	[PMID: 31546197]
MDA-MB-231	GI₅₀	< 0.01 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay	[PMID: 26994690]
MDA-MB-231	IC₅₀	< 1 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) MDA231 cells after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) MDA231 cells after 48 hr by MTT assay	10.1007/s00044-011-9884-x
MDA-MB-231	IC₅₀	< 1 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell growth by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell growth by MTT assay	[PMID: 36734533]
MDA-MB-231	IC₅₀	< 1 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 23079527]
MDA-MB-231	IC₅₀	< 1 μM Compound: Doxorubicin	Cytotoxicity against human MDA231 cells by MTT assay Cytotoxicity against human MDA231 cells by MTT assay	[PMID: 21996519]
MDA-MB-231	IC₅₀	< 1 μM Compound: doxorubicin	Cytotoxicity against human MDA-MB-231 cells by SRB assay Cytotoxicity against human MDA-MB-231 cells by SRB assay	[PMID: 33847126]
MDA-MB-231	IC₅₀	< 1 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells by SRB assay Cytotoxicity against human MDA-MB-231 cells by SRB assay	[PMID: 33371684]
MDA-MB-231	IC₅₀	< 1 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells by tetrazolium-reduction assay Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells by tetrazolium-reduction assay	10.1007/s00044-012-0450-y
MDA-MB-231	IC₅₀	0.006 μM Compound: Doxorubicin	Inhibitory activity against MDA-231 cell line using MTT assay (ER-,EGFR+,mutant p53) Inhibitory activity against MDA-231 cell line using MTT assay (ER-,EGFR+,mutant p53)	[PMID: 10780913]
MDA-MB-231	IC₅₀	0.0069 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 31264855]
MDA-MB-231	GI₅₀	0.01 μM Compound: Doxorubicin	Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay	[PMID: 26067381]
MDA-MB-231	IC₅₀	0.01 μM Compound: Doxorubicine	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)	[PMID: 33422908]
MDA-MB-231	IC₅₀	0.012 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by Hoechst 33342 staining-based assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by Hoechst 33342 staining-based assay	[PMID: 30655216]
MDA-MB-231	GI₅₀	0.02 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay	[PMID: 25827522]
MDA-MB-231	IC₅₀	0.02 μM Compound: Doxorubicin	Toxicity in human MDA-MB-231 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay Toxicity in human MDA-MB-231 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay	[PMID: 31753515]
MDA-MB-231	IC₅₀	0.02 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	[PMID: 25937235]
MDA-MB-231	GI₅₀	0.023 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells by SRB assay Antiproliferative activity against human MDA-MB-231 cells by SRB assay	[PMID: 31546197]
MDA-MB-231	IC₅₀	0.03 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as growth inhibition after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as growth inhibition after 72 hr by MTT assay	10.1007/s00044-012-0428-9
MDA-MB-231	IC₅₀	0.03 μM Compound: doxorubicin	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 17141923]
MDA-MB-231	IC₅₀	0.034 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31883489]
MDA-MB-231	GI₅₀	0.038 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 20014800]
MDA-MB-231	IC₅₀	0.04 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTS assay	[PMID: 23148652]
MDA-MB-231	IC₅₀	0.04 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs	[PMID: 34601029]
MDA-MB-231	GI₅₀	0.046 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 30360625]
MDA-MB-231	IC₅₀	0.047 nM Compound: Doxorubicine	Cytotoxicity against human MDA231 cells after 72 hrs by MTS assay Cytotoxicity against human MDA231 cells after 72 hrs by MTS assay	[PMID: 21142180]
MDA-MB-231	IC₅₀	0.06 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 33743356]
MDA-MB-231	GI₅₀	0.068 μM Compound: ADR	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 30253887]
MDA-MB-231	GI₅₀	0.068 μM Compound: ADR	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 28870801]
MDA-MB-231	IC₅₀	0.07 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay	[PMID: 18547115]
MDA-MB-231	IC₅₀	0.07 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28327308]
MDA-MB-231	IC₅₀	0.07 μM Compound: doxorubicin	Cytotoxicity against human MDA-MB-231cells after 6 days by MTT method Cytotoxicity against human MDA-MB-231cells after 6 days by MTT method	[PMID: 16309317]
MDA-MB-231	IC₅₀	0.07 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 28257197]
MDA-MB-231	GI₅₀	0.073 μM Compound: Doxorubicin	Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay	[PMID: 27964883]
MDA-MB-231	IC₅₀	0.08 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31546197]
MDA-MB-231	IC₅₀	0.08 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 30457333]
MDA-MB-231	IC₅₀	0.0805 μM Compound: Dox	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 96 hrs by MTT method Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 96 hrs by MTT method	[PMID: 34236840]
MDA-MB-231	GI₅₀	0.085 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 27209232]
MDA-MB-231	GI₅₀	0.085 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in net protein increase after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in net protein increase after 48 hrs by SRB assay	[PMID: 25462234]
MDA-MB-231	GI₅₀	0.085 μM Compound: Doxorubicin	Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by SRB assay	[PMID: 25264072]
MDA-MB-231	GI₅₀	0.086 μM Compound: ADR	Anticancer activity against human MDA-MB-231 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method Anticancer activity against human MDA-MB-231 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method	[PMID: 34500188]
MDA-MB-231	IC₅₀	0.09 μM Compound: DOX	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 6 days by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 6 days by MTT assay	[PMID: 32653698]
MDA-MB-231	IC₅₀	0.09 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 33340938]
MDA-MB-231	IC₅₀	0.09 μM Compound: DOX	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth after 72 hrs by MTT assay	[PMID: 30746062]
MDA-MB-231	IC₅₀	0.09 μM Compound: DOX	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28427016]
MDA-MB-231	IC₅₀	0.09 μM Compound: Dox	Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27231128]
MDA-MB-231	IC₅₀	0.09 μM Compound: DOX	Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 26720155]
MDA-MB-231	IC₅₀	0.09 μM Compound: Dox	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 26494582]
MDA-MB-231	IC₅₀	0.09 μM Compound: DOX	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 25259516]
MDA-MB-231	GI₅₀	0.09 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay	[PMID: 24158013]
MDA-MB-231	IC₅₀	0.1 μg/mL Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells by MTT colorimetric method Cytotoxicity against human MDA-MB-231 cells by MTT colorimetric method	[PMID: 17125220]
MDA-MB-231	IC₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells after 72 hr by MTT assay	10.1007/s00044-010-9517-9
MDA-MB-231	IC₅₀	0.1 μM Compound: Doxo	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 20334960]
MDA-MB-231	GI₅₀	0.1 μM Compound: doxorubicin	Cytotoxicity against human MDA-MB-231 cells by SRB assay Cytotoxicity against human MDA-MB-231 cells by SRB assay	[PMID: 19007287]
MDA-MB-231	GI₅₀	0.1 μM Compound: doxorubicin	Cytotoxicity against human MDA-MB-231 cells by SRB assay Cytotoxicity against human MDA-MB-231 cells by SRB assay	[PMID: 17512741]
MDA-MB-231	IC₅₀	0.1 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs	[PMID: 33139111]
MDA-MB-231	IC₅₀	0.1 μM Compound: adriamycin	Antitumor activity against human MDA-MB-231 cells by methylene blue staining method Antitumor activity against human MDA-MB-231 cells by methylene blue staining method	[PMID: 17656091]
MDA-MB-231	GI₅₀	0.112 μM Compound: ADR	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay	[PMID: 27096046]
MDA-MB-231	IC₅₀	0.12 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 3 days by MTS assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 3 days by MTS assay	10.1039/C1MD00155H
MDA-MB-231	IC₅₀	0.12 μM Compound: Doxorubicin	Cytotoxicity against estrogen receptor-deficient human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against estrogen receptor-deficient human MDA-MB-231 cells after 48 hrs by MTT assay	10.1039/C2MD20327H
MDA-MB-231	IC₅₀	0.12 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 30108986]
MDA-MB-231	IC₅₀	0.12 μM Compound: DOX	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 25619894]
MDA-MB-231	IC₅₀	0.12 μM Compound: DOX	Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 24148837]
MDA-MB-231	IC₅₀	0.12 μM Compound: Doxorubicin	Cytotoxicity against ER-negative human MDA-MB-231 cells after 1 hr by SRB assay Cytotoxicity against ER-negative human MDA-MB-231 cells after 1 hr by SRB assay	[PMID: 22770744]
MDA-MB-231	IC₅₀	0.13 μM Compound: DOX	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27668963]
MDA-MB-231	IC₅₀	0.13 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 pcDNA cells assessed as reduction in cell viability after 72 hrs by RRA assay Cytotoxicity against human MDA-MB-231 pcDNA cells assessed as reduction in cell viability after 72 hrs by RRA assay	[PMID: 33508467]
MDA-MB-231	IC₅₀	0.14 μM Compound: doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT colorimetric method Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT colorimetric method	[PMID: 17622129]
MDA-MB-231	IC₅₀	0.15 μg/mL Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 18590313]
MDA-MB-231	GI₅₀	0.15 μM Compound: Dox	Growth inhibition of human MDA-MB-231 cells after 72 hrs by MTT assay Growth inhibition of human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 24163729]
MDA-MB-231	IC₅₀	0.16 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell growth after 72 hrs by cell titer glo assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell growth after 72 hrs by cell titer glo assay	[PMID: 27080175]
MDA-MB-231	IC₅₀	0.16 μM Compound: Doxo	Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 48 hrs by MTT assay	10.1039/C2MD20302B
MDA-MB-231	IC₅₀	0.16 μM Compound: Doxorubicin	Antiproliferative activity against 2D culture of human MDA-MB-231 cells after 72 hrs MTS assay Antiproliferative activity against 2D culture of human MDA-MB-231 cells after 72 hrs MTS assay	[PMID: 27721156]
MDA-MB-231	IC₅₀	0.17 μM Compound: Dox	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 26494582]
MDA-MB-231	IC₅₀	0.17 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by resazurin/resorufin-based fluorescence assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by resazurin/resorufin-based fluorescence assay	[PMID: 23600925]
MDA-MB-231	IC₅₀	0.18 μM Compound: DOX	Cytotoxicity against human MDA-MB-231 cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human MDA-MB-231 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
MDA-MB-231	IC₅₀	0.18 μM Compound: doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay	[PMID: 18419154]
MDA-MB-231	IC₅₀	0.18 μM Compound: DOX	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 30106296]
MDA-MB-231	GI₅₀	0.18 μM Compound: Doxorubicin	Anticancer activity against human MDA-MB-231 cells by SRB assay Anticancer activity against human MDA-MB-231 cells by SRB assay	[PMID: 20732810]
MDA-MB-231	IC₅₀	0.19 μg/mL Compound: doxo	Cytotoxicity against human MDA-MB-231 cells by MTT method Cytotoxicity against human MDA-MB-231 cells by MTT method	[PMID: 17417907]
MDA-MB-231	IC₅₀	0.2 μg/mL Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by CCK-8 assay	[PMID: 22658083]
MDA-MB-231	IC₅₀	0.2 μg/mL Compound: doxorubicin	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 18973388]
MDA-MB-231	IC₅₀	0.2 μg/mL Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 16724859]
MDA-MB-231	IC₅₀	0.2 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24012378]
MDA-MB-231	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 19394829]
MDA-MB-231	IC₅₀	0.2 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 18063366]
MDA-MB-231	GI₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay	[PMID: 29112820]
MDA-MB-231	IC₅₀	0.23 μM Compound: DOX	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay	[PMID: 30106296]
MDA-MB-231	IC₅₀	0.23 μM Compound: Doxorubicin	Antiproliferative activity against 3D culture of human MDA-MB-231 cells after 72 hrs MTS assay Antiproliferative activity against 3D culture of human MDA-MB-231 cells after 72 hrs MTS assay	[PMID: 27721156]
MDA-MB-231	IC₅₀	0.24 μM Compound: Doxorubucin	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 20718475]
MDA-MB-231	IC₅₀	0.25 μM Compound: Dox	Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition under hypoxia conditions measured after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition under hypoxia conditions measured after 72 hrs by MTT assay	[PMID: 34902732]
MDA-MB-231	IC₅₀	0.25 μM Compound: Doxorubicin	Growth inhibition of human MDA-MB-231 cells after 72 hrs by MTT assay Growth inhibition of human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 30471828]
MDA-MB-231	IC₅₀	0.26 μM Compound: Dox	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 26494582]
MDA-MB-231	IC₅₀	0.3 μM Compound: DOX	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 30429098]
MDA-MB-231	IC₅₀	0.3 μM Compound: Doxorubicin	Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay	[PMID: 33940466]
MDA-MB-231	IC₅₀	0.31 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs Antiproliferative activity against human MDA-MB-231 cells after 72 hrs	[PMID: 25127463]
MDA-MB-231	IC₅₀	0.32 μM Compound: ADM	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 36332551]
MDA-MB-231	IC₅₀	0.33 μM Compound: Dox	Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition under normoxia conditions measured after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition under normoxia conditions measured after 72 hrs by MTT assay	[PMID: 34902732]
MDA-MB-231	IC₅₀	0.36 μM Compound: Doxorubicin	Cytotoxic activity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Cytotoxic activity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 28395220]
MDA-MB-231	IC₅₀	0.369 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 28406643]
MDA-MB-231	IC₅₀	0.37 μg/mL Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 34973507]
MDA-MB-231	GI₅₀	0.39 μg/mL Compound: Adriamycin	Antiproliferative activity against human MDA-MB-231 cells by SRB assay Antiproliferative activity against human MDA-MB-231 cells by SRB assay	[PMID: 18023932]
MDA-MB-231	IC₅₀	0.39 μM Compound: Adriamycin	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 21721528]
MDA-MB-231	IC₅₀	0.414 nM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 5 days by cell viability analyzer Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 5 days by cell viability analyzer	[PMID: 26291039]
MDA-MB-231	IC₅₀	0.42 μM Compound: Dox	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 35339100]
MDA-MB-231	IC₅₀	0.44 μM Compound: DOX	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 33276990]
MDA-MB-231	IC₅₀	0.44 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells under hypoxic condition by MTT assay Cytotoxicity against human MDA-MB-231 cells under hypoxic condition by MTT assay	[PMID: 29684705]
MDA-MB-231	IC₅₀	0.45 μg/mL Compound: Doxorubicin	Anticancer activity against human MDA-MB-231 cells by MTT assay Anticancer activity against human MDA-MB-231 cells by MTT assay	[PMID: 31404864]
MDA-MB-231	IC₅₀	0.45 μM Compound: DOX	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth measured after 72 hrs by CCK8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth measured after 72 hrs by CCK8 assay	[PMID: 31784322]
MDA-MB-231	IC₅₀	0.45 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as effect on cell viability measured after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as effect on cell viability measured after 48 hrs by MTT assay	[PMID: 27521588]
MDA-MB-231	IC₅₀	0.45 μM Compound: DOX	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27016707]
MDA-MB-231	IC₅₀	0.46 μg/mL Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay	[PMID: 19691312]
MDA-MB-231	IC₅₀	0.47 μM Compound: DOX	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs by MTT assay	[PMID: 35818137]
MDA-MB-231	IC₅₀	0.4817 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34325324]
MDA-MB-231	IC₅₀	0.49 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 28554092]
MDA-MB-231	GI₅₀	0.49 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 21885166]
MDA-MB-231	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by Alamar blue assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by Alamar blue assay	[PMID: 21999655]
MDA-MB-231	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 25172420]
MDA-MB-231	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 23911578]
MDA-MB-231	IC₅₀	0.501 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 24113366]
MDA-MB-231	IC₅₀	0.501 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 23764302]
MDA-MB-231	GI₅₀	0.51 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay	[PMID: 23871905]
MDA-MB-231	GI₅₀	0.51 μM Compound: Doxorubicin	Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
MDA-MB-231	GI₅₀	0.51 μM Compound: Doxorubicin	Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
MDA-MB-231	IC₅₀	0.53 μM Compound: ADR	Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28754470]
MDA-MB-231	IC₅₀	0.53 μM Compound: Dox	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 33713977]
MDA-MB-231	IC₅₀	0.53 μM Compound: Dox	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay	[PMID: 36336315]
MDA-MB-231	IC₅₀	0.55 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 34315044]
MDA-MB-231	IC₅₀	0.55 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
MDA-MB-231	IC₅₀	0.55 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell survival after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell survival after 48 hrs by MTT assay	[PMID: 28494255]
MDA-MB-231	GI₅₀	0.56 μM Compound: ADR	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay	[PMID: 25953156]
MDA-MB-231	IC₅₀	0.57 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by Sulphorhodamine assay Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by Sulphorhodamine assay	[PMID: 37146520]
MDA-MB-231	IC₅₀	0.58 μM Compound: doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by Alamar blue assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by Alamar blue assay	[PMID: 22264149]
MDA-MB-231	IC₅₀	0.58 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by resazurin/AlamarBlue dye-based fluorescence assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by resazurin/AlamarBlue dye-based fluorescence assay	[PMID: 28139929]
MDA-MB-231	IC₅₀	0.6 μg/mL Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability by MTT assay	[PMID: 32223924]
MDA-MB-231	IC₅₀	0.6 μM Compound: Doxorubicin	Anticancer activity against human MDA-MB-231 cells incubated for 24 hrs by MTT assay Anticancer activity against human MDA-MB-231 cells incubated for 24 hrs by MTT assay	[PMID: 28579122]
MDA-MB-231	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 26252628]
MDA-MB-231	IC₅₀	0.6 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability preincubated for 24 hrs under hypoxia condition further incubated for 72 hrs under normaxic condition by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability preincubated for 24 hrs under hypoxia condition further incubated for 72 hrs under normaxic condition by MTT assay	[PMID: 31546197]
MDA-MB-231	IC₅₀	0.6 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 96 hrs under normaxic condition by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 96 hrs under normaxic condition by MTT assay	[PMID: 31546197]
MDA-MB-231	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs in hypoxic condition by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs in hypoxic condition by MTT assay	[PMID: 31404864]
MDA-MB-231	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs in normoxic condition by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs in normoxic condition by MTT assay	[PMID: 31404864]
MDA-MB-231	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 24300737]
MDA-MB-231	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells by resazurin dye based Alamar blue assay Cytotoxicity against human MDA-MB-231 cells by resazurin dye based Alamar blue assay	[PMID: 29373790]
MDA-MB-231	GI₅₀	0.61 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells by SRB assay Cytotoxicity against human MDA-MB-231 cells by SRB assay	[PMID: 19596579]
MDA-MB-231	IC₅₀	0.65 μg/mL Compound: doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay	[PMID: 16252914]
MDA-MB-231	IC₅₀	0.65 μM Compound: Doxorubicin	Cytotoxicity against estrogen receptor-negative human MDA-MB-231 cells after 24 hrs by MTT assay Cytotoxicity against estrogen receptor-negative human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 24513041]
MDA-MB-231	IC₅₀	0.68 μM Compound: doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by Alamar Blue assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by Alamar Blue assay	[PMID: 24251417]
MDA-MB-231	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells incubated for 24 hrs by MTT asasy Cytotoxicity against human MDA-MB-231 cells incubated for 24 hrs by MTT asasy	[PMID: 28615134]
MDA-MB-231	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 26586599]
MDA-MB-231	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by resazurin dye based AlamarBlue assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by resazurin dye based AlamarBlue assay	[PMID: 34495663]
MDA-MB-231	IC₅₀	0.72 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 27886545]
MDA-MB-231	IC₅₀	0.73 μg/mL Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay	[PMID: 15387653]
MDA-MB-231	IC₅₀	0.75 μM Compound: DOX	Antiproliferative activity against ER negative human MDA-MB-231 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Antiproliferative activity against ER negative human MDA-MB-231 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 25737400]
MDA-MB-231	IC₅₀	0.75 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 28886509]
MDA-MB-231	GI₅₀	0.76 μM Compound: Dox	Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs and measured by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs and measured by MTT assay	[PMID: 35973342]
MDA-MB-231	IC₅₀	0.78 μM Compound: DOX	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by SRB assay	[PMID: 30106296]
MDA-MB-231	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 24780595]
MDA-MB-231	IC₅₀	0.8 μM Compound: Dox	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 24507927]
MDA-MB-231	IC₅₀	0.8 μM Compound: Dox	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 33479622]
MDA-MB-231	IC₅₀	0.81 μM Compound: DOX	Cytotoxicity against human MDA-MB-231 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells expressing high level of topoisomerase I/II measured after 72 hrs by MTT assay	[PMID: 35612499]
MDA-MB-231	IC₅₀	0.85 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as cell viability at 0.1 to 100 uM after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as cell viability at 0.1 to 100 uM after 48 hrs by MTT assay	[PMID: 26263187]
MDA-MB-231	IC₅₀	0.88 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 25419616]
MDA-MB-231	IC₅₀	0.9 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as cell death after 24 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells assessed as cell death after 24 hrs by MTS assay	[PMID: 29757646]
MDA-MB-231	IC₅₀	0.9 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 24044895]
MDA-MB-231	IC₅₀	0.91 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 2 days by MTT assay Cytotoxicity against human MDA-MB-231 cells after 2 days by MTT assay	[PMID: 23932340]
MDA-MB-231	IC₅₀	0.91 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26433616]
MDA-MB-231	IC₅₀	0.91 μM Compound: Adriamycin	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26356746]
MDA-MB-231	IC₅₀	0.91 μM Compound: Doxorubicin	In vitro cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition by MTT assay In vitro cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition by MTT assay	[PMID: 24742385]
MDA-MB-231	IC₅₀	0.91 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 24287557]
MDA-MB-231	IC₅₀	0.98 μM Compound: Adriamycin	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay	[PMID: 24717154]
MDA-MB-231	IC₅₀	1 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition by MTT assay	[PMID: 25765907]
MDA-MB-231	IC₅₀	1.07 μM Compound: DOX	Cytotoxicity against human MDA-MB-231 cells after 96 hrs under normoxic condition by MTT assay Cytotoxicity against human MDA-MB-231 cells after 96 hrs under normoxic condition by MTT assay	[PMID: 29649740]
MDA-MB-231	IC₅₀	1.13 μM Compound: Doxorubicin	Antitumor activity against human MDA231 cells after 24 to 48 hrs by MTT assay Antitumor activity against human MDA231 cells after 24 to 48 hrs by MTT assay	[PMID: 21553829]
MDA-MB-231	IC₅₀	1.2 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 29975532]
MDA-MB-231	IC₅₀	1.23 μM Compound: Doxorubicin	Cytotoxicity against triple-negative human MDA-MB-231 cells assessed as redution in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against triple-negative human MDA-MB-231 cells assessed as redution in cell viability incubated for 72 hrs by SRB assay	[PMID: 31810778]
MDA-MB-231	IC₅₀	1.246 μM Compound: Doxorubicin	Cytotoxicity activity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
MDA-MB-231	IC₅₀	1.27 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30389295]
MDA-MB-231	IC₅₀	1.3 μM Compound: Doxorubicin	Growth inhibition of human MDA-MB-231 cells by MTT assay Growth inhibition of human MDA-MB-231 cells by MTT assay	[PMID: 33901643]
MDA-MB-231	IC₅₀	1.32 μg/mL Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 21106454]
MDA-MB-231	IC₅₀	1.32 μM Compound: II	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 29289881]
MDA-MB-231	IC₅₀	1.36 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 24941129]
MDA-MB-231	IC₅₀	1.39 μg/mL Compound: doxorubicin	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 22413887]
MDA-MB-231	IC₅₀	1.4 μM Compound: Adriamycin	Cytotoxicity against human MDA-MB-231 cells after 4 days by MTT assay Cytotoxicity against human MDA-MB-231 cells after 4 days by MTT assay	[PMID: 21704436]
MDA-MB-231	IC₅₀	1.43 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31546197]
MDA-MB-231	IC₅₀	1.47 μM Compound: Dox	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 25247771]
MDA-MB-231	IC₅₀	1.546 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 25703298]
MDA-MB-231	IC₅₀	1.6 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 27496212]
MDA-MB-231	IC₅₀	1.6 μM Compound: Doxorubicin	Anticancer activity against human MDA-MB-231 cells assessed as growth inhibition incubated for 48 hrs by MTT assay Anticancer activity against human MDA-MB-231 cells assessed as growth inhibition incubated for 48 hrs by MTT assay	[PMID: 34363936]
MDA-MB-231	IC₅₀	1.67 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 26708114]
MDA-MB-231	IC₅₀	1.69 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
MDA-MB-231	IC₅₀	1.69 μM Compound: DOX	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 24487188]
MDA-MB-231	GI₅₀	1.79 μM Compound: ADR	Antiproliferative activity against human MDA-MB-231 cells by SRB method Antiproliferative activity against human MDA-MB-231 cells by SRB method	[PMID: 24835787]
MDA-MB-231	GI₅₀	1.79 μM Compound: ADR	Antiproliferative activity against human MDA-MB-231 cells by SRB assay Antiproliferative activity against human MDA-MB-231 cells by SRB assay	[PMID: 22738641]
MDA-MB-231	IC₅₀	1.8 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay	[PMID: 33316752]
MDA-MB-231	IC₅₀	1.8 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay	[PMID: 28419927]
MDA-MB-231	GI₅₀	1.8 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay	[PMID: 23964644]
MDA-MB-231	IC₅₀	1.81 μg/mL Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as cell viability after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as cell viability after 48 hr by MTT assay	10.1007/s00044-012-0168-x
MDA-MB-231	GI₅₀	1.84 μM Compound: Doxorubicin	Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-231 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 33477019]
MDA-MB-231	IC₅₀	1.93 μM Compound: Doxo	Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay	[PMID: 21800859]
MDA-MB-231	IC₅₀	10.02 μM Compound: Dox	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28549734]
MDA-MB-231	GI₅₀	10.7 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTS-PMS assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTS-PMS assay	[PMID: 27614919]
MDA-MB-231	GI₅₀	10.86 nM Compound: Doxorubicin	Antitumor activity against human estrogen receptor deficient MDA-MB-231 cells assessed as inhibition of growth after 48 hrs using sulforhodamine B dye Antitumor activity against human estrogen receptor deficient MDA-MB-231 cells assessed as inhibition of growth after 48 hrs using sulforhodamine B dye	[PMID: 19428155]
MDA-MB-231	IC₅₀	106 nM Compound: DOX	Anticancer activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Anticancer activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33901898]
MDA-MB-231	IC₅₀	1240 nM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 30429975]
MDA-MB-231	IC₅₀	14.35 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 20064676]
MDA-MB-231	IC₅₀	14.66 μM Compound: Dox	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability treated for 2 hrs measured after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability treated for 2 hrs measured after 48 hrs by MTT assay	[PMID: 28129977]
MDA-MB-231	IC₅₀	17.6 μM Compound: adriamycin	Cytotoxicity against human MDA-MB-231 cells after 4 days by MTT assay Cytotoxicity against human MDA-MB-231 cells after 4 days by MTT assay	[PMID: 17194586]
MDA-MB-231	IC₅₀	19.01 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 22818039]
MDA-MB-231	IC₅₀	2 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 25453802]
MDA-MB-231	IC₅₀	2 μM Compound: doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 20405844]
MDA-MB-231	IC₅₀	2.01 μM Compound: ADM	Cytotoxicity against human MDA-MB-231 cells after 38 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 38 hrs by MTT assay	[PMID: 25965778]
MDA-MB-231	IC₅₀	2.1 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 22749279]
MDA-MB-231	IC₅₀	2.1 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay	[PMID: 28818768]
MDA-MB-231	IC₅₀	2.1 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells by WST-1 assay Cytotoxicity against human MDA-MB-231 cells by WST-1 assay	[PMID: 22197145]
MDA-MB-231	IC₅₀	2.2 μM Compound: DOX	Antiproliferative activity against human MDA-MB-231 cells measured by MTT assay Antiproliferative activity against human MDA-MB-231 cells measured by MTT assay	[PMID: 33860662]
MDA-MB-231	IC₅₀	2.2 μM Compound: DOX	Cytotoxicity against human MDA-MB-231 cells measured by MTT assay Cytotoxicity against human MDA-MB-231 cells measured by MTT assay	[PMID: 33860662]
MDA-MB-231	IC₅₀	2.2 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 21425785]
MDA-MB-231	IC₅₀	2.25 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 28390228]
MDA-MB-231	IC₅₀	2.3 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 20832916]
MDA-MB-231	IC₅₀	2.36 μM Compound: DOX	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 32435420]
MDA-MB-231	IC₅₀	2.56 μM Compound: Doxorubicin	Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34124677]
MDA-MB-231	IC₅₀	2.76 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK-8 assay	[PMID: 34365102]
MDA-MB-231	IC₅₀	2.8 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29789258]
MDA-MB-231	IC₅₀	2.86 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 33744443]
MDA-MB-231	IC₅₀	2.9 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells after 4 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 4 hrs by MTT assay	[PMID: 25453798]
MDA-MB-231	IC₅₀	25.8 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Blue cell viability assay	[PMID: 35271771]
MDA-MB-231	IC₅₀	3.06 μM Compound: Adriamycin	Cytotoxicity against human MDA-MB-231 cells selected at 100 ug/ml vinblastine after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells selected at 100 ug/ml vinblastine after 72 hrs by MTT assay	[PMID: 21721528]
MDA-MB-231	IC₅₀	3.1 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 4 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 4 hrs by MTT assay	[PMID: 30773423]
MDA-MB-231	IC₅₀	3.18 μM Compound: DOX	Antiproliferative activity against human MDA231 cells by MTT assay Antiproliferative activity against human MDA231 cells by MTT assay	[PMID: 30216848]
MDA-MB-231	IC₅₀	3.41 μM Compound: Doxo (I)	Antiproliferative activity against human MDA-MB-231 cells by MTT assay Antiproliferative activity against human MDA-MB-231 cells by MTT assay	10.1039/C4MD00228H
MDA-MB-231	IC₅₀	3.41 μM Compound: DOX	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs	[PMID: 32736079]
MDA-MB-231	IC₅₀	3.61 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 20064676]
MDA-MB-231	IC₅₀	3.8 μM Compound: DOX	Inhibition of topoisomerase 2 in human MDA-MB-231 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay Inhibition of topoisomerase 2 in human MDA-MB-231 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay	[PMID: 30846253]
MDA-MB-231	IC₅₀	3.97 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31404864]
MDA-MB-231	IC₅₀	33.98 μM Compound: Doxorubicin	Anticancer activity against human MDA-MB-231 cells after 48 hrs by SRB assay Anticancer activity against human MDA-MB-231 cells after 48 hrs by SRB assay	[PMID: 24077528]
MDA-MB-231	IC₅₀	340 nM Compound: doxorubicin	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by XTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by XTT assay	[PMID: 22515366]
MDA-MB-231	GI₅₀	4.1 μM Compound: ADR	Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 28754470]
MDA-MB-231	IC₅₀	4.21 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 35367708]
MDA-MB-231	IC₅₀	4.4 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 48 hrs by MTT assay	[PMID: 31753800]
MDA-MB-231	IC₅₀	5.12 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 31884407]
MDA-MB-231	GI₅₀	5.95 μM Compound: Dox	Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35533562]
MDA-MB-231	IC₅₀	5.96 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 25140752]
MDA-MB-231	IC₅₀	5.98 μM Compound: DOX	Cytotoxicity against human MDA-MB-231 cells after 96 hrs under hypoxic condition by MTT assay Cytotoxicity against human MDA-MB-231 cells after 96 hrs under hypoxic condition by MTT assay	[PMID: 29649740]
MDA-MB-231	IC₅₀	6.03 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay in absence of 10% FBS Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay in absence of 10% FBS	[PMID: 26298501]
MDA-MB-231	IC₅₀	6.25 μM Compound: Doxorubicin	Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 30072225]
MDA-MB-231	IC₅₀	6.29 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay in presence of 10% FBS Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay in presence of 10% FBS	[PMID: 26298501]
MDA-MB-231	IC₅₀	6.75 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 27173802]
MDA-MB-231	IC₅₀	6.8 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 21429743]
MDA-MB-231	IC₅₀	7.46 μM Compound: Doxorubicin	Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 3 days by MTT assay Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 3 days by MTT assay	[PMID: 35007724]
MDA-MB-231	IC₅₀	7.85 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 29573910]
MDA-MB-231	IC₅₀	8.14 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	10.1039/C2MD20023F
MDA-MB-231	IC₅₀	8.14 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 22386528]
MDA-MB-231	IC₅₀	8.5 μM Compound: Dox	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs under hypoxic condition by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs under hypoxic condition by MTT assay	[PMID: 30445264]
MDA-MB-231	IC₅₀	8.53 μM Compound: DOX	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 30398868]
MDA-MB-361	IC₅₀	2.03 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-361 cells after 94 hrs by MTT assay Cytotoxicity against human MDA-MB-361 cells after 94 hrs by MTT assay	[PMID: 21868138]
MDA-MB-435	IC₅₀	0.03 μg/mL Compound: Doxorubicin	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay	[PMID: 20537433]
MDA-MB-435	IC₅₀	0.03 μM Compound: Dox	Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31306817]
MDA-MB-435	IC₅₀	0.15 μM Compound: Dox	Cytotoxicity against human MDA-MB-435 cells after 48 hrs by MTT assay in presence of verapamil Cytotoxicity against human MDA-MB-435 cells after 48 hrs by MTT assay in presence of verapamil	[PMID: 24028446]
MDA-MB-435	GI₅₀	0.2 μM Compound: adriamycin	Antitumor activity against human MDA-MB435 cells after 48 hrs by sulforhodamine B protein assay Antitumor activity against human MDA-MB435 cells after 48 hrs by sulforhodamine B protein assay	[PMID: 17448574]
MDA-MB-435	IC₅₀	0.24 μg/mL Compound: Dox	Anticancer activity against Homo sapiens (human) MDA-MB-435 cells assessed as inhibition of cell survival after 72 hr by MTT assay Anticancer activity against Homo sapiens (human) MDA-MB-435 cells assessed as inhibition of cell survival after 72 hr by MTT assay	10.1007/s00044-012-0236-2
MDA-MB-435	GI₅₀	0.25 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human MDA-MB-435 cells after 48 hrs by SRB assay Cytotoxicity against human MDA-MB-435 cells after 48 hrs by SRB assay	[PMID: 23871905]
MDA-MB-435	GI₅₀	0.25 μM Compound: Doxorubicin	Growth inhibition of human MDA-MB-435 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-435 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
MDA-MB-435	GI₅₀	0.25 μM Compound: Doxorubicin	Growth inhibition of human MDA-MB-435 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-435 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
MDA-MB-435	IC₅₀	0.4 μM Compound: doxorubicin	Antiproliferative activity against MDA-MB-435 human breast carcinoma cells in vivo using MDA-MB-435 monolayer growth assay. Antiproliferative activity against MDA-MB-435 human breast carcinoma cells in vivo using MDA-MB-435 monolayer growth assay.	[PMID: 11606134]
MDA-MB-435	IC₅₀	0.47 μg/mL Compound: Doxorubicin	Cytotoxicity against human MDA-MB-435 cells after 3 days by MTT assay Cytotoxicity against human MDA-MB-435 cells after 3 days by MTT assay	[PMID: 19159272]
MDA-MB-435	IC₅₀	0.47 μg/mL Compound: Doxorubicin	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay	[PMID: 18586355]
MDA-MB-435	IC₅₀	0.47 μg/mL Compound: doxorubicin	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay	[PMID: 17827021]
MDA-MB-435	IC₅₀	0.48 μg/mL Compound: Dox	Cytotoxicity against Homo sapiens (human) MDA-MB-435 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) MDA-MB-435 cells after 72 hr by MTT assay	10.1007/s00044-011-9894-8
MDA-MB-435	IC₅₀	0.48 μg/mL Compound: Doxorubicin	Cytotoxicity against human MDA-MB-435 cells by MTT assay Cytotoxicity against human MDA-MB-435 cells by MTT assay	[PMID: 17764956]
MDA-MB-435	IC₅₀	0.6 μM Compound: Dox	Cytotoxicity against human MDA-MB-435 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells after 48 hrs by MTT assay	[PMID: 24028446]
MDA-MB-435	IC₅₀	0.69 μg/mL Compound: Doxo	Cytotoxicity against human MDA-MB-435 cells for 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells for 72 hrs by MTT assay	[PMID: 21334795]
MDA-MB-435	IC₅₀	0.83 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-435 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24530030]
MDA-MB-435	IC₅₀	0.83 μM Compound: doxorubicin	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay	[PMID: 21381705]
MDA-MB-435	IC₅₀	0.83 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay	[PMID: 27363939]
MDA-MB-435	IC₅₀	0.86 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33158575]
MDA-MB-435	IC₅₀	0.88 μM Compound: Dox	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay	[PMID: 25147145]
MDA-MB-435	IC₅₀	0.88 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay	[PMID: 21115213]
MDA-MB-435	IC₅₀	0.88 μM Compound: DOXO	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay	[PMID: 19947600]
MDA-MB-435	IC₅₀	0.94 μM Compound: DOXO	Antiproliferative activity against human MDA-MB-435 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-435 cells after 72 hrs by MTT assay	[PMID: 28818447]
MDA-MB-435	IC₅₀	0.96 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-435 cells overexpressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells overexpressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27341379]
MDA-MB-435	IC₅₀	0.96 μM Compound: DOXO	Cytotoxicity against human MDA-MB-435 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26142490]
MDA-MB-435	IC₅₀	0.96 μM Compound: D	Antineoplastic activity against human MDA-MB-435 cells after 72 hrs by MTT assay Antineoplastic activity against human MDA-MB-435 cells after 72 hrs by MTT assay	[PMID: 22000949]
MDA-MB-435	IC₅₀	0.96 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay	[PMID: 20971532]
MDA-MB-435	IC₅₀	0.96 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay	[PMID: 19406535]
MDA-MB-435	IC₅₀	1.3 μM Compound: Doxorubicin	Antitumor activity against human MDA-MB-435 cells after 24 to 48 hrs by MTT assay Antitumor activity against human MDA-MB-435 cells after 24 to 48 hrs by MTT assay	[PMID: 21553829]
MDA-MB-435	IC₅₀	1.3 μM Compound: DOX	Antiproliferative activity against human MDA-MB-435 cells after 72 hrs by Sulforhodamine B-stain assay Antiproliferative activity against human MDA-MB-435 cells after 72 hrs by Sulforhodamine B-stain assay	[PMID: 27484508]
MDA-MB-435	IC₅₀	1.51 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-435 cells by colorimetric method Cytotoxicity against human MDA-MB-435 cells by colorimetric method	[PMID: 24387625]
MDA-MB-435	IC₅₀	1.56 μM Compound: Dox	Cytotoxicity against doxorubicin-resistant multidrug-resistant human MDA-MB-435 cells after 48 hrs by MTT assay in presence of verapamil Cytotoxicity against doxorubicin-resistant multidrug-resistant human MDA-MB-435 cells after 48 hrs by MTT assay in presence of verapamil	[PMID: 24028446]
MDA-MB-435	IC₅₀	1.67 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-435 cells after 69 hrs by MTT assay Cytotoxicity against human MDA-MB-435 cells after 69 hrs by MTT assay	[PMID: 19780590]
MDA-MB-435	IC₅₀	21.9 μM Compound: Dox	Cytotoxicity against doxorubicin-resistant multidrug-resistant human MDA-MB-435 cells after 48 hrs by MTT assay Cytotoxicity against doxorubicin-resistant multidrug-resistant human MDA-MB-435 cells after 48 hrs by MTT assay	[PMID: 24028446]
MDA-MB-435	IC₅₀	3.5 nM Compound: Doxorubicine	Cytotoxicity against human MDA435 cells after 72 hrs by MTS assay Cytotoxicity against human MDA435 cells after 72 hrs by MTS assay	[PMID: 21142180]
MDA-MB-435	IC₅₀	300 nM Compound: doxorubicin	Antiproliferative activity against MDA435/LCC6 cells by ELISA Antiproliferative activity against MDA435/LCC6 cells by ELISA	[PMID: 17154505]
MDA-MB-435	IC₅₀	300 nM Compound: doxorubicin	Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM verapamil by ELISA Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM verapamil by ELISA	[PMID: 17154505]
MDA-MB-435	IC₅₀	4690 nM Compound: doxorubicin	Antiproliferative activity against multidrug resistant MDA435/LCC6 cells by ELISA Antiproliferative activity against multidrug resistant MDA435/LCC6 cells by ELISA	[PMID: 17154505]
MDA-MB-435	IC₅₀	550 nM Compound: doxorubicin	Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA	[PMID: 17154505]
MDA-MB-436	IC₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-436 cells after 72 hrs by resazurin/resorufin-based fluorescence assay Cytotoxicity against human MDA-MB-436 cells after 72 hrs by resazurin/resorufin-based fluorescence assay	[PMID: 23600925]
MDA-MB-453	IC₅₀	0.12 μM Compound: doxorubicine	Cytotoxic activity against human MDA-MB-453 cells after 69 hrs by MTT assay Cytotoxic activity against human MDA-MB-453 cells after 69 hrs by MTT assay	[PMID: 19788290]
MDA-MB-453	IC₅₀	1.99 μM Compound: Doxorubicin	Cytotoxicity in human MDA-MB-453 cells incubated for 48 hrs by MTT assay Cytotoxicity in human MDA-MB-453 cells incubated for 48 hrs by MTT assay	[PMID: 28923381]
MDA-MB-453	IC₅₀	1.99 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-453 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-453 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
MDA-MB-453	IC₅₀	1.99 μM Compound: DOX	Cytotoxicity against human MDA-MB-453 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-453 cells after 48 hrs by MTT assay	[PMID: 24487188]
MDA-MB-468	IC₅₀	> 100 μM Compound: DOX	Cytotoxicity against human MDA-MB-468 cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human MDA-MB-468 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
MDA-MB-468	IC₅₀	0.005 μM Compound: Doxorubicin	Inhibitory activity against MDA-468 cell line using MTT assay (ER-, amplified EGFR, mutant p53) Inhibitory activity against MDA-468 cell line using MTT assay (ER-, amplified EGFR, mutant p53)	[PMID: 10780913]
MDA-MB-468	IC₅₀	0.007 μM Compound: 1 (Doxorubicin)	In vitro cytotoxic activity against human breast cancer cell line MD-MB-468 after 72 hr of drug exposure determined by the SRB assay In vitro cytotoxic activity against human breast cancer cell line MD-MB-468 after 72 hr of drug exposure determined by the SRB assay	[PMID: 14980672]
MDA-MB-468	GI₅₀	0.05 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human MDA-MB-468 cells after 48 hrs by SRB assay Cytotoxicity against human MDA-MB-468 cells after 48 hrs by SRB assay	[PMID: 23871905]
MDA-MB-468	GI₅₀	0.05 μM Compound: Doxorubicin	Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
MDA-MB-468	GI₅₀	0.05 μM Compound: Doxorubicin	Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
MDA-MB-468	IC₅₀	0.0521 μM Compound: Dox	Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 96 hrs by MTT method Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 96 hrs by MTT method	[PMID: 34236840]
MDA-MB-468	IC₅₀	0.06 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability after 48 hrs Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability after 48 hrs	[PMID: 34601029]
MDA-MB-468	IC₅₀	0.07 μM Compound: Doxorubicin	Cytotoxicity against human MDA-MB-468 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-468 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 30457333]
MDA-MB-468	GI₅₀	0.085 μM Compound: Dox	Growth inhibition of human MDA-MB-468 cells after 72 hrs by MTT assay Growth inhibition of human MDA-MB-468 cells after 72 hrs by MTT assay	[PMID: 24163729]
MDA-MB-468	IC₅₀	2.81 μM Compound: Doxorubicin	Antiproliferative activity against human MDA-MB-468 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells after 48 hrs by MTT assay	[PMID: 29547830]
MDCK	IC₅₀	0.43 μM Compound: DOXO	Cytotoxicity against MDCK cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against MDCK cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26142490]
ME-180	IC₅₀	0.39 μM Compound: Doxorubicin	Cytotoxicity against human ME180 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human ME180 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
ME-180	IC₅₀	0.39 μM Compound: DOX	Cytotoxicity against human ME180 cells after 48 hrs by MTT assay Cytotoxicity against human ME180 cells after 48 hrs by MTT assay	[PMID: 24487188]
ME-180	IC₅₀	0.39 μM Compound: Doxorubicin	Cytotoxicity against human ME180 cells after 72 hrs by MTT assay Cytotoxicity against human ME180 cells after 72 hrs by MTT assay	[PMID: 25453799]
ME-180	IC₅₀	0.5 μM Compound: Doxorubicin	Anticancer activity against human ME180 cells by MTT assay Anticancer activity against human ME180 cells by MTT assay	10.1039/C4MD00219A
MEF	IC₅₀	3.4 μM Compound: Doxorubicin	Cytotoxicity against mouse wild type MEF cells after 72 hrs by SRB assay Cytotoxicity against mouse wild type MEF cells after 72 hrs by SRB assay	[PMID: 19186946]
MEL-JUSO	IC₅₀	0.237 μM Compound: 1	Cytotoxicity in human MEL-JUSO cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay Cytotoxicity in human MEL-JUSO cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay	[PMID: 33064004]
MES-SA	GI₅₀	0.0051 μM Compound: Doxorubicin	Antiproliferative activity against human MESSA cells by SRB assay Antiproliferative activity against human MESSA cells by SRB assay	[PMID: 19394218]
MES-SA	IC₅₀	0.0097 μM Compound: Dx	Antiproliferative activity against MES-SA cells by MTT assay after 72 hrs Antiproliferative activity against MES-SA cells by MTT assay after 72 hrs	[PMID: 16824751]
MES-SA	IC₅₀	0.01 μM Compound: Doxorubicin	Antiproliferative activity against human MESSA cells after 72 hrs by SRB assay Antiproliferative activity against human MESSA cells after 72 hrs by SRB assay	[PMID: 22944121]
MES-SA	IC₅₀	0.03 μM Compound: Adriamycin	Cytotoxicity against human MES-SA cells after 72 hrs by MTT assay Cytotoxicity against human MES-SA cells after 72 hrs by MTT assay	[PMID: 21721528]
MES-SA	IC₅₀	0.03 μM Compound: Dx	Cytotoxicity against human MES-SA cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human MES-SA cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 21444205]
MES-SA	IC₅₀	0.035 μM Compound: Dox	Antiproliferative activity against human MES-SA cells after 72 hrs by MTT assay Antiproliferative activity against human MES-SA cells after 72 hrs by MTT assay	[PMID: 25998504]
MES-SA	IC₅₀	0.038 μM Compound: doxorubicin	Cytotoxicity against human MES-SA cells after 72 hrs by Presto Blue assay Cytotoxicity against human MES-SA cells after 72 hrs by Presto Blue assay	[PMID: 23360284]
MES-SA	IC₅₀	0.1 μM Compound: DOXO	Cytotoxicity against human MESSA cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MESSA cells after 72 hrs by sulforhodamine B assay	[PMID: 28342398]
MES-SA	IC₅₀	0.16 μM Compound: Doxo	Antiproliferative activity against human MES-SA cells after 72 hrs by SRB assay Antiproliferative activity against human MES-SA cells after 72 hrs by SRB assay	[PMID: 29945793]
MES-SA	IC₅₀	0.17 μM Compound: Doxorubicin	Antiproliferative activity against human MES-SA cells after 96 hrs by SRB assay Antiproliferative activity against human MES-SA cells after 96 hrs by SRB assay	[PMID: 20151639]
MES-SA	IC₅₀	0.25 μM Compound: Adriamycin (ADR)	In vitro cytotoxic activity was evaluated using the human uterine sarcoma cell line MES-SA In vitro cytotoxic activity was evaluated using the human uterine sarcoma cell line MES-SA	[PMID: 12443763]
MES-SA	IC₅₀	0.347 μM Compound: doxorubicin	Growth inhibition of doxorubicin-sensitive human MES-SA cells after 48 hrs by MTT assay Growth inhibition of doxorubicin-sensitive human MES-SA cells after 48 hrs by MTT assay	[PMID: 17888666]
MES-SA	IC₅₀	0.87 μM Compound: Adriamycin	Cytotoxicity against adriamycin-selected human MES-SA cells after 72 hrs by MTT assay Cytotoxicity against adriamycin-selected human MES-SA cells after 72 hrs by MTT assay	[PMID: 21721528]
MES-SA	IC₅₀	12 μM Compound: Adriamycin (ADR)	In vitro cytotoxic activity was evaluated using the MES-SA multidrug-resistant subline MES-SA/Dx5 In vitro cytotoxic activity was evaluated using the MES-SA multidrug-resistant subline MES-SA/Dx5	[PMID: 12443763]
MES-SA	ED₅₀	173 μM Compound: doxorubicin	Antitumor activity against human MES-SA cells after 24 hrs by MTT assay Antitumor activity against human MES-SA cells after 24 hrs by MTT assay	[PMID: 17482824]
MES-SA/Dx5	ED₅₀	> 500 μM Compound: doxorubicin	Antitumor activity against doxorubucin-resistant human MES-SA/Dx5 cells by MTT assay after 24 hrs Antitumor activity against doxorubucin-resistant human MES-SA/Dx5 cells by MTT assay after 24 hrs	[PMID: 17482824]
MES-SA/Dx5	IC₅₀	0.25 μM Compound: Doxorubicin	Antiproliferative activity against human MESSA/DX5 cells after 72 hrs by SRB assay Antiproliferative activity against human MESSA/DX5 cells after 72 hrs by SRB assay	[PMID: 22944121]
MES-SA/Dx5	IC₅₀	0.704 μM Compound: Dx	Antiproliferative activity against doxorubicin-resistant MES-SA/Dx5 cells by MTT assay after 72 hrs Antiproliferative activity against doxorubicin-resistant MES-SA/Dx5 cells by MTT assay after 72 hrs	[PMID: 16824751]
MES-SA/Dx5	GI₅₀	0.93 μM Compound: Doxorubicin	Antiproliferative activity against multidrug resistant human MES-SA/Dx5 cells by SRB assay Antiproliferative activity against multidrug resistant human MES-SA/Dx5 cells by SRB assay	[PMID: 19394218]
MES-SA/Dx5	IC₅₀	1.55 μM Compound: doxorubicin	Growth inhibition of doxorubicin-resistant human MES-SA/Dx5 cells after 48 hrs by MTT assay Growth inhibition of doxorubicin-resistant human MES-SA/Dx5 cells after 48 hrs by MTT assay	[PMID: 17888666]
MES-SA/Dx5	IC₅₀	13.9 μM Compound: DOXO	Cytotoxicity against human MESSA/DX5 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MESSA/DX5 cells after 72 hrs by sulforhodamine B assay	[PMID: 28342398]
MES-SA/Dx5	IC₅₀	16.2 μM Compound: Doxo	Antiproliferative activity against human MES-SA/Dx5 cells after 72 hrs by SRB assay Antiproliferative activity against human MES-SA/Dx5 cells after 72 hrs by SRB assay	[PMID: 29945793]
MES-SA/Dx5	IC₅₀	2.3 μM Compound: doxorubicin	Cytotoxicity against human MES-SA/Dx5 cells after 72 hrs by Presto Blue assay Cytotoxicity against human MES-SA/Dx5 cells after 72 hrs by Presto Blue assay	[PMID: 23360284]
MES-SA/Dx5	IC₅₀	2.398 μM Compound: Dx	Cytotoxicity against human MES-SA/Dx5 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human MES-SA/Dx5 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 21444205]
MES-SA/Dx5	IC₅₀	2.807 μM Compound: Dox	Antiproliferative activity against human MES-SA/Dx5 cells after 72 hrs by MTT assay Antiproliferative activity against human MES-SA/Dx5 cells after 72 hrs by MTT assay	[PMID: 25998504]
MES-SA/Dx5	IC₅₀	3.1 μM Compound: Doxorubicin	Antiproliferative activity against human MES-SA/Dx5 cells after 96 hrs by SRB assay Antiproliferative activity against human MES-SA/Dx5 cells after 96 hrs by SRB assay	[PMID: 20151639]
MG-22A	IC₅₀	< 0.001 μg/mL Compound: 1 (doxorubicin)	In vitro inhibitory activity against mouse hepatoma cell line (MG-22A) using CV coloration In vitro inhibitory activity against mouse hepatoma cell line (MG-22A) using CV coloration	[PMID: 15013011]
MG-22A	IC₅₀	0.73 μg/mL Compound: 1 (doxorubicin)	In vitro cytotoxic concentration against mouse hepatoma cell line (MG-22A) using MTT coloration In vitro cytotoxic concentration against mouse hepatoma cell line (MG-22A) using MTT coloration	[PMID: 15013011]
MG-63	IC₅₀	0.74 μM Compound: doxorubicin	Cytotoxicity against human MG63 cells after 48 hrs by MTT assay Cytotoxicity against human MG63 cells after 48 hrs by MTT assay	[PMID: 25314138]
MG-63	IC₅₀	2.7 μM Compound: Adriamycin	Cytotoxicity against human MG63 cells by MTT colorimetric method Cytotoxicity against human MG63 cells by MTT colorimetric method	[PMID: 23043498]
MG-63	IC₅₀	2.8 μM Compound: Adriamycin	Growth inhibition of human MG63 cells by MTT assay Growth inhibition of human MG63 cells by MTT assay	[PMID: 21721519]
MG-63	IC₅₀	3.17 μM Compound: Dox	Cytotoxicity against Homo sapiens (human) MG63 cells assessed as reduction of cell survival after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) MG63 cells assessed as reduction of cell survival after 48 hr by MTT assay	10.1007/s00044-012-0150-7
MG-63	IC₅₀	3.17 μM Compound: Doxorubicin	Cytotoxicity against human MG63 cells after 48 hrs by MTT assay Cytotoxicity against human MG63 cells after 48 hrs by MTT assay	[PMID: 23792352]
MG-63	IC₅₀	3.2 μM Compound: Adriamycin	Cytotoxicity against human MG63 cells by MTT assay Cytotoxicity against human MG63 cells by MTT assay	[PMID: 22647719]
MGC-803	IC₅₀	0.1 μM Compound: doxorubicin	Cytotoxicity against human MGC803 cells after 72 hrs by MTS assay Cytotoxicity against human MGC803 cells after 72 hrs by MTS assay	[PMID: 25490132]
MGC-803	IC₅₀	0.17 μM Compound: Adriamycin	Cytotoxicity against human MGC803 cells after 24 hrs by SRB assay Cytotoxicity against human MGC803 cells after 24 hrs by SRB assay	[PMID: 24370114]
MGC-803	IC₅₀	0.4 μM Compound: ADM	Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay	[PMID: 30025345]
MGC-803	IC₅₀	0.48 μM Compound: Doxorubicin	Anticancer activity against human MGC-803 cells incubated for 48 hrs by MTT assay Anticancer activity against human MGC-803 cells incubated for 48 hrs by MTT assay	[PMID: 35367708]
MGC-803	IC₅₀	0.51 μg/mL Compound: Doxorubicin	Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 34973507]
MGC-803	IC₅₀	0.7 μM Compound: ADM	Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay	[PMID: 26280921]
MGC-803	IC₅₀	0.7 μM Compound: ADM	Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay	[PMID: 25874331]
MGC-803	IC₅₀	0.7 μM Compound: ADM	Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay	[PMID: 23124210]
MGC-803	IC₅₀	0.74 μM Compound: ADM	Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay	10.1007/s00044-013-0854-3
MGC-803	IC₅₀	1.01 μM Compound: AMD	Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay	[PMID: 26900656]
MGC-803	IC₅₀	1.01 μM Compound: AMD	Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay	[PMID: 26807545]
MGC-803	IC₅₀	1.19 μM Compound: AMD	Anticancer activity against human MGC803 cells assessed as cell survival after 48 hrs by MTT assay Anticancer activity against human MGC803 cells assessed as cell survival after 48 hrs by MTT assay	[PMID: 25812966]
MGC-803	IC₅₀	3.22 μM Compound: ADM	Cytotoxicity against human MGC803 cells after 38 hrs by MTT assay Cytotoxicity against human MGC803 cells after 38 hrs by MTT assay	[PMID: 25965778]
MGC-803	IC₅₀	3.6 μM Compound: Dox	Antiproliferative activity against human MGC803 cells assessed as reduction in cell viability by MTT assay Antiproliferative activity against human MGC803 cells assessed as reduction in cell viability by MTT assay	[PMID: 31765156]
M-HeLa	IC₅₀	2.1 μM Compound: Doxorubicin	Cytotoxicity against human HelaM cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay Cytotoxicity against human HelaM cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay	[PMID: 36970146]
M-HeLa	IC₅₀	3 μM Compound: Doxorubicin	Cytotoxicity against human HelaM cells assessed as reduction in cell viability after 24 hrs by DAPI staining-based fluorescence assay Cytotoxicity against human HelaM cells assessed as reduction in cell viability after 24 hrs by DAPI staining-based fluorescence assay	[PMID: 32786882]
M-HeLa	IC₅₀	3 μM Compound: Doxorubicin	Antiproliferative activity against human M-HeLa cells by fluorescence based viable cell counting method Antiproliferative activity against human M-HeLa cells by fluorescence based viable cell counting method	[PMID: 31610378]
MIA PaCa-2	IC₅₀	< 0.1 μM Compound: DOX, Doxorubicin	Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by MTT assay Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by MTT assay	[PMID: 24095089]
MIA PaCa-2	ED₅₀	0.00101 μg/mL Compound: adriamycin	Cytotoxicity against human MIA PaCa2 cells after 7 days by MTT assay Cytotoxicity against human MIA PaCa2 cells after 7 days by MTT assay	[PMID: 10514307]
MIA PaCa-2	ED₅₀	0.0061 μg/mL Compound: adriamycin	Cytotoxicity against human MiaPaCa2 cells after 7 days by MTT assay Cytotoxicity against human MiaPaCa2 cells after 7 days by MTT assay	[PMID: 11087592]
MIA PaCa-2	IC₅₀	0.01 μM Compound: Doxorubicin	Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay	[PMID: 20207049]
MIA PaCa-2	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell growth after 72 hrs by cell titer glo assay Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell growth after 72 hrs by cell titer glo assay	[PMID: 27080175]
MIA PaCa-2	IC₅₀	0.02 μM Compound: DOX	Antitumor activity against human MiaPaCa2 cells after 72 hrs by MTT assay Antitumor activity against human MiaPaCa2 cells after 72 hrs by MTT assay	[PMID: 17935309]
MIA PaCa-2	IC₅₀	0.03 μM Compound: Doxorubicin	Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by MTT assay Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by MTT assay	[PMID: 22555152]
MIA PaCa-2	IC₅₀	0.04 μM Compound: Doxorubicin	Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 28257197]
MIA PaCa-2	IC₅₀	0.049 μM Compound: Doxorubicin	Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay	[PMID: 27856237]
MIA PaCa-2	IC₅₀	0.05 μM Compound: Doxorubicin	Cytotoxicity against human MIA PaCa2 cells after 24 hrs by MTT assay Cytotoxicity against human MIA PaCa2 cells after 24 hrs by MTT assay	[PMID: 17190470]
MIA PaCa-2	IC₅₀	0.05 μM Compound: doxorubicin	Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay	[PMID: 17286429]
MIA PaCa-2	IC₅₀	0.05 μM Compound: doxorubicin	Cytotoxicity against human MIAPaCa2 cells by MTT assay Cytotoxicity against human MIAPaCa2 cells by MTT assay	[PMID: 15620238]
MIA PaCa-2	IC₅₀	0.14 μM Compound: Doxo	Cytotoxicity against human MIAPaCa2 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells assessed as cell viability after 48 hrs by MTT assay	10.1039/C2MD20302B
MIA PaCa-2	IC₅₀	0.15 μM Compound: Doxorubicin	Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay	[PMID: 19361894]
MIA PaCa-2	IC₅₀	0.2 μM Compound: 27	Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay	[PMID: 32858470]
MIA PaCa-2	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human MIAPaCa2 cells after 72 hrs by Alamar blue assay Cytotoxicity against human MIAPaCa2 cells after 72 hrs by Alamar blue assay	[PMID: 21999655]
MIA PaCa-2	IC₅₀	0.43 μM Compound: Doxorubicin	Cytotoxicity against human MIA PaCa-2 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MIA PaCa-2 cells assessed as reduction in cell viability by MTT assay	[PMID: 32915576]
MIA PaCa-2	ED₅₀	1.32 ng/mL Compound: adriamycin	Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay	[PMID: 8676130]
MIA PaCa-2	ED₅₀	1.33 x 10^-2 μg/mL Compound: adr	Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay	[PMID: 9461654]
MIA PaCa-2	ED₅₀	1.42 ng/mL Compound: Adriamycin	Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay	[PMID: 9322367]
MIA PaCa-2	ED₅₀	1.45 ng/mL Compound: adriamycin	Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay	[PMID: 9599253]
MIA PaCa-2	ED₅₀	1.53 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay	[PMID: 9599260]
MIA PaCa-2	IC₅₀	1.75 μM Compound: Doxorubicin	Cytotoxicity against human MIAPaCa2 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 27371926]
MIA PaCa-2	ED₅₀	1.8 x 10^-2 μg/mL Compound: Adriamycin	Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay	[PMID: 9214729]
MIA PaCa-2	IC₅₀	1.9 μM Compound: Doxorubicin	Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28277681]
MIA PaCa-2	ED₅₀	1.95 ng/mL Compound: Adriamycin	Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay	[PMID: 7494147]
MIA PaCa-2	ED₅₀	2.3 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human PaCa2 cells by MTT assay Cytotoxicity against human PaCa2 cells by MTT assay	[PMID: 9917277]
MIA PaCa-2	IC₅₀	2.4 ng/mL Compound: Adriamycin	Cytotoxicity against human MIAPaCa2 cells by MTT assay Cytotoxicity against human MIAPaCa2 cells by MTT assay	[PMID: 9644064]
MIA PaCa-2	ED₅₀	2.43 ng/mL Compound: Adriamycin	Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay	[PMID: 8946743]
MIA PaCa-2	ED₅₀	2.62 ng/mL Compound: adriamycin	Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay	[PMID: 11325235]
MIA PaCa-2	ED₅₀	2.88 ng/mL Compound: adriamycin	Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay	10.1021/np970510f
MIA PaCa-2	CC₅₀	2.97 μM Compound: Doxorubicin	Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay	[PMID: 29792325]
MIA PaCa-2	IC₅₀	25.3 μM Compound: Doxorubicin	Cytotoxicity against human MIAPaCa2 cells after 48 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells after 48 hrs by MTT assay	[PMID: 21429743]
MIA PaCa-2	IC₅₀	3.1 μM Compound: Doxorubicin	Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability after 70 hrs by alamar blue assay Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability after 70 hrs by alamar blue assay	[PMID: 29471119]
MIA PaCa-2	ED₅₀	3.79 ng/mL Compound: adriamycin	Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay	[PMID: 8882434]
MIA PaCa-2	ED₅₀	3.92 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay	[PMID: 9134750]
MIA PaCa-2	IC₅₀	4 μM Compound: 1; dox	Cytotoxicity against doxorubicin-sensitive human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 30 mins by crystal violet staining assay Cytotoxicity against doxorubicin-sensitive human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 30 mins by crystal violet staining assay	[PMID: 26881291]
MIA PaCa-2	ED₅₀	4.3 ng/mL Compound: adriamycin	Cytotoxicity against human PACA2 cells after 7 days by MTT assay Cytotoxicity against human PACA2 cells after 7 days by MTT assay	[PMID: 10395501]
MIA PaCa-2	ED₅₀	4.56 ng/mL Compound: adriamycin	Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay	[PMID: 9584396]
MIA PaCa-2	IC₅₀	4.8 μM Compound: Doxo	Cytotoxicity against human MIAPaCa2 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24484281]
MIA PaCa-2	ED₅₀	6.1 ng/mL Compound: adriamycin	Cytotoxicity against human MIA PaCa2 cells after 7 days by MTT assay Cytotoxicity against human MIA PaCa2 cells after 7 days by MTT assay	[PMID: 15730242]
MIA PaCa-2	IC₅₀	66 μM Compound: 1; dox	Cytotoxicity against doxorubicin-sensitive human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 90 mins by crystal violet staining assay Cytotoxicity against doxorubicin-sensitive human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 90 mins by crystal violet staining assay	[PMID: 26881291]
MIA PaCa-2	ED₅₀	7.9 ng/mL Compound: adriamycin	Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay	[PMID: 8904848]
MKN-28	IC₅₀	0.22 μM Compound: Doxorubicin	Cytotoxicity against human MKN28 cells after 44 hrs by SRB assay Cytotoxicity against human MKN28 cells after 44 hrs by SRB assay	10.1007/s00044-013-0788-9
MKN-28	GI₅₀	0.24 μM Compound: Doxorubicin	Antiproliferative activity against human MKN28 cells after 2 days by sulforhodamine B assay Antiproliferative activity against human MKN28 cells after 2 days by sulforhodamine B assay	[PMID: 24184076]
MKN-45	IC₅₀	0.127 μM Compound: ADR	Antiproliferative activity against human MKN45 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human MKN45 cells after 72 hrs by sulforhodamine B assay	[PMID: 30241010]
MKN-45	IC₅₀	0.168 μM Compound: Doxorubicin	Cytotoxicity against human MKN45 cells after 48 hrs by MTT assay Cytotoxicity against human MKN45 cells after 48 hrs by MTT assay	[PMID: 22647723]
MKN-45	IC₅₀	0.19 nM Compound: Doxorubicin	Antiproliferative activity against human MKN45 cells after 72 hrs by methylene blue staining Antiproliferative activity against human MKN45 cells after 72 hrs by methylene blue staining	[PMID: 21067930]
MKN-45	IC₅₀	0.19 μM Compound: DOX	Cytotoxicity against human MKN45 cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human MKN45 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
MKN-74	IC₅₀	0.204 μM Compound: ADR	Antiproliferative activity against human MKN74 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human MKN74 cells after 72 hrs by sulforhodamine B assay	[PMID: 30241010]
MOLT-3	IC₅₀	0.04 μM Compound: doxorubicin	Cytotoxicity against human MOLT3 cells by XTT assay Cytotoxicity against human MOLT3 cells by XTT assay	[PMID: 19824618]
MOLT-3	IC₅₀	0.051 μM Compound: Doxorubicin	Antiproliferative activity against human MOLT3 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MOLT3 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31704206]
MOLT-4	IC₅₀	0.002 μM Compound: Doxorubicin	Antiproliferative activity against human MOLT4 cells after 72 hrs by MTT assay Antiproliferative activity against human MOLT4 cells after 72 hrs by MTT assay	[PMID: 19632833]
MOLT-4	IC₅₀	0.01 μM Compound: Doxorubicin	Antiproliferative activity against human MOLT4 cells after 72 hrs by MTT assay Antiproliferative activity against human MOLT4 cells after 72 hrs by MTT assay	[PMID: 27808511]
MOLT-4	IC₅₀	0.015 μM Compound: Doxorubicin	Antiproliferative activity against human MOLT4 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human MOLT4 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31546197]
MOLT-4	IC₅₀	0.02 μM Compound: DOX	Cytotoxicity against human MOLT4 cells after 48 hrs by MTT assay Cytotoxicity against human MOLT4 cells after 48 hrs by MTT assay	[PMID: 23218718]
MOLT-4	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human MOLT4 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MOLT4 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27623548]
MOLT-4	IC₅₀	0.02 μM Compound: DOXO	Cytotoxicity against human MOLT4 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human MOLT4 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26142490]
MOLT-4	IC₅₀	0.02 μM Compound: adriamycin	Cytotoxicity against MOLT4 cells after 72 hrs by MTT assay Cytotoxicity against MOLT4 cells after 72 hrs by MTT assay	[PMID: 17107806]
MOLT-4	IC₅₀	0.02 μM Compound: doxo	Antiproliferative activity against human MOLT4 cell line by MTT assay Antiproliferative activity against human MOLT4 cell line by MTT assay	[PMID: 16913700]
MOLT-4	GI₅₀	0.03 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human MOLT4 cells after 48 hrs by SRB assay Cytotoxicity against human MOLT4 cells after 48 hrs by SRB assay	[PMID: 23871905]
MOLT-4	GI₅₀	0.03 μM Compound: Doxorubicin	Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
MOLT-4	GI₅₀	0.03 μM Compound: Doxorubicin	Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MOLT4 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
MOLT-4	IC₅₀	0.2 μM Compound: 1, DOX	Antiproliferative activity against human Molt4/C8 cells after 72 hrs by MTT assay Antiproliferative activity against human Molt4/C8 cells after 72 hrs by MTT assay	[PMID: 25244612]
MOLT-4	IC₅₀	0.2 μM Compound: Dox	Cytotoxicity against human Molt4/C8 cells after 72 hrs by MTT assay Cytotoxicity against human Molt4/C8 cells after 72 hrs by MTT assay	[PMID: 21144624]
MOLT-4	IC₅₀	0.2 μM Compound: DOX	Cytotoxicity against human MOLT4 cells after 24 hrs by XTT assay Cytotoxicity against human MOLT4 cells after 24 hrs by XTT assay	[PMID: 24900344]
MOLT-4	IC₅₀	0.46 μg/mL Compound: DOX	Cytotoxicity against human MOLT4 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MOLT4 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29274817]
MOLT-4F	ED₅₀	0.02 μg/mL Compound: adriamycin	Cytotoxicity against human MOLT4F cells after 48 hrs by SRB assay Cytotoxicity against human MOLT4F cells after 48 hrs by SRB assay	10.1021/np50124a024
MRC5	IC₅₀	> 20 μM Compound: Doxorubicin	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 35293752]
MRC5	IC₅₀	> 50 μM Compound: DOX	Cytotoxicity against human MRC5 cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay Cytotoxicity against human MRC5 cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay	[PMID: 31671309]
MRC5	IC₅₀	> 50 μM Compound: DOX	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay	[PMID: 30576904]
MRC5	IC₅₀	> 91.99 μM Compound: Doxorubicin	Cytotoxicity against human MRC5 cells by MTT assay Cytotoxicity against human MRC5 cells by MTT assay	[PMID: 25747499]
MRC5	IC₅₀	0.039 μM Compound: Doxorubicin	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay	[PMID: 32755677]
MRC5	IC₅₀	0.04 μM Compound: Doxorubicin	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 72 hrs by CellTiter Glo assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 72 hrs by CellTiter Glo assay	[PMID: 33021377]
MRC5	IC₅₀	0.1 μM Compound: DOX	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 6 days by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 6 days by MTT assay	[PMID: 32653698]
MRC5	IC₅₀	0.1 μM Compound: DOX	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31557614]
MRC5	IC₅₀	0.1 μM Compound: DOX	Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth after 72 hrs by MTT assay	[PMID: 30746062]
MRC5	IC₅₀	0.1 μM Compound: DOX	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28427016]
MRC5	IC₅₀	0.1 μM Compound: DOX	Antiproliferative activity against human MRC5 cells after 72 hrs by MTT assay Antiproliferative activity against human MRC5 cells after 72 hrs by MTT assay	[PMID: 28135634]
MRC5	IC₅₀	0.1 μM Compound: Dox	Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27231128]
MRC5	IC₅₀	0.1 μM Compound: DOX	Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 26720155]
MRC5	IC₅₀	0.1 μM Compound: DOX	Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay	[PMID: 25259516]
MRC5	IC₅₀	0.1 μM Compound: DOX	Antiproliferative activity against human MRC5 cells after 72 hrs by MTT assay Antiproliferative activity against human MRC5 cells after 72 hrs by MTT assay	[PMID: 24021462]
MRC5	IC₅₀	0.1 μM Compound: DOX	Antiproliferative activity against human MRC5 cells after 72 hrs by MTT assay Antiproliferative activity against human MRC5 cells after 72 hrs by MTT assay	[PMID: 20359789]
MRC5	IC₅₀	0.1 μM Compound: DOX	Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay	[PMID: 18783950]
MRC5	IC₅₀	0.11 μM Compound: Dox	Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay	[PMID: 26494582]
MRC5	IC₅₀	0.12 μM Compound: Doxorubicin	Cytotoxicity against human MRC5 cells expressing estrogen receptor after 48 hrs by MTT assay Cytotoxicity against human MRC5 cells expressing estrogen receptor after 48 hrs by MTT assay	10.1039/C2MD20327H
MRC5	IC₅₀	0.12 μM Compound: Doxorubicin	Antiproliferative activity against human MRC5 cells after 48 hrs by MTT assay Antiproliferative activity against human MRC5 cells after 48 hrs by MTT assay	[PMID: 30108986]
MRC5	IC₅₀	0.12 μM Compound: DOX	Antiproliferative activity against human MRC5 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Antiproliferative activity against human MRC5 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 25737400]
MRC5	IC₅₀	0.12 μM Compound: DOX	Antiproliferative activity against human MRC5 cells after 48 hrs by MTT assay Antiproliferative activity against human MRC5 cells after 48 hrs by MTT assay	[PMID: 25619894]
MRC5	IC₅₀	0.12 μM Compound: DOX	Cytotoxicity against human MRC5 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 24148837]
MRC5	IC₅₀	0.12 μM Compound: Doxorubicin	Cytotoxicity against human MRC5 cells after 1 hr by SRB assay Cytotoxicity against human MRC5 cells after 1 hr by SRB assay	[PMID: 22770744]
MRC5	IC₅₀	0.24 μM Compound: Doxorubicin	Cytotoxicity against human MRC5 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 33340938]
MRC5	IC₅₀	0.29 μM Compound: DOX	Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells after 72 hrs by MTT assay	[PMID: 29970309]
MRC5	EC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human MRC5 cells after 96 hrs by MTT assay Cytotoxicity against human MRC5 cells after 96 hrs by MTT assay	[PMID: 26320088]
MRC5	IC₅₀	0.3 μM Compound: Doxorubicin	Antiproliferative activity against human MRC5 cells after 96 hrs by MTT assay Antiproliferative activity against human MRC5 cells after 96 hrs by MTT assay	[PMID: 19053767]
MRC5	IC₅₀	0.77 μg/mL Compound: doxo	Cytotoxicity against human MRC5 cells by MTT method Cytotoxicity against human MRC5 cells by MTT method	[PMID: 17417907]
MRC5	IC₅₀	1.4 μM Compound: Doxorubicin	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33823396]
MRC5	IC₅₀	14.84 μM Compound: Doxorubicin	Antiproliferative activity against human MRC5 cells after 48 hrs by MTT assay Antiproliferative activity against human MRC5 cells after 48 hrs by MTT assay	10.1039/C2MD20023F
MRC5	IC₅₀	14.84 μM Compound: Doxorubicin	Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay Cytotoxicity against human MRC5 cells after 48 hrs by MTT assay	[PMID: 22386528]
MRC5	IC₅₀	148 nM Compound: 5; Dox	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by AlamarBlue cell viability assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by AlamarBlue cell viability assay	[PMID: 31347843]
MRC5	IC₅₀	2.19 μM Compound: Doxorubicin	Cytotoxicity against human MRC5 cells assessed as reduction in cell growth measured after 48 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell growth measured after 48 hrs by MTT assay	[PMID: 31416738]
MRC5	IC₅₀	2.4 μM Compound: Doxorubicin	Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by alamar blue assay	[PMID: 31403289]
MRC5	IC₅₀	2.91 μM Compound: Doxorubicin	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31704206]
MRC5	IC₅₀	70.6 μM Compound: Doxorubicin	Cytotoxicity against human MRC5 cells after 24 hrs by MTT assay Cytotoxicity against human MRC5 cells after 24 hrs by MTT assay	[PMID: 27769619]
MRC5	IC₅₀	89.68 μM Compound: Doxo	Cytotoxicity against human MRC5 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 27036521]
MT4	IC₅₀	0.003 μM Compound: Doxorubicin	Antiproliferative activity against human MT4 cells after 96 hrs by MTT assay Antiproliferative activity against human MT4 cells after 96 hrs by MTT assay	[PMID: 19053767]
MT4	IC₅₀	0.01 μM Compound: Doxo	Antiproliferative activity against human MT-4 cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human MT-4 cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
MT4	IC₅₀	0.01 μM Compound: doxo	Antiproliferative activity against human MT4 cell line by MTT assay Antiproliferative activity against human MT4 cell line by MTT assay	[PMID: 16913700]
MT4	EC₅₀	0.03 μM Compound: Doxorubicin	Antiproliferative activity against human MT4 cells after 96 hrs by MTT assay Antiproliferative activity against human MT4 cells after 96 hrs by MTT assay	[PMID: 26320088]
MV4-11	IC₅₀	0.05 μM Compound: Doxorubicin	Antiproliferative activity against human MV4-11 cells after 72 hrs Antiproliferative activity against human MV4-11 cells after 72 hrs	[PMID: 26163197]
MV4-11	IC₅₀	0.16 μM Compound: DOX	Cytotoxicity against human MV4-11 cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human MV4-11 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
MX1	IC₅₀	0.42 μM Compound: DOX	Cytotoxicity against human MX1 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MX1 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29660689]
MX1	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human MX1 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human MX1 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24530030]
N2a	IC₅₀	< 0.001 μg/mL Compound: 1 (doxorubicin)	In vitro cytotoxic concentration against mouse neuroblastoma (neuro 2A) using MTT coloration In vitro cytotoxic concentration against mouse neuroblastoma (neuro 2A) using MTT coloration	[PMID: 15013011]
N2a	IC₅₀	0.004 μg/mL Compound: 1 (doxorubicin)	In vitro inhibitory activity against mouse neuroblastoma (neuro 2A) using CV coloration In vitro inhibitory activity against mouse neuroblastoma (neuro 2A) using CV coloration	[PMID: 15013011]
N2a	IC₅₀	1.2 μM Compound: Doxorubicin	Cytotoxicity against mouse Neuro2a cells by MTT assay Cytotoxicity against mouse Neuro2a cells by MTT assay	[PMID: 21996519]
N2a	EC₅₀	127 μM Compound: Doxorubicin	Cytotoxicity against mouse Neuro-2a cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against mouse Neuro-2a cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32816476]
NAMALVA	IC₅₀	0.05 μM Compound: Doxorubicin	Antiproliferative activity against human NAMALWA cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method Antiproliferative activity against human NAMALWA cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	[PMID: 25937235]
NAMALVA	IC₅₀	0.09 μM Compound: Doxorubicin	Cytotoxicity against human NAMALVA cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human NAMALVA cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 33668008]
NB1	IC₅₀	5.15 nM Compound: Doxorubicin	Cytotoxicity against human NB-1 cells after 3 days by MTT assay Cytotoxicity against human NB-1 cells after 3 days by MTT assay	[PMID: 20356655]
NB1	IC₅₀	5.15 nM Compound: Doxorubicin	Cytotoxicity against human NB-1 cells by MTT assay Cytotoxicity against human NB-1 cells by MTT assay	[PMID: 19345581]
NCI/ADR-RES	IC₅₀	> 10 μM Compound: doxorubicin	Cytotoxicity against human MCF7/ADR cells after 48 hrs by MTT assay Cytotoxicity against human MCF7/ADR cells after 48 hrs by MTT assay	[PMID: 21087017]
NCI/ADR-RES	IC₅₀	> 100000 nM Compound: Doxorubicin	Antiproliferative activity against human MCF7/ADR cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7/ADR cells after 48 hrs by MTT assay	[PMID: 29795767]
NCI/ADR-RES	IC₅₀	> 20 μM Compound: Doxo	Cytotoxicity against human MCF7/ADR cells after 24 hrs by MTT assay Cytotoxicity against human MCF7/ADR cells after 24 hrs by MTT assay	[PMID: 21885273]
NCI/ADR-RES	IC₅₀	> 20 μM Compound: DOX, Doxorubicin	Antiproliferative activity against human NCI/ADR-RES cells after 72 hrs by MTT assay Antiproliferative activity against human NCI/ADR-RES cells after 72 hrs by MTT assay	[PMID: 24095089]
NCI/ADR-RES	IC₅₀	> 50 μM Compound: Doxorubicin	Cytotoxicity against multidrug-resistant human MCF7/ADR cells after 48 hrs by MTT assay Cytotoxicity against multidrug-resistant human MCF7/ADR cells after 48 hrs by MTT assay	[PMID: 22537362]
NCI/ADR-RES	GI₅₀	0.14 μg/mL Compound: DOX; Doxo	Antiproliferative activity against human NCI-ADR-RES cells after 48 hrs by SRB assay Antiproliferative activity against human NCI-ADR-RES cells after 48 hrs by SRB assay	[PMID: 26859070]
NCI/ADR-RES	GI₅₀	0.14 μg/mL Compound: Doxorubicin	Growth inhibition of human NCI-ADR-RES cells after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-ADR-RES cells after 48 hrs by sulforhodamine B assay	[PMID: 22410248]
NCI/ADR-RES	GI₅₀	0.21 μM Compound: Dox	Antiproliferative activity against human NCI-ADR-RES cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human NCI-ADR-RES cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26454648]
NCI/ADR-RES	GI₅₀	0.33 μg/mL Compound: DOX	Growth inhibition of human NCI-ADR-RES cells after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-ADR-RES cells after 48 hrs by sulforhodamine B assay	[PMID: 21041092]
NCI/ADR-RES	GI₅₀	0.54 μg/mL Compound: DOX	Antiproliferative activity against human NCI/ADR-RES cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI/ADR-RES cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 25062010]
NCI/ADR-RES	GI₅₀	0.77 μM Compound: Dox	Growth inhibition of human NCI-ADR-RES cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay Growth inhibition of human NCI-ADR-RES cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay	[PMID: 28505535]
NCI/ADR-RES	GI₅₀	1.44 μM Compound: DOXO	Antiproliferative activity against human NCI-ADR-RES cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI-ADR-RES cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 31247374]
NCI/ADR-RES	GI₅₀	11.67 μM Compound: DOX	Growth inhibition of human MCF7/ADR cells incubated for 72 hrs by MTT assay Growth inhibition of human MCF7/ADR cells incubated for 72 hrs by MTT assay	[PMID: 31176097]
NCI/ADR-RES	GI₅₀	11.67 μM Compound: DOX	Growth inhibition of human MCF7/ADR cells after 72 hrs by MTT assay Growth inhibition of human MCF7/ADR cells after 72 hrs by MTT assay	[PMID: 30336023]
NCI/ADR-RES	GI₅₀	11.67 μM Compound: DOX	Cytotoxicity against human MCF7/ADR cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7/ADR cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29705710]
NCI/ADR-RES	IC₅₀	112.06 μM Compound: Dox	Antiproliferative activity against human MCF7/ADR cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7/ADR cells after 48 hrs by MTT assay	[PMID: 35339100]
NCI/ADR-RES	IC₅₀	13.6 μM Compound: Doxo	Cytotoxicity against human MCF7/ADR cells after 48 hrs by MTT assay Cytotoxicity against human MCF7/ADR cells after 48 hrs by MTT assay	[PMID: 21885273]
NCI/ADR-RES	IC₅₀	1574.2 μM Compound: doxorubicin	Cytotoxicity against human MCF7/ADR cells after 48 hrs by MTT assay Cytotoxicity against human MCF7/ADR cells after 48 hrs by MTT assay	[PMID: 25314138]
NCI/ADR-RES	GI₅₀	16.7 μM Compound: Doxorubicin	Tested for in vitro concentration required to inhibit growth by 50% against MCF-7/ADR human breast cancer cell line cell line Tested for in vitro concentration required to inhibit growth by 50% against MCF-7/ADR human breast cancer cell line cell line	[PMID: 11755363]
NCI/ADR-RES	IC₅₀	18.22 μM Compound: Doxorubicin	Cytotoxicity against human MCF7/ADR cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human MCF7/ADR cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33823396]
NCI/ADR-RES	IC₅₀	189 nM Compound: Doxorubicin	Antiproliferative activity against human MCF7/ADR cells assessed as cell growth inhibition measured after 48 hrs by MTS assay Antiproliferative activity against human MCF7/ADR cells assessed as cell growth inhibition measured after 48 hrs by MTS assay	[PMID: 35737669]
NCI/ADR-RES	ED₅₀	2.7 μg/mL Compound: adriamycin	Cytotoxicity against human MCF7/ADR cells after 6 days by coulter counted assay Cytotoxicity against human MCF7/ADR cells after 6 days by coulter counted assay	[PMID: 8984151]
NCI/ADR-RES	IC₅₀	2.94 μM Compound: Dox	Antiproliferative activity against human MCF7/ADR cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7/ADR cells after 72 hrs by MTT assay	[PMID: 27423028]
NCI/ADR-RES	IC₅₀	220 μM Compound: 1; dox	Cytotoxicity against doxorubicin-resistant human NCI/ADR-RES cells assessed as inhibition of cell growth incubated for 30 mins by crystal violet staining assay Cytotoxicity against doxorubicin-resistant human NCI/ADR-RES cells assessed as inhibition of cell growth incubated for 30 mins by crystal violet staining assay	[PMID: 26881291]
NCI/ADR-RES	IC₅₀	24.4 μg/mL Compound: DOX	Antiproliferative activity against human MCF7/ADR cells assessed as growth inhibition after 24 to 48 hrs by SRB assay Antiproliferative activity against human MCF7/ADR cells assessed as growth inhibition after 24 to 48 hrs by SRB assay	[PMID: 24012683]
NCI/ADR-RES	IC₅₀	25.28 μM Compound: ADR	Cytotoxicity against human MCF7/ADR cells after 72 hrs by MTT assay Cytotoxicity against human MCF7/ADR cells after 72 hrs by MTT assay	[PMID: 19523827]
NCI/ADR-RES	ED₅₀	4.7 x 10^-1 μg/mL Compound: adriamycin	Cytotoxicity against human MCF7/ADR cells after 6 days by BCA assay Cytotoxicity against human MCF7/ADR cells after 6 days by BCA assay	[PMID: 8984151]
NCI/ADR-RES	IC₅₀	45.2 μM Compound: 1, Dox	Tumor killing activity in MCF7/ADR drug-resistant cell line by MTT assay Tumor killing activity in MCF7/ADR drug-resistant cell line by MTT assay	[PMID: 16168650]
NCI/ADR-RES	GI₅₀	5.1 μM Compound: Doxorubicin	Cytotoxicity against human NCI-ADR-RES cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Cytotoxicity against human NCI-ADR-RES cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 26561866]
NCI/ADR-RES	IC₅₀	50.85 μM Compound: Doxorubicin	Antiproliferative activity against human MCF7/ADR cells incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human MCF7/ADR cells incubated for 48 hrs by CCK-8 assay	[PMID: 33725657]
NCI/ADR-RES	IC₅₀	52.5 μM Compound: ADM	Anticancer activity against human MCF7/ADR cells after 48 hrs by MTT assay Anticancer activity against human MCF7/ADR cells after 48 hrs by MTT assay	[PMID: 25462264]
NCI/ADR-RES	IC₅₀	58.47 μM Compound: Doxorubicin	Antiproliferative activity against human multidrug resistant NCI-ADR-RES cells overexpressing P-gp assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human multidrug resistant NCI-ADR-RES cells overexpressing P-gp assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 36242992]
NCI/ADR-RES	IC₅₀	620 nM Compound: 1; dox	Cytotoxicity against doxorubicin-resistant human NCI/ADR-RES cells assessed as inhibition of cell growth incubated for 90 mins by crystal violet staining assay Cytotoxicity against doxorubicin-resistant human NCI/ADR-RES cells assessed as inhibition of cell growth incubated for 90 mins by crystal violet staining assay	[PMID: 26881291]
NCI/ADR-RES	IC₅₀	64.8 μM Compound: DOX	Cytotoxicity in doxorubicin-resistant human MCF7/ADR cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in doxorubicin-resistant human MCF7/ADR cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 30860373]
NCI/ADR-RES	IC₅₀	68.434 μM Compound: Adriamycin	Cytotoxicity against human MCF7/ADR cells after 48 hrs by MTT assay Cytotoxicity against human MCF7/ADR cells after 48 hrs by MTT assay	[PMID: 24684844]
NCI/ADR-RES	GI₅₀	7.16 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human NCI/ADR-RES cells after 48 hrs by SRB assay Cytotoxicity against human NCI/ADR-RES cells after 48 hrs by SRB assay	[PMID: 23871905]
NCI/ADR-RES	GI₅₀	7.16 μM Compound: Doxorubicin	Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
NCI/ADR-RES	GI₅₀	7.16 μM Compound: Doxorubicin	Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI/ADR-RES cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
NCI/ADR-RES	IC₅₀	83.2 μM Compound: Doxorubicin	Cytotoxicity against human MCF7/ADR cells by WST-1 assay Cytotoxicity against human MCF7/ADR cells by WST-1 assay	[PMID: 22197145]
NCI/ADR-RES	IC₅₀	9.26 μM Compound: ADR	Cytotoxicity against human MCF7/ADR cells assessed as growth inhibition after 96 hrs by SRB assay Cytotoxicity against human MCF7/ADR cells assessed as growth inhibition after 96 hrs by SRB assay	[PMID: 25817774]
NCI/ADR-RES	IC₅₀	9.3 μM Compound: Adriamycin	Cytotoxicity against adriamycin-selected human NCI/ADR-RES cells after 72 hrs by MTT assay Cytotoxicity against adriamycin-selected human NCI/ADR-RES cells after 72 hrs by MTT assay	[PMID: 21721528]
NCI-H1299	IC₅₀	0.5 μM Compound: DOX	Cytotoxicity against human H1299 cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human H1299 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
NCI-H1299	IC₅₀	1.299 μM Compound: DOX	Cytotoxicity against human NCI-H1299 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human NCI-H1299 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34700239]
NCI-H157	IC₅₀	0.61 μM Compound: Doxorubicin	Antiproliferative activity against human NCI-H157 cells after 48 hrs by MTT assay Antiproliferative activity against human NCI-H157 cells after 48 hrs by MTT assay	[PMID: 28919340]
NCI-H187	IC₅₀	0.03 μM Compound: Dox	Cytotoxicity against human NCI-H187 cells after 3 days by MTT assay Cytotoxicity against human NCI-H187 cells after 3 days by MTT assay	[PMID: 21741833]
NCI-H187	IC₅₀	0.04 μg/mL Compound: doxorubicin	Cytotoxicity against human NCI-H187 cells by SRB assay Cytotoxicity against human NCI-H187 cells by SRB assay	[PMID: 19778068]
NCI-H187	IC₅₀	0.04 μg/mL Compound: doxorubicin	Cytotoxicity against human NCI-H187 cells by resazurin microplate assay Cytotoxicity against human NCI-H187 cells by resazurin microplate assay	[PMID: 20329738]
NCI-H187	IC₅₀	0.042 μg/mL Compound: doxorubicin	Cytotoxicity against human NCI-H187 cells by sulforhodamine B assay Cytotoxicity against human NCI-H187 cells by sulforhodamine B assay	[PMID: 19555123]
NCI-H187	IC₅₀	0.058 μg/mL Compound: Doxorubicin	Cytotoxicity against human NCI-H187 cells by resazurin microplate assay Cytotoxicity against human NCI-H187 cells by resazurin microplate assay	[PMID: 19456117]
NCI-H187	IC₅₀	0.06 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H187 cells after 72 hrs by resazurin based fluorescence assay Cytotoxicity against human NCI-H187 cells after 72 hrs by resazurin based fluorescence assay	[PMID: 28927795]
NCI-H187	IC₅₀	0.08 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H187 cells by SRB assay Cytotoxicity against human NCI-H187 cells by SRB assay	[PMID: 20038128]
NCI-H187	IC₅₀	0.098 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H187 cells by resazurin microplate assay Cytotoxicity against human NCI-H187 cells by resazurin microplate assay	[PMID: 21090800]
NCI-H187	IC₅₀	0.1 μM Compound: doxorubicin	Cytotoxicity against human NCI-H187 cells by resazurin reduction assay Cytotoxicity against human NCI-H187 cells by resazurin reduction assay	[PMID: 22482432]
NCI-H187	IC₅₀	0.11 μM Compound: doxorubicin	Cytotoxicity against human NCI-H187 cells by SRB assay Cytotoxicity against human NCI-H187 cells by SRB assay	[PMID: 22004007]
NCI-H187	IC₅₀	0.12 μM Compound: doxorubicin	Cytotoxicity against human NCI-H187 cells by colorimetric method Cytotoxicity against human NCI-H187 cells by colorimetric method	[PMID: 23795891]
NCI-H187	IC₅₀	0.14 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H187 cells by SRB assay Cytotoxicity against human NCI-H187 cells by SRB assay	[PMID: 23806014]
NCI-H187	IC₅₀	0.16 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H187 cells after 5 days by resazurin microplate assay Cytotoxicity against human NCI-H187 cells after 5 days by resazurin microplate assay	[PMID: 22280818]
NCI-H187	IC₅₀	0.2 μM Compound: Doxorubicine	Cytotoxicity against human NCI-H187 cells assessed as reduction in cell viability by resazurin microplate assay Cytotoxicity against human NCI-H187 cells assessed as reduction in cell viability by resazurin microplate assay	[PMID: 34748348]
NCI-H187	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H187 cells assessed as reduction in cell viability by resazurin based fluorescence assay Cytotoxicity against human NCI-H187 cells assessed as reduction in cell viability by resazurin based fluorescence assay	[PMID: 33852304]
NCI-H187	IC₅₀	0.23 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H187 cells by resazurin microplate assay Cytotoxicity against human NCI-H187 cells by resazurin microplate assay	[PMID: 32193929]
NCI-H187	IC₅₀	0.25 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H187 cells by resazurin microplate assay Cytotoxicity against human NCI-H187 cells by resazurin microplate assay	[PMID: 19739600]
NCI-H187	IC₅₀	4.05 x 10^-5 mM Compound: doxorubicin	Cytotoxicity against human NCI-H187 cells by SRB assay Cytotoxicity against human NCI-H187 cells by SRB assay	[PMID: 16933890]
NCI-H1975	IC₅₀	0.03 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 28257197]
NCI-H1975	IC₅₀	0.087 μM Compound: DOX	Cytotoxicity against human NCI-H1975 cells harboring EGFR double L858R/T790M mutant measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human NCI-H1975 cells harboring EGFR double L858R/T790M mutant measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
NCI-H1975	IC₅₀	2.676 μM Compound: DOX	Cytotoxicity against human NCI-H1975 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34700239]
NCI-H2228	IC₅₀	0.097 μM Compound: DOX	Cytotoxicity against human NCI-H2228 cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human NCI-H2228 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
NCI-H226	GI₅₀	< 10 μg/mL Compound: Doxorubicin	Cytotoxicity against human NCI-H226 cells after 48 hrs by SRB assay Cytotoxicity against human NCI-H226 cells after 48 hrs by SRB assay	10.1039/C5MD00224A
NCI-H226	IC₅₀	0.008 μM Compound: Doxorubicin	Inhibitory activity against NCI-H226 cell line using MTT assay(mutant p53) Inhibitory activity against NCI-H226 cell line using MTT assay(mutant p53)	[PMID: 10780913]
NCI-H226	GI₅₀	0.05 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human NCI-H226 cells after 48 hrs by SRB assay Cytotoxicity against human NCI-H226 cells after 48 hrs by SRB assay	[PMID: 23871905]
NCI-H226	GI₅₀	0.05 μM Compound: Doxorubicin	Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
NCI-H226	GI₅₀	0.05 μM Compound: Doxorubicin	Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
NCI-H226	IC₅₀	5.07 μM Compound: Doxorubicin	Antiproliferative activity against human NCI-H226 cells after 48 hrs by MTT assay Antiproliferative activity against human NCI-H226 cells after 48 hrs by MTT assay	[PMID: 29547830]
NCI-H23	GI₅₀	0.005 μM Compound: Doxorubicin	Cytostatic activity against human NCI-H23 cells after 5 days by SRB assay Cytostatic activity against human NCI-H23 cells after 5 days by SRB assay	[PMID: 21711054]
NCI-H23	GI₅₀	0.072 μM Compound: ADR	Anticancer activity against human NCI-H23 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method Anticancer activity against human NCI-H23 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method	[PMID: 34500188]
NCI-H23	GI₅₀	0.0726 μM Compound: ADR	Cytotoxicity against human NCI-H23 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human NCI-H23 cells after 72 hrs by sulforhodamine B assay	[PMID: 27096046]
NCI-H23	GI₅₀	0.09 μM Compound: ADR	Cytotoxicity against human NCI-H23 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human NCI-H23 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 30253887]
NCI-H23	GI₅₀	0.09 μM Compound: ADR	Cytotoxicity against human NCI-H23 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Cytotoxicity against human NCI-H23 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 28870801]
NCI-H23	GI₅₀	0.15 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human NCI-H23 cells after 48 hrs by SRB assay Cytotoxicity against human NCI-H23 cells after 48 hrs by SRB assay	[PMID: 23871905]
NCI-H23	GI₅₀	0.15 μM Compound: Doxorubicin	Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
NCI-H23	GI₅₀	0.15 μM Compound: Doxorubicin	Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
NCI-H23	GI₅₀	0.178 μM Compound: ADR	Cytotoxicity against human NCI-H23 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human NCI-H23 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 24792464]
NCI-H23	GI₅₀	0.4 μM Compound: ADR	Cytotoxicity against human NCI-H23 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay Cytotoxicity against human NCI-H23 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay	[PMID: 25953156]
NCI-H23	GI₅₀	0.51 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H23 cells by SRB assay Cytotoxicity against human NCI-H23 cells by SRB assay	[PMID: 19596579]
NCI-H23	GI₅₀	1.66 μM Compound: ADR	Antiproliferative activity against human NCI-H23 cells by SRB method Antiproliferative activity against human NCI-H23 cells by SRB method	[PMID: 24835787]
NCI-H23	GI₅₀	1.66 μM Compound: ADR	Antiproliferative activity against human NCI-H23 cells by SRB assay Antiproliferative activity against human NCI-H23 cells by SRB assay	[PMID: 22738641]
NCI-H23	GI₅₀	1.9 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H23 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human NCI-H23 cells after 48 hrs by sulforhodamine B assay	[PMID: 23964644]
NCI-H292	IC₅₀	0.02 μg/mL Compound: DOX	Cytotoxicity against human NCI-H292 cells after 72 hrs by MTT assay Cytotoxicity against human NCI-H292 cells after 72 hrs by MTT assay	[PMID: 24589485]
NCI-H292	IC₅₀	0.19 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H292 cells assessed as inhibition of cell viability after 72 hrs by MTT assay Cytotoxicity against human NCI-H292 cells assessed as inhibition of cell viability after 72 hrs by MTT assay	[PMID: 29329071]
NCI-H292	IC₅₀	0.37 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H292 cells after 72 hrs by MTT assay Cytotoxicity against human NCI-H292 cells after 72 hrs by MTT assay	[PMID: 27116711]
NCI-H292	IC₅₀	0.6 μM Compound: Doxorubicin	Growth inhibition of human NCI-H292 cells after 72 hrs by MTT assay Growth inhibition of human NCI-H292 cells after 72 hrs by MTT assay	[PMID: 28189083]
NCI-H292	IC₅₀	351 nM Compound: Doxorubicin	Cytotoxicity against human NCI-H292 cells after 72 hrs by MTT assay Cytotoxicity against human NCI-H292 cells after 72 hrs by MTT assay	[PMID: 28459574]
NCI-H322M	IC₅₀	0.03 μM Compound: Doxorubicin	Inhibitory activity against NCI-H322 cell line using MTT assay(mutant p53) Inhibitory activity against NCI-H322 cell line using MTT assay(mutant p53)	[PMID: 10780913]
NCI-H322M	GI₅₀	0.54 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human NCI-H322M cells after 48 hrs by SRB assay Cytotoxicity against human NCI-H322M cells after 48 hrs by SRB assay	[PMID: 23871905]
NCI-H322M	GI₅₀	0.54 μM Compound: Doxorubicin	Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
NCI-H322M	GI₅₀	0.54 μM Compound: Doxorubicin	Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
NCI-H322M	IC₅₀	29 μM Compound: DOX	Antiproliferative activity against human NCI-H322M cells after 72 hrs by MTT assay Antiproliferative activity against human NCI-H322M cells after 72 hrs by MTT assay	[PMID: 30429098]
NCI-H358	IC₅₀	0.13 μM Compound: Doxorubicin	Inhibitory activity against NCI-H358 cell line using MTT assay(mutant p53) Inhibitory activity against NCI-H358 cell line using MTT assay(mutant p53)	[PMID: 10780913]
NCI-H358	IC₅₀	0.9 μM Compound: Dox	Cytotoxicity against human NCI-H358 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human NCI-H358 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31306817]
NCI-H446	IC₅₀	0.0248 μg/mL Compound: DOX	Cytotoxicity against human NCI-H446 cells after 72 hrs by MTT assay Cytotoxicity against human NCI-H446 cells after 72 hrs by MTT assay	[PMID: 20722446]
NCI-H446	IC₅₀	0.39 nM Compound: Doxorubicin	Antiproliferative activity against human NCI-H446 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human NCI-H446 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 35932565]
NCI-H446	IC₅₀	5.71 nM Compound: Doxorubicin	Antiproliferative activity against Irinotecan-resistant human NCI-H446 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against Irinotecan-resistant human NCI-H446 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 35932565]
NCI-H446	IC₅₀	5.71 nM Compound: Doxorubicin	Antiproliferative activity against etoposide/cisplatin combination-resistant human NCI-H446 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against etoposide/cisplatin combination-resistant human NCI-H446 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 35932565]
NCI-H460	GI₅₀	< 0.025 μg/mL Compound: DOX; Doxo	Antiproliferative activity against human NCI-H460 cells after 48 hrs by SRB assay Antiproliferative activity against human NCI-H460 cells after 48 hrs by SRB assay	[PMID: 26859070]
NCI-H460	GI₅₀	< 0.025 μg/mL Compound: DOX	Antiproliferative activity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 25062010]
NCI-H460	GI₅₀	< 0.025 μg/mL Compound: Doxorubicin	Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay	[PMID: 22410248]
NCI-H460	GI₅₀	< 0.03 μg/mL Compound: DOX	Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay	[PMID: 21041092]
NCI-H460	GI₅₀	< 0.046 μM Compound: Dox	Antiproliferative activity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26454648]
NCI-H460	GI₅₀	< 0.046 μM Compound: Doxorubicin	Anticancer activity against human NCI-H460 cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay Anticancer activity against human NCI-H460 cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay	[PMID: 33214037]
NCI-H460	IC₅₀	> 50 μM Compound: DOX	Cytotoxicity against human doxorubicin-resistant NCI-H460 cells after 48 hrs by MTT assay Cytotoxicity against human doxorubicin-resistant NCI-H460 cells after 48 hrs by MTT assay	[PMID: 27889629]
NCI-H460	IC₅₀	0.003 μM Compound: DOX	Antiproliferative activity against human H460 cells measured after 72 hrs by MTT assay Antiproliferative activity against human H460 cells measured after 72 hrs by MTT assay	[PMID: 31431364]
NCI-H460	IC₅₀	0.0037 μM Compound: adriamycin	Antitumor activity against human NCI-H460 cells by methylene blue staining method Antitumor activity against human NCI-H460 cells by methylene blue staining method	[PMID: 17656091]
NCI-H460	IC₅₀	0.004 μM Compound: Doxorubicin	Inhibitory activity against H460pv8 cell line using MTT assay Inhibitory activity against H460pv8 cell line using MTT assay	[PMID: 10780913]
NCI-H460	IC₅₀	0.01 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H460 cells after 24 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 24 hrs by MTT assay	[PMID: 17190470]
NCI-H460	IC₅₀	0.01 μM Compound: doxorubicin	Cytotoxicity against human NCI-H460 cells after 72 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 72 hrs by MTT assay	[PMID: 17286429]
NCI-H460	IC₅₀	0.01 μM Compound: doxorubicin	Antiproliferative activity against human NCI-H460 cells by MTT assay Antiproliferative activity against human NCI-H460 cells by MTT assay	[PMID: 18247573]
NCI-H460	IC₅₀	0.01 μM Compound: doxorubicin	Antiproliferative activity against human NCI-H460 cells by MTT assay Antiproliferative activity against human NCI-H460 cells by MTT assay	[PMID: 18052326]
NCI-H460	IC₅₀	0.01 μM Compound: doxorubicin	Cytotoxicity against human NCI-H460 cells by MTT assay Cytotoxicity against human NCI-H460 cells by MTT assay	[PMID: 15921417]
NCI-H460	IC₅₀	0.01 μM Compound: doxorubicin	Cytotoxicity against human NCI-H460 cells by MTT assay Cytotoxicity against human NCI-H460 cells by MTT assay	[PMID: 15620238]
NCI-H460	IC₅₀	0.01 μM Compound: Doxorubicin	Inhibitory activity against NCI-H460 cell line using MTT assay Inhibitory activity against NCI-H460 cell line using MTT assay	[PMID: 10780913]
NCI-H460	IC₅₀	0.01 μM Compound: Doxorubicin	Inhibitory activity against NCI-H460 cell line using MTT assay(Wild type p53) Inhibitory activity against NCI-H460 cell line using MTT assay(Wild type p53)	[PMID: 10780913]
NCI-H460	IC₅₀	0.01 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 6 hrs by SRB assay	[PMID: 36691388]
NCI-H460	GI₅₀	0.02 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay	[PMID: 23871905]
NCI-H460	GI₅₀	0.02 μM Compound: Doxorubicin	Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
NCI-H460	GI₅₀	0.02 μM Compound: Doxorubicin	Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
NCI-H460	IC₅₀	0.02 μM Compound: Doxorubicin	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	[PMID: 25937235]
NCI-H460	IC₅₀	0.028 μM Compound: doxorubicin	Antiproliferative activity against human NCI-H460 cells after 72 hrs by trypan blue test Antiproliferative activity against human NCI-H460 cells after 72 hrs by trypan blue test	[PMID: 18077173]
NCI-H460	IC₅₀	0.03 μM Compound: Doxorubicin	Antiproliferative activity against human H460 cells after 72 hrs by MTT assay Antiproliferative activity against human H460 cells after 72 hrs by MTT assay	[PMID: 27448912]
NCI-H460	IC₅₀	0.03 μM Compound: Doxorubicin	Antiproliferative activity against human H460 cells after 72 hrs by MTT assay Antiproliferative activity against human H460 cells after 72 hrs by MTT assay	[PMID: 24780599]
NCI-H460	IC₅₀	0.04 μM Compound: Dox	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30615450]
NCI-H460	EC₅₀	0.04 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H460 cells after 48 hrs by resazurin dye assay Cytotoxicity against human NCI-H460 cells after 48 hrs by resazurin dye assay	[PMID: 23988351]
NCI-H460	IC₅₀	0.05 μg/mL Compound: Adriamycin	Inhibitory concentration against human lung carcinoma cell line H460 after 48 hr in MTT assay Inhibitory concentration against human lung carcinoma cell line H460 after 48 hr in MTT assay	[PMID: 15715467]
NCI-H460	IC₅₀	0.05 μM Compound: doxorubicin	Cytotoxicity against human NCI-H460 cells after 72 hrs by Alamar Blue assay Cytotoxicity against human NCI-H460 cells after 72 hrs by Alamar Blue assay	[PMID: 24251417]
NCI-H460	IC₅₀	0.05 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H460 cells assessed as cell growth inhibition measured after 24 to 72 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as cell growth inhibition measured after 24 to 72 hrs by MTT assay	[PMID: 33586438]
NCI-H460	GI₅₀	0.05 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H460 cells by sulforhodamine B assay Cytotoxicity against human NCI-H460 cells by sulforhodamine B assay	[PMID: 20413188]
NCI-H460	IC₅₀	0.05 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H460 cells after 72 hrs by resazurin-based colorimetric assay Cytotoxicity against human NCI-H460 cells after 72 hrs by resazurin-based colorimetric assay	[PMID: 27071003]
NCI-H460	IC₅₀	0.05 μM Compound: doxorubicin	Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay	[PMID: 26305181]
NCI-H460	GI₅₀	0.0547 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 31534659]
NCI-H460	IC₅₀	0.08 μg/mL Compound: Doxorubicin	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 33940463]
NCI-H460	IC₅₀	0.08 μM Compound: Adriamycin	Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay	[PMID: 24717154]
NCI-H460	IC₅₀	0.09 ug/L Compound: Doxorubicin	Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell viability after 72 hrs by SRB assay Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell viability after 72 hrs by SRB assay	[PMID: 26420384]
NCI-H460	GI₅₀	0.09 μM Compound: Dox	Growth inhibition of human NCI-H460 cells by MTT assay Growth inhibition of human NCI-H460 cells by MTT assay	[PMID: 31330449]
NCI-H460	GI₅₀	0.09 μM Compound: doxorubicin	Growth inhibition of Homo sapiens (human) NCI-H460 cells after 48 hr by SRB assay Growth inhibition of Homo sapiens (human) NCI-H460 cells after 48 hr by SRB assay	10.1007/s00044-012-0213-9
NCI-H460	IC₅₀	0.09 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Cytotoxicity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	10.1007/s00044-013-0712-3
NCI-H460	GI₅₀	0.09 μM Compound: Dox	Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay	[PMID: 28505535]
NCI-H460	GI₅₀	0.094 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay	[PMID: 15620248]
NCI-H460	GI₅₀	0.094 μM Compound: Doxorubicin	Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay	[PMID: 21435889]
NCI-H460	IC₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell proliferation measured after 72 hrs by resazurin dye based AlamarBlue assay Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell proliferation measured after 72 hrs by resazurin dye based AlamarBlue assay	[PMID: 34495663]
NCI-H460	GI₅₀	0.11 μM Compound: Doxorubicin	Growth inhibition of Homo sapiens (human) H460 cells after 48 hr by MTT assay Growth inhibition of Homo sapiens (human) H460 cells after 48 hr by MTT assay	10.1007/s00044-012-0232-6
NCI-H460	GI₅₀	0.123 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H460 cells assessed as growth inhibition measured after 48 hrs by SRB assay Cytotoxicity against human NCI-H460 cells assessed as growth inhibition measured after 48 hrs by SRB assay	[PMID: 31059248]
NCI-H460	IC₅₀	0.15 μM Compound: Doxorubicin	Cytotoxicity against human H460 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human H460 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26972921]
NCI-H460	IC₅₀	0.15 μM Compound: Dox	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33479619]
NCI-H460	IC₅₀	0.15 μM Compound: DOX	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29660689]
NCI-H460	IC₅₀	0.17 μM Compound: DOX	Antiproliferative activity against human H460 cells after 72 hrs by Sulforhodamine B-stain assay Antiproliferative activity against human H460 cells after 72 hrs by Sulforhodamine B-stain assay	[PMID: 27484508]
NCI-H460	IC₅₀	0.18 μg/mL Compound: adriamycin	Cytotoxicity against human H460 cells by SRB assay Cytotoxicity against human H460 cells by SRB assay	[PMID: 17981473]
NCI-H460	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxic activity against human H460 cells incubated for 48 hrs by MTT assay Cytotoxic activity against human H460 cells incubated for 48 hrs by MTT assay	[PMID: 28055219]
NCI-H460	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H460 cells after 72 hrs by Alamar blue assay Cytotoxicity against human NCI-H460 cells after 72 hrs by Alamar blue assay	[PMID: 21999655]
NCI-H460	GI₅₀	0.37 μM Compound: DOXO	Antiproliferative activity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI-H460 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 31247374]
NCI-H460	IC₅₀	0.38 nM Compound: Doxorubicin	Antiproliferative activity against human H460 cells after 72 hrs by methylene blue staining Antiproliferative activity against human H460 cells after 72 hrs by methylene blue staining	[PMID: 21067930]
NCI-H460	IC₅₀	0.4 μM Compound: Doxorubicin	Cytotoxicity in human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34082225]
NCI-H460	IC₅₀	0.4 μM Compound: Dox	Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 32428792]
NCI-H460	IC₅₀	0.4 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H460 cells by resazurin dye based Alamar blue assay Cytotoxicity against human NCI-H460 cells by resazurin dye based Alamar blue assay	[PMID: 29373790]
NCI-H460	IC₅₀	0.42 μM Compound: doxorubicin	Cytotoxicity against human NCI-H460 cells after 72 hrs by Alamar blue assay Cytotoxicity against human NCI-H460 cells after 72 hrs by Alamar blue assay	[PMID: 22264149]
NCI-H460	IC₅₀	0.42 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H460 cells after 72 hrs by resazurin/AlamarBlue dye-based fluorescence assay Cytotoxicity against human NCI-H460 cells after 72 hrs by resazurin/AlamarBlue dye-based fluorescence assay	[PMID: 28139929]
NCI-H460	IC₅₀	0.456 μM Compound: Dox	Cytotoxicity against human NCI-H460 cells by MTT assay Cytotoxicity against human NCI-H460 cells by MTT assay	[PMID: 21983438]
NCI-H460	IC₅₀	0.456 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay	10.1039/C0MD00219D
NCI-H460	IC₅₀	0.66 μM Compound: adriamycin	Cytotoxicity against human NCI-H460 cells by MTT assay Cytotoxicity against human NCI-H460 cells by MTT assay	[PMID: 17125240]
NCI-H460	IC₅₀	0.8 μM Compound: DOX	Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 31057738]
NCI-H460	GI₅₀	0.81 x 10^-2 μM Compound: doxorubicin	Cytotoxicity against human NCI-H460 cells by SRB assay Cytotoxicity against human NCI-H460 cells by SRB assay	[PMID: 11678649]
NCI-H460	IC₅₀	0.98 μM Compound: Doxorubicin	Cytotoxicity against human H460 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human H460 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 26874404]
NCI-H460	IC₅₀	0.98 μM Compound: Adriamycin	Cytotoxicity against human H460 cells by MTT assay Cytotoxicity against human H460 cells by MTT assay	[PMID: 24182355]
NCI-H460	IC₅₀	1.62 μM Compound: DOX	Anticancer activity against against human multi-drug resistant NCI-H460/R cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Anticancer activity against against human multi-drug resistant NCI-H460/R cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 35450348]
NCI-H460	IC₅₀	11 nM Compound: Doxorubicin	Cytotoxicity against human NCI-H460 cells after 48 hrs by [3H]thymidine incorporation assay Cytotoxicity against human NCI-H460 cells after 48 hrs by [3H]thymidine incorporation assay	[PMID: 20210346]
NCI-H460	IC₅₀	11 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 22304344]
NCI-H460	IC₅₀	180 nM Compound: Doxorubicin	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31468974]
NCI-H460	IC₅₀	2.5 μM Compound: DOX	Antiproliferative activity against human NCI-H460 cells after 48 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 28756264]
NCI-H460	IC₅₀	2.64 x 10^-1 μM Compound: Doxorubucin	Cytotoxicity against human NCI-H460 cells after 72 hrs by XTT assay Cytotoxicity against human NCI-H460 cells after 72 hrs by XTT assay	[PMID: 20538470]
NCI-H460	GI₅₀	20 nM Compound: Doxorubicin	Antiproliferative activity against human NCI-H460 cells measured after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI-H460 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27908756]
NCI-H460	IC₅₀	34 nM Compound: Doxorubicin	Cytotoxicity against human NCI-H460 cells after 72 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 72 hrs by MTT assay	[PMID: 28459574]
NCI-H460	GI₅₀	34.07 nM Compound: Doxorubicin	Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay	[PMID: 24411197]
NCI-H460	GI₅₀	35.6 nM Compound: Doxorubucin	Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay	[PMID: 21138784]
NCI-H460	GI₅₀	35.6 nM Compound: doxorubicin	Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay	[PMID: 20934235]
NCI-H460	IC₅₀	4.29 nM Compound: Doxorubicin	Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition measured after 72 hrs by crystal violet staining based assay Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition measured after 72 hrs by crystal violet staining based assay	[PMID: 34795858]
NCI-H460	IC₅₀	5.18 μM Compound: DOX	Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 30108853]
NCI-H460	IC₅₀	5.18 μM Compound: DOX	Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 27889629]
NCI-H460	IC₅₀	5.6 μM Compound: Doxorubicin	Anticancer activity against human NCI-H460 cells after 48 hrs by MTT assay Anticancer activity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 22668451]
NCI-H460	IC₅₀	6.06 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H460 cells after 48 hrs by alamar blue assay Cytotoxicity against human NCI-H460 cells after 48 hrs by alamar blue assay	[PMID: 22272829]
NCI-H460	IC₅₀	6.06 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H460 cells after 48 hrs Cytotoxicity against human NCI-H460 cells after 48 hrs	[PMID: 20873721]
NCI-H460	GI₅₀	64.1 nM Compound: Doxorubicin	Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay	[PMID: 24113365]
NCI-H460	GI₅₀	64.1 nM Compound: Doxorubicin	Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay	[PMID: 23623253]
NCI-H460	GI₅₀	86 nM Compound: Doxorubicin	Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay	[PMID: 22177409]
NCI-H460	GI₅₀	94 nM Compound: Doxorubicin	Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay	[PMID: 15270581]
NCI-H460	GI₅₀	94 nM Compound: Doxorubicin	Antitumor activity against human NCI-H460 cells assessed as inhibition of growth after 48 hrs using sulforhodamine B dye Antitumor activity against human NCI-H460 cells assessed as inhibition of growth after 48 hrs using sulforhodamine B dye	[PMID: 19428155]
NCI-H460	GI₅₀	94 nM Compound: doxorubicin	Antitumor activity against human NCI-H460 cells after 48 hrs Antitumor activity against human NCI-H460 cells after 48 hrs	[PMID: 18439831]
NCI-H460	GI₅₀	94 nM Compound: doxorubicin	Cytotoxicity against human NCI-H460 cells after 48 hrs Cytotoxicity against human NCI-H460 cells after 48 hrs	[PMID: 17964791]
NCI-H460	GI₅₀	94 nM Compound: doxorubicin	Growth inhibition of human NCI-H460 cells after 48 hrs Growth inhibition of human NCI-H460 cells after 48 hrs	[PMID: 17692432]
NCI-H460	GI₅₀	94 μM Compound: doxorubicin	Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay	[PMID: 19070942]
NCI-H460	GI₅₀	94 μM Compound: Doxorubicin	Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay Growth inhibition of human NCI-H460 cells after 48 hrs by SRB assay	[PMID: 15165162]
NCI-H460	GI₅₀	94 μM Compound: Doxorubicin	Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay	[PMID: 21504224]
NCI-H522	GI₅₀	0.03 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human NCI-H522 cells after 48 hrs by SRB assay Cytotoxicity against human NCI-H522 cells after 48 hrs by SRB assay	[PMID: 23871905]
NCI-H522	GI₅₀	0.03 μM Compound: Doxorubicin	Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
NCI-H522	GI₅₀	0.03 μM Compound: Doxorubicin	Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
NCI-H596	IC₅₀	1.08 μM Compound: Doxorubicin	Antiproliferative activity against human NCI-H596 cells measured after 48 hrs by MTT assay Antiproliferative activity against human NCI-H596 cells measured after 48 hrs by MTT assay	[PMID: 32682198]
NCI-H596	IC₅₀	1.52 μM Compound: ADM	Antiproliferative activity against NQO1-deficient human NCI-H596 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against NQO1-deficient human NCI-H596 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35803175]
NCI-H647	IC₅₀	< 0.001 μM Compound: Doxorubicin	Inhibitory activity against NCI-H647 cell line using MTT assay(mutant p53) Inhibitory activity against NCI-H647 cell line using MTT assay(mutant p53)	[PMID: 10780913]
NCI-H661	ED₅₀	0.29 μg/mL Compound: Doxorubicin	Cytotoxicity against human NCI-H661 cells by MTT assay Cytotoxicity against human NCI-H661 cells by MTT assay	[PMID: 15104488]
NCI-H661	IC₅₀	0.35 μM Compound: Dox	Cytotoxicity against human NCI-H661 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human NCI-H661 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30615450]
NCI-H661	IC₅₀	250 nM Compound: Dox	Antiproliferative activity against human NCI-H661 cells assessed as inhibition of cell viability after 3 days by XTT assay in presence of beta-glucuronidase Antiproliferative activity against human NCI-H661 cells assessed as inhibition of cell viability after 3 days by XTT assay in presence of beta-glucuronidase	10.1039/C1MD00193K
NCI-H69	IC₅₀	27.3 nM Compound: Doxorubicin	Cytotoxicity measured using the H69 parental (H69/P) human small cell lung carcinoma cell line Cytotoxicity measured using the H69 parental (H69/P) human small cell lung carcinoma cell line	[PMID: 11806724]
NCI-H69	IC₅₀	3 μM Compound: adriamycin	Cytotoxicity against human H69 cells under deem light after 96 hrs by MTT assay Cytotoxicity against human H69 cells under deem light after 96 hrs by MTT assay	[PMID: 17993275]
NCI-H69	IC₅₀	3874 nM Compound: Doxorubicin	Cytotoxicity measured using the drug resistant, P-glycoprotein (Pgp) expressing human small cell lung carcinoma cell line H69/LX4 Cytotoxicity measured using the drug resistant, P-glycoprotein (Pgp) expressing human small cell lung carcinoma cell line H69/LX4	[PMID: 11806724]
NCI-H727	IC₅₀	0 μM Compound: Doxorubicine	Cytotoxicity against human NCI-H727 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) Cytotoxicity against human NCI-H727 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)	[PMID: 33422908]
NCI-H727	IC₅₀	0.03 μM Compound: Doxorubicin	Antiproliferative activity against human NCI-H727 cells after 48 hrs by Hoechst 33342 staining-based assay Antiproliferative activity against human NCI-H727 cells after 48 hrs by Hoechst 33342 staining-based assay	[PMID: 30655216]
NCI-H727	IC₅₀	0.66 μM Compound: Doxorubicin	Toxicity in human NCI-H727 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay Toxicity in human NCI-H727 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay	[PMID: 31753515]
NCI-H929	IC₅₀	0.065 μM Compound: Doxorubicin	Cytotoxicity against human NCI-H929 cells after 72 hrs by resazurin/resorufin-based fluorescence assay Cytotoxicity against human NCI-H929 cells after 72 hrs by resazurin/resorufin-based fluorescence assay	[PMID: 23600925]
NCI-H929	IC₅₀	0.2 μM Compound: Dox	Cytotoxicity against human NCI-H929 cells after 72 hrs by MTT assay Cytotoxicity against human NCI-H929 cells after 72 hrs by MTT assay	[PMID: 30659997]
NCI-N87	IC₅₀	0.047 μM Compound: DOX	Cytotoxicity against human NCI-N87 cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human NCI-N87 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
NCI-N87	IC₅₀	1.6 μM Compound: Doxorubicin	Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay	[PMID: 27797185]
NCI-N87	IC₅₀	419.8 nM Compound: Doxorubicin	Antiproliferative activity against human NCI-N87 cells after 96 hrs by MTT assay Antiproliferative activity against human NCI-N87 cells after 96 hrs by MTT assay	[PMID: 21296467]
NCTC-2544	GI₅₀	1.32 mM Compound: Doxorubicin	Photocytotoxicity against human NCTC 2544 cells irradiated with 2.5 J cm^-2 ultraviolet radiation after 72 hrs by MTT assay Photocytotoxicity against human NCTC 2544 cells irradiated with 2.5 J cm^-2 ultraviolet radiation after 72 hrs by MTT assay	[PMID: 18023182]
NCTC-2544	GI₅₀	3.04 mM Compound: Doxorubicin	Photocytotoxicity against human NCTC 2544 cells irradiated with 1.25 J cm^-2 ultraviolet radiation after 72 hrs by MTT assay Photocytotoxicity against human NCTC 2544 cells irradiated with 1.25 J cm^-2 ultraviolet radiation after 72 hrs by MTT assay	[PMID: 18023182]
NCTC-2544	EC₅₀	32.5 μM Compound: 12	Dark toxicity in human NCTC-2544 cells assessed as decrease in cell viability after 24 hrs by MTT assay Dark toxicity in human NCTC-2544 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 29172528]
NFF	IC₅₀	125.6 nM Compound: Doxorubicin	Cytotoxicity against human NFF cells after 72 hrs by Alamar Blue assay Cytotoxicity against human NFF cells after 72 hrs by Alamar Blue assay	[PMID: 24973030]
NFS-60	IC₅₀	0.013 μM Compound: DOX	Cytotoxicity against mouse NFS60 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against mouse NFS60 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 30826510]
NFS-60	IC₅₀	13 nM Compound: Dox	Anticancer activity against human NFS-60 cells assessed as reduction in cell viability by MTT assay Anticancer activity against human NFS-60 cells assessed as reduction in cell viability by MTT assay	[PMID: 31740054]
NHDF	IC₅₀	0.011 μM Compound: Doxorubicin	Cytotoxicity against human HDF cells assessed as reduction in cell viability incubated for 7 days by CellTiter 96 aqueous one solution assay Cytotoxicity against human HDF cells assessed as reduction in cell viability incubated for 7 days by CellTiter 96 aqueous one solution assay	[PMID: 31596585]
NHDF	IC₅₀	0.137 μM Compound: Doxorubicin	Cytotoxicity against NHDF cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against NHDF cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 33261897]
NHDF	IC₅₀	0.14 μM Compound: Doxorubicin	Cytotoxicity against human NHDF cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against human NHDF cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 31962262]
NHDF	IC₅₀	0.14 μM Compound: Doxorubicin	Cytotoxicity against human NHDF cells incubated for 72 hrs by MTS assay Cytotoxicity against human NHDF cells incubated for 72 hrs by MTS assay	[PMID: 31158748]
NHDF	IC₅₀	3.38 μM Compound: DOXO	Cytotoxicity against human NHDF cells after 96 hrs by MTS assay Cytotoxicity against human NHDF cells after 96 hrs by MTS assay	[PMID: 26890119]
NHDF	GI₅₀	462 nM Compound: Doxorubicin	Antiproliferative activity against NHDF assessed as growth inhibition after 24 to 72 hrs by MTS assay Antiproliferative activity against NHDF assessed as growth inhibition after 24 to 72 hrs by MTS assay	10.1039/C0MD00179A
NIH3T3	IC₅₀	0.05 μM Compound: Adriamycin	Cytotoxicity against mouse NIH/3T3 cells after 72 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells after 72 hrs by MTT assay	[PMID: 21721528]
NIH3T3	IC₅₀	0.08 μM Compound: Adriamycin	Cytotoxicity against mouse NIH/3T3 cells selected at 30 ug/ml vincristine after 72 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells selected at 30 ug/ml vincristine after 72 hrs by MTT assay	[PMID: 21721528]
NIH3T3	GI₅₀	0.28 μM Compound: Doxorubicin	Cytotoxicity against mouse NIH/3T3 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 33477019]
NIH3T3	IC₅₀	0.38 μM Compound: Adriamycin	Cytotoxicity against mouse NIH/3T3 cells transfected with wild-type P-gp G185 after 72 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells transfected with wild-type P-gp G185 after 72 hrs by MTT assay	[PMID: 21721528]
NIH3T3	IC₅₀	0.39 μM Compound: Doxorubicin	Cytotoxicity against mouse NIH/3T3 cells after 72 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells after 72 hrs by MTT assay	[PMID: 19361894]
NIH3T3	EC₅₀	0.4 μM Compound: Doxorubicin	Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay	[PMID: 33049606]
NIH3T3	IC₅₀	0.4 μM Compound: DX	Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32422522]
NIH3T3	IC₅₀	0.53 μM Compound: Adriamycin	Cytotoxicity against mouse NIH/3T3 cells transfected with PO4 mutant harboring Ser to Asp mutation selected at 2400 ug/ml vincristine after 72 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells transfected with PO4 mutant harboring Ser to Asp mutation selected at 2400 ug/ml vincristine after 72 hrs by MTT assay	[PMID: 21721528]
NIH3T3	IC₅₀	0.69 μM Compound: Adriamycin	Cytotoxicity against mouse NIH/3T3 cells transfected with wild type p-glycoprotein ABCB1 selected at 600 ug/ml vincristine after 72 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells transfected with wild type p-glycoprotein ABCB1 selected at 600 ug/ml vincristine after 72 hrs by MTT assay	[PMID: 21721528]
NIH3T3	EC₅₀	1.3 μM Compound: DR	Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 32956968]
NIH3T3	IC₅₀	1.58 μM Compound: Adriamycin	Cytotoxicity against mouse NIH/3T3 cells selected at 1 ug/mL colchicine after 72 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells selected at 1 ug/mL colchicine after 72 hrs by MTT assay	[PMID: 21721528]
NIH3T3	IC₅₀	10.1 μM Compound: DX	Cytotoxicity against human NIH/3T3 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human NIH/3T3 cells after 48 hrs by sulforhodamine B assay	10.1039/C5MD00513B
NIH3T3	IC₅₀	1180.32 μM Compound: Dox	Cytotoxicity against mouse NIH3T3 cells assessed as cell viability measured after 24 hrs by MTT assay Cytotoxicity against mouse NIH3T3 cells assessed as cell viability measured after 24 hrs by MTT assay	[PMID: 33183865]
NIH3T3	IC₅₀	17.48 μM Compound: Adriamycin	Cytotoxicity against 2.4 ug/mL vincristine selected mouse NIH/3T3 cells transfected with P-gp Ser to Asp phosphorylation mutant after 72 hrs by MTT assay Cytotoxicity against 2.4 ug/mL vincristine selected mouse NIH/3T3 cells transfected with P-gp Ser to Asp phosphorylation mutant after 72 hrs by MTT assay	[PMID: 21721528]
NIH3T3	IC₅₀	1720 nM Compound: Doxorubicin	Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by MTT assay	[PMID: 30172625]
NIH3T3	IC₅₀	2.7 μM Compound: Adriamycin	Cytotoxicity against mouse NIH/3T3 cells transfected with PO4 mutant harboring four Ser to Arg mutation selected at 2400 ug/ml vincristine after 72 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells transfected with PO4 mutant harboring four Ser to Arg mutation selected at 2400 ug/ml vincristine after 72 hrs by MTT assay	[PMID: 21721528]
NIH3T3	IC₅₀	21.32 μM Compound: Doxorubicin	Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by MTT assay	[PMID: 29573910]
NIH3T3	IC₅₀	3.24 μM Compound: Doxorubicin	Cytotoxicity against Balb-c mouse 3T3 cells by MTT assay Cytotoxicity against Balb-c mouse 3T3 cells by MTT assay	[PMID: 23850203]
NIH3T3	IC₅₀	3.5 μM Compound: Dox	Cytotoxicity against mouse NIH/3T3 cells after 3 days by MTS assay Cytotoxicity against mouse NIH/3T3 cells after 3 days by MTS assay	[PMID: 21094049]
NIH3T3	IC₅₀	3.7 μM Compound: doxorubicin	Cytotoxicity against mouse 3T3 cells after 48 hrs by MTT assay Cytotoxicity against mouse 3T3 cells after 48 hrs by MTT assay	[PMID: 20405844]
NIH3T3	GI₅₀	4 μM Compound: Doxorubicin	Cytotoxicity against mouse NIH/3T3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Cytotoxicity against mouse NIH/3T3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 26561866]
NIH3T3	IC₅₀	5.91 μM Compound: DOX	Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by SRB method Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by SRB method	[PMID: 25933593]
NIH3T3	IC₅₀	7.211 μM Compound: Dox	Cytotoxicity against mouse NIH/3T3 cells assessed as cell killing effect after 72 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells assessed as cell killing effect after 72 hrs by MTT assay	[PMID: 26005543]
NRK-49F	IC₅₀	24.22 μM Compound: Doxo	Cytotoxicity against rat NRK-49F cells measured after 24 hrs by MTT assay Cytotoxicity against rat NRK-49F cells measured after 24 hrs by MTT assay	[PMID: 31104996]
NUGC-3	GI₅₀	0.086 μM Compound: ADR	Cytotoxicity against human NUGC3 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human NUGC3 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 30253887]
NUGC-3	GI₅₀	0.086 μM Compound: ADR	Cytotoxicity against human NUGC3 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Cytotoxicity against human NUGC3 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 28870801]
NUGC-3	GI₅₀	0.11 μg/mL Compound: Adriamycin	Antiproliferative activity against human NUGC3 cells by SRB assay Antiproliferative activity against human NUGC3 cells by SRB assay	[PMID: 18023932]
NUGC-3	GI₅₀	0.125 μM Compound: ADR	Cytotoxicity against human NUGC3 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human NUGC3 cells after 72 hrs by sulforhodamine B assay	[PMID: 27096046]
NUGC-3	GI₅₀	0.19 μM Compound: ADR	Cytotoxicity against human NUGC3 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay Cytotoxicity against human NUGC3 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay	[PMID: 25953156]
NUGC-3	GI₅₀	0.25 μM Compound: Doxorubicin	Cytotoxicity against human NUGC3 cells by SRB assay Cytotoxicity against human NUGC3 cells by SRB assay	[PMID: 19596579]
NUGC-3	GI₅₀	0.51 μM Compound: Doxorubicin	Cytotoxicity against human NUGC3 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human NUGC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 23964644]
NUGC-3	GI₅₀	1 μM Compound: ADR	Antiproliferative activity against human NUGC3 cells by SRB method Antiproliferative activity against human NUGC3 cells by SRB method	[PMID: 24835787]
NUGC-3	GI₅₀	1 μM Compound: ADR	Antiproliferative activity against human NUGC3 cells by SRB assay Antiproliferative activity against human NUGC3 cells by SRB assay	[PMID: 22738641]
OS-RC-2	IC₅₀	5.4 μM Compound: Doxorubicin	Antiproliferative activity against human OS-RC2 cells after 72 hrs by MTT assay Antiproliferative activity against human OS-RC2 cells after 72 hrs by MTT assay	[PMID: 19632833]
OVCAR	GI₅₀	0.95 μM Compound: Doxorubicin	Growth inhibition of Homo sapiens (human) OVCAR cells after 48 hr by MTT assay Growth inhibition of Homo sapiens (human) OVCAR cells after 48 hr by MTT assay	10.1007/s00044-012-0232-6
OVCAR-3	IC₅₀	> 20 μM Compound: DOX	Cytotoxicity against human OVCAR3 cells after 24 hrs by XTT assay Cytotoxicity against human OVCAR3 cells after 24 hrs by XTT assay	[PMID: 24900344]
OVCAR-3	GI₅₀	0.0087 μM Compound: DOXO	Antiproliferative activity against human OVCAR3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human OVCAR3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 31247374]
OVCAR-3	IC₅₀	0.02 μM Compound: Doxorubicin	Antiproliferative activity against human OVCAR3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method Antiproliferative activity against human OVCAR3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	[PMID: 25937235]
OVCAR-3	GI₅₀	0.07 μM Compound: Doxorubicin	Cytotoxicity against human OVCAR-3 cells by sulforhodamine B assay Cytotoxicity against human OVCAR-3 cells by sulforhodamine B assay	[PMID: 20413188]
OVCAR-3	GI₅₀	0.08 μg/mL Compound: DOX	Growth inhibition of human OVCAR-3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR-3 cells after 48 hrs by sulforhodamine B assay	[PMID: 21041092]
OVCAR-3	GI₅₀	0.09 μM Compound: Doxorubicin	Anticancer activity against human OVCAR-3 cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay Anticancer activity against human OVCAR-3 cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay	[PMID: 33214037]
OVCAR-3	GI₅₀	0.22 μM Compound: Dox	Growth inhibition of human OVCAR3 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay Growth inhibition of human OVCAR3 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay	[PMID: 28505535]
OVCAR-3	GI₅₀	0.27 μg/mL Compound: Doxorubicin	Growth inhibition of human OVCAR3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR3 cells after 48 hrs by sulforhodamine B assay	[PMID: 22410248]
OVCAR-3	IC₅₀	0.32 μM Compound: DOXO	Cytotoxicity against human OVCAR3 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human OVCAR3 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26142490]
OVCAR-3	GI₅₀	0.39 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human OVCAR3 cells after 48 hrs by SRB assay Cytotoxicity against human OVCAR3 cells after 48 hrs by SRB assay	[PMID: 23871905]
OVCAR-3	GI₅₀	0.39 μM Compound: Doxorubicin	Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
OVCAR-3	GI₅₀	0.39 μM Compound: Doxorubicin	Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR3 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
OVCAR-3	GI₅₀	0.43 μg/mL Compound: DOX	Antiproliferative activity against human OVCAR3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human OVCAR3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 25062010]
OVCAR-3	IC₅₀	0.47 μM Compound: DOX	Antiproliferative activity against human OVCAR3 cells after 72 hrs by Sulforhodamine B-stain assay Antiproliferative activity against human OVCAR3 cells after 72 hrs by Sulforhodamine B-stain assay	[PMID: 27484508]
OVCAR-3	IC₅₀	10.53 μM Compound: Doxorubicin	Cytotoxicity against human OVCAR3 cells after 48 hrs by MTT assay Cytotoxicity against human OVCAR3 cells after 48 hrs by MTT assay	[PMID: 22818039]
OVCAR-3	IC₅₀	35 nM Compound: Doxorubicin	Anti-tumor activity against human OVCAR-3 ovarian cancer cell lines by using MTT assay Anti-tumor activity against human OVCAR-3 ovarian cancer cell lines by using MTT assay	[PMID: 7699715]
OVCAR-3	IC₅₀	35 nM Compound: doxorubicin	Tested for inhibitory activity against human tumor cell line OVCAR-3, a resistant ovarian carcinoma using sulforhodamine B assay. Tested for inhibitory activity against human tumor cell line OVCAR-3, a resistant ovarian carcinoma using sulforhodamine B assay.	[PMID: 10956214]
OVCAR-4	IC₅₀	0.15 μM Compound: DOX	Antiproliferative activity against human OVCAR4 cells after 72 hrs by MTT assay Antiproliferative activity against human OVCAR4 cells after 72 hrs by MTT assay	[PMID: 30429098]
OVCAR-4	GI₅₀	0.37 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human OVCAR4 cells after 48 hrs by SRB assay Cytotoxicity against human OVCAR4 cells after 48 hrs by SRB assay	[PMID: 23871905]
OVCAR-4	GI₅₀	0.37 μM Compound: Doxorubicin	Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
OVCAR-4	GI₅₀	0.37 μM Compound: Doxorubicin	Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR4 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
OVCAR-5	GI₅₀	0.41 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human OVCAR5 cells after 48 hrs by SRB assay Cytotoxicity against human OVCAR5 cells after 48 hrs by SRB assay	[PMID: 23871905]
OVCAR-5	GI₅₀	0.41 μM Compound: Doxorubicin	Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
OVCAR-5	GI₅₀	0.41 μM Compound: Doxorubicin	Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR5 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
OVCAR-8	IC₅₀	0.09 μM Compound: Doxorubicin	Cytotoxicity against human OVCAR8 cells after 72 hrs by MTT assay Cytotoxicity against human OVCAR8 cells after 72 hrs by MTT assay	10.1039/C4MD00371C
OVCAR-8	GI₅₀	0.1 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human OVCAR8 cells after 48 hrs by SRB assay Cytotoxicity against human OVCAR8 cells after 48 hrs by SRB assay	[PMID: 23871905]
OVCAR-8	GI₅₀	0.1 μM Compound: Doxorubicin	Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
OVCAR-8	GI₅₀	0.1 μM Compound: Doxorubicin	Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR8 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
OVCAR-8	IC₅₀	0.14 μM Compound: Adriamycin	Cytotoxicity against human OVCAR8 cells after 72 hrs by MTT assay Cytotoxicity against human OVCAR8 cells after 72 hrs by MTT assay	[PMID: 21721528]
OVCAR-8	IC₅₀	0.35 μM Compound: Doxorubicin	Cytotoxicity against human OVCAR8 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human OVCAR8 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24530030]
OVCAR-8	IC₅₀	0.41 μM Compound: Doxorubicin	Cytotoxicity against human OVCAR8 cells overexpressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human OVCAR8 cells overexpressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27341379]
OVCAR-8	IC₅₀	0.41 μM Compound: DOXO	Cytotoxicity against human OVCAR8 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human OVCAR8 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26142490]
OVCAR-8	IC₅₀	0.45 μM Compound: DOX	Cytotoxicity against human OVCAR8 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human OVCAR8 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29660689]
OVCAR-8	IC₅₀	0.488 μM Compound: Doxorubicin	Cytotoxicity against human OVCAR8 cells assessed as growth inhibition by MTT assay Cytotoxicity against human OVCAR8 cells assessed as growth inhibition by MTT assay	[PMID: 24398294]
OVCAR-8	IC₅₀	0.51 μM Compound: Doxorubicin	Cytotoxicity against human OVCAR8 cells after 72 hrs by MTT assay Cytotoxicity against human OVCAR8 cells after 72 hrs by MTT assay	[PMID: 19406535]
OVCAR-8	IC₅₀	0.6 μM Compound: DOX, Doxorubicin	Antiproliferative activity against human OVCAR8 cells after 72 hrs by MTT assay Antiproliferative activity against human OVCAR8 cells after 72 hrs by MTT assay	[PMID: 24095089]
OVCAR-8	IC₅₀	0.62 μM Compound: Dox	Cytotoxicity against human OVCAR8 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human OVCAR8 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32551011]
OVCAR-8	IC₅₀	0.62 μM Compound: Dox	Cytotoxicity against human OVCAR8 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human OVCAR8 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 30108718]
P388	IC₅₀	0.02 μM Compound: 2	Compound was evaluated for the cytotoxicity against P-388 tumor cell line after 3 days of incubation Compound was evaluated for the cytotoxicity against P-388 tumor cell line after 3 days of incubation	10.1016/S0960-894X(97)10122-6
P388	IC₅₀	0.08 μM Compound: Doxorubicin	Cytotoxicity against mouse P388 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against mouse P388 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 35802519]
P388	IC₅₀	0.2 μM Compound: doxorubicin	Cytotoxicity against mouse P388 cells by MTT method Cytotoxicity against mouse P388 cells by MTT method	[PMID: 25781655]
P388	IC₅₀	0.39 μg/mL Compound: (20) adriamycin	In vitro cytotoxicity of compound against P388, mouse fibroblast leukemia was defined by microculture tetrazolium assay In vitro cytotoxicity of compound against P388, mouse fibroblast leukemia was defined by microculture tetrazolium assay	[PMID: 12620075]
P388	IC₅₀	0.83 μM Compound: Adriamycin	In Vitro Cytotoxicity was measured by quantifying clonogenic survival in soft agar following a 1 hr transient exposure of P388 mouse leukemia cells to compound In Vitro Cytotoxicity was measured by quantifying clonogenic survival in soft agar following a 1 hr transient exposure of P388 mouse leukemia cells to compound	10.1016/0960-894X(96)00230-2
P388	IC₅₀	0.83 μM Compound: adriamycin	In vitro cytotoxicity measured by quantifying clonogenic survival in soft agar following a 1-hour transient exposure of p388 mouse leukemia cells. In vitro cytotoxicity measured by quantifying clonogenic survival in soft agar following a 1-hour transient exposure of p388 mouse leukemia cells.	[PMID: 9733489]
P388	IC₅₀	0.9 μM Compound: Doxorubicin	Cytotoxicity against mouse P388 cells after 72 hrs by alamar blue assay Cytotoxicity against mouse P388 cells after 72 hrs by alamar blue assay	[PMID: 28159416]
P388	IC₅₀	0.9 μM Compound: Doxorubicin	Cytotoxicity against mouse P388 cells by Alamar blue assay Cytotoxicity against mouse P388 cells by Alamar blue assay	[PMID: 27256910]
P388	GI₅₀	12 nM Compound: adriamycin	Cytotoxicity against mouse P388 cells by MTT assay Cytotoxicity against mouse P388 cells by MTT assay	[PMID: 10691710]
P388	IC₅₀	210 nM Compound: Doxorubicin	Cytotoxicity against mouse P388 cells after 3 days by MTT assay Cytotoxicity against mouse P388 cells after 3 days by MTT assay	[PMID: 23848233]
P388	IC₅₀	22 nM Compound: doxorubicin	Antiproliferative activity against P388 cells by ELISA Antiproliferative activity against P388 cells by ELISA	[PMID: 17154505]
P388	IC₅₀	74 nM Compound: Adriamycin	Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay	[PMID: 2778449]
P388/ADR	IC₅₀	123 nM Compound: doxorubicin	Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA	[PMID: 17154505]
P388/ADR	IC₅₀	1738 nM Compound: doxorubicin	Antiproliferative activity against adriamycin resistant P388 cells by ELISA Antiproliferative activity against adriamycin resistant P388 cells by ELISA	[PMID: 17154505]
P388/ADR	GI₅₀	3.73 μM Compound: Doxorubicin	Antiproliferative activity against mouse P388/ADR cells assessed as reduction in cell viability measured after 72 hrs Antiproliferative activity against mouse P388/ADR cells assessed as reduction in cell viability measured after 72 hrs	[PMID: 31945642]
P388D1	IC₅₀	0.338 μM Compound: Doxorubicin	Anticancer activity against mouse P388D1 cells by MTT assay Anticancer activity against mouse P388D1 cells by MTT assay	[PMID: 21570750]
PA-1	IC₅₀	0.63 μM Compound: Doxorubicin	Cytotoxicity against human PA1 cells after 72 hrs by MTT assay Cytotoxicity against human PA1 cells after 72 hrs by MTT assay	[PMID: 19361894]
PA-1	IC₅₀	0.64 μM Compound: Dox	Cytotoxicity against human PA1 cells after 24 hrs by MTT assay Cytotoxicity against human PA1 cells after 24 hrs by MTT assay	10.1007/s00044-013-0584-6
PANC-1	GI₅₀	< 0.01 μM Compound: Doxorubicin	Growth inhibition of human PANC1 cells after 48 hrs by SRB assay Growth inhibition of human PANC1 cells after 48 hrs by SRB assay	10.1039/C6MD00097E
PANC-1	GI₅₀	< 0.01 μM Compound: Doxorubicin	Growth inhibition in human PANC1 cells after 48 hrs by SRB assay Growth inhibition in human PANC1 cells after 48 hrs by SRB assay	[PMID: 31546197]
PANC-1	GI₅₀	< 0.01 μM Compound: Doxorubicin	Antiproliferative activity against human PANC1 cells after 48 hrs by SRB assay Antiproliferative activity against human PANC1 cells after 48 hrs by SRB assay	[PMID: 25827522]
PANC-1	GI₅₀	0.01 μM Compound: Doxorubicin	Growth inhibition of human PANC1 cells after 48 hrs by SRB assay Growth inhibition of human PANC1 cells after 48 hrs by SRB assay	[PMID: 26067381]
PANC-1	IC₅₀	0.41 μM Compound: Doxorubicin	Antiproliferative activity against human PANC1 cells after 48 hrs by MTT assay Antiproliferative activity against human PANC1 cells after 48 hrs by MTT assay	[PMID: 28554092]
PANC-1	IC₅₀	0.73 μM Compound: Doxorubicin	Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 33261897]
PANC-1	IC₅₀	0.73 μM Compound: Doxorubicin	Antiproliferative activity against human PANC-1 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Antiproliferative activity against human PANC-1 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 31962262]
PANC-1	IC₅₀	0.73 μM Compound: Doxorubicin	Cytotoxicity against human PANC1 cells harboring mutant TP53 gene incubated for 72 hrs by MTS assay Cytotoxicity against human PANC1 cells harboring mutant TP53 gene incubated for 72 hrs by MTS assay	[PMID: 31158748]
PANC-1	IC₅₀	0.9 μg/mL Compound: Doxorubicin	Cytotoxicity against human PANC-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human PANC-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 35526504]
PANC-1	IC₅₀	1.026 μM Compound: Dox	Cytotoxicity against human PANC1 cells assessed as cell killing effect after 72 hrs by MTT assay Cytotoxicity against human PANC1 cells assessed as cell killing effect after 72 hrs by MTT assay	[PMID: 26005543]
PANC-1	IC₅₀	1.1 μM Compound: Dox	Cytotoxicity against human PANC1 cells under normoxic condition after 24 hrs by crystal violet method Cytotoxicity against human PANC1 cells under normoxic condition after 24 hrs by crystal violet method	[PMID: 25375258]
PANC-1	GI₅₀	1.41 μM Compound: Doxorubicin	Antiproliferative activity against human PANC1 cells assessed as growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human PANC1 cells assessed as growth inhibition incubated for 48 hrs by MTT assay	[PMID: 31128433]
PANC-1	IC₅₀	1.41 μM Compound: Doxorubicin	Antiproliferative activity against human PANC1 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Antiproliferative activity against human PANC1 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 31108261]
PANC-1	IC₅₀	1.664 μM Compound: Doxorubicin	Cytotoxicity activity against human PANC1 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity activity against human PANC1 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 30433783]
PANC-1	IC₅₀	1.73 μM Compound: DOX	Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32996316]
PANC-1	IC₅₀	1.9 μM Compound: Doxorubicin	Cytotoxicity against human PANC1 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay Cytotoxicity against human PANC1 cells assessed as reduction in cell viability measured after 48 hrs by SRB assay	[PMID: 28818768]
PANC-1	IC₅₀	2.2 μM Compound: Doxorubicin	Cytotoxicity against human PANC-1 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay Cytotoxicity against human PANC-1 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay	[PMID: 36970146]
PANC-1	IC₅₀	3.1 μM Compound: DOX	Cytotoxicity against human PANC-1 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human PANC-1 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34700239]
PANC-1	IC₅₀	3.2 μM Compound: Doxorubicin	Antiproliferative activity against human PANC1 cells after 48 hrs by SRB assay Antiproliferative activity against human PANC1 cells after 48 hrs by SRB assay	[PMID: 28419927]
PANC-1	IC₅₀	5.4 μM Compound: Dox	Cytotoxicity against human PANC1 cells under hypoxic condition after 24 hrs by crystal violet method Cytotoxicity against human PANC1 cells under hypoxic condition after 24 hrs by crystal violet method	[PMID: 25375258]
PANC-1	IC₅₀	6.9 μM Compound: Dox	Cytotoxicity against human PANC1 cells after 48 hrs by resazurin assay Cytotoxicity against human PANC1 cells after 48 hrs by resazurin assay	[PMID: 29107422]
PANC-1	IC₅₀	6.9 μM Compound: DOX	Antiproliferative activity against human PANC1 cells after 48 hrs by resazurin dye-based fluorescence assay Antiproliferative activity against human PANC1 cells after 48 hrs by resazurin dye-based fluorescence assay	[PMID: 29665526]
Panel NCI-60 cells	GI₅₀	97 μM Compound: Doxorubicin	Growth inhibition of human Panel NCI-60 (60 carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel NCI-60 (60 carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 33766762]
PBL	IC₅₀	0.97 μg/mL Compound: doxorubicin	Cytotoxicity against human PBL cells after 72 hrs by alamar blue assay Cytotoxicity against human PBL cells after 72 hrs by alamar blue assay	[PMID: 18053728]
PBMC	IC₅₀	> 10 μM Compound: Doxo	Cytotoxicity against human PBMC assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human PBMC assessed as cell viability after 24 hrs by MTT assay	[PMID: 24484281]
PBMC	IC₅₀	0.37 μM Compound: Doxorubicin	Cytotoxicity against human PBMC cells after 72 hrs by MTT assay Cytotoxicity against human PBMC cells after 72 hrs by MTT assay	10.1039/C4MD00371C
PBMC	IC₅₀	0.38 μM Compound: Doxorubicin	Cytotoxicity against human PBMC cells assessed as inhibition of cell viability after 72 hrs by alamar blue assay Cytotoxicity against human PBMC cells assessed as inhibition of cell viability after 72 hrs by alamar blue assay	[PMID: 29329071]
PBMC	IC₅₀	0.42 μM Compound: Doxorubicin	Cytotoxicity against human PBMC cells after 72 hrs by Alamar Blue assay Cytotoxicity against human PBMC cells after 72 hrs by Alamar Blue assay	[PMID: 21115213]
PBMC	IC₅₀	0.42 μM Compound: DOXO	Cytotoxicity against human PBMC after 72 hrs by alamar blue assay Cytotoxicity against human PBMC after 72 hrs by alamar blue assay	[PMID: 19947600]
PBMC	IC₅₀	0.42 μM Compound: Doxorubicin	Cytotoxicity against human PBMC assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human PBMC assessed as cell viability after 72 hrs by MTT assay	[PMID: 24530030]
PBMC	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human PBMC after 72 hrs by alamar blue assay Cytotoxicity against human PBMC after 72 hrs by alamar blue assay	[PMID: 19780590]
PBMC	IC₅₀	0.55 μM Compound: DOX	Cytotoxicity against human PBMC cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human PBMC cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29660689]
PBMC	IC₅₀	0.55 μM Compound: Doxorubicin	Cytotoxicity against NQO1-deficient human PBMC assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against NQO1-deficient human PBMC assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27341379]
PBMC	IC₅₀	0.55 μM Compound: DOXO	Cytotoxicity against human PBMC assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human PBMC assessed as cell viability after 72 hrs by MTT assay	[PMID: 26142490]
PBMC	IC₅₀	0.96 μg/mL Compound: Doxorubicin	Cytotoxicity against human PBMC after 72 hrs by Alamar blue assay Cytotoxicity against human PBMC after 72 hrs by Alamar blue assay	[PMID: 20537433]
PBMC	IC₅₀	1.66 μM Compound: Doxorubicin	Cytotoxicity against human PBMC after 72 hrs by Alamar Blue assay Cytotoxicity against human PBMC after 72 hrs by Alamar Blue assay	[PMID: 20971532]
PBMC	IC₅₀	1.7 μM Compound: Dox	Cytotoxicity against human PBMC assessed as decrease in cell viability after 72 hrs by Alamar blue assay Cytotoxicity against human PBMC assessed as decrease in cell viability after 72 hrs by Alamar blue assay	[PMID: 30108718]
PBMC	IC₅₀	1.7 μM Compound: Doxorubicin	Cytotoxicity against human PBMC assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human PBMC assessed as cell viability after 72 hrs by MTT assay	[PMID: 24485783]
PBMC	IC₅₀	1.77 μM Compound: Doxorubicin	Cytotoxicity against human PBMC cells after 72 hrs by alamar blue assay Cytotoxicity against human PBMC cells after 72 hrs by alamar blue assay	[PMID: 19406535]
PBMC	IC₅₀	15.51 μM Compound: doxorubicin	Cytotoxicity against human PBMC cells after 24 hrs by MTT assay Cytotoxicity against human PBMC cells after 24 hrs by MTT assay	[PMID: 18281125]
PBMC	IC₅₀	15.51 μM Compound: doxorubicin	Cytotoxicity against human PBMCs after 24 hrs by MTT assay Cytotoxicity against human PBMCs after 24 hrs by MTT assay	[PMID: 17400463]
PBMC	IC₅₀	271 nM Compound: Doxorubicn	Cytotoxicity against PHA-stimulated human PBMC cells after 48 hrs by Alamar Blue assay Cytotoxicity against PHA-stimulated human PBMC cells after 48 hrs by Alamar Blue assay	[PMID: 23673218]
PBMC	IC₅₀	9.36 μM Compound: Doxorubicin	Cytotoxicity against concanavalin-A stimulated human PBMC after 72 hrs by alamar blue assay Cytotoxicity against concanavalin-A stimulated human PBMC after 72 hrs by alamar blue assay	[PMID: 24969014]
PC-12	IC₅₀	0.52 μM Compound: DOX	Antiproliferative activity against rat PC12 cells after 72 hrs by CCK-8 assay Antiproliferative activity against rat PC12 cells after 72 hrs by CCK-8 assay	[PMID: 29597166]
PC-12	IC₅₀	5.71 μM Compound: Doxorubicin	Cytotoxicity against rat PC12 cells by MTT assay Cytotoxicity against rat PC12 cells by MTT assay	[PMID: 30015071]
PC-3	CC₅₀	< 500 nM Compound: Dox	Cytotoxicity against PSMA-negative human PC3 cells by MTT assay Cytotoxicity against PSMA-negative human PC3 cells by MTT assay	[PMID: 30904185]
PC-3	IC₅₀	> 32 nM Compound: Dox	Cytotoxicity against PSMA-negative human PC3 cells by cellTiter 96 aqueous cell proliferation assay Cytotoxicity against PSMA-negative human PC3 cells by cellTiter 96 aqueous cell proliferation assay	[PMID: 30904185]
PC-3	IC₅₀	0.002 μM Compound: Doxorubicin	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability by CellTiter Glo luminescent assay	[PMID: 32755677]
PC-3	IC₅₀	0.008 ug Compound: Doxorubicin	Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 48 hrs by SRB assay Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 48 hrs by SRB assay	[PMID: 27393950]
PC-3	IC₅₀	0.01 μM Compound: Doxorubicin	Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay	[PMID: 36126331]
PC-3	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells overexpressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human PC3 cells overexpressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27341379]
PC-3	IC₅₀	0.02 μM Compound: DOXO	Cytotoxicity against human PC3 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26142490]
PC-3	GI₅₀	0.021 μM Compound: Doxorubicin	Cytostatic activity against human PC3 cells after 5 days by SRB assay Cytostatic activity against human PC3 cells after 5 days by SRB assay	[PMID: 21711054]
PC-3	ED₅₀	0.0499 μg/mL Compound: adriamycin	Cytotoxicity against human PC-3 cells after 7 days by MTT assay Cytotoxicity against human PC-3 cells after 7 days by MTT assay	[PMID: 10514307]
PC-3	IC₅₀	0.05 μM Compound: DOXO	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 28818447]
PC-3	ED₅₀	0.0577 μg/mL Compound: adriamycin	Cytotoxicity against human PC3 cells after 7 days by MTT assay Cytotoxicity against human PC3 cells after 7 days by MTT assay	[PMID: 11087592]
PC-3	IC₅₀	0.06 μM Compound: Doxorubicine	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM)	[PMID: 33422908]
PC-3	GI₅₀	0.076 μM Compound: ADR	Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by SRB assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by SRB assay	[PMID: 30253887]
PC-3	GI₅₀	0.076 μM Compound: ADR	Cytotoxicity against human PC3 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Cytotoxicity against human PC3 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 28870801]
PC-3	IC₅₀	0.08 μM Compound: Doxorubicin	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability after 48 hrs Cytotoxicity against human PC-3 cells assessed as reduction in cell viability after 48 hrs	[PMID: 34601029]
PC-3	IC₅₀	0.08 μM Compound: Doxorubicin	Antiproliferative activity against human PC3 cells after 48 hrs by Hoechst 33342 staining-based assay Antiproliferative activity against human PC3 cells after 48 hrs by Hoechst 33342 staining-based assay	[PMID: 30655216]
PC-3	GI₅₀	0.085 μg/mL Compound: DOX; Doxo	Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay	[PMID: 26859070]
PC-3	GI₅₀	0.09 μM Compound: Doxorubicin	Antiproliferative activity against human PC3 assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human PC3 assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 21875046]
PC-3	GI₅₀	0.09 μM Compound: ADR	Anticancer activity against human PC-3 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method Anticancer activity against human PC-3 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B method	[PMID: 34500188]
PC-3	GI₅₀	0.0923 μM Compound: ADR	Cytotoxicity against human PC3 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human PC3 cells after 72 hrs by sulforhodamine B assay	[PMID: 27096046]
PC-3	IC₅₀	0.12 μM Compound: Doxorubicin	Toxicity in human PC-3 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay Toxicity in human PC-3 cells assessed as reduction in cell number after 48 hrs by Hoechst 33342 staining based assay	[PMID: 31753515]
PC-3	GI₅₀	0.13 μM Compound: Dox	Antiproliferative activity against human PC3 cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human PC3 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26454648]
PC-3	GI₅₀	0.17 μM Compound: ADR	Cytotoxicity against human PC3 cells after 48 hrs by SRB assay Cytotoxicity against human PC3 cells after 48 hrs by SRB assay	[PMID: 20673627]
PC-3	IC₅₀	0.19 μM Compound: Doxorubicin	Cytotoxicity in human PC3 cells incubated for 48 hrs by MTT assay Cytotoxicity in human PC3 cells incubated for 48 hrs by MTT assay	[PMID: 28923381]
PC-3	IC₅₀	0.19 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 24953027]
PC-3	IC₅₀	0.19 μM Compound: DOX	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 24487188]
PC-3	IC₅₀	0.2 μM Compound: DOX	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 23218718]
PC-3	IC₅₀	0.2 μM Compound: adriamycin	Antitumor activity against human PC3 cells by methylene blue staining method Antitumor activity against human PC3 cells by methylene blue staining method	[PMID: 17656091]
PC-3	GI₅₀	0.22 μg/mL Compound: Doxorubicin	Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 26561866]
PC-3	IC₅₀	0.23 μM Compound: DOX	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 30429098]
PC-3	IC₅₀	0.24 μg/mL Compound: doxorubicin	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 17827021]
PC-3	GI₅₀	0.24 μg/mL Compound: Doxorubicin	Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 22410248]
PC-3	GI₅₀	0.24 μM Compound: Doxorubicin	Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 33477019]
PC-3	GI₅₀	0.25 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 21115210]
PC-3	IC₅₀	0.25 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells after 48 hrs by SRB assay Cytotoxicity against human PC3 cells after 48 hrs by SRB assay	[PMID: 22100139]
PC-3	IC₅₀	0.25 μM Compound: doxorubicin	Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay	[PMID: 26305181]
PC-3	GI₅₀	0.28 μg/mL Compound: DOX	Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 21041092]
PC-3	GI₅₀	0.28 μM Compound: Doxorubicin	Anticancer activity against human PC3 cells by SRB assay Anticancer activity against human PC3 cells by SRB assay	[PMID: 20732810]
PC-3	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells after 72 hrs by Alamar blue assay Cytotoxicity against human PC3 cells after 72 hrs by Alamar blue assay	[PMID: 21999655]
PC-3	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human PC-3 cells assessed as cell growth inhibition measured after 24 to 72 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as cell growth inhibition measured after 24 to 72 hrs by MTT assay	[PMID: 33586438]
PC-3	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxic activity in human PC3 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Cytotoxic activity in human PC3 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 28395220]
PC-3	IC₅₀	0.31 μM Compound: DOX	Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31678743]
PC-3	GI₅₀	0.32 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human PC3 cells after 48 hrs by SRB assay Cytotoxicity against human PC3 cells after 48 hrs by SRB assay	[PMID: 23871905]
PC-3	GI₅₀	0.32 μM Compound: Doxorubicin	Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
PC-3	GI₅₀	0.32 μM Compound: Doxorubicin	Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human PC3 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
PC-3	GI₅₀	0.35 μg/mL Compound: Doxorubicin	Cytotoxicity against human PC3 cells by sulforhodamine B assay Cytotoxicity against human PC3 cells by sulforhodamine B assay	[PMID: 26913941]
PC-3	IC₅₀	0.36 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by Alamar blue assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by Alamar blue assay	[PMID: 26904921]
PC-3	IC₅₀	0.36 μM Compound: doxorubicin	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 27214307]
PC-3	IC₅₀	0.4 μg/mL Compound: Doxorubicin	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by SRB assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 30660827]
PC-3	IC₅₀	0.4 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 28641156]
PC-3	IC₅₀	0.41 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells by colorimetric method Cytotoxicity against human PC3 cells by colorimetric method	[PMID: 24387625]
PC-3	GI₅₀	0.42 μM Compound: Doxorubicin	Anticancer activity against human PC-3 cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay Anticancer activity against human PC-3 cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay	[PMID: 33214037]
PC-3	IC₅₀	0.44 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24530030]
PC-3	IC₅₀	0.442 μM Compound: Dox	Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 30108718]
PC-3	IC₅₀	0.45 μg/mL Compound: Doxorubicin	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 18586355]
PC-3	IC₅₀	0.5 μM Compound: Doxorubicin	Antiproliferative activity against human PC3 cells measured after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells measured after 48 hrs by MTT assay	[PMID: 31148449]
PC-3	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells after 96 hrs by MTT assay Cytotoxicity against human PC3 cells after 96 hrs by MTT assay	[PMID: 24852278]
PC-3	IC₅₀	0.5 μM Compound: ADR	Cytotoxicity against human PC3 cells by SRB assay Cytotoxicity against human PC3 cells by SRB assay	[PMID: 18656370]
PC-3	IC₅₀	0.5 μM Compound: ADR	Cytotoxicity against human PC3 cells by sulforhodamine B assay Cytotoxicity against human PC3 cells by sulforhodamine B assay	[PMID: 17822905]
PC-3	GI₅₀	0.52 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 23964644]
PC-3	IC₅₀	0.539 μM Compound: DOX	Cytotoxicity against human PC-3 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34700239]
PC-3	IC₅₀	0.54 μM Compound: Doxorubicin	Antiproliferative activity against human PC3 cells after 72 hrs Antiproliferative activity against human PC3 cells after 72 hrs	[PMID: 25127463]
PC-3	IC₅₀	0.59 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells assessed as growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as growth inhibition measured after 72 hrs by MTT assay	[PMID: 31383628]
PC-3	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 24780595]
PC-3	IC₅₀	0.6 μM Compound: Dox	Cytotoxicity against human PC3 cells assessed as growth inhibition after 24 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 24507927]
PC-3	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 27371926]
PC-3	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 20846862]
PC-3	IC₅₀	0.6 μM Compound: ADM	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 26280921]
PC-3	IC₅₀	0.6 μM Compound: ADM	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 25874331]
PC-3	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured for 48 hrs by resazurin dye based assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured for 48 hrs by resazurin dye based assay	[PMID: 36795859]
PC-3	IC₅₀	0.63 μM Compound: Doxorubicin	Antiproliferative activity against human PC3 cells assessed as cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as cell viability incubated for 72 hrs by MTT assay	[PMID: 25799376]
PC-3	IC₅₀	0.63 μM Compound: DOX	Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 23810282]
PC-3	IC₅₀	0.64 μM Compound: Dox	Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 33713977]
PC-3	IC₅₀	0.64 μM Compound: Dox	Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth by MTT assay	[PMID: 36336315]
PC-3	IC₅₀	0.68 μM Compound: Adriamycin	Cytotoxicity against human PC3 cells by MTT assay Cytotoxicity against human PC3 cells by MTT assay	[PMID: 23434227]
PC-3	GI₅₀	0.73 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells by SRB assay Cytotoxicity against human PC3 cells by SRB assay	[PMID: 19596579]
PC-3	GI₅₀	0.74 μM Compound: DOXO	Antiproliferative activity against human PC3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human PC3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 31247374]
PC-3	IC₅₀	0.75 μM Compound: Dox	Cytotoxicity against human PC3 cells after 24 hrs by MTT assay Cytotoxicity against human PC3 cells after 24 hrs by MTT assay	[PMID: 23802716]
PC-3	IC₅₀	0.76 μM Compound: Doxorubicin	Cytotoxicity against human PC-3 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 34778772]
PC-3	IC₅₀	0.76 μM Compound: Dox	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33479619]
PC-3	IC₅₀	0.76 μM Compound: DOX	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29660689]
PC-3	IC₅₀	0.77 μM Compound: Doxorubicin	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32736078]
PC-3	IC₅₀	0.8 μM Compound: Dox	Cytotoxicity against human PC3 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human PC3 cells after 72 hrs by sulforhodamine B assay	[PMID: 30132670]
PC-3	IC₅₀	0.82 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability by MTT assay	[PMID: 31404864]
PC-3	IC₅₀	0.87 μM Compound: AMD	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 26900656]
PC-3	IC₅₀	0.9 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells after 3 days by MTT assay Cytotoxicity against human PC3 cells after 3 days by MTT assay	[PMID: 26711890]
PC-3	GI₅₀	0.91 μM Compound: ADR	Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay	[PMID: 25953156]
PC-3	IC₅₀	0.912 μM Compound: SD-1	Cytotoxic activity against human PC3 cells after 48 hrs by MTT assay Cytotoxic activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 25245672]
PC-3	IC₅₀	0.912 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 24844756]
PC-3	IC₅₀	0.912 μM Compound: doxorubicin	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 20356064]
PC-3	IC₅₀	0.93 μM Compound: DOX	Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32996316]
PC-3	ED₅₀	1 x 10^-2 μg/mL Compound: Adriamycin	Cytotoxicity against human PC3 cells by MTT assay Cytotoxicity against human PC3 cells by MTT assay	[PMID: 7714533]
PC-3	GI₅₀	1 x 10^-2 μM Compound: Doxorubicin	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 30071406]
PC-3	GI₅₀	1 x 10^-2 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 29670691]
PC-3	IC₅₀	1 μM Compound: DOX, Doxorubicin	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 24095089]
PC-3	IC₅₀	1.01 μM Compound: ADM	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	10.1007/s00044-013-0854-3
PC-3	IC₅₀	1.03 μM Compound: DXR	Anticancer activity against human PC3 cells after 24 hrs by MTT assay Anticancer activity against human PC3 cells after 24 hrs by MTT assay	[PMID: 21600678]
PC-3	IC₅₀	1.05 μM Compound: DXR	Cytotoxicity against human androgen-independent PC3 cells by MTT assay Cytotoxicity against human androgen-independent PC3 cells by MTT assay	[PMID: 22326399]
PC-3	IC₅₀	1.07 μM Compound: doxo	Antiproliferative activity against human PC3 cells assessed as decrease in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as decrease in cell viability measured after 72 hrs by MTT assay	[PMID: 30763817]
PC-3	IC₅₀	1.1 x 10^-2 μg/mL Compound: Adriamycin	Cytotoxicity against human PC3 cells by MTT assay Cytotoxicity against human PC3 cells by MTT assay	[PMID: 9644064]
PC-3	IC₅₀	1.145 μM Compound: 1	Cytotoxicity in human PC-3 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay Cytotoxicity in human PC-3 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay	[PMID: 33064004]
PC-3	ED₅₀	1.19 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human PC3 cells after 7 days by MTT assay Cytotoxicity against human PC3 cells after 7 days by MTT assay	[PMID: 9134750]
PC-3	IC₅₀	1.22 μM Compound: Doxo	Cytotoxicity against androgen receptor-negative human PC3 cells after 48 hrs by MTT assay Cytotoxicity against androgen receptor-negative human PC3 cells after 48 hrs by MTT assay	[PMID: 21885273]
PC-3	IC₅₀	1.24 μM Compound: Doxorubicin	Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 35339645]
PC-3	IC₅₀	1.32 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 19406535]
PC-3	IC₅₀	1.4 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 27496212]
PC-3	IC₅₀	1.4 μM Compound: ADM	Antiproliferative against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay	10.1039/C1MD00038A
PC-3	IC₅₀	1.4 μM Compound: Doxorubicin	Cytotoxicity against human PC-3 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay Cytotoxicity against human PC-3 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay	[PMID: 36970146]
PC-3	IC₅₀	1.43 μM Compound: Doxorubicin	Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31546197]
PC-3	ED₅₀	1.46 x 10^-2 μg/mL Compound: Adriamycin	Cytotoxicity against human PC3 cells after 7 days by MTT assay Cytotoxicity against human PC3 cells after 7 days by MTT assay	[PMID: 9322367]
PC-3	IC₅₀	1.49 μM Compound: AMD	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 26807545]
PC-3	IC₅₀	1.63 μM Compound: DOXO	Cytotoxicity against human PC3 cells assessed as cell viability after 48 hrs by alamar blue assay Cytotoxicity against human PC3 cells assessed as cell viability after 48 hrs by alamar blue assay	[PMID: 21797280]
PC-3	IC₅₀	1.63 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells after 48 hrs by Alamar blue assay Cytotoxicity against human PC3 cells after 48 hrs by Alamar blue assay	[PMID: 20931970]
PC-3	GI₅₀	1.65 μM Compound: ADR	Antiproliferative activity against human PC3 cells by SRB method Antiproliferative activity against human PC3 cells by SRB method	[PMID: 24835787]
PC-3	GI₅₀	1.65 μM Compound: ADR	Antiproliferative activity against human PC3 cells by SRB assay Antiproliferative activity against human PC3 cells by SRB assay	[PMID: 22738641]
PC-3	IC₅₀	1.66 μM Compound: Doxorubicin	Cytotoxicity against human PC-3 cells treated for 72 hrs by MTT assay Cytotoxicity against human PC-3 cells treated for 72 hrs by MTT assay	[PMID: 35344904]
PC-3	IC₅₀	1.69 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26381063]
PC-3	IC₅₀	1.7 μM Compound: DOX	Antiproliferative activity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 22044164]
PC-3	GI₅₀	1.76 μM Compound: Doxorubicin	Growth inhibition of Homo sapiens (human) PC3 cells after 48 hr by MTT assay Growth inhibition of Homo sapiens (human) PC3 cells after 48 hr by MTT assay	10.1007/s00044-012-0232-6
PC-3	IC₅₀	1.76 μM Compound: DOX	Antiproliferative activity against human PC3 cells by MTT assay Antiproliferative activity against human PC3 cells by MTT assay	[PMID: 20171108]
PC-3	GI₅₀	1.81 μM Compound: adriamycin	Cytotoxicity against human PC3 cells after 24 hrs by SRB method Cytotoxicity against human PC3 cells after 24 hrs by SRB method	[PMID: 18262426]
PC-3	GI₅₀	1.81 μM Compound: ADR	Growth inhibition of human PC3 cells after 48 hrs by SRB assay Growth inhibition of human PC3 cells after 48 hrs by SRB assay	[PMID: 20031423]
PC-3	GI₅₀	1.81 μM Compound: ADR	Growth inhibition of human PC3 cells by SRB assay Growth inhibition of human PC3 cells by SRB assay	[PMID: 22361684]
PC-3	GI₅₀	1.81 μM Compound: ADR	Anticancer activity against human PC3 cells by SRB method Anticancer activity against human PC3 cells by SRB method	[PMID: 21676506]
PC-3	GI₅₀	1.81 μM Compound: ADR, Adriamycin	Growth inhibition of human PC3 cells by SRB method Growth inhibition of human PC3 cells by SRB method	[PMID: 18207392]
PC-3	GI₅₀	1.81 μM Compound: ADR	Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 18657979]
PC-3	GI₅₀	1.81 μM Compound: ADR	Cytotoxicity against human PC3 cells after 24 hrs by WST-1 assay Cytotoxicity against human PC3 cells after 24 hrs by WST-1 assay	[PMID: 20732817]
PC-3	ED₅₀	1.89 x 10^-2 μg/mL Compound: Adriamycin	Cytotoxicity against human PC3 cells after 7 days by MTT assay Cytotoxicity against human PC3 cells after 7 days by MTT assay	[PMID: 8946743]
PC-3	ED₅₀	1.96 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human PC3 cells after 7 days by MTT assay Cytotoxicity against human PC3 cells after 7 days by MTT assay	[PMID: 8676130]
PC-3	IC₅₀	10.2 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 29573910]
PC-3	IC₅₀	114 nM Compound: doxorubicin	Cytotoxicity against human PC3 cells assessed as viability after 96 hrs Cytotoxicity against human PC3 cells assessed as viability after 96 hrs	[PMID: 24900437]
PC-3	IC₅₀	124 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 21429743]
PC-3	IC₅₀	16.86 μM Compound: Doxorubicin	Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth after 48 hrs by SRB assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth after 48 hrs by SRB assay	[PMID: 34077833]
PC-3	IC₅₀	17 μM Compound: Doxo	Cytotoxicity against human PC3 cells after 48 hrs by alamar blue assay Cytotoxicity against human PC3 cells after 48 hrs by alamar blue assay	[PMID: 25468043]
PC-3	IC₅₀	186 nM Compound: Doxorubicine	Cytotoxicity against human PC3 cells after 72 hrs by MTS assay Cytotoxicity against human PC3 cells after 72 hrs by MTS assay	[PMID: 21142180]
PC-3	IC₅₀	19.51 μM Compound: Adriamycin	Cytotoxicity against human PC3 cells after 24 hrs by MTT assay Cytotoxicity against human PC3 cells after 24 hrs by MTT assay	[PMID: 22276650]
PC-3	ED₅₀	2 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human PC-3 cells after 7 days by MTT assay Cytotoxicity against human PC-3 cells after 7 days by MTT assay	[PMID: 10395501]
PC-3	IC₅₀	2 μM Compound: doxorubicin	Cytotoxicity against human PC3 cells by MTT method Cytotoxicity against human PC3 cells by MTT method	[PMID: 26287401]
PC-3	EC₅₀	2 μM Compound: doxorubicin	Cytotoxicity against human PC3 cells after 72 hrs Cytotoxicity against human PC3 cells after 72 hrs	[PMID: 17378530]
PC-3	IC₅₀	2.1 μM Compound: Dox	Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 27055942]
PC-3	ED₅₀	2.13 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human PC3 cells after 7 days by MTT assay Cytotoxicity against human PC3 cells after 7 days by MTT assay	10.1021/np970510f
PC-3	ED₅₀	2.23 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human PC3 cells after 7 days by MTT assay Cytotoxicity against human PC3 cells after 7 days by MTT assay	[PMID: 8882434]
PC-3	ED₅₀	2.27 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human PC3 cells after 7 days by MTT assay Cytotoxicity against human PC3 cells after 7 days by MTT assay	[PMID: 9599253]
PC-3	IC₅₀	2.3 μg/mL Compound: Doxorubicin	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 21708464]
PC-3	IC₅₀	2.51 μM Compound: Dox	Anticancer activity against human PC3 cells after 48 hrs by MTT assay Anticancer activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 22209733]
PC-3	IC₅₀	2.6 μM Compound: Dox	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 29249562]
PC-3	ED₅₀	2.62 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human PC3 cells after 7 days by MTT assay Cytotoxicity against human PC3 cells after 7 days by MTT assay	[PMID: 8904848]
PC-3	IC₅₀	2.63 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 28390228]
PC-3	ED₅₀	2.76 x 10^-2 μg/mL Compound: adr	Cytotoxicity against human PC3 cells after 7 days by MTT assay Cytotoxicity against human PC3 cells after 7 days by MTT assay	[PMID: 9461654]
PC-3	IC₅₀	3 μM Compound: Doxorubicin	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability by DAPI staining based assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability by DAPI staining based assay	[PMID: 33461146]
PC-3	IC₅₀	3.16 μM Compound: doxorubicin	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 20405844]
PC-3	IC₅₀	3.18 μM Compound: Doxorubicin	Cytotoxic activity against human PC3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxic activity against human PC3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 25966052]
PC-3	ED₅₀	3.2 x 10^-2 μg/mL Compound: Adriamycin	Cytotoxicity against human PC3 cells after 7 days by MTT assay Cytotoxicity against human PC3 cells after 7 days by MTT assay	[PMID: 9214729]
PC-3	IC₅₀	3.3 μM Compound: ADM	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 20817326]
PC-3	ED₅₀	3.55 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human PC3 cells after 7 days by MTT assay Cytotoxicity against human PC3 cells after 7 days by MTT assay	[PMID: 9584396]
PC-3	GI₅₀	3.8 μg/mL Compound: DOX	Antiproliferative activity against human PC3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human PC3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 25062010]
PC-3	IC₅₀	3.86 μM Compound: Doxorubicin	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 31200236]
PC-3	IC₅₀	32 μM Compound: Doxorubicine	Inhibitory activity against PC-3 prostate cell line using sulforhodamine B (SRB) protein assay Inhibitory activity against PC-3 prostate cell line using sulforhodamine B (SRB) protein assay	[PMID: 12039588]
PC-3	IC₅₀	38.02 μM Compound: Doxorubicin	Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth after 72 hrs by MTT assay	[PMID: 32311607]
PC-3	IC₅₀	4.1 μM Compound: Doxo	Cytotoxicity against androgen receptor-negative human PC3 cells after 24 hrs by MTT assay Cytotoxicity against androgen receptor-negative human PC3 cells after 24 hrs by MTT assay	[PMID: 21885273]
PC-3	ED₅₀	4.6 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human PC3 cells after 7 days by MTT assay Cytotoxicity against human PC3 cells after 7 days by MTT assay	[PMID: 9599260]
PC-3	ED₅₀	5.02 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human PC3 cells after 7 days by MTT assay Cytotoxicity against human PC3 cells after 7 days by MTT assay	[PMID: 11325235]
PC-3	IC₅₀	5.05 μM Compound: Doxorubicin	Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31883489]
PC-3	ED₅₀	5.77 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human PC-3 cells after 7 days by MTT assay Cytotoxicity against human PC-3 cells after 7 days by MTT assay	[PMID: 15730242]
PC-3	IC₅₀	5.9 μM Compound: Doxorubicin	Anticancer activity against human PC3 cells after 48 hrs by MTT assay Anticancer activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 22668451]
PC-3	IC₅₀	6 μM Compound: Adriamycin	Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 24910974]
PC-3	IC₅₀	6 μM Compound: Adriamycin	Antiproliferative activity against human PC3 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human PC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 23501113]
PC-3	IC₅₀	6 μM Compound: Adriamycin	Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by sulphorhodamine B assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by sulphorhodamine B assay	[PMID: 26222449]
PC-3	ED₅₀	6.2 x 10^-2 μg/mL Compound: adriamycin	Cytotoxicity against human PC-3 cells by MTT assay Cytotoxicity against human PC-3 cells by MTT assay	[PMID: 9917277]
PC-3	ED₅₀	6.24 x 10^-2 μg/mL Compound: Adriamycin	Cytotoxicity against human PC3 cells after 7 days by MTT assay Cytotoxicity against human PC3 cells after 7 days by MTT assay	[PMID: 7494147]
PC-3	IC₅₀	60 nM Compound: Adriamycin	Cytotoxicity against human PC3 cells after 48 hrs by SRB assay Cytotoxicity against human PC3 cells after 48 hrs by SRB assay	[PMID: 22858298]
PC-3	IC₅₀	7.65 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay in absence of 10% FBS Cytotoxicity against human PC3 cells after 48 hrs by MTT assay in absence of 10% FBS	[PMID: 26298501]
PC-3	IC₅₀	8.46 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells after 24 hrs by MTT assay Cytotoxicity against human PC3 cells after 24 hrs by MTT assay	[PMID: 22687747]
PC-3	IC₅₀	8.54 μM Compound: DOX	Antiproliferative activity against human PC-3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC-3 cells after 72 hrs by MTT assay	[PMID: 35964425]
PC-3	IC₅₀	8.83 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells after 48 hrs by SRB assay Cytotoxicity against human PC3 cells after 48 hrs by SRB assay	[PMID: 23994327]
PC-3	IC₅₀	8.87 μM Compound: DOX	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 37054758]
PC-3	IC₅₀	8.87 μM Compound: DOX	Anticancer activity against human PC3 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Anticancer activity against human PC3 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 32085964]
PC-3	IC₅₀	8.87 μM Compound: Doxorubicin	Antiproliferative activity against human PC3 after 24 hrs by MTT assay Antiproliferative activity against human PC3 after 24 hrs by MTT assay	[PMID: 30826188]
PC-3	IC₅₀	8.87 μM Compound: DOX	Cytotoxicity against human PC3 cells after 24 hrs by MTT assay Cytotoxicity against human PC3 cells after 24 hrs by MTT assay	[PMID: 30015070]
PC-3	IC₅₀	8.87 μM Compound: DOX	Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 36242988]
PC-3	IC₅₀	8.87 μM Compound: Dox	Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34126285]
PC-3	IC₅₀	84.23 μM Compound: Doxorubicin	Cytotoxicity against human PC-3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 33340938]
PC-3	IC₅₀	89.9 μM Compound: Dox	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 26494582]
PC-3	IC₅₀	9.5 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 27173802]
PC-3	IC₅₀	9.58 μM Compound: Doxorubicin	Growth inhibition of human PC3 cells after 48 hrs by MTT assay Growth inhibition of human PC3 cells after 48 hrs by MTT assay	[PMID: 30072225]
PC-3	IC₅₀	9.8 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay in presence of 10% FBS Cytotoxicity against human PC3 cells after 48 hrs by MTT assay in presence of 10% FBS	[PMID: 26298501]
PC-3	IC₅₀	95.61 μM Compound: Doxorubicin	Cytotoxicity against human PC3 cells expressing estrogen receptor after 48 hrs by MTT assay Cytotoxicity against human PC3 cells expressing estrogen receptor after 48 hrs by MTT assay	10.1039/C2MD20327H
PC-3	IC₅₀	95.61 μM Compound: Doxorubicin	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 30108986]
PC-3	IC₅₀	95.61 μM Compound: DOX	Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 25737400]
PC-3	IC₅₀	95.61 μM Compound: DOX	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 25619894]
PC-3	IC₅₀	95.61 μM Compound: DOX	Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 24148837]
PC-3	IC₅₀	95.61 μM Compound: Doxorubicin	Cytotoxicity against AR-negative human PC3 cells after 1 hr by SRB assay Cytotoxicity against AR-negative human PC3 cells after 1 hr by SRB assay	[PMID: 22770744]
PC-3M	IC₅₀	< 0.001 μg/mL Compound: DOX	Cytotoxicity against human PC3M cells after 72 hrs by MTT assay Cytotoxicity against human PC3M cells after 72 hrs by MTT assay	[PMID: 20722446]
PC-3M	IC₅₀	0.04 μM Compound: DOXO	Cytotoxicity against human PC3M cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human PC3M cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26142490]
PC-3M	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human PC3M cells by resazurin dye based Alamar blue assay Cytotoxicity against human PC3M cells by resazurin dye based Alamar blue assay	[PMID: 29373790]
PC-3M	IC₅₀	0.24 μM Compound: doxorubicin	Cytotoxicity against human PC3M cells after 72 hrs by Alamar blue assay Cytotoxicity against human PC3M cells after 72 hrs by Alamar blue assay	[PMID: 22264149]
PC-3M	IC₅₀	0.24 μM Compound: Doxorubicin	Cytotoxicity against human PC3M cells after 72 hrs by resazurin/AlamarBlue dye-based fluorescence assay Cytotoxicity against human PC3M cells after 72 hrs by resazurin/AlamarBlue dye-based fluorescence assay	[PMID: 28139929]
PC-3M	IC₅₀	0.25 μM Compound: Doxorubicin	Cytotoxicity against human PC3M cells after 72 hrs by resazurin-based colorimetric assay Cytotoxicity against human PC3M cells after 72 hrs by resazurin-based colorimetric assay	[PMID: 27071003]
PC-3M	IC₅₀	0.27 μM Compound: doxorubicin	Cytotoxicity against human PC3M cells after 72 hrs by Alamar Blue assay Cytotoxicity against human PC3M cells after 72 hrs by Alamar Blue assay	[PMID: 24251417]
PC-3M	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human PC3M cells after 72 hrs by Alamar blue assay Cytotoxicity against human PC3M cells after 72 hrs by Alamar blue assay	[PMID: 21999655]
PC-3M	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human PC-3M cells assessed as inhibition of cell proliferation measured after 72 hrs by resazurin dye based AlamarBlue assay Cytotoxicity against human PC-3M cells assessed as inhibition of cell proliferation measured after 72 hrs by resazurin dye based AlamarBlue assay	[PMID: 34495663]
PC-3M	IC₅₀	0.368 μM Compound: Dox	Cytotoxicity against human PC3M cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human PC3M cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 30108718]
PC-3M	IC₅₀	0.66 μM Compound: Doxorubicin	Cytotoxicity against human PC-3M cells expressing PTB/GFP fusion protein assessed as reduction in ATP level and measured after 24 to 48 hrs by ATPlite luminescence assay Cytotoxicity against human PC-3M cells expressing PTB/GFP fusion protein assessed as reduction in ATP level and measured after 24 to 48 hrs by ATPlite luminescence assay	[PMID: 35696646]
PC-3M	IC₅₀	0.86 μM Compound: Doxorubicin	Anticancer activity in human PC-3M cells expressing PTB/GFP fusion protein assessed as perinucleolar compartment disassembly and measured after 24 hrs by Hoechst 33342 staining based microscopic method Anticancer activity in human PC-3M cells expressing PTB/GFP fusion protein assessed as perinucleolar compartment disassembly and measured after 24 hrs by Hoechst 33342 staining based microscopic method	[PMID: 35696646]
PC-3M	IC₅₀	1.11 μM Compound: doxorubicin	Antiproliferative activity against human PC3M cells by MTT assay Antiproliferative activity against human PC3M cells by MTT assay	[PMID: 18247573]
PC-3M	IC₅₀	1.26 μM Compound: doxorubicin	Cytotoxicity against human PC3M cells by MTT assay Cytotoxicity against human PC3M cells by MTT assay	[PMID: 18052324]
PC-9	IC₅₀	0.22 μM Compound: Doxorubicin	Cytotoxicity against human PC-9 cells incubated for 48 hrs by MTT assay Cytotoxicity against human PC-9 cells incubated for 48 hrs by MTT assay	[PMID: 36496202]
Peritoneal macrophage	IC₅₀	1.9 μM Compound: Doxorubicin	Cytotoxicity against rat peritoneal macrophages assessed as reduction in cell viability after 46 hrs by MTT assay Cytotoxicity against rat peritoneal macrophages assessed as reduction in cell viability after 46 hrs by MTT assay	[PMID: 29138027]
PLC-PRF-5	EC₅₀	> 10 μM Compound: doxorubicin	Cytotoxicity against human PLC/PRF/5 cells expressing mutant p53 gene (codon 249) by MTT assay Cytotoxicity against human PLC/PRF/5 cells expressing mutant p53 gene (codon 249) by MTT assay	[PMID: 20455578]
PLC-PRF-5	IC₅₀	1.03 μM Compound: Doxorubicin	Cytotoxicity against human PLC-PRF-5 cells by SRB assay Cytotoxicity against human PLC-PRF-5 cells by SRB assay	[PMID: 34128674]
PSN1	GI₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human PSN1 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human PSN1 cells after 48 hrs by sulforhodamine B assay	[PMID: 29112820]
QG-56	IC₅₀	2.5 mM Compound: Adriamycin	Cytotoxicity against human QG56 cells after 24 hrs by MTT assay Cytotoxicity against human QG56 cells after 24 hrs by MTT assay	[PMID: 23685942]
QG-56	IC₅₀	2.5 mM Compound: Adriamycin	Cytotoxicity against human QG56 cells after 48 hrs by MTT assay Cytotoxicity against human QG56 cells after 48 hrs by MTT assay	[PMID: 22440624]
QGY-7703	IC₅₀	1.37 μM Compound: DOX	Cytotoxicity against human QGY7703 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human QGY7703 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 30771605]
QGY-7703	IC₅₀	1.44 μM Compound: DOX	Cytotoxicity against human QGY7703 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human QGY7703 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29909338]
QGY-7703	IC₅₀	1.9 μM Compound: DOX	Cytotoxicity against human QGY-7703 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay Cytotoxicity against human QGY-7703 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay	[PMID: 34450496]
Raji	IC₅₀	0.039 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) Raji cells after 96 hr by MTT assay Cytotoxicity against Homo sapiens (human) Raji cells after 96 hr by MTT assay	10.1007/s00044-010-9340-3
Raji	IC₅₀	0.17 μM Compound: Doxorubicin	Cytotoxicity against human Raji cells assessed as reduction in cell viability after 48 hrs by CCK-8 assay Cytotoxicity against human Raji cells assessed as reduction in cell viability after 48 hrs by CCK-8 assay	[PMID: 29288944]
Raji	IC₅₀	2 μM Compound: adriamycin	Cytotoxicity against human Raji cells under deem light after 96 hrs by MTT assay Cytotoxicity against human Raji cells under deem light after 96 hrs by MTT assay	[PMID: 17993275]
Raji	IC₅₀	2.98 μM Compound: DOX	Antiproliferative activity against human Raji cells assessed as reduction in cell viability measured after 6 days by MTT assay Antiproliferative activity against human Raji cells assessed as reduction in cell viability measured after 6 days by MTT assay	[PMID: 32653698]
Raji	IC₅₀	2.98 μM Compound: DOX	Antiproliferative activity against human Raji cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human Raji cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 31557614]
Raji	IC₅₀	2.98 μM Compound: DOX	Cytotoxicity against human Raji cells assessed as inhibition of cell growth after 72 hrs by MTT assay Cytotoxicity against human Raji cells assessed as inhibition of cell growth after 72 hrs by MTT assay	[PMID: 30746062]
Raji	IC₅₀	2.98 μM Compound: DOX	Cytotoxicity against human Raji cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human Raji cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28427016]
Raji	IC₅₀	2.98 μM Compound: DOX	Antiproliferative activity against human Raji cells after 72 hrs by MTT assay Antiproliferative activity against human Raji cells after 72 hrs by MTT assay	[PMID: 28135634]
Raji	IC₅₀	2.98 μM Compound: Dox	Cytotoxicity against human Raji cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human Raji cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27231128]
Raji	IC₅₀	2.98 μM Compound: DOX	Cytotoxicity against human Raji cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human Raji cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 26720155]
Raji	IC₅₀	2.98 μM Compound: DOX	Cytotoxicity against human Raji cells after 72 hrs by MTT assay Cytotoxicity against human Raji cells after 72 hrs by MTT assay	[PMID: 25259516]
Raji	IC₅₀	2.98 μM Compound: DOX	Antiproliferative activity against human Raji cells after 72 hrs by MTT assay Antiproliferative activity against human Raji cells after 72 hrs by MTT assay	[PMID: 24021462]
Raji	IC₅₀	2.98 μM Compound: DOX	Antiproliferative activity against human Raji cells after 72 hrs by MTT assay Antiproliferative activity against human Raji cells after 72 hrs by MTT assay	[PMID: 20359789]
Raji	IC₅₀	2.98 μM Compound: DOX	Cytotoxicity against human Raji cells after 72 hrs by MTT assay Cytotoxicity against human Raji cells after 72 hrs by MTT assay	[PMID: 18783950]
RAW264.7	IC₅₀	0.63 μM Compound: Doxorubicin	Cytotoxic activity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxic activity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 25966052]
RAW264.7	CC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31800248]
RD	IC₅₀	0.53 μM Compound: Doxorubicin	Cytotoxicity in human RD cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity in human RD cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 28923382]
RD	IC₅₀	1.27 μM Compound: DOX	Cytotoxicity against against human RD cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against against human RD cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30340899]
RD	IC₅₀	2 μM Compound: Adriamycin	Cytotoxicity against human RD cells by neutral red method Cytotoxicity against human RD cells by neutral red method	[PMID: 26291474]
REH	IC₅₀	0.285 μM Compound: Doxorubicin	Cytotoxicity against human REH cells assessed as reduction in cell viability after 48 hrs by Alamar Blue assay Cytotoxicity against human REH cells assessed as reduction in cell viability after 48 hrs by Alamar Blue assay	[PMID: 30774864]
RKO	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human RKO cells assessed as reduction in cell viability after 24 hrs by CCK8 assay Cytotoxicity against human RKO cells assessed as reduction in cell viability after 24 hrs by CCK8 assay	[PMID: 32324401]
RKO	IC₅₀	1.5 μM Compound: Dox	Antiproliferative activity against human RKO cells assessed as reduction in cell viability by MTT assay Antiproliferative activity against human RKO cells assessed as reduction in cell viability by MTT assay	[PMID: 31765156]
RPMI	ED₅₀	0.02 μg/mL Compound: Adriamycin	Cytotoxicity against human RPMI cells after 24 hrs by SRB assay Cytotoxicity against human RPMI cells after 24 hrs by SRB assay	[PMID: 20850305]
RPMI-8226	GI₅₀	0.08 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human RPMI8226 cells after 48 hrs by SRB assay Cytotoxicity against human RPMI8226 cells after 48 hrs by SRB assay	[PMID: 23871905]
RPMI-8226	GI₅₀	0.08 μM Compound: Doxorubicin	Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
RPMI-8226	GI₅₀	0.08 μM Compound: Doxorubicin	Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human RPMI8226 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
RXF 393	GI₅₀	0.1 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human RXF393 cells after 48 hrs by SRB assay Cytotoxicity against human RXF393 cells after 48 hrs by SRB assay	[PMID: 23871905]
RXF 393	GI₅₀	0.1 μM Compound: Doxorubicin	Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
RXF 393	GI₅₀	0.1 μM Compound: Doxorubicin	Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
SAOS-2	IC₅₀	0.33 μM Compound: Doxorubicin	Antiproliferative activity against human Saos2 cells after 24 and 72 hrs by MTT assay Antiproliferative activity against human Saos2 cells after 24 and 72 hrs by MTT assay	[PMID: 24941130]
SCC-25	IC₅₀	2.24 μM Compound: Doxorubicin	Cytotoxicity against human SCC25 cells assessed as reduction in cell viability after 4 hrs by MTT assay Cytotoxicity against human SCC25 cells assessed as reduction in cell viability after 4 hrs by MTT assay	[PMID: 30773423]
SF-268	IC₅₀	0.04 μM Compound: Doxorubicin	Cytotoxicity against human SF-268 cells after 24 hrs by MTT assay Cytotoxicity against human SF-268 cells after 24 hrs by MTT assay	[PMID: 17190470]
SF-268	IC₅₀	0.04 μM Compound: doxorubicin	Cytotoxicity against human SF268 cells after 72 hrs by MTT assay Cytotoxicity against human SF268 cells after 72 hrs by MTT assay	[PMID: 17286429]
SF-268	IC₅₀	0.04 μM Compound: doxorubicin	Antiproliferative activity against human SF268 cells by MTT assay Antiproliferative activity against human SF268 cells by MTT assay	[PMID: 18247573]
SF-268	IC₅₀	0.04 μM Compound: doxorubicin	Antiproliferative activity against human SF268 cells by MTT assay Antiproliferative activity against human SF268 cells by MTT assay	[PMID: 18052326]
SF-268	IC₅₀	0.04 μM Compound: doxorubicin	Cytotoxicity against human SF268 cells by MTT assay Cytotoxicity against human SF268 cells by MTT assay	[PMID: 15620238]
SF-268	IC₅₀	0.09 ug/L Compound: Doxorubicin	Cytotoxicity against human SF268 cells assessed as inhibition of cell viability after 72 hrs by SRB assay Cytotoxicity against human SF268 cells assessed as inhibition of cell viability after 72 hrs by SRB assay	[PMID: 26420384]
SF-268	GI₅₀	0.09 μM Compound: doxorubicin	Growth inhibition of Homo sapiens (human) SF268 cells after 48 hr by SRB assay Growth inhibition of Homo sapiens (human) SF268 cells after 48 hr by SRB assay	10.1007/s00044-012-0213-9
SF-268	IC₅₀	0.09 μM Compound: Doxorubicin	Cytotoxicity against human SF268 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Cytotoxicity against human SF268 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	10.1007/s00044-013-0712-3
SF-268	IC₅₀	0.09 μM Compound: DOX	Antiproliferative activity against human SF268 cells after 72 hrs by Sulforhodamine B-stain assay Antiproliferative activity against human SF268 cells after 72 hrs by Sulforhodamine B-stain assay	[PMID: 27484508]
SF-268	GI₅₀	0.093 μM Compound: Doxorubicin	Cytotoxicity against human SF268 cells after 48 hrs by SRB assay Cytotoxicity against human SF268 cells after 48 hrs by SRB assay	[PMID: 15620248]
SF-268	GI₅₀	0.094 μM Compound: Doxorubicin	Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay	[PMID: 21435889]
SF-268	GI₅₀	0.1 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human SF268 cells after 48 hrs by SRB assay Cytotoxicity against human SF268 cells after 48 hrs by SRB assay	[PMID: 23871905]
SF-268	GI₅₀	0.1 μM Compound: Doxorubicin	Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
SF-268	GI₅₀	0.1 μM Compound: Doxorubicin	Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SF268 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
SF-268	IC₅₀	0.14 μg/mL Compound: adriamycin	Cytotoxicity against human SF268 cells by SRB assay Cytotoxicity against human SF268 cells by SRB assay	[PMID: 17981473]
SF-268	IC₅₀	0.2 μM Compound: Doxorubicin	Antiproliferative activity against human SF-268 cells after 96 hrs by MTT assay Antiproliferative activity against human SF-268 cells after 96 hrs by MTT assay	[PMID: 19053767]
SF-268	IC₅₀	0.31 μM Compound: doxorubicin	Cytotoxicity against human SF268 cells after 72 hrs by Alamar Blue assay Cytotoxicity against human SF268 cells after 72 hrs by Alamar Blue assay	[PMID: 24251417]
SF-268	IC₅₀	0.45 μM Compound: Doxorubicin	Cytotoxicity against human SF268 cells after 72 hrs by resazurin-based colorimetric assay Cytotoxicity against human SF268 cells after 72 hrs by resazurin-based colorimetric assay	[PMID: 27071003]
SF-268	IC₅₀	0.45 μM Compound: doxorubicin	Cytotoxicity against human SF268 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay Cytotoxicity against human SF268 cells assessed as inhibition of cell proliferation/survival after 72 hrs by resazurin dye reduction assay	[PMID: 26305181]
SF-268	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human SF-268 cells assessed as cell growth inhibition measured after 24 to 72 hrs by MTT assay Cytotoxicity against human SF-268 cells assessed as cell growth inhibition measured after 24 to 72 hrs by MTT assay	[PMID: 33586438]
SF-268	IC₅₀	0.5 μM Compound: Doxorubicin	Cytotoxicity against human SF-268 cells assessed as inhibition of cell proliferation measured after 72 hrs by resazurin dye based AlamarBlue assay Cytotoxicity against human SF-268 cells assessed as inhibition of cell proliferation measured after 72 hrs by resazurin dye based AlamarBlue assay	[PMID: 34495663]
SF-268	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human SF268 cells after 72 hrs by Alamar blue assay Cytotoxicity against human SF268 cells after 72 hrs by Alamar blue assay	[PMID: 21999655]
SF-268	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human SF268 cells by resazurin dye based Alamar blue assay Cytotoxicity against human SF268 cells by resazurin dye based Alamar blue assay	[PMID: 29373790]
SF-268	IC₅₀	0.62 μM Compound: doxorubicin	Cytotoxicity against human SF268 cells after 72 hrs by Alamar blue assay Cytotoxicity against human SF268 cells after 72 hrs by Alamar blue assay	[PMID: 22264149]
SF-268	IC₅₀	0.62 μM Compound: Doxorubicin	Cytotoxicity against human SF268 cells after 72 hrs by resazurin/AlamarBlue dye-based fluorescence assay Cytotoxicity against human SF268 cells after 72 hrs by resazurin/AlamarBlue dye-based fluorescence assay	[PMID: 28139929]
SF-268	IC₅₀	1.55 μM Compound: adriamycin	Cytotoxicity against human SF-268 cells by MTT assay Cytotoxicity against human SF-268 cells by MTT assay	[PMID: 17125240]
SF-268	IC₅₀	2.2 x 10^-1 μM Compound: Doxorubucin	Cytotoxicity against human SF268 cells after 72 hrs by XTT assay Cytotoxicity against human SF268 cells after 72 hrs by XTT assay	[PMID: 20538470]
SF-268	GI₅₀	9.3 x 10^-2 μM Compound: doxorubicin	Cytotoxicity against human SF268 cells by SRB assay Cytotoxicity against human SF268 cells by SRB assay	[PMID: 11678649]
SF-268	GI₅₀	93 nM Compound: doxorubicin	Cytotoxicity against human SF268 cells after 48 hrs Cytotoxicity against human SF268 cells after 48 hrs	[PMID: 17964791]
SF-268	GI₅₀	93 nM Compound: doxorubicin	Growth inhibition of human SF268 cells after 48 hrs Growth inhibition of human SF268 cells after 48 hrs	[PMID: 17692432]
SF-268	GI₅₀	93 μM Compound: Doxorubicin	Growth inhibition of human SF268 cells after 48 hrs by SRB assay Growth inhibition of human SF268 cells after 48 hrs by SRB assay	[PMID: 15165162]
SF-268	GI₅₀	94 nM Compound: Doxorubicin	Cytotoxicity against human SF268 cells after 48 hrs by SRB assay Cytotoxicity against human SF268 cells after 48 hrs by SRB assay	[PMID: 15270581]
SF-268	GI₅₀	94 nM Compound: Doxorubicin	Antitumor activity against human SF268 cells assessed as inhibition of growth after 48 hrs using sulforhodamine B dye Antitumor activity against human SF268 cells assessed as inhibition of growth after 48 hrs using sulforhodamine B dye	[PMID: 19428155]
SF-268	GI₅₀	94 nM Compound: doxorubicin	Antitumor activity against human SF268 cells after 48 hrs Antitumor activity against human SF268 cells after 48 hrs	[PMID: 18439831]
SF-268	GI₅₀	94 μM Compound: Doxorubicin	Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay	[PMID: 21504224]
SF-295	IC₅₀	0.03 μM Compound: Dox	Cytotoxicity against human SF295 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human SF295 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31306817]
SF-295	IC₅₀	0.035 μM Compound: Doxorubicin	In vitro cytotoxic activity against SF-295 (CNS carcinoma) cell lines by using SRB assay In vitro cytotoxic activity against SF-295 (CNS carcinoma) cell lines by using SRB assay	[PMID: 9873661]
SF-295	IC₅₀	0.04 μg/mL Compound: Doxorubicin	Cytotoxicity against human SF295 cells after 72 hrs by MTT assay Cytotoxicity against human SF295 cells after 72 hrs by MTT assay	[PMID: 20537433]
SF-295	IC₅₀	0.08 μM Compound: Dox	Cytotoxicity against human SF295 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human SF295 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32551011]
SF-295	GI₅₀	0.1 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human SF295 cells after 48 hrs by SRB assay Cytotoxicity against human SF295 cells after 48 hrs by SRB assay	[PMID: 23871905]
SF-295	GI₅₀	0.1 μM Compound: Doxorubicin	Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
SF-295	GI₅₀	0.1 μM Compound: Doxorubicin	Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SF295 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
SF-295	IC₅₀	0.23 μg/mL Compound: Dox	Cytotoxicity against Homo sapiens (human) SF295 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) SF295 cells after 72 hr by MTT assay	10.1007/s00044-011-9894-8
SF-295	IC₅₀	0.23 μM Compound: DOX	Antiproliferative activity against human SF295 cells after 72 hrs by Sulforhodamine B-stain assay Antiproliferative activity against human SF295 cells after 72 hrs by Sulforhodamine B-stain assay	[PMID: 27484508]
SF-295	IC₅₀	0.25 μg/mL Compound: Doxorubicin	Cytotoxicity against human SF295 cells after 3 days by MTT assay Cytotoxicity against human SF295 cells after 3 days by MTT assay	[PMID: 19159272]
SF-295	IC₅₀	0.25 μg/mL Compound: Doxorubicin	Cytotoxicity against human SF295 cells after 72 hrs by MTT assay Cytotoxicity against human SF295 cells after 72 hrs by MTT assay	[PMID: 19084293]
SF-295	IC₅₀	0.25 μg/mL Compound: doxorubicin	Cytotoxicity against human SF295 cells after 72 hrs by MTT assay Cytotoxicity against human SF295 cells after 72 hrs by MTT assay	[PMID: 17827021]
SF-295	IC₅₀	0.25 μM Compound: Doxorubicin	Cytotoxicity against human SF295 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human SF295 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 31836446]
SF-295	IC₅₀	0.37 μM Compound: Doxorubicin	Cytotoxicity against human SF295 cells after 69 hrs by MTT assay Cytotoxicity against human SF295 cells after 69 hrs by MTT assay	[PMID: 19780590]
SF-295	IC₅₀	0.39 μM Compound: Doxorubicin	Cytotoxicity against human SF295 cells after 72 hrs by MTT assay Cytotoxicity against human SF295 cells after 72 hrs by MTT assay	[PMID: 27363939]
SF-295	IC₅₀	0.399 μM Compound: Dox	Cytotoxicity against human SF295 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human SF295 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 30108718]
SF-295	IC₅₀	0.4 μM Compound: Doxorubicin	Cytotoxicity against human SF295 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human SF295 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24530030]
SF-295	IC₅₀	0.4 μM Compound: doxorubicin	Cytotoxicity against human SF295 cells after 72 hrs by MTT assay Cytotoxicity against human SF295 cells after 72 hrs by MTT assay	[PMID: 21381705]
SF-295	IC₅₀	0.41 μg/mL Compound: Doxo	Cytotoxicity against human SF295 cells for 72 hrs by MTT assay Cytotoxicity against human SF295 cells for 72 hrs by MTT assay	[PMID: 21334795]
SF-295	IC₅₀	0.41 μM Compound: DOX	Cytotoxicity against human SF295 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human SF295 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29660689]
SF-295	IC₅₀	0.41 μM Compound: Doxorubicin	Cytotoxicity against human SF295 cells after 72 hrs by MTT assay Cytotoxicity against human SF295 cells after 72 hrs by MTT assay	[PMID: 21115213]
SF-295	IC₅₀	0.41 μM Compound: DOXO	Cytotoxicity against human SF295 cells after 72 hrs by MTT assay Cytotoxicity against human SF295 cells after 72 hrs by MTT assay	[PMID: 19947600]
SF-295	IC₅₀	0.423 μM Compound: Doxorubicin	Cytotoxicity against human SF295 cells assessed as growth inhibition by MTT assay Cytotoxicity against human SF295 cells assessed as growth inhibition by MTT assay	[PMID: 24398294]
SF-295	IC₅₀	0.45 μM Compound: DOXO	Antiproliferative activity against human SF295 cells after 72 hrs by MTT assay Antiproliferative activity against human SF295 cells after 72 hrs by MTT assay	[PMID: 28818447]
SF-295	IC₅₀	0.48 μg/mL Compound: Dox	Anticancer activity against Homo sapiens (human) SF295 cells assessed as inhibition of cell survival after 72 hr by MTT assay Anticancer activity against Homo sapiens (human) SF295 cells assessed as inhibition of cell survival after 72 hr by MTT assay	10.1007/s00044-012-0236-2
SF-295	IC₅₀	0.48 μM Compound: Doxorubicin	Cytotoxicity against human SF295 cells after 72 hrs by MTT assay Cytotoxicity against human SF295 cells after 72 hrs by MTT assay	10.1039/C4MD00371C
SF-295	IC₅₀	0.48 μM Compound: Doxorubicin	Cytotoxicity against human SF295 cells after 72 hrs by MTT assay Cytotoxicity against human SF295 cells after 72 hrs by MTT assay	[PMID: 20971532]
SF-295	IC₅₀	0.48 μM Compound: Doxorubicin	Cytotoxicity against human SF295 cells after 72 hrs by MTT assay Cytotoxicity against human SF295 cells after 72 hrs by MTT assay	[PMID: 19406535]
SF-295	IC₅₀	0.51 μM Compound: Doxorubicin	Cytotoxicity against human SF295 cells overexpressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human SF295 cells overexpressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27341379]
SF-295	IC₅₀	0.51 μM Compound: DOXO	Cytotoxicity against human SF295 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human SF295 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26142490]
SF-295	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human SF295 cells by colorimetric method Cytotoxicity against human SF295 cells by colorimetric method	[PMID: 24387625]
SF-295	IC₅₀	0.75 μM Compound: doxorubicine	Cytotoxic activity against human SF295 cells after 69 hrs by MTT assay Cytotoxic activity against human SF295 cells after 69 hrs by MTT assay	[PMID: 19788290]
SF-295	IC₅₀	4.4 μM Compound: Doxorubicin	Antitumor activity against human SF295 cells after 24 to 48 hrs by MTT assay Antitumor activity against human SF295 cells after 24 to 48 hrs by MTT assay	[PMID: 21553829]
SF-539	GI₅₀	0.12 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human SF539 cells after 48 hrs by SRB assay Cytotoxicity against human SF539 cells after 48 hrs by SRB assay	[PMID: 23871905]
SF-539	GI₅₀	0.12 μM Compound: Doxorubicin	Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
SF-539	GI₅₀	0.12 μM Compound: Doxorubicin	Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SF539 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
SGC-7901	IC₅₀	0.13 μM Compound: ADR	Antiproliferative activity against human SGC7901 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human SGC7901 cells after 72 hrs by sulforhodamine B assay	[PMID: 30241010]
SGC-7901	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human SGC7901 cells assessed as reduction in cell viability incubated for 72 hrs by MTT method Cytotoxicity against human SGC7901 cells assessed as reduction in cell viability incubated for 72 hrs by MTT method	[PMID: 25932671]
SGC-7901	GI₅₀	0.55 μM Compound: Adriamycin	Antiproliferative activity against human SGC7901 cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human SGC7901 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 24686011]
SGC-7901	GI₅₀	0.55 μM Compound: Adriamycin	Growth inhibition of human SGC7901 cells by sulforhodamine B assay Growth inhibition of human SGC7901 cells by sulforhodamine B assay	[PMID: 24650643]
SGC-7901	IC₅₀	0.72 μM Compound: Doxorubicin	Anticancer activity against human SGC-7901 cells incubated for 48 hrs by MTT assay Anticancer activity against human SGC-7901 cells incubated for 48 hrs by MTT assay	[PMID: 35367708]
SGC-7901	IC₅₀	0.8 μM Compound: AMD	Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay	[PMID: 26807545]
SGC-7901	IC₅₀	0.87 μM Compound: ADM	Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay Antiproliferative activity against human SGC7901 cells after 48 hrs by MTT assay	[PMID: 30025345]
SGC-7901	IC₅₀	0.9 μM Compound: Doxorubicin	Antiproliferative activity against human SGC7901 cells after 72 hrs by MTT assay Antiproliferative activity against human SGC7901 cells after 72 hrs by MTT assay	[PMID: 19632833]
SGC-7901	IC₅₀	1.2 μM Compound: Dox	Cytotoxicity against human SGC7901 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxicity against human SGC7901 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 27397495]
SGC-7901	IC₅₀	1.3 x 10^-2 μM Compound: adriamycin	Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay	[PMID: 19285863]
SGC-7901	IC₅₀	1.359 μg/mL Compound: ADM	Cytotoxicity against human SGC7901 cells by MTT assay Cytotoxicity against human SGC7901 cells by MTT assay	[PMID: 25862199]
SGC-7901	IC₅₀	1.45 μM Compound: AMD	Anticancer activity against human SGC7901 cells assessed as cell survival after 48 hrs by MTT assay Anticancer activity against human SGC7901 cells assessed as cell survival after 48 hrs by MTT assay	[PMID: 25812966]
SGC-7901	IC₅₀	1.53 μM Compound: Doxorubicin	Cytotoxicity against human SGC-7901 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human SGC-7901 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32866757]
SGC-7901	IC₅₀	2.59 μM Compound: Doxorubicin	Antiproliferative activity against human SGC7901 cells after 24 hrs by MTT assay Antiproliferative activity against human SGC7901 cells after 24 hrs by MTT assay	10.1039/C5MD00581G
SGC-7901	IC₅₀	3.41 μM Compound: AMD	Antiproliferative activity against human SGC-7901 cells measured after 48 hrs by MTT assay Antiproliferative activity against human SGC-7901 cells measured after 48 hrs by MTT assay	[PMID: 27639364]
SGC-7901	IC₅₀	3.5 μM Compound: ADM	Cytotoxicity against human SGC7901 cells after 38 hrs by MTT assay Cytotoxicity against human SGC7901 cells after 38 hrs by MTT assay	[PMID: 25965778]
SGC-7901	IC₅₀	5.72 μM Compound: Doxorubicin	Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay	[PMID: 23871222]
SH-SY5Y	IC₅₀	0.04 μM Compound: Doxorubicin	Cytotoxicity against human SH-SY5Y cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay Cytotoxicity against human SH-SY5Y cells assessed as inhibition of cell growth and measured after 72 hrs resazurin reduction assay	[PMID: 36126331]
SH-SY5Y	IC₅₀	0.14 μM Compound: D	Antiproliferative activity against human SH-SY5Y cells after 72 hrs by MTT assay Antiproliferative activity against human SH-SY5Y cells after 72 hrs by MTT assay	10.1039/C6MD00431H
SH-SY5Y	IC₅₀	0.35 μM Compound: DOX	Antiproliferative activity against human SH-SY5Y cells after 72 hrs by CCK-8 assay Antiproliferative activity against human SH-SY5Y cells after 72 hrs by CCK-8 assay	[PMID: 29597166]
SH-SY5Y	IC₅₀	0.5 μM Compound: DOXO	Cytotoxicity against human SH-SY5Y cells assessed as cell viability after 48 hrs by alamar blue assay Cytotoxicity against human SH-SY5Y cells assessed as cell viability after 48 hrs by alamar blue assay	[PMID: 21797280]
SH-SY5Y	CC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay	[PMID: 29792325]
SH-SY5Y	IC₅₀	0.8 μM Compound: DOX	Cytotoxicity against human SH-SY5Y cells expressing low level of topoisomerase I/II measured after 72 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells expressing low level of topoisomerase I/II measured after 72 hrs by MTT assay	[PMID: 35612499]
SH-SY5Y	IC₅₀	0.89 μM Compound: DOX	Antiproliferative activity against human SH-SY5Y cells after 72 hrs by CCK-8 assay Antiproliferative activity against human SH-SY5Y cells after 72 hrs by CCK-8 assay	[PMID: 29614418]
SH-SY5Y	IC₅₀	1.543 μM Compound: Dox	Antiproliferative activity against human SH-SY5Y cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human SH-SY5Y cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 36240546]
SH-SY5Y	IC₅₀	2.3 μM Compound: Doxorubicin	Neurotoxicity in human SH-SY5Y cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Neurotoxicity in human SH-SY5Y cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 33439019]
SiHa	GI₅₀	< 0.01 μM Compound: Doxorubicin	Growth inhibition of human SiHa cells after 48 hrs by SRB assay Growth inhibition of human SiHa cells after 48 hrs by SRB assay	10.1039/C6MD00097E
SiHa	GI₅₀	< 0.01 μM Compound: Doxorubicin	Growth inhibition in human SiHa cells after 48 hrs by SRB assay Growth inhibition in human SiHa cells after 48 hrs by SRB assay	[PMID: 31546197]
SiHa	GI₅₀	0.14 μM Compound: ADR	Growth inhibition of human SiHa cells by SRB assay Growth inhibition of human SiHa cells by SRB assay	[PMID: 22361684]
SiHa	GI₅₀	0.17 μM Compound: ADR	Growth inhibition of human SiHa cells after 48 hrs by SRB assay Growth inhibition of human SiHa cells after 48 hrs by SRB assay	[PMID: 20031423]
SiHa	GI₅₀	0.17 μM Compound: ADR	Anticancer activity against human SiHa cells by SRB method Anticancer activity against human SiHa cells by SRB method	[PMID: 21676506]
SiHa	GI₅₀	0.17 μM Compound: ADR	Growth inhibition of human SiHa cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SiHa cells after 48 hrs by sulforhodamine B assay	[PMID: 23849207]
SiHa	GI₅₀	0.17 μM Compound: ADR	Cytotoxicity against human SiHa cells after 24 hrs by WST-1 assay Cytotoxicity against human SiHa cells after 24 hrs by WST-1 assay	[PMID: 20732817]
SiHa	GI₅₀	0.18 μM Compound: adriamycin	Cytotoxicity against human SiHa cells after 24 hrs by SRB method Cytotoxicity against human SiHa cells after 24 hrs by SRB method	[PMID: 18262426]
SiHa	GI₅₀	0.18 μM Compound: ADR, Adriamycin	Growth inhibition of human SiHa cells by SRB method Growth inhibition of human SiHa cells by SRB method	[PMID: 18207392]
SiHa	GI₅₀	0.18 μM Compound: ADR	Cytotoxicity against human SiHa cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human SiHa cells after 48 hrs by sulforhodamine B assay	[PMID: 18657979]
SiHa	IC₅₀	0.311 μM Compound: Doxorubicin	Antiproliferative activity against human SiHa cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human SiHa cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31883489]
SiHa	IC₅₀	0.45 μM Compound: Doxorubicin	Anticancer activity against human SiHa cells after 48 hrs by MTT assay Anticancer activity against human SiHa cells after 48 hrs by MTT assay	[PMID: 21641694]
SiHa	IC₅₀	0.5 μM Compound: adriamycin	Cytotoxicity against human SIHA cells under deem light after 96 hrs by MTT assay Cytotoxicity against human SIHA cells under deem light after 96 hrs by MTT assay	[PMID: 17993275]
SiHa	IC₅₀	0.76 μM Compound: Dox	Cytotoxicity against human SiHa cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human SiHa cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30615450]
SiHa	IC₅₀	1.5 μM Compound: Doxorubicin	Cytotoxicity against human SiHa cells assessed as reduction in cell viability measured after 48 hrs by SRB assay Cytotoxicity against human SiHa cells assessed as reduction in cell viability measured after 48 hrs by SRB assay	[PMID: 28818768]
SiHa	IC₅₀	1.5 μM Compound: ADR	Cytotoxicity against human SiHa cells by SRB assay Cytotoxicity against human SiHa cells by SRB assay	[PMID: 18656370]
SiHa	IC₅₀	1.5 μM Compound: ADR	Cytotoxicity against human SiHa cells by sulforhodamine B assay Cytotoxicity against human SiHa cells by sulforhodamine B assay	[PMID: 17822905]
SiHa	IC₅₀	1.9 μM Compound: Doxorubicin	Antiproliferative activity against human SiHa cells after 48 hrs by SRB assay Antiproliferative activity against human SiHa cells after 48 hrs by SRB assay	[PMID: 28419927]
SiHa	GI₅₀	1.9 μM Compound: ADR	Anticancer activity against human SiHa cells by SRB method Anticancer activity against human SiHa cells by SRB method	[PMID: 22104151]
SiHa	IC₅₀	2.04 μM Compound: Doxorubicin	Antitumor activity against human SiHa cells assessed as inhibition of cell growth by MTT assay Antitumor activity against human SiHa cells assessed as inhibition of cell growth by MTT assay	[PMID: 25160837]
SiHa	GI₅₀	2.1 μM Compound: ADR	Cytotoxicity against human SiHa cells after 48 hrs by SRB assay Cytotoxicity against human SiHa cells after 48 hrs by SRB assay	[PMID: 20673627]
SJSA-1	IC₅₀	6.2 nM Compound: doxorubicin	Cytotoxicity against human SJSA1 cells expressing GRP78 after 6 hrs by MTT assay Cytotoxicity against human SJSA1 cells expressing GRP78 after 6 hrs by MTT assay	[PMID: 18243696]
SK-BR-3	IC₅₀	0.02 μM Compound: Doxorubicin	Inhibitory activity against SKBR-3 cell line using MTT assay (ER-amplified erB2,mutant p53) Inhibitory activity against SKBR-3 cell line using MTT assay (ER-amplified erB2,mutant p53)	[PMID: 10780913]
SK-BR-3	IC₅₀	0.034 μM Compound: DOX	Antiproliferative activity against human SKBR3 cells after 24 hrs by CellTiter-Glo assay Antiproliferative activity against human SKBR3 cells after 24 hrs by CellTiter-Glo assay	[PMID: 27769032]
SK-BR-3	IC₅₀	0.05 μM Compound: DOX	Antiproliferative activity against human SKBR3 cells after 48 hrs by CellTiter-Glo assay Antiproliferative activity against human SKBR3 cells after 48 hrs by CellTiter-Glo assay	[PMID: 27769032]
SK-BR-3	IC₅₀	0.09 μM Compound: Doxorubicin	Cytotoxicity against human SK-BR-3 cells after 72 hrs by resazurin/resorufin-based fluorescence assay Cytotoxicity against human SK-BR-3 cells after 72 hrs by resazurin/resorufin-based fluorescence assay	[PMID: 23600925]
SK-BR-3	IC₅₀	0.1 μM Compound: Doxorubicin	Antiproliferative activity against 2D culture of human SK-BR-3 cells after 72 hrs MTS assay Antiproliferative activity against 2D culture of human SK-BR-3 cells after 72 hrs MTS assay	[PMID: 27721156]
SK-BR-3	IC₅₀	0.202 μM Compound: Doxorubicin	Antiproliferative activity against human SKBR3 cells after 72 hrs by MTT reduction assay Antiproliferative activity against human SKBR3 cells after 72 hrs by MTT reduction assay	[PMID: 28551177]
SK-BR-3	IC₅₀	0.21 μM Compound: doxorubicin	Cytotoxicity against human SK-BR-3 cells after 72 hrs by CellTiter-Glo assay Cytotoxicity against human SK-BR-3 cells after 72 hrs by CellTiter-Glo assay	[PMID: 22316168]
SK-BR-3	IC₅₀	0.28 μM Compound: Doxorubicin	Cytotoxicity against HER2-positive human SKBR3 cells assessed as redution in cell viability incubated for 72 hrs by SRB assay Cytotoxicity against HER2-positive human SKBR3 cells assessed as redution in cell viability incubated for 72 hrs by SRB assay	[PMID: 31810778]
SK-BR-3	IC₅₀	0.28 μM Compound: DOX	Cytotoxicity against human SKBr3 assessed as reduction in cell viability by SRB assay Cytotoxicity against human SKBr3 assessed as reduction in cell viability by SRB assay	[PMID: 33130288]
SK-BR-3	IC₅₀	0.29 μM Compound: adriamycin	Cytotoxicity against SKBR3 cells after 72 hrs by MTT assay Cytotoxicity against SKBR3 cells after 72 hrs by MTT assay	[PMID: 17107806]
SK-BR-3	IC₅₀	0.37 μM Compound: DX	Antiproliferative activity against human SK-BR-3 cells after 72 hrs by SRB assay Antiproliferative activity against human SK-BR-3 cells after 72 hrs by SRB assay	[PMID: 30025346]
SK-BR-3	IC₅₀	1.29 μM Compound: Doxorubicin	Antiproliferative activity against 3D culture of human SK-BR-3 cells after 72 hrs MTS assay Antiproliferative activity against 3D culture of human SK-BR-3 cells after 72 hrs MTS assay	[PMID: 27721156]
SK-BR-3	IC₅₀	2.36 μM Compound: Doxorubicin	Cytotoxicity against human SK-BR-3 cells treated for 72 hrs by MTT assay Cytotoxicity against human SK-BR-3 cells treated for 72 hrs by MTT assay	[PMID: 35344904]
SK-BR-3	IC₅₀	8.48 μM Compound: Dox	Cytotoxicity against human SKBR3 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human SKBR3 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28549734]
SK-ES1	IC₅₀	0.042 μM Compound: Doxorubicin	Cytotoxicity against human SK-ES-1 cells after 72 hrs by resazurin/resorufin-based fluorescence assay Cytotoxicity against human SK-ES-1 cells after 72 hrs by resazurin/resorufin-based fluorescence assay	[PMID: 23600925]
SK-HEP1	GI₅₀	0.07 μg/mL Compound: Adriamycin	Antiproliferative activity against human SKHEP1 cells by SRB assay Antiproliferative activity against human SKHEP1 cells by SRB assay	[PMID: 18023932]
SK-HEP1	IC₅₀	0.1 μM Compound: Doxorubicin	Antiproliferative activity against human SK-HEP1 cells after 72 hrs by SRB assay Antiproliferative activity against human SK-HEP1 cells after 72 hrs by SRB assay	[PMID: 18063366]
SK-HEP1	IC₅₀	10 nM Compound: Doxorubicin	Cytotoxicity against human SKHEP1 cells after 48 hrs by [3H]thymidine incorporation assay Cytotoxicity against human SKHEP1 cells after 48 hrs by [3H]thymidine incorporation assay	[PMID: 20210346]
SK-LU-1	IC₅₀	6.7 nM Compound: Adriamycin	Cytotoxicity against human SKLU1 cells after 48 hrs by SRB assay Cytotoxicity against human SKLU1 cells after 48 hrs by SRB assay	[PMID: 22858298]
SK-MEL	IC₅₀	< 0.55 μg/mL Compound: Doxorubicin	Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red assay Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red assay	[PMID: 19105653]
SK-MEL	IC₅₀	< 1.1 μg/mL Compound: Doxorubicin	Cytotoxicity against human SK-MEL cells after 2 to 7 days by neutral red assay Cytotoxicity against human SK-MEL cells after 2 to 7 days by neutral red assay	[PMID: 11374943]
SK-MEL	IC₅₀	0.009 μM Compound: Doxorubicin	Antiproliferative activity against human SK-MEL cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human SK-MEL cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 27010926]
SK-MEL	IC₅₀	0.14 μM Compound: Doxorubicin	Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red assay relative to control Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red assay relative to control	[PMID: 25975638]
SK-MEL	IC₅₀	0.159 μM Compound: Doxorubicin	Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red dye based assay Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red dye based assay	[PMID: 29317147]
SK-MEL	IC₅₀	0.55 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) SK-MEL cells by neutral red staining Cytotoxicity against Homo sapiens (human) SK-MEL cells by neutral red staining	10.1007/s00044-011-9587-3
SK-MEL	IC₅₀	0.6 μg/mL Compound: doxorubicin	Cytotoxicity against human SK-MEL cells after 48 hrs by Neutral Red dye Cytotoxicity against human SK-MEL cells after 48 hrs by Neutral Red dye	[PMID: 20550123]
SK-MEL	IC₅₀	0.6 μg/mL Compound: doxorubicin	Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red dye staining Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red dye staining	[PMID: 19928902]
SK-MEL	IC₅₀	0.6 μg/mL Compound: doxorubicin	Cytotoxicity against human SKMEL cells by neutral red assay Cytotoxicity against human SKMEL cells by neutral red assay	[PMID: 17976995]
SK-MEL	IC₅₀	1.1 μM Compound: Doxorubicin	Cytotoxicity against human SK-MEL cells assessed as cell growth inhibition after 48 hrs by neutral red assay Cytotoxicity against human SK-MEL cells assessed as cell growth inhibition after 48 hrs by neutral red assay	[PMID: 26005918]
SK-MEL	IC₅₀	1.11 μg/mL Compound: Doxorubicin	Cytotoxicity against human SK-MEL cells assessed as cell growth inhibition after 48 hrs by neutral red dye based assay Cytotoxicity against human SK-MEL cells assessed as cell growth inhibition after 48 hrs by neutral red dye based assay	[PMID: 27769668]
SK-MEL	IC₅₀	1.2 μM Compound: Doxorubicin	Cytotoxicity against human SK-MEL cells after 48 hrs by Neutral red assay Cytotoxicity against human SK-MEL cells after 48 hrs by Neutral red assay	[PMID: 19658408]
SK-MEL	IC₅₀	1.5 μM Compound: Doxorubicin	Cytotoxicity against human SK-MEL cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay Cytotoxicity against human SK-MEL cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay	[PMID: 27618204]
SK-MEL	IC₅₀	1.5 μM Compound: doxorubicin	Cytotoxicity against human SK-MEL cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against human SK-MEL cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]
SK-MEL	IC₅₀	1.57 μg/mL Compound: Doxorubicin	Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red staining Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red staining	[PMID: 15165136]
SK-MEL	IC₅₀	1.6 μM Compound: doxorubicin	Cytotoxicity against human SK-MEL cells assessed as viable cells by neutral red dye method Cytotoxicity against human SK-MEL cells assessed as viable cells by neutral red dye method	[PMID: 22530813]
SK-MEL	IC₅₀	1.73 μM Compound: doxorubicin	Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red assay Cytotoxicity against human SK-MEL cells after 48 hrs by neutral red assay	[PMID: 19879765]
SK-MEL-1	IC₅₀	3.092 μM Compound: Doxorubicin	Cytotoxicity against human SK-MEL-1 cells after 94 hrs by MTT assay Cytotoxicity against human SK-MEL-1 cells after 94 hrs by MTT assay	[PMID: 21868138]
SK-MEL-2	ED₅₀	0.001 μg/mL Compound: Doxorubicin	Cytotoxicity against human SK-MEL-2 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human SK-MEL-2 cells after 48 hrs by sulforhodamine B assay	[PMID: 19783438]
SK-MEL-2	IC₅₀	0.001 μM Compound: Doxorubicin	Cytotoxicity against human SK-MEL-2 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay Cytotoxicity against human SK-MEL-2 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay	[PMID: 27856237]
SK-MEL-2	IC₅₀	0.001 μM Compound: Doxorubicin	Cytotoxicity against human SK-MEL-2 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Cytotoxicity against human SK-MEL-2 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 25981688]
SK-MEL-2	IC₅₀	0.001 μM Compound: Doxorubicin	Cytotoxicity against human SK-MEL-2 cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human SK-MEL-2 cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 25466198]
SK-MEL-2	ED₅₀	0.002 μg/mL Compound: Doxorubicin	Cytotoxicity against human SK-MEL-2 cells by sulforhodamine B method Cytotoxicity against human SK-MEL-2 cells by sulforhodamine B method	[PMID: 12193011]
SK-MEL-2	IC₅₀	0.002 μM Compound: Doxorubicin	Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay	[PMID: 22483395]
SK-MEL-2	IC₅₀	0.002 μM Compound: Doxorubicin	Cytotoxicity against human SK-MEL-2 cells by SRB assay Cytotoxicity against human SK-MEL-2 cells by SRB assay	[PMID: 20719504]
SK-MEL-2	IC₅₀	0.0025 μM Compound: Doxorubicin	Cytotoxicity against human SK-MEL-2 cells by sulforhodamine B bioassay Cytotoxicity against human SK-MEL-2 cells by sulforhodamine B bioassay	[PMID: 25098650]
SK-MEL-2	ED₅₀	0.003 μg/mL Compound: doxorubicin	Cytotoxicity against human SK-MEL-2 cells by SRB method Cytotoxicity against human SK-MEL-2 cells by SRB method	[PMID: 16252909]
SK-MEL-2	IC₅₀	0.004 μM Compound: Doxorubicin	Cytotoxicity against human SK-MEL-2 cells by SRB assay Cytotoxicity against human SK-MEL-2 cells by SRB assay	[PMID: 22951040]
SK-MEL-2	IC₅₀	0.009 μM Compound: Doxorubicin	Antiproliferative activity against human SK-MEL-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human SK-MEL-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 27010926]
SK-MEL-2	ED₅₀	0.01 μg/mL Compound: doxorubicin	Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay	[PMID: 15921415]
SK-MEL-2	IC₅₀	0.01 μM Compound: Doxorubicin	Cytotoxicity against human SK-MEL-2 cells assessed as growth inhibition by SRB assay Cytotoxicity against human SK-MEL-2 cells assessed as growth inhibition by SRB assay	[PMID: 23634786]
SK-MEL-2	IC₅₀	0.01 μM Compound: Doxorubicin	Cytotoxicity against human SK-MEL-2 cells by sulforhodamine B assay Cytotoxicity against human SK-MEL-2 cells by sulforhodamine B assay	[PMID: 23815260]
SK-MEL-2	IC₅₀	0.012 μM Compound: Doxorubicin	Cytotoxicity against human SK-MEL-2 cells by SRB assay Cytotoxicity against human SK-MEL-2 cells by SRB assay	[PMID: 20594848]
SK-MEL-2	IC₅₀	0.015 μg/mL Compound: doxorubicin	Anticancer activity against human SK-MEL-2 cells after 72 hrs by sulforhodamine B assay Anticancer activity against human SK-MEL-2 cells after 72 hrs by sulforhodamine B assay	[PMID: 19342127]
SK-MEL-2	IC₅₀	0.019 μM Compound: doxorubicin	Cytotoxicity against human SK-MEL-2 cells after 3 days by SRB assay Cytotoxicity against human SK-MEL-2 cells after 3 days by SRB assay	[PMID: 18321715]
SK-MEL-2	IC₅₀	0.028 μM Compound: Doxorubicin	Anticancer activity against human SK-MEL-2 cells by sulforhodamine B assay Anticancer activity against human SK-MEL-2 cells by sulforhodamine B assay	[PMID: 19819696]
SK-MEL-2	IC₅₀	0.03 μg/mL Compound: adriamycin	Cytotoxicity against human SK-MEL-2 cells by SRB assay Cytotoxicity against human SK-MEL-2 cells by SRB assay	[PMID: 15921426]
SK-MEL-2	IC₅₀	0.04 μM Compound: Doxorubicin	Cytotoxicity against human SK-MEL-2 cells by SRB assay Cytotoxicity against human SK-MEL-2 cells by SRB assay	[PMID: 20176479]
SK-MEL-2	ED₅₀	0.05 μg/mL Compound: adriamycin	Cytotoxicity against human SK-MEL-2 cells by SRB assay Cytotoxicity against human SK-MEL-2 cells by SRB assay	10.1021/np960188t
SK-MEL-2	IC₅₀	0.07 μM Compound: doxorubicin	Cytotoxicity against human SK-MEL-2 cells by SRB assay Cytotoxicity against human SK-MEL-2 cells by SRB assay	[PMID: 17194596]
SK-MEL-2	IC₅₀	0.09 μg/mL Compound: Doxorubicin	Cytotoxicity against human SK-MEL-2 cells by sulforhodamine B assay Cytotoxicity against human SK-MEL-2 cells by sulforhodamine B assay	[PMID: 21684168]
SK-MEL-2	IC₅₀	0.097 μM Compound: Doxorubicin	Anticancer activity against human SK-MEL-2 cells after 48 hrs by SRB assay Anticancer activity against human SK-MEL-2 cells after 48 hrs by SRB assay	[PMID: 17070967]
SK-MEL-2	ED₅₀	0.11 μg/mL Compound: doxorubicin	Cytotoxicity against human SK-MEL-2 cells by SRB assay Cytotoxicity against human SK-MEL-2 cells by SRB assay	[PMID: 9392887]
SK-MEL-2	GI₅₀	0.11 μM Compound: Doxorubicin	Growth inhibition of human SK-MEL-2 cells after 72 hrs by SRB assay Growth inhibition of human SK-MEL-2 cells after 72 hrs by SRB assay	[PMID: 18585035]
SK-MEL-2	IC₅₀	0.117 μM Compound: doxorubicin	Cytotoxicity against human SK-MEL-2 cells by SRB assay Cytotoxicity against human SK-MEL-2 cells by SRB assay	[PMID: 19435339]
SK-MEL-2	ED₅₀	0.117 μM Compound: doxorubicin	Cytotoxicity against human SK-MEL-2 cells by SRB assay Cytotoxicity against human SK-MEL-2 cells by SRB assay	[PMID: 18314958]
SK-MEL-2	IC₅₀	0.16 μM Compound: doxorubicin	Cytotoxicity against human SK-MEL-2 cells after 48 hrs Cytotoxicity against human SK-MEL-2 cells after 48 hrs	[PMID: 17673337]
SK-MEL-2	GI₅₀	0.17 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay	[PMID: 23871905]
SK-MEL-2	GI₅₀	0.21 μM Compound: Doxorubicin	Growth inhibition of human SK-MEL-2 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SK-MEL-2 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
SK-MEL-2	IC₅₀	11.7 nM Compound: Doxorubicin	Antiproliferative activity against human SK-MEL-2 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay Antiproliferative activity against human SK-MEL-2 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay	[PMID: 31655432]
SK-MEL-2	IC₅₀	4.78 μM Compound: doxorubicin	Cytotoxicity against human SK-MEL-2 cells by SRB assay Cytotoxicity against human SK-MEL-2 cells by SRB assay	[PMID: 17827007]
SK-MEL-2	IC₅₀	4.78 μM Compound: Doxorubicin	Cytotoxic activity against SK-MEL-2 human melanoma cell line, using sulforhodamine B (SRB) assay. Cytotoxic activity against SK-MEL-2 human melanoma cell line, using sulforhodamine B (SRB) assay.	[PMID: 14643344]
SK-MEL-28	IC₅₀	0.02 μM Compound: 2	Compound was evaluated for the cytotoxicity against MEL-28 tumor cell line after 3 days of incubation Compound was evaluated for the cytotoxicity against MEL-28 tumor cell line after 3 days of incubation	10.1016/S0960-894X(97)10122-6
SK-MEL-28	IC₅₀	0.06 μM Compound: Doxo	Antiproliferative activity against human SKMEL-28 cells assessed as cell viability measured after 4 days by MTT assay Antiproliferative activity against human SKMEL-28 cells assessed as cell viability measured after 4 days by MTT assay	[PMID: 31869654]
SK-MEL-28	GI₅₀	0.08 μM Compound: Doxorubicin	Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
SK-MEL-28	GI₅₀	0.21 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human SK-MEL-28 cells after 48 hrs by SRB assay Cytotoxicity against human SK-MEL-28 cells after 48 hrs by SRB assay	[PMID: 23871905]
SK-MEL-28	GI₅₀	0.21 μM Compound: Doxorubicin	Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
SK-MEL-28	IC₅₀	0.25 μM Compound: Doxorubicin	Antiproliferative activity against human SK-MEL-28 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human SK-MEL-28 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 34851111]
SK-MEL-28	IC₅₀	0.25 μM Compound: Doxorubicin	Cytotoxicity against human SK-MEL-28 cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay Cytotoxicity against human SK-MEL-28 cells assessed as reduction in cell viability after 72 hrs by CellTiter96 AQueous one solution cell proliferation assay	[PMID: 28617598]
SK-MEL-28	IC₅₀	0.6 μM Compound: Doxorubicin	Antitumor activity against human SK-MEL-28 cells after 24 to 48 hrs by MTT assay Antitumor activity against human SK-MEL-28 cells after 24 to 48 hrs by MTT assay	[PMID: 21553829]
SK-MEL-28	EC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human SK-MEL-28 cells after 96 hrs by MTT assay Cytotoxicity against human SK-MEL-28 cells after 96 hrs by MTT assay	[PMID: 26320088]
SK-MEL-28	IC₅₀	1.64 μM Compound: Dox	Cytotoxicity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Cytotoxicity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 35635947]
SK-MEL-28	IC₅₀	1.8 μM Compound: Doxorubicin	Anticancer activity against human SK-MEL-28 cells assessed as growth inhibition incubated for 48 hrs by MTT assay Anticancer activity against human SK-MEL-28 cells assessed as growth inhibition incubated for 48 hrs by MTT assay	[PMID: 34363936]
SK-MEL-28	IC₅₀	3 μM Compound: Doxorubicin	Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay	[PMID: 30783501]
SK-MEL3	ED₅₀	0.02 μg/mL Compound: Doxorubicin	Cytotoxicity against human SK-MEL-3 cells after 48 hrs by SRB assay Cytotoxicity against human SK-MEL-3 cells after 48 hrs by SRB assay	[PMID: 11325244]
SK-MEL-5	GI₅₀	0.03 μg/mL Compound: adriamycin	Cytotoxicity against human SK-MEL-5 cells by MTT assay Cytotoxicity against human SK-MEL-5 cells by MTT assay	[PMID: 11000028]
SK-MEL-5	GI₅₀	0.08 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human SK-MEL-5 cells after 48 hrs by SRB assay Cytotoxicity against human SK-MEL-5 cells after 48 hrs by SRB assay	[PMID: 23871905]
SK-MEL-5	GI₅₀	0.08 μM Compound: Doxorubicin	Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
SK-MEL-5	GI₅₀	0.14 μM Compound: Doxorubicin	Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SK-MEL-5 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
SK-MEL-5	ED₅₀	2.8 x 10^-4 μg/mL Compound: Adriamycin	Cytotoxicity against human SK-MEL-5 cells by MTT assay Cytotoxicity against human SK-MEL-5 cells by MTT assay	[PMID: 7714533]
SK-MES-1	EC₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity against human SKMES1 cells after 96 hrs by MTT assay Cytotoxicity against human SKMES1 cells after 96 hrs by MTT assay	[PMID: 26320088]
SK-N-MC	IC₅₀	0.12 μM Compound: Doxorubicin	Cytotoxicity against human SK-N-MC cells after 72 hrs by MTT assay Cytotoxicity against human SK-N-MC cells after 72 hrs by MTT assay	[PMID: 20303768]
SK-N-SH	IC₅₀	0.97 μM Compound: Doxorubicin	Antiproliferative activity against human SK-N-SH cells after 48 hrs by MTT assay Antiproliferative activity against human SK-N-SH cells after 48 hrs by MTT assay	10.1039/C2MD20023F
SK-N-SH	IC₅₀	0.97 μM Compound: Doxorubicin	Cytotoxicity against human SK-N-SH cells after 48 hrs by MTT assay Cytotoxicity against human SK-N-SH cells after 48 hrs by MTT assay	[PMID: 22386528]
SK-N-SH	IC₅₀	1.1 μM Compound: Doxorubicin	Cytotoxicity against human SK-N-SH cells after 48 hrs by MTT assay Cytotoxicity against human SK-N-SH cells after 48 hrs by MTT assay	[PMID: 20832916]
SK-N-SH	IC₅₀	10.88 μM Compound: Doxorubicin	Cytotoxicity against human SK-N-SH cells after 24 hrs by MTT assay Cytotoxicity against human SK-N-SH cells after 24 hrs by MTT assay	10.1039/C3MD00013C
SK-N-SH	IC₅₀	19.9 μM Compound: DOX	Cytotoxicity against Homo sapiens (human) SK-N-SH cells assessed as growth inhibition after 48 hr by MTT assay Cytotoxicity against Homo sapiens (human) SK-N-SH cells assessed as growth inhibition after 48 hr by MTT assay	10.1007/s00044-012-0018-x
SK-N-SH	IC₅₀	19.9 μM Compound: DOX	Cytotoxicity against human SK-N-SH cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxicity against human SK-N-SH cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 21440337]
SK-N-SH	IC₅₀	2.42 μM Compound: Doxorubicin	Antiproliferative activity against human SK-N-SH cells incubated for 24 hrs by MTT assay Antiproliferative activity against human SK-N-SH cells incubated for 24 hrs by MTT assay	[PMID: 29409753]
SK-N-SH	IC₅₀	2.85 μM Compound: DOX	Antiproliferative activity against human SK-N-SH cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human SK-N-SH cells assessed as cell growth inhibition by MTT assay	[PMID: 32631524]
SK-N-SH	IC₅₀	6.3 μM Compound: Doxorubicin	Antiproliferative activity against human SK-N-SH cells by MTT reduction assay Antiproliferative activity against human SK-N-SH cells by MTT reduction assay	[PMID: 33421712]
SK-N-SH	IC₅₀	6.42 μM Compound: Doxo	Cytotoxicity against human SK-N-SH cells measured after 24 hrs by MTT assay Cytotoxicity against human SK-N-SH cells measured after 24 hrs by MTT assay	[PMID: 31104996]
SK-N-SH	IC₅₀	7.36 μM Compound: Doxorubicin	Cytotoxicity against human SK-N-SH cells assessed as cell viability by SRB assay Cytotoxicity against human SK-N-SH cells assessed as cell viability by SRB assay	[PMID: 26022842]
SK-N-SH	IC₅₀	8.5 μM Compound: Doxorubicin	Cytotoxicity against human SK-N-SH cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human SK-N-SH cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 25140752]
SK-OV-3	IC₅₀	< 0.55 μg/mL Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red assay Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red assay	[PMID: 19105653]
SK-OV-3	IC₅₀	< 1.1 μg/mL Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells after 2 to 7 days by neutral red assay Cytotoxicity against human SKOV3 cells after 2 to 7 days by neutral red assay	[PMID: 11374943]
SK-OV-3	IC₅₀	> 20 μM Compound: DOX	Cytotoxicity against human SKOV3 cells after 24 hrs by XTT assay Cytotoxicity against human SKOV3 cells after 24 hrs by XTT assay	[PMID: 24900344]
SK-OV-3	IC₅₀	0.001 μM Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells by SRB assay Cytotoxicity against human SKOV3 cells by SRB assay	[PMID: 20719504]
SK-OV-3	IC₅₀	0.00184 μM Compound: Doxorubicin	Antiproliferative activity against human SKOV3 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human SKOV3 cells after 48 hrs by CCK-8 assay	[PMID: 30253344]
SK-OV-3	IC₅₀	0.002 μM Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay	[PMID: 22483395]
SK-OV-3	ED₅₀	0.003 μg/mL Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human SKOV3 cells after 48 hrs by sulforhodamine B assay	[PMID: 19783438]
SK-OV-3	IC₅₀	0.003 μM Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells by SRB assay Cytotoxicity against human SKOV3 cells by SRB assay	[PMID: 20594848]
SK-OV-3	IC₅₀	0.004 μM Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells by SRB assay Cytotoxicity against human SKOV3 cells by SRB assay	[PMID: 22951040]
SK-OV-3	IC₅₀	0.009 μM Compound: Doxorubicin	Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 27010926]
SK-OV-3	IC₅₀	0.01 μg/mL Compound: doxorubicin	Cytotoxicity against human SKOV3 cells after 2 to 7 days by neutral red assay Cytotoxicity against human SKOV3 cells after 2 to 7 days by neutral red assay	[PMID: 8984156]
SK-OV-3	ED₅₀	0.01 μg/mL Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells by sulforhodamine B method Cytotoxicity against human SKOV3 cells by sulforhodamine B method	[PMID: 12193011]
SK-OV-3	IC₅₀	0.01 μM Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells assessed as growth inhibition by SRB assay Cytotoxicity against human SKOV3 cells assessed as growth inhibition by SRB assay	[PMID: 23634786]
SK-OV-3	IC₅₀	0.01 μM Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells by sulforhodamine B assay Cytotoxicity against human SKOV3 cells by sulforhodamine B assay	[PMID: 23815260]
SK-OV-3	IC₅₀	0.012 μM Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay	[PMID: 25981688]
SK-OV-3	IC₅₀	0.012 μM Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells assessed as cell growth inhibition after 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells assessed as cell growth inhibition after 48 hrs by SRB assay	[PMID: 25466198]
SK-OV-3	IC₅₀	0.02 μM Compound: Doxorubicin	In vitro cytotoxic activity against SK-OV-3 (ovarian carcinoma) cell lines by using SRB assay In vitro cytotoxic activity against SK-OV-3 (ovarian carcinoma) cell lines by using SRB assay	[PMID: 9873661]
SK-OV-3	IC₅₀	0.02 μM Compound: 1 (Doxorubicin)	In vitro cytotoxic activity against human ovarian carcinoma cell line SK-OV-3 after 72 hr of drug exposure determined by the SRB assay In vitro cytotoxic activity against human ovarian carcinoma cell line SK-OV-3 after 72 hr of drug exposure determined by the SRB assay	[PMID: 14980672]
SK-OV-3	IC₅₀	0.02 μM Compound: Doxorubicin	Antiproliferative activity against human SKOV3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method Antiproliferative activity against human SKOV3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	[PMID: 25937235]
SK-OV-3	GI₅₀	0.021 μM Compound: Doxorubicin	Antiproliferative activity against human SKOV3 cells by SRB assay Antiproliferative activity against human SKOV3 cells by SRB assay	[PMID: 19394218]
SK-OV-3	IC₅₀	0.0217 μM Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells by sulforhodamine B bioassay Cytotoxicity against human SKOV3 cells by sulforhodamine B bioassay	[PMID: 25098650]
SK-OV-3	IC₅₀	0.024 μg/mL Compound: doxorubicin	Anticancer activity against human SKOV3 cells after 72 hrs by sulforhodamine B assay Anticancer activity against human SKOV3 cells after 72 hrs by sulforhodamine B assay	[PMID: 19342127]
SK-OV-3	IC₅₀	0.0251 μM Compound: Doxorubicin	Inhibitory concentration the viability of SKOV 3 cell population by 50%. Inhibitory concentration the viability of SKOV 3 cell population by 50%.	[PMID: 9003520]
SK-OV-3	ED₅₀	0.03 μg/mL Compound: doxorubicin	Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay	[PMID: 15921415]
SK-OV-3	IC₅₀	0.03 μM Compound: Adriamycin	Cytotoxicity against human SKOV3 cells after 72 hrs by WST8 assay Cytotoxicity against human SKOV3 cells after 72 hrs by WST8 assay	[PMID: 23039861]
SK-OV-3	IC₅₀	0.032 μM Compound: Doxorubicin	Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay	[PMID: 31264855]
SK-OV-3	IC₅₀	0.041 μM Compound: doxorubicin	Cytotoxicity against human SKOV3 cells after 3 days by SRB assay Cytotoxicity against human SKOV3 cells after 3 days by SRB assay	[PMID: 18321715]
SK-OV-3	IC₅₀	0.046 μM Compound: Doxorubicin	Anticancer activity against human SKOV3 cells by sulforhodamine B assay Anticancer activity against human SKOV3 cells by sulforhodamine B assay	[PMID: 19819696]
SK-OV-3	IC₅₀	0.05 μM Compound: DOX	Antiproliferative activity against human SKOV3 cells after 72 hrs by Sulforhodamine B-stain assay Antiproliferative activity against human SKOV3 cells after 72 hrs by Sulforhodamine B-stain assay	[PMID: 27484508]
SK-OV-3	IC₅₀	0.056 μM Compound: doxorubicin	Cytotoxicity against human SKOV3 cells by SRB assay Cytotoxicity against human SKOV3 cells by SRB assay	[PMID: 19435339]
SK-OV-3	ED₅₀	0.056 μM Compound: doxorubicin	Cytotoxicity against human SKOV3 cells by SRB assay Cytotoxicity against human SKOV3 cells by SRB assay	[PMID: 18314958]
SK-OV-3	IC₅₀	0.073 μM Compound: Dox	Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay	[PMID: 27089210]
SK-OV-3	IC₅₀	0.074 μM Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells assessed as reduction in cell proliferation measured after 48 hrs by SRB assay	[PMID: 27856237]
SK-OV-3	IC₅₀	0.078 μM Compound: Doxirubicin	Concentration required to inhibit SKOV-3-cell growth by 50% Concentration required to inhibit SKOV-3-cell growth by 50%	[PMID: 9703471]
SK-OV-3	GI₅₀	0.0789 μM Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells assessed as growth inhibition measured after 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells assessed as growth inhibition measured after 48 hrs by SRB assay	[PMID: 31059248]
SK-OV-3	IC₅₀	0.08 μg/mL Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells by sulforhodamine B assay Cytotoxicity against human SKOV3 cells by sulforhodamine B assay	[PMID: 21684168]
SK-OV-3	GI₅₀	0.0875 μM Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay	[PMID: 31534659]
SK-OV-3	ED₅₀	0.11 μg/mL Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay	[PMID: 11325244]
SK-OV-3	ED₅₀	0.11 μg/mL Compound: adriamycin	Cytotoxicity against human SKOV3 cells by SRB assay Cytotoxicity against human SKOV3 cells by SRB assay	10.1021/np960188t
SK-OV-3	ED₅₀	0.12 μg/mL Compound: doxorubicin	Cytotoxicity against human SKOV3 cells by SRB method Cytotoxicity against human SKOV3 cells by SRB method	[PMID: 16252909]
SK-OV-3	GI₅₀	0.12 μM Compound: Doxorubicin	Growth inhibition of human SKOV3 cells after 72 hrs by SRB assay Growth inhibition of human SKOV3 cells after 72 hrs by SRB assay	[PMID: 18585035]
SK-OV-3	ED₅₀	0.13 μg/mL Compound: doxorubicin	Cytotoxicity against human SKOV3 cells by SRB assay Cytotoxicity against human SKOV3 cells by SRB assay	[PMID: 9392887]
SK-OV-3	IC₅₀	0.16 μM Compound: DOX	Cytotoxicity against human SKOV3 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human SKOV3 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 31999451]
SK-OV-3	IC₅₀	0.17 μM Compound: ADR	Cytotoxicity against human SKOV3 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human SKOV3 cells after 72 hrs by sulforhodamine B assay	[PMID: 20949916]
SK-OV-3	IC₅₀	0.18 μg/mL Compound: adriamycin	Cytotoxicity against human SKOV3 cells by SRB assay Cytotoxicity against human SKOV3 cells by SRB assay	[PMID: 15921426]
SK-OV-3	IC₅₀	0.181 μM Compound: Doxorubicin	Anticancer activity against human SKOV3 cells after 48 hrs by SRB assay Anticancer activity against human SKOV3 cells after 48 hrs by SRB assay	[PMID: 17070967]
SK-OV-3	IC₅₀	0.19 μM Compound: ADM	Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 36332551]
SK-OV-3	IC₅₀	0.2 μM Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red assay relative to control Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red assay relative to control	[PMID: 25975638]
SK-OV-3	GI₅₀	0.22 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay	[PMID: 23871905]
SK-OV-3	GI₅₀	0.22 μM Compound: Doxorubicin	Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
SK-OV-3	GI₅₀	0.22 μM Compound: Doxorubicin	Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SKOV3 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
SK-OV-3	IC₅₀	0.23 μM Compound: doxorubicin	Cytotoxicity against human SK-OV3 cells after 48 hrs Cytotoxicity against human SK-OV3 cells after 48 hrs	[PMID: 17673337]
SK-OV-3	EC₅₀	0.29 μM Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells after 48 hrs by resazurin dye assay Cytotoxicity against human SKOV3 cells after 48 hrs by resazurin dye assay	[PMID: 23988351]
SK-OV-3	IC₅₀	0.29 μM Compound: doxorubicin	Cytotoxicity against human SK-OV-3 cells by SRB assay Cytotoxicity against human SK-OV-3 cells by SRB assay	[PMID: 17194596]
SK-OV-3	IC₅₀	0.321 μM Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red dye based assay Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red dye based assay	[PMID: 29317147]
SK-OV-3	IC₅₀	0.38 μM Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells by SRB assay Cytotoxicity against human SKOV3 cells by SRB assay	[PMID: 20176479]
SK-OV-3	IC₅₀	0.42 μM Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28327308]
SK-OV-3	IC₅₀	0.6 μg/mL Compound: doxorubicin	Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red dye staining Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red dye staining	[PMID: 19928902]
SK-OV-3	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells incubated for 24 hrs by MTT asasy Cytotoxicity against human SKOV3 cells incubated for 24 hrs by MTT asasy	[PMID: 28615134]
SK-OV-3	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells assessed as cell growth inhibition by MTT assay Cytotoxicity against human SKOV3 cells assessed as cell growth inhibition by MTT assay	[PMID: 27187861]
SK-OV-3	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability by MTT assay	[PMID: 26774921]
SK-OV-3	IC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability by MTT assay	[PMID: 26646219]
SK-OV-3	IC₅₀	0.75 μg/mL Compound: doxorubicin	Cytotoxicity against human SK-OV3 cells by neutral red assay Cytotoxicity against human SK-OV3 cells by neutral red assay	[PMID: 17976995]
SK-OV-3	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells by MTT assay Cytotoxicity against human SKOV3 cells by MTT assay	[PMID: 26586599]
SK-OV-3	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells after 48 hrs by Neutral red assay Cytotoxicity against human SKOV3 cells after 48 hrs by Neutral red assay	[PMID: 19658408]
SK-OV-3	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against Homo sapiens (human) SKOV3 cells by neutral red staining Cytotoxicity against Homo sapiens (human) SKOV3 cells by neutral red staining	10.1007/s00044-011-9587-3
SK-OV-3	IC₅₀	1.1 μM Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells assessed as cell growth inhibition after 48 hrs by neutral red assay Cytotoxicity against human SKOV3 cells assessed as cell growth inhibition after 48 hrs by neutral red assay	[PMID: 26005918]
SK-OV-3	IC₅₀	1.17 μM Compound: Doxorubicin	Cytotoxic activity against SKOV-3 human ovarian tumor cell line, using sulforhodamine B (SRB) assay. Cytotoxic activity against SKOV-3 human ovarian tumor cell line, using sulforhodamine B (SRB) assay.	[PMID: 14643344]
SK-OV-3	IC₅₀	1.2 μg/mL Compound: doxorubicin	Cytotoxicity against human SKOV3 cells after 48 hrs by Neutral Red dye Cytotoxicity against human SKOV3 cells after 48 hrs by Neutral Red dye	[PMID: 20550123]
SK-OV-3	IC₅₀	1.3 μg/mL Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells assessed as cell growth inhibition after 48 hrs by neutral red dye based assay Cytotoxicity against human SKOV3 cells assessed as cell growth inhibition after 48 hrs by neutral red dye based assay	[PMID: 27769668]
SK-OV-3	IC₅₀	1.5 μM Compound: doxorubicin	Cytotoxicity against human SKOV3 cells assessed as viable cells by neutral red dye method Cytotoxicity against human SKOV3 cells assessed as viable cells by neutral red dye method	[PMID: 22530813]
SK-OV-3	IC₅₀	1.53 μg/mL Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red staining Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red staining	[PMID: 15165136]
SK-OV-3	IC₅₀	1.7 μM Compound: DOX	Antiproliferative activity against human SKOV3 cells after 48 hrs by MTT assay Antiproliferative activity against human SKOV3 cells after 48 hrs by MTT assay	[PMID: 28756264]
SK-OV-3	IC₅₀	128 nM Compound: Doxorubicin	Cytotoxicity against arrested non-proliferative human SKOV3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against arrested non-proliferative human SKOV3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 30429975]
SK-OV-3	IC₅₀	16.37 μM Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells by MTT assay Cytotoxicity against human SKOV3 cells by MTT assay	[PMID: 26873414]
SK-OV-3	IC₅₀	2.04 μM Compound: doxorubicin	Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red assay Cytotoxicity against human SKOV3 cells after 48 hrs by neutral red assay	[PMID: 19879765]
SK-OV-3	ED₅₀	2.5 ng/mL Compound: Adriamycin	Cytotoxicity against human SKOV3 cells by MTT assay Cytotoxicity against human SKOV3 cells by MTT assay	[PMID: 7714533]
SK-OV-3	IC₅₀	2.6 μM Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay	[PMID: 27618204]
SK-OV-3	IC₅₀	2.6 μM Compound: doxorubicin	Cytotoxicity against human SKOV3 cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against human SKOV3 cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]
SK-OV-3	IC₅₀	2.947 μM Compound: Doxorubicin	Anticancer activity against human SKOV3 cells by MTT assay Anticancer activity against human SKOV3 cells by MTT assay	[PMID: 21570750]
SK-OV-3	IC₅₀	25.04 μM Compound: Doxo	Cytotoxicity against human SKOV3 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay Cytotoxicity against human SKOV3 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay	[PMID: 27036521]
SK-OV-3	IC₅₀	25.83 nM Compound: Doxorubicin	Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition measured after 72 hrs by crystal violet staining based assay Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition measured after 72 hrs by crystal violet staining based assay	[PMID: 34795858]
SK-OV-3	IC₅₀	3 μM Compound: DOX	Cytotoxicity against human SKOV3 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human SKOV3 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 31589431]
SK-OV-3	IC₅₀	3.12 μM Compound: DOX	Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 36252396]
SK-OV-3	IC₅₀	32.6 nM Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human SKOV3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 30429975]
SK-OV-3	IC₅₀	34.2 nM Compound: Doxorubicin	Antiproliferative activity against human SKOV3 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay Antiproliferative activity against human SKOV3 cells assessed as reduction in cell viability incubated for 24 hrs by SRB assay	[PMID: 31655432]
SK-OV-3	IC₅₀	36 nM Compound: Doxorubicin	Human tumor cell cytotoxicity assay was performed using MTT (SK-OV3 cell line ) Human tumor cell cytotoxicity assay was performed using MTT (SK-OV3 cell line )	[PMID: 8576914]
SK-OV-3	IC₅₀	36 nM Compound: Doxorubicin	Cytotoxicity was determined in vitro in SK-OV-3 cells (ovarian) of human tumor cell lines by using MTT assay Cytotoxicity was determined in vitro in SK-OV-3 cells (ovarian) of human tumor cell lines by using MTT assay	[PMID: 7853331]
SK-OV-3	IC₅₀	4.15 μM Compound: Doxorubicin	Cytotoxicity against human ovarian adenocarcinoma (SK-OV-3) cell line using MTT assay Cytotoxicity against human ovarian adenocarcinoma (SK-OV-3) cell line using MTT assay	[PMID: 9873387]
SK-OV-3	IC₅₀	4.16 nM Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells by MTT assay Cytotoxicity against human SKOV3 cells by MTT assay	[PMID: 19345581]
SK-OV-3	IC₅₀	4.16 μM Compound: Doxorubicin	Cytotoxicity against human SKOV3 cells after 3 days by MTT assay Cytotoxicity against human SKOV3 cells after 3 days by MTT assay	[PMID: 20356655]
SK-OV-3	IC₅₀	41 nM Compound: Doxorubicine	Cytotoxicity against human SKOV3 cells after 72 hrs by MTS assay Cytotoxicity against human SKOV3 cells after 72 hrs by MTS assay	[PMID: 21142180]
SK-OV-3	IC₅₀	5 μM Compound: Dox	Cytotoxicity against human SKOV3 cells after 48 hrs Cytotoxicity against human SKOV3 cells after 48 hrs	[PMID: 22276998]
SK-OV-3	IC₅₀	55.7 μM Compound: DOX	Cytotoxicity against human SKOV3 cells after 24 hrs by XTT assay Cytotoxicity against human SKOV3 cells after 24 hrs by XTT assay	[PMID: 24900668]
SK-OV-3	IC₅₀	6.7 μM Compound: Doxorubicin	Cytotoxicity against human SK-OV-3 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay Cytotoxicity against human SK-OV-3 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay	[PMID: 36970146]
SK-OV-3	GI₅₀	8.8 μM Compound: Dox	Antiproliferative activity against human SK-OV-3 cells incubated for 72 hrs and measured by MTT assay Antiproliferative activity against human SK-OV-3 cells incubated for 72 hrs and measured by MTT assay	[PMID: 35973342]
SK-OV-3	GI₅₀	9.1 μM Compound: Dox	Anticancer activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Anticancer activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35533562]
SK-UT-1	IC₅₀	0.076 μM Compound: Doxorubicin	Cytotoxicity against human SK-UT-1 cells after 72 hrs by resazurin/resorufin-based fluorescence assay Cytotoxicity against human SK-UT-1 cells after 72 hrs by resazurin/resorufin-based fluorescence assay	[PMID: 23600925]
SK-VLB	IC₅₀	0.009 μM Compound: Doxorubicin	Antiproliferative activity against human SK-VLB cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human SK-VLB cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 27010926]
SK-VLB	IC₅₀	5600 nM Compound: Doxorubicin	Human tumor cell cytotoxicity assay was performed using MTT (SKVLB cell line ) Human tumor cell cytotoxicity assay was performed using MTT (SKVLB cell line )	[PMID: 8576914]
SK-VLB	IC₅₀	5650 nM Compound: Doxorubicin	Cytotoxicity was determined in vitro in SKVLB cells(ovarian with upregulated MDRp-glycoprotein) of human tumor cell lines by using MTT assay Cytotoxicity was determined in vitro in SKVLB cells(ovarian with upregulated MDRp-glycoprotein) of human tumor cell lines by using MTT assay	[PMID: 7853331]
SK-VLB	IC₅₀	6.54 μM Compound: Doxorubicin	Inhibitory concentration that reduced the viability of SKVLB cell population by 50%. Inhibitory concentration that reduced the viability of SKVLB cell population by 50%.	[PMID: 9003520]
SMMC-7721	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human SMMC7721 cells after 24 hrs by MTT assay Cytotoxicity against human SMMC7721 cells after 24 hrs by MTT assay	[PMID: 25554367]
SMMC-7721	IC₅₀	0.37 μM Compound: Doxorubicin	Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 22537362]
SMMC-7721	IC₅₀	0.37 μM Compound: doxorubicin	Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 21087017]
SMMC-7721	IC₅₀	0.46 μM Compound: Doxorubicin	Anticancer activity against human SMMC-7721 cells incubated for 48 hrs by MTT assay Anticancer activity against human SMMC-7721 cells incubated for 48 hrs by MTT assay	[PMID: 35367708]
SMMC-7721	IC₅₀	0.57 μM Compound: Doxorubicin	Cytotoxicity against human SMMC7721 cells assessed as growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human SMMC7721 cells assessed as growth inhibition incubated for 72 hrs by MTT assay	[PMID: 26280922]
SMMC-7721	IC₅₀	0.706 μM Compound: Doxorubicin	Cytotoxicity against human SMMC-7721 cells by SRB assay Cytotoxicity against human SMMC-7721 cells by SRB assay	[PMID: 34128674]
SMMC-7721	IC₅₀	0.73 μM Compound: ADM	Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 30025345]
SMMC-7721	IC₅₀	1.02 μM Compound: Doxorubicin	Cytotoxicity against human SMMC-7721 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human SMMC-7721 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 34838335]
SMMC-7721	IC₅₀	1.06 μM Compound: Doxorubicin	Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 20846862]
SMMC-7721	IC₅₀	1.1 μM Compound: doxorubicin	Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 25314138]
SMMC-7721	IC₅₀	1.2 μM Compound: Doxorubicin	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
SMMC-7721	IC₅₀	1.22 μM Compound: AMD	Anticancer activity against human SMMC7721 cells assessed as cell survival after 48 hrs by MTT assay Anticancer activity against human SMMC7721 cells assessed as cell survival after 48 hrs by MTT assay	[PMID: 25812966]
SMMC-7721	IC₅₀	1.39 μM Compound: Dox	Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 27397495]
SMMC-7721	IC₅₀	1.4 μM Compound: DOX	Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 32371335]
SMMC-7721	IC₅₀	1.47 μM Compound: DOX	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29909338]
SMMC-7721	IC₅₀	1.59 μM Compound: Doxorubicin	Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay	[PMID: 29172084]
SMMC-7721	IC₅₀	1.8 μM Compound: DOX	Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay	[PMID: 34450496]
SMMC-7721	IC₅₀	1.95 μM Compound: AMD	Antiproliferative activity against human SMMC-7721 cells measured after 48 hrs by MTT assay Antiproliferative activity against human SMMC-7721 cells measured after 48 hrs by MTT assay	[PMID: 27639364]
SMMC-7721	IC₅₀	2.3 μM Compound: Doxorubicin	Antiproliferative activity against human SMMC7721 cells by MTT assay Antiproliferative activity against human SMMC7721 cells by MTT assay	[PMID: 30660827]
SMMC-7721	IC₅₀	2.5 μM Compound: Doxorubicin	Antiproliferative activity against human SMMC7721 cells after 24 to 72 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 24 to 72 hrs by MTT assay	[PMID: 30660827]
SMMC-7721	IC₅₀	2.75 μM Compound: DOX	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 30771605]
SN12C	GI₅₀	0.07 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human SN12C cells after 48 hrs by SRB assay Cytotoxicity against human SN12C cells after 48 hrs by SRB assay	[PMID: 23871905]
SN12C	GI₅₀	0.07 μM Compound: Doxorubicin	Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
SN12C	GI₅₀	0.07 μM Compound: Doxorubicin	Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SN12C cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
SNB-19	ED₅₀	0.002 μg/mL Compound: Doxorubicin	Cytotoxicity against human SNB19 cells by sulforhodamine B method Cytotoxicity against human SNB19 cells by sulforhodamine B method	[PMID: 12193011]
SNB-19	GI₅₀	0.04 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human SNB19 cells after 48 hrs by SRB assay Cytotoxicity against human SNB19 cells after 48 hrs by SRB assay	[PMID: 23871905]
SNB-19	GI₅₀	0.04 μM Compound: Doxorubicin	Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
SNB-19	GI₅₀	0.04 μM Compound: Doxorubicin	Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SNB19 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
SNB-19	IC₅₀	0.15 μM Compound: DOX	Antiproliferative activity against human SNB19 cells after 72 hrs by MTT assay Antiproliferative activity against human SNB19 cells after 72 hrs by MTT assay	[PMID: 30429098]
SNB-19	IC₅₀	0.76 μM Compound: Doxorubicin	Antiproliferative activity against human SNB-19 cells assessed as reduction in cell viability by MTT assay Antiproliferative activity against human SNB-19 cells assessed as reduction in cell viability by MTT assay	[PMID: 34715305]
SNB-19	IC₅₀	0.8 μM Compound: Doxorubicin	Antitumor activity against human SNB19 cells after 24 to 48 hrs by MTT assay Antitumor activity against human SNB19 cells after 24 to 48 hrs by MTT assay	[PMID: 21553829]
SNB-19	IC₅₀	1.2 μM Compound: Doxorubicin	Cytotoxicity against human SNB-19 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human SNB-19 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 34778772]
SNB-75	GI₅₀	0.07 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human SNB75 cells after 48 hrs by SRB assay Cytotoxicity against human SNB75 cells after 48 hrs by SRB assay	[PMID: 23871905]
SNB-75	GI₅₀	0.07 μM Compound: Doxorubicin	Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
SNB-75	GI₅₀	0.07 μM Compound: Doxorubicin	Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SNB75 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
SNU1	IC₅₀	0.27 μg/mL Compound: Doxorubicin	In vitro cytotoxic activity against SNU-1(stomach cancer cell) by using SRB assay after 72 hr of drug exposure In vitro cytotoxic activity against SNU-1(stomach cancer cell) by using SRB assay after 72 hr of drug exposure	10.1016/0960-894X(96)00156-4
SNU1	IC₅₀	4 μM Compound: adriamycin	Cytotoxicity against human SNU1 cells by rapid colorimetric assay Cytotoxicity against human SNU1 cells by rapid colorimetric assay	[PMID: 19585998]
SNU-354	IC₅₀	0.54 μg/mL Compound: Doxorubicin	In vitro cytotoxic activity against SNU-354(liver cancer cell) by using SRB assay after 72 hr of drug exposure In vitro cytotoxic activity against SNU-354(liver cancer cell) by using SRB assay after 72 hr of drug exposure	10.1016/0960-894X(96)00156-4
SNU-398	GI₅₀	0.39 μM Compound: Doxorubicin	Induction of apoptosis in human SNU398 cells assessed as caspase activation after 48 hrs Induction of apoptosis in human SNU398 cells assessed as caspase activation after 48 hrs	[PMID: 19282188]
SNU-5	IC₅₀	0.237 μM Compound: ADR	Antiproliferative activity against human SNU5 cells after 72 hrs by CCK8 assay Antiproliferative activity against human SNU5 cells after 72 hrs by CCK8 assay	[PMID: 30241010]
SNU-638	IC₅₀	0.052 μM Compound: doxorubicin	Cytotoxicity against human SNU638 cells after 3 days by SRB assay Cytotoxicity against human SNU638 cells after 3 days by SRB assay	[PMID: 18321715]
SNU-638	IC₅₀	0.06 μM Compound: doxorubicin	Cytotoxicity against human SNU638 cells by SRB assay Cytotoxicity against human SNU638 cells by SRB assay	[PMID: 17194596]
SNU-638	IC₅₀	0.07 μM Compound: Doxorubicin	Antiproliferative activity against human SNU638 cells after 72 hrs by SRB assay Antiproliferative activity against human SNU638 cells after 72 hrs by SRB assay	[PMID: 18063366]
SNU-638	GI₅₀	0.13 μM Compound: Doxorubicin	Growth inhibition of human HCT116 cells after 2 days by SRB assay Growth inhibition of human HCT116 cells after 2 days by SRB assay	[PMID: 22000924]
SNU-638	IC₅₀	0.84 μM Compound: Adriamycin	Cytotoxicity against human SNU638 cells by MTT assay Cytotoxicity against human SNU638 cells by MTT assay	[PMID: 23608763]
SR	GI₅₀	0.03 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human SR cells after 48 hrs by SRB assay Cytotoxicity against human SR cells after 48 hrs by SRB assay	[PMID: 23871905]
SR	GI₅₀	0.03 μM Compound: Doxorubicin	Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
SR	GI₅₀	0.03 μM Compound: Doxorubicin	Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
SUM149PT	IC₅₀	0.36 μM Compound: Doxorubicin	Antiproliferative activity against human SUM149PT cells after 48 hrs by SRB assay Antiproliferative activity against human SUM149PT cells after 48 hrs by SRB assay	[PMID: 29407962]
SUP-T1	IC₅₀	0.04 μM Compound: Doxorubicin	Cytotoxicity against human SupT1 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human SupT1 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27623548]
SW 1116	IC₅₀	6.9 μM Compound: Doxorubicin	Antiproliferative activity against human SW1116 cells assessed as inhibition of cell growth after overnight incubation by MTT assay Antiproliferative activity against human SW1116 cells assessed as inhibition of cell growth after overnight incubation by MTT assay	[PMID: 32165076]
SW1990	IC₅₀	> 100 μM Compound: Doxorubicin	Cytotoxicity against human SW1990 cells after 48 hrs by MTT assay Cytotoxicity against human SW1990 cells after 48 hrs by MTT assay	[PMID: 22304344]
SW480	IC₅₀	0.06 μM Compound: Doxorubicin	Anticancer activity against human SW480 cells after 48 hrs by MTT assay Anticancer activity against human SW480 cells after 48 hrs by MTT assay	[PMID: 21641694]
SW480	IC₅₀	0.29 μM Compound: Doxorubicin	Cytotoxicity against human SW480 cells assessed as growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as growth inhibition measured after 72 hrs by MTT assay	[PMID: 31383628]
SW480	IC₅₀	0.406 μM Compound: Doxorubicin	Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay	[PMID: 28406643]
SW480	IC₅₀	0.53 μM Compound: Doxorubicin	Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay	10.1039/C5MD00163C
SW480	IC₅₀	0.75 μM Compound: DOX	Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31678743]
SW480	IC₅₀	2.43 μM Compound: Doxorubicin	Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay	[PMID: 24418772]
SW480	IC₅₀	65.25 μM Compound: Doxorubicin	Cytotoxicity against human SW480 cells after 24 hrs by MTT assay Cytotoxicity against human SW480 cells after 24 hrs by MTT assay	[PMID: 22182926]
SW-620	IC₅₀	> 10 μg/mL Compound: doxorubicin	Cytotoxicity against human SW620 cells after 3 days by MTT assay Cytotoxicity against human SW620 cells after 3 days by MTT assay	[PMID: 19456120]
SW-620	ED₅₀	0.003 μg/mL Compound: Doxorubicin	Cytotoxicity against human SW620 cells by sulforhodamine B method Cytotoxicity against human SW620 cells by sulforhodamine B method	[PMID: 12193011]
SW-620	IC₅₀	0.01 μM Compound: Adriamycin	Cytotoxicity against human SW620 cells after 72 hrs by MTT assay Cytotoxicity against human SW620 cells after 72 hrs by MTT assay	[PMID: 21721528]
SW-620	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human SW620 cells after 72 hrs by MTT assay Cytotoxicity against human SW620 cells after 72 hrs by MTT assay	[PMID: 20207049]
SW-620	IC₅₀	0.02 μM Compound: DOX	Antitumor activity against human SW620 cells after 72 hrs by MTT assay Antitumor activity against human SW620 cells after 72 hrs by MTT assay	[PMID: 17935309]
SW-620	GI₅₀	0.03 μM Compound: Doxorubicin	Growth inhibition of Homo sapiens (human) SW620 cells after 48 hr by MTT assay Growth inhibition of Homo sapiens (human) SW620 cells after 48 hr by MTT assay	10.1007/s00044-012-0232-6
SW-620	IC₅₀	0.04 μM Compound: Doxorubicin	Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay	[PMID: 22555152]
SW-620	IC₅₀	0.08 μM Compound: Doxorubicin	Cytotoxicity against human SW620 cells after 72 hrs by MTT assay Cytotoxicity against human SW620 cells after 72 hrs by MTT assay	[PMID: 19361894]
SW-620	GI₅₀	0.09 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human SW620 cells after 48 hrs by SRB assay Cytotoxicity against human SW620 cells after 48 hrs by SRB assay	[PMID: 23871905]
SW-620	GI₅₀	0.09 μM Compound: Doxorubicin	Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
SW-620	GI₅₀	0.09 μM Compound: Doxorubicin	Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SW620 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
SW-620	IC₅₀	0.11 μM Compound: Doxorubicin	Antiproliferative activity against human SW620 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human SW620 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31975579]
SW-620	IC₅₀	0.12 μM Compound: Doxorubicin	Antitumor activity against human SW620 cells after 24 to 48 hrs by MTT assay Antitumor activity against human SW620 cells after 24 to 48 hrs by MTT assay	[PMID: 21553829]
SW-620	IC₅₀	0.12 μM Compound: Adriamycin	Cytotoxicity against human SW620 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay Cytotoxicity against human SW620 cells assessed as inhibition of cell proliferation after 48 hrs by XTT assay	[PMID: 24717154]
SW-620	IC₅₀	0.17 μM Compound: Doxorubicin	Growth inhibition of human SW620 cells after 72 hrs by SRB assay Growth inhibition of human SW620 cells after 72 hrs by SRB assay	[PMID: 25215856]
SW-620	IC₅₀	0.178 μM Compound: Doxorubicin	Cytotoxicity against human SW620 cells after 24 hrs by SRB method Cytotoxicity against human SW620 cells after 24 hrs by SRB method	[PMID: 18429610]
SW-620	IC₅₀	0.21 μM Compound: Doxorubicin	Cytotoxicity against human SW620 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human SW620 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29501942]
SW-620	IC₅₀	0.23 μM Compound: Dox	Cytotoxicity against human SW620 cells after 3 days by MTT assay Cytotoxicity against human SW620 cells after 3 days by MTT assay	[PMID: 21741833]
SW-620	IC₅₀	0.24 μM Compound: Adriamycin	Cytotoxicity against human SW620 cells selected at 20 ng/mL adriamycin after 72 hrs by MTT assay Cytotoxicity against human SW620 cells selected at 20 ng/mL adriamycin after 72 hrs by MTT assay	[PMID: 21721528]
SW-620	IC₅₀	0.26 μM Compound: DOX	Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31678743]
SW-620	IC₅₀	0.29 μM Compound: DOXO	Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay	[PMID: 28818447]
SW-620	IC₅₀	0.77 μM Compound: Dox	Cytotoxicity against human SW620 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human SW620 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31306817]
SW-620	IC₅₀	1.33 μM Compound: DOX	Antiproliferative activity against human SW620 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human SW620 cells after 72 hrs by sulforhodamine B assay	[PMID: 25981689]
SW620/AD300	IC₅₀	15.24 μM Compound: Doxorubicin	Cytotoxicity against human SW620/AD300 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human SW620/AD300 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29501942]
SW620/AD300	IC₅₀	28.2 μM Compound: Doxorubicin	Growth inhibition of human SW620/AD300 cells after 72 hrs by SRB assay Growth inhibition of human SW620/AD300 cells after 72 hrs by SRB assay	[PMID: 25215856]
SW620/AD300	IC₅₀	4.9 μM Compound: Doxorubicin	Antiproliferative activity against human SW620/AD300 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human SW620/AD300 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31975579]
SW872	IC₅₀	0.14 μM Compound: Doxorubicin	Cytotoxicity against human SW872 cells after 72 hrs by resazurin/resorufin-based fluorescence assay Cytotoxicity against human SW872 cells after 72 hrs by resazurin/resorufin-based fluorescence assay	[PMID: 23600925]
T-24	IC₅₀	0.96 μM Compound: DOX	Cytotoxicity against human T24 cells after 48 hrs by MTT assay Cytotoxicity against human T24 cells after 48 hrs by MTT assay	[PMID: 31057738]
T47D	IC₅₀	0.007 μM Compound: Doxorubicin	Inhibitory activity against T47D cell line using MTT assay (ER+,mutant p53) Inhibitory activity against T47D cell line using MTT assay (ER+,mutant p53)	[PMID: 10780913]
T47D	IC₅₀	0.007 μM Compound: 1 (Doxorubicin)	In vitro cytotoxic activity against human breast cancer cell line T-47D after 72 hr of drug exposure determined by the SRB assay In vitro cytotoxic activity against human breast cancer cell line T-47D after 72 hr of drug exposure determined by the SRB assay	[PMID: 14980672]
T47D	IC₅₀	0.02 μM Compound: Doxorubicin	Antiproliferative activity against human T47D cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method Antiproliferative activity against human T47D cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	[PMID: 25937235]
T47D	IC₅₀	0.027 μM Compound: adriamycin	Antitumor activity against human T47D cells by methylene blue staining method Antitumor activity against human T47D cells by methylene blue staining method	[PMID: 17656091]
T47D	GI₅₀	0.06 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human T47D cells after 48 hrs by SRB assay Cytotoxicity against human T47D cells after 48 hrs by SRB assay	[PMID: 23871905]
T47D	GI₅₀	0.06 μM Compound: Doxorubicin	Growth inhibition of human T47D cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human T47D cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
T47D	GI₅₀	0.06 μM Compound: Doxorubicin	Growth inhibition of human T47D cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human T47D cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
T47D	IC₅₀	0.08 μM Compound: Doxorubicin	Antiproliferative activity against 2D culture of human T47D cells after 72 hrs MTS assay Antiproliferative activity against 2D culture of human T47D cells after 72 hrs MTS assay	[PMID: 27721156]
T47D	IC₅₀	0.1 μM Compound: Doxorubicin	Antiproliferative activity against human T47D cells after 72 hrs by SRB assay Antiproliferative activity against human T47D cells after 72 hrs by SRB assay	[PMID: 18063366]
T47D	IC₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity against human T47D cells after 72 hrs by resazurin/resorufin-based fluorescence assay Cytotoxicity against human T47D cells after 72 hrs by resazurin/resorufin-based fluorescence assay	[PMID: 23600925]
T47D	IC₅₀	0.16 μM Compound: Dox	Antiproliferative activity against human T47D cells assessed as growth inhibition under normoxia conditions measured after 72 hrs by MTT assay Antiproliferative activity against human T47D cells assessed as growth inhibition under normoxia conditions measured after 72 hrs by MTT assay	[PMID: 34902732]
T47D	IC₅₀	0.18 μM Compound: Dox	Antiproliferative activity against human T47D cells assessed as growth inhibition under hypoxia conditions measured after 72 hrs by MTT assay Antiproliferative activity against human T47D cells assessed as growth inhibition under hypoxia conditions measured after 72 hrs by MTT assay	[PMID: 34902732]
T47D	IC₅₀	0.25 μM Compound: Doxorubicin	Cytotoxicity against human T47D cells after 2 days by MTT assay Cytotoxicity against human T47D cells after 2 days by MTT assay	[PMID: 20800481]
T47D	IC₅₀	0.33 μM Compound: Doxorubicin	Cytotoxicity against human T47D cells after 72 hrs by MTT assay Cytotoxicity against human T47D cells after 72 hrs by MTT assay	[PMID: 22677031]
T47D	IC₅₀	0.41 μM Compound: Adriamycin	Cytotoxicity against human T47D cells after 2 days by CCK-8 assay Cytotoxicity against human T47D cells after 2 days by CCK-8 assay	[PMID: 24013413]
T47D	EC₅₀	0.57 μM Compound: Doxorubicin	Induction of apoptosis in human T47D cells assessed as caspase activation after 48 hrs Induction of apoptosis in human T47D cells assessed as caspase activation after 48 hrs	[PMID: 19282188]
T47D	IC₅₀	0.7 μM Compound: Doxorubicin	Antiproliferative activity against human T47D cells assessed as reduction in cell growth after 24 hrs by MTS assay Antiproliferative activity against human T47D cells assessed as reduction in cell growth after 24 hrs by MTS assay	[PMID: 25300820]
T47D	IC₅₀	0.84 μM Compound: Dox	Cytotoxicity against human T47D cells after 2 days Cytotoxicity against human T47D cells after 2 days	[PMID: 24904965]
T47D	IC₅₀	0.88 μM Compound: Doxorubicin	Cytotoxicity against human T47D cells assessed as reduction in cell growth measured after 48 hrs by MTT assay Cytotoxicity against human T47D cells assessed as reduction in cell growth measured after 48 hrs by MTT assay	[PMID: 31416738]
T47D	IC₅₀	1 μM Compound: Doxorubicin	Antiproliferative activity against human T47D cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human T47D cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
T47D	IC₅₀	1.01 μM Compound: Doxorubicin	Antiproliferative activity against 3D culture of human T47D cells after 72 hrs MTS assay Antiproliferative activity against 3D culture of human T47D cells after 72 hrs MTS assay	[PMID: 27721156]
T47D	IC₅₀	1.05 μM Compound: Adriamycin	Cytotoxicity against human T47D cells after 2 days by cell counting kit-8 analysis Cytotoxicity against human T47D cells after 2 days by cell counting kit-8 analysis	[PMID: 22503656]
T47D	IC₅₀	1.34 μM Compound: adriamycin	Cytotoxicity against human T47D cells measured on day 4 by CCK8 assay Cytotoxicity against human T47D cells measured on day 4 by CCK8 assay	[PMID: 25936262]
T47D	IC₅₀	1.82 μM Compound: ADR	Cytotoxicity against human T47D cells after 72 hrs by MTT assay Cytotoxicity against human T47D cells after 72 hrs by MTT assay	[PMID: 22819942]
T47D	IC₅₀	1.88 μM Compound: Adriamycin	Cytotoxicity against human T47D cells after 2 days by CCK8 assay Cytotoxicity against human T47D cells after 2 days by CCK8 assay	[PMID: 26361737]
T47D	IC₅₀	1.9 μM Compound: doxorubicin	Cytotoxicity against human T47D cells after 72 hrs by CellTiter-Glo assay Cytotoxicity against human T47D cells after 72 hrs by CellTiter-Glo assay	[PMID: 22316168]
T47D	IC₅₀	1.9 μM Compound: DOX	Cytotoxicity against human T47D cells measured after 2 days by MTT assay Cytotoxicity against human T47D cells measured after 2 days by MTT assay	[PMID: 26334499]
T47D	IC₅₀	15.53 μM Compound: DOX	Anticancer activity against human T47D cells assessed as inhibition of tumor cell proliferation after 48 hrs by MTT assay Anticancer activity against human T47D cells assessed as inhibition of tumor cell proliferation after 48 hrs by MTT assay	[PMID: 25064350]
T47D	IC₅₀	2.91 μM Compound: Adriamycin	Cytotoxicity against human T47D cells by MTT assay Cytotoxicity against human T47D cells by MTT assay	[PMID: 23608763]
T47D	IC₅₀	3.2 μM Compound: Doxorubicin	Antiproliferative activity against human T47D cells assessed as cell growth inhibition incubated for 4 hrs under normoxia condition by MTT colorimetric assay Antiproliferative activity against human T47D cells assessed as cell growth inhibition incubated for 4 hrs under normoxia condition by MTT colorimetric assay	[PMID: 35551035]
T47D	IC₅₀	3.8 μM Compound: Doxorubicin	Antiproliferative activity against human T47D cells assessed as cell growth inhibition incubated for 4 hrs under hypoxia condition by MTT colorimetric assay Antiproliferative activity against human T47D cells assessed as cell growth inhibition incubated for 4 hrs under hypoxia condition by MTT colorimetric assay	[PMID: 35551035]
T47D	IC₅₀	4.61 μM Compound: DOX	Cytotoxicity against human T47D cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human T47D cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28531811]
T47D	IC₅₀	72 nM Compound: Doxorubicin	Cytotoxicity was determined in vitro in T47D cells(breast) of human tumor cell lines by using MTT assay Cytotoxicity was determined in vitro in T47D cells(breast) of human tumor cell lines by using MTT assay	[PMID: 7853331]
T47D	IC₅₀	9.8 μM Compound: Doxorubicin	Antiproliferative activity against human T47D cells after 48 hrs by SRB assay Antiproliferative activity against human T47D cells after 48 hrs by SRB assay	[PMID: 28427017]
T47D	IC₅₀	9.8 μM Compound: Doxorubicin	Cytotoxicity against human T47D cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human T47D cells after 48 hrs by sulforhodamine B assay	[PMID: 27770735]
T98G	IC₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity against p53 mutated human T98G cells asessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against p53 mutated human T98G cells asessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 31324563]
T98G	IC₅₀	0.5 μM Compound: doxorubicin	Antiproliferative activity against human T98G cells after 24 hrs by EZ-Tox assay Antiproliferative activity against human T98G cells after 24 hrs by EZ-Tox assay	[PMID: 26631318]
T98G	IC₅₀	1 μM Compound: Doxorubicin	Cytotoxicity against human T98G cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay Cytotoxicity against human T98G cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay	[PMID: 36970146]
T98G	IC₅₀	7 μM Compound: Doxorubicin	Cytotoxicity against human T98G cells assessed as reduction in cell viability by DAPI staining based assay Cytotoxicity against human T98G cells assessed as reduction in cell viability by DAPI staining based assay	[PMID: 33461146]
TERT-RPE1	IC₅₀	< 6.25 μM Compound: DOX	Cytotoxicity against hTERT-RPE1 cells after 48 hrs by resazurin dye-based fluorescence assay Cytotoxicity against hTERT-RPE1 cells after 48 hrs by resazurin dye-based fluorescence assay	[PMID: 29665526]
TERT-RPE1	IC₅₀	1 μM Compound: Dox	Cytotoxicity against human TERT-RPE1 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Cytotoxicity against human TERT-RPE1 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 32428792]
TERT-RPE1	IC₅₀	13.965 μM Compound: Dox	Cytotoxicity against human RPE1 cells after 48 hrs by resazurin assay Cytotoxicity against human RPE1 cells after 48 hrs by resazurin assay	[PMID: 29107422]
TERT-RPE1	IC₅₀	2.76 μM Compound: ADR	Cytotoxicity in human hTERT-RPE1 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity in human hTERT-RPE1 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 28754470]
THLE-2	CC₅₀	12.7 μM Compound: Doxorubicin	Cytotoxicity against human THLE2 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human THLE2 cells assessed as reduction in cell viability by MTT assay	[PMID: 33784602]
THP-1	IC₅₀	0.008 μM Compound: Doxorubicin	Cytotoxicity against human THP1 cells after 72 hrs by flow cytometry Cytotoxicity against human THP1 cells after 72 hrs by flow cytometry	[PMID: 20833057]
THP-1	IC₅₀	0.008 μM Compound: Doxorubicin	Cytotoxicity against human THP1 cells after 72 hrs by MTT assay Cytotoxicity against human THP1 cells after 72 hrs by MTT assay	[PMID: 25846065]
THP-1	CC₅₀	0.008 μM Compound: Doxorubicin	Cytotoxicity against human THP1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 25559208]
THP-1	IC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human THP-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human THP-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34782182]
THP-1	IC₅₀	0.05 μM Compound: Doxorubicin	Cytotoxicity against human THP1 cells assessed as cell viability after 72 hrs by Alamar blue assay Cytotoxicity against human THP1 cells assessed as cell viability after 72 hrs by Alamar blue assay	[PMID: 19914747]
THP-1	IC₅₀	0.05 μM Compound: Doxorubicin	Cytotoxicity against human THP1 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24650715]
THP-1	IC₅₀	0.05 μM Compound: doxorubicin	Cytotoxicity against human THP1 cells by MTT assay Cytotoxicity against human THP1 cells by MTT assay	[PMID: 17981462]
THP-1	IC₅₀	0.05 μM Compound: Doxorubicine	Cytotoxicity against human THP1 cells after 72 hrs by propidium iodide staining-based flow cytometry Cytotoxicity against human THP1 cells after 72 hrs by propidium iodide staining-based flow cytometry	[PMID: 19748781]
THP-1	IC₅₀	0.07 μM Compound: Doxorubicin	Cytotoxicity against human THP1 cells using propidium iodide staining after 72 hrs by flow cytometry Cytotoxicity against human THP1 cells using propidium iodide staining after 72 hrs by flow cytometry	[PMID: 20638854]
THP-1	IC₅₀	0.11 μM Compound: Doxorubicin	Antiproliferative activity against human THP1 cells after 72 hrs by XTT assay Antiproliferative activity against human THP1 cells after 72 hrs by XTT assay	10.1039/C1MD00234A
THP-1	CC₅₀	0.58 μM Compound: Doxorubicin	Cytotoxicity against human THP1 cells assessed as growth inhibition after 120 hrs by Alamar blue dye based fluorometric analysis Cytotoxicity against human THP1 cells assessed as growth inhibition after 120 hrs by Alamar blue dye based fluorometric analysis	[PMID: 33493972]
THP-1	GI₅₀	0.6 μM Compound: Dox	Cytotoxicity against human THP-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human THP-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]
THP-1	IC₅₀	0.67 μM Compound: DOX	Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29421568]
THP-1	CC₅₀	0.7 μM Compound: Doxorubicin	Cytotoxicity against human THP-1 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human THP-1 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 32652409]
THP-1	CC₅₀	1.4 μM Compound: Doxorubicin	Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30092366]
THP-1	IC₅₀	1.8 μM Compound: Doxorubicin	Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 120 hrs by alamar blue assay Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 120 hrs by alamar blue assay	[PMID: 32073851]
THP-1	IC₅₀	15.7 μg/mL Compound: Doxorubicin	Cytotoxicity against human THP-1 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human THP-1 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 35526504]
THP-1	GI₅₀	23.1 μM Compound: Dox	Antiproliferative activity against human THP-1 cells incubated for 72 hrs and measured by MTT assay Antiproliferative activity against human THP-1 cells incubated for 72 hrs and measured by MTT assay	[PMID: 35973342]
THP-1	IC₅₀	3 μg/mL Compound: Doxorubicin	Cytotoxicity against human THP-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human THP-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 35526504]
THP-1	IC₅₀	3.5 μM Compound: Doxorubicin	Antiproliferative activity against human THP1 cells after 48 hrs by MTT assay Antiproliferative activity against human THP1 cells after 48 hrs by MTT assay	[PMID: 25453802]
THP-1	IC₅₀	6.5 μg/mL Compound: Doxorubicin	Cytotoxicity against human THP-1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against human THP-1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 35526504]
THP-1	IC₅₀	7.19 μM Compound: DOX	Antiproliferative activity against human THP1 cells after 48 hrs by MTT assay Antiproliferative activity against human THP1 cells after 48 hrs by MTT assay	[PMID: 27108400]
TK-10	IC₅₀	0.02 μM Compound: Doxorubicin	Antiproliferative activity against human TK10 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method Antiproliferative activity against human TK10 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	[PMID: 25937235]
TK-10	GI₅₀	0.18 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human TK10 cells after 48 hrs by SRB assay Cytotoxicity against human TK10 cells after 48 hrs by SRB assay	[PMID: 23871905]
TK-10	GI₅₀	0.38 μM Compound: Doxorubicin	Growth inhibition of human TK10 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human TK10 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
TK-10	GI₅₀	0.38 μM Compound: Doxorubicin	Growth inhibition of human TK10 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human TK10 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
TK-10	GI₅₀	57 x 10^-2 μM Compound: doxorubicin	Cytotoxicity against human TK10 cells by SRB assay Cytotoxicity against human TK10 cells by SRB assay	[PMID: 11678649]
TRAMP-C1A	GI₅₀	20.4 nM Compound: Doxorubicin	Cytotoxicity against mouse TRAMP-C1A cells assessed as inhibition of cell growth measured for 72 hrs by MTT assay Cytotoxicity against mouse TRAMP-C1A cells assessed as inhibition of cell growth measured for 72 hrs by MTT assay	[PMID: 31945642]
TRAMP-C1A	GI₅₀	20.4 nM Compound: DOX	Growth inhibition of mouse C1A cells after 72 hrs by MTT assay Growth inhibition of mouse C1A cells after 72 hrs by MTT assay	[PMID: 17181166]
TRAMP-C1A	IC₅₀	75.9 nM Compound: Doxorubicin	Inhibitory concentration to inhibit growth of C1A prostate cancer cell line by using MTT assay Inhibitory concentration to inhibit growth of C1A prostate cancer cell line by using MTT assay	[PMID: 14971910]
TRAMP-C2H	GI₅₀	15.8 nM Compound: Doxorubicin	Cytotoxicity against mouse TRAMP-C2H cells assessed as inhibition of cell growth measured for 72 hrs by MTT assay Cytotoxicity against mouse TRAMP-C2H cells assessed as inhibition of cell growth measured for 72 hrs by MTT assay	[PMID: 31945642]
TRAMP-C2H	GI₅₀	15.8 nM Compound: DOX	Growth inhibition of mouse C2H cells after 72 hrs by MTT assay Growth inhibition of mouse C2H cells after 72 hrs by MTT assay	[PMID: 17181166]
TRAMP-C2H	IC₅₀	30.3 nM Compound: Doxorubicin	Inhibitory concentration to inhibit growth of C2H prostate cancer cell line by using MTT assay Inhibitory concentration to inhibit growth of C2H prostate cancer cell line by using MTT assay	[PMID: 14971910]
U-251	GI₅₀	< 0.025 μg/mL Compound: DOX; Doxo	Antiproliferative activity against human U251 cells after 48 hrs by SRB assay Antiproliferative activity against human U251 cells after 48 hrs by SRB assay	[PMID: 26859070]
U-251	GI₅₀	< 0.046 μM Compound: Dox	Antiproliferative activity against human U251 cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human U251 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26454648]
U-251	GI₅₀	< 0.046 μM Compound: Doxorubicin	Anticancer activity against human U-251 cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay Anticancer activity against human U-251 cells assessed as cell growth inhibition measured after 48 hrs by sulforhodamine B assay	[PMID: 33214037]
U-251	ED₅₀	0.001 μg/mL Compound: Doxorubicin	Cytotoxicity against human U251 cells by sulforhodamine B method Cytotoxicity against human U251 cells by sulforhodamine B method	[PMID: 12193011]
U-251	ED₅₀	0.02 μg/mL Compound: Adriamycin	Cytotoxicity against human U251 cells after 24 hrs by SRB assay Cytotoxicity against human U251 cells after 24 hrs by SRB assay	[PMID: 20850305]
U-251	GI₅₀	0.039 μg/mL Compound: DOX	Antiproliferative activity against human U251 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human U251 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 25062010]
U-251	GI₅₀	0.04 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human U251 cells after 48 hrs by SRB assay Cytotoxicity against human U251 cells after 48 hrs by SRB assay	[PMID: 23871905]
U-251	GI₅₀	0.04 μM Compound: Doxorubicin	Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
U-251	GI₅₀	0.04 μM Compound: Doxorubicin	Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human U251 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
U-251	IC₅₀	0.05 μM Compound: Doxorubicin	Antiproliferative activity against human U251 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Antiproliferative activity against human U251 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 31962262]
U-251	IC₅₀	0.05 μM Compound: Doxorubicin	Cytotoxicity against human U251 cells harboring mutant TP53 gene incubated for 72 hrs by MTS assay Cytotoxicity against human U251 cells harboring mutant TP53 gene incubated for 72 hrs by MTS assay	[PMID: 31158748]
U-251	IC₅₀	0.052 μM Compound: Doxorubicin	Cytotoxicity against human U-251 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against human U-251 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 33261897]
U-251	GI₅₀	0.068 μg/mL Compound: Doxorubicin	Growth inhibition of human U251 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human U251 cells after 48 hrs by sulforhodamine B assay	[PMID: 22410248]
U-251	EC₅₀	0.07 μM Compound: Doxorubicin	Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35567964]
U-251	IC₅₀	0.09 μM Compound: Doxorubicine	Inhibitory activity against U251 CNS cell line using sulforhodamine B (SRB) protein assay Inhibitory activity against U251 CNS cell line using sulforhodamine B (SRB) protein assay	[PMID: 12039588]
U-251	IC₅₀	0.106 μM Compound: Doxorubicin	Antiproliferative activity against human U-251 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human U-251 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34325324]
U-251	EC₅₀	0.12 μM Compound: Adriamycin	Inhibition of HIF1 activation in human U251 cells stably transfected in pGL2-TK-HRE plasmid under hypoxic condition after 16 to 24 hrs by luciferase reporter gene assay Inhibition of HIF1 activation in human U251 cells stably transfected in pGL2-TK-HRE plasmid under hypoxic condition after 16 to 24 hrs by luciferase reporter gene assay	[PMID: 19405508]
U-251	GI₅₀	0.14 μM Compound: Dox	Growth inhibition of human U251 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay Growth inhibition of human U251 cells after 48 hrs by sulforhodamine B dye-based spectrophotometric assay	[PMID: 28505535]
U-251	IC₅₀	0.17 μM Compound: DOX	Cytotoxicity against human U251 cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human U251 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
U-251	GI₅₀	0.21 μM Compound: DOXO	Antiproliferative activity against human U251 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay Antiproliferative activity against human U251 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay	[PMID: 31247374]
U-251	IC₅₀	0.32 μM Compound: Adriamycin	Cytotoxicity against human U251 cells after 48 hrs by SRB assay Cytotoxicity against human U251 cells after 48 hrs by SRB assay	[PMID: 17125233]
U-251	IC₅₀	0.45 μM Compound: ADM	Cytotoxicity against human U251 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human U251 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 36332551]
U-251	IC₅₀	0.6 μM Compound: Doxorubicin	Antiproliferative activity against human U251 cells after 72 hrs by MTT assay Antiproliferative activity against human U251 cells after 72 hrs by MTT assay	[PMID: 19632833]
U-251	IC₅₀	0.61 μM Compound: DOX	Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 34968902]
U-251	GI₅₀	0.89 μM Compound: Dox	Anticancer activity against human U-251 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Anticancer activity against human U-251 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 35533562]
U-251	IC₅₀	2.2 μM Compound: DOX	Antiproliferative activity against human U251 cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human U251 cells after 72 hrs by sulforhodamine B assay	[PMID: 25981689]
U-251	IC₅₀	3.3 μM Compound: Dox	Cytotoxicity against human U251 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human U251 cells after 72 hrs by sulforhodamine B assay	[PMID: 28504888]
U-251	IC₅₀	3.9 μM Compound: DOX	Antiproliferative activities against human U-251 cells by SRB assay Antiproliferative activities against human U-251 cells by SRB assay	[PMID: 32864967]
U-251	IC₅₀	6.8 μM Compound: Dox	Antiproliferative activity against human U251 cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human U251 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 31584271]
U-266	IC₅₀	0.67 μM Compound: Doxorubicin	Cytotoxicity against human U266 cells after 72 hrs by resazurin/resorufin-based fluorescence assay Cytotoxicity against human U266 cells after 72 hrs by resazurin/resorufin-based fluorescence assay	[PMID: 23600925]
U2OS	IC₅₀	0.3 μM Compound: DOX, Doxorubicin	Antiproliferative activity against human U2OS cells after 72 hrs by MTT assay Antiproliferative activity against human U2OS cells after 72 hrs by MTT assay	[PMID: 24095089]
U2OS	IC₅₀	0.563 μM Compound: Doxorubicin	Antiproliferative activity against human U2OS cells after 48 hrs by MTT assay Antiproliferative activity against human U2OS cells after 48 hrs by MTT assay	[PMID: 28406643]
U2OS	IC₅₀	0.65 μM Compound: doxorubicin	Cytotoxicity against human U2OS cells after 48 hrs by MTT assay Cytotoxicity against human U2OS cells after 48 hrs by MTT assay	[PMID: 25314138]
U2OS	IC₅₀	3.4 μM Compound: Doxorubicin	Cytotoxicity against human U2OS cells after 72 hrs by MTT assay Cytotoxicity against human U2OS cells after 72 hrs by MTT assay	[PMID: 22749279]
U-87MG ATCC	IC₅₀	0.08 μM Compound: Doxorubicin	Antiproliferative activity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31546197]
U-87MG ATCC	IC₅₀	0.09 μM Compound: Doxorubicin	Cytotoxicity against human U-87 MG cells assessed as reduction in cell viability by CellTiter Glo luminescent assay Cytotoxicity against human U-87 MG cells assessed as reduction in cell viability by CellTiter Glo luminescent assay	[PMID: 32755677]
U-87MG ATCC	IC₅₀	0.11 μM Compound: DOX	Cytotoxicity against human U87 cells measured after 72 hrs by Celltiter-Glo assay Cytotoxicity against human U87 cells measured after 72 hrs by Celltiter-Glo assay	[PMID: 31820976]
U-87MG ATCC	IC₅₀	0.14 μM Compound: DOX	Antiproliferative activity against human U87 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Antiproliferative activity against human U87 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 34968902]
U-87MG ATCC	IC₅₀	0.1864 μM Compound: Doxorubicin	Antiproliferative activity against human U87 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human U87 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34325324]
U-87MG ATCC	IC₅₀	0.25 μM Compound: ADM	Antiproliferative activity against human U87 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human U87 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 36332551]
U-87MG ATCC	IC₅₀	0.26 μM Compound: Doxorubicin	Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by RRA assay Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by RRA assay	[PMID: 33508467]
U-87MG ATCC	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human U87MG cells assessed as reduction in cell survival after 96 hrs by MTT assay Cytotoxicity against human U87MG cells assessed as reduction in cell survival after 96 hrs by MTT assay	[PMID: 28471664]
U-87MG ATCC	IC₅₀	0.381 μM Compound: 1	Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 2 hrs by Cell-titer-blue assay	[PMID: 33064004]
U-87MG ATCC	IC₅₀	0.4 μM Compound: Dox	Cytotoxicity against human U87MG cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human U87MG cells after 72 hrs by sulforhodamine B assay	[PMID: 28504888]
U-87MG ATCC	IC₅₀	0.48 μM Compound: ADM	Antiproliferative activity against human U87 cells after 48 hrs by MTT assay Antiproliferative activity against human U87 cells after 48 hrs by MTT assay	[PMID: 30025345]
U-87MG ATCC	IC₅₀	0.57 μM Compound: Doxorubicin	Anticancer activity against human U87 cells incubated for 48 hrs by MTT assay Anticancer activity against human U87 cells incubated for 48 hrs by MTT assay	[PMID: 35367708]
U-87MG ATCC	IC₅₀	0.6 μM Compound: DOX	Antiproliferative activities against human U-87 MG cells by SRB assay Antiproliferative activities against human U-87 MG cells by SRB assay	[PMID: 32864967]
U-87MG ATCC	IC₅₀	0.93 μM Compound: DOX	Antiproliferative activity against human U87MG cells after 72 hrs by sulforhodamine B assay Antiproliferative activity against human U87MG cells after 72 hrs by sulforhodamine B assay	[PMID: 25981689]
U-87MG ATCC	IC₅₀	1 μM Compound: Doxorubicin	Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 46 hrs by MTT assay Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 46 hrs by MTT assay	[PMID: 29138027]
U-87MG ATCC	IC₅₀	1.6 μM Compound: Dox	Antiproliferative activity against human U87MG cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human U87MG cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 31584271]
U-87MG ATCC	IC₅₀	1.7 μM Compound: Doxorubicin	Anticancer activity against human U-87 MG cells assessed as growth inhibition incubated for 48 hrs by MTT assay Anticancer activity against human U-87 MG cells assessed as growth inhibition incubated for 48 hrs by MTT assay	[PMID: 34363936]
U-87MG ATCC	IC₅₀	18 nM Compound: Doxorubicin	Cytotoxicity against human U87MG cells after 48 hrs by [3H]thymidine incorporation assay Cytotoxicity against human U87MG cells after 48 hrs by [3H]thymidine incorporation assay	[PMID: 20210346]
U-87MG ATCC	IC₅₀	450 nM Compound: Doxorubicin	Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 48 hrs under normoxia condition by MTT assay Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 48 hrs under normoxia condition by MTT assay	[PMID: 32186874]
U-87MG ATCC	IC₅₀	5.939 μM Compound: Doxorubicin	Antiproliferative activity against human U87 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human U87 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31883489]
U-87MG ATCC	IC₅₀	790 nM Compound: doxorubicin	Antiproliferative activity against human U87MG cells after 48 hrs by XTT assay Antiproliferative activity against human U87MG cells after 48 hrs by XTT assay	[PMID: 22515366]
U-87MG ATCC	IC₅₀	980 nM Compound: Doxorubicin	Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 48 hrs under hypoxia condition by MTT assay Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 48 hrs under hypoxia condition by MTT assay	[PMID: 32186874]
U-87MG ATCC	IC₅₀	99.6 μM Compound: Doxorubicin	Antiproliferative activity against human U87 cells assessed as reduction in cell viability after 72 hrs by CellTiter Glo assay Antiproliferative activity against human U87 cells assessed as reduction in cell viability after 72 hrs by CellTiter Glo assay	[PMID: 33016067]
U-937	IC₅₀	> 100 μM Compound: Dox	Cytotoxicity against human U937 assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human U937 assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33065435]
U-937	IC₅₀	0.05 μM Compound: Doxorubicin	Cytotoxicity against human U-937 cells incubated for 48 hrs by MTT assay Cytotoxicity against human U-937 cells incubated for 48 hrs by MTT assay	[PMID: 36496202]
U-937	IC₅₀	0.077 μM Compound: DOX	Cytotoxicity against human U937 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human U937 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 26638041]
U-937	IC₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity against human U937 cells after 72 hrs by CCK8 assay Cytotoxicity against human U937 cells after 72 hrs by CCK8 assay	[PMID: 28398051]
U-937	IC₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity in human U-937 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human U-937 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34082225]
U-937	IC₅₀	0.1 μM Compound: Dox	Cytotoxicity against human U937 cells after 72 hrs by MTT assay Cytotoxicity against human U937 cells after 72 hrs by MTT assay	[PMID: 30659997]
U-937	IC₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 72 hrs by MTT method Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 72 hrs by MTT method	[PMID: 25932671]
U-937	IC₅₀	0.12 μM Compound: Dox	Cytotoxicity against human U937 cells after 24 hrs by MTT assay Cytotoxicity against human U937 cells after 24 hrs by MTT assay	[PMID: 23802716]
U-937	IC₅₀	0.28 μM Compound: Doxorubicin	Cytotoxicity activity against human U937 cells assessed as reduction in cell viability after 48 hrs by CCK-8 assay Cytotoxicity activity against human U937 cells assessed as reduction in cell viability after 48 hrs by CCK-8 assay	[PMID: 29288944]
U-937	IC₅₀	0.42 μM Compound: Doxorubicin	Cytotoxicity against human U937 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human U937 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27623548]
U-937	IC₅₀	0.8 μM Compound: doxorubicin	Cytotoxicity against human U937 cells after 24 to 48 hrs by MTT assay Cytotoxicity against human U937 cells after 24 to 48 hrs by MTT assay	[PMID: 21058726]
U-937	IC₅₀	0.93 μM Compound: Doxorubicin	Antitumor activity against human U937 cells after 24 to 48 hrs by MTT assay Antitumor activity against human U937 cells after 24 to 48 hrs by MTT assay	[PMID: 21553829]
U-937	IC₅₀	4.45 nM Compound: Doxorubicin	Cytotoxicity against human U937 cells after 3 days by MTT assay Cytotoxicity against human U937 cells after 3 days by MTT assay	[PMID: 20356655]
U-937	IC₅₀	4.45 nM Compound: Doxorubicin	Cytotoxicity against human U937 cells by MTT assay Cytotoxicity against human U937 cells by MTT assay	[PMID: 19345581]
U-937/GTB	IC₅₀	0.1 μM Compound: Doxorubicin	Cytotoxicity against human U937/GTB cells after 72 hrs by trypan blue exclusion method Cytotoxicity against human U937/GTB cells after 72 hrs by trypan blue exclusion method	[PMID: 14987049]
U-937/GTB	IC₅₀	0.11 μM Compound: doxorubicin	Cytotoxicity against human U937 GTB cells after 72 hrs by fluorometric microculture cytotoxicity assay Cytotoxicity against human U937 GTB cells after 72 hrs by fluorometric microculture cytotoxicity assay	[PMID: 16562840]
U-937/GTB	IC₅₀	0.16 μM Compound: Doxorubicin	Cytotoxicity against human U937/GTB cells after 72 hrs by fluorometric microculture cytotoxicity assay Cytotoxicity against human U937/GTB cells after 72 hrs by fluorometric microculture cytotoxicity assay	[PMID: 21434649]
UACC-257	GI₅₀	0.12 μM Compound: Doxorubicin	Growth inhibition of human UACC257 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human UACC257 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
UACC-257	GI₅₀	0.14 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human UACC257 cells after 48 hrs by SRB assay Cytotoxicity against human UACC257 cells after 48 hrs by SRB assay	[PMID: 23871905]
UACC-257	GI₅₀	0.14 μM Compound: Doxorubicin	Growth inhibition of human UACC257 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human UACC257 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
UACC-257	IC₅₀	0.6 μM Compound: Doxorubicin	Cytotoxicity against human UACC257 cells after 72 hrs by MTT assay Cytotoxicity against human UACC257 cells after 72 hrs by MTT assay	[PMID: 19406535]
UACC-375	IC₅₀	112 nM Compound: Doxorubicin	Anti-tumor activity against human UACC375 melanoma cell lines by using MTT assay Anti-tumor activity against human UACC375 melanoma cell lines by using MTT assay	[PMID: 7699715]
UACC-375	IC₅₀	112 nM Compound: doxorubicin	Tested for inhibitory activity against human tumor cell line UA375 of melanoma using sulforhodamine B assay. Tested for inhibitory activity against human tumor cell line UA375 of melanoma using sulforhodamine B assay.	[PMID: 10956214]
UACC-62	GI₅₀	0.05 μM Compound: Dox	Antiproliferative activity against human UACC62 cells assessed as growth inhibition after 48 hrs by SRB assay Antiproliferative activity against human UACC62 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26454648]
UACC-62	GI₅₀	0.09 μg/mL Compound: DOX	Growth inhibition of human UACC62 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human UACC62 cells after 48 hrs by sulforhodamine B assay	[PMID: 21041092]
UACC-62	GI₅₀	0.12 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human UACC62 cells after 48 hrs by SRB assay Cytotoxicity against human UACC62 cells after 48 hrs by SRB assay	[PMID: 23871905]
UACC-62	GI₅₀	0.14 μM Compound: Doxorubicin	Growth inhibition of human UACC62 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human UACC62 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
UACC-62	GI₅₀	0.18 μM Compound: Doxorubicin	Cytotoxicity against human UACC62 cells by sulforhodamine B assay Cytotoxicity against human UACC62 cells by sulforhodamine B assay	[PMID: 20413188]
UACC-62	GI₅₀	9.4 x 10^-2 μM Compound: doxorubicin	Cytotoxicity against human UACC62 cells by SRB assay Cytotoxicity against human UACC62 cells by SRB assay	[PMID: 11678649]
UACC-62	GI₅₀	94 μM Compound: Doxorubicin	Growth inhibition of human UACC62 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human UACC62 cells after 48 hrs by sulforhodamine B assay	[PMID: 21504224]
UO-31	IC₅₀	0.1 μM Compound: adriamycin	Antitumor activity against human UO31 cells by methylene blue staining method Antitumor activity against human UO31 cells by methylene blue staining method	[PMID: 17656091]
UO-31	ED₅₀	0.3 μg/mL Compound: adriamycin	Cytotoxicity against human UO31 cells after 48 hrs by SRB assay Cytotoxicity against human UO31 cells after 48 hrs by SRB assay	10.1021/np50124a024
UO-31	IC₅₀	0.36 μM Compound: DOX	Antiproliferative activity against human UO31 cells after 72 hrs by Sulforhodamine B-stain assay Antiproliferative activity against human UO31 cells after 72 hrs by Sulforhodamine B-stain assay	[PMID: 27484508]
UO-31	GI₅₀	0.49 μM Compound: Doxorubicin hydrochloride, NSC 123127	Cytotoxicity against human UO31 cells after 48 hrs by SRB assay Cytotoxicity against human UO31 cells after 48 hrs by SRB assay	[PMID: 23871905]
UO-31	GI₅₀	0.49 μM Compound: Doxorubicin	Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 29102177]
UO-31	GI₅₀	0.49 μM Compound: Doxorubicin	Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 28329730]
UO-31	IC₅₀	6.44 μM Compound: Doxorubicin	Antiproliferative activity against human UO31 cells after 48 hrs by MTT assay Antiproliferative activity against human UO31 cells after 48 hrs by MTT assay	[PMID: 29547830]
UO-31	IC₅₀	7.453 nM Compound: Dox	Antiproliferative against human UO31 cells incubated for 24 hrs by MTT assay Antiproliferative against human UO31 cells incubated for 24 hrs by MTT assay	[PMID: 31539778]
V79	IC₅₀	0.24 μM Compound: Doxorubicin	Cytotoxicity against chinese hamster V79 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against chinese hamster V79 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24530030]
V79	IC₅₀	0.25 μM Compound: DOXO	Antiproliferative activity against chinese hamster V79 cells after 72 hrs by MTT assay Antiproliferative activity against chinese hamster V79 cells after 72 hrs by MTT assay	[PMID: 28818447]
V79	IC₅₀	0.28 μM Compound: Doxorubicin	Cytotoxicity against NQO1-deficient chinese hamster V79 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against NQO1-deficient chinese hamster V79 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27341379]
V79	IC₅₀	0.28 μM Compound: DOXO	Cytotoxicity against chinese hamster V79 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against chinese hamster V79 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26142490]
V79	IC₅₀	2.21 μM Compound: Doxorubicin	Cytotoxicity against Chinese Hamster V79 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against Chinese Hamster V79 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 31753514]
Vero	IC₅₀	> 10 μg/mL Compound: Doxorubicin	Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 48 hrs by neutral red dye based assay Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 48 hrs by neutral red dye based assay	[PMID: 27769668]
Vero	IC₅₀	> 10 μg/mL Compound: Doxorubicin	Cytotoxicity against African green monkey Vero cells assessed as reduction in viable cells measured after 48 hrs by neutral red dye-based method Cytotoxicity against African green monkey Vero cells assessed as reduction in viable cells measured after 48 hrs by neutral red dye-based method	[PMID: 27584935]
Vero	IC₅₀	> 10 μM Compound: Doxorubicin	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by neutral red dye-based assay	[PMID: 27618204]
Vero	IC₅₀	> 100 μM Compound: Doxorubicin	Cytotoxicity against African green monkey Vero cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 26433616]
Vero	IC₅₀	> 5 μg/mL Compound: Doxorubicin	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by neutral red assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by neutral red assay	[PMID: 25686593]
Vero	IC₅₀	> 5 μg/mL Compound: doxorubicin	Cytotoxicity against african green monkey Vero cell after 48 hrs by Neutral Red dye Cytotoxicity against african green monkey Vero cell after 48 hrs by Neutral Red dye	[PMID: 20550123]
Vero	IC₅₀	> 5 μg/mL Compound: Doxorubicin	Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red	[PMID: 23891181]
Vero	IC₅₀	> 5 μM Compound: Doxorubicin	Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells by neutral red staining Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells by neutral red staining	10.1007/s00044-011-9587-3
Vero	IC₅₀	> 9 μM Compound: Doxorubicin	Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 48 hrs by neutral red assay Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 48 hrs by neutral red assay	[PMID: 26005918]
Vero	IC₅₀	> 9.2 μM Compound: doxorubicin	Cytotoxicity against african green monkey Vero cells assessed as growth inhibition measured after 48 hrs by XTT assay Cytotoxicity against african green monkey Vero cells assessed as growth inhibition measured after 48 hrs by XTT assay	[PMID: 23547843]
Vero	IC₅₀	0.92 μM Compound: Doxorubicin	Cytotoxicity against African green monkey Vero cells after 48 hrs by neutral red assay relative to control Cytotoxicity against African green monkey Vero cells after 48 hrs by neutral red assay relative to control	[PMID: 25975638]
Vero	IC₅₀	1.3 μM Compound: Doxorubicin	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay	[PMID: 31820973]
Vero	IC₅₀	1.4 μM Compound: Doxorubicin	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay	[PMID: 28927795]
Vero	IC₅₀	1.5 μg/mL Compound: doxorubicin	Cytotoxicity against african green monkey Vero cells after 2 to 7 days by neutral red assay Cytotoxicity against african green monkey Vero cells after 2 to 7 days by neutral red assay	[PMID: 8984156]
Vero	IC₅₀	1.87 μM Compound: Doxorubicin	Cytotoxicity against african green monkey Vero cells incubated for 72 hrs by Sulphorhodamine assay Cytotoxicity against african green monkey Vero cells incubated for 72 hrs by Sulphorhodamine assay	[PMID: 37146520]
Vero	IC₅₀	1.93 μM Compound: DOX	Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 26638041]
Vero	IC₅₀	10.4 μM Compound: Dox	Cytotoxicity against african green monkey Vero cells after 3 days by MTS assay Cytotoxicity against african green monkey Vero cells after 3 days by MTS assay	[PMID: 21094049]
Vero	IC₅₀	14 μM Compound: Doxorubicin	Cytotoxicity against African green monkey Vero cells measured after 48 hrs by neutral red assay Cytotoxicity against African green monkey Vero cells measured after 48 hrs by neutral red assay	[PMID: 27750201]
Vero	IC₅₀	23.94 μM Compound: Doxorubicin	Cytotoxicity against african geen monkey Vero cells after 4 days by GFP reporter assay Cytotoxicity against african geen monkey Vero cells after 4 days by GFP reporter assay	[PMID: 23313636]
Vero	IC₅₀	28.81 μM Compound: Doxorubicin	Cytotoxicity against african green monkey Vero cells expressing GFP after 4 days by fluorescence assay Cytotoxicity against african green monkey Vero cells expressing GFP after 4 days by fluorescence assay	[PMID: 22280818]
Vero	IC₅₀	3.2 μg/mL Compound: Doxorubicin	Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red assay Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red assay	[PMID: 19105653]
Vero	IC₅₀	3.6 μM Compound: DOX	Cytotoxicity against african green monkey Vero cells assessed as cell growth after 48 hrs by hemocytometry Cytotoxicity against african green monkey Vero cells assessed as cell growth after 48 hrs by hemocytometry	[PMID: 20961671]
Vero	IC₅₀	5.12 μM Compound: Doxorubicin	Cytotoxicity against african green monkey Vero cells assessed as inhibition of [3H]hypoxanthine incorporation after 48 hrs Cytotoxicity against african green monkey Vero cells assessed as inhibition of [3H]hypoxanthine incorporation after 48 hrs	[PMID: 21256013]
Vero	IC₅₀	5.12 μM Compound: Doxorubicin	Cytotoxicity against african green monkey Vero cells assessed as inhibition of [3H]hypoxanthine incorporation after 48 hrs Cytotoxicity against african green monkey Vero cells assessed as inhibition of [3H]hypoxanthine incorporation after 48 hrs	[PMID: 20634081]
Vero	IC₅₀	5.4 μg/mL Compound: Doxorubicin	Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability incubated for 48 hrs by neutral red based assay Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability incubated for 48 hrs by neutral red based assay	[PMID: 26371504]
Vero	IC₅₀	5.4 μg/mL Compound: Doxorubicin	Cytotoxicity against African green monkey Vero cells assessed as cell viability after 48 hrs by neutral red-based assay Cytotoxicity against African green monkey Vero cells assessed as cell viability after 48 hrs by neutral red-based assay	[PMID: 26469557]
Vero	IC₅₀	6.3 μM Compound: Doxorubicin	Cytotoxicity against african green monkey Vero cells after 48 hrs by Neutral red assay Cytotoxicity against african green monkey Vero cells after 48 hrs by Neutral red assay	[PMID: 19658408]
Vero	IC₅₀	6.6 μM Compound: Doxorubicin	Antiproliferative activity against African green monkey Vero cells by MTT assay Antiproliferative activity against African green monkey Vero cells by MTT assay	[PMID: 29072457]
Vero	IC₅₀	7 μM Compound: Doxorubicin	Cytotoxicity against african green monkey Vero cells after 48 hrs by Neutral Red assay Cytotoxicity against african green monkey Vero cells after 48 hrs by Neutral Red assay	10.1039/C3MD00097D
Vero	IC₅₀	7.4 μM Compound: DOX	Cytotoxicity against african green monkey Vero cells after 48 hrs by [3H]hypoxanthine incorporation assay Cytotoxicity against african green monkey Vero cells after 48 hrs by [3H]hypoxanthine incorporation assay	[PMID: 20362359]
Vero	IC₅₀	7.5 μg/mL Compound: Doxorubicin	Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells after 48 hr by neutral red assay Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells after 48 hr by neutral red assay	[PMID: 23024574]
Vero	IC₅₀	7.5 μg/mL Compound: doxorubicin	Cytotoxicity against african green monkey Vero cells by neutral red assay Cytotoxicity against african green monkey Vero cells by neutral red assay	[PMID: 17976995]
Vero	IC₅₀	7.5 μg/mL Compound: DOX	Cytotoxicity against Vero cells by neutral red method Cytotoxicity against Vero cells by neutral red method	[PMID: 17181171]
Vero	IC₅₀	7.5 μg/mL Compound: doxorubicin	Cytotoxicity against Vero cells by neutral red assay Cytotoxicity against Vero cells by neutral red assay	[PMID: 17070063]
Vero	IC₅₀	8.6 μM Compound: doxorubicin	Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red assay Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red assay	[PMID: 24900509]
WI-38	IC₅₀	> 10 μM Compound: adriamycin	Cytotoxicity against human WI38 cells after 72 hrs by SRB assay Cytotoxicity against human WI38 cells after 72 hrs by SRB assay	[PMID: 19028425]
WI-38	IC₅₀	0.0266 μM Compound: DOX	Cytotoxicity against human WI38 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human WI38 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 30826510]
WI-38	IC₅₀	0.04 μM Compound: Doxorubicin	Antiproliferative activity against human WI38 cells after 72 hrs by MTT assay Antiproliferative activity against human WI38 cells after 72 hrs by MTT assay	[PMID: 22555152]
WI-38	IC₅₀	0.079 μg/mL Compound: E; DOX	Antiproliferative activity against human WI-38 cells measured after 48 hrs by MTT assay Antiproliferative activity against human WI-38 cells measured after 48 hrs by MTT assay	[PMID: 35963130]
WI-38	IC₅₀	0.3 μM Compound: Doxorubicin	Cytotoxicity against human WI38 cells after 24 hrs by MTT assay Cytotoxicity against human WI38 cells after 24 hrs by MTT assay	[PMID: 17190470]
WI-38	IC₅₀	0.3 μM Compound: doxorubicin	Cytotoxicity against human WI38 cells by MTT assay Cytotoxicity against human WI38 cells by MTT assay	[PMID: 15620238]
WI-38	IC₅₀	0.35 μM Compound: Doxorubicin	Cytotoxicity against human WI38 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay Cytotoxicity against human WI38 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay	[PMID: 28257197]
WI-38	IC₅₀	0.38 μM Compound: ADM	Growth inhibition of human WI38 cells after 48 hrs by WST8 assay Growth inhibition of human WI38 cells after 48 hrs by WST8 assay	[PMID: 16499322]
WI-38	IC₅₀	0.4 μM Compound: Doxorubicin	Cytotoxicity against human WI-38 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay Cytotoxicity against human WI-38 cells assessed as number of viable cells measured after 48 hrs by MTT based colorimetric assay	[PMID: 36970146]
WI-38	IC₅₀	0.59 μM Compound: Doxorubicin	Cytotoxicity against human WI38 cells after 72 hrs by MTT assay Cytotoxicity against human WI38 cells after 72 hrs by MTT assay	[PMID: 31264855]
WI-38	IC₅₀	0.66 μM Compound: ADM	Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay	[PMID: 15730243]
WI-38	IC₅₀	0.66 μM Compound: ADM	Cytotoxicity against human WI38 cells by WST-8 assay Cytotoxicity against human WI38 cells by WST-8 assay	[PMID: 16933868]
WI-38	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human WI38 cells after 72 hrs by Alamar blue assay Cytotoxicity against human WI38 cells after 72 hrs by Alamar blue assay	[PMID: 21999655]
WI-38	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human WI-38 cells assessed as cell growth inhibition measured after 24 to 72 hrs by MTT assay Cytotoxicity against human WI-38 cells assessed as cell growth inhibition measured after 24 to 72 hrs by MTT assay	[PMID: 33586438]
WI-38	IC₅₀	0.8 μM Compound: Doxorubicin	Cytotoxicity against human WI-38 cells assessed as inhibition of cell proliferation measured after 72 hrs by resazurin dye based AlamarBlue assay Cytotoxicity against human WI-38 cells assessed as inhibition of cell proliferation measured after 72 hrs by resazurin dye based AlamarBlue assay	[PMID: 34495663]
WI-38	IC₅₀	1.3 μM Compound: Doxorubicin	Cytotoxicity against human WI-38 cells assessed as reduction in cell viability after 24 hrs by DAPI staining-based fluorescence assay Cytotoxicity against human WI-38 cells assessed as reduction in cell viability after 24 hrs by DAPI staining-based fluorescence assay	[PMID: 32786882]
WI-38	IC₅₀	1.3 μM Compound: Doxorubicin	Cytotoxicity against human WI-38 cells assessed as reduction in cell viability by DAPI staining based assay Cytotoxicity against human WI-38 cells assessed as reduction in cell viability by DAPI staining based assay	[PMID: 33461146]
WI-38	IC₅₀	1.96 μM Compound: Doxorubicin	Cytotoxicity against human WI-38 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay Cytotoxicity against human WI-38 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay	[PMID: 33744686]
WI-38	IC₅₀	12.3 μM Compound: Doxorubicin	Antiproliferative activity against human WI38 cells after 24 hrs by BrdU incorporation assay Antiproliferative activity against human WI38 cells after 24 hrs by BrdU incorporation assay	[PMID: 27555286]
WI-38	IC₅₀	26.6 nM Compound: Dox	Cytotoxicity against human WI-38 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human WI-38 cells assessed as reduction in cell viability by MTT assay	[PMID: 31740054]
WI-38	IC₅₀	34.1 nM Compound: DOX	Cytotoxicity against human WI-38 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human WI-38 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 33901898]
WI-38	IC₅₀	6.68 μM Compound: Doxorubicin	Cytotoxicity against human W138 cells after 48 hrs by MTT assay Cytotoxicity against human W138 cells after 48 hrs by MTT assay	[PMID: 30138804]
WI-38	IC₅₀	6.68 μM Compound: Doxorubicin	Cytotoxicity against human W138 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human W138 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 29702448]
WI-38	IC₅₀	6.72 μM Compound: DOX	Cytotoxicity against human WI-38 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Cytotoxicity against human WI-38 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 37054758]
WI-38	IC₅₀	6.72 μM Compound: DOX	Cytotoxicity against human WI-38 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Cytotoxicity against human WI-38 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 36242988]
WI-38	IC₅₀	6.72 μM Compound: Dox	Cytotoxicity against human WI-38 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human WI-38 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32527460]
WI-38	IC₅₀	6.72 μM Compound: DOX	Cytotoxicity against human WI38 cells by MTT assay Cytotoxicity against human WI38 cells by MTT assay	[PMID: 33388654]
WI-38	IC₅₀	6.72 μM Compound: Doxorubicin	Cytotoxicity against human WI38 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human WI38 cells assessed as reduction in cell viability by MTT assay	[PMID: 33065442]
WI-38	IC₅₀	71 nM Compound: Doxorubicin	Cytotoxicity against human WI38 cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against human WI38 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 28600080]
WI-38	IC₅₀	79.7 μM Compound: Doxorubicin	Cytotoxicity against human WI-38 cells assessed as inhibition of cell growth incubated for 3 days by MTT assay Cytotoxicity against human WI-38 cells assessed as inhibition of cell growth incubated for 3 days by MTT assay	[PMID: 35007724]
WI-38	IC₅₀	9 μM Compound: Doxorubicin	Cytotoxicity against human WI38 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human WI38 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28327308]
WI-38 VA13	IC₅₀	0.22 μM Compound: ADM	Growth inhibition of human VA13 cells after 48 hrs by WST8 assay Growth inhibition of human VA13 cells after 48 hrs by WST8 assay	[PMID: 16499322]
WI-38 VA13	IC₅₀	0.38 μM Compound: ADM	Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay	[PMID: 15730243]
WI-38 VA13	IC₅₀	0.38 μM Compound: ADM	Cytotoxicity against human VA-13 cells by by WST-8 assay Cytotoxicity against human VA-13 cells by by WST-8 assay	[PMID: 16933868]
WiDr	ED₅₀	0.12 μg/mL Compound: Doxorubicin	Cytotoxicity against human WiDr cells by MTT assay Cytotoxicity against human WiDr cells by MTT assay	[PMID: 17315955]
WiDr	IC₅₀	130 nM Compound: doxorubicin	Tested for inhibitory activity against a multi drug resistant (MDR) strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein). Tested for inhibitory activity against a multi drug resistant (MDR) strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein).	[PMID: 10956214]
WiDr	IC₅₀	53 nM Compound: doxorubicin	Tested for inhibitory activity against a sensitive strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein). Tested for inhibitory activity against a sensitive strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein).	[PMID: 10956214]
WIL2-NS	CC₅₀	0.02 μM Compound: Doxorubicin	Cytotoxicity against human WIL2-NS cells after 96 hrs by MTT assay Cytotoxicity against human WIL2-NS cells after 96 hrs by MTT assay	[PMID: 26119992]
WIL2-NS	IC₅₀	0.02 μM Compound: doxo	Antiproliferative activity against human Wil2-NS cells by MTT assay Antiproliferative activity against human Wil2-NS cells by MTT assay	[PMID: 16913700]
WIL2-NS	EC₅₀	0.04 μM Compound: Doxorubicin	Cytotoxicity against human WIL2-NS cells after 96 hrs by MTT assay Cytotoxicity against human WIL2-NS cells after 96 hrs by MTT assay	[PMID: 26320088]
WISH	IC₅₀	3.18 μM Compound: Doxorubicin	Cytotoxicity against human WISH cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human WISH cells assessed as reduction in cell viability by MTT assay	[PMID: 33065442]
WISH	IC₅₀	8.14 μM Compound: Doxorubicin	Cytotoxicity against human WISH cells after 48 hrs by MTT assay Cytotoxicity against human WISH cells after 48 hrs by MTT assay	[PMID: 30138804]
WISH	IC₅₀	8.14 μM Compound: Doxorubicin	Cytotoxicity against human WISH cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human WISH cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 29702448]
WM 266-4	IC₅₀	0.15 μM Compound: Doxorubicin	Antiproliferative activity against human WM266.4 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method Antiproliferative activity against human WM266.4 cells assessed as inhibition of cell proliferation incubated for 72 hrs by conventional ATP quantification method	[PMID: 25937235]
WM793	GI₅₀	0.6 μM Compound: Dox	Cytotoxicity against human WM793 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human WM793 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 34634616]
WM793	GI₅₀	0.9 μM Compound: Dox	Antiproliferative activity against human WM793 cells incubated for 72 hrs and measured by MTT assay Antiproliferative activity against human WM793 cells incubated for 72 hrs and measured by MTT assay	[PMID: 35973342]
XF498	IC₅₀	0.009 μM Compound: Doxorubicin	Antiproliferative activity against human XF498 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human XF498 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 27010926]
XF498	ED₅₀	0.01 μg/mL Compound: doxorubicin	Cytotoxicity against human XF498 cells after 48 hrs by SRB assay Cytotoxicity against human XF498 cells after 48 hrs by SRB assay	[PMID: 15921415]
XF498	ED₅₀	0.01 μg/mL Compound: doxorubicin	Cytotoxicity against human XF498 cells by SRB method Cytotoxicity against human XF498 cells by SRB method	[PMID: 16252909]
XF498	IC₅₀	0.015 μM Compound: Doxorubicin	Cytotoxicity against human XF498 cells after 48 hrs by SRB assay Cytotoxicity against human XF498 cells after 48 hrs by SRB assay	[PMID: 22483395]
XF498	ED₅₀	0.029 μg/mL Compound: Doxorubicin	Cytotoxicity against human XF498 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human XF498 cells after 48 hrs by sulforhodamine B assay	[PMID: 19783438]
XF498	IC₅₀	0.04 μM Compound: doxorubicin	Cytotoxicity against human XF498 cells by SRB assay Cytotoxicity against human XF498 cells by SRB assay	[PMID: 17194596]
XF498	IC₅₀	0.044 μM Compound: doxorubicin	Cytotoxicity against human XF498 cells after 3 days by SRB assay Cytotoxicity against human XF498 cells after 3 days by SRB assay	[PMID: 18321715]
XF498	ED₅₀	0.08 μg/mL Compound: Doxorubicin	Cytotoxicity against human XF498 cells after 48 hrs by SRB assay Cytotoxicity against human XF498 cells after 48 hrs by SRB assay	[PMID: 11325244]
XF498	ED₅₀	0.1 μg/mL Compound: adriamycin	Cytotoxicity against human XF498 cells by SRB assay Cytotoxicity against human XF498 cells by SRB assay	10.1021/np960188t
XF498	IC₅₀	0.112 μM Compound: Doxorubicin	Anticancer activity against human XF498 cells after 48 hrs by SRB assay Anticancer activity against human XF498 cells after 48 hrs by SRB assay	[PMID: 17070967]
XF498	IC₅₀	0.12 μg/mL Compound: adriamycin	Cytotoxicity against human XF498 cells by SRB assay Cytotoxicity against human XF498 cells by SRB assay	[PMID: 15921426]
XF498	IC₅₀	0.16 μM Compound: Doxorubicin	Antiproliferative activity against human XF498 cells after 96 hrs by MTT assay Antiproliferative activity against human XF498 cells after 96 hrs by MTT assay	[PMID: 19053767]
XF498	IC₅₀	0.19 μg/mL Compound: doxorubicin	Anticancer activity against human XF498 cells after 72 hrs by sulforhodamine B assay Anticancer activity against human XF498 cells after 72 hrs by sulforhodamine B assay	[PMID: 19342127]
XF498	ED₅₀	0.23 μg/mL Compound: doxorubicin	Cytotoxicity against human XF498 cells by SRB assay Cytotoxicity against human XF498 cells by SRB assay	[PMID: 9392887]
XF498	IC₅₀	0.35 μM Compound: Doxorubicin	Anticancer activity against human XF498 cells by sulforhodamine B assay Anticancer activity against human XF498 cells by sulforhodamine B assay	[PMID: 19819696]
ZR-75-1	GI₅₀	< 0.1 μM Compound: ADR	Anticancer activity against human ZR-75-1 cells by SRB method Anticancer activity against human ZR-75-1 cells by SRB method	[PMID: 22104151]
ZR-75-1	IC₅₀	0.009 μM Compound: Doxorubicin	Inhibitory activity against ZR-75-1 cell line using MTT assay (ER+,pgr+,mutant p53) Inhibitory activity against ZR-75-1 cell line using MTT assay (ER+,pgr+,mutant p53)	[PMID: 10780913]
ZR-75-1	IC₅₀	0.04 μM Compound: doxorubicin	Cytotoxicity against human ZR751cells by SRB microtiter plate assay Cytotoxicity against human ZR751cells by SRB microtiter plate assay	[PMID: 17585747]
ZR-75-1	GI₅₀	0.11 μM Compound: ADR	Cytotoxicity against human ZR-75-1 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human ZR-75-1 cells after 48 hrs by sulforhodamine B assay	[PMID: 21737288]
ZR-75-1	GI₅₀	0.13 μM Compound: ADR	Cytotoxicity against human ZR-75-1 cells after 48 hrs by SRB assay Cytotoxicity against human ZR-75-1 cells after 48 hrs by SRB assay	[PMID: 20673627]
ZR-75-1	IC₅₀	0.6 μM Compound: ADR	Cytotoxicity against human ZR751 cells by SRB assay Cytotoxicity against human ZR751 cells by SRB assay	[PMID: 18656370]
ZR-75-1	IC₅₀	0.6 μM Compound: ADR	Cytotoxicity against human ZR-75-1 cells by sulforhodamine B assay Cytotoxicity against human ZR-75-1 cells by sulforhodamine B assay	[PMID: 17822905]
ZR-75-1	GI₅₀	1.79 μM Compound: ADR	Growth inhibition of human ZR-75-1 cells after 48 hrs by SRB assay Growth inhibition of human ZR-75-1 cells after 48 hrs by SRB assay	[PMID: 20031423]
ZR-75-1	GI₅₀	1.79 μM Compound: ADR	Growth inhibition of human ZR-75-1 cells by SRB assay Growth inhibition of human ZR-75-1 cells by SRB assay	[PMID: 22361684]
ZR-75-1	GI₅₀	1.79 μM Compound: ADR	Anticancer activity against human ZR-75-1 cells by SRB method Anticancer activity against human ZR-75-1 cells by SRB method	[PMID: 21676506]
ZR-75-1	GI₅₀	1.79 μM Compound: ADR, Adriamycin	Growth inhibition of human Zr-75-1 cells by SRB method Growth inhibition of human Zr-75-1 cells by SRB method	[PMID: 18207392]
ZR-75-1	GI₅₀	1.79 μM Compound: ADR	Growth inhibition of human ZR-75-1 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human ZR-75-1 cells after 48 hrs by sulforhodamine B assay	[PMID: 23849207]
ZR-75-1	GI₅₀	1.79 μM Compound: ADR	Growth inhibition of human ZR-75-1 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human ZR-75-1 cells after 48 hrs by sulforhodamine B assay	[PMID: 22364746]
ZR-75-1	GI₅₀	1.79 μM Compound: ADR	Cytotoxicity against human Zr-75-1 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human Zr-75-1 cells after 48 hrs by sulforhodamine B assay	[PMID: 18657979]
ZR-75-1	GI₅₀	1.79 μM Compound: ADR	Cytotoxicity against human ZR-75-1 cells after 24 hrs by WST-1 assay Cytotoxicity against human ZR-75-1 cells after 24 hrs by WST-1 assay	[PMID: 20732817]

In Vitro

Combination of Doxorubicin (Hydroxydaunorubicin) and Simvastatin (HY-17502) in the highest tested concentrations (2 μM and 10 μM, respec-tively) kills 97% of the Hela cells^[4].
Doxorubicin can label neuron cells, and it is bright red under Rhodamine filter bag, and light red-orange under catecholamine filter bag^[8].
Doxorubicin (5 μM; 10-30 min) can be accumulated in B16-F10 melanoma cell line CRL-6475 in a time-dependent manner, and can be detected by green or red fluorescence (green fluorescence has higher detection sensitivity) with a maximum excitation wavelength (λ_ex) and a maximum emission wavelength (λ_em) of 470 nm and 560 nm, respectively^[10].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Doxorubicin (4-8 mg/kg) can delay tumor growth and reduce the expression of c-FLIP in PC3 xenograft nude mice.
Doxorubicin (Intraperitoneal injection; single dose (10 mg/kg) / once daily for 10 days (1 mg/kg) / once per week for 5 weeks (2 mg/kg)) has cardiotoxicity in Sprague-Dawley rats, but compared with a single dose of 10 mg/kg, cumulative dosing of 10 mg/kg over several days or weeks can increase the survival rate of rats.^[6] Doxorubicin (4%-20%; Intrastriatal injection; Single dose) is neurotoxic in Sprague-Dawley rats^[8].
Doxorubicin can be coupled to gold nanoparticles (Au NPs) by PH-sensitive bonding under acidic conditions, allowing it to pass through the blood-brain barrier with a maximum absorption wavelength of 528 nm^[9].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Athymic male nude mice model of xenografts of PC3 prostate carcinoma cells^[5]
Dosage:	2 mg/kg, 4 mg/kg, 8 mg/kg
Administration:	ntraperitoneal injection (i.p.); Single dose .After injected PC3 cells (4 × 106) subcutaneously into the flank of mice.
Result:	A dose of 2 mg/ kg did not affect tumor growth while higher dosages (4 mg/kg, 8 mg/kg) delayed tumor growth initially.

Animal Model:	Male Sprague-Dawley rats model^[6]
Dosage:	10 mg/kg (schedule 1), 1 mg/kg (schedule 2), 2 mg/kg (schedule 3)
Administration:	Intraperitoneal injection (i.p.) ; Single dose (schedule 1). Intraperitoneal injection (i.p.); Once daily for 10 days (schedule 2). Intraperitoneal injection (i.p.); Once per week, for 5 weeks(schedule 3).
Result:	In schedule 1, caused 30% of the rats to die at the end of week 2 and 80% by day 28. In schedule 2 , caused 55% of the rats to die at the end of week 13 and 80% by day 107. In schedule 3, caused 42% of the rats to die at the end of week 13 and 80% by day 98.

Animal Model:	Male Sprague-Dawley rats^[8]
Dosage:	1%, 2%, 4%, 5%, 6%, 10%, 20%
Administration:	Intrastriatal injection; Single dose
Result:	In doses of 4, 5, 6, 10 or 20% caused obvious loss of ipsilateral SNc and VTA neuronsz and doses of 1 or 2% failed to produce obvious neuron loss.

Clinical Trial

Molecular Weight

543.52

Formula

C₂₇H₂₉NO₁₁

CAS No.

23214-92-8

SMILES

COC1=C2C(C(C(C(O)=C(C[C@](C(CO)=O)(O)C[C@@H]3O[C@@]4([H])C[C@H](N)[C@H](O)[C@H](C)O4)C3=C5O)=C5C2=O)=O)=CC=C1

Structure Classification

Initial Source

Microorganisms

Streptomyces peucetius.

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Solvent & Solubility

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

The following protocol is derived from the literature and is for reference only. It is recommended to first try a small sample.

Protocol 1

Doxorubicin (dissolved with distilled water) is incorporated into 0.035% CaCl₂ solution^[5].
Protocol 2

Doxorubicin (Adriamycin) is prepared in vehicle (PBS)^[6].

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Nitiss JL, et al. Targeting DNA topoisomerase II in cancer chemotherapy.Nat Rev Cancer. 2009 May;9(5):338-50. [Content Brief]

[2]. Rhee HK, et al. Synthesis, cytotoxicity, and DNA topoisomerase II inhibitory activity of benzofuroquinolinediones. Bioorg Med Chem. 2007 Feb 15;15(4):1651-8. [Content Brief]

[3]. Foglesong PD, et al. Doxorubicin inhibits human DNA topoisomerase I. Cancer Chemother Pharmacol. 1992;30(2):123-5. [Content Brief]

[4]. Sadeghi-Aliabadi H, et al. Cytotoxic evaluation of doxorubicin in combination with simvastatin against human cancer cells. Res Pharm Sci. 2010 Jul;5(2):127-33. [Content Brief]

[5]. El-Zawahry A, et al. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancerxenografts. BMC Cancer. 2005 Jan 7;5:2. [Content Brief]

[6]. Hayward R, et al. Doxorubicin cardiotoxicity in the rat: an in vivo characterization. J Am Assoc Lab Anim Sci. 2007 Jul;46(4):20-32. [Content Brief]

[7]. Johansson S, et al. Elimination of HIV-1 infection by treatment with a doxorubicin-conjugated anti-envelope antibody. AIDS. 2006;20(15):1911-1915. [Content Brief]

[8]. Koda LY, Van der Kooy D. Doxorubicin: a fluorescent neurotoxin retrogradely transported in the central nervous system. Neurosci Lett. 1983 Mar 28;36(1):1-8. doi: 10.1016/0304-3940(83)90476-7. PMID: 6190113. 9 [Content Brief]

[9]. Mirza A Z, Shamshad H. Preparation and characterization of doxorubicin functionalized gold nanoparticles[J]. European journal of medicinal chemistry, 2011, 46(5): 1857-1860.

[10]. Kauffman MK, Kauffman ME, Zhu H, Jia Z, Li YR. Fluorescence-Based Assays for Measuring Doxorubicin in Biological Systems. React Oxyg Species (Apex). 2016;2(6):432-439. doi: 10.20455/ros.2016.873. PMID: 29707647; PMCID: PMC5921830. [Content Brief]

Doxorubicin Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Doxorubicin (Synonyms: Hydroxydaunorubicin)

Other Forms of Doxorubicin:

430 Publications Citing Use of MCE Doxorubicin

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All ADC Cytotoxin Isoform Specific Products:

View All Antibiotic Isoform Specific Products:

View All Topoisomerase Isoform Specific Products:

View All AMPK Isoform Specific Products:

View All HIV Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Doxorubicin Related Classifications

Keywords:

Your Recently Viewed Products:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Doxorubicin (Synonyms: Hydroxydaunorubicin)

Other Forms of Doxorubicin:

Doxorubicin Related Antibodies

430 Publications Citing Use of MCE Doxorubicin

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All ADC Cytotoxin Isoform Specific Products:

View All Antibiotic Isoform Specific Products:

View All Topoisomerase Isoform Specific Products:

View All AMPK Isoform Specific Products:

View All HIV Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Doxorubicin Related Antibodies

Molarity Calculator

Dilution Calculator

Doxorubicin Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report